<SEC-DOCUMENT>0001558370-21-007409.txt : 20210517
<SEC-HEADER>0001558370-21-007409.hdr.sgml : 20210517
<ACCEPTANCE-DATETIME>20210517162434
ACCESSION NUMBER:		0001558370-21-007409
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		47
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210517
DATE AS OF CHANGE:		20210517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MARINUS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001267813
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36576
		FILM NUMBER:		21931151

	BUSINESS ADDRESS:	
		STREET 1:		5 RADNOR CORPORATE CENTER SUITE 500
		STREET 2:		100 MATSONFORD RD
		CITY:			RADNOR
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		484-801-4670

	MAIL ADDRESS:	
		STREET 1:		5 RADNOR CORPORATE CENTER SUITE 500
		STREET 2:		100 MATSONFORD RD
		CITY:			RADNOR
		STATE:			PA
		ZIP:			19087
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mrns-20210331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/17/2021 8:23:29 PM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: 8876a42c-9fc2-4e63-aeaf-5e1acb765d77 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:mrns="http://www.marinuspharma.com/20210331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" xs:nil="true" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" name="us-gaap:TreasuryStockValue" id="Hidden_FrwVqWPd5Uu639TYjhsx3g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" xs:nil="true" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" name="us-gaap:TreasuryStockValue" id="Hidden_k0sGbtc31ky9iG80YzL8RA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_i4ZJeDhk3U6qg2ej0yRhjA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_dow7_ZuMpUWqCMzjx0ZHwQ">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityCentralIndexKey" id="Tc_B53x9hAptUW-SvKVqd2NVQ_3_1">0001267813</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:CurrentFiscalYearEndDate" id="Tc_wS24HH6aL0Kwhm-hZxhDxQ_4_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:DocumentFiscalYearFocus" id="Tc_UUvPAA5sJ0mn0Zh-4h5xEQ_5_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_IM7Eag56DUGIxWP0DuZGVQ_6_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:AmendmentFlag" id="Tc_JzGgH3aovkC47l6TKzKU8w_7_1">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_zvqnfLCJd0yr4jXmjicT5Q">us-gaap:OtherAccruedLiabilitiesNoncurrent us-gaap:AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_mFAODsPqSk-Q7CVVsygbpQ">us-gaap:OtherAccruedLiabilitiesNoncurrent us-gaap:AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_CcYeHKS1dEGZIBACVsWKZw">4753</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_BdERH6GTDk-WwMAmTfEUMQ">4753</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw" contextRef="Duration_9_23_2020_To_9_23_2020_4pfvEsABsU28FwAbvP4CKg" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_pGDrPi0GAkW2ail2SFXw3w">0.25</ix:nonFraction><ix:nonNumeric contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_z1I9GUU03U6WTDF7U-xORg" name="mrns:DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" id="Hidden_6rtYHnKztUW0WBec3xybnQ">P6M</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mrns-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9qSklwBu70CQBbrRqgCIeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xe6FgdUkT0W6DZbRuNQ59g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_23_2020_To_9_23_2020_4pfvEsABsU28FwAbvP4CKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-23</xbrli:startDate><xbrli:endDate>2020-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p3HF39Ap80yUDNAvRPhqUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oJu87ySZZki8kiQ1GgZDcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q90XYQ7tOkisnJxjUpL-ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AxRkO1I5G0qDl6t4aKuHoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__1HOy6MZR0e8GBW9z_KEVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LVfSiRHgy0mWRf270n3lEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LMklHntNS0KTgOI-HIEIZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_38j9McOA-0-YH6InNJKJ4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YoVSkI9ULUWZpDKnuk0EFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_8LfUPpiv40evSUbKT82rhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_XPMAdE0OMUeOyqAqZ3qvag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sebYK2miu0aqZYM6o8RohQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrns:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_vfbrhNgDVUi6DlCWD3nLsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RYRdkpHKOUS-exHXDlAIug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_4wMl9Q4G70GOJY3bS-fs4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrns:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_Sj-IYJqIT0uvP3_uuR6sEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VGad9KiNbkCwtKgt7DZ1aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_CTJ2VL88jESgyvVb6KfD6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_njBmuTxXb0KulNqEpHrpQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zOQDZ8Ya_keC_MZKml4WdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bG_5QgjxIkC2qi039sgXpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_StockOptionAndIncentivePlan2005Member_sjKwPS8R-k2wWxUVOhk1vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:StockOptionAndIncentivePlan2005Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlanEmployeeMember_pk1X2Uuu6kuHPbfxMPJLKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlanEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_Tlqw9BGm20WqLo6p9EcJFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YOD3KDe7RkmYKbUKW8SRfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlanEmployeeMember_caVUlUeydkqE7PHUeTsG9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlanEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_gLlExmIpREOOfxJPC2-Pbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_WbOyI-9dVEWarpASvcUfqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_i4ZJeDhk3U6qg2ej0yRhjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BRnhyVEI0ESba0YijHvmHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_yYSr99WKYE6jflmONGtLZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrns:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_XPNC2p02pUyKefB5bvQ_xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrns:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrns:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrns:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uY0NqY9x4UOmsA4sPTj80w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GIw8jfZogk2-5MB_FX3uBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_9f43HPsrZUqXrvBNmnWl-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_ZwEUgE2a10mD4z6DCHCsrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CertificatesOfDepositMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z1HxUQ7enE6srbvlBfnnog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CertificatesOfDepositMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_57Xm1ecNsEuUhzUcp-ldRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_KbsB3GMfAUq42-N8CF5g_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_1yiPQ20dfUWNVt0Z6jH0tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_QQZsn1a07kGp7D1O83thbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheBMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_ZmO_zJI8K06Yju3bXZvlvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoansTranche2Member_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_WxLVUu7A2kuoA3YQnOT7vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoansTranche2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoansTranche1Member_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_OrcnVjZcjkCJd82NJIXdYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoansTranche1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_23_2020_OiMX-o5boE2EQwMEi2ZK0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_PlanNameAxis_mrns_StockOptionAndIncentivePlan2005Member_pY1EQZSCQUasDgjSyWC4ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:StockOptionAndIncentivePlan2005Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_GCzbaEQkcUGyXqr_QnLvtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_-5H7uHTQeUmpUP0b5XFP-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_EtowpBGbYUOlW68H-Qhr0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6x5DJ-CH0kaeJKGdgTq8DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ISpIebOIi0K7bmbED0LKSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gL2saeIEhkKPbHdqHSO8XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0gArs46GskGjg-CwXqnRlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-8-0nnBWpUmAFY7t2su3eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__S1TL6asNEie8J964p41pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IzM8ejDq1U-vXqJ7UOOeDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjNZhWbkFkS38HEN4C5ekA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_2cQC38nN50yIRWLWCjpsrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_FpMZWQoGrEyhGmLadR_5Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_aw6tpevnx0S7VX16wF9x-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_oVLJcKieMkeJ0tQmMG3asQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_JVIEoiUCiEixZFqFpl2TMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_8zaVZ-69uEiVQSid1i2tuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mJOVLW9KpUmbnUt7bOmsLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ixflgqi17U--7GUSGs7m5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_sxnFk15oLESa5jxtU2OmMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qtmIWYk-lEaiK7KXwRoNrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_fWJfXvsKtk6Kfv55TO39uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_AEmW4zZq7kqttYoG44orKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4XykMpFDvkyUJxaaGlZIDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_9G2E0G-1K0CaojyNjXJupA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nU2_qSegwUeO8XJe6mN6gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7Cd3y9g6skeNkAsc9FaMAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_NjRPlVBuoU-719KqeaSsww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrns:BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_z1I9GUU03U6WTDF7U-xORg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-11</xbrli:startDate><xbrli:endDate>2021-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_0C8_gqPMo0uWm48asEGVyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-11</xbrli:startDate><xbrli:endDate>2021-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-11</xbrli:startDate><xbrli:endDate>2021-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_PIGm1dm3nUqea624wnjONw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrns:BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lPrWUD3wcUerfah8Cn28qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrns:BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oMWaBvb6M0CZ9X6c2Oqqrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6LQBITHZ60WRlNBE8j_w_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_14_2021_nqLk6j5gAUKPkNMDBhI2ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001267813</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_vnw-gVYtlEWJf_vMJ-ObdA"><xbrli:measure>mrns:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:58.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:6pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_becc1f92_6ab8_4b79_8f2e_be8bfa3027f3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:DocumentType" id="Narr_qP2K_NFYKk2exwU_56yaZQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:DocumentQuarterlyReport" id="Narr_0FmRdi5Wh06sflP-FHFdgg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:DocumentPeriodEndDate" id="Narr_XVOXIQcdE0Sro70Es_f1iQ"><b style="font-size:7pt;font-weight:bold;">MARCH 31, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:DocumentTransitionReport" id="Narr_BJH3fxJElEOh45vLju-vvA"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:21.6pt;text-align:center;text-indent:-21.6pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">For the transition period from              to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">COMMISSION FILE NUMBER </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityFileNumber" id="Narr_yueqAxkBbEyrBHaW-MNKNg"><b style="font-size:7pt;font-weight:bold;">001-36576</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrns-20210331x10q004.jpg" alt="Graphic" style="display:inline-block;height:58.3pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:245.55pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityRegistrantName" id="Narr_ODMo6ovKrEifALrCnOxUDA"><b style="font-size:9pt;font-weight:bold;">MARINUS PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_288f444c_a779_46e3_95cf_244a6b1b4ad5"></a><a id="Tc_Q9QZ8R7L0EmVvOqJEVVITg_2_0"></a><a id="Tc_OTmOeCI-n0KMe3oreR8arw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_QSWaTUEBA0Kt_xJ7j8JWYw_1_0"><b style="font-size:7pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityTaxIdentificationNumber" id="Tc_eDAR9ysKnkmrP05EJATmFw_1_2"><b style="font-size:7pt;font-weight:bold;">20-0198082</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of<br />incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer<br />Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityAddressAddressLine1" id="Narr_v3WzqqSTG02UZqZjEfIQrA"><b style="font-size:7pt;font-weight:bold;">5 Radnor Corporate Center, Suite 500</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityAddressAddressLine2" id="Narr_Vbjmpg8pqEifp1nvx_i6xw"><b style="font-size:7pt;font-weight:bold;">100 Matsonford Rd</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityAddressCityOrTown" id="Narr_ziGiDqa9lkCtgpEoE-aEvw"><b style="font-size:7pt;font-weight:bold;">Radnor</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityAddressStateOrProvince" id="Narr_nZv3E8yUdkiCYBaLFuLeug"><b style="font-size:7pt;font-weight:bold;">PA</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityAddressPostalZipCode" id="Narr_2k-r9KhfsEW3FhEwqeOL4g"><b style="font-size:7pt;font-weight:bold;">19087</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of registrant&#8217;s principal executive offices, including zip code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:CityAreaCode" id="Narr_IXRuQpm5TU-1fPwfcGLtsA"><b style="font-size:7pt;font-weight:bold;">484</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:LocalPhoneNumber" id="Narr_Tul5p9PzOU2sKZSvdwQIdw"><b style="font-size:7pt;font-weight:bold;">801-4670</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:8pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_92e932f9_0eb2_40e5_a4c5_6cd558b61627"></a><a id="Tc_CJeU2FpfzEulFl_fifbiLw_1_0"></a><a id="Tc_LEAg2iSjlkeFITc0weSqig_1_2"></a><a id="Tc_ipWnzyksqE28Phb8mpBMnQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.1%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:29.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.77%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:Security12bTitle" id="Tc_vuOsnsW37Eu3fWmzNp6vbg_2_0"><span style="font-size:7pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:TradingSymbol" id="Tc_bcxKFJYFuESGnV4Xj6rNHw_2_2"><span style="font-size:7pt;">MRNS</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:SecurityExchangeName" id="Tc_jeM31ZsZgEqNxMeyT7AU1g_2_4"><span style="font-size:7pt;">Nasdaq Global Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. &#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityCurrentReportingStatus" id="Narr_DJVNHl1sTECk3nNdZlHnBA"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b><span style="font-size:7pt;"> No.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;</span><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b><span style="font-size:7pt;">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityInteractiveDataCurrent" id="Narr_uarIQYuV906jduao2EWdqQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b><span style="font-size:7pt;"> &#160;No.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:24.5pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Large&#160;accelerated&#160;filer <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:4.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b><span style="white-space:pre-wrap;">  </span></p></td></tr><tr><td style="vertical-align:top;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityFilerCategory" id="Narr_OkimuC54j0y6uPQOGZ0LJQ"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;white-space:pre-wrap;">   </span><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:4.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntitySmallBusiness" id="Narr_jxJZNUUNYk6yR3cn9g2EBw"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityEmergingGrowthCompany" id="Narr_r4AK3f8ERUCKZwV5D1KYkQ"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:24.5pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="dei:EntityShellCompany" id="Narr_VQwTLkAUI0-HJ7Hbaq5hkQ"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b></ix:nonNumeric><span style="font-size:7pt;">Yes&#160;</span><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b><span style="font-size:7pt;">&#160;No.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, as of May 14, 2021 was: <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_5_14_2021_nqLk6j5gAUKPkNMDBhI2ug" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr__Fky5Nksn0if7R-t6K8kAg">36,633,490</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:6pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_971ef481_2307_4b14_b6ac_cefdf391dab2"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risk Factor Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following summarizes the principal factors that make an investment in us speculative or risky, all of which are more fully described in the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the material risks facing our business.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have not generated any revenue to date from product sales. We may never achieve or sustain profitability, which could depress the market price of our common stock, and could cause you to lose all or a part of your investment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We will require additional capital to fund our operations and if we fail to obtain necessary financing, we may be unable to complete the development and commercialization of ganaxolone.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our failure to comply with the covenants or other terms of the Credit Agreement, including as a result of events beyond our control, could result in a default under the Credit Agreement that could materially and adversely affect the ongoing viability of our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our Credit Agreement contains restrictions that limit our flexibility in operating our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Raising additional capital could dilute our stockholders, restrict our operations or require us to relinquish rights to ganaxolone or any other future product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We intend to expend our limited resources to pursue our sole clinical stage product candidate, ganaxolone, and may fail to capitalize on other technologies or product candidates that may be more profitable or for which there may be a greater likelihood of success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Clinical Development and Regulatory Approval of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our future success is dependent on the successful clinical development, regulatory approval and commercialization of ganaxolone, which is being studied in four clinical trials and will require significant capital resources and years of additional clinical development effort.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We plan to submit an NDA for ganaxolone for the treatment of CDD in mid-2021 and we may not receive regulatory approval of our application.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, ganaxolone may not have favorable results in later clinical trials or receive regulatory approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Ganaxolone may cause undesirable side effects or have other properties that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any marketing approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The therapeutic efficacy and safety of ganaxolone are unproven, and we may not be able to successfully develop and commercialize ganaxolone in the future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Clinical development of product candidates involves a lengthy and expensive process with an uncertain outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Even if ganaxolone receives regulatory approval, we will still face regulatory difficulties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We may not be able to obtain orphan drug exclusivity for ganaxolone, which could limit the potential profitability of ganaxolone.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Even though we have received&#160;RPD Designation for ganaxolone for the treatment of CDD, we may not receive a&#160;rare&#160;pediatric&#160;disease&#160;priority review voucher.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Failure to obtain regulatory approval in international jurisdictions would prevent ganaxolone from being marketed in these jurisdictions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to the Commercialization of Our Product</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our commercial success depends upon attaining significant market access and acceptance of ganaxolone, if approved, among physicians, patients, government and private payers and others in the medical community and attaining sufficient reimbursement for ganaxolone.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell ganaxolone, we may be unable to generate any revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Even if we are able to commercialize ganaxolone, it may not receive coverage and adequate reimbursement from third-party payers, which could harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If the market opportunities for ganaxolone are smaller than we believe they are, our results of operations may be adversely affected and our business may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their duties in compliance with contractual and/or regulatory requirements or meet expected deadlines, our development plans may be adversely affected and we may not be able to obtain regulatory approval for or commercialize ganaxolone.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our experience manufacturing ganaxolone is limited to the needs of our preclinical studies and clinical trials. We have no experience manufacturing ganaxolone on a commercial scale and have no manufacturing facility. We are dependent on third-party manufacturers for the manufacture of ganaxolone as well as on third parties for our supply chain, and if we experience problems with any such third parties, the manufacturing of ganaxolone could be delayed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Government funding for certain of our programs adds uncertainty to our research efforts with respect to those programs and may impose requirements that increase the costs of commercialization and production of product candidates developed under those government-funded programs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Compliance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize ganaxolone and affect the prices we may obtain.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product candidates, our competitive position could be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third parties, such as Ovid Therapeutics, Inc., may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We may not be able to protect our intellectual property rights throughout the world.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on government funding for certain of our research and development activities and we may develop intellectual property through such activities and therefore may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S. based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to our Business Operations and Ownership of Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:54pt;text-indent:-54pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:13.5pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>The COVID-19 pandemic could adversely affect our business and our ability to conduct and complete clinical trials.</div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The market price of our stock has been, and may continue to be, highly volatile, and you could lose all or part of your investment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Insiders have substantial influence over us and could delay or prevent a change in corporate control.</span></td></tr></table><a id="_2a9e1077_4782_447f_99d5_36369045b5a3"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC.</b><b style="font-weight:bold;"> AND SUBSIDIARY</b></p><a id="Toc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX TO FORM 10-Q</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE QUARTER ENDED MARCH 31, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:96.46%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><a href="#PARTI_263591"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1FinancialStatements_723735"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1FinancialStatements_723735"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Financial Statements (unaudited)</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#BALANCESHEETS_267722"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_459660"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_596702"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#EQUITY_134594"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Stockholders&#8217; Equity for the three months ended March 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#a1Description_464092"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item2ManagementsDiscussion_251995"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item2ManagementsDiscussion_251995"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosure About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_322196"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_322196"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:96.46%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><a href="#PARTII_783516"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1LegalProceedings_405261"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1LegalProceedings_405261"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1ARiskFactors_482494"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1ARiskFactors_482494"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofUnregisteredSecu"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofUnregisteredSecu"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item3DefaultsuponSeniorSecurities_975187"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item3DefaultsuponSeniorSecurities_975187"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_306061"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_306061"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item5OtherInformation_942864"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item5OtherInformation_942864"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item6Exhibits_280778"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item6Exhibits_280778"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.2%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#SIGNATURES_571022"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:3.53%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;Marinus,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Marinus Pharmaceuticals, Inc. and its wholly owned subsidiary, Marinus Pharmaceuticals Emerald Limited, an Ireland company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5e90a5db_7f3c_4ada_9cef_d066183411d9"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_263591"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="Item1FinancialStatements_723735"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1. Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_ab78c53b_0a97_4070_90be_86a56242d392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="BALANCESHEETS_267722"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9a5db48a_5467_4051_aac1_47ad6733d1cb"></a><a id="Tc_bgP7n9SFz0Wp83dlJ7nhew_2_2"></a><a id="Tc_mGqEd1FDJ0a-ZrsLjY2T-A_2_5"></a><a id="Tc_fldofxjI_0mjjan5oUGmTQ_3_2"></a><a id="Tc_hc19C8EPME-JuJizI_Idkg_3_5"></a><a id="Tc_CYt6elJ8TEytw_UBEM9qKw_5_0"></a><a id="Tc_2bvABBnp_0ScpDHielnEfA_6_0"></a><a id="Tc_B-hbWAPcCEq5S7cN0G-YwQ_7_0"></a><a id="Tc_faFWJJc_8Ea1zkMyZgbYdQ_7_2"></a><a id="Tc_l-1VJbp8U06o5f7qGE19MQ_7_5"></a><a id="Tc_vkhwqPuqHUmiWt6bJUI_aw_8_0"></a><a id="Tc_gQv34dV4jE2pXtuTbUEhCQ_8_3"></a><a id="Tc_QcndtisRy0S__DIG4JzUmg_9_0"></a><a id="Tc_82iNqNMtJk-C8BRL9sBRUQ_10_0"></a><a id="Tc_gIZMiXxIy0m_QJ305b2SXQ_11_0"></a><a id="Tc_HwpiMGFM-Uqh5sbgxV9-_Q_12_0"></a><a id="Tc_dUIDQYaNPEqnVlrQ-O_5fw_13_0"></a><a id="Tc_I2d2wSDtokOC0u28hJw9JQ_14_0"></a><a id="Tc_f0fp8FdHeEqND6v2m9WRKg_14_2"></a><a id="Tc__JYqadRTb0ad0F_--WOa8w_14_5"></a><a id="Tc_B3CWP0pUd0i-OGe1b3Ru0A_15_0"></a><a id="Tc_1NpnHbqe7ky_af3YyohyLA_16_0"></a><a id="Tc_SY-gvNj8aEyieYhcsrl1-A_17_0"></a><a id="Tc_fRWX568tW0uY4kPmlp4e9Q_17_2"></a><a id="Tc_mi0eVd5DMk2FXKuVSElryA_17_5"></a><a id="Tc_Zj6Ja0B8pEe4DkOlXAHJcw_18_0"></a><a id="Tc_gl0M173LZkKnxTlO_kLPRw_19_0"></a><a id="Tc_j5erFQB6_UCrWlmlR8uE-w_20_0"></a><a id="Tc_ropYSBZTW02kKRff6H-ArQ_21_0"></a><a id="Tc_bFrLk2MiEEOOLORyaajEJw_22_0"></a><a id="Tc_OfCcfeLOKUmRItUFD2hqQA_23_0"></a><a id="_5d20f372_b15f_4d38_8b42_08894a8642a6"></a><a id="_5d20f372_b15f_4d38_8b42_08894a8642a6_2"></a><a id="_5d20f372_b15f_4d38_8b42_08894a8642a6_3"></a><a id="Tc_Bl6MUJIA_0iWDq0Am5Dd9g_24_0"></a><a id="Tc_2h6zY-rpF0G_tF2U_05Wug_25_0"></a><a id="Tc_Sj0lC90zGkmp3ocxHDlZMw_26_0"></a><a id="Tc_QOkbgJib7E6j5BDpfse0dQ_27_0"></a><a id="Tc_3Q9jgppdG0yDkrPyGcJJsw_28_0"></a><a id="Tc_RZVcnD2ImUeEkTJp6eYvhg_29_0"></a><a id="Tc_4aEbxcDx7kedmQOtVOgBqQ_29_2"></a><a id="Tc_3uoS317BekGvX2g_lICfPw_29_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_bCFr77N0U0CPwO_WFOjItQ_7_3">123,472</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_FrGFdpjWdkOc_ihWNJzxHg_7_6">138,509</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_LL8pEJfLGkaROhJAS9aiWQ_8_6">1,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal contract revenue receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="Tc_VMprOfBg50CytytqJLcSOg_9_3">2,650</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="Tc_dj5FtzhDoEaUqibpEN7X6g_9_6">1,646</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_9xliDVjvYUGOG5Rlf1awjA_10_3">3,676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_75aaw6oSNkCKWimYrw_Snw_10_6">4,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_8zobtrHcAk64-y6ceBs-UA_11_3">129,798</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_ub7rwYtKW06xOpPQRBGvww_11_6">146,267</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_mTlx4KtI5Ua1Z_n0wSOv8g_12_3">1,894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_a2tFgIdE1k6rD2p0Owrxmg_12_6">1,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_UM-trd681UuS8JqW3puopw_13_3">2,167</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_ihe9QBgwAE6X_fbqcIl4VQ_13_6">2,250</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_oKds0bD3TkKOHqYC3KjeWw_14_3">133,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_k_XCsERZX0Gq9i2GgfDXYA_14_6">150,462</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_ErPcH8bRgkKhdpq_naIHJw_17_3">5,167</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_VvD90Yebzk6HtZQYRCqszQ_17_6">2,211</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_9DTjM-hxMUq1iMWP-uXU6Q_18_3">10,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_j2Am4pMapkS-mjc-gGxayQ_18_6">8,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_i4xgUz0k0Ea5BgZUGJDiMw_19_3">16,121</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Gu2jW3Bn90-dGtq0LaX7ew_19_6">10,729</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="3" id="Tc_zw7XnSbMCUOcrehZ841GwA_20_3">2,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="3" id="Tc_BTKJqIoC00C9rJruBXmvVw_20_6">2,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_euA4bAq_PkeTQmQr6K_Aow_21_3">18,525</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_l4MVI1w_ZEejumf5Lp93Xg_21_6">13,263</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Series A convertible preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_RbL98xfqSkCpj-YjfgyQAw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_cMXVx0mJeE6VjLi8apRMLw">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_K_xJ5I4UZECsX77shOyVHw"><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_vgc1JamcO0CDtOWhAb3X-g">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_lQfB-cwd4UCm6k8arDPqWg"><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_BdNNYuY4WkqIskMr0KR7gQ">4,753</ix:nonFraction></ix:nonFraction> shares issued&#160;and outstanding at March 31, 2021 and December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_iZtBQrxVLUSEYVfvv1NhNg_23_3">4,469</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_mQQnpmV150SlKnPnI_E8kg_23_6">4,469</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_oFB1EpncoUiNhzs4szuCgw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_aBT-Aq7BcU-ZvIEnQKL-bA">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_jTsY0EJXhkul8IRCmpMc-A"><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_1fNA0fk8VEi9w9S4nTUiZw">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_m9JLJkRB2UCvEg7E3qPrfg">36,640,797</ix:nonFraction> issued and <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_ybwR8D92H0KXtm39WFQIAg">36,633,490</ix:nonFraction> outstanding at March 31, 2021 and <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_PMgrC7zv4k22cgA1JXEV9g">36,585,767</ix:nonFraction> issued and <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_LmZ8tyIvnEuDmcNyHUVoyg">36,578,400</ix:nonFraction> outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc__hrjIsdBxkWv6oP01xGptw_24_3">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_sS55s-LMFUCM1s9DXQnUCQ_24_6">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_nFoQ2XDHYUGBz6CupFTzeA_25_3">449,898</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_H2tOmowMbEOFwuD-lNdzZA_25_6">444,622</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Treasury stock at cost, <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="Narr_yeibdIGBvUeB9aXtUXmLYw"><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="Narr_i3wzAMg8h0eYHa-3aFI9xw">7,307</ix:nonFraction></ix:nonFraction> shares at March 31, 2021 and December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FrwVqWPd5Uu639TYjhsx3g;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_k0sGbtc31ky9iG80YzL8RA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_KQ9Q86mL8kCGZ3eREN2TCQ_27_3">339,070</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_0CF39gn3Okq3LDz7x5quaQ_27_6">311,929</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Xv8eNnpwpkSW2e2HOE8VnA_28_3">115,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fVTt3u0LFESvSulCRuZYtw_28_6">137,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_R5F4Pw9lTUe9EaR8tT86JQ_29_3">133,859</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ih42WeCUzUqnAaAMcY1bwg_29_6">150,462</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2e43d0b6_f27b_4233_9def_2af47550b965"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="STATEMENTSOFOPERATIONS_459660"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND </b><b style="font-weight:bold;">COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_adb9187d_97c6_4105_87b8_2abcee98ec84"></a><a id="Tc_okkJZa85X0KY3R4RwHwqfA_1_2"></a><a id="Tc_QSTwXRU5AUmiJ44QKBbP3g_2_2"></a><a id="Tc_2kzN24PZ5Ee20WQVieTGow_2_5"></a><a id="Tc_oiKhWljcWkiE7_cyfOJzcA_4_0"></a><a id="Tc_wJOfGxkV2EepQ_NmZpZANw_4_2"></a><a id="Tc_4JShMxr-QUW_8ao4azDVKA_4_5"></a><a id="Tc_AGcyhr9A9ESRYDzyQ_aY7Q_4_6"></a><a id="Tc__erHVxrONUyLGk4kqMk7zA_5_0"></a><a id="Tc_vs4I6NwMT0m4KH4hBZmvMQ_6_0"></a><a id="Tc_O1mZht13ckGQ33AztSHuCw_6_2"></a><a id="Tc_Pm8vxz0UQEyXWmcMaHB9mg_6_5"></a><a id="Tc_YBifGjbR1Ee-kmsG1hApBw_7_0"></a><a id="Tc_qkVKdifdPEadiTPp-_v8nQ_8_0"></a><a id="Tc_CpxZv_RyrUeqGJP1lJ-3_Q_9_0"></a><a id="Tc_C8Pn16VCSkuWA5P7KT7Btw_10_0"></a><a id="Tc_Kp7LwfEUM0a1bJR-e2KuNA_11_0"></a><a id="Tc_BQE13D5F0E-Z4Q1jRn-5kw_11_2"></a><a id="Tc_YmhI8wTANUC6WS-SqkudQw_11_5"></a><a id="Tc_e69WTFCTVE2Ig48eCfzsHw_12_0"></a><a id="Tc_bUqfKGaKB0muefgB4Wxr9w_12_3"></a><a id="Tc_BayLSrDEL0STFgUImD5O-g_13_0"></a><a id="Tc_lfRTb8QFhkeD6Y0lLoZnsQ_13_2"></a><a id="Tc_W3wdoi4_KkCTNoi0KBrusA_13_5"></a><a id="Tc_ZLJ47E-VCkeny7ZtgEaeUg_14_0"></a><a id="Tc_ldY_0A2JBUyY0FEHpJQP-g_15_0"></a><a id="Tc_k_M7PFFGpU24G5abQWhltA_15_2"></a><a id="Tc_GLa7Mn_ge0OTjokt_I05eQ_15_5"></a><a id="Tc_1a9FwtjA6EKkZ3V-RvGhAw_16_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal contract revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_CNux-Uwxfky68MOYpK6fIw_4_3">1,806</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_0ZXpxWAVHkS1p2eo9BeMsg_6_3">18,591</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_FtBS4GMX1USZdIIreQ-KAg_6_6">15,004</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_YrSnmvwcrU6-ig7QW5PrxA_7_3">10,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Fuak0ENeBUyKZhu9ekfo-Q_7_6">3,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_aLPZpfa7cUS61c6BA_OlWQ_8_3">27,161</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_-xwpQncX3EOjSmsLNocwjA_8_6">18,854</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_8W-ah3Q_EkmT1ey2Q2NL7A_9_3">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_XO1QPRKx8U-4t2WfWfoudA_9_6">222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_SeXjiwiQYUCZfK7HGvm1ug_10_3">4</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_KuKo6XqcQkWH7edIW0aMlQ_10_6">40</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VPfQwRh2fEOi11PW2fZv4Q_11_3">27,141</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JMGrplYhr0e8kxu6ZqBgKw_11_6">18,672</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deemed dividends on convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityDividendsAdjustment" scale="3" id="Tc_F1_M7FbCDk-jqzG_libBZQ_12_6">8,880</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss and comprehensive loss applicable to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc__Te9__wMqEWe__50cDIAtg_13_3">27,141</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_oDuiMrCOW06IkmLVe3TIsw_13_6">27,552</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share information:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss per share of common stock&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_FAPXelY2fUSQqGusWT6kOQ_15_3">0.74</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_eo-ldEjdj0e07T5wqBKe-w_15_6">1.27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Basic and diluted weighted average shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_xaFc8nlc-EWioRVIAxwWlA_16_3">36,599,701</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_fCf7ahiQ0kCbr0I4Lcs-xA_16_6">21,665,461</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7a88950d_e41f_49a1_ae83_d804fcd4776a"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="STATEMENTSOFCASHFLOWS_596702"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_d3e09f89_e5b8_4048_ab27_732d1e64ae47"></a><a id="Tc_3Uaw2LBx50Giw5oZ1BC6lw_1_2"></a><a id="Tc_SZegBro6skuiPo-7f1kylg_2_2"></a><a id="Tc_L9v9dhn4zUarjj1meHas8g_2_5"></a><a id="Tc_Yyc7mjnUcEWS-CF4dfPZDA_4_0"></a><a id="Tc_c-OuMMHlVE2JZH8CXLsqEw_5_0"></a><a id="Tc_XoEBbL5-_kSq3__A3NqoXA_5_2"></a><a id="Tc_bBCkFAc2zUO0K9xy3iQsHg_5_5"></a><a id="Tc_m7z0OxxZBE-sB6ROncQrdg_6_0"></a><a id="Tc_5kV3WrqTDk6PNjTeLeg7Cw_7_0"></a><a id="Tc_x12sBYgmgEebfleJKkiY_w_8_0"></a><a id="Tc_6bNcCJggXUODTPFN1K5DSA_9_0"></a><a id="Tc_6GaUHbDrKEqG2_bKUOSlgA_10_0"></a><a id="Tc_kgt7HLkI-06hYhIAm4ol7w_11_0"></a><a id="Tc_rSpOBBiEeEuqYnNGjCKPEA_11_3"></a><a id="Tc_4KJp9mQx0EW7Twtk_9_qGg_12_0"></a><a id="Tc_j2pfIz6rA0-T5cMuz2wXlw_13_0"></a><a id="Tc_jRQ3-mcDiUyQlNQGSLWx_Q_14_0"></a><a id="Tc_EISFVHcB6U2UYb77hPq4HQ_15_0"></a><a id="Tc_oda3TgEKHkCjRfC6f-1yTQ_16_0"></a><a id="Tc_5CKaL3u-EUa2ovl9g6FXVg_17_0"></a><a id="Tc_iX4R4eq58UitXMqwh2_82Q_18_0"></a><a id="Tc_5uyH9C7Svke8lxKIIx4ZYQ_18_3"></a><a id="Tc_oaDmNUsmKUW87sNERnD5tA_19_0"></a><a id="Tc_seBIqaC9H0Wm4A89fmMfVg_19_6"></a><a id="Tc_Dp3uG1it-UqI16v0-29eJQ_20_0"></a><a id="Tc_ZXNHaq54p0-KydQX2N1Chg_21_0"></a><a id="Tc_UfhOLCBxT0ynI8TmGG_NgA_22_0"></a><a id="Tc_PzpvI4TZqEeigmyMSaK58g_23_0"></a><a id="Tc_MTLXJt6c_ka-8H2YNcqOCw_24_0"></a><a id="Tc_GjYlOxGQVUe2qoPidvHRCQ_25_0"></a><a id="Tc_kGarAwBXMUyvgkc7NCST7g_26_0"></a><a id="Tc_lFY-k5_sdUm4xw7_4Djicg_27_0"></a><a id="Tc_ld0gNTDiSkexNrlkKPjTgw_28_0"></a><a id="Tc_d6ka4ksDYU62znmpaVI9ig_28_2"></a><a id="Tc_TUk-_SOVjkq0MHmdsZM7aA_28_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_m4oIbA3acEq7ihnt1yGIaw_5_3">27,141</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_8pqeQbMaaU-j1QM_oU8R6Q_5_6">18,672</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_8x3JuqKSiUyn6xAELaAmBg_7_3">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_c3Q9ZYOL-0KiEYmjygVMqg_7_6">84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Dwce8ZH8ZU2LlsuPUk6T4g_8_3">5,035</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ZM94s1ar6kO1NZ9UXmGUog_8_6">1,876</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Noncash lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="mrns:NonCashOperatingLeaseExpenseOperatingActivities" scale="3" id="Tc_GN0IU57MvEWCwW4eg_tCEg_9_3">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="mrns:NonCashOperatingLeaseExpenseOperatingActivities" scale="3" id="Tc_RqnEeOzJRk2gMCIxy5Remw_9_6">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Noncash lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="mrns:InterestExpenseIncomeOnLeaseLiabilities" scale="3" id="Tc_IJ_wBDfCZkyTMo5oVdcXBQ_10_3">82</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="mrns:InterestExpenseIncomeOnLeaseLiabilities" scale="3" id="Tc_Jk3lnALohk674sPyCwnEMg_10_6">95</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of discount on investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" sign="-" scale="3" id="Tc_Tz4Xx8p7Bk6owdP4wlueQQ_11_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other current and non-current assets and federal contract revenue receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_LKhHiLYrvEq4U5EKewbG6A_13_3">366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_bIzR55ml7Uq50jnw2SQ3ag_13_6">258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable, accrued expenses and other long term-liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_PmBfOcwSQUW3eKEk7qQRaQ_14_3">5,325</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_hcz2u2A5eUOYMZZzbWbgJQ_14_6">2,259</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_BbweGBsfjU2QTZ7NnQRTYQ_15_3">16,175</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ppXal1VfL0G0LjKnKI9kog_15_6">14,037</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturities of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="Tc_Q6UzVFOheUKk_E-ObBB7sQ_17_3">1,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="Tc_-BioWM3nf0mvK8jX16ytkw_17_6">1,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of short-term investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="Tc_lptuMEaWmUyUYWmp-Yy96w_18_6">8,433</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deposit on property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="mrns:PaymentsForDepositAndPropertyAndEquipment" scale="3" id="Tc_gkcsKqH7I0yXzxcM4oQ5YA_19_3">404</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="Tc_hc2Yiug5TEGdaVfh3OC4wg_20_3">28</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="Tc_LFR652UUokKmzoao2Chd0Q_20_6">1</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc__7Bbajc8bE66_BNzY2TA9A_21_3">1,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_xZIBFrNgOkuPL8SN-Pg52w_21_6">6,697</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_Xgtld55OZUWgvJabFE3Ojg_23_3">244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_HG3HVpX53Eu8jaCo3CJKUw_23_6">312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_z-kaJCht9ku8_sbLecHHWw_24_3">148</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_JlY5dYrit0C7jKLLpT8e9w_24_6">195</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_gKLRT-CERk62__LJeETrlw_25_3">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_lIbEAnXH6kC088Rjtr7RBg_25_6">117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_cRS7h6wERk2s6JKSMgdWyQ_26_3">15,037</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_XlCwApaLEkiBzN81YRZFnA_26_6">20,617</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents&#8212;beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_JUFlKf3dCkeQN-cqYyL9EQ_27_3">138,509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2019_EtowpBGbYUOlW68H-Qhr0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_wCCHoPcq-0iMzGJdOymiKQ_27_6">90,943</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents&#8212;end of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_vwfb7rJGaUe8_1pl0OioJA_28_3">123,472</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2020_-5H7uHTQeUmpUP0b5XFP-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_SFzjmIZm0EiX4rCP6RGBpQ_28_6">70,326</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_d89a216e_b891_4a9a_95b3_3361fc4e72f7"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="EQUITY_134594"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share amounts) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_d0d1cb7f_6a23_40c0_b24a_312422fb9cad"></a><a id="Tc_2CNfI0jpGkaBM0n0utuXjA_1_20"></a><a id="Tc_dgJNtgcNo0KffPyTgjxxmw_2_2"></a><a id="Tc_m8hWyRLlGUSmQG2pEbISnw_2_12"></a><a id="Tc_mxD8OfhlvEKtO-6PtMW5oQ_2_20"></a><a id="Tc_HQpFrCosB0OwVR99O5V1fg_2_26"></a><a id="Tc_2da9iEcE9kq5O-YgWLKWvQ_3_2"></a><a id="Tc_q5dPZMg5P0CYJOzS1B95PA_3_7"></a><a id="Tc_SW0UkqGw1EKrRF0AyYnS6g_3_12"></a><a id="Tc_DVzVOQEjkkK6trqI8VAvdw_3_15"></a><a id="Tc_64XZs7d2Qk64axGrif7dwg_3_20"></a><a id="Tc_ZQQo6s0gSUWr8ttFSOLvDA_3_23"></a><a id="Tc_b0ZLZbXzrUeJDkKoaIfi_g_3_26"></a><a id="Tc_1u_LYOBnT0SL6mRSqFhAeg_4_2"></a><a id="Tc_XQ8sZ_6Db0qb360vdXnyIw_4_4"></a><a id="Tc_eWlThFVtNkijvqRIKZ1EYw_4_7"></a><a id="Tc_ayUaUniSrU2M73_LRLqkvA_4_9"></a><a id="Tc_ZhmKYLBwDUewiHnz82EPjQ_4_12"></a><a id="Tc_MswOeKjPKky58p2Q6aa4RA_4_15"></a><a id="Tc_-_C8sEabEEyygfVeqIWqBQ_4_17"></a><a id="Tc_LcB0O0RZg0GMzE_AzApoww_4_20"></a><a id="Tc_HVwZ3EyJHUSmiRbIS7cCYw_4_23"></a><a id="Tc_3Fdf4jnvz0mAFo1a_HUMKg_4_26"></a><a id="Tc_K_ZiuJqeTUOAxAFTiwYNNA_5_0"></a><a id="Tc_FOPq2wsPRUylkEDBx-lLiw_5_2"></a><a id="Tc_NPCzTeNAo0y6uMurjI9uRg_5_4"></a><a id="Tc_Y94OeHYhBkiNcX86EU01sw_5_5"></a><a id="Tc_U16ZzduiJ0KPtBWEWI9FvQ_5_9"></a><a id="Tc_x7nMoTfC80WWOg--Zl5-Qw_5_12"></a><a id="Tc_-H87GSwPJk6f-CABE5MA3g_5_17"></a><a id="Tc_CPjP4FJObEqP9cBLBD97DA_5_18"></a><a id="Tc_Sd8FfC53hkyD3-Y1I7jwdQ_5_20"></a><a id="Tc_bg8LeB8oUUC453l1qzafqQ_5_21"></a><a id="Tc_Qbiuhv4BhEW39LBIM1LrnA_5_23"></a><a id="Tc_zZwgx7QPBkOTzN_BXs_G9w_5_26"></a><a id="Tc_zbbULgtolUyjCsg-jDQNEQ_6_0"></a><a id="Tc_hRASAxzmlkyQ0wVYhpcdfw_7_0"></a><a id="Tc_9wQiO0uxHUqHB-aF06Bb0g_8_0"></a><a id="Tc_Sk5WC3Z8VkmQ62hS3pXLrg_8_27"></a><a id="Tc_xTvT5KJGk0qaPp97r_joOQ_9_0"></a><a id="Tc_j0tQlbIt60-DUoAjrUQ9cg_10_0"></a><a id="Tc_2ZINGVTYkk2oQNH4yE3EiQ_10_27"></a><a id="Tc_0TyFZr2br0SPovGNavmYOA_11_0"></a><a id="Tc_vi_XlGkO602jSgbbn8Yomw_12_0"></a><a id="Tc_D1e__nhAu0igrZTDZetLnA_12_2"></a><a id="Tc___Yb4iXDgEOfsoBiQLMgAA_12_5"></a><a id="Tc_MgCy7YRtY0Gv_W0pnfBY6g_12_18"></a><a id="Tc_sEztY33gf06j9g9imbi2Dg_14_0"></a><a id="Tc_gigaWGWgZEepCSKLhmHTfQ_14_4"></a><a id="Tc_BLToxIODn0Wxyn-tYhcPMQ_14_9"></a><a id="Tc_9VcL2rLYY0KBMYvbaipFSA_14_12"></a><a id="Tc_545pVlem_0mkmI-BQrjjSw_14_17"></a><a id="Tc_e4mz2S1hEESbx-BBUkOFdg_14_18"></a><a id="Tc_6G5oZMcEWE6HZLuF0ehTmQ_14_20"></a><a id="Tc_Nlm7HgWnGUa0yU01sxwisQ_14_21"></a><a id="Tc_M-LvUcP0cE6ssnJ2Y1QRDA_14_23"></a><a id="Tc_6-dkWxFl_0GA5_EMM9a02A_14_26"></a><a id="Tc_ot-3YocQUUuwSr_r7dL8Sg_15_0"></a><a id="Tc_PaDbU4GPukGEsVUu8atsRQ_16_0"></a><a id="Tc_Y0jgbRVfi0qeV4J-X33maA_17_0"></a><a id="Tc_ATbyW7eYDky9EW1Le_xCvg_18_0"></a><a id="Tc__xPcbCtUfE2ye4z6zyJGng_18_7"></a><a id="Tc_W1GbhiapEEOb2wQ7zHsQyw_18_10"></a><a id="Tc_hvrN1FG4QUWPNKe1QwfXUg_18_13"></a><a id="Tc_gLCjsj--rEeM7MiY9EveJw_18_15"></a><a id="Tc_WKC4wVqqAkeahWeH9bgAew_18_18"></a><a id="Tc_AHqJ_oKS3E6Q6Dvc8vJkmg_18_21"></a><a id="Tc_yibFqHimTU6gp2GZ7x2bgQ_19_0"></a><a id="Tc_XgHbrAixF0iJea5ptHkzHQ_19_4"></a><a id="Tc_Gnk4hXOptESBmswDUWclxQ_19_9"></a><a id="Tc_w8ZMt9EDNUyIYO2DCTU2zQ_19_12"></a><a id="Tc_efJ-ifZ5rUGufK7TaPmbYQ_19_17"></a><a id="Tc_KyvJGNfVtE2-i9M37CRD2A_19_18"></a><a id="Tc_okk7jJwTiE6nzQ3HdyMrzw_19_20"></a><a id="Tc_ou30sfCDGUy63_fKeL-wvQ_19_21"></a><a id="Tc_vfTY3peHB0iR6jcyOsDc6A_19_23"></a><a id="Tc_26PlTch7_Ueg5ZHSDLpnDQ_19_26"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.21042633%;padding-left:0pt;padding-right:0pt;width:100.42%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible&#160;Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Treasury&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bG_5QgjxIkC2qi039sgXpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_dF3crfRJeUa-Ct7aFH-_Hg_5_7">21,625,088</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bG_5QgjxIkC2qi039sgXpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8tuJyqPTHkOD973ZeX-K8A_5_10">22</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YoVSkI9ULUWZpDKnuk0EFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_v_aafKq3DEKaVwEi3-0Kdw_5_13">295,056</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zOQDZ8Ya_keC_MZKml4WdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_wIJncaDoM0GnjAM1e4YSLA_5_15">7,307</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_38j9McOA-0-YH6InNJKJ4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_s78IAdrnNkiR9EHVmu-4LA_5_24">235,574</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2019_EtowpBGbYUOlW68H-Qhr0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_b6szLHUVDk275_bgvfwABg_5_27">59,569</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-Based Compensation Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6LQBITHZ60WRlNBE8j_w_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_E8m2N96aN0WXIrSUJG_T1A_6_13">1,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_b3GkF-N1IUOmf2sDD1YHUA_6_27">1,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xe6FgdUkT0W6DZbRuNQ59g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_DVIsCMLFBUagDoikwFKbDw_7_7">59,978</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6LQBITHZ60WRlNBE8j_w_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_zMdGPP96AUGjGckdVgagEA_7_13">312</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_KucI-BbCC0yhcFGLPtFOJQ_7_27">312</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xe6FgdUkT0W6DZbRuNQ59g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="Tc_VA2vfrK3Wk23lbjvaxp78A_8_7">5,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Unrealized gain on investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uY0NqY9x4UOmsA4sPTj80w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_QZPEVJSLq0q82piEBUpTqg_9_21">28</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_yDlCbORj70as59iH4DbeOQ_9_27">28</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Deemed dividend on beneficial conversion feature - Series A convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6LQBITHZ60WRlNBE8j_w_g" decimals="-3" format="ixt:numdotdecimal" name="mrns:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" scale="3" id="Tc_MEySj9EXBkC_A97XUDq9nw_10_13">8,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oMWaBvb6M0CZ9X6c2Oqqrw" decimals="-3" format="ixt:numdotdecimal" name="mrns:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" sign="-" scale="3" id="Tc_oiX89DSebEe_Ks-JdWmTMQ_10_24">8,880</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net Loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oMWaBvb6M0CZ9X6c2Oqqrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_uu3KIwlLvEqJgxRLDx50lA_11_24">18,672</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rvAalXez002MrlHpZ3B6qA_11_27">18,672</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, March&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_njBmuTxXb0KulNqEpHrpQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_O8kP-j94BkuUFgKIK-glGA_12_7">21,690,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_njBmuTxXb0KulNqEpHrpQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZsrcZPmD1Ee6w7LPBKF_8w_12_10">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LVfSiRHgy0mWRf270n3lEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rs1a_-tutEOlyx9vsWuhRQ_12_13">306,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_CTJ2VL88jESgyvVb6KfD6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_jgl5tlso9UKx6F7c9SRPKA_12_15">7,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LMklHntNS0KTgOI-HIEIZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TP1bzcXG9EKst51Nmd3O9w_12_21">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__1HOy6MZR0e8GBW9z_KEVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_c46pemDUl02buhm-j169tQ_12_24">263,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2020_-5H7uHTQeUmpUP0b5XFP-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_SXF1zp_8M0Ch-LXUbxgYlQ_12_27">43,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_4wMl9Q4G70GOJY3bS-fs4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc__09iZnqdsECuEYh3alrZFg_14_2">4,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_4wMl9Q4G70GOJY3bS-fs4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_286nMANgTkCdg169Con2AQ_14_5">4,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VGad9KiNbkCwtKgt7DZ1aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_XkKH0qFNh0SCdhIjSGwMlw_14_7">36,585,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VGad9KiNbkCwtKgt7DZ1aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6moTdAYvekiuRfrxqT1A0A_14_10">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AxRkO1I5G0qDl6t4aKuHoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KYncWdqNdkWkHJGj7GpyHw_14_13">444,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_Sj-IYJqIT0uvP3_uuR6sEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_D2sL0OYVaEa7IkM75BTmoQ_14_15">7,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q90XYQ7tOkisnJxjUpL-ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6vlgUgX8bkiVaO53oXTzJg_14_24">311,929</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eu7d1EXeBEqbmtumslZp8g_14_27">137,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-Based Compensation Expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7Cd3y9g6skeNkAsc9FaMAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lPdYKV3Q9E6E8aQl4KexYw_15_13">5,035</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_-YCln3PlLUKf2ZzAXvnhCA_15_27">5,035</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9qSklwBu70CQBbrRqgCIeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_oYr7Zdwo9EKEvvQ5fEnNNw_16_7">55,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7Cd3y9g6skeNkAsc9FaMAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fjvXEQSWsUqeV7l6QkeFrA_16_13">244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_GUL_rPM2jkWJ_LjxU7N-rw_16_27">244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Financing Costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7Cd3y9g6skeNkAsc9FaMAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_OXVZyvohfkiH2QOhBfmckw_17_13">3</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_seA9Fshiw0-disWREKbY_A_17_27">3</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GIw8jfZogk2-5MB_FX3uBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rGrwBViUf0uPQdYd726NLw_18_24">27,141</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZsQ82YWhDkCB77td-18jig_18_27">27,141</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sebYK2miu0aqZYM6o8RohQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_lacfZGqNMU-jSRsHXEolKA_19_2">4,753</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sebYK2miu0aqZYM6o8RohQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_m_FWmUNl90yY5dwdOTXLPA_19_5">4,469</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RYRdkpHKOUS-exHXDlAIug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_IWouHfpvSkuD06LnMpnHOA_19_7">36,640,797</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RYRdkpHKOUS-exHXDlAIug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fOqLIe9F2k26UzzEt7f8Uw_19_10">37</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oJu87ySZZki8kiQ1GgZDcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZVwWh4nexECFCvIfeZDtkg_19_13">449,898</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_vfbrhNgDVUi6DlCWD3nLsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_Hmg37uRwmEyTun83RYwbkw_19_15">7,307</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p3HF39Ap80yUDNAvRPhqUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_hSajshnwdU6EB05EJhNg1A_19_24">339,070</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QRzx8BMnXk2EcJAmO8YDRA_19_27">115,334</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NotestoFinancialStatements"></a><a id="a1Description_464092"></a><a id="_cp_text_1_1024"></a><a id="_cp_text_1_1025"></a><a id="_cp_text_1_1027"></a><a id="_cp_text_1_1029"></a><a id="_cp_text_1_1030"></a><a id="_cp_text_1_1032"></a><a id="_cp_text_1_1034"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="mrns:BusinessDescriptionAndLiquidityTextBlock" id="Tb_IUwT6vGKvkij8bzJCbURtw" continuedAt="Tb_IUwT6vGKvkij8bzJCbURtw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Description of the Business and Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Our clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABA<sub style="font-size:7.5pt;vertical-align:sub;">A</sub>&#160;that is being developed in formulations for two different routes of administration: intravenous (IV)&#160;and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. The different formulations are intended to maximize potential therapeutic applications of ganaxolone for adult and pediatric patient populations, in both acute and chronic care, and for both in-patient and self-administered settings. Ganaxolone acts at both synaptic and extrasynaptic GABA<sub style="font-size:7.5pt;vertical-align:sub;">A</sub>&#160;receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus was declared a pandemic by the World Health Organization in March 2020 and has spread to nearly every country in the world, including the United States (U.S.). Efforts to contain the spread of COVID-19 have intensified and many countries, including the U.S., have implemented severe travel restrictions, business shutdowns and social distancing measures that have impacted clinical development through supply chain shortages and clinical trial enrollment difficulties as hospitals reduce and redeploy staff, divert resources to patients suffering from COVID-19 and limit hospital access for non-patients. The pandemic poses the risk that we, our employees, contractors, suppliers, or other partners may be prevented from conducting normal business activities for an indefinite period of time, including those due to shutdowns that may be requested or mandated by governmental authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The continued global spread of COVID-19 has impacted our operations but did not have a material impact on our business, operating results, financial condition or cash flows as of and for the three months ended March 31, 2021. For example, several of our Phase 1 trials of oral ganaxolone to support the development of CDD have experienced delays in enrollment due to COVID-19; however we do not expect these delays to impact our ability to file an NDA. Further, i<span style="white-space:pre-wrap;">n response to COVID-19, for our ongoing clinical trials, we have implemented multiple measures consistent with the U.S. Food and Drug Administration&#8217;s guidance on the conduct of clinical trials of medical products during the COVID-19 pandemic, including implementing remote site monitoring and remote visits using telemedicine where needed. However, COVID-19 may still adversely impact our clinical trials.  For example, our Phase 3 clinical trial in RSE is conducted in hospitals and resources related to the COVID-19 outbreak may divert staffing in hospitals, taking resources away from our clinical trial.  Our ganaxolone clinical trials in the outpatient setting may be negatively impacted if patients and their caregivers do not want to participate in a clinical trial while COVID-19 outbreaks continue. Although operations have not been materially affected by the COVID-19 pandemic as of and for the three months ended March 31, 2021, we are unable to predict the impact that COVID-19 will have in the future on our business, financial position, operating results and cash flows due to numerous uncertainties. The duration and severity of the pandemic and its long-term impact on our business are uncertain at this time, and our ability to raise sufficient additional financing depends on many factors beyond our control, including the current volatility in the capital markets as a result of the COVID-19 pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have not generated any product revenues and have incurred operating losses since inception, including losses of $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_K9tNWKi26EaeZIshBH_TFg">27.1</ix:nonFraction> million for the three months ended March 31, 2021. There is no assurance that profitable operations will ever be achieved, and if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, if approved, and commercialization of our product candidates will require significant additional financing.   Our accumulated deficit as of March 31, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_7yCDlLuCkUSJoBCay4gNXQ">339.1</ix:nonFraction> million and we expect to incur substantial losses in future periods.  We plan to finance our future operations with a combination of proceeds from the issuance of equity securities, the issuance of debt, government funding, collaborations, licensing transactions and other commercial transactions and revenues from future product sales, if any. We have not generated positive cash flows from operations, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS (Continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_1038"></a><a id="_cp_text_1_1039"></a><a id="_cp_text_1_1041"></a><a id="_cp_text_1_1043"></a><a id="_cp_text_1_1044"></a><a id="_cp_text_1_1046"></a><a id="_cp_text_1_1048"></a><a id="_cp_text_4_1049"></a><a id="_cp_text_4_1050"></a><a id="_cp_text_1_1051"></a><a id="_cp_text_1_1053"></a><ix:continuation id="Tb_IUwT6vGKvkij8bzJCbURtw_cont1" continuedAt="Tb_IUwT6vGKvkij8bzJCbURtw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">and there are no assurances that we will be successful in obtaining an adequate level of financing for the development and, if approved, commercialization of our product candidates.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 11, 2021 (the Closing Date), we entered into a Credit Agreement and Guaranty (as amended by that certain letter agreement on May 17, 2021, the Credit Agreement) with Oaktree Fund Administration, LLC, as administrative agent and the lenders party thereto that provides for a <ix:nonNumeric contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_iqnukyZBtUepuUxI6Y_n4Q">five-year</ix:nonNumeric> senior secured term loan facility in an aggregate original principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_KbsB3GMfAUq42-N8CF5g_g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_6QUD_RIVDkWAqBZP5ipkfA">125.0</ix:nonFraction> million available to us in <ix:nonFraction unitRef="Unit_Standard_tranche_vnw-gVYtlEWJf_vMJ-ObdA" contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g" decimals="INF" format="ixt-sec:numwordsen" name="mrns:NumberOfTranches" scale="0" id="Narr_jygqPm6P5kaxjO2fHH-iCQ">five</ix:nonFraction> tranches as follows (collectively, the Term Loans):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoansTranche1Member_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_OrcnVjZcjkCJd82NJIXdYw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_zEBbHJHSJUa5SvirRhyTOw">15.0</ix:nonFraction> million of tranche A-1 term loans advanced on the Closing Date. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoansTranche2Member_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_WxLVUu7A2kuoA3YQnOT7vg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_CblPLfMIsEeAfAHwznqj0w">30.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million of tranche A-2 term loans subject to written acceptance by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) filing relating to the use of ganaxolone in the treatment of CDKL5 deficiency disorder (CDD).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheBMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_ZmO_zJI8K06Yju3bXZvlvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_C179B5_tn0-e31m8BhQ8ew">30.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million of tranche B term loans subject to receipt of written approval from the FDA of an NDA permitting the marketing of ganaxolone in interstate commerce in the United States to treat CDD (the FDA Approval).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_QQZsn1a07kGp7D1O83thbw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_qPFyitpXxUeCEX75OPYYGA">25.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million of tranche C term loans subject to receipt of the FDA Approval and the completion of one or more financings, including through the issuance of common stock, convertible debt, subordinated debt, a synthetic royalty or a sublicense in which we receive gross proceeds in an aggregate amount of at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_0C8_gqPMo0uWm48asEGVyA" decimals="-5" format="ixt:numdotdecimal" name="mrns:DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" scale="6" id="Narr_jlMKPs5ohEONtnIFXsvn0Q">40.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million and net proceeds in an aggregate amount of at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_0C8_gqPMo0uWm48asEGVyA" decimals="-6" format="ixt:numdotdecimal" name="mrns:DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" scale="6" id="Narr_CureKLKPl0a9J_dtokSgRA">36.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million. In addition, the availability of this tranche is subject to either our current Phase 3 trial in RSE or a Phase 3 trial in tuberous sclerosis complex (TSC) achieving statistical significance (p value &lt; 0.05) across all primary endpoints and ganaxolone must be generally well tolerated, with a safety profile generally consistent with previous clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_1yiPQ20dfUWNVt0Z6jH0tw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_ry_QrNwV1U2PKjtdZ4DoUg">25.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million of tranche D term loans subject to receipt of the FDA Approval and us earning at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_z1I9GUU03U6WTDF7U-xORg" decimals="-6" format="ixt:numdotdecimal" name="mrns:DebtInstrumentFundingAvailableNetProductRevenueMinimum" scale="6" id="Narr_yXUk6isQ6U2Tl5pDyJQ0Gw">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million in net product revenue in the United States for a period of </span><span style="-sec-ix-hidden:Hidden_6rtYHnKztUW0WBec3xybnQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> consecutive months.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Term Loans will bear interest at a fixed per annum rate (subject to increase during an event of default) of <ix:nonFraction unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw" contextRef="As_Of_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_KbsB3GMfAUq42-N8CF5g_g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_L1Gp5yV70EiqSvPjF7yVXA">11.50</ix:nonFraction>% and are scheduled to mature on the fifth anniversary of the Closing Date (the Maturity Date). In addition, at the time of funding of any tranche of the Term Loans, we are required to pay an upfront fee of <ix:nonFraction unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw" contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g" decimals="3" format="ixt:numdotdecimal" name="mrns:DebtInstrumentUpfrontFeesPercentage" scale="-2" id="Narr_rOWyNrQXg0O5aJWl_6_YIA">2.0</ix:nonFraction>% of the aggregate principal amount being funded. We are required to make quarterly interest payments until the Maturity Date. We are also required to make principal payments, which are payable in quarterly installments beginning on the last day of the first quarter ending after the third anniversary of the Closing Date in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw" contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g" decimals="3" format="ixt:numdotdecimal" name="mrns:DebtInstrumentPeriodicPaymentPrincipalPercentage" scale="-2" id="Narr_veP1GQ_nZ0Kl0zC802IAyA">5.0</ix:nonFraction>% of the aggregate amount of the Term Loans outstanding on the date of the first such quarterly principal payment and continuing until the Maturity Date, on which date all outstanding Term Loans and other amounts owed under the Credit Agreement will be required to be paid in full. A commitment fee of <ix:nonFraction unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw" contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g" decimals="4" format="ixt:numdotdecimal" name="mrns:DebtInstrumentCommitmentFee" scale="-4" id="Narr_J4VPiGRxJEm7k-FLJE4-3w">75</ix:nonFraction> basis points per annum will accrue on each of the tranche B, C and D commitments for the period beginning <ix:nonNumeric contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g" format="ixt-sec:durwordsen" name="mrns:DebtInstrumentCommitmentFeeAccrualPeriod" id="Narr_OcrNnxvV4E2vgqMVAFud4w">120 days</ix:nonNumeric> after the funding date of the tranche A-2 term loans until the applicable tranche is either funded or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">In September 2020, we entered into a contract (BARDA Contract) with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response. Under the BARDA Contract, we receive</span><span style="background-color:#ffffff;">d</span><span style="background-color:#ffffff;"> an award of up to an estimated </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_NjRPlVBuoU-719KqeaSsww" decimals="-6" format="ixt:numdotdecimal" name="mrns:MaximumAwardAvailableUnderContract" scale="6" id="Narr_XtIrRwzfMUi0r9Zq-SPf0Q">51</ix:nonFraction></span><span style="background-color:#ffffff;"> million for development of IV-administered ganaxolone for the treatment of refractory status epilepticus (RSE). </span><span style="background-color:#ffffff;">The BARDA Contract provides for </span><span style="background-color:#ffffff;">f</span><span style="background-color:#ffffff;">unding </span><span style="background-color:#ffffff;">to </span><span style="background-color:#ffffff;">include support</span><span style="background-color:#ffffff;">, </span><span style="background-color:#ffffff;">on a cost-sharing basis</span><span style="background-color:#ffffff;">, the </span><span style="background-color:#ffffff;">completion of a Phase 3 clinical trial of IV-administered ganaxolone in patients with RSE </span><span style="background-color:#ffffff;">(our </span><span style="background-color:#ffffff;">Phase 3 clinical trial evaluating IV </span><span style="background-color:#ffffff;">ganaxolone for the treatment of RSE </span><span style="background-color:#ffffff;">(RAISE Trial)) </span><span style="background-color:#ffffff;">, funding of pre-clinical studies to </span><span style="background-color:#ffffff;">provide support </span><span style="background-color:#ffffff;">that IV-administered </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS (Continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_1055"></a><a id="_cp_text_1_1057"></a><a id="_cp_text_1_1059"></a><a id="_cp_text_1_1061"></a><a id="_cp_text_1_1063"></a><a id="_cp_text_1_1065"></a><a id="_cp_text_1_1066"></a><ix:continuation id="Tb_IUwT6vGKvkij8bzJCbURtw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">ganaxolone </span><span style="background-color:#ffffff;">could be </span><span style="background-color:#ffffff;">an effective treatment for RSE due to chemical nerve gas agent exposure, and funding of certain manufacturing scale-up and regulatory activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The BARDA Contract consists of an approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_PIGm1dm3nUqea624wnjONw" format="ixt-sec:durwordsen" name="mrns:ContractBasePeriod" id="Narr_vJFyZa34-0Oo9QUeGD0zwA">two-year</ix:nonNumeric> base period-during which BARDA will provide approximately $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-6" format="ixt:numdotdecimal" name="mrns:ContractFundingProvidedDuringBasePeriod" scale="6" id="Narr_-40Nw_hdsk6bzBJNGqQp3w">21</ix:nonFraction> million of funding for the RAISE Trial on a cost share basis and funding of additional preclinical studies of ganaxolone in nerve agent exposure models. Following successful completion of the RAISE Trial and preclinical studies in the base period, the BARDA Contract provides for approximately $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lPrWUD3wcUerfah8Cn28qQ" decimals="-6" format="ixt:numdotdecimal" name="mrns:ContractAdditionalFundingToBeProvidedFollowingBasePeriod" scale="6" id="Narr_rFOp4Gw8Y0-sKlyQLRILfw">30</ix:nonFraction> million of additional BARDA funding for three options in support of manufacturing, supply chain, clinical, regulatory and toxicology activities. Under the BARDA Contract, we will be responsible for cost sharing in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lPrWUD3wcUerfah8Cn28qQ" decimals="-6" format="ixt:numdotdecimal" name="mrns:ContractCostSharingAmount" scale="6" id="Narr_EWeL9rc_xk6EeFjBf6l4dg">33</ix:nonFraction> million and BARDA will be responsible for approximately $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lPrWUD3wcUerfah8Cn28qQ" decimals="-6" format="ixt:numdotdecimal" name="mrns:ContractCostSharingAmountCounterparty" scale="6" id="Narr_VkZHTTPmXUKZ90DTPfcjoA">51</ix:nonFraction> million, if all development options are completed. The contract period-of-performance (base period plus option exercises) is up to approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_PIGm1dm3nUqea624wnjONw" format="ixt-sec:durwordsen" name="mrns:ContractPeriodOfPerformance" id="Narr_LFEFP_p-LUKnHhJI7MxZ6g">five years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the closing of an equity financing in December 2020, we issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_yYSr99WKYE6jflmONGtLZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YCHxMOV_W0qbnVz44xYuvA">5,000,000</ix:nonFraction> shares of common stock in an underwritten public offering resulting in aggregate net proceeds, after underwriting discounts and commissions in the public offering and other estimated offering expenses, of $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_yYSr99WKYE6jflmONGtLZg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_O43haOvfykeRmZlSFmy79w">64.9</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In connection with the closing of an equity financing in June 2020, we issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_XPNC2p02pUyKefB5bvQ_xQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_hIFlLO6TPUyHqStKHJqVLA">4,600,000</ix:nonFraction> shares of common stock in an underwritten public offering resulting in aggregate net proceeds, after underwriting discounts and commissions in the public offering and other estimated offering expenses, of $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_XPNC2p02pUyKefB5bvQ_xQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_Ka3nY5NDUE2FtZ4VWunocQ">42.9</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We believe that our cash and cash equivalents balances as of March 31, 2021, including the net upfront proceeds received in May 2021 from our Credit Agreement, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse stock split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On September 23, 2020, we effected a <span style="-sec-ix-hidden:Hidden_pGDrPi0GAkW2ail2SFXw3w;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1</span></span>-for-4 reverse split of shares of our common stock (Reverse Split), as approved by our board of directors and stockholders. The par value per share of our common stock was not adjusted as a result of the Reverse Split, and our authorized shares of common stock was reduced to <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_9_23_2020_OiMX-o5boE2EQwMEi2ZK0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr__fU8kTXKD0CXqygcvISthg">150,000,000</ix:nonFraction><span style="white-space:pre-wrap;">.  All of the share and per share amounts included in the accompanying financial statements and these notes have been adjusted to reflect the Reverse Split</span><span style="white-space:pre-wrap;">.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_sAmFP7aQ_E-aZJ1cxZwrfg" continuedAt="Tb_sAmFP7aQ_E-aZJ1cxZwrfg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_VhCSYLLJGk-h1l6yYZKy4Q" continuedAt="Tb_VhCSYLLJGk-h1l6yYZKy4Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying unaudited interim consolidated financial statements include the accounts of Marinus Pharmaceuticals, Inc. (a Delaware corporation) as well as the accounts of Marinus Pharmaceuticals Emerald Limited (an Ireland company incorporated in February 2021), a wholly owned subsidiary requiring consolidation. Marinus Pharmaceuticals Emerald Limited serves as a corporate presence in the European Union for regulatory purposes. The unaudited interim consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the U.S. (GAAP) for annual financial statements. In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of our financial position and results of operations and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2020 and accompanying notes thereto included in our annual report on Form&#160;10-K filed with the SEC on March 9, 2021.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS (Continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sAmFP7aQ_E-aZJ1cxZwrfg_cont1"><ix:continuation id="Tb_VhCSYLLJGk-h1l6yYZKy4Q_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:UseOfEstimates" id="Tb_zHDPI6JllkO-ALImKk0AyQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_BCaRHlroFUCe50dmo2J5mQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Federal Contract Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="white-space:pre-wrap;">We recognize federal contract revenue from the BARDA Contract in the period in which the allowable research and development expenses are incurred, and receivables associated with this revenue are recorded as federal contract revenue receivable on our interim consolidated balance sheets.  This revenue is not within the scope of Accounting Standards Codification (ASC) 606 &#8211; Revenue from contracts with customers.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_B6dx9oHMI0SNPa269Z1TLQ" continuedAt="Tb_B6dx9oHMI0SNPa269Z1TLQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">3. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level&#160;1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level&#160;2 &#8212; Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level&#160;3 &#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS (Continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4a8314ef_02e9_46cd_94f8_2115cf6967af"></a><a id="Tc_JE0C75Aaq0e9uD2_EMzobQ_1_2"></a><a id="Tc_dgqcUDs0FU28Z8xbmfQbqQ_1_5"></a><a id="Tc_LW5bCLYOpE-TNTws0YmcBQ_1_8"></a><a id="Tc_7cKI0Lyazka6lccO_K6u4Q_1_11"></a><a id="Tc_pdrvyTMN9EGv87LZ4TLtug_2_0"></a><a id="Tc_mqs41rZq10aCLurGOetjcA_3_0"></a><a id="Tc_aMb7QDhtsUqR5WDACU-7hw_4_0"></a><a id="Tc_KGAOUFR3ekqRibkh7Q3t2g_4_2"></a><a id="Tc_goC3KTeHY0qt4NPiUINJ7A_4_5"></a><a id="Tc_8dH9THnCfkSnMV0f9Y_aag_4_6"></a><a id="Tc_npK7vpnrZkaP8BGrZ3pUSw_4_8"></a><a id="Tc_JRZYC57_4kugLf6mMda4lQ_4_9"></a><a id="Tc_jvEVASFC6UC6lGRIK5m-4A_4_11"></a><a id="Tc_HGTmxW_WD0Shsew7R8qxuA_5_0"></a><a id="Tc_02Y5RuqrV0WViG2ZYNoHAg_5_2"></a><a id="Tc_zuUAWCeei0aFr6HT4t_-UA_5_5"></a><a id="Tc_cKquFKCVSUawyOB1FjAyTQ_5_6"></a><a id="Tc_4Hgdkq5lxE23-Wt6YsS-FA_5_8"></a><a id="Tc_allI0N1MLU-EQV5OJqDwQg_5_9"></a><a id="Tc_Al2IzQ-SmkSbvOS_cqv0sw_5_11"></a><a id="Tc_-bXKHRHOREqZVZ22BvP57g_6_0"></a><a id="Tc_m_jqSQt-LUaCFSDf6pYlbw_7_0"></a><a id="Tc_hWG--5tNt0-4TxtoLslEIw_8_0"></a><a id="Tc_1GMuitr_J0-brS7ye-Ch9A_8_2"></a><a id="Tc_uoymgZLNU0-BiaKXRN-AjQ_8_5"></a><a id="Tc_I5CPnBhvEUCSyeWS9SEkhQ_8_6"></a><a id="Tc_Ia-XQKUOkESa2XQfHwRxng_8_8"></a><a id="Tc_290Kk1vNaUSEisAJMU63XQ_8_9"></a><a id="Tc_kta9HbNJLEW6HiRdgmMKaA_8_11"></a><a id="Tc_xkWbSQaIrEGLxEsd_f1sDQ_9_0"></a><a id="Tc_2Yc7cXbeNUqk2rsxB0aJTQ_9_6"></a><a id="Tc_uhQ96oex60SOJse11bFLXQ_9_9"></a><a id="Tc_inuwW3NwtkOhJ5Bck_LGEA_10_0"></a><a id="Tc_9fRMJrhAX0Gz5lA_z5yraw_10_2"></a><a id="Tc_JFQGpYqvGESM2ELJIEjQWQ_10_5"></a><a id="Tc_xKG7azFnCUe32PokhvPNOQ_10_6"></a><a id="Tc_MM7zMFZ_gECWrK1VsZWRBA_10_8"></a><a id="Tc_HW8mmoUXGkmBe6qsMv8yiQ_10_9"></a><a id="Tc_ty1GFNVj8Uq675p14JADlA_10_11"></a><ix:continuation id="Tb_B6dx9oHMI0SNPa269Z1TLQ_cont1"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_i8GJYDhwZ0G19Ka3pSJs0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6x5DJ-CH0kaeJKGdgTq8DA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Bdkw3hwpJkCR643WUttP5A_4_3">122,210</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ISpIebOIi0K7bmbED0LKSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_kDpr_jT1g0WCuMZ2DMriFw_4_12">122,210</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-8-0nnBWpUmAFY7t2su3eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_o57FWSHAikajpZK0mirFOA_5_3">122,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__S1TL6asNEie8J964p41pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_5Yu2U8mPCUugn0TNmkX69A_5_12">122,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gL2saeIEhkKPbHdqHSO8XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_K18Rs0-HkU63XAKwHFW_bA_8_3">138,509</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0gArs46GskGjg-CwXqnRlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_ywoZYHZznUqVnsP9uzr3cg_8_12">138,509</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CertificatesOfDepositMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z1HxUQ7enE6srbvlBfnnog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_YOhdb3yQTECGrrAQ4DYgeA_9_3">1,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CertificatesOfDepositMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_57Xm1ecNsEuUhzUcp-ldRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_DBeBoj80R0-fcsYbe8pZhg_9_12">1,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IzM8ejDq1U-vXqJ7UOOeDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_9xBahyPuw0GnzM5yLl-IWQ_10_3">139,983</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjNZhWbkFkS38HEN4C5ekA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_--mUzuvfwkOSmQXjBFge9g_10_12">139,983</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cc7cd67e_820d_443e_987e_8728cceba436"></a><a id="Tc_yJ_LAOrvkUa6Sx02yyPxWA_1_2"></a><a id="Tc_jOblN5cg50ilGsPSjNBr6Q_1_5"></a><a id="Tc_mWjJxVuG30qfrhP5Nerz3Q_2_2"></a><a id="Tc_Ct0PxAk0zUSnXuAZniFIug_2_5"></a><a id="Tc_c5wVgH-6BE6pdzppCbz5Rg_3_0"></a><a id="Tc_5L7FM4uSJ0KcDilTILBPJw_3_2"></a><a id="Tc_oqBj52rNAkajVStJl3vkEg_3_5"></a><a id="Tc_GrPnoQWTb0CZlhysAgZTdQ_4_0"></a><a id="Tc_hV06yaZjg0qfYoWPvFO1UQ_5_0"></a><a id="Tc_WXbb0fQkhEOrrtYKHIvJtQ_6_0"></a><a id="Tc_LjGHo66WN0a7RftgJgXnAw_7_0"></a><a id="Tc_EX6iuD3kvkuKs6tP0yuupg_8_0"></a><a id="Tc_SjVkMH9VWEyj7v_MxxRHFQ_8_2"></a><a id="Tc_vgNhU1t0nEWvJCjagNXY2g_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_zeeW9s0jxUy0nttFO_HwPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">4. Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_QzuOFaDz0EiTKsFN7JnK1w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_Bx9mMfGowUyv2mc-KzssLw_3_3">2,533</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_bfNuG5uyfEqRsiDfDAQlVg_3_6">4,097</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trials and drug development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="mrns:ClinicalTrialsAndDrugDevelopmentCurrent" scale="3" id="Tc_EVe5uPSkX02DiqG55uyPrg_4_3">6,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="mrns:ClinicalTrialsAndDrugDevelopmentCurrent" scale="3" id="Tc_dkLqOeEoskqHkT1WtbzI8g_4_6">2,452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_Qmelyphzf0StP9SxGAvV7A_5_3">1,158</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_YWF22-yvJUGUOcppsTzOFA_5_6">927</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="mrns:LeaseLiabilityShortTerm" scale="3" id="Tc__87lCCoss06A4lZ0GYs0Ow_6_3">519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="mrns:LeaseLiabilityShortTerm" scale="3" id="Tc_O-qwZEKb2UuTL66r9qHA1g_6_6">510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_bJYUlPrsLUmszglJbQkyDQ_7_3">99</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_lIQuCBkte0KCrfpO_o1-3w_7_6">532</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_5VpHm7lOLU2e12V3qmlrhg_8_3">10,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_GsvNzuO8f0S37mlvwKpU4w_8_6">8,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="mrns:InvestmentsDisclosureTextBlock" id="Tb_SXum22ruxU-X9RJT8mM_Ew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We did not have any investments as of March 31, 2021. As of December 31, 2020, our investments consisted of certificates of deposit with various financial institutions with original maturities of six to nine months.&#160;&#160;Investments are classified as short- or long-term investments on our balance sheets based on original maturity. Certificates of deposits were classified as held-to-maturity and were recorded at amortized cost, which approximated fair value.&#160; <span style="color:#222222;">We have never experienced a credit loss on the principal or interest receivable of our cash equivalents or short-term investments.&#160;</span><span style="color:#222222;white-space:pre-wrap;"> Our certificates of deposit are each individually and fully insured by the federal Depsot Insurance Company (FDIC).  Accordingly, we did not record any allowance for potential credit losses as of December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS (Continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-FiORfetcUGufpScF1SAvw_1_2"></a><a id="Tc_M5dMzA2Pc0mI3hkJKOZXUA_2_2"></a><a id="Tc_nVrhybK4lEGhvTSkROb0fg_2_4"></a><a id="Tc_a90X8ptb_U-W-F5UFFm49Q_3_0"></a><a id="Tc_2o7rf_ZTYU6gH8po6WBLbg_4_0"></a><a id="Tc_l8-JwgZvHEO6k_iVg1_ilA_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_Ra8wnd6sBk2Dp9QNkKvA-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6. Loss Per Share of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. These potentially dilutive securities are more fully described in Note&#160;7, and summarized in the table below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_9wyFyUBGmUWt9_8LE2LDAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_aw6tpevnx0S7VX16wF9x-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_TY5x_1mTNEGBlE23F9J8Nw_3_2">950,600</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_8zaVZ-69uEiVQSid1i2tuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_kdQbfeGVAESLjp6P7HQ1XQ_3_4">6,000,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_FpMZWQoGrEyhGmLadR_5Fw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__lP5L8rpC0y235Pzcff53g_4_2">22,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_JVIEoiUCiEixZFqFpl2TMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_H8u9S7-dIE2XQWCLTS42mg_4_4">5,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_2cQC38nN50yIRWLWCjpsrA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_OsAPFP57IEim1mjNZTkYQQ_5_2">4,436,778</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_oVLJcKieMkeJ0tQmMG3asQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_mr2F3ZJkd0a_sfdMOX_1Dw_5_4">3,264,041</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_rZXbzWKGYUmpVbbvlA3cNA_6_2">5,409,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ZN5OKD9S0U69t69Wv5XThw_6_4">9,269,291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_GeRfjbyTrE6TAqPuidnWmA" continuedAt="Tb_GeRfjbyTrE6TAqPuidnWmA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">7. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In 2005, we adopted the 2005 Stock Option and Incentive Plan (2005 Plan) that authorizes us to grant stock options, restricted stock and other equity-based awards. As of March 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_StockOptionAndIncentivePlan2005Member_sjKwPS8R-k2wWxUVOhk1vg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_4NnGknZSkUO0MlOLACM1bA">6,565</ix:nonFraction><span style="white-space:pre-wrap;"> options to purchase shares of common stock were outstanding pursuant to grants in connection with the 2005 Plan.  </span><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_PlanNameAxis_mrns_StockOptionAndIncentivePlan2005Member_pY1EQZSCQUasDgjSyWC4ug" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_X7mDt7Q8JkCwPn3aXk9d2w">No</ix:nonFraction><span style="white-space:pre-wrap;"> additional shares are available for issuance under the 2005 Plan.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In August 2014, we adopted our 2014 Equity Incentive Plan, most recently amended in May 2020 (2014 Plan), that authorizes us to grant stock options, restricted stock, and other equity-based awards, subject to adjustment in accordance with the 2014 Plan.  The amount, terms of grants, and exercisability provisions are determined and set by our board of directors.  As of March 31, 2021, </span><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_Tlqw9BGm20WqLo6p9EcJFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_VMOgT22_90q_Ks3j1R3rWQ">3,386,335</ix:nonFraction> options to purchase shares of common stock were outstanding pursuant to grants in connection with the 2014 Plan, and <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_GCzbaEQkcUGyXqr_QnLvtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_sxamlrEO00e91f94iSd81w">646,221</ix:nonFraction> shares of common stock were available for future issuance.<span style="white-space:pre-wrap;"> The amount, terms of grants, and exercisability provisions are determined and set by our board of directors.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YOD3KDe7RkmYKbUKW8SRfA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_lVZgSy3RP0mB2K7Mj8-IqA">4,436,778</ix:nonFraction> stock options outstanding as of March 31, 2021 at a weighted-average exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g" contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YOD3KDe7RkmYKbUKW8SRfA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Narr_zLc4VPC3D0WsXawQxobxtg">11.97</ix:nonFraction> per share, including <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlanEmployeeMember_pk1X2Uuu6kuHPbfxMPJLKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_zKNCLlpnYEqkp2BsqMH7sA">1,043,878</ix:nonFraction><span style="white-space:pre-wrap;"> stock options outstanding outside of the 2014 Plan, granted as inducements to new employees.  </span>During the three months ended March 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_gmzBTjUy006g5LDT3kUS6w">1,235,351</ix:nonFraction> options were granted to employees and directors at a weighted-average exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_TAiJjJARcUeIKDwr_7IPGw">13.33</ix:nonFraction><span style="white-space:pre-wrap;"> per share.  Of the options granted, <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_gLlExmIpREOOfxJPC2-Pbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_U5qXTzPMYUesbQi4NTHlzQ">1,005,038</ix:nonFraction> options were granted pursuant to the 2014 Plan and <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlanEmployeeMember_caVUlUeydkqE7PHUeTsG9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_79KB3vE6X0uQHfMTewy1Sg">230,313</ix:nonFraction> were granted outside of the 2014 Plan as inducements for new employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS (Continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_347cf27a_26da_41f5_953a_f0da4ffd6744"></a><a id="Tc_1cDccC_h_kS8hekghbJ3RQ_1_2"></a><a id="Tc_iJQZMRwNXkCAiHpITZvszg_2_2"></a><a id="Tc_BT_5yD_sfEm23312u6R_8g_3_2"></a><a id="Tc_AKTc1zwFz0m4GEe664LGXA_3_5"></a><a id="Tc_Wik_OeBlAkC-I_ZmwlSFsg_4_0"></a><a id="Tc_ssxC16Z7dEC5rLcMZprGmw_4_2"></a><a id="Tc_Di3kHNr6dEuPbZEdPc_nNw_4_5"></a><a id="Tc_7jHfeUDxNUmXhWGeXUjhRA_5_0"></a><a id="Tc_Lbl5xvkxvk2fMdnBztpJQw_6_0"></a><a id="Tc_x8Ek9t6V1k2oOrReoaQ_vA_6_2"></a><a id="Tc_4s7pbdF390S37ReQI47wxw_6_5"></a><a id="_c128cde4_96da_4ced_9fb2_af9f4074dc8a"></a><a id="Tc_6Nf1qCNqukq7RKgA8M9ySQ_1_2"></a><a id="Tc_CPgEQUKnS0qo9gVCYtuUow_2_2"></a><a id="Tc_ekkTS0VskE2HVW2bbW75Qw_3_2"></a><a id="Tc_j3TKJLPCKk6THV3w8ASc-w_3_5"></a><a id="Tc_IS0-QgoXH0enC4T7sXhxvQ_4_0"></a><a id="Tc_f2XdjBplMEaIQU_kauNPbw_5_0"></a><a id="Tc_KJK_beo3N06WRkqStaH8Vg_5_2"></a><a id="Tc_Lodb78o4SkOeit1OXdGMTQ_5_5"></a><ix:continuation id="Tb_GeRfjbyTrE6TAqPuidnWmA_cont1"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_gayTwzj3vEyZ-r815Zbyqg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total compensation cost recognized for all stock option awards in the statements of operations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ixflgqi17U--7GUSGs7m5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NaXn4jbBfkuMdFathvHW0Q_4_3">1,190</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_AEmW4zZq7kqttYoG44orKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wKofTD2_U06Q1xufAC4C9Q_4_6">729</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_sxnFk15oLESa5jxtU2OmMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XyaomUpcEUOnYmJTk16pQQ_5_3">3,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4XykMpFDvkyUJxaaGlZIDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6Yogu3ayDUWbNsL5Pd1KPQ_5_6">1,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9GM5uKusL0OT1l1KWNHtWQ_6_3">4,980</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nU2_qSegwUeO8XJe6mN6gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9wLGtd3Uqk6OEAVfjvm7zQ_6_6">1,875</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">All issued and outstanding restricted shares of common stock are time-based, and become vested between <span style="-sec-ix-hidden:Hidden_dow7_ZuMpUWqCMzjx0ZHwQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one</span></span> and <ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BRnhyVEI0ESba0YijHvmHw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_k5cP1t73HkW1T0Jwg3oc7w">three years</ix:nonNumeric><span style="white-space:pre-wrap;"> after the grant date.  Compensation expense is recorded ratably over the requisite service period. Compensation expense related to restricted stock is measured based on the fair value using the closing market price of our common stock on the date of the grant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We issued <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qtmIWYk-lEaiK7KXwRoNrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_RxvOgn7E20uQL39sT9tG_A">0</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_9G2E0G-1K0CaojyNjXJupA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_PDigX9SzBkezVuE9wZLT0g">5,250</ix:nonFraction> restricted shares of common stock during the three months ended March 31, 2021 and 2020, respectively.  As of March 31, 2021 there were <ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_WbOyI-9dVEWarpASvcUfqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Narr_K-k8UVWp-kKouJszHpuD-g">22,000</ix:nonFraction> restricted shares of common stock outstanding.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qtmIWYk-lEaiK7KXwRoNrQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_U9dSvG-_eEOH3WxVtpm2dw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total compensation cost recognized for all restricted stock awards in the statements of operations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mJOVLW9KpUmbnUt7bOmsLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cgKJovDGNUiILBcZv_AS-w_4_3">55</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_fWJfXvsKtk6Kfv55TO39uQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_dfZVGLOYzkWheiBUXGsP8A_4_6">1</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qtmIWYk-lEaiK7KXwRoNrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-Fr_OvARbUC5wiOOC9nUnQ_5_3">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_9G2E0G-1K0CaojyNjXJupA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6r98Ss4lxkGKeeY78xt5Pw_5_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background-color:#ffffff;">As of March 31, 2021, </span><span style="background-color:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_xjbNxnlg_Uui6Mi052SOcA">4,753</ix:nonFraction> </span><span style="background-color:#ffffff;">shares of our Series A Convertible Preferred Stock (Preferred Stock) remained outstanding, convertible into </span><span style="background-color:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_aQlkf7uJDkiwh3Btns-LmQ">950,600</ix:nonFraction></span><span style="background-color:#ffffff;white-space:pre-wrap;"> shares of our common stock.  In May 2020, a registration statement covering the resale of shares of our common stock underlying our Preferred Stock was declared effective by the SEC.  In accordance with the securities purchase agreements underlying the Preferred Stock, the liquidation preference was terminated, and we reclassified the Preferred Stock into permanent equity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Deemed Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">On March 31, 2020, our stockholders approved an </span><span style="white-space:pre-wrap;">amendment to our company charter, which was filed with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock, which resulted in the recognition of a beneficial conversion feature on our Preferred Stock.  Accordingly, we recorded </span>$<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-5" format="ixt:numdotdecimal" name="mrns:ConvertiblePreferredStockDeemedDividends" scale="6" id="Narr_2BKoatKLAkWJqPjcHYP-3Q">8.9</ix:nonFraction> million in deemed dividends in the three months ended March 31, 2020, which was calculated as t<span style="background-color:#ffffff;">he difference between the conversion price and the fair value of our common stock on the commitment date (transaction date) i</span>n connection with the closing of concurrent equity financings during the fourth quarter of 2019.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS (Continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_VtuSckQiEkKloQNgizUhRw" continuedAt="Tb_VtuSckQiEkKloQNgizUhRw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into operating leases for real estate. These leases have terms which range from <ix:nonNumeric contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_9f43HPsrZUqXrvBNmnWl-A" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_LGse8HE1r06Gzdfw13wWSA">36</ix:nonNumeric> to <ix:nonNumeric contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_ZwEUgE2a10mD4z6DCHCsrQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_eNYiVPFDq061UL6zz2blqw">78 months</ix:nonNumeric>, and include renewal terms which can extend the lease terms by <ix:nonNumeric contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_9f43HPsrZUqXrvBNmnWl-A" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_45LMaQKP10irvvFahqXfzA">24</ix:nonNumeric> to <ix:nonNumeric contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_ZwEUgE2a10mD4z6DCHCsrQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_HrQPiEEV1k2ik785QYvAZA">60 months</ix:nonNumeric>, which are included in the lease term when it is reasonably certain that we will exercise the option.&#160;&#160;As of March 31, 2021, our operating leases had a weighted average remaining lease term of <ix:nonNumeric contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_bIkD_ldMEkOnTA_YWaj_FA">53 months</ix:nonNumeric>.&#160;&#160;These right-of-use (ROU) assets are included in &quot;Other assets&quot; on our interim consolidated balance sheets as of March 31, 2021 and December 31, 2020, respectively, and represent our right to use the underlying asset for the lease term. Our obligations to make lease payments are included in &quot;Accrued expenses&quot; and &quot;Other long-term liabilities&quot; on our interim consolidated balance sheets as of <span style="-sec-ix-hidden:Hidden_zvqnfLCJd0yr4jXmjicT5Q;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">March 31, 2021</span></span> and <span style="-sec-ix-hidden:Hidden_mFAODsPqSk-Q7CVVsygbpQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">December 31, 2020, respectively</span></span>.&#160;&#160;The ROU assets were initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred, less any lease incentives received.&#160;&#160;The ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2021 and December 31, 2020, ROU assets were $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_gPa_JoDbeU-pIl4AZTA9FA">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_yjNeJ8VcTkC87AeGsa-gBA">2.0</ix:nonFraction> million, respectively, and operating lease liabilities were $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_NczADI5sYU26pOqNyT8qkQ">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_0WJrPmHKxU-Kd93NNiJR8g">3.0</ix:nonFraction> million, respectively. We have entered into various short-term operating leases, primarily for clinical trial equipment, with an initial term of twelve months or less. These leases are not recorded on our balance sheets. All operating lease expense is recognized on a straight-line basis over the lease term. During each of the three months ended March 31, 2021 and 2020, we recognized $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="Narr_eLeaoKsntEq673NkxxcjEg"><ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="Narr_DHOT8A3vEUqc0cchp7Q62Q">0.2</ix:nonFraction></ix:nonFraction> million in total lease costs, which included less than $<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_XPMAdE0OMUeOyqAqZ3qvag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="6" id="Narr_XE6Ms7V3LU-Z3pKnsP7qQg"><ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_8LfUPpiv40evSUbKT82rhw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="6" id="Narr_j710FdGgMUGQvznxPFtrQg">0.1</ix:nonFraction></ix:nonFraction> million in short-term lease costs related to short-term operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because the rate implicit in each lease is not readily determinable, we use our incremental borrowing rate to determine the present value of the lease payments. The weighted average incremental borrowing rate used to determine the initial value of ROU assets and lease liabilities was <ix:nonFraction unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_rq2GrdlpKkiRIwL761vMRg">11.0</ix:nonFraction>%, derived from a corporate yield curve based on a synthetic credit rating model using a market signal analysis. We have certain contracts for real estate which may contain lease and non-lease components which we have elected to treat as a single lease component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ROU assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment &#8211; Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&#160;&#160;As of March 31, 2021 and December 31, 2020, we have not recognized any impairment losses for our ROU assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We monitor for events or changes in circumstances that require a reassessment of one of our leases. When a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in our interim consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS,&#160;INC. AND SUBSIDIARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED NOTES TO FINANCIAL STATEMENTS (Continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c2ec7c44_4cf0_466b_bbfb_031454496f53"></a><a id="Tc_7IQsQ2wmYUG4BdkFwajwrQ_3_0"></a><a id="Tc_lIMEn81HEUSpePBIw4hNqA_4_0"></a><a id="Tc_Wk3tIxVyo0S2tE8GIqA_UQ_5_0"></a><a id="Tc_97UtN5pCMEmngMKSaVfUVg_6_0"></a><a id="Tc_GiGf6HvnIEmfVR-q_IPWSw_7_0"></a><a id="Tc_J_7gdmoPoUWlPZS6bm1PRw_9_0"></a><a id="Tc_Sq-RFYm3bk-aS-IYGhdPeA_10_0"></a><a id="Tc_Xnbvzv8SB0S6dZzz4tvTNQ_10_2"></a><a id="Tc_rDVdP9XdP0aTpBURtGO37Q_12_0"></a><a id="Tc_B8GS2YJFFkmj3AAvEL3LEw_12_2"></a><a id="Tc_lTP2xTVq90eyvybHKZ64eA_13_0"></a><a id="Tc_M9a0Tc-LoUiXJw6Xf74sKQ_14_0"></a><a id="Tc_e73nqqMM_EOmjgFF7iG09w_14_2"></a><ix:continuation id="Tb_VtuSckQiEkKloQNgizUhRw_cont1"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_I73bbuL4tUGMeOKoIVShCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Maturities of operating lease liabilities as of March 31, 2021 were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remaining nine months of 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" scale="3" id="Tc_CDgVrPzrBkePlKV277b8Jw_3_3">616</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" id="Tc_7NfNZWUxXUKMmVpxNIJ4-A_4_3">807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="3" id="Tc_BtF4ZK4wQ0WE3MPQXAzvyQ_5_3">823</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="3" id="Tc_OIe_Hk1Oq0G2MKi6uhHpjA_6_3">840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" scale="3" id="Tc_-RENL7TgAkqaf2OKkt_XuQ_7_3">642</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc__qZ5KnuHZE2LTil-uZUaMw_8_3">3,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: imputed interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_chPazXN3lUWri-FdVtaZTQ_9_3">805</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_b9eT3uBwrUuOFRziTUvjnw_10_3">2,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_L9SaWWfdbkiOR8nazwOXbA_12_3">519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_kt4Ahuj9UEaRoUDttyfmxw_13_3">2,404</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg" contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_PZERjAL6_0qu2D4NwB2KBg_14_3">2,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_5445d771_6c52_444d_9a2c_b46f083142ea"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item2ManagementsDiscussion_251995"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to develop and commercialize ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">status, timing and results of preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">design of and enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, or the attainment of clinical trial results that will be supportive of regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the potential benefits of ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing of seeking marketing approval of ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to obtain and maintain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our estimates of expenses and future revenue and profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our estimates regarding our capital requirements and our needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our plans to develop and market ganaxolone and the timing of our development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our estimates of the size of the potential markets for ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our selection and licensing of ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to attract collaborators with acceptable development, regulatory and commercial expertise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the benefits to be derived from corporate collaborations, license agreements, and other collaborative or acquisition efforts, including those relating to the development and commercialization of ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">sources of revenue, including contributions from our contract (BARDA Contract) with the Biomedical Advanced Research and Development Authority (BARDA), corporate collaborations, license agreements, and other collaborative efforts for the development and commercialization of ganaxolone and our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to create an effective sales and marketing infrastructure if we elect to market and sell ganaxolone directly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the rate and degree of market acceptance of ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing and amount of reimbursement for ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the success of other competing therapies that may become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the manufacturing capacity for ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the extent to which our ability to market and sell ganaxolone may be negatively impacted by third party patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to maintain and protect our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our results of operations, financial condition, liquidity, prospects, and growth strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the industry in which we operate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the extent to which our business may be adversely impacted by the effects of the COVID-19 coronavirus pandemic or by other pandemics, epidemics or outbreaks;</span></td></tr></table><div style="margin-top:12pt;"><a id="_cp_blt_1_34"></a><a id="_cp_text_1_32"></a><a id="_cp_text_4_33"></a><a id="_cp_text_1_35"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">t</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">he enforceability of the exclusive forum provisions in our fourth </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">amended and restated certificate of incorporation</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; and </span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the trends that may affect the industry or us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should refer to Part II Item&#160;1A. &#8220;Risk Factors&#8221; of this Quarterly Report on this Form 10-Q for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form&#160;10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following <i style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i> should be read in conjunction with: (i)&#160;the interim consolidated financial statements and related notes thereto which are included in this Quarterly Report on Form 10-Q; and (ii)&#160;our annual financial statements for the year ended December&#160;31, 2020 which are included in our Annual Report on Form 10-K filed with the SEC on March 9, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are a clinical stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Our clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABA<sub style="font-size:7.5pt;vertical-align:sub;">A</sub> that is being developed in formulations for two different routes of administration: intravenous (IV)&#160;and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">neurosteroid. The different formulations are intended to maximize potential therapeutic applications of ganaxolone for adult and pediatric patient populations, in both acute and chronic care, and for both in-patient and self-administered settings. Ganaxolone acts at both synaptic and extrasynaptic GABA<sub style="font-size:7.5pt;vertical-align:sub;">A</sub> receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential.</p><a id="_cp_text_1_158"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COVID-19 </b></p><a id="_cp_text_4_159"></a><a id="_cp_text_1_160"></a><a id="_cp_text_4_161"></a><a id="_cp_text_1_162"></a><a id="_cp_text_4_163"></a><a id="_cp_text_4_164"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus was declared a pandemic by the World Health Organization in March 2020 and has spread to nearly every country in the world, including the U.S. Efforts to contain the spread of COVID-19 have intensified and many countries, including the U.S., have implemented severe travel restrictions, business shutdowns and social distancing measures that have impacted clinical development through supply chain shortages and clinical trial enrollment difficulties as hospitals reduce and redeploy staff, divert resources to patients suffering COVID-19 and limit hospital access for non-patients. The pandemic poses the risk that we, our contractors, suppliers, or other partners may be prevented from conducting normal business activities for an indefinite period of time, including those due to shutdowns that may be requested or mandated by governmental authorities.</p><a id="_cp_text_4_165"></a><a id="_cp_text_1_166"></a><a id="_cp_text_4_167"></a><a id="_cp_text_1_168"></a><a id="_cp_text_4_169"></a><a id="_cp_text_1_170"></a><a id="_cp_text_4_171"></a><a id="_cp_text_1_172"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The continued global spread of COVID-19 has affected our operations but did <span style="white-space:pre-wrap;">not have a material impact on our business, operating results, financial condition or cash flows as of and for the three months ended March 31, 2021. For example, several of our Phase 1 trials of oral ganaxolone to support the development of CDD have experienced delays in enrollment due to COVID-19; however, we do not expect these delays to impact our ability to file an NDA.  Further, in response to COVID-19, for our ongoing clinical trials, we have implemented multiple measures consistent with guidance of the FDA on the conduct of clinical trials of medical products during the COVID-19 pandemic, including implementing remote site monitoring and remote visits using telemedicine where needed. </span>However, COVID-19 may still adversely impact our clinical trials. For example, our RAISE Trial in refractory status epilepticus (RSE) is being conducted in hospitals, and resources related to the COVID-19 pandemic may divert staffing in hospitals, <span style="white-space:pre-wrap;">taking resources away from our clinical trial.  Our ganaxolone clinical trials in the outpatient setting may be negatively impacted if patients and their caregivers do not want to participate in a clinical trial while </span>COVID-19 outbreaks continue. Although operations were not materially affected by the COVID-19 pandemic as of and for the three months ended March 31, 2021, we are unable to predict the impact that COVID-19 will have in the future on our business, financial position, operating results and cash flows due to numerous uncertainties. The duration and severity of the pandemic and its long-term impact on our business are uncertain at this time, and our ability to raise sufficient additional financing depends on many factors beyond our control, including the current volatility in the capital markets as a result of the COVID-19 pandemic.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:277.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are developing ganaxolone in indications where there is a mechanistic rationale for ganaxolone to provide a benefit, including&#160;the following indications:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrns-20210331x10q007.jpg" alt="Graphic" style="display:inline-block;height:277.65pt;width:486pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Status Epilepticus (SE)</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Status epilepticus (SE) is a life-threatening condition characterized by continuous, prolonged seizures or rapidly recurring seizures without intervening recovery of consciousness. If SE is not treated urgently, permanent neuronal damage may occur, which contributes to high rates of morbidity and mortality. Patients with SE who do not respond to first-line benzodiazepine treatment are classified as having established SE (ESE) and those who then progress to and then fail at least one second-line antiepileptic drug (AED) are classified as having refractory status epilepticus (RSE). In RSE, synaptic GABA<sub style="font-size:7.5pt;vertical-align:sub;">A</sub> receptors are internalized into the neuron, resulting in decreased responsiveness to drugs such as benzodiazepines. Treatment for RSE unresponsive to one or more second-line AEDs is IV&#160;<span style="white-space:pre-wrap;">anesthesia to terminate seizures and prevent neuronal injury and other complications. The IV anesthetic is increased to a level that induces deep coma and is maintained at that rate for 24 hours or more. SE that recurs following an attempted wean of IV anesthesia is classified as super refractory status epilepticus (SRSE).  In April 2016, we were granted FDA orphan drug designation for IV formulation of ganaxolone for the treatment of SE, which includes RSE.&#160; </span></p><a id="_cp_text_1_225"></a><a id="_cp_text_1_227"></a><a id="_cp_text_1_230"></a><a id="_cp_text_1_236"></a><a id="_cp_text_1_239"></a><a id="_cp_text_1_241"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In January 2021, we enrolled the first patient in a Phase 3 pivotal clinical trial (the RAISE Trial). The RAISE Trial is a randomized, double-blind, placebo-controlled clinical trial in patients with RSE. Approximately 80 trial sites in hospitals across the U.S. will participate in the RAISE Trial. The RAISE Trial is designed to enroll approximately 124 patients, who will be randomized to receive ganaxolone or placebo added to standard of care. With this number of patients, the trial will provide over 90 percent power to detect a 30 percent efficacy difference between ganaxolone and placebo. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The co-primary endpoints for the RAISE Trial are (1) proportion of patients with RSE who experience seizure cessation within 30 minutes of treatment initiation without other medications for RSE treatment, and (2) proportion of patients with no progression to IV anesthesia for 36 hours following initiation of the study drug. We plan to announce </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">top-line data from the trial in the first half of 2022. Planning continues for a separate RSE trial to be conducted in Europe (the RAISE II Trial). Following a meeting with the EMA in the first quarter of 2021, at which we discussed study design, trial initiation is planned for the first half of 2022. The RAISE II Trial will be a double blind, placebo-controlled pivotal registration study expected to enroll 70 patients who have failed first-line benzodiazepine treatment and at least one prior second-line AED. Patients will receive either ganaxolone or placebo, administered in combination with a standard-of-care second-line AED. The RAISE II Trial in Europe differs from the RAISE trial in the U.S., with the RAISE II Trial using adjunctive ganaxolone that can be initiated earlier in the course of RSE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CDKL5 Deficiency Disorder (CDD)</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">CDD is a serious and rare genetic disorder that is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome. It predominantly affects females and is characterized by early-onset, difficult-to-control seizures and severe neuro-developmental impairment. The CDKL5 gene encodes proteins essential for normal brain function. Most children affected by CDD cannot walk normally, talk, or care for themselves. Many also suffer from scoliosis, visual impairment, gastrointestinal difficulties or sleep disorders. There are no medications approved specifically for the treatment of CDD. Genetic testing is available to determine if a patient has a mutation in the CDKL5 gene. To our knowledge, no previous late-stage clinical trials have been conducted in this patient population. In June 2017, we were granted FDA orphan drug designation for ganaxolone for the treatment of CDKL5 Disorder. &#160;Additionally,&#160;in November 2019, the European Medicine Agency&#8217;s (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug designation for ganaxolone for the treatment of CDD. </p><a id="_cp_text_1_268"></a><a id="_cp_text_1_269"></a><a id="_cp_text_1_270"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In September 2020, we announced in top-line results that ganaxolone achieved the primary endpoint in a pivotal Phase&#160;3 clinical trial (Marigold Study), which evaluated the use of oral ganaxolone in children and young adults with CDD. <span style="background-color:#ffffff;">We have </span>received feedback from the FDA that the efficacy and safety data resulting from the Marigold Study appear capable of supporting the filing of an NDA for ganaxolone in the treatment of CDD. The adequacy of these data to support an approval of ganaxolone for the proposed indication will be a matter of review for the FDA. We had a pre-NDA meeting with the FDA <span style="white-space:pre-wrap;">in March 2021 to discuss the proposed format and content of the NDA. The top-line results reported for the Marigold Study in September 2020 indicated that the primary endpoint, median 28-day major motor seizure frequency reduction, was 32.2 percent for ganaxolone compared to 4.0 percent for placebo (p=0.002). In connection with the preparation of the NDA submission for CDD, we determined that the top-line data previously reported in September 2020 included seizure diary entries that were duplicates of seizures that parents or caregivers had already entered.  The duplicate data, which was the result of programming and data transfer errors, affected approximately 1.7 percent of total seizures reported.  These duplicate entries were deleted from the final data analysis that will be submitted in the NDA  for the Marigold Study.  The final data analysis of the primary endpoint resulted in a median 28-day major motor seizure frequency reduction of 30.7 percent compared to 6.9 percent for placebo (p=0.0036).   We do not believe these changes affect the statistical or clinical conclusions of the Marigold Study</span><span style="background-color:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We also had a pre-Marketing Authorization Application (MAA) meeting with the EMA in March 2021 to discuss the proposed format and content of the MAA. W<span style="background-color:#ffffff;">e plan to submit an NDA for ganaxolone in the treatment of CDD to the FDA in mid-2021 and an MAA for ganaxolone for the treatment of CDD to the EMA at the end of the third quarter of 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In July 2020, the FDA granted Rare Pediatric Disease (RPD) Designation for ganaxolone for the treatment of&#160;<span style="white-space:pre-wrap;">CDD.  FDA grants RPD Designation for diseases that affect fewer than 200,000 people in the U.S. in which the serious or life-threatening manifestations occur primarily in individuals 18 years of age and younger. If an NDA for ganaxolone in CDD is approved, Marinus may be eligible to receive a priority review voucher from the FDA, which can be redeemed for priority review in a subsequent marketing application. The authority for the FDA to award rare pediatric disease priority review vouchers for drugs after September 30, 2024 is currently limited to drugs that RPD Designation on or prior to September 30, 2024, and the FDA may only award rare pediatric disease priority review vouchers through September 30, 2026. If the NDA for ganaxolone is not approved on or prior to September 30, 2026 for any reason, it will not be eligible for a priority review voucher. However, it is possible that the authority for the FDA to award rare pediatric disease priority review vouchers will be further extended by Congress</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#212529;">In September 2020, Ovid Therapeutics, Inc. (Ovid) contacted us and disclosed that it owns two recently issued patents that include claims that encompass our product candidates for the treatment of CDD and PCDH19. Ovid may file </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">a lawsuit against us alleging infringement of its patents and/or we may challenge the validity of Ovid&#8217;s patents with the USPTO or through the courts. Any such proceeding, regardless of its outcome, would likely result in the expenditure of significant financial resources and the diversion of management&#8217;s time and resources. In addition, any such proceeding may cause negative publicity, adversely impact patients, and we may be prohibited from marketing or selling ganaxolone for CDD and PCDH19, during such proceedings or if we are not successful in such proceedings. If Ovid does decide to bring an infringement lawsuit, we do not expect that it will be filed before a commercial launch of ganaxolone for CDD, or PCDH19, as applicable, based upon the &#8220;safe harbor&#8221; provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). We may need to acquire or obtain a license to the Ovid patents to market or sell ganaxolone for CDD and PCDH19, which may not be available on commercially acceptable terms or at all. If we are not able to acquire the Ovid patents or negotiate a license on acceptable terms, and if our product is determined to infringe Ovid&#8217;s patents and the patents are determined to be valid, then we may be forced to pay Ovid royalties, damages and costs, or we may be prevented from commercializing ganaxolone for CDD and PCDH19 altogether, which would have a material adverse impact on our business. We are also aware of a pending patent application by Ovid in the same patent family that includes claims that encompass our product candidate for the treatment of SE. This pending patent application is in the early stages of examination at the USPTO. It is possible that this pending patent application may issue as a patent with claims that encompass our product candidate for the treatment of RSE, in which case, the above risks would also apply to any such patent that was issued.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Tuberous Sclerosis Complex (TSC)</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">TSC is a rare genetic disorder that affects many organs and causes non-malignant tumors in the brain, skin, kidney, heart, eyes, and lungs. The condition is caused by inherited mutations in either the <i style="font-style:italic;">TSC1</i> gene or the <i style="font-style:italic;">TSC2</i> gene. TSC occurs with a frequency of 1:6,000 live births and a mutation is found in 85% of patients. While the disease phenotype can be extremely variable, epilepsy occurs in up to 85% of TSC patients. TSC is a leading cause of genetic epilepsy, often manifesting in the first year of life as either focal seizures or infantile spasms. There are currently few&#160;disease-specific treatments approved for seizures in TSC. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We are conducting a Phase&#160;2 open-label trial (CALM Study) to evaluate the safety and tolerability of adjunctive ganaxolone treatment in patients with TSC. The trial is expected to enroll approximately 25 patients ages 2 to 65 and consists of a four-week baseline period followed by a 12-week treatment period and a 24-week extension. Patients will receive up to 600 mg of ganaxolone (oral liquid suspension) three times a day. The primary endpoint is the percent change in 28-<span style="white-space:pre-wrap;">day seizure frequency during the treatment period relative to baseline. We expect to report top-line data in the third quarter of 2021 and also plan to further explore whether allopregnanolone sulfate levels represent a response biomarker. Our interim evaluation of the dataset in the CALM Study supports our plan to move to a Phase 3 trial in the third quarter of 2021.  An end of Phase 2 meeting with the FDA is targeted for the third quarter of 2021 and a meeting with the EMA is targeted for the fourth quarter of 2021 with the first patient enrolled in the Phase 3 clinical trial in the fourth quarter of 2021. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">PCDH19-Related Epilepsy (PCDH19-RE)</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">PCDH19-RE is a rare epileptic syndrome characterized by early-onset seizures, cognitive and sensory impairment, and psychiatric and behavioral disturbances. Seizures occur in clusters lasting from several hours to days. The disorder is caused by a mutation in the PCDH19 gene on the X-chromosome. Unlike other X-linked disorders, it selectively affects females with very few cases reported in males. The gene encodes a protein involved in cell adhesion that is widely expressed in the central nervous system. There are no drugs approved specifically for the treatment of seizures associated with PCDH19-RE. </p><a id="_cp_text_1_296"></a><a id="_cp_text_1_298"></a><a id="_Hlk38273480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We conducted a Phase 2 proof-of-concept (POC) clinical trial (Violet Study) of ganaxolone treatment in patients with PCDH19-RE, in which enrollment was stratified based on allopregnanolone sulfate, a potential biomarker for the antiepileptic efficacy of ganaxolone.&#160; We enrolled<span style="white-space:pre-wrap;"> 21 patients in one of two strata based on baseline allopregnanolone sulfate levels.  The trial consisted of a 12-week prospective baseline period, followed by a 17-week double-blind treatment phase. Patients were titrated over four weeks to a dose of up to 600 mg </span><span style="white-space:pre-wrap;">of ganaxolone oral liquid suspension or matching placebo three times daily and maintain that dose for the following 13 weeks. Physicians have been offered the opportunity to continue treating patients with ganaxolone following the completion of the protocol-specified treatment on a compassionate-use basis.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The primary efficacy endpoint was the percent change in 28-day primary seizure frequency during the 17-week double-blind phase relative to the baseline. The primary seizure types were defined in the protocol as countable focal seizures that included progressive hypotonia and impaired awareness, or any countable focal or generalized seizure with a clear motor component. Focal and generalized nonmotor seizures and myoclonic seizures did not count as the primary seizure types for the primary efficacy endpoint. The analyses of the primary endpoint were performed on the sum of the individual countable seizures and each series of continuous uncountable seizures (each contributes one to the sum).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="white-space:pre-wrap;">In March 2021, we announced top-line data from the Violet Study. In the trial, patients on ganaxolone experienced a median 61.5% reduction in primary endpoint seizure frequency compared to a median 24.0% reduction in patients on placebo (p=0.17).  Ganaxolone was generally well tolerated, with one patient in the ganaxolone arm discontinuing treatment due to a serious adverse event (SAE), psychogenic nonepileptic seizures, judged by the investigator to be ganaxolone-related.  Allopregnanolone sulfate levels were not predictive of ganaxolone response, indicating that levels of this compound do not represent a response biomarker in the disorder.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Lennox-Gestaut Syndrome (LGS)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>LGS is a severe form of epilepsy that typically begins between one and eight years of age. Affected children experience multiple seizure types that are often unresponsive to treatment, the most common being atonic, tonic and atypical absence seizures. Children with LGS may also have neurodevelopmental delay and behavioral problems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We are pursuing the development of ganaxolone for LGS, given the overlap in seizure types and etiologies with other disorders where ganaxolone has potential to improve clinical outcomes, such as CDD and TSC. We plan to present additional details on clinical development plans for LGS in the second half of 2021, targeting initiation of a Phase 2 clinical trial in mid-2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reverse stock split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="white-space:pre-wrap;">On September 23, 2020, we effected a 1-for-4 reverse split of shares of our common stock (Reverse Split), as approved by our Board of Directors and stockholders.  The par value per share of our common stock was not adjusted as a result of the Reverse Split, and our authorized shares of common stock was reduced to 150,000,000.  All of the share and per share amounts included in this Quarterly Report on Form 10-Q have been adjusted to reflect the Reverse Split.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations to date have consisted primarily of organizing and staffing our company and developing ganaxolone, including conducting preclinical studies, clinical trials and raising capital. We have funded our operations primarily through sales of equity and debt securities. At March 31, 2021, we had cash and cash equivalents of $123.5&#160;<span style="white-space:pre-wrap;">million.  We have no products currently available for sale, have incurred operating losses since inception, have not generated any product sales revenue and have not achieved profitable operations. We incurred a net loss of $27.1 million and $18.7 million for the three months ended March 31, 2021 and 2020, respectively.  Our accumulated deficit as of March 31, 2021 was $339.1&#160;million, and we expect to continue to incur substantial losses in future periods. We anticipate that our operating expenses will increase substantially as we continue to advance our clinical-stage product candidate, ganaxolone. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our expenses will increase substantially as we:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">conduct later stage clinical trials in targeted indications;</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">continue the research, development and scale-up manufacturing capabilities to optimize ganaxolone and dose forms for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">conduct other preclinical studies and clinical trials to support the filing of NDAs with the FDA, MMAs with the EMA and other marketing authorization filings with regulatory agencies in other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">acquire the rights to other product candidates and fund their development; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">maintain, expand and protect our global intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">hire additional clinical, manufacturing and scientific personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">add operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">We believe that our cash and cash equivalents balances as of March 31, 2021, including the net upfront proceeds received in May 2021 from our Credit Agreement, will enable us to fund our operating expenses and capital expenditure requirements through the second quarter of 2022. However, we will need to secure additional funding in the future, from one or more equity or debt financings, government funding, collaborations, licensing transactions, other commercial transactions or other sources, in order to carry out all of our planned research, development and commercialization activities with respect to ganaxolone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal Contract Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background-color:#ffffff;">In September 2020, we entered into a contract (the BARDA Contract) with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response. Under the BARDA Contract, we will receive an award of up to an estimated $51 million for development of IV administered ganaxolone for the treatment of RSE. Funding will include support on a cost-sharing basis for completion of a Phase 3 clinical trial of IV-administered ganaxolone in patients with RSE who are refractory to second line anti-epileptic drugs, funding of pre-clinical studies to assess whether IV-administered ganaxolone is an effective treatment for RSE due to chemical nerve gas agent exposure, and funding of certain manufacturing scale-up and regulatory activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The BARDA Contract consists of an approximately two-year base period-during which BARDA will provide approximately $21 million of funding for the RSE Phase 3 clinical trial on a cost share basis and funding of additional preclinical studies of ganaxolone in nerve agent exposure models. Following successful completion of the RSE Phase 3 clinical trial and preclinical studies in the base period, the BARDA Contract provides for approximately $30 million of additional BARDA funding for three options in support of manufacturing, supply chain, clinical, regulatory and toxicology activities. Under the BARDA Contract, we will be responsible for cost sharing in the amount of approximately $33 million and BARDA in the amount of approximately $51 million if all development options are completed. The contract period-of-performance (base period plus option exercises) is up to approximately five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="white-space:pre-wrap;">We recognize federal contract revenue from the BARDA Contract in the period in which the allowable research and development expenses are incurred.  We expect federal contract revenue to increase as the associated costs with our RSE Phase 3 clinical trial increase.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses consist primarily of costs incurred for the development of ganaxolone, which include:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">expenses incurred under agreements with clinical research organizations (CROs) and investigative sites that conduct our clinical trials and preclinical studies;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the cost of acquiring, developing and manufacturing clinical trial materials;</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">costs associated with preclinical activities and regulatory operations.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We expense research and development costs when we incur them. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations and information our vendors provide to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We will incur substantial costs beyond our present and planned clinical trials in order to file an NDA and Supplemental New Drug Applications (sNDAs), or an MAA outside the US, for ganaxolone for various clinical indications, and in each case, the nature, design, size and cost of further clinical trials and other studies will depend in large part on the outcome of preceding studies and trials and discussions with regulators. It is difficult to determine with certainty the costs and duration of our current or future clinical trials and preclinical studies, or if, when or to what extent we will generate revenue from the commercialization and sale of ganaxolone if we obtain regulatory approval. We may never succeed in achieving regulatory approval for ganaxolone. The duration, costs and timing of clinical trials and development of ganaxolone will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the probability of success for our clinical programs will depend on numerous factors, including competition, manufacturing capability and commercial viability. See &#8220;Risk Factors.&#8221; Our commercial success depends upon attaining significant market acceptance, if approved, among physicians, patients, healthcare payers and the medical community. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success, as well as an assessment of commercial potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">General and administrative expenses consist principally of salaries and related costs for executive and other administrative personnel and consultants, including stock-based compensation and travel expenses. Other general and administrative expenses include professional fees for legal, patent review, consulting and accounting services. General and administrative expenses are expensed when incurred. We expect that our general and administrative expenses will increase in the future as a result of employee hiring and our scaling-up of operations commensurate with supporting more advanced clinical trials and in preparation for commercial infrastructure. These increases will likely include increased costs for insurance, hiring of additional personnel, outside consultants, legal counsel and accountants, among other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest income consists principally of interest income earned on cash and cash equivalents and investment balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal Contract Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Federal contract revenue was $1.8 million for the three months ended March 31, 2021, compared to $0 for the three months ended March 31, 2020 as a result of the BARDA Contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research</span><i style="font-style:italic;"> </i><span style="font-style:italic;font-weight:bold;">and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We allocate direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, and costs related to manufacturing or purchasing clinical trial materials, to specific product development programs. We do not allocate employee and contractor-related costs, costs associated with our facility expenses, including depreciation or other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">indirect costs, to specific product programs because these costs are deployed across multiple product programs under research and development and, as such, are separately classified. The table below shows our research and development expenses incurred with respect to each active program, in thousands. The primary drivers of our research and development expenditures are currently in our product development programs in RSE, CDD, TSC and PCDH19-RE.  We expect our research and development expenses for ganaxolone will continue to increase during subsequent periods. We did not allocate research and development expenses to any other specific product development programs during the periods presented (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CDKL5 deficiency disorder (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,757</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,598</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Refractory status epilepticus (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,463</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PCDH19-related epilepsy (3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,039</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,180</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tuberous Sclerosis (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,755</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 428</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indirect research and development (5)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,847</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,335</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,591</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,004</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Note: Certain prior year expenses have been reclassified to conform to current year presentation.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The decrease in the three months ended March 31, 2021 was due to completion of the Phase 3 trial and data read out in the third quarter of 2020. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The increase is due primarily to enhanced drug development activity, including preclinical studies and manufacturing activities for our ongoing Phase 3 clinical trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Costs related to PCDH19-related epilepsy remained flat for the three months ended March 31, 2021 compared to March 31, 2020. During the three months ended March 31, 2021, we primarily incurred study closeout activities as a result of reducing the scope of the clinical trial in 2020 from a Phase 3 trial to a Phase 2 proof-of-concept trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The increase was due to the fact that we began making preparations for a Phase 2 clinical trial in TSC during the first quarter of 2020, and enrollment was ongoing in an open label extension during the first quarter of 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Indirect research and development expenses in support of all our programs have increased due to the overall increase in preclinical, clinical, manufacturing and commercialization activities, and increased headcount.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">General and administrative expenses were $10.4 million and $3.9 million for the three months ended March 31, 2021 and 2020, respectively. The primary drivers of the increase were $1.8 million in increased commercialization preparation, $1.6 million in increased personnel costs and $2.7 million in increased noncash stock-based compensation.  Of the increased noncash stock-based compensation, $2.1 million was due to modifications of stock options in connection with a severance agreement with our former Chief Financial Officer.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Since inception, we have incurred net losses and negative cash flows from our operations. We incurred net losses of $27.1 million and $18.7 million for the three months ended March 31, 2021 and 2020, respectively.  Our cash used in operating activities was $16.2 million for the three months ended March 31, 2021 compared to&#160;</span><span style="white-space:pre-wrap;">$14.0 million for the same period a year ago.  Historically, we have financed our operations principally through the sale of common stock, preferred stock and convertible debt, and the use of term loans.  At March 31, 2021, we had cash and cash equivalents of $123.5 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Oaktree Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 11, 2021 (the Closing Date), we entered into a Credit Agreement and Guaranty (as amended by that certain letter agreement on May 17, 2021, the Credit Agreement) with Oaktree Fund Administration, LLC, as administrative agent and the lenders party thereto that provides for a five-year senior secured term loan facility in an aggregate original principal amount of up to $125.0 million available to us in five tranches as follows (collectively, the Term Loans):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$15.0 million of tranche A-1 term loans advanced on the Closing Date. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$30.0 million of tranche A-2 term loans subject to written acceptance by the FDA of an NDA filing relating to the use of ganaxolone in the treatment of CDD.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$30.0 million of tranche B term loans subject to receipt of written approval from the FDA of an NDA permitting the marketing of ganaxolone in the United States to treat CDD (the FDA Approval).</span></td></tr></table><a id="_Hlk71288605"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">$25.0 million of tranche C term loans subject to receipt of the FDA Approval and the completion of one or more financings, including through the issuance of common stock, convertible debt, subordinated debt, a synthetic royalty or a sublicense in which we receive gross proceeds in an aggregate amount of at least $40.0 million and net proceeds in an aggregate amount of at least $36.0 million.  In addition, the availability of this tranche is subject to  either our current Phase 3 trial in RSE or a Phase 3 trial in TSC achieving statistical significance (p value &lt; 0.05) across all primary endpoints and ganaxolone must be generally well tolerated, with a safety profile generally consistent with previous clinical trials.</span></td></tr></table><a id="_Hlk71288441"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$25 million of tranche D term loans subject to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">receipt of the FDA Approval and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">us earning at least $50 million in net product revenue in the United States for a period of six consecutive months.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Term Loans will bear interest at a fixed per annum rate (subject to increase during an event of default) of 11.50% and are scheduled to mature on the fifth anniversary of the Closing Date (the Maturity Date). In addition, at the time of funding of any tranche of the Term Loans, we are required to pay an upfront fee of 2.0% of the aggregate principal amount being funded. We are required to make quarterly interest payments until the Maturity Date. We are also required to make principal payments, which are payable in quarterly installments beginning on the last day of the first quarter ending after the third anniversary of the Closing Date in an amount equal to 5.0% of the aggregate amount of the Term Loans outstanding on the date of the first such quarterly principal payment and continuing until the Maturity Date, on which date all outstanding Term Loans and other amounts owed under the Credit Agreement will be required to be paid in full. A commitment fee of 75 basis points per annum will accrue on each of the tranche B, C and D commitments for the period beginning 120 days after the funding date of the tranche A-2 term loans until the applicable tranche is either funded or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">BARDA Contract</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="background-color:#ffffff;">In September 2020, we entered into the BARDA Contract with BARDA. Under the BARDA Contract, we will receive an award of up to an estimated $51 million for development of IV administered ganaxolone for the treatment of </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;">RSE. Funding will include support on a cost-sharing basis for completion of a Phase 3 clinical trial of IV-administered ganaxolone in patients with RSE who are refractory to second line anti-epileptic drugs, funding of pre-clinical studies to assess whether IV-administered ganaxolone is an effective treatment for RSE due to chemical nerve gas agent exposure, and funding of certain manufacturing scale-up and regulatory activities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">The BARDA Contract consists of an approximately two-year base period-during which BARDA will provide approximately $21 million of funding for the RSE Phase 3 clinical trial on a cost share basis and funding of additional preclinical studies of ganaxolone in nerve agent exposure models. Following successful completion of the RSE Phase 3 clinical trial and preclinical studies in the base period, the BARDA Contract provides for approximately $30 million of additional BARDA funding for three options in support of manufacturing, supply chain, clinical, regulatory and toxicology activities. Under the BARDA Contract, we will be responsible for cost sharing in the amount of approximately $33 million and BARDA in the amount of approximately $51 million if all development options are completed. The contract period-of-performance (base period plus option exercises) is up to approximately five years<span style="background-color:#ffffff;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Financings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">In connection with the closing of an equity financing in December 2020, we issued a total of 5,000,000 shares of common stock in an underwritten public offering resulting in aggregate net proceeds, after underwriting discounts and commissions in the public offering and other estimated offering expenses, of $64.9 million</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">In connection with the closing of an equity financing in June 2020, we issued a total of 4,600,000 shares of common stock in an underwritten public offering resulting in aggregate net proceeds, after underwriting discounts and commissions in the public offering and other estimated offering expenses, of $42.9 million.</p><a id="_cp_text_1_68"></a><a id="_cp_text_1_69"></a><a id="_cp_text_1_71"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">In October 2017, we entered into an Equity Distribution Agreement (Prior EDA) with JMP Securities LLC (JMP), under which JMP, as our exclusive agent, at our discretion and at such times that we may determine from time to time, may sell over a three-year period from the execution of the agreement up to a maximum of $50 million of shares of our common stock. During the year ended December 31, 2020, we issued 78,807 shares of our common stock pursuant to the Prior <span style="white-space:pre-wrap;">EDA for aggregate net proceeds of $0.6 million.  </span>On July 9, 2020, we entered into a new Equity Distribution Agreement (New EDA) with JMP to create an at the market equity program under which we from time to time may offer and sell shares of our common stock having an aggregate offering price of up to $60.0 million through or to JMP. Subject to the terms and conditions of the New EDA, JMP will use its commercially reasonable efforts to sell shares of our common stock from time to time, based upon our instructions. JMP will be entitled to a commission of up to 3.0% of the gross proceeds from each sale of shares of our common stock. The New EDA superseded and terminated the Prior EDA effective immediately upon effectiveness of our shelf registration statement on Form S-3 (File No. 333-239780) filed with the Securities and Exchange Commission on July 9, 2020 and declared effective by the Securities and Exchange Commission on July 27, 2020.<span style="white-space:pre-wrap;">  We did not sell any shares of our common stock during the three months ended March 31, 2021 under the New EDA. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Activities.</i><span style="white-space:pre-wrap;">  Cash used in operating activities increased to $16.2 million for the three months ended March 31, 2021 compared to $14.0&#160;</span><span style="white-space:pre-wrap;">million for the same period a year ago. The increase was driven primarily by a $8.5 million increase in net loss, offset by an increase of $3.1 million in the change in accounts payable, accrued expenses and other  non-current liabilities as we make commercial preparations and continue enrollment in our Phase 3 clinical trial in RSE and a $3.2 million increase in noncash stock based compensation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities.</i><span style="white-space:pre-wrap;">  Cash provided by investing activities for the three months ended March 31, 2021 represents the maturity of short-term investments of $1.5 million offset by $0.4 million in deposits on fixed assets.  Cash used in investing activities for the three months ended March 31, 2020 represents purchases of investments of $8.4 million offset by $1.7 million in maturities of short-term investments.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities.</i><span style="white-space:pre-wrap;">  Cash provided by financing activities for the three months ended March 31, 2021 and 2020 each represents proceeds from the exercise of stock options offset by payments of financing costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not achieved profitability since our inception, and we expect to continue to incur net losses for the foreseeable future. We expect our cash expenditures to increase in the near term as we fund our continuing and planned clinical trials for ganaxolone, as well as scale up our operations and prepare for the potential commercialization of ganaxolone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our cash and cash equivalents as of March 31, 2021, including the net upfront proceeds received in May 2021 from our Credit Agreement, will enable us to fund our operating expenses and capital expenditure requirements through the second quarter of 2022. However, we will need to raise substantial additional financing in the future to fund our operations. In order to meet these additional cash requirements, we may seek to sell additional equity or convertible debt securities that may result in dilution to our stockholders, or engage in federal contracts or other partnerships. If we raise additional funds through the issuance of convertible debt securities, these securities could have rights senior to those of our common stock and could contain covenants that restrict our operations. There can be no assurance that we will be able to obtain additional equity or debt financing on terms acceptable to us, if at all. Further, the continued spread of COVID-19 has also led to severe disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets in the future. Our failure to obtain sufficient funds on acceptable terms when needed could have a negative impact on our business, results of operations, and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the effects of the COVID-19 pandemic on our business, the medical community and the global economy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the results of our preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the development, formulation and commercialization activities related to ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the scope, progress, results and costs of researching and developing ganaxolone or any other future product candidates, and conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing of, and the costs involved in, obtaining regulatory approvals for ganaxolone or any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the cost of commercialization activities if ganaxolone or any other future product candidates are approved for sale, including marketing, sales and distribution costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the cost of manufacturing and formulating ganaxolone, or any other future product candidates, to internal and regulatory standards for use in preclinical studies, clinical trials and, if approved, commercial sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to receive funding under the BARDA Contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">any product liability, infringement or other lawsuits related to our product candidates and, if approved, products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">capital needed to attract and retain skilled personnel;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing, receipt and amount of sales of, or royalties on, future approved products, if any.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Please see &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Discussion of Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires us to use judgment in making certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in our financial statements and accompanying notes. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require difficult, subjective and complex judgments by management in order to make estimates about the effect of matters that are inherently uncertain. During the three months ended March 31, 2021, there were no significant changes to our critical accounting policies from those described in our annual financial statements for the year ended December&#160;31, 2020, which we included in our Annual Report on Form 10-K and was filed with the SEC on March 9, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a6d7d205_437b_4e80_bd54_fa58ab540c5f"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 3. Quantitative and Qualitative D</b><b style="font-weight:bold;">isclosures About Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (Exchange Act) and are not required to provide the information under this item</span>.</p><a id="_2fa8ae2d_18d0_429b_938d_06ffc0de7923"></a><a id="Item4ControlsandProcedures_322196"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 4. Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">(a) <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Evaluation of Disclosure Controls and Procedures</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form&#160;10-Q to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules&#160;and forms, and that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">(b) <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Changes in Internal Control Over Financial Reporting</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_5b6e35fc_7147_45ce_a90c_c68d4bbe1129"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII_783516"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">PART II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OTHER INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Item1LegalProceedings_405261"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1. Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.</p><a id="_5585d5f8_9aca_4651_a515_4be6a157bbdc"></a><a id="Item1ARiskFactors_482494"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1A. Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_cp_blt_2_23"></a><a id="_cp_text_1_48"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our business is subject to substantial risks and uncertainties. The occurrence of any of the following risks and uncertainties, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations or prospects. In these circumstances, the market price of our common stock could decline and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Risks and uncertainties of general applicability and additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business, financial condition, results of operations or prospects.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses since our inception, including a net loss of $27.1 million for the three months ended March 31, 2021. As of March 31, 2021, we had an accumulated deficit of $339.1 million. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Our losses have resulted principally from costs incurred in our research and development activities. We anticipate that our operating losses will substantially increase over the next several years as we execute our plan to expand our research, development and commercialization activities, including the clinical development and planned commercialization of our product candidate, ganaxolone. In addition, if we obtain regulatory approval of ganaxolone, we may incur significant sales and marketing expenses. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or whether or when we will become profitable, if ever. The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have not generated any revenue to date from product sales. We may never achieve or sustain profitability, which could depress the market price of our common stock, and could cause you to lose all or a part of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have no products approved for commercial sale and have not generated any revenue from sales of any of our product candidates, and we do not know when, or if, we will generate revenues in the future. Our ability to generate revenue from product sales and achieve profitability will depend upon our ability to successfully gain regulatory approval and commercialize ganaxolone or other product candidates that we may develop, in-license or acquire in the future. Even if we obtain regulatory approval for ganaxolone, we do not know when we will generate revenue from product sales, if at all. Our ability to generate revenue from product sales of ganaxolone or any other future product candidates also depends on a number of additional factors, including our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">successfully complete pre-clinical and clinical development activities, including enrollment of clinical trial participants, completion of the necessary pre-clinical studies and clinical trials and attainment of study and trial results that will support regulatory approvals;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">complete and submit NDAs to the FDA, MAAs with the EMA and other marketing authorization filings with regulatory agencies in other countries, and obtain regulatory approval for indications for which there is a commercial market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">make or have made commercial quantities of our products at acceptable cost levels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">develop a commercial organization capable of manufacturing, selling, marketing and distributing any products we intend to sell ourselves in the markets in which we choose to commercialize on our own;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">find suitable partners to help us market, sell and distribute our approved products in other markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">obtain adequate pricing, coverage and reimbursement from third parties, including government and private payers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">launch and commercialize product candidates for which we obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">obtain market acceptance of our product candidates as viable treatment options; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">address any competing technological and market developments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">implement additional internal systems and infrastructure, as needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">identify and validate new product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">negotiate favorable terms in any collaboration, licensing or other commercial arrangements into which we may enter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">maintain, protect and expand our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">attract, hire and retain qualified personnel. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, because of the numerous risks and uncertainties associated with product development, including that ganaxolone may not advance through development or achieve the endpoints of applicable preclinical studies and clinical trials, we are unable to predict the timing or amount of increased expenses, or if or when we will be able to achieve or maintain profitability. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies, domestic or foreign, to perform preclinical studies and clinical trials or other studies in addition to those that we currently anticipate. Even if we are able to complete the development and regulatory process for ganaxolone, we anticipate incurring significant costs associated with commercializing ganaxolone. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we are able to generate revenue from the sale of ganaxolone or any future commercial products, we may not become profitable and will need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, and we are not successful in obtaining additional funding, then we may be unable to continue our operations at planned levels, or at all, which would likely materially and adversely affect our business and the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will require additional capital to fund our operations and if we fail to obtain necessary financing, we may be unable to complete the development and commercialization of ganaxolone.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical and regulatory development of ganaxolone and, if approved, commercialize ganaxolone. We will require additional capital for the further development, regulatory submission and potential commercialization of ganaxolone and may also need to raise additional funds sooner should we choose to accelerate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">development of ganaxolone. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents as of March 31, 2021, including the net upfront proceeds received in May 2021 from our Credit Agreement, will enable us to fund our operating expenses and capital expenditure requirements through the second quarter of 2022. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to the:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for ganaxolone or any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">clinical development plans we establish for ganaxolone and any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">obligation to make royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our existing or any future licensing agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to receive funding under the BARDA Contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">number and characteristics of product candidates that we discover or in-license and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outcome, timing and cost of regulatory review by the FDA, the EMA and other comparable foreign regulatory authorities, including the potential for the FDA, the EMA or other comparable foreign regulatory authorities to require that we perform more studies or clinical trials than those that we currently expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">effects of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our obligations to make principal and interest payments under the Credit Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">costs and timing of the implementation of commercial-scale manufacturing activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">costs and timing of establishing sales, marketing and distribution capabilities for ganaxolone or any other product candidates for which we may receive regulatory approval.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.  Failure to progress our product development or commercialization of ganaxolone as anticipated will have a negative effect on our business, future prospects and ability to obtain further financing on acceptable terms, if at all, and the value of the enterprise, which could require us to, among other things:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">significantly delay, scale back or discontinue the development or commercialization of ganaxolone or one or more of our other research and development initiatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">sell or license on unfavorable terms our rights to ganaxolone or one of our future product candidates that we otherwise would seek to develop or commercialize ourselves; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seek bankruptcy protection.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our failure to comply with the covenants or other terms of the Credit Agreement, including as a result of events beyond our control, could result in a default under the Credit Agreement that could materially and adversely affect the ongoing viability of our business.</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_9"></a><a id="_cp_text_1_10"></a><a id="_cp_text_1_11"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On May 11, 2021 (the Closing Date), we entered into a Credit Agreement and Guaranty (as amended by that certain letter agreement on May 17, 2021, the Credit Agreement) with Oaktree Fund Administration, LLC, as administrative agent (the Administrative Agent) and the lenders party thereto (the Lenders) that provides for a five-year senior secured term loan facility in an aggregate original principal amount of up to $125.0 million, consisting of (i) tranche A-1 term loans in an aggregate principal amount of $15.0 million advanced on the Closing Date, (ii) tranche A-2 term loans in an aggregate principal amount of $30.0 million, (iii) tranche B term loans in an aggregate principal amount of $30.0 million, (iv) tranche C term loans in an aggregate principal amount of $25.0 million and (v) tranche D term loans in an aggregate principal amount of $25.0 million (collectively, the Term Loans).  Our ability to draw each tranche of the Term Loans is subject to the satisfaction of certain conditions applicable to each tranche as specified in the Credit Agreement.  The Term Loans bear interest at a fixed per annum rate (subject to increase during an event of default) of 11.50% and are scheduled to mature on the fifth anniversary of the Closing Date (the Maturity Date). In addition, at the time of funding of any tranche of the Term Loans, we are required to pay an upfront fee of 2.0% of the aggregate principal amount being funded. We are required to make quarterly interest payments until the Maturity Date. We are also required to make principal payments, which are payable in quarterly installments beginning on the last day of the first quarter ending after the third anniversary of the Closing Date, in an amount equal to 5.0% of the aggregate amount of the Term Loans outstanding on the date of the first such quarterly principal payment and continuing until the Maturity Date, on which date all outstanding Term Loans and other amounts owed under the Credit Agreement will be required to be paid in full.  A commitment fee of 75 basis points per annum will accrue on each of the tranche B, C and D commitments for the period beginning 120 days after the funding date of the tranche A-2 term loans until the applicable tranche is either funded or terminated.  The Term Loans will be guaranteed by certain of our future subsidiaries.  Our obligations under the Credit Agreement and the guarantee of such obligations are secured by a pledge of substantially all of our assets and will be secured by a pledge of substantially all of the assets of the future guarantors.&#160;&#160;&#160;&#160;</span>The Credit Agreement contains various covenants that limit our ability to engage in specified types of transactions without the Administrative Agent&#39;s prior consent, as well as a financial covenant that requires us to maintain at all times cash and cash equivalents in certain deposit accounts in an amount at least equal to (i) from the Closing Date until the funding of the tranche A-2 term loans, $10.0 million, (ii) from the funding date of the tranche A-2 term loans until the funding date of the tranche B term loans, $20.0 million, and (iii) from the funding of the tranche B term loans until the Maturity Date, $15.0 million<span style="white-space:pre-wrap;">.  </span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Administrative Agent may elect to accelerate the repayment of all unpaid principal of the Term Loans, accrued interest and other amounts owed under the Credit Agreement upon consummation of a specified change of control transaction or the occurrence of certain events of default (as specified in the Credit Agreement), including, among other things:</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our default in a payment obligation under the Credit Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our breach of the restrictive covenants or other terms of the Credit Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our breach of reporting obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our failure to properly maintain the collateral;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">certain regulatory actions that causes an ongoing delay in commercialization of ganaxolone and which could reasonably be expected to result in a material adverse effect; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a recall of ganaxolone that could reasonably be expected to result in a material adverse effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">following the sale of ganaxolone by us in the United States to treat CDD, an injunction against the sale or manufacture of ganaxolone for more than 45 days that could, after the termination of such 45-day period, reasonably be expected to result in a material adverse effect; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">certain specified insolvency and bankruptcy-related events.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subject to any applicable cure period set forth in the Credit Agreement, all amounts outstanding with respect to the Term Loans (principal and accrued interest), as well as any applicable prepayment premiums, interest &#8220;make-whole&#8221; payments or exit fees, would become due and payable (i) immediately, in the case of a payment or bankruptcy event of default or (ii) in the case of any other event of default, upon the request of Lenders holding at least a majority of the outstanding Term Loans and Term Loan commitments, at a default interest rate of 13.50%. Our assets or cash flow may not be sufficient to fully repay our obligations under the Term Loans if the obligations thereunder are accelerated upon any events of default. The duration and magnitude of any negative impact from the COVID-19 pandemic on ganaxolone commercialization, development or net revenues could also affect our ability to meet the requirements to draw on one or more of the Term Loan tranches and to remain in compliance with our liquidity financial covenant. Further, if we are unable to repay, refinance or restructure our obligations under the Term Loans, the Administrative Agent on behalf of the Lenders could proceed to protect and enforce their rights under the Credit Agreement and other loan documents by exercising such remedies (including foreclosure on the assets securing our obligations under the Credit Agreement and the other loan documents) as are available to the Administrative Agent and Lenders and in respect thereof under applicable law, either by suit in equity or by action at law, or both, whether for specific performance of any covenant or other agreement contained in the Credit Agreement or other loan documents or in aid of the exercise of any power granted in the Credit Agreement or other loan documents. The foregoing would materially and adversely affect the ongoing viability of our business.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our Credit Agreement contains restrictions that limit our flexibility in operating our business.</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Credit Agreement contains various covenants that limit our ability to engage in specified types of transactions without the prior consent of the Administrative Agent and the Lenders holding a majority of the Term Loan commitments. These covenants limit our ability to, among other things:</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">sell, transfer, lease or dispose of our assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">create, incur or assume additional indebtedness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">encumber or permit liens on certain of our assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">make restricted payments, including paying dividends on, repurchasing or making distributions with respect to our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">make specified investments (including acquisitions, loans and advances);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">enter into certain transactions with our affiliates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">grant certain license rights related to our products, technology and other intellectual property rights; and</span></td></tr></table><a id="_cp_text_1_12"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">permit our cash and cash equivalents held in certain deposit accounts to at any time be less than (i) from the Closing Date until the funding of the tranche A-2 term loans, $10.0 million, (ii) from the funding of the tranche A-2 term loans</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> until the funding of the tranche B term loans</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, $20.0 million and (ii) from the funding date of the tranche B term loans until the Maturity Date, $15.0 million</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The covenants in our Credit Agreement and related security agreements may limit our ability to take certain actions that may be in our long-term best interests. In the event that we breach one or more covenants, the Administrative Agent may choose to declare an event of default and require that we immediately repay all amounts outstanding under the Credit Agreement, plus penalties and interest, terminate the Lenders&#8217; commitments to fund any undrawn Term Loan tranches and foreclose on the collateral granted to them to secure the obligations under the Credit Agreement and the other loan </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">documents. Such repayment could have a material adverse effect on our business, operating results and financial condition.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital could dilute our stockholders, restrict our operations or require us to relinquish rights to ganaxolone or any other future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until we can generate substantial revenue from product sales, if ever, we expect to seek additional capital through a combination of private and public equity offerings, debt financings, government funding, collaborations, licensing arrangements and other commercial transactions and funding opportunities. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of stockholders. Debt financing or other commercial transactions, if available, may involve agreements that include liens or restrictive covenants limiting our ability to take important actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, licensing arrangements or other commercial with third parties, we may have to relinquish valuable rights to ganaxolone or any other future product candidates in particular countries, or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market ganaxolone or any other future product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We intend to expend our limited resources to pursue our sole clinical stage product candidate, ganaxolone, and may fail to capitalize on other technologies or product candidates that may be more profitable or for which there may be a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we are focusing on research programs relating to ganaxolone, which concentrates the risk of product failure in the event ganaxolone proves to be ineffective or inadequate for clinical development or commercialization. As a result, we may forego or delay pursuit of opportunities for other technologies or product candidates that later could prove to have greater commercial potential. We may be unable to capitalize on viable commercial products or profitable market opportunities as a result of our resource allocation decisions. Our spending on proprietary research and development programs relating to ganaxolone may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for ganaxolone, we may relinquish valuable rights to ganaxolone through collaboration, licensing or other commercial arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to ganaxolone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations to date have been limited to conducting preclinical and clinical development activities for ganaxolone and performing research and development with respect to our preclinical and clinical programs. In addition, as a clinical stage pharmaceutical company, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical area. Nor have we demonstrated an ability to obtain regulatory approval to commercialize any product candidate. Consequently, any predictions about our future performance may not be as accurate as they would be if we had a history of successfully developing and commercializing pharmaceutical products. Further, our budgeted expense levels are based in part on our expectations concerning the costs of our research, preclinical development and clinical trials, which depend on the success of such activities, and our ability to effectively and efficiently conduct such research, preclinical development, clinical trials and our expectations related to our efforts to achieve FDA or foreign regulatory approval with respect to ganaxolone. Our limited operating history and clinical trial experience make these costs difficult to forecast accurately. We may be unable to adjust our operations in a timely manner to compensate for any unexpected increase in costs. Further, our manufacturing costs and operating expenses may increase significantly as we expand our operations. Accordingly, a significant increase in costs could have an immediate and material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, we had U.S. net operating loss, or NOL, carryforwards of approximately $212.0 million for U.S. federal income tax and approximately $209.5 million for state income tax purposes available to offset future taxable income and U.S. federal and state research and development tax credits of approximately $11.5 million, prior to consideration of annual limitations that may be imposed under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382. Our U.S. NOL carryforwards begin to expire in 2023 if not utilized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our U.S. NOL and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under Section&#160;<span style="white-space:pre-wrap;">382, and corresponding provisions of U.S. state law, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change U.S. NOLs and other pre-change tax attributes, such as research and development tax credits, to offset its post-change income may be limited. We have completed several financings since our inception that may have resulted in &#8220;ownership changes&#8221; within the meaning of Section 382. We have not evaluated the ownership history of our company to determine if there were any ownership changes as defined under Section 382 and the effects any ownership change may have had. We may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, including through completed or contemplated financings, some of which may be outside of our control. If we determine that a future ownership change has occurred and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.  Furthermore, the losses could expire before we generate sufficient income to utilize them.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Clinical Development and Regulatory Approval of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success is dependent on the successful clinical development, regulatory approval and commercialization of ganaxolone, which is being studied in clinical trials and will require significant capital resources and years of additional clinical development effort.</span></p><a id="_cp_text_1_2406"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have any products that have gained regulatory approval in any jurisdiction. Our only clinical stage product candidate is ganaxolone. As a result, our business is dependent on our ability to successfully complete clinical development, scale-up manufacturing, obtain regulatory approval, and, if approved, commercialize ganaxolone in a timely manner. We cannot commercialize ganaxolone in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize ganaxolone outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of ganaxolone for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials and, with respect to approval in the United States, to the satisfaction of the FDA, that ganaxolone is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has provided guidance to the industry that the substantial evidence requirement for effectiveness, which had generally been interpreted as calling for two adequate and well-controlled clinical trials, could also be met by a single clinical trial plus confirmatory evidence. In September 2020, we announced that ganaxolone achieved the primary endpoint in the Marigold Study, which evaluated the use of oral ganaxolone in children and young adults with CDD. We requested feedback from the FDA as to whether the Marigold Study could serve as a single pivotal efficacy trial to support the approval of ganaxolone for the treatment of CDD.&#160; Based on the information we provided the FDA, which included supportive data from an earlier clinical trial, the FDA responded that the efficacy and safety data to be included in our planned NDA appear capable of supporting the filing of our planned NDA.&#160; The adequacy of these data to support an approval of ganaxolone for CDD will be a matter for FDA review of the application.&#160; &#160;There is a risk that the FDA may determine as a result of their review of our NDA, that we have not met the FDA requirements for ganaxolone approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, ganaxolone is metabolized extensively in animals and humans. During the development of CDD, one major metabolite (M2) was present in plasma of humans that was not found in plasma of rats or dogs. The chemical structure of M2 has been identified. In October 2020, the FDA communicated that the characterization of the activity of the M2 metabolite would need to be included at the time of submission; results from any additional studies that may be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">required based on an evaluation of these data could be submitted during the review or, if unavailable, in response to a post-marketing requirement(s) if the application is approved. If such additional non-clinical data indicates a safety issue, it may impact approvability or the FDA may impose serious and extensive restrictions on the commercialization of oral ganaxolone for CDD, which could have a material adverse impact on our business, results of operations and financial condition. We have recently completed an activity assay for the M2 metabolite and believe the results are consistent with our expectations and supportive of a mid-year 2021 filing. We plan to submit an NDA for oral ganaxolone in the treatment of CDD to the FDA in mid-2021 and an MAA for oral ganaxolone for the treatment of CDD to the EMA at the end of the third quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are conducting the RAISE Trial in RSE, which is a life threatening medical condition involving prolonged seizure activity in seriously ill patients.&#160;&#160;The RAISE Trial requires expertise in electroencephalogram (EEG) interpretation, which may be subject to variability, and the FDA or foreign regulatory authorities could find the data generated&#160;in this trial inadequate or difficult to interpret, which could delay, limit or prevent regulatory approval for this indication. Additionally, the clinical trial endpoints of the RAISE Trial are based on treatment outcomes, including initiation of anesthesia for treatment of RSE. Practice variability in the use of anesthesia for SE treatment could adversely impact the ability to show a treatment effect with ganaxolone. Even if ganaxolone were to obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations, such as restrictions as to specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval trial or risk management requirements. If we are unable to obtain regulatory approval for ganaxolone in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other product candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for ganaxolone, we will still need to develop a commercial organization, establish commercially viable pricing and obtain adequate reimbursement from third-party and government payers. If we are unable to successfully commercialize ganaxolone, we may not be able to earn sufficient revenue to continue our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, ganaxolone may not have favorable results in later clinical trials or receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will generate adequate data to demonstrate the efficacy and safety of ganaxolone. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience, have suffered significant setbacks in clinical trials, even after seeing promising results in earlier studies and clinical trials. For example, while ganaxolone showed statistical separation from placebo in a Phase 2 clinical trial in adjunctive treatment of adults with focal onset seizures, ganaxolone failed to show a similar statistically significant separation in a Phase 3 clinical trial for the same indication. As a result, we discontinued our program in adult focal onset seizures and began to focus our efforts on advancing ganaxolone in RSE and pediatric orphan genetic epilepsy indications. We do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market ganaxolone in any particular jurisdiction or indication. If clinical trials underway or conducted in the future do not produce favorable results, our ability to achieve regulatory approval for ganaxolone may be adversely impacted. Further, even if we believe the data collected from our clinical trials of ganaxolone are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Pre-clinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us, which could delay, limit or prevent regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;">Ganaxolone may cause undesirable side effects or have other properties, such as abuse potential, that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#212529;">Undesirable side effects caused by ganaxolone could cause us, an international review board (IRB), or regulatory authorities to interrupt, delay or halt clinical trials and could result in a restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. Although ganaxolone has generally been safe and well-tolerated by patients in our clinical trials to date, in some cases there were side effects, and some of </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">the side effects were severe. The most frequent side effects were dizziness, fatigue and somnolence (or drowsiness). More side effects of the CNS were categorized as severe as compared to side effects of other body systems.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">If these side effects are reported in future clinical trials, or if other safety or toxicity issues are reported in our future clinical trials, we may not receive approval to market ganaxolone or approval may be limited, which could prevent us from ever generating material revenue or achieving profitability. Furthermore, although we are currently developing ganaxolone for multiple indications, negative safety findings in any one indication could force us to delay or discontinue development in other indications. Results of our clinical trials could reveal an unacceptably high severity and prevalence of side effects. In such an event, our clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development, or deny approval, of ganaxolone for any or all targeted indications. Drug-related side effects could affect trial subject recruitment or the ability of enrolled patients to complete our future clinical trials and may result in potential product liability claims.</span></p><a id="_cp_text_1_597"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">In addition, ganaxolone is metabolized extensively in animals and humans. During the development of CDD, one major metabolite (M2) was present in plasma of humans that was not found in plasma of rats or dogs.&#160;The chemical structure of M2 has been identified.&#160;</span>In October 2020, the FDA communicated that the characterization of the activity of the M2 metabolite would need to be included at the time of submission; results from any additional studies that may be required based on an evaluation of these data could be submitted during the review or, if unavailable, in response to a post-marketing requirement(s) if the application is approved. <span style="color:#212529;">If such additional non-clinical data indicates a safety issue, it may impact approvability or the FDA may impose serious and extensive restrictions on the commercialization of CDD, which could have a material adverse impact on our business, results of operations and financial condition. </span>We have recently completed an activity assay for the M2 metabolite and believe the results are consistent with our expectations and supportive of a mid-year 2021 filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">If ganaxolone receives marketing approval, and we or others later identify undesirable side effects caused by ganaxolone, a number of potentially significant negative consequences could result, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may be forced to suspend marketing of ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">regulatory authorities may withdraw their approvals of ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">regulatory authorities may require additional warnings on the label that could diminish the usage or otherwise limit the commercial success of ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may be required to conduct post-marketing trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may be required to develop a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Evaluation and Mitigation Strategy (REMS)</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> for ganaxolone or if a REMS is already in place, to incorporate additional requirements under the REMS, and comparable regulatory authorities outside the United States may require similar risk management strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we could be sued and held liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="color:#212529;">Any of these events could prevent us from achieving or maintaining market acceptance of ganaxolone, if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, the FDA may recommend scheduling of ganaxolone as a controlled substance if it determines ganaxolone has abuse potential. In such event, the U.S. Drug Enforcement Administration (the DEA) will need to determine the controlled substance schedule of the product, taking into account the recommendation of the FDA. The timing of the scheduling process is uncertain and may delay our ability to market ganaxolone if approved. If ganaxolone is determined to be a controlled substance, the manufacture, import, export, distribution, storage, sale, dispensing, prescribing, and use will be subject to a significant degree of additional regulation by the DEA as well as state regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">authorities. The restrictive nature of these regulations could also limit commercialization and market acceptance of ganaxolone, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The therapeutic efficacy and safety of ganaxolone are unproven, and we may not be able to successfully develop and commercialize ganaxolone in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ganaxolone is a novel compound and its potential therapeutic benefit is unproven. Our ability to generate revenue from ganaxolone, which we do not expect will occur for at least the next several years, if ever, will depend on our successful development and commercialization after regulatory approval, which is subject to many potential risks and may not occur. Ganaxolone may interact with human biological systems in unforeseen, ineffective or harmful ways. If ganaxolone is associated with undesirable side effects or has characteristics that are unexpected, we may need to abandon its development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early stage testing for treating the target indications for ganaxolone have later been found to cause side effects that prevented further development of the compound. As a result of these and other risks described herein that are inherent in the development of novel therapeutic agents, we may never successfully develop, enter into or maintain third-party licensing or collaboration transactions with respect to, or successfully commercialize, ganaxolone, in which case we will not achieve profitability and the value of our stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical development of product candidates involves a lengthy and expensive process with an uncertain outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials are expensive, can take many years to complete, and are inherently uncertain as to outcome. Failure can occur at any time during the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may experience delays in our ongoing or future clinical trials and we do not know whether planned clinical trials will begin or enroll patients on time, need to be redesigned or be completed on schedule, if at all. There can be no assurance that the FDA or other foreign regulatory authorities will not put clinical trials of ganaxolone on clinical hold now or in the future. Clinical trials may be delayed, suspended or prematurely terminated for a variety of reasons, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able to execute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay or failure in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><a id="_cp_blt_1_277"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">ny shelter-in-place orders from local, state or federal governments or clinical trial site policies resulting from the COVID-19 pandemic that determine essential and non-essential functions and staff, which may impact the ability of site staff to conduct assessments, or result in delays to the conduct of the assessments, as part of our clinical trial protocols, or the ability to enter assessment results into clinical trial databases in a timely manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay or failure in obtaining IRB approval or the approval of other reviewing entities, including comparable foreign regulatory authorities, to conduct a clinical trial at each site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the ineligibility of a site to participate in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay or failure in recruiting and enrolling suitable trial patients to participate in a trial;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay or failure in trial patients completing a trial or returning for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">clinical sites and investigators deviating from a trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs, including some that may be for competing product candidates with the same indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">failure of our third-party clinical trial managers to satisfy their contractual duties or meet expected deadlines;</span></td></tr></table><a id="_cp_blt_1_281"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">l</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">imitations on our or our third-party clinical trial managers&#8217; ability to access and verify clinical trial data captured at clinical trial sites through monitoring and source document verification;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay or failure in adding new clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">ambiguous or negative interim results or results that are inconsistent with earlier results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">feedback from the FDA or a comparable regulatory authority outside the United States, IRBs, or data safety monitoring boards, or results from earlier stage or concurrent preclinical studies and clinical trials, that might require modification to the protocol for the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">decision by the FDA or a comparable regulatory authority outside the United States, an IRB or us, or a recommendation by a data safety monitoring board to suspend or terminate clinical trials at any time for safety issues or for any other reason;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">unacceptable risk-benefit profile, unforeseen safety issues or adverse side effects or AEs associate with a product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">failure of a product candidate to demonstrate any or enough of a benefit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">difficulties in manufacturing or obtaining from third parties sufficient quantities of a product candidate for use in clinical trials that meet internal and regulatory standards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">lack of adequate funding to continue the clinical trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional clinical trials or increased expenses associated with the services of our CROs and other third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">political developments that affect our ability to develop and obtain approval for ganaxolone or impair our license rights to develop and obtain approval for ganaxolone in other countries; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes in governmental regulations or administrative actions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Trial subject enrollment, which significantly impacts the timing of clinical trials, is affected by many factors including the size and nature of the subject population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, ability to obtain and maintain patient consents, risk that enrolled patients will drop out before completion, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved or product candidates that may be studied in competing clinical trials for the indications we are investigating.  Some of our clinical trials are directed at small patient populations.  Patient enrollment in these trials could be particularly challenging.  In the past, we have experienced delays in enrolling patients in trials directed at small patient populations. We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">and while we have agreements governing their committed activities, we have limited influence over their actual performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we experience delays in the completion of any clinical trial of ganaxolone, the commercial prospects of ganaxolone may be harmed, and our ability to generate product revenue from ganaxolone, if approved, will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our development and approval process for ganaxolone and jeopardize our ability to commence product sales and generate revenues. In addition, many of the factors that could cause a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of ganaxolone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if ganaxolone receives regulatory approval, we will still face regulatory difficulties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for ganaxolone, it would be subject to ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety surveillance, patient registry, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The safety profile of ganaxolone will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If new safety information becomes available after approval of ganaxolone, the FDA or comparable foreign regulatory authorities may require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on ganaxolone&#8217;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval trials or post-market surveillance. We will also be subject to continued compliance with current good manufacturing practices (cGMP) and good clinical practices (GCP) requirements for any clinical trials that we conduct post-approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP and other regulations. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events (AEs) of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, ganaxolone or the manufacturing facilities for ganaxolone fail to comply with applicable regulatory requirements, a regulatory authority may, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issue warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seek an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">suspend or withdraw regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">suspend any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">refuse to approve pending applications or supplements to applications filed by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The occurrence of any event or penalty described above may inhibit or preclude our ability to commercialize ganaxolone and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval for ganaxolone that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</p><a id="_cp_text_1_287"></a><a id="_cp_text_1_290"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advertising and promotion of ganaxolone, if approved by the FDA, will be heavily scrutinized by, among others, the FDA, the United States Department of Justice (DOJ), the Office of the Inspector General of the United States Department of Health and Human Services (HHS OIG), state attorneys general, members of Congress and the public. <span style="white-space:pre-wrap;">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct-to-consumer advertising, advertising and promotion to healthcare professionals, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A product cannot be promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for &#8220;off-label&#8221; uses &#8212; that is, uses not approved by the FDA and not described in the product&#8217;s labeling &#8212; because the FDA does not regulate the practice of medicine. However, FDA regulations impose restrictions on manufacturers&#8217; communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label use, but under certain conditions may engage in non-promotional, balanced, scientific communication regarding off-label use.  Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action, including </span>enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or other government agencies. In addition, advertising and promotion of ganaxolone, if approved outside of the United States, will be heavily scrutinized by comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, promoting ganaxolone for unapproved indications can also subject us to false claims litigation under federal and state statutes, and other litigation and/or investigation, which can lead to civil and criminal penalties and fines and agreements that materially restrict the manner in which we promote or distribute our drug products. These false claims statutes include the False Claims Act (FCA), which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the lawsuit, the individual will share in any fines or settlement funds. If we do not lawfully promote our approved products, we may become subject to such litigation and/or investigation and, if we are not successful in defending against such actions, those actions could adversely affect our business prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the European Union (EU), strict requirements and restrictions regarding advertising and promotion apply, the details of which may vary per EU Member States. Violation of those rules could subject us to litigation, investigations and/or civil and criminal penalties, which could adversely affect our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to obtain orphan drug exclusivity for ganaxolone, which could limit the potential profitability of ganaxolone.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for an indication for which it receives the designation, then the product is entitled to a period of marketing exclusivity that precludes the FDA from approving another marketing application for the same drug for the same indication for the exclusivity period except in limited situations. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For purposes of small molecule drugs, the FDA defines &#8220;same drug&#8221; as a drug that contains the same active moiety and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have received orphan drug designation in the United States for treating Infantile Spasms, SE, CDD, and PCDH19-Related Epilepsy (PCDH19-RE) with ganaxolone and expect that we may in the future pursue orphan drug designations for ganaxolone for one or more additional indications. However, obtaining an orphan drug designation can be difficult and we may not be successful in doing so for additional ganaxolone indications. Orphan drug exclusivity for a product candidate may not effectively protect the product from the competition of different drugs for the same condition, which could be approved during the exclusivity period. In addition, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain or maintain an orphan drug designation for any indication of ganaxolone that we may develop, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of ganaxolone to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</p><a id="_cp_text_1_294"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, we have received orphan designation for treating CDD with ganaxolone. Orphan designation would entitle us to receive ten years of orphan market exclusivity in the EU, but only if the product continues to meet the orphan designation criteria when the marketing authorization is granted. If a similar medicinal product (i.e., a medicinal product with an identical active substance, or an active substance with the same principal molecular structural features and which acts via the same mechanism) receives marketing authorization for the same indication before we receive marketing authorization, the other product&#8217;s orphan market exclusivity may prevent ganaxolone from receiving marketing authorization, unless we are able to demonstrate that ganaxolone is safer, more effective or otherwise clinically superior. In the EU, if we obtain and maintain orphan designation for ganaxolone upon marketing authorization, the European Commission could subsequently approve a similar medicinal product for the same indication if the European Commission, after assessment by the EMA, concludes that the similar medicinal product is safer, more effective or otherwise clinically superior. Orphan market exclusivity rights in the EU may also be lost if we are unable to supply sufficient quantities of the product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The failure to obtain or maintain an orphan drug designation for any indication of ganaxolone that we may develop, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of ganaxolone to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even though we have received&#160;RPD Designation for ganaxolone for the treatment of CDD, we may not receive a&#160;rare&#160;pediatric&#160;disease&#160;priority review voucher</span><span style="font-family:'Cambria';font-style:italic;font-weight:bold;">.</span></p><a id="_cp_text_1_302"></a><a id="_cp_text_1_304"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In July 2020, the FDA granted RPD Designation for ganaxolone for the treatment of CDD.  The FDA grants RPD Designation for diseases that affect fewer than 200,000 people in the U.S. in which serious or life-threatening manifestations occur primarily in individuals 18 years of age and younger. If an NDA for ganaxolone in CDD is approved, we may be eligible to receive a priority review voucher from the FDA, which can be redeemed for priority review in a subsequent marketing application. However, receiving an&#160;RPD&#160;Designation for ganaxolone for the treatment of CDD does not </span>guarantee that an NDA for ganaxolone for the treatment of CDD <span style="white-space:pre-wrap;">will meet the eligibility criteria for a RPD priority review voucher at the time the application is approved.  Under the Federal Food, Drug, and Cosmetic Act (the FDC Act), we will need to request an RPD priority review voucher in our original NDA for ganaxolone. The FDA may determine that the NDA for ganaxolone, if approved, does not meet the eligibility criteria for an RPD priority review voucher, including for the following reasons:</span></p><a id="_cp_blt_1_305"></a><a id="_cp_text_1_306"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">C</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">DD no longer meets the definition of an RPD;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_blt_1_307"></a><a id="_cp_text_1_308"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">g</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">anaxolone contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in an application;</span></td></tr></table><a id="_cp_blt_1_309"></a><a id="_cp_text_1_310"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">t</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">he NDA is not deemed eligible for priority review;</span></td></tr></table><a id="_cp_blt_1_311"></a><a id="_cp_text_1_312"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">t</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">he NDA does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population; or</span></td></tr></table><a id="_cp_blt_1_313"></a><a id="_cp_text_1_314"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">t</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">he NDA seeks approval for a different adult indication than the rare pediatric disease for which ganaxolone is designated.</span></td></tr></table><div style="margin-top:12pt;"><a id="_cp_text_1_315"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The authority for the FDA to award RPD priority review vouchers for drugs after September 30, 2024 is currently limited to drugs that receive rare pediatric disease designation on or prior to September 30, 2024, and the FDA may only award RPD priority review vouchers through September 30, 2026. If the NDA for ganaxolone is not approved on or prior to September 30, 2026 for any reason, it will not be eligible for a priority review voucher. However, it is possible the authority for the FDA to award RPD priority review vouchers will be further extended by Congress.</p><a id="_cp_text_1_317"></a><a id="_cp_text_1_321"></a><a id="_cp_text_1_323"></a><a id="_cp_text_1_325"></a><a id="_cp_text_1_326"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:48.95pt;margin:0pt;">If a priority review voucher is granted, we may use the voucher for our own FDA approval processes or decide to sell the voucher to other biotech or pharmaceutical companies. The market for priority review vouchers has a limited history and disclosed sales prices may not be indicative of the current value of vouchers, which may also fluctuate significantly. The Consolidated Appropriations Act, 2021, which was enacted on December 27, 2020, extended the priority review voucher program such that drugs designated for an RPD by September 30, 2024 can receive a voucher if the drug is submitted and approved by September 30, 2026. Further, the potential award of a voucher would trigger an obligation to market the relevant&#160;RPD&#160;product within one year from FDA approval or the FDA may revoke the voucher. Finally, a voucher award subjects us to additional post-marketing reporting obligations to the FDA.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:48.95pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain regulatory approval in international jurisdictions would prevent ganaxolone from being marketed in these jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">In order to market and sell our products in the EU and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, many countries outside the United States require that a product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of ganaxolone by regulatory authorities in the EU or another country or jurisdiction, the commercial prospects of ganaxolone may be significantly diminished and our business prospects could decline.</p><a id="_cp_text_1_94"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ganaxolone may be regulated as a controlled substance, the making, use, sale, importation, exportation, and distribution of which is subject to significant regulation by the DEA and other regulatory agencies.</span></p><a id="_cp_text_1_95"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The FDA may recommend controlled substance scheduling for ganaxolone.  In such event, the DEA will need to determine the controlled substance schedule taking into account the recommendation of the FDA.  The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.  If ganaxolone is determined to be a controlled substance, the manufacturing, shipping, distribution, import, export, packaging, storing, prescribing, dispensing, selling and use of ganaxolone will be subject to an additional regulation, including under the CSA and DEA regulations. Regulations </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">associated with controlled substances also govern production and procurement quotas, recordkeeping, reporting, handling, and disposal  Additionally, if ganaxolone is determined to be a controlled substance, facilities conducting research, manufacturing, distributing, importing or exporting, or dispending ganaxolone must be registered (licensed) to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent drug loss and intervention.  All these facilities must renew their registrations annually, except dispensing facilities, which must renew every three years.  The DEA, and some states, also conduct periodic inspections of registered establishments that handle controlled substances.  These regulations increase the personnel needs and the expense associated with development commercialization of products.  Because of their restrictive nature, these laws and regulations could also limit commercialization of ganaxolone, if approved. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities, consent decrees, criminal and civil penalties and state actions, among other consequences.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Various states also independently regulate controlled substances. Though state controlled substances laws often mirror federal law, because states are separate jurisdictions, they may separately schedule drugs as well.  While some states automatically schedule a drug when the DEA does so, in other states there must be a rulemaking or a legislative action.  State scheduling may delay commercial sale of ganaxolone, if approved, and adverse scheduling could impair the commercial attractiveness of ganaxolone. We must also obtain separate state registrations in order to be able to obtain, handle and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Commercialization of Our Product</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our commercial success depends upon attaining significant market access and acceptance of ganaxolone, if approved, among physicians, patients, government and private payers and others in the medical community and attaining sufficient reimbursement for ganaxolone.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if ganaxolone receives regulatory approval, it may not gain market acceptance among physicians, patients, government and private payers, or others in the medical community. Market acceptance of ganaxolone, if we receive approval, depends on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">clinically and commercially viable product profile as supported by clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">efficacy and safety of ganaxolone, or ganaxolone administered with other drugs, each as demonstrated in clinical trials and post-marketing experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">clinical indications for which ganaxolone is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">acceptance by physicians and patients of ganaxolone as a safe and effective treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">potential and perceived advantages of ganaxolone over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">safety of ganaxolone seen in a broader patient group, including its use outside the approved indications should physicians choose to prescribe for such uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">prevalence and severity of any side effects and drug interactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">product labeling or product insert requirements of the FDA or comparable foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">timing of market introduction of ganaxolone as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">cost of treatment in relation to alternative treatments;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">availability of coverage and adequate reimbursement and pricing by government and private payers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">effectiveness of our sales and marketing strategy and efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">adequate commercial investment; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">stability and continuity of product supply chains.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If ganaxolone is approved but fails to achieve market acceptance among physicians, patients, government or private payers or others in the medical community, or the products or product candidates that are being administered with ganaxolone are restricted, withdrawn or recalled, or fail to be approved, as the case may be, we may not be able to generate significant revenues, which would compromise our ability to become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of new drug products is highly competitive. We face competition with respect to ganaxolone and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing ganaxolone. Some of these competitive products and therapies are based on scientific approaches that are the same as, or similar to, our approach, and others are based on entirely different approaches. For example, there are several companies developing product candidates that target the same GABA<sub style="font-size:7.5pt;vertical-align:sub;">A</sub> neuroreceptor that we are targeting or that are testing product candidates in the same indications that we are testing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ganaxolone is presently being developed as an antiepileptic therapeutic. There are a variety of marketed therapies available for these patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Specifically, there are more than 25 approved antiepileptic drugs (AEDs) available in the United States and worldwide, including the generic products levetiracetam, lamotrigine, carbamazepine, oxcarbazepine, valproic acid and topiramate. Recent market entrants include branded products developed by Lundbeck, UCB, Eisai, Jazz Pharmaceuticals (via acquisition of GW Pharmaceuticals), Zogenix, SK Biopharmaceuticals and Sunovion Pharmaceuticals. In addition, there are several drugs in development for the treatment of pediatric orphan indications, including compounds being developed by Jazz Pharmaceuticals (via acquisition of GW Pharmaceuticals), Zogenix, Zynerba and Ovid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of the approved drugs are well established therapies or products and are widely accepted by physicians, patients and third-party payers. Insurers and other third-party payers may also encourage the use of generic products. These factors may make it difficult for us to achieve market acceptance at desired levels or in a timely manner to ensure viability of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">More established companies may have a competitive advantage over us due to their greater size, cash flows and institutional experience. Compared to us, many of our competitors may have significantly greater financial, technical and human resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a result of these factors, our competitors may obtain regulatory approval of their products before we are able to, which may limit our ability to develop or commercialize ganaxolone. Our competitors may also develop products that are safer, more effective, more widely used and cheaper than ours, and may also be more successful than us in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">manufacturing and marketing their products. These appreciable advantages could render ganaxolone obsolete or non-competitive before we can recover the expenses of ganaxolone&#8217;s development and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell ganaxolone, we may be unable to generate any revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently have an organization for the sale, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market ganaxolone, if approved by the FDA or comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies. To the extent we rely on third parties to commercialize ganaxolone, if approved, we may have little or no control over the marketing and sales efforts of such third parties, and our revenues from product sales may be lower than if we had commercialized ganaxolone ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize ganaxolone, it may not receive coverage and adequate reimbursement from third-party payers, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize ganaxolone successfully will depend, in part, on the extent to which coverage and adequate reimbursement for ganaxolone and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payers have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs. Third-party payers may also seek additional clinical evidence, beyond the data required to obtain marketing approval, demonstrating clinical benefits and value in specific patient populations before covering ganaxolone for those patients. We cannot be sure that coverage and adequate reimbursement will be available for ganaxolone and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, ganaxolone, if we obtain marketing approval. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize ganaxolone even if we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payers often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to obtain coverage </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and profitable reimbursement rates from both government-funded and private payers for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the market opportunities for ganaxolone are smaller than we believe they are, our results of operations may be adversely affected and our business may suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We focus our research and product development on therapeutics to treat patients suffering from rare seizure disorders. Our projections of both the number of people who have these disorders, as well as the subset of people with these diseases who have the potential to benefit from treatment with ganaxolone, are based on estimates. These estimates may prove to be incorrect and new studies or clinical trials may change the estimated incidence or prevalence of these disorders. The number of patients in the United States and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with ganaxolone, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A variety of risks associated with marketing ganaxolone internationally could materially adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to seek regulatory approval for ganaxolone outside of the United States, and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">differing regulatory requirements in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">viable pricing awarded in international markets to support commercial investment is required;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">foreign taxes, including with respect to our Irish subsidiary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">difficulties staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">business interruptions resulting from geo-political actions, including war and terrorism, as well as from pandemics, including the COVID-19 pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of ganaxolone or other product candidates that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability exposure related to the testing of ganaxolone by us or our investigators in human clinical trials and will face an even greater risk if ganaxolone receives regulatory approval and we subsequently commercialize it. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling ganaxolone. If we cannot successfully defend ourselves against claims that ganaxolone caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in, for example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">decreased demand for ganaxolone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">termination of clinical trial sites, entire clinical trials or development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">withdrawal of clinical trial patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">substantial monetary awards to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">diversion of management and scientific resources from our business operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the inability to commercialize ganaxolone; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">increased scrutiny and potential investigation by, among others, the FDA, the DOJ, the HHS OIG, state attorneys general, members of Congress and the public.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have product liability insurance coverage, which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our product liability insurance coverage to include the sale of commercial products if we obtain marketing approval for ganaxolone, but we may be unable to obtain commercially reasonable product liability insurance for ganaxolone, if approved for marketing. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could have a material adverse effect on our business and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><a id="_cp_text_1_619"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their duties in compliance with contractual terms and/or regulatory requirements or meet expected deadlines, </span><span style="font-style:italic;font-weight:bold;">our development plans may be adversely affected and </span><span style="font-style:italic;font-weight:bold;">we may not be able to obtain regulatory approval for or commercialize ganaxolone.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We also rely on third parties to assist in conducting our preclinical studies in accordance with GLP and the Animal Welfare Act requirements, where applicable. We and our CROs are required to comply with federal regulations and GCP, which are international requirements meant to protect the rights and health of patients that are enforced by the FDA, the competent authorities of the EU Member States and comparable foreign regulatory authorities for ganaxolone. Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Failure to comply with these regulations may require us to repeat or conduct additional preclinical studies and clinical trials, which would delay the regulatory approval process.</p><a id="_cp_text_1_622"></a><a id="_cp_text_1_624"></a><a id="_cp_text_1_627"></a><a id="_cp_text_1_628"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we depend heavily on these parties and have contractual agreements governing their activities, we cannot control them and therefore, we cannot be assured that these third parties will devote sufficient time and resources to our ongoing clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our preclinical studies and clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize ganaxolone. As a result, our results of operations and the commercial prospects for ganaxolone would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><a id="_cp_text_1_629"></a><a id="_cp_text_4_630"></a><a id="_cp_text_1_631"></a><a id="_cp_text_4_632"></a><a id="_cp_text_4_633"></a><a id="_cp_text_1_634"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of our relations terminate, switching or adding additional CROs would involve additional cost and require management time and focus. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. In addition, there is a natural transition period when a new CRO commences work. If any of our relationships with our third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. As a result, delays my occur, which can materially impact our ability to meet our desired development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our experience manufacturing ganaxolone is limited to the needs of our preclinical studies and clinical trials. We have no experience manufacturing ganaxolone on a commercial scale and have no manufacturing facility. We are dependent on third-party manufacturers for the manufacture of ganaxolone as well as on third parties for our supply chain, and if we experience problems with any such third parties, the manufacturing of ganaxolone could be delayed.</span></p><a id="_cp_text_1_336"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We do not own or operate facilities for the manufacture of ganaxolone. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We currently rely on contract manufacturing organizations (CMOs) for the chemical manufacture of raw materials and active pharmaceutical ingredients for ganaxolone and other CMOs for the production of the ganaxolone nanoparticulate formulation into capsules, liquid suspension and IV, and we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">plan to rely on CMOs for the manufacture of ganaxolone for commercial use, if approved. To meet our projected needs for preclinical and clinical supplies to support our activities through regulatory approval and commercial manufacturing, the CMOs with whom we currently work will need to increase the scale of production. We may need to identify additional CMOs for continued production of supply for ganaxolone. Although alternative third-party suppliers with the necessary manufacturing and regulatory expertise and facilities exist, it could be expensive and take a significant amount of time to arrange for alternative suppliers. If we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms, in a timely manner or at all, we may not be able to complete development of ganaxolone, or market or distribute ganaxolone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured ganaxolone ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control, including a failure to synthesize and manufacture ganaxolone, and the possibility of termination or nonrenewal of the manufacturing agreement by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities will require that ganaxolone be manufactured according to cGMP and similar foreign standards. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of ganaxolone in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of ganaxolone. In addition, such failure could be the basis for the FDA or other regulatory authorities to issue a warning letter, withdraw approvals for ganaxolone previously granted to us, or take other regulatory or legal action, including recall or seizure of outside supplies of ganaxolone, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction, or imposing civil and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any significant disruption in our supplier relationships could harm our business. Any significant delay in the supply of ganaxolone or its key raw materials for an ongoing preclinical study or clinical trial could considerably delay completion of such preclinical study or clinical trial, product testing and potential regulatory approval of ganaxolone. If our manufacturers or we are unable to purchase these key raw materials after regulatory approval has been obtained for ganaxolone, the commercial launch of ganaxolone would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of ganaxolone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government funding for certain of our programs adds uncertainty to our research efforts with respect to those programs and may impose requirements that increase the costs of commercialization and production of product candidates developed under those government-funded programs.</span></p><a id="_cp_text_1_647"></a><a id="_cp_text_1_649"></a><a id="_cp_text_1_650"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.05pt;margin:0pt 2pt 12pt 0pt;">In September 2020, we entered into the BARDA Contract with BARDA, a division of the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response. Under the BARDA Contract, we received an award of up to an estimated $51 million for development of IV administered ganaxolone for the treatment of RSE. The BARDA Contract consists of an approximately two-year base period-during which BARDA will provide approximately $21 million of funding for the RSE Phase 3 clinical trial on a cost share basis and funding of additional preclinical studies of ganaxolone in nerve agent exposure models. Following successful completion of the RSE Phase 3 clinical trial and preclinical studies in the base period, the BARDA Contract provides for approximately $30 million of additional BARDA funding for three options in support of manufacturing, supply chain, clinical, regulatory and toxicology activities. Under the BARDA Contract, we will be responsible for cost sharing in the amount of approximately $33 million and BARDA will be responsible for approximately $51 million, if all development options are completed. The contract period-of-performance (base period plus option exercises) is up to approximately five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Programs funded by the United States government and its agencies include provisions that confer on the government substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">terminate agreements, in whole or in part, for any reason or no reason;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">claim rights, including intellectual property rights, in products and data developed under such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">audit contract-related costs and fees, including allocated indirect costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">impose United States manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">suspend or debar the contractor from doing future business with the government; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">control and potentially prohibit the export of products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not have the right to prohibit the United States government from using or allowing others to use certain technologies developed by us, and we may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the United States government. The United States government generally obtains the right to royalty-free use of technologies that are developed under United States government contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, government contracts normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">specialized accounting systems unique to government contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination and affirmative action programs and environmental compliance requirements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to maintain compliance with these requirements, we may be subject to potential contract liability and to termination of our contracts. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us. In addition, under U.S. government purchasing regulations, some of our costs may not be reimbursable or allowed under the BARDA Contract. Further, as a U.S. government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, changes in government budgets and agendas may result in a decreased and de-prioritized emphasis on supporting the RSE development program. Any reduction or delay in BARDA funding may force us to seek alternative funding in order to progress our RSE program, which may not be available on non-dilutive terms, terms favorable to us or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may elect to enter into license or collaboration agreements to partner ganaxolone in territories currently retained by us. Our dependence on such relationships may adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited resources, we have and expect that we will continue to enter into license or collaboration agreements with other pharmaceutical or biotechnology companies. Any failure by our partners to perform their obligations or any decision by our partners to terminate these agreements could negatively impact our ability to successfully develop, obtain regulatory approvals for and commercialize ganaxolone. In the event we grant exclusive rights to such partners, we would be precluded from potential commercialization of ganaxolone within the territories in which we have a partner. In addition, any termination of our license or collaboration agreements will terminate the funding we may receive under the relevant license or collaboration agreement and may impair our ability to fund further development efforts and our progress in our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercialization strategy for ganaxolone may depend on our ability to enter into agreements with partners to obtain assistance and funding for the development and potential commercialization of ganaxolone in the territories in which we seek to partner. Despite our efforts, we may be unable to secure license or collaboration agreements or other arrangements that are necessary for us to further develop and commercialize ganaxolone. Supporting diligence activities conducted by potential licensees or collaborators and negotiating the financial and other terms of a license or collaboration agreement are long and complex processes with uncertain results. Even if we are successful in entering into one or more license or collaboration agreements, such agreements may involve greater uncertainty for us, as we would have less control over certain aspects of our partnered programs than we do over our un-partnered programs. We may determine that continuing a license or collaboration under the terms provided is not in our best interest, and we may terminate the license or collaboration. Our potential future partners could delay or terminate their agreements, and as a result ganaxolone may never be successfully commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, our potential future partners may develop alternative products or pursue alternative technologies either on their own or in collaboration with others, including our competitors, and the priorities or focus of our partners may shift such that ganaxolone receives less attention or resources than we would like, or they may be terminated altogether. Any such actions by our potential future partners may adversely affect our business prospects and ability to earn revenue. In addition, we could have disputes with our potential future partners, such as the interpretation of terms in our agreements. Any such disagreements could lead to delays in the development or commercialization of ganaxolone or could result in time-consuming and expensive litigation or arbitration, which may not be resolved in our favor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical, radioactive and hazardous materials. We cannot completely eliminate the risk of contamination or injury resulting from medical, radioactive or hazardous materials. As a result of any such contamination or injury we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical radioactive or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Compliance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize ganaxolone and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern, among other things, marketing approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of ganaxolone, restrict or regulate post-approval activities and affect our ability to successfully sell ganaxolone, if we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Medicare Prescription Drug,&#160;Improvement, and Modernization Act of 2003 (the Medicare Modernization Act) changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by eligible beneficiaries and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In recent years, Congress has considered further reductions in Medicare reimbursement for drugs administered by physicians. Centers for Medicare &amp; Medicaid Services (CMS) also has the authority to revise reimbursement rates and to implement coverage restrictions for drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products, which in turn would affect the price we can receive for those products. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for ganaxolone, if approved, or additional pricing pressures.</p><a id="_cp_text_1_660"></a><a id="_cp_text_1_661"></a><a id="_cp_text_1_664"></a><a id="_cp_text_1_666"></a><a id="_cp_text_1_668"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the Affordable Care Act) is intended to reduce the cost of, improve the quality of, and expand access to healthcare, among other things. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability to include covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, increased the minimum rebate due for innovator drugs from 15.1% of average manufacturer price (AMP) to 23.1% of AMP and capped the total rebate amount for innovator drugs at 100.0% of AMP. The Affordable Care Act and subsequent legislation also changed the definition of AMP. Furthermore, the Affordable Care Act imposed a significant annual, nondeductible fee on companies that manufacture or import certain branded prescription drug products. Certain provisions of the Affordable Care Act have been subject to judicial challenges as well as efforts to repeal, replace or otherwise modify them or to alter their interpretation and implementation. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible, but the nature and extent of such potential changes or challenges are uncertain at this time. The implications of the Affordable Care Act, and efforts to repeal, replace, or otherwise modify or invalidate, the Affordable Care Act or its implementing regulations, or portions thereof, or the political uncertainty surrounding any efforts to repeal, replace, or otherwise modify the Affordable Care Act for our business and financial condition, if any, are not clear. We will continue to evaluate the effect that the Affordable Care Act as well as its possible repeal, replacement, modification, or invalidation, in whole or in part, has on our business.</p><a id="_cp_text_1_670"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of, on average, 2.0% per fiscal year, starting in 2013 and continuing through 2030 (with the exception of a temporary suspension from May 1, 2020 through December 31, 2021) unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">overpayments to providers from three to five years. If we ever obtain regulatory approval and commercialization of ganaxolone, these laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of ganaxolone may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the EU and other potentially significant markets for ganaxolone, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules&#160;and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for ganaxolone in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenue we are able to generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in ganaxolone even if ganaxolone obtains marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we participate in the Medicaid Drug Rebate Program and fail to comply with our reporting and payment obligations under that program or other governmental pricing programs that we participate in, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p><a id="_cp_text_1_339"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to participate in and have certain price reporting obligations to the Medicaid Drug Rebate Program. Under the Medicaid Drug Rebate Program, if we successfully commercialize one or more products for which we receive regulatory approval, we would be required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid and Medicare Part&#160;B. Those rebates are based on pricing data, such as average manufacturer price and best price, that we would have to report on a monthly and quarterly basis to the CMS, the federal agency that administers the Medicaid Drug Rebate Program. These data include the average manufacturer price and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the United States in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions. The Affordable Care Act made significant changes to the Medicaid Drug Rebate Program, and CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. On December 21, 2020, CMS issued a final regulation that modified existing Medicaid Drug Rebate Program regulations to permit reporting multiple Best Price figures with regard to value-based purchasing arrangements (beginning in 2022); provide definitions for &#8220;line extension,&#8221; &#8220;new formulation,&#8221; and related terms with the practical effect of expanding the scope of drugs considered to be line extensions (beginning in 2022); and revise AMP and Best Price exclusions of manufacturer-sponsored patient benefit programs, specifically regarding inapplicability of such exclusions in the context of pharmacy benefit manager &#8220;accumulator&#8221; programs (beginning in 2023). Our failure to comply with the aforementioned price reporting and rebate payment obligations if we participate in the Medicaid Drug Rebate Program could negatively impact our financial results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_677"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Federal law requires that any company that participates in the Medicaid Drug Rebate Program also participate in the 340B program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part&#160;B. The 340B program, which is administered by the Health Resources and Services Administration (HRSA), requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The Affordable Care Act expanded the list of covered entities to include certain free-standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals, but exempts &#8220;orphan drugs&#8221; from the ceiling price requirements for these covered entities. The 340B ceiling price is calculated using a statutory formula based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program, and in general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. Any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the Affordable Care Act or other legislation or regulation could affect our 340B ceiling price calculations and negatively impact our results of operations if we successfully commercialize one or more products for which we receive regulatory approval.</p><a id="_cp_text_1_678"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HRSA issued a final regulation, effective January 1, 2019, regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities. HRSA also has implemented a ceiling price reporting requirement, pursuant to which manufacturers must report the 340B ceiling prices for their covered outpatient drugs to HRSA on a quarterly basis. HRSA then publishes those prices to 340B covered entities. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution (ADR) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result in additional liability. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</p><a id="_cp_text_1_680"></a><a id="_cp_text_1_681"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Federal law also requires that a company that participates in the Medicaid Drug Rebate Program report average sales price information each quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. Manufacturers calculate the average sales price based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. In a November 20, 2020 interim final rule, CMS established a &#8220;Most Favored Nation&#8221; demonstration model that would lower Medicare Part B reimbursement of certain drugs based on international reference prices. The rule has become subject to judicial challenges, and federal courts have enjoined the rule at this time. There is also proposed legislation pending that would establish an international reference price-based payment methodology.</p><a id="_cp_text_1_682"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by the manufacturer, governmental or regulatory agencies, and the courts. &#160;If we participate in the Medicaid Drug Rebate Program and consequently the 340B program, we could be held liable for errors associated with our submission of pricing data. In addition to retroactive Medicaid rebates and the potential for 340B program refunds, if we are found to have knowingly submitted false average manufacturer price or best price information to the government, we may be liable for significant civil monetary penalties per item of false information. If we are found to have made a misrepresentation in the reporting of our average sales price, the Medicare statute provides for significant civil monetary penalties for each misrepresentation for each day in which the misrepresentation was applied. Civil monetary penalties can also be applied if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. &#160;A covered entity or association representing covered entities can also bring claims against us through HRSA&#8217;s 340B ADR process. Our failure to submit monthly/quarterly average manufacturer price and best price data on a timely basis could result in a significant civil monetary penalty per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we would be participating in the Medicaid Drug Rebate Program. In the event that CMS terminates our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CMS and the HHS OIG have pursued manufacturers that were alleged to have failed to report these data to the government in a timely manner. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. If we participate in the Medicaid Drug Rebate Program and consequently the 340B program, we cannot assure you that our submissions will not be found to be incomplete or incorrect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to be eligible to have our products that we successfully commercialize paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we also would have to participate in the Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program. As part of this program, we would be obligated to make our products available for procurement on an FSS contract under which we must comply with standard government terms and conditions and charge a price that is no higher than the statutory Federal Ceiling Price (FCP) to four federal agencies (VA, Department of Defense (DOD), Public Health Service, and U.S. Coast Guard).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FCP is based on the Non-Federal Average Manufacturer Price (Non-FAMP), which we would be required to calculate and report to the VA on a quarterly and annual basis. Pursuant to applicable law, knowing provision of false information in connection with a Non-FAMP filing can subject a manufacturer to significant civil monetary penalties for each item of false information. The FSS pricing and contracting obligations also contain extensive disclosure and certification requirements.</p><a id="_cp_text_1_684"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we successfully commercialize one or more products for which we receive regulatory approval, we also would participate in the Tricare Retail Pharmacy program, under which we would be required to pay quarterly rebates on utilization of innovator products that are dispensed through the Tricare Retail Pharmacy network to Tricare beneficiaries. The rebates are calculated as the difference between the annual Non-FAMP and FCP. We would be required to list our innovator products on a Tricare Agreement in order for them to be eligible for DOD formulary inclusion. If we overcharge the government in connection with our FSS contract or Tricare Agreement, whether due to a misstated FCP or otherwise, we would be required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges could result in allegations against us under the FCA and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling product candidates outside of the United States and require us to develop and implement costly compliance programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As we seek to expand our operations outside of the United States, we must comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Foreign Corrupt Practices Act (FCPA) prohibits any United States individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring such companies to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The SEC is involved with enforcement of the books and records provisions of the FCPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain foreign nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expanding presence outside of the United States will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling ganaxolone outside of the United States, which could limit our growth potential and increase our development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the United States government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on United States exchanges for violations of the FCPA&#8217;s accounting provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with customers and third-party payers will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and others will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with healthcare professionals, third-party payers, patients and others will expose us to broadly applicable fraud and abuse, anti-kickback, false claims, and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payers, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our operations (including our marketing, promotion, educational programs, pricing, and relationships with healthcare providers or other entities, among other things) and expose us to areas of risk including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal Anti-Kickback Statute (AKS) prohibits, among other things, knowingly and willfully soliciting, offering, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, or arranging for the purchase, lease, or order of, any healthcare item or service, for which payment may be made under a federal healthcare program such as Medicare &amp; Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the FCA prohibits, among other things, individuals or entities from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false record or statement material to an obligation to pay money to the government, or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively, HIPAA) imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, including private third-party payors, and also prohibits knowingly and willfully falsifying, </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal Physician Payments Sunshine Act, implemented as the Open Payments Program, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or Children&#8217;s Health Insurance Program, to report annually to CMS information related to payments and other transfers of value to physicians, and teaching hospitals, and starting in 2022 certain other health care professionals, and ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, as well as other state laws and regulations governing pharmaceutical manufacturers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">state and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties are compliant with applicable healthcare laws and regulations will involve the expenditure of appropriate, and possibly significant, resources. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare &amp; Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p><a id="_cp_text_1_698"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business, which could impose significant regulatory hurdles on our business. </span></p><a id="_cp_text_1_699"></a><a id="_cp_text_4_700"></a><a id="_cp_text_1_701"></a><a id="_cp_text_4_702"></a><a id="_cp_text_1_703"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HIPAA imposes requirements relating to the privacy, security and transmission of individually identifiable health information. HIPAA imposes privacy and security obligations on covered entity health care providers, health plans, and health care clearinghouses, as well as their &#8220;business associates&#8221;&#8212;independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, other than potentially with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. In addition, numerous other federal and state laws and regulations govern privacy and security, including state data breach notification laws, state health information and/or genetic privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the FTC Act, and the California Consumer Privacy Act (CCPA), many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Compliance with these laws is difficult, constantly evolving, and time consuming. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys have been and will likely continue to be active in this space.</p><a id="_cp_text_1_704"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In California, the CCPA took effect on January 1, 2020.  The CCPA establishes certain requirements for data use and sharing transparency and creates new data privacy rights for consumers. These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. Similarly, there are a number of legislative proposals in the EU, the United States, at both the federal and state level, as well as other jurisdictions that could impose new obligations or limitations in areas affecting our business. In addition, </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">some countries are considering or have passed legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of delivering our services and research activities. These laws and regulations, as well as any associated claims, inquiries, or investigations or any other government actions may lead to unfavorable outcomes including increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, and remedies that harm our business, including fines or demands or orders that we modify or cease existing business practices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If we, our agents, or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection and privacy laws and regulations, or if we were to experience a data breach involving personal information, we could be subject to government enforcement actions or private lawsuits.  Any associated claims, inquiries, or investigations or other government actions could lead to unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other remedies that harm our business, including orders that we modify or cease existing business practices.</span></p><a id="_cp_text_1_99"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition to laws and regulations enacted in the United States, including the new California Consumer Privacy Act of 2018, the EU&#8217;s legislative and regulatory landscape for privacy and data security continues to evolve.  There has been increased attention to privacy and data security issues that could potentially affect our business, including the EU General Data Protection Regulation (GDPR), which entered into effect on May 25, 2018 and imposes penalties up to 4% of annual global turnover for breaches of related obligations.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the event we enroll patients in our ongoing or future clinical trials in the European Economic Area (the EEA), we will be subject to the additional privacy restrictions imposed by the General Data Protection Regulation (the GDPR), including restrictions relating to the collection, use, storage, transfer, and other processing of personal data, including personal health data, regarding individuals in the EEA as governed by the GDPR and the related national data protection laws of the individual EEA countries.  The GDPR imposes several requirements on companies that process personal data, with especially strict rules on the transfer of personal data out of the EEA, including to the U.S, and fines and penalties for failure to comply with the requirements of the GDPR and the related national data protection laws of the individual EEA countries. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. The obligations under the GDPR may be onerous and adversely affect our business, financial condition, results of operations and prospects. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any EEA activities. Further, the United Kingdom&#8217;s exit from the EU, often referred to as Brexit, has created uncertainty with regard to future data protection regulation in the United Kingdom.</span></p><a id="_cp_text_1_101"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Because of the remote work policies we implemented due to the COVID-19 pandemic, information that is normally protected, including company confidential information, may be less secure.  Cybersecurity and data security threats continue to evolve and raise the risk of an incident that could affect our operations or compromise our business information or sensitive personal information, including health data.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We may also need to collect more extensive health-related information from our employees to manage our workforce.  If we or our third party partners fail to comply or are alleged to have failed to comply with applicable data protection and privacy laws and regulations, and related employment rules, or if we were to experience a data breach involving personal information, we could be subject to government enforcement actions or private lawsuits.  </span></p><a id="_cp_text_1_103"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition, our business could be adversely impacted if our ability to transfer personal data outside of the EEA or Switzerland is restricted, which could adversely impact our operating results.  For example, in July 2020, the Court of Justice of the European Union, or the Court of Justice, declared the Privacy Shield Decision (Decision 2018/1250) invalid, which could adversely impact our ability to transfer personal data from the EU to the U.S. The Court of Justice </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">further ruled that in order to transfer data outside of the EU, under the existing mechanism known as the Standard Contractual Clauses (SCCs), the importing country&#8217;s level of protection must be adequate.  </span></p><a id="_cp_text_1_104"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On September 8, 2020, the Federal Data Protection and Information Commissioner (FDPIC) of Switzerland issued an opinion concluding that the Swiss-U.S. Privacy Shield Framework does not provide an adequate level of protection for data transfers from Switzerland to the United States. The FDPIC also found that SCCs may still be legally adequate at an individual level provided that they can pass a risk assessment conducted by the FDPIC.  If the level of protection in the U.S. or any other importing country is called into question under the SCCs, this could further impact our ability to transfer data outside of the EU or Switzerland.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The impact of Brexit on the on-going validity in the UK of current EU authorizations for medicinal products, whether granted through the centralized procedure, decentralized procedure, or mutual recognition, and on the future process for obtaining marketing authorization for pharmaceutical products manufactured or sold in the UK remains uncertain. Although the body of the UK-EU Trade and Cooperation Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extend to procedures such as batch release certification. Among the changes that will now occur are that Great Britain, comprised of England, Scotland and Wales, will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. As part of the UK-EU Trade and Cooperation Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The UK-EU Trade and Cooperation Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to accept EU batch testing and batch release for a period of at least two years until January 1, 2023. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great Britain will have a separate regulatory submission process, approval process and a separate national MA. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the EC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product candidates, our competitive position could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our technology and products. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the United States and abroad related to our novel technologies and products that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patents, including those patent rights licensed to us by third parties, are highly uncertain. The steps we or our licensors have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the United States. Further, the examination process may require us or our licensors to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The rights already granted under any of our currently issued patents or those licensed to us and those that may be granted under future issued patents may not provide us with the protection or competitive advantages we are seeking. If we or our licensors are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">technology and products may be adversely affected. It is also possible that we or our licensors will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them.</p><a id="_cp_text_1_344"></a><a id="_cp_text_1_345"></a><a id="_cp_text_1_346"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With respect to patent rights, <span style="white-space:pre-wrap;">the ganaxolone compound and its original synthesis were published in the early 1990s and we do not own or license patent rights on the ganaxolone compound.  We seek patent protection in the United States and internationally for synthetic methods for making ganaxolone, ganaxolone nanoparticles, which are used in certain oral solid, oral liquid, and IV dose formulations, other injectable and oral ganaxolone formulations, and methods of treatment using ganaxolone. We </span>do not know whether any of our granted or issued patents will, or if any of our pending patent applications will grant as patents that will, effectively prevent others from commercializing competitive technologies and products. There is a risk that others, including companies that make generic pharmaceuticals, may develop ganaxolone for the same as similar uses as us, and that our patents will not effectively prevent them from commercializing their ganaxolone products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing or in some cases not at all, until they are issued as a patent. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and products. Protecting against the unauthorized use of our or our licensors&#8217; patented technology, trademarks and other intellectual property rights is expensive, difficult and may in some cases not be possible. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents or misappropriate or otherwise violate our intellectual property rights. To counter infringement or unauthorized use, litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Also, third parties may initiate legal proceedings against us to challenge the validity or scope of intellectual property rights we own or control. These proceedings can be expensive and time consuming. Many of our current and potential competitors have the ability to dedicate substantially greater resources to defend their intellectual property rights than we can. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. Litigation could result in substantial costs and diversion of management resources, which could harm our business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned or controlled by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our commercial success depends upon our ability to develop, manufacture, market and sell our products, all of which contain ganaxolone, if approved, and to use our related technologies. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to one or more of our products, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">including interference or derivation proceedings before the United States Patent and Trademark Office (USPTO). Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue commercializing one or more of our products. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Under certain circumstances, we could be forced, including by court order, to cease commercializing one or more of our products. In addition, in any such proceeding or litigation, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing one or more of our products or force us to cease some of our business operations, which could materially harm our business. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar negative impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our product candidates are in preclinical studies and clinical trials, we believe that the use of our product candidates in these preclinical studies and clinical trials falls within the scope of the exemptions provided by 35 U.S.C. Section&#160;271(e)&#160;in the United States, which exempts from patent infringement liability activities reasonably related to the development and submission of information to the FDA (Federal Development Patent Infringement Exemption). As our product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. While ganaxolone itself is off patent, we attempt to ensure that our product candidates and the methods we employ to manufacture ganaxolone do not infringe other parties&#8217; patents and other proprietary rights. There can be no assurance they do not, however, and competitors or other parties may assert that we infringe their proprietary rights in any event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">In September 2020, Ovid Therapeutics, Inc. (Ovid) contacted us and disclosed that it owns two recently issued patents that include claims that encompass our product candidates for the treatment of CDD and PCDH19. Ovid may file a lawsuit against us alleging infringement of its patents and/or we may challenge the validity of Ovid&#8217;s patents with the USPTO or through the courts. Any such proceeding, regardless of its outcome, would likely result in the expenditure of significant financial resources and the diversion of management&#8217;s time and resources. In addition, any such proceeding may cause negative publicity, adversely impact patients, and we may be prohibited from marketing or selling ganaxolone for CDD and PCDH19, during such proceedings or if we are not successful in such proceedings. If Ovid does decide to bring an infringement lawsuit, we do not expect that it will be filed before a commercial launch of ganaxolone for CDD, or PCDH19, as applicable, based upon the &#8220;safe harbor&#8221; provisions of the Hatch-Waxman Act. We may need to acquire or obtain a license to the Ovid patents to market or sell ganaxolone for CDD and PCDH19, which may not be available on commercially acceptable terms or at all. If we are not able to acquire the Ovid patents or negotiate a license on acceptable terms, and if our product is determined to infringe Ovid&#8217;s patents and the patents are determined to be valid, then we may be forced to pay Ovid royalties, damages and costs, or we may be prevented from commercializing ganaxolone for CDD and PCDH19 altogether, which would have a material adverse impact on our business. We are also aware of a pending patent application by Ovid in the same patent family that includes claims that encompass our product candidate for the treatment of SE. This pending patent application is in the early stages of examination at the USPTO. It is possible that this pending patent application may issue as a patent with claims that encompass our product candidate for the treatment of RSE, in which case, the above risks would also apply to any such patent that was issued.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Filing, prosecuting and defending patents on our product candidates and any future product candidates throughout the world would be prohibitively expensive, and our or our licensors&#8217; intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and practices of some foreign countries, particularly those relating to pharmaceuticals, do not protect intellectual property rights to the same extent as federal and state laws in the United States.  For example, novel formulations and methods of medical treatment and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. Many countries, including EU countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">a license to a third party, which could materially diminish the value of our patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from our intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions into or within the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing with us in these jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Given the amount of time required for the development, testing and regulatory review of new product candidates, such as our product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For example, certain patents licensed to us by CyDex that relate to Captisol&#174;, which is used in some of our product candidates, have expired, and sulfobutylether beta-cyclodextrin compounds that are similar to CyDex&#8217;s Captisol&#174; are available from other suppliers.  It is possible that others may seek to develop ganaxolone formulations using sulfobutylether beta-cyclodextrin compounds obtained from such other suppliers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits under certain circumstances a patent term extension of up to five years beyond the normal expiration of a patent. However, the applicable authorities, including the FDA and the USPTO in the United States, and any analogous regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent laws could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve technological and legal complexity, and obtaining and enforcing pharmaceutical patents is costly, time-consuming, and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. For example, the United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce existing patents and patents we may obtain in the future. Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Leahy-Smith America Invents Act (Leahy-Smith Act) includes a number of provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned to a &#8220;first to file&#8221; system in which the first inventor to file&#160;a patent application is entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO and may become involved in derivation, reexamination, inter-partes review or post-grant review proceedings challenging our patent rights or the patent rights of our licensors. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate patent rights, which could adversely affect our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of our employees were previously employed at universities or at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, including each member of our senior management, executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on government funding for certain of our research and development activities and we may develop intellectual property through such activities and therefore may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S. based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In September 2020, we entered into the BARDA Contract for the completion of pre-clinical and clinical development activities for IV administered ganaxolone for the treatment of RSE. We may generate intellectual property rights through the use of this U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act), and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we to disclose the invention to the government and fail to file an application to register the intellectual property in the specified manner and within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others may be able to make compounds or ganaxolone formulations that are similar to our product candidates but that are not covered by the claims of the patents that we own or control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may not develop additional proprietary technologies that are patentable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to our Business Operations</b></p><a id="_cp_text_4_105"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic could adversely affect our business and our ability to conduct and complete clinical trials. </span></p><a id="_cp_text_4_106"></a><a id="_cp_text_1_725"></a><a id="_cp_text_1_726"></a><a id="_cp_text_1_728"></a><a id="_cp_text_1_730"></a><a id="_cp_text_1_731"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus was declared a pandemic by the World Health Organization in March 2020 and has spread to nearly every country in the world, including the United States. Many countries, including the United States, have implemented severe travel restrictions, business shutdowns and social distancing measures in order to contain the spread of COVID-19 that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">have impacted clinical development through supply chain shortages and clinical trial enrollment difficulties as hospitals reduce and redeploy staff, divert resources to patients suffering from COVID-19 and limit hospital access for non-patients. The pandemic poses the risk that we, our employees, contractors, suppliers, or other partners may be prevented from conducting normal business activities for an indefinite period of time, including those due to shutdowns that may be requested or mandated by governmental authorities.</p><a id="_cp_text_4_107"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The continued global spread of COVID-19 has impacted our operations and such impacts may continue and become material to our operations. For example, several of our Phase 1 trials of oral ganaxolone to support the development of CDD have experienced delays in enrollment due to COVID-19. Further, in response to COVID-19, for our ongoing clinical trials, we have implemented multiple measures consistent with the guidance of the FDA on the conduct of clinical trials of medical products during the COVID-19 pandemic, including implementing remote site monitoring and remote visits using telemedicine where needed. However, COVID-19 may still adversely impact our clinical trials.  For example, our Phase 3 clinical trial in RSE is conducted in hospitals and resources related to the COVID-19 outbreak may divert staffing in hospitals, taking resources away from our clinical trial.  Our ganaxolone clinical trials in the outpatient setting may be negatively impacted if patients and their caregivers do not want to participate in a clinical trial while COVID-19 outbreaks continue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a patient participating in one of our clinical trials contracts COVID-19, this could negatively impact the data readouts from these trials; for example, the patient may be unable to participate further (or may have to limit participation) in our clinical trial, the patient may show a different efficacy assessment than if the patient had not been infected, or the patient could experience an AE that could be attributed to our product candidate.</p><a id="_cp_text_4_108"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is also a risk that clinical supplies of our product candidates may be significantly delayed or may become unavailable as a result of COVID-19 and the resulting impact on our suppliers&#8217; labor forces and operations, including as a result of governmental restrictions on business operations and the movement of people and goods in an effort to curtail the spread of the virus. There can be no assurance that we would be able to timely implement any mitigation plans. Disruptions in our supply chain, whether as a result of restricted travel, quarantine requirements or otherwise, could negatively impact clinical supplies of our product candidates, which could materially adversely impact our clinical trial and development timelines.</p><a id="_cp_text_4_109"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The global spread of COVID-19 has also led to severe disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets in the future. It is likely that the continued spread of COVID-19 will cause an economic slowdown or recession or cause other unpredictable events, each of which could adversely affect our business, results of operations or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the COVID-19 outbreak and the actions to contain the outbreak or treat its impact, among others. Moreover, the COVID-19 outbreak has begun to have indeterminable adverse effects on general commercial activity and the world economy, and our business and results of operations could be adversely affected to the extent that COVID-19 or any other pandemic harms the global economy generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2021, we had 82 full-time and two part-time employees. As our development and commercialization plans and strategies develop, or as a result of any future acquisitions, we will need additional managerial, operational, sales, marketing, financial and other resources. In addition, it may become more cost effective to bring in house certain resources currently outsourced to consultants and other third-parties. Our management, personnel and systems currently in place may not be adequate to support our future growth. Future growth would impose significant added responsibilities on members of management, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">managing our clinical trials effectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">identifying, recruiting, maintaining, motivating and integrating additional employees;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">improving our managerial, development, operational and finance systems; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">expanding our facilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As our operations expand, we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize ganaxolone, if approved, and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Our Common Stock</b></p><a id="_cp_text_1_746"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our stock </span><span style="font-style:italic;font-weight:bold;">has been, and may continue to be, </span><span style="font-style:italic;font-weight:bold;">highly volatile, and you could lose all or part of your investment.</span></p><a id="_cp_text_1_747"></a><a id="_cp_text_1_749"></a><a id="_cp_text_1_750"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, the trading price of our common stock has been highly volatile, and it is likely that such price will continue to be volatile in the future. The trading price of our common stock could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed elsewhere in this &#8220;Risk Factors&#8221; section, these factors could include: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the success of competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">regulatory actions with respect to our products or our competitors&#8217; products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">actual or anticipated changes in our growth rate relative to our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></td></tr></table><a id="_cp_blt_2_751"></a><a id="_cp_blt_2_753"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><a id="_cp_blt_2_755"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the level of expenses related to our clinical development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the results of our efforts to in-license or acquire additional product candidates or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">sales of our common stock by us, our insiders or our other stockholders;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes in the structure of healthcare payment systems; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">other events or factors, many of which are beyond our control.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock market in general, the Nasdaq Global Market and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of these risks or any of a broad range of other risks, including those described in these &#8220;Risk Factors,&#8221; could have a dramatic and material adverse impact on the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Insiders have substantial influence over us and could delay or prevent a change in corporate control.</span></p><a id="_cp_text_1_763"></a><a id="_cp_text_1_768"></a><a id="_cp_blt_2_773"></a><a id="_cp_text_4_770"></a><a id="_cp_text_1_771"></a><a id="_cp_blt_2_775"></a><a id="_cp_blt_2_777"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We estimate that our executive officers, directors and holders of 5% or more of our capital stock collectively beneficially own approximately 42.7<span style="white-space:pre-wrap;">% of our voting stock.  Upon conversion of all of our outstanding convertible preferred stock, as of March 31, 2021, our executive officers, directors and holders of 5% or more of our capital stock collectively would beneficially own approximately 40.6% of our voting stock</span>.<span style="font-style:italic;font-weight:bold;"> </span> This concentration of ownership could harm the market price of our common stock by delaying, deferring or preventing a strategic transaction, even if such a transaction would benefit other stockholders.; The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might negatively affect the prevailing market price for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our operating results may fluctuate significantly in the future, which may cause our results to fall below the expectations of securities analysts, stockholders and investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operating results may fluctuate significantly in the future as a result of a variety of factors, many of which are outside of our control. These factors include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing, implementation and cost of our research, preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to attract and retain personnel with the necessary strategic, technical and creative skills required for effective operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">introduction of new technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">product liability litigation, class action and derivative action litigation, or other litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the amount and timing of capital expenditures and other costs relating to the expansion of our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the state of the debt and/or equity capital markets at the time of any proposed offering we choose to initiate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to successfully integrate new acquisitions into our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">government regulation and legal developments regarding ganaxolone in the United States and in the foreign countries in which we may operate in the future; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">general economic conditions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a strategic response to changes in the competitive environment, we may from time to time make pricing, service, technology or marketing decisions or business or technology acquisitions that could have a material adverse effect on our operating results. Due to any of these factors, our operating results may fall below the expectations of securities analysts, stockholders and investors in any future period, which may cause our stock price to decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of March 31, 2021, we had outstanding a total of 36,578,460 shares of common stock and 4,753 shares of Series&#160;A Participating Convertible Preferred Stock, par value $0.001 per share (Series&#160;A Preferred Stock). The Series A Preferred Stock were convertible into 950,600 shares of common stock as of March 31, 2021, subject to certain ownership limitations. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans or otherwise will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and either the registration of such shares under the Securities Act of 1933, as amended (Securities Act) or the application of exemptions from such registration with respect to any sales such as Rule&#160;144 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Provisions in our fourth amended and restated certificate of incorporation, as amended (Certificate of Incorporation) and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These include provisions that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">permit our board of directors to issue up to 25,000,000 shares of preferred stock, with any rights, preferences and privileges as it may designate, of which 4,753 shares of Series A Preferred Stock are outstanding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">establish a classified board of directors such that only one of three classes of directors is elected each year;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">provide that directors can only be removed for cause;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">provide that special meetings of our stockholders may be called only by the chairperson of the board of directors, the chief executive officer or the board of directors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">by the provisions of Section&#160;203 of the Delaware General Corporation Law (DGCL), which prohibits, with some exceptions, stockholders owning in excess of 15.0% of our outstanding capital stock from merging or combining with us.</p><a id="_cp_text_1_121"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Certificate of Incorporation contains exclusive forum provisions, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span></p><a id="_cp_text_1_122"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (a)&#160;any derivative action or proceeding brought on our behalf, (b)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, (c)&#160;any action asserting a claim arising pursuant to any provision of the DGCL, or (d)&#160;any action asserting a claim that is governed by the internal affairs doctrine, in each such case subject to such Court of Chancery&#8217;s having personal jurisdiction over the indispensable parties named as defendants therein.</p><a id="_cp_text_1_123"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, the exclusive forum provisions described above do not apply to any claims arising under the Securities Act or under the Exchange Act. Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The choice of forum provisions in our Certificate of Incorporation may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. The applicable courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. With respect to the provision making the Court of Chancery the sole and exclusive forum for certain types of actions, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. Finally, if a court were to find these provisions of our Certificate of Incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><a id="_cp_text_1_736"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or those of any business partners.</span><span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, loss of funds or information from phishing or other fraudulent schemes, attachments to emails, persons inside our organization, or persons with access to systems inside our organization or those with whom we do business. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Such an event could cause interruption of our operations or loss of Company funds and have a negative financial consequence on our business. In addition, our systems safeguard important confidential personal data regarding patients enrolled in our clinical trials. If a disruption event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of data relating to completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and cause us to incur significant additional costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, misappropriation of funds to unintended recipients, or inappropriate disclosure of confidential, proprietary </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or personal information, we could incur material legal claims and liabilities and damage to our reputation and the further development of ganaxolone could be delayed. Additionally, breach remediation costs may be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce ganaxolone. Our ability to obtain clinical supplies of ganaxolone could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. In addition, while we believe that we currently have sufficient supply of our product candidates to continue our ongoing clinical trials, some of our product candidates, or materials contained therein, come from facilities located in areas impacted by the COVID-19 pandemic. There is no guarantee that the COVID-19 pandemic, or any potential future outbreak or pandemic, would not materially impact our future supply chain. The ultimate impact on us, our significant suppliers and our general infrastructure of being in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</p><a id="_4cff4a18_9755_4a65_9eca_f748145f6420"></a><a id="Item2UnregisteredSalesofUnregisteredSecu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d69d8a5b_1f10_4bc7_8499_7f22f801ccf7"></a><a id="Item3DefaultsuponSeniorSecurities_975187"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 3. Defaults upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_27241959_a876_4918_a14d_019c8006c268"></a><a id="Item4MineSafetyDisclosures_306061"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 4. Mine Safety Disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_6a94b6db_4d91_4ff7_b5b5_dca204bc06c8"></a><a id="Item5OtherInformation_942864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 5. Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 11, 2021 (the Closing Date), we entered into a Credit Agreement and Guaranty (as amended by that certain letter agreement on May 17, 2021, the Credit Agreement) with Oaktree Fund Administration, LLC, as administrative agent (the Administrative Agent) and the lenders party thereto that provides for a five-year senior secured term loan facility in an aggregate original principal amount of up to $125.0 million available to us in five tranches as follows (collectively, the Term Loans):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$15.0 million of tranche A-1 term loans advanced on the Closing Date. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$30.0 million of tranche A-2 term loans subject to written acceptance by the Food and Drug Administration (FDA) of a New Drug Application (NDA) filing relating to the use of ganaxolone in treatment of CDKL5 deficiency disorder (CDD).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$30.0 million of tranche B term loans subject to receipt of written approval from the FDA of an NDA permitting the marketing of ganaxolone in interstate commerce in the United States to treat CDD (the FDA Approval).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">$25.0 million of tranche C term loans subject to receipt of the FDA Approval and the completion of one or more financings, including through the issuance of common stock, convertible debt, subordinated debt, a synthetic royalty or a sublicense in which we receive gross proceeds in an aggregate amount of at least $40.0 million and net proceeds in an aggregate amount of at least $36.0 million.  . In addition, the availability of this tranche is subject to either our current Phase 3 trial in RSE or a Phase 3 trial in TSC achieving statistical significance (p value &lt; 0.05) across all primary </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">endpoints and ganaxolone must be generally well tolerated, with a safety profile generally consistent with previous clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$25.0 million of tranche D term loans subject to receipt of the FDA Approval and us earning at least $50 million in net product revenue in the United States for a period of six consecutive months.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The Term Loans will bear interest at a fixed per annum rate (subject to increase during an event of default) of 11.50% and are scheduled to mature on the fifth anniversary of the Closing Date (the Maturity Date). In addition, at the time of funding of any tranche of the Term Loans, we are required to pay an upfront fee of 2.0% of the aggregate principal amount being funded. We are required to make quarterly interest payments until the Maturity Date. We are also required to make principal payments, which are payable in quarterly installments beginning on the last day of the first quarter ending after the third anniversary of the Closing Date in an amount equal to 5.0% of the aggregate amount of the Term Loans outstanding on the date of the first such quarterly principal payment and continuing until the Maturity Date, on which date all outstanding Term Loans and other amounts owed under the Credit Agreement will be required to be paid in full. A commitment fee of 75 basis points per annum will accrue on each of the tranche B, C and D commitments for the period beginning 120 days after the funding date of the tranche A-2 term loans until the applicable tranche is either funded or terminated.<br /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Subject to certain exceptions, we are required to make mandatory prepayments of the Term Loans, with the proceeds of asset sales, casualty and condemnation events and prohibited debt issuances, and resulting from an event of default under the Credit Agreement upon the occurrence of a change of control (as defined in the Credit Agreement). In addition, we may make voluntary prepayments of the Term Loans, in whole or in part. All mandatory and voluntary prepayments of the Term Loans are subject to the payment of prepayment premiums as follows: (i) if prepayment (or termination of the tranche A-2 term loan commitment) occurs on or before the second anniversary of the Closing Date, an amount equal to 4% of the principal prepaid (or the tranche A-2 term loan commitment amount terminated) <i style="font-style:italic;">plus </i>a &#8220;make-whole&#8221; amount in respect of any such principal payments (whether mandatory or voluntary) described in this clause (i), in an amount equal to the interest that would have accrued through the second anniversary of the Closing Date but for such principal repayment, (ii) if prepayment (or termination of the tranche A-2 term loan commitment) occurs after the second anniversary of the Closing Date but on or before the third anniversary of the Closing Date, an amount equal to 4% of the principal prepaid (or the tranche A-2 term loan commitment amount terminated), (iii) if prepayment occurs after the third anniversary of the Closing Date but on or before the fourth anniversary of the Closing Date, an amount equal to 2% of the principal prepaid, and (iv) if prepayment occurs after the fourth anniversary of the Closing Date, no prepayment premium is due; provided that, in lieu of paying the foregoing amounts (including the &#8220;make-whole&#8221; amount described in the foregoing clause (i)), if such prepayment occurs as a result of or in connection with a change of control, the prepayment premium shall be (i) if such prepayment occurs on or before the first anniversary of the Closing Date, 12.5% of the principal prepaid (or the tranche A-2 term loan commitment amount terminated) or (ii) if such prepayment occurs after the first anniversary of the Closing Date but on or before the second anniversary of the Closing Date, 10.0% of the principal prepaid (or the tranche A-2 term loan commitment amount terminated). We are also required to pay an exit fee in an amount equal to 2.0% of all principal repaid, whether as a prepayment or a scheduled repayment.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The Term Loans will be guaranteed by certain of our future subsidiaries that are required to become a party thereto as guarantors (the Guarantors).  Our obligations under the Credit Agreement and the guarantee of such obligations are secured by a pledge of substantially all of our assets and will be secured by a pledge of substantially all of the assets of the Guarantors pursuant to the terms of the Security Agreement dated as of the Closing Date by and among us, the Administrative Agent and the Guarantors from time to time party thereto (the Security Agreement).&#160;&#160;&#160;&#160;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_15"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Credit Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on our and our subsidiaries&#8217; abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the Credit Agreement contains a financial covenant that requires us to maintain at all times cash and cash equivalents in certain deposit accounts in an amount at least equal to (i) from the Closing Date until the funding of the tranche A-2 term loans, $10.0 million, (ii) from the funding of the tranche A-2 term loans until the funding of the tranche B term loans, $20.0 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_16"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">million, and (iii) from the funding date of the tranche B term loans until the Maturity Date, $15.0 million. The foregoing amounts are reflected in the letter agreement, which revised the minimum liquidity requirements set forth in the original Credit Agreement entered into on the Closing Date, which required a minimum liquidity of $10.0 from the Closing Date until the funding of the tranche B term loans and a minimum liquidity of $15.0 million from the funding date of the tranche B term loans until the Maturity Date.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Credit Agreement also contains representations and warranties of us and of the Guarantors customary for financings of this type. In addition, such representations and warranties (i)&#160;are intended not as statements of fact, but rather as a way of allocating the risk between the parties to the Credit Agreement and (ii)&#160;may apply standards of materiality in a way that is different from what may be viewed as material by our stockholders or other investors. Accordingly, the Credit Agreement is included with this filing only to provide investors with information regarding the terms of the transaction, and not to provide stockholders or other investors with any other factual information regarding us. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of us or any of our subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Credit Agreement, which subsequent information may or may not be fully reflected in public disclosures.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;margin:0pt;">The Credit Agreement also includes events of default customary for financings of this type, in certain cases subject to customary periods to cure, following which the Administrative Agent may accelerate all amounts outstanding under the Loan.</p><a id="_cp_text_1_18"></a><a id="_cp_text_1_19"></a><a id="_cp_text_1_21"></a><a id="_cp_text_1_22"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;margin:0pt;">The foregoing description of the Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement, the Security Agreement and the letter agreement, which are filed herewith as Exhibits 10.1, 10.2 and 10.3 to this Quarterly Report on Form 10-Q,&#160;respectively, and are incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2d882e0c_4989_475a_a18c_448a9cdeaa61"></a><a id="Item6Exhibits_280778"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 6. Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:90%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1267813/000110465914057958/a14-9429_21ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on August 7, 2014.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1267813/000110465920042426/tm2014438d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment of the Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on April 2, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1267813/000110465920066366/tm2021040d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment of the Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on May 27, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1267813/000110465920107215/tm2030376d3_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment of the Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on September 22, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1267813/000110465920107215/tm2030376d3_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment of the Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.2 to Form 8-K current report filed on September 22, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1267813/000110465914057958/a14-9429_21ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated By-laws. (Incorporated by reference to Exhibit 3.2 to Form 8-K current report filed on August 7, 2014.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1267813/000110465914057958/a14-9429_21ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Designations, Preferences and Rights of Series A Participating Convertible Preferred Stock. (Incorporated by reference to Exhibit 3.1 to Form 8-K current report filed on December 13, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1267813/000104746914006260/a2220612zex-4_1.htm"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Specimen Certificate evidencing shares of the Company&#8217;s common stock. (Incorporated by reference to Exhibit 4.1 to Form S-1/A registration statement filed on July 18, 2014.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrns-20210331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Credit Agreement and Guaranty, dated May 11, 2021, by and among Marinus Pharmaceuticals, Inc., as Borrower, Oaktree Fund Administration, LLC, as Administrative Agent, and the other lenders party thereto. (filed herewith)</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrns-20210331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Security Agreement, dated May 11, 2021, by and among Marinus Pharmaceuticals, Inc., as Grantor, and Oaktree Fund Administration, LLC, as Administrative Agent. (filed herewith)</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td colspan="2" style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrns-20210331xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Letter Agreement, dated May 17, 2021, by and among Marinus Pharmaceuticals, Inc., as Borrower, Oaktree Fund Administration, LLC, as Administrative Agent, and the other lenders party thereto. (filed herewith)</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrns-20210331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act (filed herewith).</span></a></p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrns-20210331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act (filed herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrns-20210331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer (furnished herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema </p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase</p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase</p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Labels Linkbase</p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase</p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File &#8211; The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_38f821cb_ea7b_4474_824f_16491215fe76"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_571022"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:34.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:42.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.1%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:middle;width:34.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:42.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:34.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-variant:small-caps;">/</span>s<span style="font-variant:small-caps;">/ </span>SCOTT BRAUNSTEIN</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">President and Chief Executive Officer (principal executive officer) and Director</p></td><td rowspan="2" style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;">May 17, 2021</p></td></tr><tr><td style="vertical-align:middle;width:34.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt 0pt 1pt 0pt;">Scott Braunstein</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:42.74%;margin:0pt;padding:0pt;"></td><td style="display:none;vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:18.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:middle;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:34.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt 0pt 1pt 0pt;">/s/ STEVEN PFANSTIEL</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Chief Financial Officer and Treasurer (principal financial and accounting officer)</p></td><td rowspan="2" style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;">May 17, 2021</p></td></tr><tr><td style="vertical-align:middle;width:34.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Steven Pfanstiel</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:42.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>mrns-20210331xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/17/2021 08:23:02 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.1</b></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:612pt;"><td style="vertical-align:middle;width:100%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="padding-bottom:1.0px;padding-top:1.0px;border-bottom:3.0pt solid #000000;border-top:3.0pt solid #000000;margin:4.5pt 28.65pt 12pt 27.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CREDIT AGREEMENT AND GUARANTY</b></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:2.21;text-align:center;margin:9.05pt 106.6pt 0pt 93.65pt;"><b style="font-weight:bold;">dated as of May 11, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 28.65pt 12.5pt 27.7pt;"><b style="font-weight:bold;">by and among</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 28.65pt 0pt 27.75pt;"><b style="font-weight:bold;">MARINUS PHARMACEUTICALS, INC.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 28.65pt 12.5pt 27.6pt;"><b style="font-weight:bold;">as the Borrower,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 28.65pt 0pt 27.9pt;"><b style="font-weight:bold;">THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 28.65pt 12.5pt 27.55pt;"><b style="font-weight:bold;">as the Guarantors,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 28.65pt 0pt 27.75pt;"><b style="font-weight:bold;">THE LENDERS FROM TIME TO TIME PARTY HERETO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:2.21;text-align:center;margin:0pt 202.1pt 0pt 201.1pt;"><b style="font-weight:bold;">as the Lenders, and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 28.65pt 0pt 27.75pt;"><b style="font-weight:bold;">OAKTREE FUND ADMINISTRATION, LLC,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 28.65pt 24pt 27.7pt;"><b style="font-weight:bold;">as the Administrative Agent</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:7.9pt 28.65pt 12pt 27.65pt;"><b style="font-weight:bold;">&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:7.9pt 28.65pt 12pt 27.65pt;"><b style="font-weight:bold;">U.S. $125,000,000</b></p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TABLE OF CONTENTS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 1. DEFINITIONS</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">1</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">1.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Certain Defined Terms</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">1</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">1.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Accounting Terms and Principles</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">35</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">1.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Interpretation</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">36</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">1.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Division</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">37</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">1.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Currency Generally.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">37</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 2. THE COMMITMENT AND THE LOANS</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">37</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">2.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Loans</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">37</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">2.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Borrowing Procedures</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">38</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">2.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Notes</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">38</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">2.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Use of Proceeds</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">38</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">2.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Commitment Fees</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">39</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">2.07</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Defaulting Lenders.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">39</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 3. PAYMENTS OF PRINCIPAL AND INTEREST, ETC.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">40</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Scheduled Repayments and Prepayments Generally; Application</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">40</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Interest</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">40</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Prepayments</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">41</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Commitment Termination</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">44</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exit Fee</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">44</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Original Issue Discount</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">44</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 4. PAYMENTS, ETC.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">45</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">4.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Payments</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">45</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">4.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Computations</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">46</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">4.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Set-Off</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">46</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 5. YIELD PROTECTION, TAXES, ETC.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">47</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">5.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Additional Costs</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">47</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">5.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">[Reserved]</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">48</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">5.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Taxes</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">48</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">5.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Mitigation Obligations; Replacement of Lenders</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">52</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">5.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Survival</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">53</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 6. CONDITIONS</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">53</font></font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">6.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Conditions to the Closing Date</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">53</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">6.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Conditions to the Borrowing of All Loans</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">56</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 7. REPRESENTATIONS AND WARRANTIES</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">57</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Power and Authority</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">57</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Authorization; Enforceability</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">58</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Governmental and Other Approvals; No Conflicts</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">58</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Financial Statements; Material Adverse Change</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">58</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Properties</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">59</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">No Actions or Proceedings</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">62</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.07</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Compliance with Laws and Agreements</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">62</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.08</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Taxes</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">63</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.09</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Full Disclosure</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">63</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.10</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Investment Company Act and Margin Stock Regulation</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">64</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.11</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Solvency</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">64</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.12</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Subsidiaries</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">64</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.13</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">[Reserved]</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">64</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.14</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Material Agreements</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">64</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.15</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Restrictive Agreements</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">65</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.16</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Real Property</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">65</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.17</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Pension Matters</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">65</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.18</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Regulatory Approvals</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">65</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.19</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">[Reserved]</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">67</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.20</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">OFAC; Anti-Terrorism Laws</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">67</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.21</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Anti-Corruption</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">68</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.22</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Priority of Obligations</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">68</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.23</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Royalty and Other Payments</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">68</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.24</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Non-Competes</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">68</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">7.25</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Reimbursement from Medical Reimbursement Programs</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">68</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 8. AFFIRMATIVE COVENANTS</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">68</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Financial Statements and Other Information</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">68</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Notices of Material Events</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">71</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Existence</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">72</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Payment of Obligations</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">72</font></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Insurance</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">73</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Books and Records; Inspection Rights</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">73</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.07</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Compliance with Laws and Other Obligations</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">74</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.08</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Maintenance of Properties, Etc.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">74</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.09</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Licenses</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">74</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.10</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">[Reserved]</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">74</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.11</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Use of Proceeds</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">74</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.12</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Certain Obligations Respecting Subsidiaries; Further Assurances</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">74</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.13</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Termination of Non-Permitted Liens</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">76</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.14</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Board Materials</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">76</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.15</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">[Reserved]</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">77</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.16</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Maintenance of Regulatory Approvals, Contracts, Intellectual Property, Etc.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">77</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.17</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">ERISA Compliance</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">77</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.18</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Cash Management</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">77</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8.19</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Post-Closing Obligations</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">78</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 9. NEGATIVE COVENANTS</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">79</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Indebtedness</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">79</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Liens</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">81</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Fundamental Changes and Acquisitions</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">83</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Lines of Business</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">84</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Investments</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">85</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Restricted Payments</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">87</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.07</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Payments of Indebtedness</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">88</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.08</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Change in Fiscal Year</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">88</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.09</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Sales of Assets, Etc.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">88</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.10</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Transactions with Affiliates</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">90</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.11</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Restrictive Agreements</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">90</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.12</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Modifications and Terminations of Material Agreements and Organic Documents</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">91</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.13</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Outbound Licenses</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">91</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.14</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Sales and Leasebacks</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">91</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.15</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Hazardous Material</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">92</font></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.16</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Accounting Changes</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">92</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.17</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Compliance with ERISA</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">92</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9.18</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Sanctions; Anti-Corruption Use of Proceeds</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">92</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 10. FINANCIAL COVENANT</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">92</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">10.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Minimum Liquidity</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">92</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 11. EVENTS OF DEFAULT</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">93</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">11.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Events of Default</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">93</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">11.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Remedies</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">96</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">11.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Additional Remedies</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">97</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">11.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">[Reserved]</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">97</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">11.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">[Reserved]</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">97</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">11.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Payment of Yield Protection Premium and Exit Fee</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">97</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 12. THE ADMINISTRATIVE AGENT</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">98</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Appointment and Duties</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">98</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Binding Effect</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">100</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Use of Discretion</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">100</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Delegation of Rights and Duties</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">100</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Reliance and Liability</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">101</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Administrative Agent Individually</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">102</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.07</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Lender Credit Decision</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">102</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.08</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Expenses; Indemnities</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">102</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.09</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Resignation of the Administrative Agent</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">103</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.10</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Release of Collateral or Guarantors</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">104</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.11</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Additional Secured Parties</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">105</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.12</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Agent May File Proofs of Claim</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">105</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.13</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Intercreditor Agreement</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">106</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12.14</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Acknowledgements of Lenders</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">106</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 13. GUARANTY</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">109</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">13.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The Guaranty</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">109</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">13.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Obligations Unconditional</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">109</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">13.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Reinstatement</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">113</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">13.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Subrogation</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">113</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">13.07</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Remedies</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">114</font></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">13.08</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Instrument for the Payment of Money</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">114</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">13.09</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Continuing Guarantee</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">114</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">13.11</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">General Limitation on Guarantee Obligations</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">115</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section 14. MISCELLANEOUS</font></font><font style="bottom:3.0957031pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">115</font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.01</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">No Waiver</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">115</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.02</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Notices</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">115</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.03</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Expenses, Indemnification, Etc.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">115</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.04</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Amendments, Etc.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">117</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.05</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Successors and Assigns</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">118</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.06</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Survival</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">121</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.07</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Captions</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">121</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.08</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Counterparts, Effectiveness</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">122</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.09</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Governing Law</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">122</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.10</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Jurisdiction, Service of Process and Venue</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">122</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.11</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Waiver of Jury Trial</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">122</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.12</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Waiver of Immunity</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">123</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.13</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Entire Agreement</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">123</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.14</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Severability</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">123</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.15</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">No Fiduciary Relationship</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">123</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.16</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Confidentiality</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">123</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.17</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Interest Rate Limitation</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">124</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.18</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Judgment Currency</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">124</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.19</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">USA PATRIOT Act</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">125</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.20</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Acknowledgement and Consent to Bail-In of EEA Financial Institutions</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">125</font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:8.33%;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">14.21</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Certain ERISA Matters</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">126</font></font></p></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SCHEDULES AND EXHIBITS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 1</font></font>-<font style="display:inline-block;width:32pt;"></font>Loans Schedule</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 2</font></font>-<font style="display:inline-block;width:32pt;"></font>Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 3</font></font>-<font style="display:inline-block;width:32pt;"></font>Permitted Licenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 4</font></font>-<font style="display:inline-block;width:32pt;"></font>Permitted Convertible Debt Pricing</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">Schedule 7.05(b)<font style="display:inline-block;width:26.02pt;"></font>-<font style="display:inline-block;width:32pt;"></font>Certain Intellectual Property </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">Schedule 7.06(a)<font style="display:inline-block;width:26.7pt;"></font>-<font style="display:inline-block;width:32pt;"></font>Litigation </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">Schedule 7.06(c)<font style="display:inline-block;width:26.7pt;"></font>-<font style="display:inline-block;width:32pt;"></font>Collective Bargaining Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 7.08</font></font>-<font style="display:inline-block;width:32pt;"></font>Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 7.12</font></font>-<font style="display:inline-block;width:32pt;"></font>Information Regarding Subsidiaries </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">Schedule 7.13(a)<font style="display:inline-block;width:26.7pt;"></font>-<font style="display:inline-block;width:32pt;"></font>Existing Indebtedness</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">Schedule 7.13(b)<font style="display:inline-block;width:26.02pt;"></font>-<font style="display:inline-block;width:32pt;"></font>Existing Liens </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 7.14</font></font><font style="display:inline-block;width:36pt;"></font>Material Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 7.15</font></font>-<font style="display:inline-block;width:32pt;"></font>Restrictive Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 7.16</font></font>-<font style="display:inline-block;width:32pt;"></font>Real Property Owned or Leased by Obligors </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 7.17</font></font>-<font style="display:inline-block;width:32pt;"></font>Pension Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">Schedule 7.18(c)<font style="display:inline-block;width:26.7pt;"></font>-<font style="display:inline-block;width:32pt;"></font>Adverse Findings</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 7.19</font></font>-<font style="display:inline-block;width:32pt;"></font>Transactions with Affiliates </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 7.23</font></font>-<font style="display:inline-block;width:32pt;"></font>Royalties and Other Payments </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">Schedule 9.05(a)<font style="display:inline-block;width:26.7pt;"></font>-<font style="display:inline-block;width:32pt;"></font>Existing Investments </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">Schedule 9.05(s)<font style="display:inline-block;width:27.35pt;"></font>-<font style="display:inline-block;width:32pt;"></font>Potential Investments </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 9.09</font></font>-<font style="display:inline-block;width:32pt;"></font>Sale of Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Schedule 9.14</font></font>-<font style="display:inline-block;width:32pt;"></font>Existing Sales and Leasebacks</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit A</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Note</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit B</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Borrowing Notice</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit C</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Guarantee Assumption Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit D-1</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes) </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit D-2</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit D-3</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes) </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit D-4</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit E</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Compliance Certificate </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit F</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Assignment and Assumption </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit G</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Landlord Consent</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit H</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Intercompany Subordination Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit I</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Solvency Certificate</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:144pt;text-indent:-144pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibit J</font></font>-<font style="display:inline-block;width:32pt;"></font>Form of Funding Date Certificate</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CREDIT AGREEMENT AND GUARANTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CREDIT AGREEMENT AND GUARANTY, dated as of May 11, 2021 (this &#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221;), among <b style="font-weight:bold;">MARINUS PHARMACEUTICALS, INC.</b>, a Delaware corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Borrower</font>&#8221;), certain Subsidiaries of the Borrower that may be required to provide Guarantees from time to time hereunder (each a &#8220;<font style="font-style:italic;font-weight:bold;">Guarantor</font>&#8221; and collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Guarantors</font>&#8221;), the lenders from time to time party hereto (each a &#8220;<font style="font-style:italic;font-weight:bold;">Lender</font>&#8221; and collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Lenders</font>&#8221;), and <b style="font-weight:bold;">OAKTREE FUND ADMINISTRATION, LLC</b>, as administrative agent for the Lenders (in such capacity, the &#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">WITNESSETH:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Borrower has requested that the Lenders provide a senior secured term loan facility to the Borrower in an aggregate principal amount of $125,000,000, consisting of (a) a $15,000,000 Tranche A-1 Term Loan to be extended on the Closing Date, (b)&#160;a $30,000,000 Tranche A-2 Term Loan to be extended on the Applicable Funding Date for the Tranche A-2 Term Loan, (c)&#160;a $30,000,000 Tranche B Term Loan to be extended on the Applicable Funding Date for the Tranche B Term Loan, (d) a $25,000,000 Tranche C Term Loan to be extended on the Applicable Funding Date for the Tranche C Term Loan, and (e) a $25,000,000 Tranche D Term Loan to be extended on the Applicable Funding Date for the Tranche D Term Loan; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Lenders are willing, on the terms and subject to the conditions set forth herein, to provide such senior secured term loan facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, the parties hereto agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 1.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000306"></a><a name="_Toc256000153"></a><a name="_Toc256000000"></a><a name="_Ref40129955"></a><a name="_Toc69324575"></a><a name="_Toc70875872"></a>DEFINITIONS</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">1.01</font><a name="_Toc256000307"></a><a name="_Toc256000154"></a><a name="_Toc256000001"></a><a name="_Ref40129956"></a><a name="_Toc69324576"></a><a name="_Toc70875873"></a>Certain Defined Terms<font style="font-weight:normal;">. As used herein, the following terms have the following respective meanings:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Account Control Agreement Completion Date</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section 8.19(a)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Acquisition</font>&#8221; means any transaction, or any series of related transactions, by which any Person (for purposes of this definition, an &#8220;<font style="font-style:italic;font-weight:bold;">acquirer</font>&#8221;) directly or indirectly, by means of amalgamation, merger, purchase of assets, purchase of Equity Interests, or otherwise, <a name="DocXTextRef2"></a>(i) acquires all or substantially all of the assets of any other Person, (ii) acquires an entire business line or unit or division of any other Person, (iii) with respect to any other Person that is managed or governed by a Board, acquires control of Equity Interests of such other Person representing more than fifty percent (50%) of the ordinary voting power (determined on a fully-diluted basis) for the election of directors of such Person&#8217;s Board, or (iv) acquires control of more than fifty percent (50%) of the Equity Interests in any other Person (determined on a fully-diluted basis) that is not managed by a Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221; has the meaning set forth in the preamble hereto. </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Affiliate</font>&#8221; means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221; has the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">ANDA</font>&#8221; means <a name="DocXTextRef3"></a>(i) <a name="DocXTextRef4"></a>(x) an abbreviated new drug application (as defined in the FD&amp;C Act) and <a name="DocXTextRef5"></a>(y) any similar application or functional equivalent relating to any new drug application applicable to or required by any non-U.S. Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Anti-Terrorism Laws</font>&#8221; means any laws relating to terrorism or money laundering, including, without limitation, (i) the Money Laundering Control Act of 1986 (e.g., 18 U.S.C. &#167;&#167; 1956 and 1957), (ii) the Bank Secrecy Act of 1970 (e.g., 31 U.S.C. &#167;&#167; 5311 &#8211; 5330), as amended by the Patriot Act, (iii) the laws, regulations and Executive Orders administered by the United States Department of the Treasury&#8217;s Office of Foreign Assets Control (&#8220;<b style="font-weight:bold;">OFAC</b>&#8221;), (iv) the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010 and implementing regulations by the United States Department of the Treasury, (v) any law prohibiting or directed against terrorist activities or the financing of terrorist activities (e.g., 18 U.S.C. &#167;&#167; 2339A and 2339B), or (vi) any similar laws enacted in the United States, European Union or any other jurisdictions in which the parties to this agreement operate, and all other present and future legal requirements of any Governmental Authority governing, addressing, relating to, or attempting to eliminate, terrorist acts and acts of war.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Applicable Availability Period</font>&#8221; means the Tranche A-2 Availability Period, the Tranche B Availability Period, the Tranche C Availability Period or the Tranche D Availability Period, as the context may require. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Applicable Commitment</font>&#8221; means the Tranche A-1 Commitment, the Tranche A-2 Commitment, the Tranche B Commitment, the Tranche C Commitment or the Tranche D Commitment, as the context may require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Applicable Funding Condition</font>&#8221; means the Tranche A-1 Funding Condition, the Tranche A-2 Funding Condition, the Tranche B Funding Condition, the Tranche C Funding Condition or the Tranche D Funding Condition, as the context may require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Applicable Funding Date</font>&#8221; means, with respect to each Applicable Commitment, the date on or prior to the expiration of the Applicable Availability Period for such Applicable Commitment on which all conditions precedent set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">6.02</b> are satisfied or waived in accordance with the terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Arm&#8217;s Length Transaction</font>&#8221; means, with respect to any transaction, the terms of such transaction shall not be less favorable to the Borrower or any of its Subsidiaries than commercially reasonable terms that would be obtained in a transaction with a Person that is an unrelated third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Asset Sale</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.09</b>.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Assignment and Assumption</font>&#8221; means an assignment and assumption entered into by a Lender and an assignee of such Lender substantially in the form of <b style="font-weight:bold;">Exhibit F</b>, or such other form as agreed by the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;"> &#8220;</font><font style="font-style:italic;font-weight:bold;">Bail-In Action</font>&#8221; means the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial Institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Bail-In Legislation</font>&#8221; means, with respect to any EEA Member Country implementing <a name="DocXTextRef8"></a>Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Bailee Letter</font>&#8221; means a bailee letter substantially in the form of Exhibit F to the Security Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Bankruptcy Code</font>&#8221; means Title <a name="DocXTextRef9"></a>11 of the United States Code entitled &#8220;Bankruptcy.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Benefit Plan</font>&#8221; means any employee benefit plan as defined in Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise) to which any Obligor or Subsidiary thereof incurs or otherwise has any obligation or liability, contingent or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Beneficial Ownership Certification</font>&#8221; means a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Beneficial Ownership Regulation</font>&#8221; means 31 C.F.R. &#167; 1010.230.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">BLA</font>&#8221; means <a name="DocXTextRef10"></a>(i) <a name="DocXTextRef11"></a>(x) a biologics license application (as defined in the Public Health Service Act) to introduce, or deliver for introduction, a biologic product, including vaccines into commerce in the U.S., or any successor application or procedure and <a name="DocXTextRef12"></a>(y) any similar application or functional equivalent relating to biologics licensing applicable to or required by any non-U.S. Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Board</font>&#8221; means, with respect to any Person, the board of directors or equivalent management or oversight body of such Person or any committee thereof authorized to act on behalf of such board (or equivalent body).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Borrower</font>&#8221; has the meaning set forth in the preamble hereto. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Borrower Party</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.03(b)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Borrowing</font>&#8221; means the borrowing of the Loans on each Applicable Funding Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Borrowing Notice</font>&#8221; means a written notice substantially in the form of <b style="font-weight:bold;">Exhibit B</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Bringdown Date</font>&#8221; means each date on which a Loan is advanced pursuant to <b style="font-weight:bold;">Section 2.01</b> and any other date the representations and warranties under the Loan Documents are required to be made (other than the Closing Date).</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Business Day</font>&#8221; means a day (other than a Saturday or Sunday) on which commercial banks are not authorized or required to close in New York City.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Capital Lease Obligations</font>&#8221; means, as to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal property, which obligations are required to be classified and accounted for as a capital lease on a balance sheet of such Person under GAAP, and for the purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Casualty Event</font>&#8221; means the damage, destruction or condemnation, as the case may be, of property of the Borrower or any of its Subsidiaries in excess of $2,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">CFC</font>&#8221; means a Subsidiary that is a &#8220;controlled foreign corporation&#8221; within the meaning of <a name="DocXTextRef14"></a>Section 957 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">CFC Holding Company</font>&#8221; means any Domestic Subsidiary that owns no material assets (directly or indirectly) other than Equity Interests and debt of one or more CFCs or Domestic Subsidiaries that are themselves CFC Holding Companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Change of Control</font>&#8221; means an event or series of events <a name="DocXTextRef17"></a>(i) as a result of which any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are used in <a name="DocXTextRef22"></a>Sections 13(d) and <a name="DocXTextRef15"></a>14(d) of the Securities Act, but excluding any of such person or its Subsidiaries, and any Person acting in its capacity as trustee, agent or other fiduciary or administrator of any Plan) becomes the &#8220;beneficial owner&#8221; (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, except that a person or group shall be deemed to have &#8220;beneficial ownership&#8221; of all Equity Interests that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an &#8220;<font style="font-style:italic;font-weight:bold;">option right</font>&#8221;)), directly or indirectly, of fifty percent (50%) or more of the Equity Interests of the Borrower entitled to vote for members of the Board of the Borrower on a fully-diluted basis (and taking into account all such Equity Interests that such person or group has the right to acquire pursuant to any option right); (ii) as a result of which, during any period of twelve <a name="DocXTextRef16"></a>(12) consecutive months, a majority of the members of the Board of the Borrower cease to be composed of individuals <a name="DocXTextRef18"></a>(x) who were members of such Board on the first day of such period, <a name="DocXTextRef19"></a>(y) who were elected, appointed or nominated to such Board, or whose election, appointment or nomination to such Board was approved, by individuals referred to in <b style="font-weight:bold;">clause (x) </b>above constituting at the time of such election, appointment, nomination or approval at least a majority of such Board or equivalent governing body or <a name="DocXTextRef20"></a>(z) who were elected, appointed or nominated to such Board, or whose election, appointment or nomination to such Board was approved, by individuals referred to in <b style="font-weight:bold;">clauses (x) </b>and <a name="DocXTextRef21"></a><b style="font-weight:bold;">(y)</b> above constituting at the time of such election, appointment, nomination or approval at least a majority of such Board; (iii) that results in the sale of all or substantially all of the assets or businesses of the Borrower and its Subsidiaries, taken as a whole, or (iv) except to the extent permitted by this Agreement, that results in the Borrower&#8217;s failure to own, directly or indirectly, beneficially and of record, one-hundred percent (100%) of all issued and outstanding Equity Interests of each Subsidiary Guarantor.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Claims</font>&#8221; means (and includes) any claim, demand, complaint, grievance, action, application, suit, cause of action, order, charge, indictment, prosecution, judgement or other similar process, whether in respect of assessments or reassessments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel, and all costs incurred in investigating or pursuing any of the foregoing or any proceeding relating to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Closing Date</font>&#8221; means the date on which the conditions precedent specified in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">6.01</b> are satisfied (or waived in accordance with <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.04</b>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated thereunder from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Collateral</font>&#8221; means any real, personal and mixed property (including Equity Interests), whether tangible or intangible, in which Liens are granted or purported to be granted to the Administrative Agent as security for the Obligations under any Loan Document on or after the Closing Date, including future acquired or created assets or property (or collectively, all such real, personal and mixed property, as the context may require); provided, for the avoidance of doubt, &#8220;Collateral&#8221; shall not include any Excluded Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Commitment</font>&#8221; means, with respect to each Lender, the obligation of such Lender to make Loans to the Borrower on each Applicable Funding Date in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#8217;s name on <a name="DocXTextRef26"></a><b style="font-weight:bold;">Schedule 1</b><b style="font-weight:bold;"> </b>under the caption &#8220;Applicable Commitment&#8221;, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Commitments on the date of this Agreement equals $125,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Commitment Fee</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.06</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Commitment Termination Date</font>&#8221; means (i) with respect to the Applicable Commitments of the Tranche A-1 Term Loans, the Closing Date; (i) with respect to the Applicable Commitments of the Tranche A-2 Term Loans, December 31, 2021; (ii) with respect to the Applicable Commitments of the Tranche B Term Loans, December 31, 2022; (iii) with respect to the Applicable Commitments of the Tranche C Term Loans, June 30, 2023; and (iv) with respect to the Applicable Commitments of the Tranche D Term Loans, December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Company Competitor</font>&#8221; means <a name="DocXTextRef27"></a>(i) any competitor of the Borrower or any of its Subsidiaries primarily operating in the same line of business as the Borrower or any of its Subsidiaries and (ii) any of such competitor&#8217;s Affiliates (other than any Person that is a bona fide debt fund primarily engaged in the making, purchasing, holding or other investing in commercial loans, notes, bonds or similar extensions of credit or securities in the Ordinary Course) that are either clearly identifiable as an Affiliate of any such competitor on the basis of such Person&#8217;s name or identified by name in writing by the Borrower to the Administrative Agent from time to time. Notwithstanding anything to the contrary contained in this Agreement, (a) the Administrative Agent shall not be responsible or have any liability for, or have any duty to ascertain, inquire into, monitor or enforce, compliance with the provisions hereof relating to </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Company Competitor and (b) the Borrower, the Guarantors and the Lenders acknowledge and agree that the Administrative Agent shall have no responsibility or obligation to determine whether any Lender or potential Lender is a Company Competitor and that the Administrative Agent shall have no liability with respect to any assignment or participation made to a Company Competitor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Compliance Certificate</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.01(c)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Connection Income Taxes</font>&#8221; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Contracts</font>&#8221; means any contract, license, lease, agreement, obligation, promise, undertaking, understanding, arrangement, document, commitment, entitlement or engagement under which a Person has, or will have, any liability or contingent liability (in each case, whether written or oral, express or implied, and whether in respect of monetary or payment obligations, performance obligations or otherwise).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Control</font>&#8221; means, in respect of a particular Person, the possession by one or more other Persons, directly or indirectly, of the power to direct or cause the direction of the management or policies of such particular Person, whether through the ability to exercise voting power, by contract or otherwise. &#8220;Controlling&#8221; and &#8220;Controlled&#8221; have meanings correlative thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Controlled Account</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.18(a)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Copyright</font>&#8221; means all copyrights (including with respect to published and unpublished works of authorship, software, website and mobile content, data, databases and other compilations of information), copyright registrations and applications for copyright registrations, including all renewals, restorations, reversions and extensions thereof and all other rights whatsoever accruing thereunder or pertaining thereto throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Default</font>&#8221; means any Event of Default and any event that, upon the giving of notice, the lapse of time or both, would constitute an Event of Default.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Default Rate</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">3.02(b)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Defaulting Lender</font>&#8221; means, subject to <b style="font-weight:bold;">Section 2.07(b)</b>, any Lender, as determined by the Administrative Agent, that (a) has failed to perform any of its funding obligations hereunder, including with respect to any Tranche A-1 Commitments, any Tranche A-2 Commitments, any Tranche B Commitments, any Tranche C Commitments or any Tranche D Commitments, within three (3) Business Days of the date required to be funded by it hereunder, (b) has notified the Borrower or the Administrative Agent that it does not intend to comply with its funding obligations hereunder or (c) has, or has a direct or indirect parent company that has, (i) become the subject of an Insolvency Proceeding, (ii) had a receiver, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or a custodian appointed for it, (iii) taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment or (iv) become the subject of a Bail-In Action; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u>, a Lender shall not be a Defaulting Lender solely </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">by virtue of the ownership or acquisition of any Equity Interests in that Lender or any direct or indirect parent company thereof by a Governmental Authority.  Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of </font><u style="text-decoration:underline;text-decoration-color:#000000;">clauses (a)</u> through <u style="text-decoration:underline;text-decoration-color:#000000;">(c)</u> above, and of the effective date of such status, shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Section 2.07(b)</b>) as of the date established therefor by the Administrative Agent in a written notice of such determination, which shall be delivered by the Administrative Agent to the Borrower and each Lender promptly following such determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Deferred Acquisition Consideration</font>&#8221; means any purchase price adjustments, royalty, earn-out, milestone payments, contingent or other deferred payment payments of a similar nature (including any non-compete payments and consulting payments) made in connection with any Permitted Acquisition or other acquisition or investment permitted under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Designated Jurisdiction</font>&#8221; means any country or territory to the extent that such country or territory is the subject of country- or territory-wide Sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Disqualified Equity Interests</font>&#8221; means, with respect to any Person, any Equity Interest of such Person that, by its terms (or by the terms of any security or other Equity Interest into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition <a name="DocXTextRef34"></a>(i) matures <font style="background-color:#ffffff;">(excluding any maturity as the result of an optional redemption by the issuer thereof) </font>or is mandatorily redeemable (other than solely for (x) Qualified Equity Interests<font style="background-color:#ffffff;"> and (y) cash in lieu of fractional shares</font>), including pursuant to a sinking fund obligation or otherwise, (ii) is redeemable at the option of the holder thereof (other than solely for (x) Qualified Equity Interests <font style="background-color:#ffffff;">and (y) cash in lieu of fractional shares</font><a name="DocXTextRef33"></a>), in whole or in part, (iii) provides for the scheduled payments of dividends or other distributions in cash <font style="background-color:#ffffff;">(other than the payment of cash in lieu of redemption of fractional shares)</font> or other securities that would constitute Disqualified Equity Interests, or (iv) is or becomes convertible into or exchangeable for <font style="background-color:#ffffff;">(unless at the sole option of the issuer thereof)</font> Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests, in each case, prior to the date that is 180 days after the Maturity Date; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u>, any Equity Interests that would not constitute Disqualified Equity Interests but for provisions thereof giving holders thereof (or the holders of any security into or for which such Equity Interests are convertible, exchangeable or exercisable) the right to require the issuer thereof to redeem or repurchase such Equity Interests upon the occurrence of a change in control occurring prior to the 180<sup style="font-size:9pt;vertical-align:top;">th</sup> day after the Maturity Date shall not constitute Disqualified Equity Interests if such Equity Interests provide, to the satisfaction of the Administrative Agent in its sole discretion, that the issuer thereof will not redeem or repurchase any such Equity Interests pursuant to such provisions prior to the payment in full of all Obligations (other than contingent indemnification obligations for which no claim has been asserted) under the Loan Documents; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u>, if such Equity Interests are issued pursuant to a plan for the benefit of employees of the Borrower or any Subsidiary or by any such plan to such employees, such Equity Interests shall not constitute Disqualified Equity Interests solely because such employee may deliver such Equity Interests to the Borrower and its Subsidiaries (or the Borrower or such Subsidiary withholds such Equity Interests) in satisfaction of any exercise price or tax withholding obligations with respect to such Equity Interests.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Disqualified Lender</font>&#8221; means any Person designated by the Borrower as a &#8220;Disqualified Lender&#8221; by written notice delivered to the Administrative Agent on or prior to the date of this Agreement. Notwithstanding anything to the contrary contained in this Agreement, (a) the Administrative Agent shall not be responsible or have any liability for, or have any duty to ascertain, inquire into, monitor or enforce, compliance with the provisions hereof relating to Disqualified Lenders and (b) the Borrower, the Guarantors and the Lenders acknowledge and agree that the Administrative Agent shall have no responsibility or obligation to determine whether any Lender or potential Lender is a Disqualified Lender and that the Administrative Agent shall have no liability with respect to any assignment or participation made to a Disqualified Lender.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Division</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">1.04</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Dollars</font>&#8221; and &#8220;<font style="font-style:italic;font-weight:bold;">$</font>&#8221; means lawful money of the United States of America. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Domestic Subsidiary</font>&#8221; means any Subsidiary that is a corporation, limited liability company, partnership or similar business entity incorporated, formed or organized under the laws of the United States, any state of the United States or the District of Columbia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">EEA Financial Institution</font>&#8221; means <a name="DocXTextRef35"></a>(a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, <a name="DocXTextRef36"></a>(b) any entity established in an EEA Member Country which is a parent of an institution described in <b style="font-weight:bold;">clause (a) </b>of this definition, or <a name="DocXTextRef37"></a>(c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in <b style="font-weight:bold;">clauses (a) </b>or <a name="DocXTextRef38"></a><b style="font-weight:bold;">(b)</b><b style="font-weight:bold;"> </b>of this definition and is subject to consolidated supervision with its parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">EEA Member Country</font>&#8221; means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">EEA Resolution Authority</font>&#8221; means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Eligible Transferee</font>&#8221; means and includes <a name="DocXTextRef39"></a>(i) any commercial bank, (ii) any insurance company, (iii) any finance company, (iv) any financial institution, <a name="DocXTextRef40"></a>(v) any Person that is a bona fide debt fund primarily engaged in the making, purchasing, holding or other investing in commercial loans, notes, bonds or similar extensions of credit or securities in the Ordinary Course, (vi) with respect to any Lender, any of its Affiliates or such Lender&#8217;s or Affiliate&#8217;s managed funds or accounts, and (vii) any other &#8220;accredited investor&#8221; (as defined in Regulation D of the Securities Act) that is principally in the business of managing investments or holding assets for investment purposes; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that, an Eligible Transferee shall not include (x) any Company Competitor, Disqualified Lender or Defaulting Lender, or (y) any Person that primarily invests in distressed debt or other distressed financial assets; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>; <u style="text-decoration:underline;text-decoration-color:#000000;">further</u> that <a name="DocXTextRef43"></a>(A) neither clause (x) or (y) above shall apply retroactively to any Person that previously acquired an assignment or participation interest hereunder to the extent such Person was not a Company Competitor or a Person of the type described in clause (y) above at the time of the applicable assignment or participation, as the case may be, and <a name="DocXTextRef45"></a>(B) with respect to both clauses (x) and </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">(y)above, the Administrative Agent shall not have any duty or obligation to carry out due diligence in order to identify or determine whether a Person would be excluded as an Eligible Transferee as a result of the application of either such proviso.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Employee Benefit Plan</font>&#8221; means any of (a) an &#8220;employee benefit plan&#8221; (as defined in ERISA) that is subject to Title I of ERISA, (b) a &#8220;plan&#8221; as defined in and subject to Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such &#8220;employee benefit plan&#8221; or &#8220;plan&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Enhanced Liquidity Amount</font>&#8221; means, as of any date of determination, the aggregate amount of cash and Permitted Cash Equivalent Investments held by the Obligors sufficient to fund any payments (including all milestone and similar payments) to be made in connection with the applicable Acquisition and all other Acquisitions consummated after the Closing Date and prior to such date and the Obligors&#8217; operations for a period of not less than eighteen (18) months following the consummation of such Acquisition (it being understood that the sufficiency of such amount shall be based on the most recent financial forecast presented to the Board). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Environmental Claims</font>&#8221; means any investigation, notice, notice of violation, claim, action, suit, proceeding, demand, information request, abatement order or other order or directive (conditional or otherwise), by any Governmental Authority or any other Person, arising (i) pursuant to or in connection with any actual or alleged violation of any Environmental Law; (ii) in connection with any Hazardous Material or any actual or alleged Hazardous Materials Activity; or (iii) in connection with any actual or alleged damage, injury, threat or harm to health, safety, natural resources or the environment, arising out of a violation of Environmental Law or any Hazardous Materials Activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Environmental Law</font>&#8221; means all laws (including common law and any federal, state, provincial or local governmental law), rule, regulation, order, writ, judgment, notice, requirement, binding agreement, injunction or decree, whether U.S. or non-U.S., relating in any way to (i) environmental matters, including those relating to any Hazardous Materials Activity; (ii) the generation, use, storage, transportation or disposal of Hazardous Materials; or (iii) to the extent related to Hazardous Materials Activity, occupational safety and health, industrial hygiene, land use, natural resources or the protection of human, plant or animal health or welfare, in any manner applicable to the Borrower or any of its Subsidiaries or any Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Environmental Liability</font>&#8221; means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of any Obligor or any of its Subsidiaries directly or indirectly resulting from or based upon (i)&#160;violation of any Environmental Law, (ii)&#160;the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (iii)&#160;exposure to any Hazardous Materials, (iv)&#160;the release or threatened release of any Hazardous Materials into the environment or (v) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Equity Interests</font>&#8221; means, with respect to any Person (for purposes of this defined term, an &#8220;<font style="font-style:italic;font-weight:bold;">issuer</font>&#8221;), all shares of, interests or participations in, or other equivalents in respect of such </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">issuer&#8217;s capital stock, including all membership interests, partnership interests or equivalent, whether now outstanding or issued after the Closing Date, and in each case, however designated and whether voting or non-voting. Notwithstanding the foregoing, in no event shall any Indebtedness convertible or exchangeable into Equity Interests constitute &#8220;Equity Interests&#8221; hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Equivalent Amount</font>&#8221; means, with respect to an amount denominated in one currency, the amount in another currency that could be purchased by the amount in the first currency determined by reference to the Exchange Rate at the time of determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">ERISA</font>&#8221; means the United States Employee Retirement Income Security Act of 1974, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">ERISA Affiliate</font>&#8221; means, collectively, any Obligor, Subsidiary thereof, and any Person under common control, or treated as a single employer, with any Obligor or Subsidiary thereof, within the meaning of <a name="DocXTextRef50"></a>Section 414(b) or <a name="DocXTextRef47"></a>(c) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">ERISA Event</font>&#8221; means <a name="DocXTextRef64"></a>(i) a reportable event as defined in Section 4043 of ERISA with respect to a Title IV Plan, excluding, however, such events as to which the PBGC by regulation has waived the requirement of Section 4043(a) of ERISA that it be notified within thirty (30) days of the occurrence of such event; (ii) the applicability of the requirements of Section 4043(b) of ERISA with respect to a contributing sponsor, as defined in Section 4001(a)(13) of ERISA, to any Title IV Plan where an event described in paragraph <a name="DocXTextRef51"></a>(9), <a name="DocXTextRef55"></a>(10), <a name="DocXTextRef56"></a>(11), <a name="DocXTextRef57"></a>(12) or <a name="DocXTextRef58"></a>(13) of Section 4043(c) of ERISA is reasonably expected to occur with respect to such plan within the following thirty (30) days; (iii) a withdrawal by any Obligor or any ERISA Affiliate thereof from a Title IV Plan or the termination of any Title IV Plan resulting in liability under Sections 4063 or 4064 of ERISA; (iv) the withdrawal of any Obligor or any ERISA Affiliate thereof in a complete or partial withdrawal (within the meaning of Section 4203 and <a name="DocXTextRef82"></a>4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by any Obligor or any ERISA Affiliate thereof of notice from any Multiemployer Plan that it is insolvent pursuant to Section 4245 of ERISA; <a name="DocXTextRef65"></a>(v)<a name="DocXTextRef68"></a><a name="DocXTextRef77"></a><a name="DocXTextRef69"></a><a name="DocXTextRef70"></a><a name="DocXTextRef59"></a><a name="DocXTextRef83"></a><a name="DocXTextRef71"></a><a name="DocXTextRef60"></a><a name="DocXTextRef84"></a> the filing of a notice of intent to terminate, the treatment of a plan amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Title IV Plan or Multiemployer Plan, but in the case of a multiple-employer plan or a Multiemployer Plan, only once notice has been received from the plan administrator; (vi) the imposition of liability on any Obligor or any ERISA Affiliate thereof pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (vii) the failure by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Title IV Plan, or the failure to meet the minimum funding standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in accordance with Section 412(c) of the Code) or the failure to make by its due date a required installment under Section 430 of the Code with respect to any Title IV Plan or the failure to make any required contribution to a Multiemployer Plan; (viii) the determination that any Title IV Plan is considered an at-risk plan or a plan in endangered to critical status within the meaning of Sections 430, 431 and 432 of the Code or Sections 303, 304 and 305 of ERISA, but in the case of a multiple-employer plan or a Multiemployer Plan, only once notice has been received from the plan administrator; (ix) an event or condition which might reasonably be expected to constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="DocXTextRef66"></a><a name="DocXTextRef72"></a><a name="DocXTextRef73"></a><a name="DocXTextRef74"></a><a name="DocXTextRef61"></a><a name="DocXTextRef75"></a><a name="DocXTextRef62"></a><a name="DocXTextRef78"></a><a name="DocXTextRef76"></a><a name="DocXTextRef52"></a><a name="DocXTextRef67"></a><a name="DocXTextRef63"></a><a name="DocXTextRef79"></a>administer, any Title IV Plan or Multiemployer Plan; (x) the imposition of any liability under Title I or Title IV of ERISA, other than PBGC premiums due but not delinquent under Section 4007 of ERISA, upon any Obligor or any ERISA Affiliate thereof; (xi) an application for a funding waiver under Section 303 of ERISA or an extension of any amortization period pursuant to Section 412 of the Code with respect to any Title IV Plan, but in the case of a multiple-employer plan, only once notice has been received from the plan administrator; (xii) the occurrence of a non-exempt prohibited transaction under Sections 406 or 407 of ERISA for which any Obligor or any Subsidiary thereof could reasonably be expected to be directly or indirectly liable; (xiii) a violation of the applicable requirements of Section 404 or 405 of ERISA or the exclusive benefit rule under Section 401(a) of the Code by any fiduciary or disqualified person for which any Obligor or any ERISA Affiliate thereof may be directly or indirectly liable; (xiv) the occurrence of an act or omission which could reasonably be expected to give rise to the imposition on any Obligor or any ERISA Affiliate thereof of fines, penalties, taxes or related charges under Chapter 43 of the Code or under Sections 409, 502(c), (i) or (1) or 4071 of ERISA; (xv) the assertion of a material claim (other than routine claims for benefits) against any Plan or the assets thereof, but in the case of a multiple-employer plan, only once notice has been received from the plan administrator, or against any Obligor or any Subsidiary thereof in connection with any such plan; (xvi) receipt from the IRS of notice of the failure of any Qualified Plan to qualify under Section 401(a) of the Code, or the failure of any trust forming part of any Qualified Plan to fail to qualify for exemption from taxation under <a name="DocXTextRef80"></a>Section 501(a) of the Code that is not corrected under the IRS&#8217;s Employee Plans Compliance Resolution System (EPCRS), but in the case of a multiple-employer plan, only once notice has been received from the plan administrator; (xvii) the imposition of any lien (or the fulfillment of the conditions for the imposition of any lien) on any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, in either case pursuant to Title I or IV, including <a name="DocXTextRef81"></a>Section 302(f) or <a name="DocXTextRef53"></a>303(k) of ERISA or to Section 401(a)(29) or <a name="DocXTextRef54"></a>430(k) of the Code; or (xviii) the establishment or amendment by any Obligor or any Subsidiary thereof of any &#8220;welfare plan&#8221;, as such term is defined in Section 3(1) of ERISA, that provides post-employment welfare benefits in a manner that would increase the liability of any Obligor, other than payment of premiums otherwise required by section 4980B of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">ERISA Funding Rules</font>&#8221; means the rules regarding minimum required contributions (including any installment payment thereof) to Title IV Plans, as set forth in <a name="DocXTextRef90"></a>Sections 412, <a name="DocXTextRef85"></a>430, <a name="DocXTextRef86"></a>431, <a name="DocXTextRef87"></a>432 and <a name="DocXTextRef92"></a>436 of the Code and <a name="DocXTextRef91"></a>Sections 302, <a name="DocXTextRef88"></a>303, <a name="DocXTextRef89"></a>304 and <a name="DocXTextRef93"></a>305 of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Erroneous Payment</font>&#8221; has the meaning assigned to it in Section 12.14(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Erroneous Payment Deficiency Assignment</font>&#8221; has the meaning assigned to it in Section 12.14(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Erroneous Payment Impacted Class</font>&#8221; has the meaning assigned to it in Section 12.14(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Erroneous Payment Return Deficiency</font>&#8221; has the meaning assigned to it in Section 12.14(d).</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Erroneous Payment Subrogation Rights</font>&#8221; has the meaning assigned to it in Section 12.14(d). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">EU Bail-In Legislation Schedule</font>&#8221; means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Event of Default</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Exchange Rate</font>&#8221; means, as of any date, the rate at which any currency may be exchanged into another currency, as set forth on the relevant Bloomberg screen at or about 11:00 a.m. (Eastern time) on such date. In the event that such rate does not appear on the Bloomberg screen, the &#8220;Exchange Rate&#8221; shall be determined by reference to such other publicly available service for displaying exchange rates as may be reasonably designated by the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Excluded Accounts</font>&#8221; means (i) deposit accounts exclusively used for payroll, payroll Taxes and other employee wage and benefit payments to or for the benefit of any Obligor&#8217;s employees, (ii) zero balance accounts swept no less frequently than weekly to a Controlled Account (including any such account where payments pursuant to Medicaid, Medicare, TRICARE or other state or federal healthcare payor programs are deposited), (iii) accounts (including trust accounts) used exclusively for bona fide escrow purposes, insurance or fiduciary purposes, (iv) cash collateral for Permitted Liens, (v) collateral accounts in respect of any Revenue Interest Financing and (vi) any other deposit accounts established after the Closing Date only for so long as, in the case of this clause (vi), the amounts of deposit therein do not exceed $500,000 in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Excluded Taxes</font>&#8221; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient: <a name="DocXTextRef97"></a>(i) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes, in each case, <a name="DocXTextRef98"></a>(x) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivisions thereof) or <a name="DocXTextRef99"></a>(y) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which <a name="DocXTextRef95"></a>(1)<font style="white-space:pre-wrap;"> such Lender acquires such interest in the Loan or Commitment  or </font><a name="DocXTextRef96"></a>(2) such Lender changes its lending office, except in each case to the extent that, pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03</b>, amounts with respect to such Taxes were payable either to such Lender&#8217;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#8217;s failure to comply with <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(f)</b>, and (iv) any withholding Taxes imposed under FATCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Excluded Prepayment Amount</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section 3.03(f)</b>.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Exit Fee</font>&#8221; has the meaning assigned to such term in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">3.05</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Facility</font>&#8221; means any real property (including all buildings, fixtures or other improvements located thereon) now, hereafter or heretofore owned, leased or operated by any Obligor or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">FATCA</font>&#8221; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">FD&amp;C Act</font>&#8221; means the U.S. Food, Drug and Cosmetic Act, <a name="DocXTextRef103"></a>21 U.S.C. &#167;&#167; <a name="DocXTextRef104"></a>301 et seq. (or any successor thereto), as amended from time to time, and the rules, regulations and guidelines issued or promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">FDA</font>&#8221; means the U.S. Food and Drug Administration and any successor entity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Federal Funds Effective Rate</font>&#8221; means, for any day, the rate calculated by the Federal Reserve Bank of New York based on such day&#8217;s federal funds transactions by depositary institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the federal funds effective rate; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that (a)&#160;if such day is not a Business Day, the Federal Funds Effective Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day, and (b)&#160;if no such rate is so published on such next succeeding Business Day, the Federal Funds Effective Rate for such day shall be the average rate charged to three (3) major banks on such day on such transactions as determined by the Administrative Agent; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>,<u style="text-decoration:underline;text-decoration-color:#000000;"> further</u><font style="white-space:pre-wrap;">,  that if the Federal Funds Effective Rate as so determined would be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Fee Letter</font>&#8221; means the Fee Letter, dated as of the date of this Agreement, among the Borrower, the Lenders and the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Foreign Lender</font>&#8221; means a Lender that is not a U.S. Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Foreign Subsidiary</font>&#8221; means any Subsidiary that is not a Domestic Subsidiary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Funding Date Certificate</font>&#8221; means a certificate substantially in the form of Exhibit&#160;J.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">GAAP</font>&#8221; means generally accepted accounting principles in the United States of America, as in effect from time to time, set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements of the Financial Accounting Standards Board and in such other statements by such other entity as may be in general use by significant segments of the accounting profession that are applicable to the circumstances as of the date of determination. </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">All references to &#8220;GAAP&#8221; shall be to GAAP applied consistently with the principles used in the preparation of the financial statements delivered pursuant to <b style="font-weight:bold;">Section 6.1(f)(i)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk70626077"></a>&#8220;<font style="font-style:italic;font-weight:bold;">Ganaxolone</font>&#8221; means the compound further described on <b style="font-weight:bold;">Schedule 2 </b>attached hereto, together with any improvements or modifications thereto, including any current or future pharmaceutical or biological product (including any product in development or that may be developed) that is derivative of, or includes such compound (including any improvements or modifications thereto).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Governmental Approval</font>&#8221; means any consent, authorization, approval, order, license, franchise, permit, certification, accreditation, registration, clearance or exemption that is issued or granted by or from (or pursuant to any act of) any Governmental Authority, including any application or submission related to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Governmental Authority</font>&#8221; means any nation, government, branch of power (whether executive, legislative or judicial), state, province or municipality or other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative functions of or pertaining to government, including without limitation regulatory authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other law-, rule- or regulation-making organizations or entities of any state, territory, county, city or other political subdivision of any country, in each case whether U.S. or non-U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Guarantee</font>&#8221; of or by any Person (the &#8220;<font style="font-style:italic;font-weight:bold;">guarantor</font>&#8221;) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the &#8220;<font style="font-style:italic;font-weight:bold;">primary obligor</font>&#8221;) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, <a name="DocXTextRef106"></a>(i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (ii) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (iv) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><a name="DocXTextRef107"></a><a name="DocXTextRef108"></a>, that the term Guarantee shall not include (x) endorsements for collection or deposit and (y) guarantees of operating leases, in each case, in the Ordinary Course.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Guarantee Assumption Agreement</font>&#8221; means a Guarantee Assumption Agreement substantially in the form of <b style="font-weight:bold;">Exhibit C </b>by an entity that, pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.12(a)</b>, is required to become a &#8220;Subsidiary Guarantor.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Guaranteed Obligations</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section 13.01</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Guaranty</font>&#8221; means the Guaranty made by the Subsidiary Guarantors under <b style="font-weight:bold;">Section 13</b> in favor of the Secured Parties (including any Guaranty assumed by an entity that is required to become a &#8220;Subsidiary Guarantor&#8221; pursuant to a Guarantee Assumption Agreement).</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Hazardous Material</font>&#8221; means any chemical, material or substance, exposure to which is prohibited, limited or regulated by any Governmental Authority or which may or would reasonably be expected to pose a hazard to the health and safety of the owners, occupants or any Persons in the vicinity of any Facility or to the indoor or outdoor environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Hazardous Materials Activity</font>&#8221; means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous Materials, including the use, manufacture, possession, storage, holding, presence, existence, location, release, threatened release, discharge, placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal, recycling, disposition or handling of any Hazardous Materials, and any investigation, monitoring, corrective action or response action with respect to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Healthcare Laws</font>&#8221; means, collectively, all Laws and Product Authorizations applicable to the business, any Product or the Product Commercialization and Development Activities of any Obligor, whether U.S. or non-U.S., regulating the distribution, dispensing, importation, exportation, quality, manufacturing, marketing, labeling, promotion and provision of and payment for drugs, biological products, or healthcare products, items and services, including, without limitation, the FD&amp;C Act, the Social Security Act, the Federal Anti-Kickback Statute, the federal False Claims Act, the Stark Law, the PDMA, and all rules, regulations and guidance with respect to the coverage of prescription drugs pursuant to the Medicare and Medicaid programs, the TRICARE Program, and federal employee health benefit plans; and all rules, regulations and guidance promulgated under or pursuant to any of the foregoing, including any state and non-U.S. equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Hedging Agreement</font><font style="white-space:pre-wrap;">&#8221; means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement.  Notwithstanding anything to the contrary in the foregoing, neither any Permitted Bond Hedge nor any Permitted Warrant Transaction shall be a Hedging Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Immaterial Subsidiary</font>&#8221; means any Subsidiary of the Borrower that <a name="DocXTextRef118"></a>(i) individually constitutes or holds less than two and one half percent (2.5%) of the Borrower&#8217;s consolidated total assets or generates less than two and one half percent (2.5%) of the Borrower&#8217;s consolidated total revenue, and (ii) when taken together with all then existing Immaterial Subsidiaries, such Subsidiary and such Immaterial Subsidiaries, in the aggregate, would constitute or hold less than five percent (5%) of the Borrower&#8217;s consolidated total assets or generate less than five percent (5%) of the Borrower&#8217;s consolidated total revenue, in each case of the foregoing clauses as of the last day of, or for, the most recently ended fiscal period for which financial statements were required to have been delivered pursuant to <b style="font-weight:bold;">8.01(a)</b><b style="font-weight:bold;"> </b>or <a name="DocXTextRef119"></a><b style="font-weight:bold;">(b)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">IND</font>&#8221; means <a name="DocXTextRef121"></a>(i) <a name="DocXTextRef122"></a>(x) an investigational new drug application (as defined in the FD&amp;C Act) that is required to be filed with the FDA before beginning clinical testing in human subjects, or any successor application or procedure and <a name="DocXTextRef123"></a>(y) any similar application or functional equivalent relating to any investigational new drug application applicable to or required by any non-U.S. Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to the foregoing.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Indebtedness</font>&#8221; of any Person means, without duplication, <a name="DocXTextRef124"></a>(i) all obligations of such Person for borrowed money, (ii) all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or similar instruments, (iii) all obligations of such Person upon which interest charges are customarily paid (excluding interest penalties for late payments under commercial contracts entered into in the Ordinary Course and, for the avoidance of doubt, which commercial contracts do not relate to obligations for borrowed money or purchase money indebtedness), (iv) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, <a name="DocXTextRef125"></a>(v) all obligations of such Person in respect of the deferred purchase price of property or services (excluding (A) any royalty payments or similar payments based on a percentage of sales under any such license or other agreement and (B) deferred compensation and accounts payable incurred in the ordinary course of business and not overdue by more than forty-five (45) days or otherwise being disputed in good faith), (vi) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (vii) all Guarantees by such Person of Indebtedness of others, (viii) all Capital Lease Obligations of such Person, (ix) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, <a name="DocXTextRef126"></a>(x) obligations under any Hedging Agreement, currency swaps, forwards, futures or derivatives transactions, (xi) all obligations, contingent or otherwise, of such Person in respect of bankers&#8217; acceptances, (xii) <a name="_Hlk70583311"></a>all milestone and similar payments of such Person under any license or other agreements (but excluding any such payments based on a percentage of sales under any such license or other agreement), (xiii) any Disqualified Equity Interests of such Person, and (xiv) all other obligations required to be classified as indebtedness of such Person under GAAP; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that, notwithstanding the foregoing, Indebtedness shall not include accrued expenses, deferred rent, deferred taxes, deferred compensation or customary obligations under employment agreements. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person&#8217;s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Indemnified Party</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.03(b)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Indemnified Taxes</font>&#8221; means <a name="DocXTextRef130"></a>(i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any Obligation and (ii) to the extent not otherwise described in <b style="font-weight:bold;">clause (i)</b>, Other Taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Information Certificate</font>&#8221; means the Information Certificate delivered pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">6.01(c)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Insolvency Proceeding</font>&#8221; means <a name="DocXTextRef132"></a>(i) any case, action or proceeding before any court or other Governmental Authority relating to bankruptcy, reorganization, insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors, or (ii) any general assignment for the benefit of creditors, composition, marshaling of assets for creditors, or other, similar arrangement in respect of any Person&#8217;s creditors generally or any substantial portion of such Person&#8217;s creditors, in each case undertaken under U.S. federal, state or foreign law, including the Bankruptcy Code.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Intellectual Property</font>&#8221; means all intellectual property or proprietary rights anywhere in the world, including any rights in or to Patents, Trademarks, Copyrights, and Technical Information, in each case, whether U.S. or non U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Intercompany Subordination Agreement</font>&#8221; means a subordination agreement to be executed and delivered by each Obligor and each of its Subsidiaries, pursuant to which all obligations in respect of any Indebtedness owing to any such Person by an Obligor shall be subordinated to the prior payment in full in cash of all Obligations, such agreement to be in substantially the form attached hereto as <b style="font-weight:bold;">Exhibit H</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Interest Rate</font>&#8221; means 11.5% per annum, as may be increased pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">3.02(b)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Invention</font>&#8221; means any novel, inventive and useful art, apparatus, method, process, machine (including any article or device), manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including article or device), manufacture or composition of matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Investment</font>&#8221; means, for any Person: <a name="DocXTextRef139"></a>(i)<font style="white-space:pre-wrap;"> the acquisition (whether for cash, property, services or securities or otherwise) of any debt or Equity Interests, bonds, notes, debentures, partnership or other ownership interests or other securities of any other Person (including any &#8220;short sale&#8221; or any sale of any securities at a time when such securities are not owned by the Person entering into such sale); (ii) the making of any deposit with, or advance, loan, assumption of debt or other extension of credit to, or capital contribution in any other Person (including the purchase of property from another Person subject to an understanding or agreement, contingent or otherwise, to resell such property to such Person), but excluding any such advance, loan or extension of credit having a term not exceeding ninety (90) days arising in connection with the sale of inventory or supplies by such Person in the Ordinary Course; or (iii) the entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other liability of any other Person and (without duplication) any amount committed to be advanced, lent or extended to such Person.  The amount of an Investment </font><a name="_cp_text_2_1045"></a>shall be the amount actually invested (which, in the case of any Investment constituting the contribution of an asset or property, shall be based on such Person&#8217;s good faith estimate of the fair market value of such asset or property at the time such Investment is made), less the amount of cash received or returned for such Investment, without adjustment for subsequent increases or decreases in the value of such Investment or write-ups, write-downs or write-offs with respect thereto; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that in no event shall such amount be less than zero or increase any basket or amount pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.05</b> above the fixed amount set forth therein. Notwithstanding anything to the contrary in the foregoing, the purchase of any Permitted Bond Hedge Transaction by the Borrower or any of its Subsidiaries and the performance of its obligations thereunder shall not be an Investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">IRS</font>&#8221; means the U.S. Internal Revenue Service or any successor agency, and to the extent relevant, the U.S. Department of the Treasury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Joint Venture</font>&#8221; means a joint venture, partnership or other similar arrangement, in corporate, partnership or similar legal form with a Person other than Borrower or its Subsidiaries. </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Landlord Consent</font>&#8221; means a Landlord Consent substantially in the form of <b style="font-weight:bold;">Exhibit G.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Law</font>&#8221; means, collectively, all U.S. or non-U.S. federal, state, provincial, territorial, municipal or local statute, treaty, rule, guideline, regulation, ordinance, code or administrative or judicial precedent or authority, including any interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Lenders</font>&#8221; has the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Lien</font>&#8221; means (a) any mortgage, lien, license, pledge, hypothecation, charge, security interest, or other encumbrance of any kind or character whatsoever, whether or not filed, recorded or otherwise perfected under applicable Law, or any lease, title retention agreement, mortgage, restriction, easement, right-of-way, option or adverse claim (of ownership or possession) (including any conditional sale or other title retention agreement, any lease in the nature thereof, and any other encumbrance on title to real property, any option or other agreement to sell, or give a security interest in, such asset and any filing of or agreement to give any financing statement under the Uniform Commercial Code (or equivalent statutes of any jurisdiction)) or any preferential arrangement that has the practical effect of creating a security interest and (b) in the case of Equity Interests, any purchase option, call or similar right of a third party with respect to such Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Loan</font>&#8221; means each loan advanced by a Lender pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.01</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Loan Documents</font>&#8221; means, collectively, this Agreement, the Notes, the Security Documents, the Fee Letter, any Guarantee Assumption Agreement, the Intercompany Subordination Agreement and any subordination agreement, intercreditor agreement or other present or future document, instrument, agreement or certificate delivered to the Administrative Agent (for itself or for the benefit of any other Secured Party) in connection with this Agreement or any of the other Loan Documents, in each case, as amended or otherwise modified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Loans Schedule</font>&#8221; means <b style="font-weight:bold;">Schedule 1</b> attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Loss</font>&#8221; means judgments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel on a full indemnity basis, and all costs incurred in investigating or pursuing any Claim or any proceeding relating to any Claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Majority Lenders</font>&#8221; means, at any time, Lenders having at such time in excess of fifty percent (50%) of the aggregate unused Commitments then in effect and the outstanding principal amount of the Loans at such time. The Commitments of any Defaulting Lender shall be disregarded in determining Majority Lenders at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Mandatory Prepayment</font><a name="_Hlk68778136"></a>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section 3.03(b)(i)</b>.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Margin Stock</font>&#8221; means &#8220;margin stock&#8221; within the meaning of Regulations U and X. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Material Adverse Change</font>&#8221; and &#8220;<font style="font-style:italic;font-weight:bold;">Material Adverse Effect</font>&#8221; mean a material adverse change in or effect on <a name="DocXTextRef141"></a>(i) the business, financial performance, operations, financial condition, assets or liabilities of the Borrower and its Subsidiaries taken as a whole, (ii) the ability of the Obligors, taken as a whole, to perform their payment obligations under the Loan Documents, as and when due, (iii) the legality, validity, binding effect or enforceability of any Loan Document or (iv) the rights, remedies and benefits available to, or conferred upon, the Administrative Agent or the Secured Parties under any Loan Document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Material Agreement</font>&#8221; means any Contract required to be disclosed (including amendments thereto) under regulations promulgated under the Securities Act of 1933 or Securities Exchange Act of 1934, as may be amended, solely to the extent that the absence or termination of such Contract would reasonably be expected to result in a Material Adverse Effect or in a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone. For the avoidance of doubt, employment and management contracts shall not be Material Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Material Environmental Liability</font>&#8221; means any Environmental Liability that has had or could reasonably be expected to have a Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Material Indebtedness</font>&#8221; means, at any time, any Indebtedness of any Obligor or Subsidiary thereof, the outstanding principal amount of which, individually or in the aggregate, exceeds $5,000,000 (or the Equivalent Amount in other currencies).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Material Intellectual Property</font>&#8221; means all Intellectual Property, whether currently owned by (or purported to be owned by), or subject to a license, covenant not to sue or similar right to (or purported to be subject to a license, covenant not to sue or similar right to) the Borrower or any of its Subsidiaries, or acquired, developed, obtained by, or otherwise subject to a license, covenant not to sue or similar right to the Borrower or any of its Subsidiaries after the date hereof, in each case, the loss of which could reasonably be expected to result in (i) a Material Adverse Effect or (ii) a <a name="_Hlk70637192"></a>material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Material Product Authorizations</font>&#8221; means any and all Product Authorizations, in each case, necessary to be held or maintained by, or for the benefit of, any Obligor or any of its Subsidiaries for any Product Commercialization and Development Activities with respect to Ganaxolone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Material Subsidiary</font>&#8221; means any Subsidiary of the Borrower that is not an Immaterial Subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Maturity Date</font>&#8221; means the fifth (5<sup style="font-size:9pt;vertical-align:top;">th</sup>) anniversary of the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Medicaid</font>&#8221; means that government-sponsored entitlement program under Title XIX, P.L. <a name="DocXTextRef152"></a>89-97 of the Social Security Act, which provides federal grants to states for medical assistance based on specific eligibility criteria, as set forth on Section 1396, et seq. of Title <a name="DocXTextRef153"></a>42 of the United States Code.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Medicare</font>&#8221; means that government-sponsored insurance program under Title XVIII, P.L. <a name="DocXTextRef154"></a>89-97, of the Social Security Act, which provides for a health insurance system for eligible elderly and disabled individuals, as set forth at Section 1395, et seq. of Title <a name="DocXTextRef155"></a>42 of the United States Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Minimum Liquidity Amount</font>&#8221; means (i) from the Closing Date until the Applicable Funding Date of the Tranche B Term Loans, $10,000,000 and (ii) from the Applicable Funding Date of the Tranche B Term Loans until the Maturity Date, $15,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Multiemployer Plan</font>&#8221; means any multiemployer plan, as defined in <a name="DocXTextRef156"></a>Section 400l(a)(3) of ERISA, to which any ERISA Affiliate incurs or otherwise has any obligation or liability, contingent or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">NDA</font>&#8221; means <a name="DocXTextRef157"></a>(i) <a name="DocXTextRef158"></a>(x) a new drug application (as defined in the FD&amp;C Act) and <a name="DocXTextRef159"></a>(y) any similar application or functional equivalent relating to any new drug application applicable to or required by any non-U.S. country, jurisdiction or Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Net Cash Proceeds</font>&#8221; means, <a name="DocXTextRef160"></a>(i) with respect to any Casualty Event experienced or suffered by any Obligor or any of its Subsidiaries, the amount of cash proceeds received from time to time by or on behalf of such Person in respect thereof (other than the proceeds of any business interruption insurance) after deducting therefrom only <a name="DocXTextRef161"></a><a name="DocXTextRef162"></a>(w) reasonable costs and expenses related thereto incurred by such Obligor or such Subsidiary in connection therewith, (x) Taxes (including transfer Taxes or net income Taxes) paid or payable in connection therewith, (y) reasonable reserves established for liabilities estimated to be payable in respect of such Casualty Event and deposited into escrow with a third party escrow agent on terms reasonably acceptable to the Administrative Agent or set aside in a separate Deposit Account that is subject to a Control Agreement in favor of the Administrative Agent and (z) any amounts required to be used to prepay Permitted Indebtedness pursuant to <b style="font-weight:bold;">Sections </b><b style="font-weight:bold;">9.01(j)</b><b style="font-weight:bold;"> and 9.01(l)</b><a name="DocXTextRef163"></a><a name="DocXTextRef164"></a> secured by the assets subject to such Casualty Event (other than (A) Indebtedness owing to the Administrative Agent or any Lender under this Agreement or the other Loan Documents and (B) Indebtedness assumed by the purchaser of such asset); and (ii) with respect to any Asset Sale by any Obligor or any of its Subsidiaries, the amount of cash proceeds received from time to time by or on behalf of such Person in respect thereof after deducting therefrom only (w) reasonable costs and expenses related thereto incurred by such Obligor or such Subsidiary in connection therewith, (x) Taxes (including transfer Taxes or net income Taxes) paid or payable in connection therewith, (y) reasonable reserves established for liabilities estimated to be payable in respect of such Asset Sale and deposited into escrow with a third party escrow agent on terms reasonably acceptable to the Administrative Agent or set aside in a separate Deposit Account that is subject to a Control Agreement in favor of the Administrative Agent and (z) any amounts required to be used to prepay Permitted Indebtedness pursuant to <b style="font-weight:bold;">Sections </b><b style="font-weight:bold;">9.01(j)</b><b style="font-weight:bold;"> and 9.01(l)</b> secured by the assets subject to such Asset Sale (other than (A) Indebtedness owing to the Administrative Agent or any Lender under this Agreement or the other Loan Documents and (B) Indebtedness assumed by the purchaser of such asset); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that, in each case of <b style="font-weight:bold;">clauses (i) </b>and <b style="font-weight:bold;">(ii)</b><a name="DocXTextRef165"></a><a name="DocXTextRef166"></a>, costs and expenses shall only be deducted to the extent, that the amounts so deducted are (x) actually paid or payable to a Person that is not an Affiliate of any Obligor or any of its Subsidiaries and (y) properly attributable to such Casualty Event or Asset Sale, as the case may be; it being </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">understood that &#8220;Net Cash Proceeds&#8221; shall include, without limitation, any cash received upon the sale or other disposition of any non-cash consideration received by any Obligor in any Casualty Event or Asset Sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Note</font>&#8221; means a promissory note, in substantially the form of <b style="font-weight:bold;">Exhibit A </b>hereto, executed and delivered by the Borrower to any Lender in accordance with <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.04</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">NY UCC</font>&#8221; means the UCC as in effect from time to time in New York. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Oaktree Lender</font>&#8221; means any Lender that is an Affiliate or managed fund or account of Oaktree Capital Management, L.P. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Obligations</font>&#8221; means, with respect to any Obligor, all amounts, obligations, liabilities, covenants and duties of every type and description owing by such Obligor to any Secured Party (including all Guaranteed Obligations) any other indemnitee hereunder or any participant, arising out of, under, or in connection with, any Loan Document, whether direct or indirect (regardless of whether acquired by assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument or for the payment of money, including, without duplication, <a name="DocXTextRef168"></a>(i) if such Obligor is the Borrower, all Loans, (ii) all interest, whether or not accruing after the filing of any petition in bankruptcy or after the commencement of any insolvency, reorganization or similar proceeding, and whether or not a claim for post- filing or post-petition interest is allowed in any such proceeding, and (iii) all other fees, expenses (including fees, charges and disbursement of counsel), interest, Commitment Fees, Yield Protection Premium, Exit Fee, commissions, charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to such Obligor under any Loan Document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Obligors</font>&#8221; means, collectively, the Borrower and the Subsidiary Guarantors and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">OFAC</font><font style="white-space:pre-wrap;">&#8221; has the meaning assigned to such term in the definition of &#8220;Anti-Terrorism Laws.&#8221;  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Ordinary Course</font>&#8221; means ordinary course of business or ordinary trade activities that are customary for similar businesses in the normal course of their ordinary operations and not while in financial distress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Organic Document</font>&#8221; means, for any Person, such Person&#8217;s formation documents, including, as applicable, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate of formation, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements applicable to such Person&#8217;s Equity Interests, or any equivalent document of any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Other Connection Taxes</font>&#8221; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Other Taxes</font>&#8221; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(g)</b>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Participant</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(e)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Participant Register</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(e)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Patents</font>&#8221; means all patents and patent applications, the Inventions and improvements described and claimed therein, the reissues, divisionals, continuations, renewals, extensions, and continuations in part thereof, and all rights whatsoever accruing thereunder or pertaining to the foregoing throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Patriot Act</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.19</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Payment Date</font><font style="font-size:12pt;">&#8221; means </font><font style="font-size:12pt;"><a name="DocXTextRef174"></a></font><font style="font-size:12pt;">(</font><font style="font-size:12pt;">i) the last Business Day of each March, June, September and December of each year, commencing on the first such date to occur after the Closing Date (provided, that if such date is not a Business Day, then on the immediately preceding Business Day); and (ii) the Maturity Date</font><font style="font-size:11.5pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Payment Recipient</font>&#8221; has the meaning assigned to it in Section 12.14(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">PBGC</font>&#8221; means the United States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">PDMA</font>&#8221; means the Prescription Drug Marketing Act of 1987, 21 U.S.C. &#167;&#167; 321 et seq. (or any successor thereto), as amended from time to time, and the rules, regulations, guidelines, guidance documents and compliance policy guides issued or promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Acquisition</font>&#8221; means any Acquisition by the Borrower or any of its Subsidiaries, whether by purchase, merger or otherwise; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(a)</font></font>immediately prior to, and immediately after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or could reasonably be expected to result therefrom;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(b)</font></font>such Acquisition shall comply in all material respects with all applicable Laws and all applicable Governmental Approvals;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(c)</font></font>in the case of any Acquisition of Equity Interests of another Person, after giving effect to such Acquisition, all Equity Interests of such other Person acquired by the Borrower or any of its Subsidiaries shall be owned, directly or indirectly, beneficially </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">and of record, by the Borrower or any of its Subsidiaries, and, the Borrower shall cause such acquired Person to satisfy each of the actions set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.12</b><b style="font-weight:bold;"> </b>as and when required by such Section;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(d)</font></font>on a Pro Forma Basis after giving effect to such Acquisition, the Borrower and its Subsidiaries shall be in compliance with the financial covenant set forth in <b style="font-weight:bold;">Section 10</b>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(e)</font></font>in the event that, on a Pro Forma Basis after giving effect to such Acquisition, the Borrower and its Subsidiaries shall not have satisfied the Enhanced Liquidity Amount, to the extent that all or any portion of the purchase price (including reasonable estimates of any Deferred Acquisition Consideration) for any such Acquisition is paid in cash, the amount thereof shall not exceed $5,000,000 (or the Equivalent Amount in other currencies) in the aggregate with any other such Acquisitions in any fiscal year;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(f)</font></font>to the extent that all or any portion of the purchase price for any such Acquisition is paid in Equity Interests, all such Equity Interests shall be Qualified Equity Interests;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(g)</font></font><a name="DocXTextRef179"></a>in the case of any such Acquisition that has a purchase price (including reasonable estimates of any Deferred Acquisition Consideration) in excess of $25,000,000, (A) the Borrower shall provide to the Administrative Agent (i)&#160;at least ten (10) Business Day&#8217;s prior written notice of any such Acquisition, together with summaries, prepared in reasonable detail, of all due diligence conducted by or on behalf of the Borrower or the applicable Subsidiary, as applicable, prior to such Acquisition, in each case subject to customary confidentiality restrictions, (ii) subject to customary confidentiality restrictions, a copy of the draft purchase agreement related to the proposed Acquisition (and any related documents reasonably requested by the Administrative Agent), (iii) pro forma financial statements of the Borrower and its Subsidiaries (as of the last day of the most recently ended fiscal quarter prior to the date of consummation of such Acquisition for which financial statements are required to be delivered pursuant to <b style="font-weight:bold;">8.01(a)</b><b style="font-weight:bold;"> </b><a name="DocXTextRef180"></a>or <b style="font-weight:bold;">(b)</b><font style="white-space:pre-wrap;">) after giving effect to such Acquisition, and (iv) subject to customary confidentiality restrictions, any other information reasonably requested (to the extent available), by the Administrative Agent and available to the Obligors, (B) in the event that, on a Pro Forma Basis after giving effect to such Acquisition, the Borrower and its Subsidiaries shall not have satisfied the Enhanced Liquidity Amount, to the extent the cash purchase price exceeds $25,000,000, the Administrative Agent shall have consented to in writing to such Acquisition in its sole discretion  and (C) to the extent the cash purchase price exceeds $50,000,000, the Administrative Agent shall have consented to in writing to such Acquisition in its sole discretion;</font><sup style="font-size:9pt;vertical-align:top;"> </sup>and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(h)</font></font><a name="DocXTextRef182"></a>no Obligor or any of its Subsidiaries (including any acquired Person) shall, in connection with any such Acquisition, assume or remain liable with respect to (x) any Indebtedness of the related seller or the business, Person or assets acquired, except to the extent permitted pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.01(l)</b><a name="DocXTextRef183"></a>, (y) any Lien on any business, Person or assets acquired, except to the extent permitted pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.02</b><a name="DocXTextRef184"></a>, (z) any other </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">liabilities (including Tax, ERISA and environmental liabilities), except to the extent the assumption of such liability could not reasonably be expected to result in a Material Adverse Effect. Any other such Indebtedness, liabilities or Liens not permitted to be assumed, continued or otherwise supported by any Obligor or Subsidiary thereof hereunder shall be paid in full or released within sixty (60) days of the acquisition date (or such longer period of time as agreed by the Administrative Agent in its sole discretion) as to the business, Persons or properties being so acquired on or before the consummation of such Acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Bond Hedge Transaction</font>&#8221; means any call or capped call option (or substantively equivalent derivative transaction) relating to the Borrower&#8217;s common stock (or other securities or property following a merger event, reclassification or other similar fundamental change of the Borrower, or adjustment with respect to the common stock of the Borrower) that is (A) purchased or otherwise entered into by the Borrower in connection with the issuance of any Permitted Convertible Debt, (B) settled in common stock of the Borrower (or such other securities or property), cash or a combination thereof (such amount of cash determined by reference to the price of the Borrower&#8217;s common stock or such other securities or property), and cash in lieu of fractional shares of common stock of the Borrower and (C) on terms and conditions customary for bond hedge transactions in respect of transactions related to public market convertible indebtedness (pursuant to a public offering or an offering under Rule 144A or Regulation S of the Securities Act) as reasonably determined by the Borrower; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u>, the purchase price for such Permitted Bond Hedge Transaction, less the proceeds received by the Borrower from the sale of any related Permitted Warrant Transaction (or in the case of capped calls, where such proceeds are not received but are reflected in a reduction of the premium), does not result in the incurrence of additional Indebtedness by the Borrower (other than Indebtedness from the issuance of Permitted Convertible Debt in connection with such Permitted Bond Hedge Transaction). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Cash Equivalent Investments</font>&#8221; means <a name="DocXTextRef187"></a>(i) marketable direct obligations issued or unconditionally guaranteed by the United States or any member states of the European Union or any agency or any state thereof having maturities of not more than two (2) years from the date of acquisition, (ii) commercial paper maturing no more than three hundred sixty-five (365) days after the date of acquisition thereof and having the highest rating from either Standard &amp; Poor&#8217;s Ratings Group or Moody&#8217;s Investors Service, Inc., (iii) certificates of deposit maturing no more than two (2) years after issue that are issued by any bank organized under the Laws of the United States, or any state thereof, or the District of Columbia, or any U.S. branch of a foreign bank having, at the date of acquisition thereof, combined capital and surplus of not less than $500,000,000, (iv) any money market or similar funds that exclusively hold any of the foregoing, and (v) other short term liquid investments approved in writing by the Administrative Agent in its sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Convertible Debt</font>&#8221; means Indebtedness having a feature which entitles the holder thereof to convert or exchange all or a portion of such Indebtedness into Equity Interests of the Borrower; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u> (i) such Permitted Convertible Debt shall be unsecured, (ii) no Subsidiary of the Borrower shall guarantee Permitted Convertible Debt, (iii) Permitted Convertible Debt shall not include any financial maintenance covenants and shall only include covenants, defaults and conversion rights that are customary for public market convertible </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">indebtedness (pursuant to a public offering or an offering under Rule 144A or Regulation S of the Securities Act) as of the date of issuance, as determined by the Borrower in its good faith judgment, (iv) no Default or Event of Default shall have occurred and be continuing at the time of incurrence of such Permitted Convertible Debt or would result therefrom, (v) such Permitted Convertible Debt shall not have a scheduled maturity date and shall not be subject to any mandatory repurchase or redemption (other than in connection with a customary change of control or &#8220;fundamental change&#8221; provision) earlier than 180 calendar days after the Maturity Date, (vi) such Permitted Convertible Debt shall not have an all-in-yield (excluding any arrangement, amendment, syndication, commitment, underwriting, structuring, ticking or other similar fees payable in connection therewith that are not generally shared with all of the holders of such Indebtedness) greater than the applicable amount set forth on <b style="font-weight:bold;">Schedule 4</b> as determined in good faith by the Administrative Agent (with any original issue discount equated to interest based on the convertible debt maturity date and excluding any additional or special interest that may become payable from time to time) and (vii) the Borrower shall have delivered to the Administrative Agent a certificate of a Responsible Officer of Parent certifying as to the foregoing clauses (i) through (v). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Hedging Agreement</font>&#8221; means a Hedging Agreement entered into by any Obligor in such Obligor&#8217;s Ordinary Course for the purpose of hedging currency risks or interest rate risks (and not for speculative purposes) and (x)&#160;with respect to hedging currency risks, in an aggregate notional amount for all such Hedging Agreements not in excess of $5,000,000 (or the Equivalent Amount in other currencies) and (y)&#160;with respect to hedging interest rate risks, in an aggregate notional amount for all such Hedging Agreements in excess of 50%, but not more than 100%, of the aggregate principal amount of Loans outstanding at such time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Indebtedness</font>&#8221; means any Indebtedness permitted under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.01</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Intercreditor Agreement</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">12.13</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Licenses</font>&#8221; means: (A) licenses of off-the-shelf software that is commercially available to the public, (B) intercompany licenses <a name="_Hlk70629535"></a>or grants of rights for development, manufacture, production, commercialization (including commercial sales to end users), marketing, promotion, co-promotion, sales or distribution <a name="_Hlk69481018"></a>among the Obligors, (C) any non-exclusive license for the use of (or covenant not to sue with respect to) the Intellectual Property of Borrower or any of its Subsidiaries or non-exclusive grants of rights for development, manufacture, production, commercialization (including commercial sales to end users), marketing, promotion, co-promotion, sales or distribution of any Product, in each case, entered into in the Ordinary Course; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that, with respect to each such license or grant described in clause (C) above, (i) no Event of Default has occurred or is continuing at the time of such license or grant, and (ii) such license or grant constitutes an Arm&#8217;s Length Transaction, the terms of which do not provide for a sale or assignment of Intellectual Property; (D) licenses in connection with any Revenue Interest Financing, (E) other licenses to which the Administrative Agent shall have consented to in writing (such consent not to be unreasonably withheld); and (F) any non-exclusive or exclusive license of (or covenant not to sue with respect to) Intellectual Property or technology or a grant of rights for development, manufacture, production, commercialization (including commercial sales to end users), marketing, co-promotion, or </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">distribution existing on or contemplated as of the Closing Date, in each case, to the extent set forth on <b style="font-weight:bold;">Schedule 3</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Liens</font>&#8221; means any Liens permitted under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.02</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Refinancing</font>&#8221; means, with respect to any Indebtedness permitted to be refinanced, extended, renewed or replaced hereunder, any refinancings, extensions, renewals and replacements of such Indebtedness; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that such refinancing, extension, renewal or replacement shall not <a name="DocXTextRef190"></a>(i) increase the outstanding principal amount of the Indebtedness being refinanced, extended, renewed or replaced, except by an amount equal to accrued interest and a reasonable premium or other reasonable amount paid, and fees and expenses reasonably incurred in connection therewith, (ii) contain terms relating to outstanding principal amount, amortization, maturity, collateral security (if any) or subordination (if any), or other material terms that, taken as a whole, are less favorable in any material respect to the Obligors and their respective Subsidiaries or the Secured Parties than the terms of any agreement or instrument governing such existing Indebtedness, (iii) have an applicable interest rate which does not exceed the greater of <a name="DocXTextRef191"></a>(A) the rate of interest of the Indebtedness being replaced and <a name="DocXTextRef192"></a>(B) the then applicable market interest rate, (iv) contain any new requirement to grant any Lien or to give any Guarantee that was not an existing requirement of such Indebtedness and <a name="DocXTextRef193"></a>(v) after giving effect to such refinancing, extension, renewal or replacement, no Default or Event of Default shall have occurred or could reasonably be expected to occur as a result thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Permitted Warrant Transaction</font>&#8221; means any call option, warrant or right to purchase (or substantively equivalent derivative transaction) relating to the Borrower&#8217;s common stock (or other securities or property following a merger event, reclassification or other change of the common stock of the Borrower) sold by the Borrower and with recourse to the Borrower only, substantially concurrently with any purchase by the Borrower of a Permitted Bond Hedge Transaction and settled in common stock of the Borrower, cash or a combination thereof (such amount of cash determined by reference to the price of the Borrower&#8217;s common stock or such other securities or property), and cash in lieu of fractional shares of common stock of the Borrower, with a strike price higher than the strike price of the Permitted Bond Hedge Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Person</font>&#8221; means any individual, corporation, company, voluntary association, partnership, limited liability company, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221; means any employee pension benefit plan (as defined in Section 3(2) of ERISA) (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or <a name="DocXTextRef194"></a>Section 412 of the Code or <a name="DocXTextRef195"></a>Section 302 of ERISA, and in respect of which the Borrower or any ERISA Affiliate is (or, if such plan were terminated, would under Section 4069 of ERISA be deemed to be) an &#8220;employer&#8221; as defined in Section 3(5) of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Pledged Entity</font>&#8221; means any Subsidiary of the Borrower, Equity Interests of which have been pledged to the Administrative Agent pursuant to the Security Documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Prepayment Price</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">3.03(a)(i)</b>.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Principal Payment Date</font>&#8221; means (i) the first Payment Date to occur after the third (3<sup style="font-size:9pt;vertical-align:top;">nd</sup>) anniversary of the Closing Date, (ii) thereafter, each Payment Date and, if applicable, (iii)&#160;the Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Pro Forma Basis</font>&#8221; shall mean, with respect to the calculation of any financial ratio or the determination of the Enhanced Liquidity Amount, as of any date, that <i style="font-style:italic;">pro forma</i> effect will be given to the Transactions, any Acquisition, any issuance, incurrence, assumption or permanent repayment of Indebtedness (including Indebtedness issued, incurred or assumed as a result of, or to finance, any relevant transaction and for which any such financial ratio is being calculated), all sales, transfers and other dispositions or discontinuance of any subsidiary, line of business or division, or any conversion of a Subsidiary Guarantor to Subsidiary or of a Subsidiary to a Subsidiary Guarantor, in each case that have occurred during the four consecutive fiscal quarter period of the Borrower being used to calculate such financial ratio (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Reference Period</u>&#8221;), or subsequent to the end of the Reference Period but prior to such date or prior to or simultaneously with the event for which a determination under this definition is made (including any such event occurring at a person who became a Restricted Subsidiary after the commencement of the Reference Period), as if each such event occurred on the first day of the Reference Period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Product</font>&#8221; means <a name="DocXTextRef201"></a>(i) those pharmaceutical or biological products (and described in reasonable detail) on <a name="DocXTextRef200"></a><b style="font-weight:bold;">Schedule 2</b><b style="font-weight:bold;"> </b>attached hereto, and (ii) any current or future pharmaceutical or biological product developed, distributed, dispensed, imported, exported, labeled, promoted, manufactured, licensed, marketed, sold or otherwise commercialized by any Obligor or any of its Subsidiaries, including any such product in development or which may be developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Product Authorizations</font>&#8221; means any and all Governmental Approvals, whether U.S. or non-U.S. (including all applicable ANDAs, NDAs, BLAs, INDs, Product Standards, supplements, amendments, pre- and post- approvals, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity) of any Regulatory Authority, in each case, necessary to be held or maintained by, or for the benefit of, any Obligor or any of its Subsidiaries for the ownership, use or commercialization of any Product or for any Product Commercialization and Development Activities with respect thereto in any country or jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Product Commercialization and Development Activities</font>&#8221; means, with respect to any Product, any combination of research, development, testing, manufacture, formulation, import, use, sale, licensing, importation, exportation, shipping, storage, handling, design, labeling, marketing, promotion, supply, distribution, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing (including, without limitation, in respect of licensing, royalty or similar payments), or any similar or other activities the purpose of which is to commercially exploit such Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Product Related Information</font>&#8221; means, with respect to any Product, all books, records, lists, ledgers, files, manuals, correspondence, reports, plans, drawings, data and other information of every kind (in any form or medium), and all techniques and other know-how, owned or possessed by the Obligors or any of their respective Subsidiaries that are necessary or useful for any Product Commercialization and Development Activities relating to such Product, </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">including <a name="DocXTextRef202"></a>(i) brand materials and packaging, customer targeting and other marketing, promotion and sales materials and information, referral, customer, supplier and other contact lists and information, product, business, marketing and sales plans, research, studies and reports, sales, maintenance and production records, training materials and other marketing, sales and promotional information and (ii) clinical data, information included or supporting any Product Authorization, any regulatory filings, updates, notices and correspondence (including adverse event and other pharmacovigilance and other post-marketing reports and information, etc.), technical information, product development and operational data and records, and all other documents, records, files, data and other information, used in connection with the Product Commercialization Development Activities for such Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Product Standards</font>&#8221; means all safety, quality and other specifications and standards applicable to any Product, including all pharmaceutical, biological and other standards promulgated by Standards Bodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Prohibited Payment</font>&#8221; means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of money or anything of value (including meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or supra-national organization (such as the United Nations), any political candidate, any royal family member or any other person who is connected or associated personally with any of the foregoing that is prohibited under any Law for the purpose of influencing any act or decision of such payee in his official capacity, inducing such payee to do or omit to do any act in violation of his lawful duty, securing any improper advantage or inducing such payee to use his influence with a government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Proportionate Share</font>&#8221; means, with respect to any Lender, the percentage obtained by dividing <a name="DocXTextRef203"></a>(i) the sum of the Commitment (or, if the Commitments are terminated, the outstanding principal amount of the Loans) of such Lender then in effect by (ii) the sum of the Commitments (or, if the Commitments are terminated, the outstanding principal amount of the Loans) of all Lenders then in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Qualified Equity Interest</font>&#8221; means, with respect to any Person, any Equity Interest of such Person that is not a Disqualified Equity Interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Qualified Plan</font>&#8221; means an employee pension benefit plan (as defined in Section 3(2) of ERISA) other than a Multiemployer Plan <a name="DocXTextRef204"></a>(i) that is or was at any time within the preceding five years maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has within the preceding five years ever made, or was within the preceding five years ever obligated to make, contributions, and (ii) that is intended to be tax qualified under <a name="DocXTextRef205"></a>Section 401(a) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Real Property Security Documents</font>&#8221; means any Landlord Consents or Bailee Letters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Recipient</font>&#8221; means any Lender or any other recipient of any payment to be made by or on account of any Obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Referral Source</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">7.07(b)</b>. </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Register</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(d)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Regulation T</font>&#8221; means Regulation T of the Board of Governors of the Federal Reserve System, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Regulation U</font>&#8221; means Regulation U of the Board of Governors of the Federal Reserve System, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Regulation X</font>&#8221; means Regulation X of the Board of Governors of the Federal Reserve System, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Regulatory Authority</font>&#8221; means any Governmental Authority, whether U.S. or non-U.S., that is concerned with or has regulatory or supervisory oversight with respect to any Product or any Product Commercialization and Development Activities relating to any Product, including the FDA and all equivalent Governmental Authorities, whether U.S. or non-U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Reinvestment Period</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">3.03(b)</b><b style="font-weight:bold;">(i)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Related Parties</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.16</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Repatriation</font>&#8221; and &#8220;<font style="font-style:italic;font-weight:bold;">Repatriated</font>&#8221; have the meanings set forth in <b style="font-weight:bold;">Section 3.03(f)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Resignation Effective Date</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section 12.09</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Responsible Officer</font>&#8221; of any Person means each of the president, chief executive officer, chief financial officer, general counsel and similar officer of such Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Restricted Payment</font>&#8221; means any dividend or other distribution (whether in cash, Equity Interests or other property) with respect to any Equity Interests of any Obligor or any of its Subsidiaries, or any payment (whether in cash, Equity Interests or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such Equity Interests of any Obligor or any of its Subsidiaries, any payment of interest, principal or fees in respect of any Indebtedness owed by any Obligor or any of its Subsidiaries to any holder of any Equity Interests of any Obligor or any of its Subsidiaries or any option, warrant or other right to acquire any such Equity Interests of any Obligor or any of its Subsidiaries; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that the issuance of, entry into (including any payments of premiums in connection therewith), performance of obligations under (including any payments of interest), and conversion, exercise, repurchase, redemption, settlement or early termination or cancellation of (whether in whole or in part and including by netting or set-off) (in each case, whether in cash, common stock of the Borrower or, following a merger event or other change of the common stock of Borrower, other securities or property), or the satisfaction of any condition that would permit or require any of the foregoing, any Permitted Convertible Debt, any Permitted Bond Hedge Transaction and any Permitted Warrant Transaction, including any payment or delivery in connection with a Permitted Warrant Transaction by (i) delivery of shares of the Borrower&#8217;s common stock upon net share settlement thereof and any related purchase of such common stock required to be made in connection with such delivery, (ii) set-off or payment of an early termination payment or similar payment thereunder, in each case, in the Borrower&#8217;s common stock upon any early termination thereof or (iii) in the event of cash settlement upon </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">settlement, any payment of a cash settlement or equivalent amount, in each case, shall not constitute a Restricted Payment by the Borrower or any Subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Restrictive Agreement</font>&#8221; means any Contract or other arrangement that prohibits, restricts or imposes any condition upon <a name="DocXTextRef210"></a>(i) the ability of any Obligor or any of its Subsidiaries to create, incur or permit to exist any Lien upon any of its properties or assets (other than <a name="DocXTextRef211"></a>(x) customary provisions in Contracts (including without limitation leases and in-bound licenses of Intellectual Property) restricting the assignment thereof and <a name="DocXTextRef212"></a>(y) restrictions or conditions imposed by any Contract governing secured Permitted Indebtedness permitted under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.01(j)</b>, to the extent that such restrictions or conditions apply only to the property or assets securing such Indebtedness), or (ii) the ability of any Obligor or any of its Subsidiaries to make Restricted Payments with respect to any of their respective Equity Interests or to make or repay loans or advances to any other Obligor or any of its Subsidiaries or such other Obligor or to Guarantee Indebtedness of any other Obligor or any of its Subsidiaries thereof or such other Obligor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk68866891"></a>&#8220;<font style="font-style:italic;font-weight:bold;">Revenue Interest Financing</font>&#8221; means any sale of, or financing or similar transaction based on, revenues or net sales derived from, and/or other proceeds arising out of or <a name="_Hlk70584147"></a>relating to, Ganaxolone and related Intellectual Property, including distribution income, service payments, royalty payments and license income, that is secured by Liens on (i) royalty payments and proceeds resulting from sales of Ganaxolone, rights deriving therefrom and collateral accounts in respect of such Revenue Interest Financing in the United States in an amount not exceeding 5% of net sales of Ganaxolone in the United States as calculated in accordance with GAAP (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Revenue Strip Proceeds</font>&#8221;) and/or (ii) subject to <b style="font-weight:bold;">Section 12.13</b> and the consent of the Administrative Agent (such consent not to be unreasonably withheld), the Intellectual Property, Accounts (as defined in the UCC), payment intangibles arising therefrom and Proceeds (as defined in the UCC) thereof relating to Ganaxolone, and which are subject to a Permitted Intercreditor Agreement; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that Revenue Interest Financing shall only be permitted upon receipt of the Ganaxolone FDA Approval by the Borrower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Revenue Strip Proceeds</font>&#8221; has the meaning set forth in the definition of Revenue Interest Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Sanction</font>&#8221; means any international economic or financial sanction or trade embargo imposed, administered or enforced from time to time by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or its Member States, Her Majesty&#8217;s Treasury or other relevant sanctions authority where the Borrower is located or conducts business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Sanctioned Person</font>&#8221; means, at any time, (i) any Person listed in any Sanctions-related list of designated Persons maintained by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or its Member States, Her Majesty&#8217;s Treasury or other relevant sanctions authority, (ii) any Person organized or resident in a Designated Jurisdiction or (iii) any Person fifty percent (50%) or more owned or is controlled by any such Person or Persons described in the foregoing clauses (i) or (ii).</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Secured Parties</font>&#8221; means the Lenders, the Administrative Agent and any of their respective permitted transferees or assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Security Agreement</font>&#8221; means the Security Agreement, delivered pursuant to <b style="font-weight:bold;">Section&#160;</b><b style="font-weight:bold;">6.01(f)</b>, among the Obligors and the Administrative Agent, granting a security interest in the Obligors&#8217; personal property in favor of the Administrative Agent, for the benefit of the Secured Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Security Documents</font>&#8221; means, collectively, the Security Agreement, each Short-Form IP Security Agreement, each Real Property Security Document, and each other security document, control agreement or financing statement required or recommended to perfect Liens in favor of the Secured Parties for purposes of securing the Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Short-Form IP Security Agreements</font>&#8221; means short-form copyright, patent or trademark (as the case may be) security agreements, dated as of the Closing Date and substantially in the form of Exhibit C, D and E to the Security Agreement, entered into by one or more Obligors in favor of the Secured Parties, each in form and substance reasonably satisfactory to the Administrative Agent (and as amended, modified or replaced from time to time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Solvent</font>&#8221; means, as to any Person as of any date of determination, that on such date <a name="DocXTextRef215"></a>(i) the fair value of the property of such Person is greater than the total amount of liabilities, including contingent liabilities, of such Person, (ii) the present fair saleable value of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured in the ordinary course of business, (iii) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person&#8217;s ability to pay such debts and liabilities as they mature in the ordinary course and (iv) such Person is not engaged in a business or transaction, and is not about to engage in a business or transaction, for which such Person&#8217;s property would constitute an unreasonably small capital after giving due consideration to the prevailing practice in the industry in which such Person is engaged or is to engage. The amount of any contingent liability at any time shall be computed as the amount that, in light of all of the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Standard Bodies</font>&#8221; means any of the organizations that create, sponsor or maintain safety, quality or other standards, including ISO, ANSI, CEN and SCC and the like.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Subsidiary</font>&#8221; means, with respect to any Person (the &#8220;<font style="font-style:italic;font-weight:bold;">parent</font>&#8221;) at any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent&#8217;s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity <a name="DocXTextRef217"></a>(i) of which securities or other ownership interests representing more than fifty percent (50%) of the equity or more than fifty percent (50%) of the ordinary voting power or, in the case of a partnership, more than fifty percent (50%) of the general partnership interests are, as of such </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">date, owned, controlled or held, directly or indirectly, or (ii) that is, as of such date, otherwise Controlled, by the parent or one or more direct or indirect subsidiaries of the parent or by the parent and one or more direct or indirect subsidiaries of the parent. Unless otherwise specified, all references herein to a &#8220;Subsidiary&#8221; or to &#8220;Subsidiaries&#8221; shall refer to a Subsidiary or Subsidiaries of the Borrower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Subsidiary Guarantors</font>&#8221; means each Subsidiary of the Borrower identified under the caption &#8220;SUBSIDIARY GUARANTORS&#8221; on the signature pages hereto and each Subsidiary of the Borrower that becomes, or is required to become, a &#8220;Subsidiary Guarantor&#8221; after the date hereof pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.12(a)</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">8.12(b)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Taxes</font>&#8221; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Technical Information</font>&#8221; means all Product Related Information and, with respect to any Products or Product Commercialization and Development Activities, all related know-how, trade secrets and other proprietary or confidential information, any information of a scientific, technical, or business nature in any form or medium, Invention disclosures, all documented research, developmental, demonstration or engineering work, and all other technical data and information related thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Termination Conditions</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section 13.03</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Title IV Plan</font>&#8221; means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan <a name="DocXTextRef220"></a>(i) that is or was at any time within the preceding five years maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has within the preceding five years ever made, or was within the preceding five years obligated to make, contributions, and (ii) that is or was subject to <a name="DocXTextRef221"></a>Section 412 of the Code, <a name="DocXTextRef222"></a>Section 302 of ERISA or Title IV of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Trademarks</font>&#8221; means all trade names, trademarks and service marks, logos and other indicia of origin, trademark and service mark registrations, and applications for trademark and service mark registrations, including <a name="DocXTextRef223"></a>(i) all renewals of trademark and service mark registrations and (ii) all rights whatsoever accruing thereunder or pertaining thereto throughout the world, together, in each case, with the goodwill associated therewith or symbolized thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-1 Commitment</font>&#8221; means, with respect to each Lender, the obligation of such Lender to make Tranche A-1 Term Loans to the Borrower on the Closing Date for Tranche A-1 Term Loans in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#8217;s name on <b style="font-weight:bold;">Schedule 1 </b>under the caption &#8220;Applicable Commitment&#8221; for Tranche A-1 Term Loans, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Tranche A-1 Commitments on the date of this Agreement equals $15,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-1 Funding Condition</font>&#8221; has the meaning set forth in the Loans Schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-1 Term Loans</font>&#8221; has the meaning assigned to such term in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.01(a)</b><b style="font-weight:bold;">(i)</b>.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-2 Availability Period</font>&#8221; has the meaning set forth in the Loans Schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-2 Commitment</font>&#8221; means, with respect to each Lender, the obligation of such Lender to make Tranche A-2 Term Loans to the Borrower on the Applicable Funding Date for Tranche A-2 Term Loans in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#8217;s name on <b style="font-weight:bold;">Schedule 1 </b>under the caption &#8220;Applicable Commitment&#8221; for Tranche A-2 Term Loans, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Tranche A-2 Commitments on the date of this Agreement equals $30,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-2 Funding Condition</font>&#8221; has the meaning set forth in the Loans Schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-2 Term Loans</font>&#8221; has the meaning assigned to such term in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.01(a)</b><b style="font-weight:bold;">(ii)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche B Availability Period</font>&#8221; has the meaning set forth in the Loans Schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche B Commitment</font>&#8221; means, with respect to each Lender, the obligation of such Lender to make Tranche B Term Loans to the Borrower on the Applicable Funding Date for Tranche B Term Loans in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#8217;s name on <b style="font-weight:bold;">Schedule 1 </b>under the caption &#8220;Applicable Commitment&#8221; for Tranche B Term Loans, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Tranche B Commitments on the date of this Agreement equals $30,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche B Funding Condition</font>&#8221; has the meaning set forth in the Loans Schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche B Term Loans</font>&#8221; has the meaning assigned to such term in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.01(a)</b><b style="font-weight:bold;">(iii)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche C Availability Period</font>&#8221; has the meaning set forth in the Loans Schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche C Commitment</font>&#8221; means, with respect to each Lender, the obligation of such Lender to make Tranche C Term Loans to the Borrower on the Applicable Funding Date for Tranche C Term Loans in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#8217;s name on <b style="font-weight:bold;">Schedule 1 </b>under the caption &#8220;Applicable Commitment&#8221; for Tranche C Term Loans, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Tranche C Commitments on the date of this Agreement equals $25,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche C Funding Condition</font>&#8221; has the meaning set forth in the Loans Schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche C Term Loans</font>&#8221; has the meaning assigned to such term in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.01(a)</b><b style="font-weight:bold;">(iv)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche D Availability Period</font>&#8221; has the meaning set forth in the Loans Schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche D Commitment</font>&#8221; means, with respect to each Lender, the obligation of such Lender to make Tranche D Term Loans to the Borrower on the Applicable Funding Date for </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Tranche D Term Loans in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#8217;s name on <b style="font-weight:bold;">Schedule 1 </b>under the caption &#8220;Applicable Commitment&#8221; for Tranche D Term Loans, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Tranche D Commitments on the date of this Agreement equals $25,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche D Funding Condition</font>&#8221; has the meaning set forth in the Loans Schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Tranche D Term Loans</font>&#8221; has the meaning assigned to such term in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.01(a)</b><b style="font-weight:bold;">(v)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Transactions</font>&#8221; means (a) the negotiation, preparation, execution, delivery and performance by each Obligor of this Agreement and the other Loan Documents to which such Obligor is (or is intended to be) a party, the making of the Loans hereunder, and all other transactions contemplated pursuant to this Agreement and the other Loan Documents, including the creation of the Liens pursuant to the Security Documents and (b) the payment of all fees and expenses incurred or paid by the Obligors in connection with the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">UCC</font>&#8221; means, with respect to any applicable jurisdictions, the Uniform Commercial Code as in effect in such jurisdiction, as may be modified from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">United States</font>&#8221; or &#8220;<font style="font-style:italic;font-weight:bold;">U.S.</font>&#8221; means the United States of America, its fifty states and the District of Columbia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">U.S. Person</font>&#8221; means a &#8220;United States Person&#8221; within the meaning of Section 7701(a)(30) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">U.S. Tax Compliance Certificate</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(f)(ii)</b><b style="font-weight:bold;">(B)(3)</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Withdrawal Liability</font>&#8221; means, at any time, any liability incurred (whether or not assessed) by any ERISA Affiliate and not yet satisfied or paid in full at such time with respect to any Multiemployer Plan pursuant to Section 4201 of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Withholding Agent</font>&#8221; means the Borrower and the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Write-Down and Conversion Powers</font>&#8221; means, with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Yield Protection Premium</font>&#8221; means with respect to (x) any prepayment of all or any portion of the Loans, whether by optional or mandatory prepayment, acceleration or otherwise (in each case, other than any scheduled amortization payment) or (y) termination of the <a name="_Hlk70631437"></a>Tranche A-2 Commitments in accordance with the last sentence of <b style="font-weight:bold;">Section 3.04</b>, occurring <a name="DocXTextRef198"></a>(i) on or prior to the second anniversary of the Closing Date, an amount equal to the amount of interest that would have been paid on the principal amount of the Loans being so repaid or prepaid for the period from and including the date of such repayment or prepayment (excluding, for the avoidance of doubt, any interest on the Loans paid prior to such date) to but excluding the date </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">that is the two (2) year anniversary of the Closing Date, <i style="font-style:italic;">plus </i>four percent (4%) of the principal amount of the Loans being so repaid or prepaid or the Tranche A-2 Commitments being so terminated, (ii) at any time after the second anniversary of the Closing Date but on or prior to the third anniversary of the Closing Date, an amount equal to four percent (4%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid or the Tranche A-2 Commitments being so terminated, (iii) at any time after the third anniversary of the Closing Date but on or prior to the fourth anniversary of the Closing Date, an amount equal to two percent (2%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid or the Tranche A-2 Commitments being so terminated and (iv) if the prepayment is made after the fourth anniversary of the Closing Date, 0%; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that if such prepayment occurs as a result of or in connection with a Change of Control and in lieu of any amounts required by the foregoing sentence: (A) on or prior to the first anniversary of the Closing Date, the Yield Protection Premium shall be twelve and a half percent (12.5%) of the principal amount of the Loans being so repaid or prepaid or the Tranche A-2 Commitments being so terminated, or (B) at any time after the first anniversary of the Closing Date but on or prior to the second anniversary of the Closing Date, the Yield Protection Premium shall be ten percent (10%) of the principal amount of the Loans being so repaid or prepaid or the Tranche A-2 Commitments being so terminated.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">1.02</font><a name="_Toc256000308"></a><a name="_Toc256000155"></a><a name="_Toc256000002"></a><a name="_Ref40129957"></a><a name="_Toc69324577"></a><a name="_Toc70875874"></a>Accounting Terms and Principles<font style="font-weight:normal;">. Unless otherwise specified, all accounting terms used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under </font>Section 10 <font style="font-weight:normal;"><a name="DocXTextRef226"></a><a name="DocXTextRef227"></a><a name="DocXTextRef228"></a>and any definitions used in such calculations) shall be made, in accordance with GAAP. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for the Borrower and its Subsidiaries, in each case without duplication. If the Borrower requests an amendment to any provision hereof to eliminate the effect of (a) any change in GAAP or the application thereof or (b) the issuance of any new accounting rule or guidance or in the application thereof, in each case, occurring after the date of this Agreement, then the Lenders and Borrower agree that they will negotiate in good faith amendments to the provisions of this Agreement that are directly affected by such change or issuance with the intent of having the respective positions of the Lenders and Borrower after such change or issuance conform as nearly as possible to their respective positions as of the date of this Agreement and, until any such amendments have been agreed upon, (i) the provisions in this Agreement shall be calculated as if no such change or issuance has occurred and (ii) the Borrower shall provide to the Lenders a written reconciliation in form and substance reasonably satisfactory to the Lenders, between calculations of any baskets and other requirements hereunder before and after giving effect to such change or issuance. Notwithstanding any other provision contained in this Agreement, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made, without giving effect to any change to GAAP occurring before or after the Closing Date as a result of ASU 2016-02, Leases (Topic 842) issued by the Financial Accounting Standards Board or any other proposals issued by the Financial Accounting Standards Board in connection therewith, in each case if such change would require treating any lease (or similar arrangement conveying the right to use) as a capital lease where such lease (or similar arrangement) was not required to be so treated under GAAP as in effect prior to such change.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">1.03</font><a name="_Toc256000309"></a><a name="_Toc256000156"></a><a name="_Toc256000003"></a><a name="_Ref40129958"></a><a name="_Toc69324578"></a><a name="_Toc70875875"></a>Interpretation<font style="font-weight:normal;">. For all purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires,</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40129959"></a>the terms defined in this Agreement include the plural as well as the singular and vice versa;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40129960"></a>words importing gender include all genders;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40129961"></a>any reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to, this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40129962"></a><a name="DocXTextRef230"></a><a name="DocXTextRef231"></a>any reference to &#8220;this Agreement&#8221; refers to this Agreement, including all Annexes, Schedules and Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40129963"></a>references to days, months and years refer to calendar days, months and years, respectively;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40129964"></a>all references herein to &#8220;include&#8221; or &#8220;including&#8221; shall be deemed to be followed by the words &#8220;without limitation&#8221;;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40129965"></a>the word &#8220;from&#8221; when used in connection with a period of time means &#8220;from and including&#8221; and the word &#8220;until&#8221; means &#8220;to but not including&#8221;;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40129966"></a>the words &#8220;asset&#8221; and &#8220;property&#8221; shall be construed to have the same meaning and effect and to refer broadly to any and all assets and properties, whether tangible or intangible, real or personal, including cash, securities, rights under contractual obligations and permits and any right or interest in any such assets or property;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40129967"></a>accounting terms not specifically defined herein (other than &#8220;property&#8221; and &#8220;asset&#8221;) shall be construed in accordance with GAAP, subject to Section 1.02;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40129968"></a>the word &#8220;will&#8221; shall have the same meaning as the word &#8220;shall&#8221;;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40129969"></a>where any provision in this Agreement or any other Loan Document refers to an action to be taken by any Person, or an action which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or, to the knowledge of such Person, indirectly; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref40129970"></a>references to any Lien granted or created hereunder or pursuant to any other Loan Document securing any Obligations shall deemed to be a Lien for the benefit of the Secured Parties.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;">Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents. Any definition or reference to any Law shall include all </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">If any payment required to be made pursuant to the terms and conditions of any Loan Document falls due on a day which is not a Business Day, then such required payment date shall be extended to the immediately following Business Day. For purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, Indebtedness of the Obligors and their Subsidiaries will be deemed to be equal to 100% of the outstanding principal amount thereof or payment obligations with respect thereto at the time of determination thereof, or with respect to any Hedging Agreements, the amount that would be payable if the agreement governing such Hedging Agreements were terminated on the date of termination.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">1.04</font><a name="_Toc256000310"></a><a name="_Toc256000157"></a><a name="_Toc256000004"></a><a name="_Ref40457945"></a><a name="_Toc69324579"></a><a name="_Toc70875876"></a>Division<font style="font-weight:normal;">. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws) (a &#8220;</font>Division<font style="font-weight:normal;">&#8221;), if (a) any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its equity interests at such time.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">1.05</font><a name="_Toc256000311"></a><a name="_Toc256000158"></a><a name="_Toc256000005"></a><a name="_Toc69324580"></a><a name="_Toc70875877"></a>Currency Generally.<font style="font-weight:normal;white-space:pre-wrap;"> For purposes of determining compliance with Section 9 with respect to the amount of any Indebtedness or Investment in a currency other than Dollars, no Default or Event of Default shall be deemed to have occurred solely as a result of changes in rates of currency exchange occurring after the time such Indebtedness or Investment is incurred, made or acquired (so long as such Indebtedness or Investment, at the time incurred, made or acquired, was permitted hereunder).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 2.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000312"></a><a name="_Toc256000159"></a><a name="_Toc256000006"></a><a name="_Ref40129971"></a><a name="_Toc69324581"></a><a name="_Toc70875878"></a>THE COMMITMENT AND THE LOANS</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">2.01</font><a name="_Toc256000313"></a><a name="_Toc256000160"></a><a name="_Toc256000007"></a><a name="_Ref40129972"></a><a name="_Ref40172893"></a><a name="_Toc69324582"></a><a name="_Toc70875879"></a>Loans<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40172896"></a><a name="_Ref40129973"></a>On the terms and subject to the conditions of this Agreement, each Lender agrees:</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;text-align:center;vertical-align:text-top;white-space:nowrap;width:99pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"><a name="_Ref71207247"></a></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">to make Loans to the Borrower in a principal amount equal to the amount of such Lender&#8217;s Tranche A-1 Commitment on the Closing Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Tranche A-1 Term Loans</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;text-align:center;vertical-align:text-top;white-space:nowrap;width:99pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"><a name="_Ref71207230"></a></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">to make Loans to the Borrower in a principal amount equal to the amount of such Lender&#8217;s Tranche A-2 Commitment on a date specified by the Borrower in accordance with </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Section </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">2.02</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Tranche A-2 Term Loans</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;text-align:center;vertical-align:text-top;white-space:nowrap;width:99pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"><a name="_Ref40172902"></a></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">to make Loans to the Borrower in a principal amount equal to the amount of such Lender&#8217;s Tranche B Commitment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Tranche B Term Loans</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;), on a date specified by the Borrower in accordance with </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Section </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">2.02</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> during the Applicable Availability Period for the Tranche B Loans;</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;text-align:center;vertical-align:text-top;white-space:nowrap;width:99pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">to make Loans to the Borrower in a principal amount equal to the amount of such Lender&#8217;s Tranche C Commitment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Tranche C Term Loans</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;), on a date specified by the Borrower in accordance with </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Section </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">2.02</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> during the Applicable Availability Period for the Tranche C Loans; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;text-align:center;vertical-align:text-top;white-space:nowrap;width:99pt;padding:0pt;">(v)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">to make Loans to the Borrower in a principal amount equal to the amount of such Lender&#8217;s Tranche D Commitment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Tranche D Term Loans</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;), on a date specified by the Borrower in accordance with </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">Section </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;line-height:1.19;text-align:left;">2.02</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> during the Applicable Availability Period for the Tranche D Loans.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40129974"></a>No amounts paid or prepaid with respect to any Loan may be reborrowed.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40129975"></a>Any term or provision hereof (or of any other Loan Document) to the contrary notwithstanding, Loans made to the Borrower will be denominated solely in Dollars and will be repayable solely in Dollars and no other currency.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">2.02</font><a name="_Toc256000314"></a><a name="_Toc256000161"></a><a name="_Toc256000008"></a><a name="_Ref40129976"></a><a name="_Ref40172728"></a><a name="_Toc69324583"></a><a name="_Toc70875880"></a>Borrowing Procedures<font style="font-weight:normal;">. At least five (5) Business Days prior to any Applicable Funding Date (or such shorter period agreed by the Administrative Agent), the Borrower shall deliver to the Administrative Agent an irrevocable Borrowing Notice in the form of </font>Exhibit B<font style="font-weight:normal;"> signed by a duly authorized representative of the Borrower (which notice, if received by the Administrative Agent on a day that is not a Business Day or after 10:00 A.M. (Eastern time) on a Business Day, shall be deemed to have been delivered on the next Business Day). Each Borrowing Notice shall be for the full amount of each of the Applicable Commitments and no Borrowing Notice for less than such full amount shall be permitted. Notwithstanding anything herein to the contrary, the Borrower shall submit a Borrowing Notice with respect to the Tranche A-2 Term Loans promptly upon receipt of the Ganaxolone Filing Acceptance.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;line-height:1.28;text-align:left;">2.03</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Funding of Borrowings</b><font style="font-family:'Times New Roman','Times','serif';">. Promptly following receipt of any written Borrowing Request the Administrative Agent shall advise each Lender of the details thereof and of the amount of such Lender&#8217;s Loan to be made as part of the requested Borrowing. Each Lender shall make each Loan to be made by it hereunder on the proposed date thereof solely by wire transfer of immediately available funds, by 2:00 p.m. New York City time, to the account of the Administrative Agent most recently designated by it for such purpose by notice to the Lenders. Upon receipt of all funds the Administrative Agent will make such Loans available to the Borrower promptly by wire transfer of the amounts so received, in like funds, to an account designated by the Borrower in the applicable Borrowing Request.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">2.4</font><a name="_Toc256000315"></a><a name="_Toc256000162"></a><a name="_Toc256000009"></a><a name="_Ref40129977"></a><a name="_Toc69324584"></a><a name="_Toc70875881"></a>Notes<font style="font-weight:normal;">. If requested by any Lender, the Loan of such Lender shall be evidenced by one or more Notes. The Borrower shall prepare, execute and deliver to the Lender such promissory note(s) substantially in the form attached hereto as </font>Exhibit A<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">2.03</font><a name="_Toc256000316"></a><a name="_Toc256000163"></a><a name="_Toc256000010"></a><a name="_Ref40129978"></a><a name="_Toc69324585"></a><a name="_Toc70875882"></a>Use of Proceeds<font style="font-weight:normal;"><a name="DocXTextRef232"></a>. The Borrower shall use the proceeds of the Loans for (i) the NDA filing and clinical development related to Ganaxolone, (ii) support of the launch activities and commercialization efforts for Ganaxolone and (iii) other working capital and general corporate purposes, including the payment of fees and expenses associated with this Agreement.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">2.04</font><a name="_Toc256000317"></a><a name="_Toc256000164"></a><a name="_Toc256000011"></a><a name="_Ref40787021"></a><a name="_Toc40859580"></a><a name="_Toc69324586"></a><a name="_Toc70875883"></a>Commitment Fees<font style="font-weight:normal;">. The Borrower shall pay to the Administrative Agent for the account of the Lenders a commitment fee (the &#8220;</font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">Commitment Fee</u><font style="font-weight:normal;">&#8221;) on the full amount of each Applicable Commitment (other than the Tranche A-1 Commitments and the Tranche A-2 Commitments) at a rate per annum equal to 0.75% for the period from and including the day that is 120 days after the funding of the Tranche A-2 Term Loans (or termination of the Tranche A-2 Commitments) to (but excluding) the earlier of (x) the date such Applicable Commitment terminates pursuant to </font>Section 3.04<font style="font-weight:normal;"> and (y) the Applicable Funding Date. </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accrued Commitment Fees shall be payable on the termination date of the Applicable Commitment or the Applicable Funding Date, as the case may be.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">2.05</font><a name="_Toc256000318"></a><a name="_Toc256000165"></a><a name="_Toc256000012"></a><a name="_Toc54526950"></a><a name="_Toc54527106"></a><a name="_Toc54658110"></a><a name="_Toc57743262"></a><a name="_Toc58209003"></a><a name="_Toc70875884"></a>Defaulting Lenders.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Adjustments</b><font style="white-space:pre-wrap;">.  Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><b style="font-weight:bold;">Waivers and Amendment</b><font style="white-space:pre-wrap;">.  The Defaulting Lender&#8217;s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in </font><b style="font-weight:bold;">Section 14.04</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><b style="font-weight:bold;">Reallocation of Payments</b><font style="white-space:pre-wrap;">.  Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to </font><b style="font-weight:bold;">Section 11</b> or otherwise, and including any amounts made available to the Administrative Agent by that Defaulting Lender pursuant to <b style="font-weight:bold;">Section 4.03</b>), shall be applied at such time or times as may be determined by the Administrative Agent as follows: <u style="text-decoration:underline;text-decoration-color:#000000;">first</u>, to the payment of any amounts owing by that Defaulting Lender to the Administrative Agent hereunder; <u style="text-decoration:underline;text-decoration-color:#000000;">second</u>, as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which that Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; <u style="text-decoration:underline;text-decoration-color:#000000;">third</u>, if so determined by the Administrative Agent and the Borrower, to be held in a non-interest bearing deposit account and released in order to satisfy obligations of that Defaulting Lender to fund Loans under this Agreement; <u style="text-decoration:underline;text-decoration-color:#000000;">fourth</u>, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against that Defaulting Lender as a result of that Defaulting Lender&#8217;s breach of its obligations under this Agreement; <u style="text-decoration:underline;text-decoration-color:#000000;">fifth</u>, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against that Defaulting Lender as a result of that Defaulting Lender&#8217;s breach of its obligations under this Agreement; and <u style="text-decoration:underline;text-decoration-color:#000000;">sixth</u>, to that Defaulting Lender or as otherwise directed by a court of competent jurisdiction; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u>, if (x) such payment is a payment of the principal amount of any Loans in respect of which that Defaulting Lender has not fully funded its appropriate share and (y) such Loans were made at a time when the conditions set forth in <b style="font-weight:bold;">Section 6.02</b> were satisfied or waived, such payment shall be applied solely to pay the Loans of all non-Defaulting Lenders on a <i style="font-style:italic;">pro rata</i> basis prior to being applied to the payment of any Loans of that Defaulting Lender. Any payments, prepayments, repayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender pursuant to this <b style="font-weight:bold;">Section </b></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><b style="font-weight:bold;">2.07(a)(ii)</b><a name="_Hlk70632070"></a> shall be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents hereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Defaulting Lender Cure</b>. If the Borrower and the Administrative Agent agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein, that Lender will cease to be a Defaulting Lender; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u>, no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u>, except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender having been a Defaulting Lender.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Certain Fees</b>. No Defaulting Lender shall be entitled to receive any Commitment Fee payable under <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Section&#160;2.06</b> or any upfront fee set forth in the Fee Letter for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be required to pay any such Commitment Fee or upfront fee that otherwise would have been required to have been paid to that Defaulting Lender).</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 3.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000319"></a><a name="_Toc256000166"></a><a name="_Toc256000013"></a><a name="_Ref40129979"></a><a name="_Toc69324587"></a><a name="_Toc70875885"></a>PAYMENTS OF PRINCIPAL AND INTEREST, ETC.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">3.01</font><a name="_Toc256000320"></a><a name="_Toc256000167"></a><a name="_Toc256000014"></a><a name="_Ref40129980"></a><a name="_Toc69324588"></a><a name="_Toc70875886"></a>Scheduled Repayments and Prepayments Generally; Application<font style="font-weight:normal;">. The Borrower hereby promises to pay to the Administrative Agent for the account of each Lender (as such amounts may in each case be reduced from time to time in accordance with </font>Section 3.03<font style="font-weight:normal;">): (a) on each Principal Payment Date other than the Maturity Date, an amount equal to five percent (5%) of the principal aggregate amount of Loans outstanding on the first such Principal Payment Date and (b)&#160;on the Maturity Date, all outstanding Obligations in full (together with the Exit Fee, accrued and unpaid interest, any accrued and unpaid Commitment Fee and any other accrued and unpaid charges thereon and all other obligations due and payable by the Borrower under this Agreement). Except as otherwise provided in this Agreement, each payment (including each repayment and prepayment) by the Borrower (other than fees payable pursuant to the Fee Letter) will be deemed to be made ratably in accordance with the Lenders&#8217; Proportionate Shares and applied ratably among each tranche of the Loans. On any date occurring prior to the Maturity Date that payment or prepayment in full of the Loans hereunder occurs, the Borrower shall pay in full all outstanding Obligations, which shall include the Yield Protection Premium, if applicable, any accrued and unpaid Commitment Fee and the Exit Fee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">3.02</font><a name="_Toc256000321"></a><a name="_Toc256000168"></a><a name="_Toc256000015"></a><a name="_Ref40129981"></a><a name="_Toc69324589"></a><a name="_Toc70875887"></a>Interest<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40129982"></a><b style="font-weight:bold;">Interest Generally</b>. The outstanding principal amount of the Loans shall accrue interest from the date made to repayment (whether by acceleration or otherwise and whether voluntary or mandatory) at the Interest Rate.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40129983"></a><b style="font-weight:bold;">Default Interest</b>. Notwithstanding the foregoing, upon the occurrence and during the continuance of any Event of Default, the Interest Rate shall increase (i) automatically, in the case of any Event of Default under <b style="font-weight:bold;">Section</b> <b style="font-weight:bold;">11.01(a)</b>, <b style="font-weight:bold;">11.01(b)</b> or <b style="font-weight:bold;">11.01(h)</b> and (ii) upon the request of the Majority Lenders, in the case of any other Event of Default, by two percent (2.0%) <i style="font-style:italic;">per annum </i>(the Interest Rate, as increased pursuant to this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">3.02(b)</b>, being the &#8220;<font style="font-style:italic;font-weight:bold;">Default Rate</font>&#8221;); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> <u style="text-decoration:underline;text-decoration-color:#000000;">that</u><font style="white-space:pre-wrap;"><a name="_Hlk70632643"></a>, with respect to the preceding clause (ii), the Majority Lenders may impose the Default Rate retroactively to the occurrence of such Event of Default.  If any Obligation (including, without limitation, fees, costs and expenses payable hereunder) is not paid when due (giving effect to any applicable grace period) under any applicable Loan Document, the amount thereof shall accrue interest at the Default Rate.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40129984"></a><b style="font-weight:bold;">Interest Payment Dates</b>. Accrued interest on the Loans shall be payable in arrears on each Payment Date in cash, and upon the payment or prepayment of the Loans (on the principal amount being so paid or prepaid); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that interest payable at the Default Rate shall also be payable in cash from time to time on demand by the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">3.03</font><a name="_Toc256000322"></a><a name="_Toc256000169"></a><a name="_Toc256000016"></a><a name="_Ref40129985"></a><a name="_Ref40177217"></a><a name="_Ref40186328"></a><a name="_Toc69324590"></a><a name="_Toc70875888"></a>Prepayments<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40129986"></a><b style="font-weight:bold;">Optional Prepayments</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40129987"></a>Subject to prior written notice pursuant to <b style="font-weight:bold;">clause (ii) </b><a name="DocXTextRef235"></a><a name="DocXTextRef236"></a><a name="DocXTextRef237"></a>below, the Borrower shall have the right to optionally prepay in whole or in part the outstanding principal amount of the Loans and/or any tranche thereof (i.e., any of the Tranche A-1 Term Loans, the Tranche A-2 Term Loans, the Tranche B Term Loans, the Tranche C Term Loans and the Tranche D Term Loans) on any Business Day for an amount equal to the sum of (A) the aggregate principal amount of the Loans being prepaid, (B) any accrued but unpaid interest on the principal amount of the Loans being prepaid, (C) any applicable Yield Protection Premium and (D) the Exit Fee and other unpaid amounts then due and owing pursuant to this Agreement and the other Loan Documents (such aggregate amount, the &#8220;<font style="font-style:italic;font-weight:bold;">Prepayment Price</font>&#8221;); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that each partial prepayment of principal of Loans shall be in an aggregate amount at least equal to $5,000,000 and integral multiples of $1,000,000 in excess thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40129988"></a>A notice of optional prepayment shall be effective only if received by the Administrative Agent not later than 2:00 p.m. (Eastern time) on a date not less than three (3) (nor more than five (5)) Business Days prior to the proposed prepayment date; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that a notice of optional prepayment may state that such notice is conditional upon the effectiveness of other credit facilities or the receipt of the proceeds from the issuance of other Indebtedness or the occurrence of some other identifiable event or condition, in which case such notice of prepayment may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified date of prepayment) if such condition is not satisfied. Each notice of optional prepayment shall specify the proposed prepayment date, the Prepayment Price, the principal amount to be prepaid, the applicable tranche or tranches to be prepaid (if a partial prepayment) and any conditions to prepayment (if applicable).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40129989"></a><b style="font-weight:bold;">Mandatory Prepayments</b>. </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><b style="font-weight:bold;">Mandatory Prepayments for Casualty Events or Asset Sales</b>. Upon the occurrence of any Casualty Event or any Asset Sale (other than pursuant to <b style="font-weight:bold;">Section 9.09 (a), (b), (c), (d), (e), (f), (i), (m), (n), (o), (p), (q)</b> or<b style="font-weight:bold;"> (r)</b>)<b style="font-weight:bold;"> </b>for which the Net Cash Proceeds from such individual Casualty Event or Asset Sale exceeds $2,000,000, or which causes the aggregate total of Net Cash Proceeds from all such Casualty Events or Asset Sales to exceed $5,000,000, the Borrower shall make a mandatory prepayment of the Loans, together with any accrued but unpaid interest on any principal amount of the Loans being prepaid and any applicable Yield Protection Premium and Exit Fee (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Mandatory Prepayment</font>&#8221;), which Mandatory Prepayment (which, for avoidance of doubt, shall include any accrued but unpaid interest on any principal amount of the Loans being prepaid and any applicable Yield Protection Premium and Exit Fee) shall be in an amount equal to one hundred percent (100%) of the Net Cash Proceeds received by the Borrower or any of its Subsidiaries with respect to such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event, as the case may be; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that, so long as no Default has occurred and is continuing or shall result therefrom, if, within fifteen (15) Business Days following the receipt of such Net Cash Proceeds, a Responsible Officer of the Borrower delivers to the Administrative Agent a notice to the effect that the Borrower or the applicable Subsidiary intends to apply the Net Cash Proceeds from such Asset Sale (which Net Cash Proceeds, in the case of an Asset Sale, shall be in an aggregate amount of less than $5,000,000, and in the case of a Casualty Event, shall be in an aggregate amount of less than $10,000,000) or insurance proceeds or condemnation awards in respect of such Casualty Event, to reinvest in the business of the Borrower or any of its Subsidiaries (a &#8220;<font style="font-style:italic;font-weight:bold;">Reinvestment</font>&#8221;), then such Net Cash Proceeds of such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event may be applied for such purpose in lieu of such mandatory prepayment to the extent such Net Cash Proceeds of such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event are actually applied for such purpose; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, that, if such Casualty Event or Asset Sale occurs with respect to any Obligor, such Reinvestment shall be made in the business of an Obligor; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, that, in the event that Net Cash Proceeds have not been so applied within two hundred seventy (270) days following the receipt of such Net Cash Proceeds with respect to an Asset Sale or within three hundred sixty-five (365) days following the receipt of such Net Cash Proceeds with respect to a Casualty Event (such applicable period, the &#8220;<font style="font-style:italic;font-weight:bold;">Reinvestment Period</font><font style="white-space:pre-wrap;"><a name="_Ref40129990"></a>&#8221;) (or, if the Borrower or any of its Subsidiaries has entered into a binding commitment prior to the last day of such Reinvestment Period to reinvest such proceeds no later than ninety-five (95) days following the last day of the Reinvestment Period, ninety-five (95) days after the expiry of the Reinvestment Period), the Borrower shall no later than the end of such period make a Mandatory Prepayment (which, for avoidance of doubt, shall include any accrued but unpaid interest on any principal amount of the Loans being prepaid and any applicable Yield Protection Premium and Exit Fee) in an aggregate amount equal to one hundred percent (100%) of the unused balance of such Net Cash Proceeds received by any Obligor or any of its Subsidiaries with respect to such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><b style="font-weight:bold;">Mandatory Prepayments for Debt Issuances</b>. Immediately upon receipt by any Obligor or any of its Subsidiaries of proceeds from any issuance, incurrence or assumption of Indebtedness other than Indebtedness permitted by <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.01</b>, on or after the Closing Date, the Borrower shall prepay the Loans and other Obligations in an amount equal to </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">100% of the cash proceeds received, <i style="font-style:italic;">plus</i> the Yield Protection Premium, if applicable, any accrued and unpaid Commitment Fee and the Exit Fee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><b style="font-weight:bold;">Notice</b>. A notice of mandatory prepayment shall be effective only if received by the Administrative Agent not later than 2:00 p.m. (New York City time) on a date not less than one (1) Business Day (or such shorter period agreed by the Administrative Agent) prior to the proposed prepayment date. Each notice of mandatory prepayment shall specify the proposed prepayment date, the amount of the Mandatory Prepayment, the principal amount to be prepaid and the subsection under which the prepayment is required.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Application</b>. All optional prepayments of the Loans shall be applied in the manner specified by the Borrower at the time of such prepayment, including to any principal installments on the Loans; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that if not specified by the Borrower, optional prepayments of the Loans shall be applied to principal installments of the Loans in the direct order of maturity. All mandatory prepayments of the Loans shall be applied <u style="text-decoration:underline;text-decoration-color:#000000;">first</u> to the next two (2) scheduled principal installments on the Loans in direct order of maturity and <u style="text-decoration:underline;text-decoration-color:#000000;">second</u> to principal installments on the Loans ratably among such remaining installments by maturity.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Yield Protection Premium</b>. Without limiting the foregoing, whenever the Yield Protection Premium is in effect and payable pursuant to the terms hereof or any other Loan Document, such Yield Protection Premium shall be payable on each prepayment of all or any portion of the Loans, whether by optional or mandatory prepayment, acceleration or otherwise (other than any prepayment pursuant to any scheduled amortization payment).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40129991"></a><b style="font-weight:bold;">Partial Prepayments</b>. Prepayments shall be accompanied by accrued interest to the extent required by <b style="font-weight:bold;">Section 3.02</b> and the Exit Fee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><b style="font-weight:bold;">Repatriation</b>. Notwithstanding the foregoing terms of <b style="font-weight:bold;">Section 3.03(b)(i)</b>, to the extent any or all of the Net Cash Proceeds of any Asset Sale by, or receipt of the Net Cash Proceeds of any Casualty Event by, a Subsidiary that is a CFC or CFC Holding Company otherwise giving rise to a prepayment pursuant to <b style="font-weight:bold;">Section 3.03(b)(i)</b>, is prohibited by any applicable local requirements of Law from being repatriated to the Borrower or any Subsidiary that is a Domestic Subsidiary including through the repayment of intercompany Indebtedness (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Repatriation</font>&#8221;; with &#8220;<font style="font-style:italic;font-weight:bold;">Repatriated</font>&#8221; having a correlative meaning), the Borrower and its Subsidiaries shall take all commercially reasonable actions available under local Law to permit such Repatriation; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that if the Repatriation of any such amount would reasonably be expected to result in material adverse tax consequences with respect to the Borrower and its Subsidiaries, taken as a whole (taking into account any foreign tax credit or benefit reasonably expected to be received in connection with such Repatriation), an amount equal to the portion of such Net Cash Proceeds so affected (such amount, the &#8220;<font style="font-style:italic;font-weight:bold;">Excluded Prepayment Amount</font>&#8221;), will not be required to be applied to prepay Loans at the times provided in this <b style="font-weight:bold;">Section 3.03</b>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, that if and to the extent any such Repatriation ceases to be prohibited, restricted or delayed by applicable local requirements of Law or if and to the extent any such Repatriation ceases, to result in material adverse tax consequences with respect to the Borrower and its Subsidiaries, taken as a whole (taking into account any foreign tax credit or benefit reasonably expected to be received in connection with such Repatriation), at any time following the date on which the applicable mandatory prepayment pursuant to <b style="font-weight:bold;">Section 3.03(b)(i)</b> was </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">otherwise required to be made, the Borrower shall promptly pay an amount equal to such portion of the Excluded Prepayment Amount to the Lenders, which payment shall be applied in accordance with this <b style="font-weight:bold;">Section 3.03</b><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">3.04</font><a name="_Toc256000323"></a><a name="_Toc256000170"></a><a name="_Toc256000017"></a><a name="_Ref40795347"></a><a name="_Toc69324591"></a><a name="_Toc70875889"></a>Commitment Termination<font style="font-weight:normal;">. Each Applicable Commitment shall terminate automatically without further action upon the earlier of (i) the making by the Lenders of the Loans to which such Applicable Commitment relates on the Applicable Funding Date and (ii) the last day of the Applicable Availability Period. The Borrower shall have the right at any time or from time to time to terminate in full (but not in part) all of the then outstanding Applicable Commitments with respect to the Tranche B Term Loans, the Tranche C Term Loans and/or the Tranche D Term Loans; </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"> that the Borrower shall give the Lender and the Administrative Agent at least three (3) Business Days&#8217; notice of each such termination. For avoidance of doubt, the Borrower shall not have the right to voluntarily terminate the Applicable Commitments with respect to the Tranche A-2 Term Loans (other than in connection with a Change of Control; </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"> that the Borrower shall give the Lender at least three (3) Business Days&#8217; notice of any such termination of the Tranche A-2 Commitments.) &#160;Any notice of termination delivered pursuant to this </font>Section 3.04<font style="font-weight:normal;"> may state that such notice is conditional upon the effectiveness of other credit facilities or the receipt of the proceeds from the issuance of other Indebtedness or the occurrence of some other identifiable event or condition, in which case such notice of termination may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified date of termination) if such condition is not satisfied. &#160;The termination of any Applicable Commitment shall be permanent. Notwithstanding the foregoing, if the Ganaxolone Filing Acceptance is received within the Applicable Availability Period for the Tranche A-2 Term Loans and the Borrower fails to submit a Borrowing Notice promptly, and in any event within five (5) Business Days, following receipt of the Ganaxolone Filing Acceptance in accordance with the last sentence of </font>Section 2.02<font style="font-weight:normal;"> or upon the occurrence of a Change of Control, the Tranche A-2 Commitments shall terminate and the Borrower shall pay to each of the Lenders for its own account the Yield Protection Premium and Exit Fee on such Lender&#8217;s Tranche A-2 Commitments as if the Tranche A-2 Term Loans had been drawn and repaid in full (or, if greater, the amount specified in the definition of Yield Protection Premium with respect to a Change of Control). </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">3.05</font><a name="_Toc256000324"></a><a name="_Toc256000171"></a><a name="_Toc256000018"></a><a name="_Ref40187058"></a><a name="_Toc69324592"></a><a name="_Toc70875890"></a>Exit Fee<font style="font-weight:normal;">. Upon any payment or prepayment in full or in part of the Loans hereunder, whether voluntary or involuntary, prior to, on or after the Maturity Date or following the acceleration of the Obligations hereunder, including as a result of the commencement of any Insolvency Proceeding, the Borrower shall pay to each of the Lenders for its own account a fee equal to 2.0% of the aggregate principal amount of such Loans to be paid or prepaid (the &#8220;</font>Exit Fee<font style="font-weight:normal;white-space:pre-wrap;">&#8221;).  The Exit Fee shall be earned, due and payable immediately upon any such payment or prepayment, and shall be in addition to any accrued and unpaid interest, reimbursement obligations, Yield Protection Premium or other amounts payable in connection therewith.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:8pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">3.06</font><a name="_Toc256000325"></a><a name="_Toc256000172"></a><a name="_Toc256000019"></a><a name="_Toc69324593"></a><a name="_Toc70875891"></a>Original Issue Discount<font style="font-size:11pt;font-weight:normal;line-height:1.28;">. The Borrower and the Lenders acknowledge that the Loans will be treated as issued with original issue discount for U.S. federal tax purposes, within the meaning of section 1273 of the Code. The issue price, amount of original issue discount, issue date and yield to maturity for the Loans may be obtained by submitting a written request for such information to the Borrower care of Chief Financial Officer at 5 Radnor Corporate Center, 100 Matsonford Rd, Suite 500, Radnor, PA 19087 (which request shall also be sent via email to spfanstiel@marinuspharma.com). </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 4.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000326"></a><a name="_Toc256000173"></a><a name="_Toc256000020"></a><a name="_Ref40129992"></a><a name="_Toc69324594"></a><a name="_Toc70875892"></a>PAYMENTS, ETC.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">4.01</font><a name="_Toc256000327"></a><a name="_Toc256000174"></a><a name="_Toc256000021"></a><a name="_Ref40129993"></a><a name="_Toc69324595"></a><a name="_Toc70875893"></a>Payments<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40129994"></a><b style="font-weight:bold;">Payments Generally</b><a name="DocXTextRef245"></a>. Each payment of principal, interest and other amounts to be made by the Obligors under this Agreement or any other Loan Document shall be made (i) in Dollars, in immediately available funds, without deduction, set off or counterclaim, to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, to the deposit account of the Administrative Agent designated by the Administrative Agent by notice to the Borrower, and (ii) not later than 2:00 p.m. (Eastern time) on the date on which such payment is due (each such payment made after such time on such due date may, in the Administrative Agent&#8217;s discretion, be deemed to have been made on the next succeeding Business Day).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40129995"></a><b style="font-weight:bold;">Application of Payments</b>. Notwithstanding anything herein to the contrary, following the occurrence and continuance of an Event of Default, all payments shall be applied as follows:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(A)</font><a name="_Ref40129996"></a><u style="text-decoration:underline;text-decoration-color:#000000;">first</u>, to the payment of that portion of the Obligations constituting unpaid fees, indemnities, expenses or other amounts (including fees and disbursements and other charges of counsel payable under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.03</b>) payable to the Administrative Agent in its capacity as such;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(B)</font><a name="_Ref40129997"></a><u style="text-decoration:underline;text-decoration-color:#000000;">second</u>, to the payment of that portion of the Obligations constituting unpaid fees, indemnities, costs, expenses and other amounts (other than principal and interest, but including fees and disbursements and other charges of counsel payable under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.03</b>,<b style="font-weight:bold;"> </b>any Commitment Fees, Yield Protection Premium and any Exit Fees) payable to the Lenders arising under the Loan Documents, ratably among them in proportion to the respective amounts described in this <b style="font-weight:bold;">clause (B) </b>payable to them;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(C)</font><a name="_Ref40129998"></a><u style="text-decoration:underline;text-decoration-color:#000000;">third</u>, to the payment of that portion of the Obligations constituting accrued and unpaid interest on the Loans, ratably among the Lenders in proportion to the respective amounts described in this <b style="font-weight:bold;">clause (C) </b>payable to them;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(D)</font><a name="_Ref40129999"></a><u style="text-decoration:underline;text-decoration-color:#000000;">fourth</u>, to the payment of that portion of the Obligations constituting unpaid principal of the Loans, ratably among the Lenders in proportion to the respective amounts described in this <b style="font-weight:bold;">clause (D) </b>payable to them;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(E)</font><a name="_Ref40130000"></a><u style="text-decoration:underline;text-decoration-color:#000000;">fifth</u>, in reduction of any other Obligation then due and owing, ratably among the Administrative Agent and the Lenders based upon the respective aggregate amount of all such Obligations owing to them in accordance with the respective amounts thereof then due and payable; and</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(F)</font><a name="_Ref40130001"></a><u style="text-decoration:underline;text-decoration-color:#000000;">sixth</u>, the balance, if any, after all Obligations have been indefeasibly paid in full, to the Borrower or such other Person as may be lawfully entitled to or directed by the Borrower to receive the remainder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130002"></a><b style="font-weight:bold;">Non-Business Days</b>. If the due date of any payment under this Agreement (whether in respect of principal, interest, fees, costs or otherwise) would otherwise fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall continue to accrue and be payable for the period of such extension; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that if such next succeeding Business Day would fall after the Maturity Date, payment shall be made on the immediately preceding Business Day.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">4.02</font><a name="_Toc256000328"></a><a name="_Toc256000175"></a><a name="_Toc256000022"></a><a name="_Ref40130003"></a><a name="_Toc69324596"></a><a name="_Toc70875894"></a>Computations<font style="font-weight:normal;">. All computations of interest and fees hereunder shall be computed on the basis of a year of three hundred and sixty (360) days and actual days elapsed during the period for which payable.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">4.03</font><a name="_Toc256000329"></a><a name="_Toc256000176"></a><a name="_Toc256000023"></a><a name="_Ref40130004"></a><a name="_Toc69324597"></a><a name="_Toc70875895"></a>Set-Off<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130005"></a><b style="font-weight:bold;">Set-Off Generally</b><font style="white-space:pre-wrap;"><a name="_cp_text_2_4434"></a>.  Upon the occurrence and during the continuance of any Event of Default, the Administrative Agent, each of the Lenders and each of their Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Administrative Agent, any Lender and any of their Affiliates to or for the credit or the account of any Obligor against any and all of the Obligations, whether or not such Person shall have made any demand and although such obligations may be unmatured</font>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">that</u>, in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Section 2.07</b> and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. Any Person exercising rights of set off hereunder agrees promptly to notify the Borrower after any such set-off and application; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Administrative Agent, the Lenders and each of their Affiliates under this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">4.03</b><b style="font-weight:bold;"> </b>are in addition to other rights and remedies (including other rights of set-off) that such Persons may have.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130006"></a><b style="font-weight:bold;">Exercise of Rights Not Required</b>. Nothing contained in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">4.03(a)</b><b style="font-weight:bold;"> </b>shall require the Administrative Agent, any Lender or any of their Affiliates to exercise any such right or shall affect the right of such Persons to exercise, and retain the benefits of exercising, any such right with respect to any other indebtedness or obligation of any Obligor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:3.59pt 8.45pt 12.14pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:30pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130007"></a><b style="font-weight:bold;">Payments Set Aside. </b>To the extent that any payment by or on behalf of any Obligor is made to the Administrative Agent or any Lender, or the Administrative Agent, any Lender or any Affiliate of the foregoing exercises its right of setoff pursuant to this <b style="font-weight:bold;">Section&#160;</b><b style="font-weight:bold;">4.03</b>, and such payment or the proceeds of such setoff or any part thereof is </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:3.59pt 8.45pt 12.14pt 6pt;">subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, such Lender or such Affiliate in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any Insolvency Proceeding or otherwise, then <a name="DocXTextRef251"></a>(i) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (ii) each Lender severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Effective Rate from time to time in effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 5.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000330"></a><a name="_Toc256000177"></a><a name="_Toc256000024"></a><a name="_Ref40130008"></a><a name="_Toc69324598"></a><a name="_Toc70875896"></a>YIELD PROTECTION, TAXES, ETC.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">5.01</font><a name="_Toc256000331"></a><a name="_Toc256000178"></a><a name="_Toc256000025"></a><a name="_Ref40130009"></a><a name="_Toc69324599"></a><a name="_Toc70875897"></a>Additional Costs<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130010"></a><b style="font-weight:bold;">Change in Law Generally</b><a name="DocXTextRef252"></a>. If, on or after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), the adoption of any Law, or any change in any Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or administration thereof, or compliance by the Administrative Agent or any of the Lenders (or its lending office) with any request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending office) or shall impose on a Lender (or its lending office) any other condition affecting the Loans or the Commitment, and the result of any of the foregoing is to increase the cost to such Lender of making or maintaining the Loans, or to reduce the amount of any sum received or receivable by such Lender under this Agreement or any other Loan Document, or subject any Lender to any Taxes on its Loan, Commitment or other obligations, or its deposits, reserves, other liabilities or capital (if any) attributable thereto by an amount reasonably deemed by such Lender in good faith to be material (other than (i) Indemnified Taxes, (ii) Taxes described in <b style="font-weight:bold;">clauses (ii) </b>through <b style="font-weight:bold;">(iv) </b>of the definition of Excluded Taxes and (iii) Connection Income Taxes), then the Borrower shall pay to such Lender, within ten (10) Business Days of receipt of the certificate contemplated by <b style="font-weight:bold;">Section 5.01(c)</b>, such additional amount or amounts as will compensate such Lender for such increased cost or reduction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130011"></a><b style="font-weight:bold;">Change in Capital Requirements</b>. If a Lender shall have determined that, on or after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), the adoption of any Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or administration thereof, or any request or directive regarding capital adequacy (whether or not having the force of law) of any such </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Governmental Authority, in each case that becomes effective after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), has or would have the effect of reducing the rate of return on capital of a Lender (or its parent) as a consequence of a Lender&#8217;s obligations hereunder or the Loans to a level below that which a Lender (or its parent) could have achieved but for such adoption, change, request or directive by an amount reasonably deemed by it to be material, then the Borrower shall pay to such Lender, within ten (10) Business Days of receipt of the certificate contemplated by <b style="font-weight:bold;">Section 5.01(c)</b>, such additional amount or amounts as will compensate such Lender (or its parent) for such reduction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130012"></a><b style="font-weight:bold;">Notification by Lender</b>. Each Lender promptly will notify the Borrower of any event of which it has knowledge, occurring after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), which will entitle such Lender to compensation pursuant to this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b>. Before giving any such notice pursuant to this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01(c)</b><b style="font-weight:bold;"> </b><a name="DocXTextRef253"></a>such Lender shall designate a different lending office if such designation (x)&#160;<a name="DocXTextRef254"></a>will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (y) will not, in the reasonable judgment of such Lender, be materially disadvantageous to such Lender. A certificate of such Lender claiming compensation under this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b>, setting forth the additional amount or amounts to be paid to it hereunder, shall be conclusive and binding on the Borrower in the absence of manifest error. The Borrower shall not be required to compensate a Lender pursuant to the foregoing provisions of this <b style="font-weight:bold;">Section 5.01</b> for any increased costs incurred or reductions suffered more than six (6) months prior to the date that such Lender notifies the Borrower of the change in law giving rise to such increased costs or reductions and of such Lender&#8217;s intention to claim compensation therefor (except that, if the change in law giving rise to such increased costs or reductions is retroactive, then the six-month period referred to above shall be extended to include the period of retroactive effect thereof).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130013"></a><a name="DocXTextRef258"></a><a name="DocXTextRef259"></a>Notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute a change in Law for all purposes of this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b>, regardless of the date enacted, adopted or issued.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">5.02</font><a name="_Toc256000332"></a><a name="_Toc256000179"></a><a name="_Toc256000026"></a><a name="_Toc69324600"></a><a name="_Toc70875898"></a>[Reserved]<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">5.03</font><a name="_Toc256000333"></a><a name="_Toc256000180"></a><a name="_Toc256000027"></a><a name="_Ref40130015"></a><a name="_Toc69324601"></a><a name="_Toc70875899"></a>Taxes<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130016"></a><b style="font-weight:bold;">Payments Free of Taxes</b>. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for any Taxes, except as required by any Law. If any Law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Laws and, if such Tax is an Indemnified Tax, then the sum payable by such Obligor shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">applicable to additional sums payable under this <b style="font-weight:bold;">Section 5</b>) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130017"></a><b style="font-weight:bold;">Payment of Other Taxes by the Borrower</b>. The Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable Laws, or at the option of the Administrative Agent or each Lender, timely reimburse it for the payment of any Other Taxes.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130018"></a><b style="font-weight:bold;">Evidence of Payments</b>. As soon as practicable after any payment of Taxes by the Borrower to a Governmental Authority pursuant to this <b style="font-weight:bold;">Section 5</b>, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130019"></a><b style="font-weight:bold;">Indemnification by the Borrower</b>. The Borrower shall reimburse and indemnify each Recipient, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this <b style="font-weight:bold;">Section 5</b>) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender shall be conclusive absent manifest error.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130020"></a><b style="font-weight:bold;">Indemnification by the Lender</b><a name="DocXTextRef265"></a>. Each Lender shall severally indemnify the Administrative Agent, within ten (10) days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), and (ii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the Lender from any other source against any amount due to the Administrative Agent under this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(e)</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130021"></a><b style="font-weight:bold;">Status of Lenders</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130022"></a>Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by Law as reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two <a name="DocXTextRef267"></a>(2) sentences, the completion, execution and submission of such documentation (other than such documentation set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(f)(ii)</b><b style="font-weight:bold;">(A), (ii)(B), </b>and <b style="font-weight:bold;">(ii)(D)</b>) shall not be required if in such Lender&#8217;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130023"></a>Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Person:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(A)</font><a name="_Ref40130024"></a>any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 (or successor form) certifying that such Lender is exempt from U.S. federal backup withholding tax;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(B)</font><a name="_Ref40130025"></a>any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font><a name="_Ref40130026"></a><a name="DocXTextRef269"></a><a name="DocXTextRef270"></a>in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;interest&#8221; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;business profits&#8221; or &#8220;other income&#8221; article of such tax treaty;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font><a name="_Ref40130027"></a>executed copies of IRS Form W-8ECI (or successor form);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(3)</font><a name="_Ref40130028"></a><a name="DocXTextRef273"></a><a name="DocXTextRef271"></a>in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of <b style="font-weight:bold;">Exhibit D-1 </b>to the effect that such Foreign Lender is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, a &#8220;10 percent shareholder&#8221; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a &#8220;controlled foreign corporation&#8221; related to the Borrower as described in Section 881(c)(3)(C) of the Code (a &#8220;<font style="font-style:italic;font-weight:bold;">U.S. Tax Compliance Certificate</font>&#8221;) and <a name="DocXTextRef272"></a>(y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms); or</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(4)</font><a name="_Ref40130029"></a>to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY (or successor form), accompanied by IRS Form W-8ECI (or successor form), IRS Form W-8BEN or IRS Form W-8BEN-E (or successor form), a U.S. Tax Compliance Certificate, substantially in the form of <b style="font-weight:bold;">Exhibit D-2 </b>or <b style="font-weight:bold;">D-3</b>, IRS Form W-9 (or successor form), and/or other certification documents from each beneficial owner, as applicable;<u style="text-decoration:underline;text-decoration-color:#000000;"> provided</u> that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of <b style="font-weight:bold;">Exhibit D-4 </b>on behalf of each such direct and indirect partner.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(C)</font><a name="_Ref40130030"></a>any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Laws as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable Laws to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(D)</font><a name="_Ref40130031"></a>if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#8217;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this <b style="font-weight:bold;">clause (D)</b>, &#8220;FATCA&#8221; shall include any amendments made to FATCA after the date of this Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130032"></a><b style="font-weight:bold;">Treatment of Certain Tax Benefits</b>. If any party to this Agreement determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this <b style="font-weight:bold;">Section 5</b><b style="font-weight:bold;"> </b>(including by the payment of additional amounts pursuant to this <b style="font-weight:bold;">Section 5</b>), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this <b style="font-weight:bold;">Section 5</b><b style="font-weight:bold;"> </b>with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">pursuant to this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(g)</b><b style="font-weight:bold;"> </b>(plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(g)</b>, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(g)</b><b style="font-weight:bold;"> </b>the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(g)</b><b style="font-weight:bold;"> </b>shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">5.04</font><a name="_Toc256000334"></a><a name="_Toc256000181"></a><a name="_Toc256000028"></a><a name="_Toc69324602"></a><a name="_Toc70875900"></a><a name="_Ref40130033"></a>Mitigation Obligations; Replacement of Lenders<font style="font-weight:normal;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>If the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any Governmental Authority for the account of any Lender pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03</b><a name="DocXTextRef281"></a>, then such Lender shall (at the request of the Borrower) use commercially reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates if, in the sole reasonable judgment of such Lender, such designation or assignment and delegation would (i) eliminate or reduce amounts payable pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b><b style="font-weight:bold;"> </b>or this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03</b>, as the case may be, in the future, (ii) not subject such Lender to any unreimbursed cost or expense and (iii) not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>If any Lender requests compensation pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b>, or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any Governmental Authority for the account of any Lender pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03</b>, and such Lender has declined or is unable to designate a different lending office in accordance with <b style="font-weight:bold;">Section 5.04(a)</b>, or if any Lender is a Defaulting Lender, then the Borrower may, at such Lender&#8217;s sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, <b style="font-weight:bold;">Section 14.05(b)</b><i style="font-style:italic;"> </i>(other than such Lender&#8217;s consent), all of its interests, rights (other than its existing rights to payments pursuant to <b style="font-weight:bold;">Section 5.01</b> or <b style="font-weight:bold;">Section 5.03</b>) and obligations under this Agreement and the related Loan Documents to an Eligible Assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><i style="font-style:italic;"> </i><font style="white-space:pre-wrap;">that: (i) the Borrower  shall have provided all of the documentation and information in accordance with </font><b style="font-weight:bold;">Section 14.05(b)</b>; (ii) such Lender shall have received payment of an amount equal to (A) the outstanding principal of its Loans, (B) accrued interest thereon, (C) accrued fees and (D) all other amounts payable to it hereunder and under the other Loan Documents from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts); (iii) in the case of any such assignment resulting from a claim for compensation under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b><i style="font-style:italic;"> </i>or payments required to be made pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03</b>, such assignment will result in a reduction in such compensation or payments thereafter; and (iv) such assignment does </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">not conflict with applicable Law. A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">5.05</font><a name="_Toc256000335"></a><a name="_Toc256000182"></a><a name="_Toc256000029"></a><a name="_Toc69324603"></a><a name="_Toc70875901"></a>Survival<font style="font-weight:normal;">. Each party&#8217;s obligations under this </font>Section 5 <font style="font-weight:normal;white-space:pre-wrap;"><a name="_Ref40130034"></a>shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all Obligations under any Loan Document.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 6.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000336"></a><a name="_Toc256000183"></a><a name="_Toc256000030"></a><a name="_Ref40130035"></a><a name="_Toc69324604"></a><a name="_Toc70875902"></a>CONDITIONS</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">6.01</font><a name="_Ref40130036"></a><a name="_Ref40202305"></a><a name="_Toc256000337"></a><a name="_Toc256000184"></a><a name="_Toc256000031"></a><a name="_Toc69324605"></a><a name="_Toc70875903"></a>Conditions to the Closing Date<font style="font-weight:normal;">. The obligation of each Lender to make the Tranche A-1 Terms Loans shall be subject to the delivery of a Borrowing Notice as required pursuant to </font>Section 2.02<font style="font-weight:normal;"> and the prior or concurrent satisfaction or waiver of each of the conditions precedent set forth below in this </font>Section 6.01<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40204637"></a><a name="_Ref40130037"></a><b style="font-weight:bold;">Loan Documents</b>. The Administrative Agent shall have received each Loan Document required to be executed by the appropriate Obligor on the Closing Date and delivered by each applicable Obligor in such number as reasonably requested by the Administrative Agent (which may be delivered by facsimile or other electronic means for the purposes of satisfying this clause (a) on the Closing Date) and such Loan Documents shall be in form and substance satisfactory to the Administrative Agent and the Lenders and their respective counsels.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Secretary&#8217;s Certificate, Etc. </b><a name="DocXTextRef289"></a><a name="DocXTextRef290"></a>The Administrative Agent shall have received from each Obligor (x) a copy of a good standing certificate, dated a date reasonably close to the Closing Date, for each such Person and (y) a certificate, dated as of the Closing Date, duly executed and delivered by such Person&#8217;s Responsible Officer, as to:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130038"></a>resolutions of each such Person&#8217;s Board then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the Transactions;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130039"></a>the incumbency and signatures of Responsible Officers authorized to execute and deliver each Loan Document to be executed by such Person; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40130040"></a>the full force and validity of each Organic Document of such Person and copies thereof;</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">upon which certificates shall be in form and substance reasonably satisfactory to the Administrative Agent and upon which the Administrative Agent and the Lenders may conclusively rely until they shall have received a further certificate of the Responsible Officer of any such Person cancelling or amending the prior certificate of such Person.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40259133"></a><a name="_Ref40130042"></a><b style="font-weight:bold;">Information Certificate</b>. The Administrative Agent shall have received a fully completed Information Certificate in form and substance reasonably satisfactory to the Administrative Agent, dated as of the Closing Date, duly executed and delivered by a Responsible Officer of the Borrower. All documents and agreements required to be appended<font style="letter-spacing:-0.9pt;"> </font>to </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">the Information Certificate, shall be in form and substance reasonably satisfactory to the Administrative Agent, shall have been executed and delivered by the requisite parties and shall be in full force and<font style="letter-spacing:-0.05pt;"> </font>effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130044"></a><b style="font-weight:bold;">Financial Information, Etc. </b><a name="_Ref40130045"></a>The Administrative Agent shall have received, or such information shall be publicly available on &#8220;EDGAR,&#8221; audited consolidated financial statements of the Borrower and its Subsidiaries for the fiscal year ended December 31, 2020.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130048"></a><b style="font-weight:bold;">Solvency</b>. The Administrative Agent shall have received a solvency certificate, substantially in the form of <b style="font-weight:bold;">Exhibit I</b>, duly executed and delivered by the chief financial officer of the Borrower, dated as of the Closing Date, in form and substance reasonably satisfactory to the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130049"></a><b style="font-weight:bold;">Security Documents</b>. The Administrative Agent shall have received executed counterparts of a Security Agreement, in form and substance reasonably acceptable to the Administrative Agent, dated as of the Closing Date, duly executed and delivered by each Obligor, together with all documents (including share certificates, transfers and stock transfer forms, notices or any other instruments) required to be delivered or filed under the Security Documents and evidence satisfactory to it that arrangements have been made with respect to all registrations, notices or actions required under the Security Documents to be effected, given or made in order to establish a valid and perfected first priority security interest in the Collateral in accordance with the terms of the Security Documents, including:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130050"></a><a name="DocXTextRef297"></a><a name="DocXTextRef298"></a>delivery of all certificates (in the case of Equity Interests that are certificated securities (as defined in the UCC)) evidencing the issued and outstanding capital securities owned by each Obligor that are required to be pledged and so delivered under the Security Agreement, which certificates in each case shall be accompanied by undated instruments of transfer duly executed in blank, or, in the case of Equity Interests that are uncertificated securities (as defined in the UCC), confirmation and evidence reasonably satisfactory to the Administrative Agent and the Lenders that the security interest required to be pledged therein under the Security Agreement has been transferred to and perfected by the Administrative Agent and the Lenders in accordance with Articles 8 and 9 of the NY UCC and all laws otherwise applicable to the perfection of the pledge of such Equity Interests; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that for purposes of satisfying the condition set forth in <b style="font-weight:bold;">Section 6.01(f)</b>, such certificated securities and instruments of transfer with respect to Marinus Pharmaceuticals Emerald Limited may be delivered in electronic copy, with originals to be delivered to the Administrative Agent within five (5) Business Days of the Closing Date (or such later date as the Administrative Agent may agree in its sole discretion);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130051"></a>financing statements naming each Obligor as a debtor and the Administrative Agent as the secured party, or other similar instruments or documents, in each case suitable for filing, filed under the UCC (or equivalent law) of all jurisdictions as may be necessary or, in the opinion of the Administrative Agent, desirable to perfect the Liens of the Secured Parties pursuant to the Security Agreement;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40130052"></a>UCC-3 termination statements, if any, necessary to release all Liens and other rights of any Person in any collateral described in the Security Agreement previously granted by any Person;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref40130053"></a>all applicable Short-Form IP Agreements required to be provided under the Security Agreement, each dated as of the Closing Date, duly executed and delivered by each applicable Obligor; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>the Intercompany Subordination Agreement or such other subordination agreement in form and substance reasonably satisfactory to the Administrative Agent. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130055"></a><b style="font-weight:bold;">Lien Searches</b>. The Administrative Agent shall be satisfied with Lien searches regarding the Borrower and the Subsidiary Guarantors made as of a date reasonably close to the Closing Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40130058"></a><b style="font-weight:bold;">Opinions of Counsel</b>. The Administrative Agent shall have received a duly executed legal opinion of counsel to the Obligors dated as of the Closing Date, in form and substance reasonably acceptable to the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130059"></a><b style="font-weight:bold;">Fee Letter</b>. The Administrative Agent shall have received an executed counterpart of the Fee Letter, duly executed and delivered by the Borrower.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40130060"></a><b style="font-weight:bold;">Closing Fees, Expenses, Etc</b><a name="DocXTextRef299"></a>. Each of the Administrative Agent and each Lender shall have received for its own account, (i) the upfront fee as set forth in the Fee Letter, which shall be paid by way of the Administrative Agent retaining such amount from the proceeds of the Loan and (ii) all fees, costs and expenses due and payable to it pursuant to the Fee Letter and <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.03</b>, including all reasonable closing costs and fees and all unpaid reasonable expenses of the Administrative Agent and the Lenders incurred in connection with the Transactions (including the Administrative Agent&#8217;s and the Lenders&#8217; legal fees and expenses) in an amount not to exceed $300,000, in each case, (A) to the extent invoiced (or as to which a good faith estimate has been provided to the Borrower) at least two (2) Business Days prior to the Closing Date and (B) in the case of the fees, costs and expenses pursuant to clause (ii), net of any amounts previously paid by the Borrower to the Administrative Agent or any Lender as a deposit against such fees, costs and expenses.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40130061"></a><b style="font-weight:bold;">Material Adverse Change</b>. Since December 31, 2020, no event, circumstance or change shall have occurred that has caused or could reasonably be expected to cause, either individually or in the aggregate, a Material Adverse Change, both before and after giving effect to the Loans to be made on the Closing Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref40130063"></a><b style="font-weight:bold;">Know Your Customer</b>. The Administrative Agent shall have received, as applicable, all documentation and other information required by bank regulatory authorities under applicable &#8220;know your customer&#8221; and Anti-Terrorism Laws, and a duly executed W-9 (or other applicable tax form) of the Borrower.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_Toc480909537"></a><b style="font-weight:bold;">No Default</b>. No event shall have occurred or be continuing that would constitute a Default or Event of Default.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><b style="font-weight:bold;">Representations and Warranties</b>. The representations and warranties contained in this Agreement and in the other Loan Documents delivered pursuant to 6.01<i style="font-style:italic;">(</i>a)<i style="font-style:italic;"> </i>shall be true and correct in all material respects (unless such representations are already qualified by reference to materiality, Material Adverse Effect or similar language, in which case such representations and warranties shall be true and correct in all respects) on and as of the Closing Date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects on and as of such earlier date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><b style="font-weight:bold;">Minimum Liquidity</b>. The Administrative Agent shall have received written evidence reasonably satisfactory to it that, as of the Closing Date, the Borrower is in compliance with <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">10.01</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font><b style="font-weight:bold;">Beneficial Ownership Certificate</b><i style="font-style:italic;white-space:pre-wrap;">.  </i>To the extent requested by any Lender or the Administrative Agent, the Borrower shall have provided to such Lender and the Administrative Agent all documentation and other information so requested, including a duly executed W-9 of the Borrower (or such other applicable tax form), in connection with applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including the Patriot Act, and if the Borrower qualifies as a &#8220;legal entity customer&#8221; under the Beneficial Ownership Regulation, a Beneficial Ownership Certification, in each case prior to the Closing Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">6.02</font><a name="_Toc256000338"></a><a name="_Toc256000185"></a><a name="_Toc256000032"></a><a name="_Ref40201114"></a><a name="_Toc69324606"></a><a name="_Toc70875904"></a>Conditions to the Borrowing of All Loans<font style="font-weight:normal;">. The obligation of each Lender to make all Loans (other than the Tranche A-1 Term Loans) shall be subject to the delivery of a Borrowing Notice as required pursuant to </font>Section 2.02<font style="font-weight:normal;">, and the prior or concurrent satisfaction or waiver of each of the conditions precedent set forth below in this </font>Section&#160;6.02<font style="font-weight:normal;">:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Applicable Funding Date Certificate</b>. The Administrative Agent shall have received a Funding Date Certificate dated as of the Applicable Funding Date, duly executed and delivered by a Responsible Officer of the Borrower.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Delivery of Notes</b>. The Administrative Agent shall have received a Note to the extent requested by any Lender pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.04</b><b style="font-weight:bold;"> </b>for the Loans made on such Applicable Funding Date duly executed and delivered by a Responsible Officer of the Borrower.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Solvency</b>. The Administrative Agent shall have received a solvency certificate, substantially in the form of <b style="font-weight:bold;">Exhibit I</b>, duly executed and delivered by the chief financial officer of the Borrower, dated as of the Applicable Funding Date, in form and substance reasonably satisfactory to the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Fees, Expenses, Etc.</b> Each of the Administrative Agent and each Lender shall have received for its own account all Commitment Fees and other fees, costs and expenses due and payable to it on or prior to the Applicable Funding Date pursuant to the Fee Letter, <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">2.06</b><b style="font-weight:bold;"> </b>and <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.03</b>, including all reasonable closing costs and fees and all unpaid reasonable expenses of the Administrative Agent and the Lenders incurred in connection with the Transactions (including the Administrative Agent&#8217;s and the Lenders&#8217; legal fees and expenses) in each case, to the extent invoiced (or as to which a good faith estimate has been provided to the Borrower) at least two (2) Business Days prior to the Applicable Funding Date.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><b style="font-weight:bold;">Material Adverse Change</b>. Since December 31, 2020, no event, circumstance or change shall have occurred that has caused or would reasonably be expected to cause, either individually or in the aggregate, a Material Adverse Change, both before and after giving effect to the Loans to be made on the Applicable Funding Date; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that for purposes of this <b style="font-weight:bold;">Section 6.02(e)</b><a name="_cp_change_423"></a><a name="_cp_change_426"></a>, (i) the impacts of the COVID-19 pandemic on the business, operations or financial condition of the Borrower and its Subsidiaries that (x) occurred prior to the Closing Date and (y) were disclosed in public filings made with the SEC or in writing to the Administrative Agent and the Lenders, in each case prior to the Closing Date, shall be disregarded and (ii) the specific results of any clinical trial with respect to Ganaxolone that could not reasonably be expected to have (A) a Material Adverse Effect or (B) a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone shall not constitute an event, circumstance or change that has caused or could reasonably be expected to cause a Material Adverse Change. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><b style="font-weight:bold;">No Default</b>. No event shall have occurred or be continuing or would result from the making of the Loans on the Applicable Funding Date that would constitute a Default or Event of Default.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><b style="font-weight:bold;">Representations and Warranties; Updated Schedules</b><font style="white-space:pre-wrap;">.  The representations and warranties contained in this Agreement and in the other Loan Documents delivered pursuant to </font><b style="font-weight:bold;">Section </b><b style="font-weight:bold;">6.01(a)</b><i style="font-style:italic;"> </i><font style="white-space:pre-wrap;"><a name="_Hlk68729976"></a>shall be true and correct in all material respects (unless such representations are already qualified by reference to materiality, Material Adverse Effect or similar language, in which case such representations and warranties shall be true and correct in all respects) on and as of the Applicable Funding Date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects on and as of such earlier date.  The Borrower shall have delivered to the Administrative Agent updated copies of </font><b style="font-weight:bold;">Schedules 7.06(c)</b>, <b style="font-weight:bold;">7.12</b>, <b style="font-weight:bold;">7.16</b>, <b style="font-weight:bold;">7.17</b> and <b style="font-weight:bold;">7.23</b>, to the extent required to satisfy the foregoing requirements set forth in this <b style="font-weight:bold;">Section 6.02(g)</b><font style="white-space:pre-wrap;">.  </font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><b style="font-weight:bold;">Applicable Funding Condition</b>. The Applicable Funding Condition shall have been satisfied as set forth on the Loans Schedule. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><b style="font-weight:bold;">Applicable Availability Period</b>. The Loans shall be borrowed on or prior to the last day of the Applicable Availability Period.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 7.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000339"></a><a name="_Toc256000186"></a><a name="_Toc256000033"></a><a name="_Ref40130064"></a><a name="_Toc69324607"></a><a name="_Toc70875905"></a>REPRESENTATIONS AND WARRANTIES</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Borrower and each other Obligor hereby jointly and severally represents and warrants to the Administrative Agent and each Lender on the Closing Date and each Bringdown Date, as set forth below:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.01</font><a name="_Toc256000340"></a><a name="_Toc256000187"></a><a name="_Toc256000034"></a><a name="_Ref40130065"></a><a name="_Toc69324608"></a><a name="_Toc70875906"></a>Power and Authority<font style="font-weight:normal;"><a name="DocXTextRef301"></a>. Each Obligor and each of its Subsidiaries (i)</font><font style="font-weight:normal;"> is duly organized and validly existing under the laws of its jurisdiction of organization, (ii) has all requisite corporate or other power, and has all Governmental Approvals necessary to own its assets and </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">carry on its business as now being or as proposed to be conducted, except to the extent that failure to have the same could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (iii) is qualified to do business and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such qualification necessary except where failure so to qualify could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and (iv) has full power, authority and legal right to enter into and perform its obligations under each of the Loan Documents to which it is a party and, in the case of the Borrower, to borrow the Loans hereunder.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.02</font><a name="_Toc256000341"></a><a name="_Toc256000188"></a><a name="_Toc256000035"></a><a name="_Ref40130066"></a><a name="_Toc69324609"></a><a name="_Toc70875907"></a>Authorization; Enforceability<font style="font-weight:normal;"><a name="DocXTextRef302"></a>. Each Transaction to which an Obligor is a party (or to which it or any of its assets or properties is subject) are within such Obligor&#8217;s corporate or other organizational powers and have been duly authorized by all necessary corporate or other organizational action including, if required, approval by all necessary holders of Equity Interests. This Agreement has been duly executed and delivered by each Obligor and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute, a legal, valid and binding obligation of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors&#8217; rights and (ii) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.03</font><a name="_Toc256000342"></a><a name="_Toc256000189"></a><a name="_Toc256000036"></a><a name="_Ref40130067"></a><a name="_Toc69324610"></a><a name="_Toc70875908"></a>Governmental and Other Approvals; No Conflicts<font style="font-weight:normal;"><a name="DocXTextRef306"></a>. None of the execution, delivery and performance by each Obligor of the Loan Documents to which it is a party or the consummation by each Obligor of the Transactions (i)&#160;<a name="DocXTextRef307"></a><a name="DocXTextRef308"></a>requires any Governmental Approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (x) such as have been obtained or made and are in full force and effect, (y)&#160;<a name="DocXTextRef303"></a><a name="DocXTextRef304"></a><a name="DocXTextRef305"></a>filings and recordings in respect of perfecting or recording the Liens created pursuant to the Security Documents and (z) filings required under applicable securities laws, (ii) will violate (1) any Law, (2) any Organic Document of any Obligor or any of its Subsidiaries or (3) any order of any Governmental Authority, that in the case of </font>clause&#160;(ii)(1)<font style="font-weight:normal;"> or </font>clause (ii)(3)<font style="font-weight:normal;">, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect, (iii) will violate or result in a default under any Material Agreement binding upon any Obligor or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect or (iv) will result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of any Obligor or any of its Subsidiaries.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.04</font><a name="_Toc256000343"></a><a name="_Toc256000190"></a><a name="_Toc256000037"></a><a name="_Ref40130068"></a><a name="_Toc69324611"></a><a name="_Toc70875909"></a>Financial Statements; Material Adverse Change<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130069"></a><b style="font-weight:bold;">Financial Statements</b>. The Borrower has heretofore furnished to the Administrative Agent (who shall forward to the Lenders) consolidated financial statements required to be delivered pursuant to this Agreement. Such financial statements present fairly, in all material respects, the consolidated financial position and results of operations and cash flows of the Borrower and its Subsidiaries as of such dates and for such periods in accordance with GAAP, subject to year-end audit adjustments and the absence of footnotes in the case of the statements of the type described in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.01(a)</b>. </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130070"></a><b style="font-weight:bold;">No Material Adverse Change</b>. Since December 31, 2020, no event, circumstance or change has occurred that has caused or could reasonably be expected to cause, individually or in the aggregate, a Material Adverse Change; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that for purposes of this <b style="font-weight:bold;">Section 7.04(b)</b>, (i) the impacts of the COVID-19 pandemic on the business, operations or financial condition of the Borrower and its Subsidiaries that (x) occurred prior to the Closing Date and (y) were disclosed in public filings made with the SEC or in writing to the Administrative Agent and the Lenders, in each case prior to the Closing Date, shall be disregarded and (ii) the specific results of any clinical trial with respect to Ganaxolone that could not reasonably be expected to have (A) a Material Adverse Effect or (B) a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone shall not constitute an event, circumstance or change that has caused or could reasonably be expected to cause a Material Adverse Change. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.05</font><a name="_Toc256000344"></a><a name="_Toc256000191"></a><a name="_Toc256000038"></a><a name="_Ref40130071"></a><a name="_Toc69324612"></a><a name="_Toc70875910"></a>Properties<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130072"></a><b style="font-weight:bold;">Property Generally</b><a name="DocXTextRef311"></a>. Each Obligor and each of its Subsidiaries has good and marketable fee simple title to, or valid leasehold interests in, or license to, all its real and personal property material to its business, including all properties and assets, whether tangible or intangible, relating to its Products or Product Commercialization and Development Activities and all Material Intellectual Property, subject only to Permitted Liens and except for defects in title that (i) do not interfere in any material respect with its ability to conduct its business as currently conducted or to utilize such properties for their intended purposes and (ii) could not reasonably be expected to prevent or interfere with the ability of any Obligor or any of its Subsidiaries to conduct any Product Commercialization and Development Activities with respect to Ganaxolone in any material respect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130073"></a><b style="font-weight:bold;">Intellectual Property</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref70868702"></a><a name="_Ref40130074"></a>Except as set forth in <b style="font-weight:bold;">Schedule 7.05(b)(i)</b>, </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(A)</font>the Obligors are the sole and exclusive beneficial owners of all right, title and interest in and to all Material Intellectual Property, in each case, that is owned or purported to be owned by Borrower or any of its Subsidiaries, free and clear of:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font>any Claims that could reasonably be expected to (x) as of the Closing Date, result in material liability to any of the Obligors or (y) as of any Bringdown Date, result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone, or </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font>any Liens other than Permitted Liens; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(B)</font>the Obligors own or have sufficient and valid rights to use all Material Intellectual Property necessary to conduct the businesses of the Borrower and its Subsidiaries as currently conducted and planned to be conducted, including the Product Commercialization and Development Activities with respect to Ganaxolone. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>Without limiting <b style="font-weight:bold;">Section 7.05(b)</b><b style="font-weight:bold;">(i)</b>, and except as set forth in <b style="font-weight:bold;">Schedule 7.05(b)(ii)</b>:</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(A)</font><a name="_Ref40130075"></a><a name="DocXTextRef312"></a><a name="DocXTextRef313"></a>other than (1) customary restrictions in in-bound licenses of Material Intellectual Property and non-disclosure agreements, or (2) as would have been or is permitted by <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.09</b>, there are no judgments, licenses, covenants not to sue, grants, Liens (other than Permitted Liens), or other Claims, agreements or arrangements relating to any Material Intellectual Property, which materially restrict Borrower or any of its Subsidiaries with respect to its use, enforcement, or other exploitation of any Material Intellectual Property in connection with such Person&#8217;s Product Commercialization and Development Activities with respect to Ganaxolone;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(B)</font><a name="_Ref40130076"></a><a name="_Ref40130077"></a>the operation and conduct of the business of the Borrower or any of its Subsidiaries, including the exploitation of Material Intellectual Property in such Person&#8217;s Ordinary Course, does not violate, infringe or constitute a misappropriation of any valid rights arising under any Intellectual Property of any other Person (1) as of the Closing Date, in any material respect and (2) as of any Bringdown Date, that could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(C)</font><a name="_Hlk70638328"></a>(1) there are no material pending Claims, or Claims threatened in writing, against Borrower or any of its Subsidiaries asserted by any other Person relating to any of such Person&#8217;s Intellectual Property, including any Claims of adverse ownership, invalidity, infringement, misappropriation, or violation of such Person&#8217;s Intellectual Property, in each case, (x) as of the Closing Date, which are material in any respect or (y) as of any Bringdown Date, which could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone; and (2) neither Borrower nor any of its Subsidiaries has received any notice from, or Claim by, any Person that the operation and conduct of the business of the Borrower or any of its Subsidiaries (including their exploitation of Material Intellectual Property), or any Product Commercialization and Development Activities with respect to Ganaxolone, infringes upon, violates or constitutes a misappropriation of, any Intellectual Property of any other Person (x) as of the Closing Date, in any material respect and (y) as of any Bringdown Date, which could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:114pt;margin:3.59pt 22.4pt 12pt 0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:30pt;text-indent:0pt;white-space:nowrap;">(D)</font><a name="_Ref40130078"></a>to the knowledge of the Obligors, no Material Intellectual Property is being infringed, violated, or misappropriated by any other Person (1) as of the Closing Date, in any material respect and (2) as of any Bringdown Date, which could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone; and (x) as of the Closing Date and (y) as of any Bringdown Date, except, in the case of this clause (y), as could not reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone, neither Borrower nor any of its Subsidiaries has put any other Person on notice of such actual or potential infringement, violation or misappropriation of any such Material Intellectual Property or initiated the enforcement of any Claim with respect to any such Material Intellectual Property;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(E)</font><a name="_Ref40130079"></a><font style="white-space:pre-wrap;"><a name="_Hlk70637930"></a>to the knowledge of  the Obligors (1) as of the Closing Date and (y) as of any Bringdown Date, except, in the case of this clause (2), where the failure to do so could not reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone, all current and former employees and contractors that have developed Material Intellectual Property for or on behalf of Borrower or any of its Subsidiaries have executed written confidentiality and invention assignment Contracts with Borrower or such Subsidiary, as applicable, that irrevocably and presently assign to Borrower or such Subsidiary, as applicable, or its designee all rights of such employees and contractors in or to any such Material Intellectual Property, except as would vest initially in the Obligor or its Subsidiary by operation of Law;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(F)</font><a name="_Ref40130080"></a>Borrower and each of its Subsidiaries has taken reasonable precautions to protect the secrecy, confidentiality and value of its Material Intellectual Property consisting of trade secrets and confidential information (1) as of the Closing Date and (2) as of any Bringdown Date, except in the case of this clause (2), where the failure to do could not reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40130081"></a>With respect to Material Intellectual Property consisting of Patents, except as set forth in <b style="font-weight:bold;">Schedule 7.05(b)(iii)</b>, and without limiting the representations and warranties in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">7.05(b)(i)</b><b style="font-weight:bold;"> </b>and <b style="font-weight:bold;">Section 7.05(b)(ii)</b>:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(A)</font><a name="_Ref40130082"></a>to the knowledge of the Obligors, each of the issued claims in such Patents is valid and enforceable, and (1) as of the Closing Date and (2) as of any Bringdown Date, except, in the case of this clause (2), as could not reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone, neither Borrower nor any of its Subsidiaries has received any written notice asserting that any such Patent or any issued claims therein is invalid or unenforceable;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(B)</font><a name="_Ref40130083"></a>subsequent to the issuance of such Patents, neither Borrower nor any of its Subsidiaries or, to the knowledge of the Obligors, any of its predecessors-in-interest, has filed any disclaimer or made or permitted any other voluntary reduction in the scope of the Inventions claimed in such Patents, in each case, (1) as of the Closing Date and (2) as of any Bringdown Date that could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(C)</font><a name="_Ref40130084"></a>to the knowledge of the Obligors, (1) no allowable or allowed subject matter of such Patents is subject to any competing conception claims of allowable or allowed subject matter of any patent applications or patents of any third party or has been the subject of any interference, re-examination, opposition, or any other post-grant proceedings, and (2) there is no basis for any such interference, re-examination, opposition, <i style="font-style:italic;">inter partes </i>review, post grant review, or any other post-grant proceedings, in each case of (1) and (2), (x) as of the Closing Date and (y) as of any Bringdown Date that could not reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(D)</font><a name="_Ref40130086"></a>all maintenance fees, annuities, and the like due or payable on or with respect to any such Patents have been timely paid (1) as of the Closing Date, and (2) as of the Bringdown Date that could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.06</font><a name="_Toc256000345"></a><a name="_Toc256000192"></a><a name="_Toc256000039"></a><a name="_Ref40130088"></a><a name="_Toc69324613"></a><a name="_Toc70875911"></a>No Actions or Proceedings<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130089"></a><b style="font-weight:bold;">Litigation</b>. Except as set forth in <b style="font-weight:bold;">Schedule 7.06(a)</b><a name="DocXTextRef316"></a>, there is no litigation, investigation or proceeding pending or, to the knowledge of any Obligor threatened in writing, with respect to such Obligor or any such Subsidiaries by or before any Governmental Authority or arbitrator that, (i) individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or (ii) involves this Agreement or any other Loan Document.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130090"></a><b style="font-weight:bold;">Environmental Matters</b>. Except with respect to any matters that (either individually or in the aggregate) could not reasonably be expected to result in a Material Adverse Effect, no Obligor nor any of its Subsidiaries (i) has failed to comply with any Environmental Law in all material respects or to obtain, maintain or comply with any material permit, license or other approval required under any Environmental Law, (ii) has become subject to any material Environmental Liability, (iii) has received any material Environmental Claim, or has knowledge that any is threatened, (iv) has entered into any agreement in which such Obligor or any Subsidiary has assumed or undertaken material responsibility or obligations of any other person with respect to any Environmental Liability or (v) has knowledge of any basis for any other material Environmental Liability.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130091"></a><b style="font-weight:bold;">Labor Matters</b><a name="DocXTextRef317"></a><a name="DocXTextRef318"></a>. No Obligor or any of its Subsidiaries has engaged in unfair labor practices as defined in 29 U.S.C. &#167; &#167;152(8) and 158 of the National Labor Relations Act and there are no pending or threatened in writing labor actions, disputes, grievances, arbitration proceedings, or similar Claims or actions involving the employees of any Obligor or any of its Subsidiaries, in each case, that could reasonably be expected to have a Material Adverse Effect. There are no strike or work stoppages in existence or threatened in writing against any Obligor and to the knowledge of such Obligor, no union organizing activity is taking place, in each case, that could reasonably be expected to have a Material Adverse Effect. Except as set forth on <b style="font-weight:bold;">Schedule 7.06(c)</b> (as such schedule may be updated on any Bringdown Date), there are no collective bargaining agreements covering employees of any Obligor or any of its Subsidiaries<font style="font-style:italic;font-weight:bold;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.07</font><a name="_Toc256000346"></a><a name="_Toc256000193"></a><a name="_Toc256000040"></a><a name="_Ref40130092"></a><a name="_Toc69324614"></a><a name="_Toc70875912"></a>Compliance with Laws and Agreements<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130093"></a>Each Obligor is in compliance with all Laws and all Contracts binding upon it or its property, except where the failure to do so could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. No Default has occurred and is continuing. The Obligors and their Subsidiaries are, and all Product Commercialization and Development Activities of such Persons are being conducted in compliance with all applicable Healthcare Laws (i) as of the Closing Date, in all material respects and (ii) as of the each Bringdown Date, except where the failure to do so could not reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130094"></a>To the knowledge of the Obligors, any physician, other licensed healthcare professional, or any other Person who is in a position to refer patients or other business to the Borrower, any other Obligor or any Subsidiaries (collectively, a &#8220;<font style="font-style:italic;font-weight:bold;">Referral Source</font>&#8221;) who has a direct ownership, investment, or financial interest in the Borrower, any other Obligor or any such Subsidiary paid fair market value for such ownership, investment or financial interest; any ownership or investment returns distributed to any Referral Source is in proportion to such Referral Source&#8217;s ownership, investment or financial interest; and no preferential treatment or more favorable terms were or are offered to such Referral Source compared to investors or owners who are not in a position to refer patients or other business. No Obligor, nor any of its Subsidiaries, directly or indirectly, has or will guarantee a loan, make a payment toward a loan or otherwise subsidize a loan for any Referral Source including, without limitation, any loans related to financing the Referral Source&#8217;s ownership, investment or financial interest in the Borrower, any other Obligor or any such Subsidiary.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130095"></a>Without limiting the generality of the foregoing:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130096"></a><a name="DocXTextRef319"></a>Except where the failure to do so could not reasonably be expected to have any Material Adverse Effect or material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone, to the knowledge of the Obligors, (a) each Referral Source complies with the Federal Anti-Kickback Statute, the Stark Law and all other applicable anti-kickback and self-referral laws, whether U.S. or non-U.S.; (b) the transactions between the Borrower or any of its Subsidiaries and each Referral Source reflect fair market value, have commercially reasonable terms, and were negotiated at arm&#8217;s length; and (c) the Borrower and its Subsidiaries do not obligate the Referral Source to purchase, use, recommend or arrange for the use of any products or services of any Obligor or any of its Subsidiaries; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130097"></a>each Obligor and each of its Subsidiaries shall have implemented prior to Ganaxolone FDA Approval policies and procedures to monitor, collect, and report any payments or transfers of value to certain healthcare providers and teaching hospitals, in accordance, in all material respects, with industry standards and the Affordable Care Act of 2010 and the Physician Payments Sunshine Act and their implementing regulations and state disclosure and transparency laws.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.08</font><a name="_Toc256000347"></a><a name="_Toc256000194"></a><a name="_Toc256000041"></a><a name="_Ref40130098"></a><a name="_Toc69324615"></a><a name="_Toc70875913"></a>Taxes<font style="font-weight:normal;white-space:pre-wrap;">.  Except as set forth on </font>Schedule 7.08<font style="font-weight:normal;"><a name="DocXTextRef322"></a><a name="DocXTextRef323"></a>, each Obligor and its Subsidiaries has timely filed or caused to be filed all tax returns and reports required to have been filed and has paid or caused to be paid all taxes required to have been paid by it, except (a) taxes that are being contested in good faith by appropriate proceedings and for which such Obligor or such Subsidiary, as applicable, has set aside on its books adequate reserves with respect thereto in accordance with GAAP or (b) to the extent that the failure to do so would not reasonably be expected to have an Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.09</font><a name="_Toc256000348"></a><a name="_Toc256000195"></a><a name="_Toc256000042"></a><a name="_Ref40130099"></a><a name="_Toc69324616"></a><a name="_Toc70875914"></a>Full Disclosure<font style="font-weight:normal;">. None of the reports, financial statements, certificates or other written information (other than projections, forward-looking information and information of a general economic or industry specific nature) furnished by or on behalf of the Obligors or any of their Subsidiaries to the Administrative Agent (on behalf of itself and the Lenders) in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder or thereunder (as modified or supplemented by other information so furnished) contains when </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">furnished any material misstatement of material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not materially misleading; </font><u style="color:#000000;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;"> that, with respect to projected financial information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time delivered, and it being understood that such projected financial information and all other forward looking information are not to be viewed as facts and are subject to significant uncertainties and contingencies, many of which are beyond the control of the Borrower or any of its Subsidiaries, including whether or not the Borrower will receive Ganaxolone FDA Approval, and that actual results during the period or periods covered thereby may differ significantly from such projected results and that the differences may be material.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.10</font><a name="_Toc256000349"></a><a name="_Toc256000196"></a><a name="_Toc256000043"></a><a name="_Ref40130100"></a><a name="_Toc69324617"></a><a name="_Toc70875915"></a>Investment Company Act and Margin Stock Regulation<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130101"></a><b style="font-weight:bold;">Investment Company Act</b>. No Obligor is an &#8220;investment company&#8221; as defined in, or subject to regulation under, the Investment Company Act of 1940, as amended.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130102"></a><b style="font-weight:bold;">Margin Stock</b>. No Obligor is engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part of the proceeds of the Loans will be used, whether immediately, incidentally or ultimately, to buy or carry any Margin Stock, to extend credit to others for the purpose of buying or carrying any Margin Stock, or in any way that is in violation of Regulation T, U or X.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.11</font><a name="_Toc256000350"></a><a name="_Toc256000197"></a><a name="_Toc256000044"></a><a name="_Ref40130103"></a><a name="_Toc69324618"></a><a name="_Toc70875916"></a>Solvency<font style="font-weight:normal;">. The Obligors, on a consolidated basis, are and, immediately after giving effect to the making of the Loans, the use of proceeds thereof, and the consummation of the Transactions, will be, Solvent.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.12</font><a name="_Toc256000351"></a><a name="_Toc256000198"></a><a name="_Toc256000045"></a><a name="_Ref40130104"></a><a name="_Toc69324619"></a><a name="_Toc70875917"></a>Subsidiaries<font style="font-weight:normal;">. Set forth on </font>Schedule 7.12 <font style="font-weight:normal;">is a complete and correct list of all direct and indirect Subsidiaries of the Borrower (as such schedule may be updated on any Bringdown Date). Each such Subsidiary is duly organized and validly existing under the jurisdiction of its organization shown in said </font>Schedule 7.12<font style="font-weight:normal;">, and the percentage ownership by each Obligor of each such Subsidiary thereof is as shown in said </font>Schedule 7.12<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.13</font><a name="_Toc256000352"></a><a name="_Toc256000199"></a><a name="_Toc256000046"></a><a name="_Toc69324620"></a><a name="_Toc70875918"></a>[Reserved]<font style="font-weight:normal;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.14</font><a name="_Toc256000353"></a><a name="_Toc256000200"></a><a name="_Toc256000047"></a><a name="_Ref40130106"></a><a name="_Toc69324621"></a><a name="_Toc70875919"></a>Material Agreements<font style="font-weight:normal;">. Except as set forth on </font>Schedule 7.14<font style="font-weight:normal;"><a name="DocXTextRef328"></a>, no Obligor nor any of its Subsidiaries is in default under any Material Agreement (x) as of the Closing Date, in any material respect and (y) as of any Bringdown Date, that could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone, nor does any Obligor have knowledge of (i) any Claim against it or any of its Subsidiaries for any breach of any such Material Agreement (x) as of the Closing Date, in any material respect and (y) as of any Bringdown Date, that could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone or (ii) any default by any party to any such Material Agreement (x) as of the Closing Date, in any material respect and (y) as of any Bringdown Date, that could reasonably be expected to result in a </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.15</font><a name="_Toc256000354"></a><a name="_Toc256000201"></a><a name="_Toc256000048"></a><a name="_Ref40130107"></a><a name="_Toc69324622"></a><a name="_Toc70875920"></a>Restrictive Agreements<font style="font-weight:normal;"><a name="DocXTextRef331"></a>. Except as set forth in </font>Schedule 7.15<font style="font-weight:normal;"><a name="DocXTextRef330"></a>, as of the Closing Date, no Obligor or any of its Subsidiaries is subject to any Restrictive Agreement, except (i) those permitted under </font>Section 9.11<font style="font-weight:normal;">, (ii) restrictions and conditions imposed by Law or by this Agreement, (iii) any stockholder agreement, charter, by-laws, or other organizational documents of an Obligor or any of its Subsidiaries as in effect on the date hereof and (iv) limitations associated with Permitted Liens.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.16</font><a name="_Toc256000355"></a><a name="_Toc256000202"></a><a name="_Toc256000049"></a><a name="_Ref40130108"></a><a name="_Toc69324623"></a><a name="_Toc70875921"></a>Real Property<font style="font-weight:normal;">. </font>Schedule 7.16 <font style="font-weight:normal;">correctly sets forth all real property that is owned or leased by the Obligors (as such schedule may be updated on any Bringdown Date), indicating in each case whether the respective property is owned or leased, the identity of the owner and lessee (if applicable) and the location of the respective property. Except as set forth in </font>Schedule 7.16 <font style="font-weight:normal;">(as such schedule may be updated on any Bringdown Date), no Obligor owns or leases (as tenant thereof) any real property as of the Closing Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.17</font><a name="_Toc256000356"></a><a name="_Toc256000203"></a><a name="_Toc256000050"></a><a name="_Ref40130109"></a><a name="_Toc69324624"></a><a name="_Toc70875922"></a>Pension Matters<font style="font-weight:normal;">. </font>Schedule 7.17 <font style="font-weight:normal;"><a name="DocXTextRef335"></a><a name="DocXTextRef336"></a><a name="DocXTextRef337"></a><a name="DocXTextRef338"></a>sets forth (as such schedule may be updated on any Bringdown Date), a complete and correct list of, and that separately identifies, (i) all Title IV Plans, (ii) all Multiemployer Plans and (iii) all material Benefit Plans. Each Qualified Plan, and each trust thereunder, has received a favorable determination or may rely upon an opinion letter for a prototype plan letter from the IRS or an application for such a letter is currently being processed by the IRS with respect thereto and, as of the date of this Agreement, to the knowledge of the Obligors, nothing has occurred that would reasonably be expected to prevent, or cause the loss of, such qualification. Except for those that could not, in the aggregate, reasonably be expected to result in a Material Adverse Effect, (x) each Benefit Plan is in compliance with applicable provisions of ERISA, the Code and other Laws, (y) there are no existing or pending (or to the knowledge of any Obligor, threatened) claims (other than routine claims for benefits in the normal course), sanctions, actions, lawsuits or other proceedings or investigation involving any Benefit Plan to which any Obligor or Subsidiary thereof incurs or otherwise has or could have an obligation or any liability or Claim and (z)</font><font style="font-weight:normal;"> no ERISA Event is reasonably expected to occur. The Borrower and each of its ERISA Affiliates has met all applicable requirements under the ERISA Funding Rules with respect to each Title IV Plan, and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained. As of the most recent valuation date for any Title IV Plan, the funding target attainment percentage (as defined in Section 430(d)(2) of the Code) is at least sixty percent (60%), and neither any Obligor nor any of its ERISA Affiliates knows of any facts or circumstances that could reasonably be expected to cause the funding target attainment percentage to fall below sixty percent (60%) as of the most recent valuation date. As of the Closing Date, no ERISA Event has occurred in connection with which obligations and liabilities (contingent or otherwise) remain outstanding. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.18</font><a name="_Toc256000357"></a><a name="_Toc256000204"></a><a name="_Toc256000051"></a><a name="_Ref40130110"></a><a name="_Toc69324625"></a><a name="_Toc70875923"></a>Regulatory Approvals<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130111"></a>Each Obligor and each of its Subsidiaries holds, either directly or through licensees and agents, all Material Product Authorizations necessary or required for the Borrower and each of its Subsidiaries to conduct, their respective operations and businesses, including its Product Commercialization and Development Activities with respect to Ganaxolone, in the </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">manner currently conducted (x) as of the Closing Date, in all material respects and (y) as of any Bringdown Date, expect where the failure to hold any such Material Product Authorizations could not reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130112"></a>No Obligor nor its Subsidiaries has received any written notice from the FDA or any Governmental Authority that (i) it is considering suspending, revoking or materially limiting any Material Product Authorization (x) as of the Closing Date and (y) as of any Bringdown Date, that could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone or (ii) as of the Closing Date, it is not likely to approve any applications made to such Governmental Authority with respect to any of the Products or any Material Agreement. To the knowledge of the Obligors, the Obligors and their Subsidiaries have made all required notices, registrations and reports (including field alerts or other reports of adverse drug experiences) and other filings with respect to Ganaxolone and its Product Commercialization and Development Activities with respect to Ganaxolone, in each case, (x) as of the Closing Date, which are material and (y) as of any Bringdown Date, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect or a material adverse effect on its Product Commercialization and Development Activities with respect to Ganaxolone.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130113"></a>Except as set forth on <b style="font-weight:bold;">Schedule 7.18(c)</b><a name="DocXTextRef342"></a><a name="DocXTextRef343"></a><a name="DocXTextRef340"></a>, and without limiting the generality of any other representation or warranty made by any Obligor hereunder or under any other Loan Document (x) as of the Closing Date and (y) as of any Bringdown Date, except as could not reasonably be expected to have a Material Adverse Effect or a material adverse effect on its Product Commercialization and Development Activities with respect to Ganaxolone: (i) no Obligor, nor any of its Subsidiaries nor, to the knowledge of any Obligor, any of their respective agents, suppliers, licensors or licensees have received any inspection reports, warning letters or notices or similar documents with respect to Ganaxolone or any Product Commercialization and Development Activities with respect to Ganaxolone from any Regulatory Authority within the last two (2) years that asserts material lack of compliance with any applicable Healthcare Laws or Material Product Authorizations; (ii) no Obligor, nor any of its Subsidiaries nor, to the knowledge of any Obligor, any of their respective agents, suppliers, licensors or licensees have received any material notification from any Regulatory Authority within the last two (2) years, asserting that Ganaxolone or any Product Commercialization and Development Activities with respect to Ganaxolone lacks a Material Product Authorization; (iii) there is no pending regulatory action, investigation or inquiry (other than non-material routine or periodic inspections or reviews) against any Obligor, any of its Subsidiaries or, to the knowledge of any Obligor, any of their respective suppliers, licensors or licensees with respect to Ganaxolone or any Product Commercialization and Development Activities with respect to Ganaxolone, and, to the knowledge of any Obligor, there is no basis in fact for any material adverse regulatory action against such Obligor or any of its Subsidiaries or, to the knowledge of any Obligor, any of their respective suppliers agents, licensors or licensees with respect to Ganaxolone or any Product Commercialization and Development Activities with respect to Ganaxolone; and (iv) without limiting the foregoing, (A) (1) there have been no material product recalls, safety alerts, corrections, withdrawals, marketing suspensions, removals or the like conducted, undertaken or issued by any Obligor or any of its Subsidiaries, whether voluntary, at the request, demand or </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><a name="DocXTextRef341"></a><a name="DocXTextRef344"></a>order of any Regulatory Authority or otherwise, with respect to Ganaxolone, any Product Commercialization and Development Activities with respect to Ganaxolone or any Material Product Authorization within the last two (2) years, (2) no such product recall, safety alert, correction, withdrawal, marketing suspension, removal or the like has been requested, demanded or ordered by any Regulatory Authority within the last two (2) years, and, to the knowledge of any Obligor, there is no basis in fact for the issuance of any such product recall, safety alert, correction, withdrawal, marketing suspension, removal or the like with respect to Ganaxolone or any Product Commercialization and Development Activities with respect to Ganaxolone, and (B) no criminal, injunctive, seizure, detention or civil penalty action has been commenced or threatened in writing by any Regulatory Authority within the last two (2) years with respect to or in connection with Ganaxolone or any Product Commercialization and Development Activities with respect to Ganaxolone, and there are no consent decrees (including plea agreements) that relate to Ganaxolone or any Product Commercialization and Development Activities with respect to Ganaxolone, and, to the knowledge of each Obligor, there is no basis in fact for the commencement of any criminal injunctive, seizure, detention or civil penalty action by any Regulatory Authority relating to Ganaxolone or any Product Commercialization and Development Activities with respect to Ganaxolone or for the issuance of any consent decree. No Obligor nor any of its Subsidiaries, nor, to the knowledge of any Obligor, any of their respective agents, suppliers, licensees or licensors, is employing or utilizing the services of any individual, in connection with Product Commercialization and Development Activities with respect to Ganaxolone, who has been debarred from any federal healthcare program, which could reasonably be expect to have a Material Adverse Effect or a material adverse effect on the Product Commercialization and Development Activities with respect to Ganaxolone.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.19</font><a name="_Toc256000358"></a><a name="_Toc256000205"></a><a name="_Toc256000052"></a><a name="_Toc69324626"></a><a name="_Toc70875924"></a>[Reserved]<font style="font-weight:normal;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.20</font><a name="_Ref40130115"></a><a name="_Toc256000359"></a><a name="_Toc256000206"></a><a name="_Toc256000053"></a><a name="_Toc69324627"></a><a name="_Toc70875925"></a>OFAC; Anti-Terrorism Laws<font style="font-weight:normal;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Toc480909588"></a>Neither the Borrower nor any of its Subsidiaries is in violation of any Anti-Terrorism Law or engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any applicable Anti-Terrorism Laws.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="DocXTextRef346"></a>Neither the Borrower nor any of its Subsidiaries, nor, to the knowledge of the Borrower, any of their respective directors, officers, or employees (i) is currently the target of any Sanctions, (ii) is located, organized or residing in any Designated Jurisdiction in violation of Sanctions, or (iii) is or has been (within the previous five (5) years) engaged in any transaction with, or for the benefit of, any Person who is now or was then the target of Sanctions or who is located, organized or residing in any Designated Jurisdiction, in violation of Sanctions. No Loan, nor the proceeds from any Loan, has been or will be used, directly or, to the knowledge of the Borrower, indirectly, to lend, contribute or provide to, or has been or will be otherwise made available for the purpose of funding, any activity or business in any Designated Jurisdiction in violation of Sanctions or for the purpose of funding any activity or business of any Person located, organized or residing in any Designated Jurisdiction or who is the subject of any Sanctions, in violation of Sanctions, or in any other manner that will result in any violation by any party to this Agreement of Sanctions.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.21</font><a name="_Toc256000360"></a><a name="_Toc256000207"></a><a name="_Toc256000054"></a><a name="_Ref40130116"></a><a name="_Toc69324628"></a><a name="_Toc70875926"></a>Anti-Corruption<font style="font-weight:normal;"><a name="DocXTextRef347"></a>. Neither the Borrower nor any of its Subsidiaries, nor, to the knowledge of the Borrower, any of their respective directors, officers or employees, directly or indirectly, has (i) materially violated or is in material violation of any applicable anti-corruption Law, or (ii) made, offered to make, promised to make or authorized the payment or giving of, directly or indirectly, any Prohibited Payment.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.22</font><a name="_Toc256000361"></a><a name="_Toc256000208"></a><a name="_Toc256000055"></a><a name="_Ref40130118"></a><a name="_Toc69324629"></a><a name="_Toc70875927"></a>Priority of Obligations<font style="font-weight:normal;">. The Obligations constitute unsubordinated obligations of the Obligors, and except for any obligations which have priority under applicable Law, rank at least pari passu in right of payment with all other unsubordinated Indebtedness of the Obligors.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.23</font><a name="_Toc256000362"></a><a name="_Toc256000209"></a><a name="_Toc256000056"></a><a name="_Ref40130119"></a><a name="_Toc69324630"></a><a name="_Toc70875928"></a>Royalty and Other Payments<font style="font-weight:normal;">. Except as set forth on </font>Schedule 7.23 <font style="font-weight:normal;"><a name="_Hlk70583521"></a>(as such schedule may be updated on any Bringdown Date), no Obligor, nor any of its Subsidiaries, is obligated to pay any royalty, milestone payment or any other contingent payment in respect of Ganaxolone.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.24</font><a name="_Toc256000363"></a><a name="_Toc256000210"></a><a name="_Toc256000057"></a><a name="_Ref40130120"></a><a name="_Toc69324631"></a><a name="_Toc70875929"></a>Non-Competes<font style="font-weight:normal;">. Neither the Borrower, any other Obligor, nor any of their respective Subsidiaries, nor any of their respective directors, officers or employees, is subject to a non-compete agreement that prohibits or will interfere in any material respect with any of the Product Commercialization and Development Activities with respect to Ganaxolone, including the development, commercialization or marketing of Ganaxolone.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">7.25</font><a name="_Toc256000364"></a><a name="_Toc256000211"></a><a name="_Toc256000058"></a><a name="_Ref40130122"></a><a name="_Toc69324632"></a><a name="_Toc70875930"></a>Reimbursement from Medical Reimbursement Programs<font style="font-weight:normal;">. There is no investigation, audit, claim review, or other action pending with respect to any Obligor or, to the knowledge of any Obligor, threatened in writing which could reasonably be expected to result in a revocation, suspension, termination, probation, restriction, limitation, or non-renewal of any provider number issued to any Obligor or result in the exclusion of any Obligor from Medicare or Medicaid, nor is there any action pending or, to the knowledge of any Obligor, threatened in writing, pursuant to which any Governmental Authority seeks to impose material sanctions with respect to such Obligor&#8217;s business that could reasonably be expected to have a Material Adverse Effect or a material adverse effect on any of the Product Commercialization and Development Activities with respect to Ganaxolone.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 8.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000365"></a><a name="_Toc256000212"></a><a name="_Toc256000059"></a><a name="_Ref40130123"></a><a name="_Toc69324633"></a><a name="_Toc70875931"></a>AFFIRMATIVE COVENANTS</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Obligor covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations (other inchoate indemnification and expense reimbursement obligations for which no claim has been made) have been indefeasibly paid in full in cash:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.01</font><a name="_Toc256000366"></a><a name="_Toc256000213"></a><a name="_Toc256000060"></a><a name="_Ref40130124"></a><a name="_Ref40264501"></a><a name="_Toc69324634"></a><a name="_Toc70875932"></a>Financial Statements and Other Information<font style="font-weight:normal;">. The Borrower will furnish to the Administrative Agent:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130125"></a><a name="DocXTextRef349"></a><a name="DocXTextRef350"></a>as soon as available and in any event within forty-five (45) days after the end of the first three (3) fiscal quarters of each fiscal year (i) the consolidated balance sheets of the Borrower and its Subsidiaries as of the end of such fiscal quarter and (ii) the related consolidated statements of income, shareholders&#8217; equity and cash flows of the Borrower and its Subsidiaries for such quarter and the portion of the fiscal year through the end of such fiscal quarter, in each case prepared in accordance with GAAP consistently applied, all in reasonable detail and setting </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with (iii) a certificate of a Responsible Officer of the Borrower stating that <a name="DocXTextRef351"></a>(x) such financial statements fairly present in all material respects the financial condition of the Borrower and its Subsidiaries as at such date and <a name="DocXTextRef352"></a>(y) the results of operations of the Borrower and its Subsidiaries for the period ended on such date have been prepared in accordance with GAAP consistently applied, subject to changes resulting from normal, year-end audit adjustments and except for the absence of notes; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that documents required to be furnished pursuant to this <b style="font-weight:bold;">Section</b> <b style="font-weight:bold;">8.01(a)</b><b style="font-weight:bold;"> </b>shall be deemed furnished on the date that such documents are publicly available on &#8220;EDGAR&#8221; or the Borrower&#8217;s website (with the related certificate separately delivered);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130126"></a><a name="DocXTextRef354"></a>as soon as available and in any event within ninety (90) days after the end of each fiscal year (i) the consolidated balance sheets of the Borrower and its Subsidiaries as of the end of such fiscal year and (ii) the related consolidated statements of income, shareholders&#8217; equity and cash flows of the Borrower and its Subsidiaries for such fiscal year, in each case prepared in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year, accompanied by a report and opinion thereon of Ernst &amp; Young LLP or another firm of independent certified public accountants of recognized national standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in accordance with generally accepted auditing standards and shall not be subject to any &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote or any qualification or exception as to the scope of such audit, and in the case of such consolidated financial statements, certified by a Responsible Officer of the Borrower; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that documents required to be furnished pursuant to this Section <b style="font-weight:bold;">8.01(b)</b><b style="font-weight:bold;"> </b>shall be deemed furnished on the date that such documents are publicly available on &#8220;EDGAR&#8221; or the Borrower&#8217;s website; provided, however, that any such report shall not be considered qualified due to the inclusion of an emphasis of matter paragraph in the audit opinion based on the impending maturity date of any Indebtedness under this Agreement within 12 months of the date of such report, the prospective breach of any financial covenant hereunder or liquidity issues due to ordinary course liabilities;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130127"></a>together with the financial statements required pursuant to <b style="font-weight:bold;">8.01(a)</b><b style="font-weight:bold;"> </b><a name="DocXTextRef356"></a>and <b style="font-weight:bold;">(b)</b>, a compliance certificate signed by a Responsible Officer of the Borrower as of the end of the applicable accounting period (which delivery may be by electronic communication including fax or email and shall be deemed to be an original, authentic counterpart thereof for all purposes) substantially in the form of <b style="font-weight:bold;">Exhibit E </b>(a &#8220;<font style="font-style:italic;font-weight:bold;">Compliance Certificate</font>&#8221;) including details of any issues that are material that are raised by auditors and any occurrence or existence of any event, circumstance, act or omission that would cause any representation or warranty contained in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">7.07</b>, <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">7.18</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">7.22</b><b style="font-weight:bold;"> </b>to be incorrect in any material respect (or in any respect if such representation or warranty is qualified by materiality or by reference to Material Adverse Effect or Material Adverse Change) if such representation or warranty were to be made at the time of delivery of a Compliance Certificate. For the avoidance of doubt, no representation or warranty contained in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">7.07</b>, <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">7.18</b> or <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">7.22</b><b style="font-weight:bold;"> </b>is required to be, shall be or shall be deemed to be made in connection with a delivery of any Compliance Certificate; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130128"></a><font style="white-space:pre-wrap;">after being prepared by the Borrower and approved by its Board, and promptly following the Administrative Agent&#8217;s request therefor, a consolidated  budget for the Borrower </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">and its Subsidiaries for the fiscal year to which such budget relates; </font><u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that, for each fiscal year, on or before the sixtieth (60th) day following the beginning of such fiscal year, the Borrower shall prepare, and its Board shall approve such consolidated budget for such fiscal year, and the Borrower shall notify the Administrative Agent promptly after the Board has given such approval;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130129"></a>promptly after the same are released, copies of all press releases (other than any press release that is immaterial, routine or administrative in nature); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that documents required to be furnished pursuant to this Section <b style="font-weight:bold;">8.01(e)</b><b style="font-weight:bold;"> </b>shall be deemed furnished on the date that such documents are publicly available on &#8220;EDGAR&#8221; or the Borrower&#8217;s website;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130130"></a>promptly, and in any event within five (5) Business Days after receipt thereof by an Obligor thereof, copies of each notice or other correspondence received from any securities regulator or exchange to the authority of which the Borrower may become subject from time to time concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of such Obligor, in each case, excluding any investigation or inquiry that is immaterial, routine or administrative in nature; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that documents required to be furnished pursuant to this Section <b style="font-weight:bold;">8.01(f)</b><b style="font-weight:bold;"> </b>shall be deemed furnished on the date that such documents are publicly available on &#8220;EDGAR&#8221; or the Borrower&#8217;s website;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130131"></a>promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the stockholders of each Obligor and its Subsidiaries (other than any report or any communication that is immaterial, routine or administrative in nature), and copies of all annual, regular, periodic and special reports and registration statements which any Obligor or its Subsidiaries may file or be required to file with any securities regulator or exchange to the authority of which such Obligor or such Subsidiary, as applicable, may become subject from time to time; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that documents required to be furnished pursuant to this Section <b style="font-weight:bold;">8.01(g)</b><b style="font-weight:bold;"> </b>shall be deemed furnished on the date that such documents are publicly available on &#8220;EDGAR&#8221; or the Borrower&#8217;s website;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40130132"></a>the information regarding insurance maintained by the Borrower and its Subsidiaries as and when required under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.05</b>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130133"></a>promptly, and in any event within five (5) Business Days after the Borrower obtains knowledge of any Claim related to any Product or inventory involving more than $2,500,000 (or the Equivalent Amount in other currencies), written notice thereof from a Responsible Officer of the Borrower which notice shall include a statement setting forth details of such return, recovery, dispute or claim;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40130134"></a>as soon as possible and in any event within five (5) Business Days after the end of each fiscal month, evidence reasonably satisfactory to the Administrative Agent, based upon the Borrower&#8217;s bank account statements that the Borrower has met its minimum liquidity requirement set out in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">10.01</b>; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40130135"></a>such other information respecting the businesses, financial performance, operations condition of the assets or liabilities of the Obligors (including with respect to the </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Collateral), taken as a whole, as the Administrative Agent may from time to time reasonably request.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.02</font><a name="_Toc256000367"></a><a name="_Toc256000214"></a><a name="_Toc256000061"></a><a name="_Ref40130136"></a><a name="_Toc69324635"></a><a name="_Ref70778822"></a><a name="_Toc70875933"></a>Notices of Material Events<font style="font-weight:normal;">. The Borrower will furnish to the Administrative Agent written notice of the following (x) with respect to </font>clause (a) <font style="font-weight:normal;">below within three (3) Business Days of and (y) with respect to </font>clause (b)<font style="font-weight:normal;"> through </font>(m)<font style="font-weight:normal;"> below, within five (5) Business Days, in each case, after a Responsible Officer of the Borrower first learns of or acquires knowledge with respect to:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130137"></a>the occurrence of any Default or Event of Default;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130138"></a>the occurrence of any event with respect to the property or assets of the Borrower or any of its Subsidiaries resulting in a Loss aggregating $5,000,000 (or the Equivalent Amount in other currencies) or more;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130139"></a>(i) any proposed acquisition of stock, assets or property by the Borrower or any of its Subsidiaries that could reasonably be expected to result in Material Environmental Liability, and (ii) any spillage, leakage, discharge, disposal, leaching, migration or release of any Hazardous Material by the Borrower or any of its Subsidiaries required to be reported to any Governmental Authority and that would reasonably be expected to result in Material Environmental Liability;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>the assertion of any Claim under any Environmental Law by any Person against, or with respect to the activities of, the Borrower or any of its Subsidiaries and any alleged liability or non-compliance with any Environmental Laws or any permits, licenses or authorizations issued pursuant to Environmental Laws, in each case, which could reasonably be expected to result in a Material Environmental Liability;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130141"></a>the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against or affecting the Borrower or any of its Affiliates that would reasonably be expected to result in a Material Adverse Effect;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130142"></a><a name="DocXTextRef372"></a>(i) the intention of any ERISA Affiliate to file any notice of intent to terminate any Title IV Plan, a copy of such notice and (ii) the filing by any ERISA Affiliate of a request for a minimum funding waiver under Section 412 of the Code with respect to any Title IV Plan or Multiemployer Plan, in each case in writing and in reasonable detail (including a description of any action that any ERISA Affiliate proposes to take with respect thereto, together with a copy of any notice filed with the PBGC or the IRS pertaining thereto);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130143"></a>(i) the termination of any Material Agreement other than in accordance with its terms and not as a result of a breach or default, (ii) the receipt by the Borrower or any of its Subsidiaries of any notice of a material breach or default under any Material Agreement (and a copy thereof) asserting a default by such Obligor or any of its Subsidiaries where such alleged default would permit such counterparty to terminate such Material Agreement, (iii) the entering into of any new Material Agreement by any Obligor (and a copy thereof) or (iv) any material amendment to a Material Agreement that would be adverse in any material respect to the Lenders (and a copy thereof); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that the Borrower shall not be required to provide such </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">notice if such documents become publicly available on &#8220;EDGAR&#8221; or the Borrower&#8217;s website within the time period notice would otherwise be required pursuant to this <b style="font-weight:bold;">Section 8.02</b>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40130144"></a>any material change in accounting policies or financial reporting practices by the Borrower or any of its Subsidiaries (other than as required under GAAP);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130145"></a>any labor controversy resulting in or threatening to result in any strike, work stoppage, boycott, shutdown or other material labor disruption against or involving an Obligor that could reasonably be expected to result in a Material Adverse Effect;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40130146"></a>any licensing agreement or arrangement entered into by the Borrower or any of its Subsidiaries in connection with any material Claim of violation, infringement or misappropriation (or alleged violation, infringement or misappropriation) of Intellectual Property by or against the Borrower or any of its Subsidiaries;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40130147"></a>the creation, development or other acquisition (including any in-bound exclusive licenses) of any Material Intellectual Property by the Borrower or any Subsidiary after the Closing Date that is registered or becomes registered or the subject of an application for registration with the any Governmental Authority; provided that, with respect to any such Material Intellectual Property created, developed or acquired (including through any in-bound exclusive license) in any fiscal year, notice thereof pursuant to this <b style="font-weight:bold;">Section 8.02(k)</b> shall be made in accordance with the timing of the financial statements for such fiscal year required pursuant to<b style="font-weight:bold;"> Section 8.01(b)</b>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref40130148"></a>any change to any Obligor&#8217;s or any of its Subsidiaries&#8217; ownership of any Controlled Account, by delivering the Administrative Agent a notice setting forth a complete and correct list of all such accounts as of the date of such change; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_Ref40130149"></a>any other development that results in, or could reasonably be expected to result in, a Material Adverse Effect.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Each notice delivered under this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.02</b><b style="font-weight:bold;"> </b>shall be accompanied by a statement of a Responsible Officer of the Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto. Nothing in this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.02</b><b style="font-weight:bold;"> </b>is intended to waive, consent to or otherwise permit any action or omission that is otherwise prohibited by this Agreement or any other Loan Document.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.03</font><a name="_Toc256000368"></a><a name="_Toc256000215"></a><a name="_Toc256000062"></a><a name="_Ref40130150"></a><a name="_Toc69324636"></a><a name="_Ref70778839"></a><a name="_Toc70875934"></a>Existence<font style="font-weight:normal;">. Such Obligor shall, and shall cause each of its Subsidiaries to, preserve, renew and maintain in full force and effect its legal existence; </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"> that the foregoing shall not prohibit any merger, amalgamation, consolidation, liquidation or dissolution permitted under </font>Section 9.03<font style="font-weight:normal;"> or any Asset Sale permitted under </font>Section 9.09<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.04</font><a name="_Toc256000369"></a><a name="_Toc256000216"></a><a name="_Toc256000063"></a><a name="_Ref40130151"></a><a name="_Toc69324637"></a><a name="_Toc70875935"></a>Payment of Obligations<font style="font-weight:normal;"><a name="DocXTextRef378"></a>. Such Obligor will, and will cause each of its Subsidiaries to, pay and discharge its obligations, including (i) all material Taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which penalties attach thereto, and all lawful claims for labor, materials and supplies which, if unpaid, might become a Lien upon any properties or assets of the Borrower or any of its Subsidiaries not constituting a Permitted Lien, except to the extent such Taxes, fees, assessments </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">or governmental charges or levies or such claims are being contested in good faith by appropriate proceedings and are adequately reserved against in accordance with GAAP and (ii) all lawful claims which, if unpaid, would by law become a Lien upon its property not constituting a Permitted Lien.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.05</font><a name="_Toc256000370"></a><a name="_Toc256000217"></a><a name="_Toc256000064"></a><a name="_Ref40130152"></a><a name="_Toc69324638"></a><a name="_Ref70778852"></a><a name="_Toc70875936"></a>Insurance<font style="font-weight:normal;"><a name="DocXTextRef379"></a>. Such Obligor will, and will cause each of its Subsidiaries to maintain, with financially sound and reputable insurance companies, insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses operating in the same or similar locations. Upon the request of the Administrative Agent, the Borrower shall furnish the Administrative Agent from time to time with (i) material information as to the insurance carried by it and, if so requested, copies of all such insurance policies and (ii) a certificate from the Borrower&#8217;s insurance broker or other insurance specialist stating that all premiums then due on the policies relating to insurance on the Collateral have been paid and that such policies are in full force and effect. Receipt of notice of termination or cancellation of any such insurance policies or reduction of coverages or amounts thereunder shall entitle the Secured Parties to renew any such policies, cause the coverages and amounts thereof to be maintained at levels required pursuant to the first sentence of this </font>Section 8.05 <font style="font-weight:normal;">or otherwise to obtain similar insurance in place of such policies, in each case, the Borrower will be responsible for the reasonable and documented cost of such insurance (to be payable on demand). The amount of any such reasonable and documented expenses shall accrue interest at the Default Rate if not paid on demand and shall constitute &#8220;Obligations.&#8221;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.06</font><a name="_Toc256000371"></a><a name="_Toc256000218"></a><a name="_Toc256000065"></a><a name="_Ref40130153"></a><a name="_Toc69324639"></a><a name="_Toc70875937"></a>Books and Records; Inspection Rights<font style="font-weight:normal;">. Such Obligor will, and will cause each of its Subsidiaries to, keep proper books of record and account in which full, true and correct (in all material respects) entries are made of all dealings and transactions in relation to its business and activities. Such Obligor will, and will cause each of its Subsidiaries to, permit any representatives designated by the Administrative Agent or the Lenders, upon reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs, finances and condition (financial or otherwise) with its officers and independent accountants (so long as a representative of the Borrower is provided a reasonable opportunity to participate in any such discussion), during normal business hours (but not more often than once per year in total for all such visits and inspections unless an Event of Default has occurred and is continuing) as the Administrative Agent or the Lenders may reasonably request; </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"><a name="DocXTextRef381"></a> that such representative shall use its commercially reasonable efforts to minimize disruption to the business and affairs of the Borrower as a result of any such visit, inspection, examination or discussion. Notwithstanding anything to the contrary contained herein or any other provision of the Loan Documents, no Obligor nor any of its Subsidiaries will be required to disclose or permit the inspection or discussion of, any document, information or other matter (i)</font><font style="font-weight:normal;"> that constitutes trade secrets or proprietary information, (ii) in respect of which disclosure to any Lender (or their respective representatives or contractors) is prohibited by any applicable Law or any binding agreement with a third party (so long as such agreement is not entered into in contemplation of this Agreement) or (iii) that is subject to attorney-client or similar privilege, which could reasonably be expected to be lost or forfeited if disclosed to the Administrative Agent or any Lender. The Borrower shall pay all reasonable and documented costs of all such inspections.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.07</font><a name="_Toc256000372"></a><a name="_Toc256000219"></a><a name="_Toc256000066"></a><a name="_Ref40130154"></a><a name="_Toc69324640"></a><a name="_Toc70875938"></a>Compliance with Laws and Other Obligations<font style="font-weight:normal;"><a name="DocXTextRef382"></a>. Such Obligor will, and will cause each of its Subsidiaries to, (i) comply with all Laws (including Anti-Terrorism Laws, Sanctions and Environmental Laws) applicable to it and its business activities, (ii) comply with all Healthcare Laws and Governmental Approvals (including Product Authorizations) applicable to it and its business activities and (iii) maintain in full force and effect, remain in compliance with, and perform all obligations under all Material Agreement to which it is a party, except, in the case of </font>clauses (i)<font style="font-weight:normal;">, </font>(ii) <font style="font-weight:normal;">and </font>(iii) <font style="font-weight:normal;">above, where the failure to do so could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Within 60 days after the Closing Date, each Obligor shall institute (if not already in effect) and thereafter maintain in effect and enforce policies and procedures reasonably designed to promote compliance by such Obligor, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Terrorism Laws and Sanctions. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.08</font><a name="_Toc256000373"></a><a name="_Toc256000220"></a><a name="_Toc256000067"></a><a name="_Ref40130155"></a><a name="_Toc69324641"></a><a name="_Toc70875939"></a>Maintenance of Properties, Etc.<font style="font-weight:normal;white-space:pre-wrap;"> Such Obligor shall, and shall cause each of its Subsidiaries to, maintain and preserve all of its assets and properties, including all assets and properties, whether tangible or intangible, relating to its Products or Product Commercialization and Development Activities, necessary or useful in the conduct of its business in good working order and condition in accordance with the general practice of other Persons of similar character and size, ordinary wear and tear and damage from casualty or condemnation excepted and except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.09</font><a name="_Toc256000374"></a><a name="_Toc256000221"></a><a name="_Toc256000068"></a><a name="_Ref40130156"></a><a name="_Toc69324642"></a><a name="_Toc70875940"></a>Licenses<font style="font-weight:normal;">. Such Obligor shall, and shall cause each of its Subsidiaries to, obtain and maintain all Governmental Approvals necessary in connection with the execution, delivery and performance of the Loan Documents, the consummation of the Transactions or the operation and conduct of its business and ownership of its properties (including its Product Commercialization and Development Activities), except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.10</font><a name="_Toc256000375"></a><a name="_Toc256000222"></a><a name="_Toc256000069"></a><a name="_Toc69324643"></a><a name="_Toc70875941"></a>[Reserved]<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.11</font><a name="_Toc256000376"></a><a name="_Toc256000223"></a><a name="_Toc256000070"></a><a name="_Ref40130158"></a><a name="_Toc69324644"></a><a name="_Ref70778863"></a><a name="_Toc70875942"></a>Use of Proceeds<font style="font-weight:normal;">. The proceeds of the Loans will be used only as provided in </font>Section 2.05<font style="font-weight:normal;">. No part of the proceeds of the Loans will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board of Governors of the Federal Reserve System, including Regulations T, U and X.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.12</font><a name="_Toc256000377"></a><a name="_Toc256000224"></a><a name="_Toc256000071"></a><a name="_Ref40130159"></a><a name="_Toc69324645"></a><a name="_Ref70778876"></a><a name="_Toc70875943"></a>Certain Obligations Respecting Subsidiaries; Further Assurances<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130160"></a><b style="font-weight:bold;">Subsidiary Guarantors, etc</b>. Subject to <b style="font-weight:bold;">clauses (c) </b><a name="DocXTextRef384"></a>and <b style="font-weight:bold;">(d)</b><b style="font-weight:bold;"> </b>below, in the event that the Borrower or any of its Subsidiaries shall form or acquire any new Subsidiary, the Borrower shall promptly (and in any event within thirty (30) calendar days):</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130161"></a>cause such new Subsidiary to become a &#8220;Subsidiary Guarantor&#8221; hereunder pursuant to a Guarantee Assumption Agreement and a &#8220;Grantor&#8221; under the Security Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:72pt;margin:3.59pt 7.1pt 12.5pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:30pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130162"></a>take such action or cause such Subsidiary to take such action (including joining the Security Agreement and delivering shares of stock together with undated transfer powers executed in blank, applicable control agreements and other instruments) as shall be </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:3.59pt 7.1pt 12.5pt 6pt;">reasonably necessary or desirable or reasonably requested by the Administrative Agent in order to create and perfect, in favor of the Administrative Agent, for the benefit of the Secured Parties, valid and enforceable first priority Liens (subject only to Permitted Liens), on substantially all of the personal property of such new Subsidiary as collateral security for the Obligations hereunder as and when required by the terms of the Security Agreement; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that any such security interest or Lien shall be subject to the relevant requirements of the Security Documents and the Intercompany Subordination Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40130163"></a>to the extent that the parent of such Subsidiary is not a party to the Security Agreement or has not otherwise pledged Equity Interests in its Subsidiaries in accordance with the terms of the Security Agreement and this Agreement, cause the parent (if possible) of such Subsidiary to execute and deliver a pledge agreement in favor of the Administrative Agent, for the benefit of the Secured Parties, in respect of all outstanding issued shares of such Subsidiary;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref40130164"></a>deliver such proof of corporate action, incumbency of officers, and other applicable documents as is consistent with those delivered by each Obligor pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">6.01</b> or as the Administrative Agent shall reasonably request; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><a name="_Ref40130165"></a>cause each new Subsidiary (other than any Subsidiary that is neither an Obligor nor a Pledged Entity) to become a party to the Intercompany Subordination Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130166"></a><b style="font-weight:bold;">Further Assurances</b>. Subject to <b style="font-weight:bold;">clauses (c) </b><a name="DocXTextRef386"></a>and <b style="font-weight:bold;">(d)</b><b style="font-weight:bold;"> </b>below:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130167"></a>such Obligor will take such action from time to time as shall reasonably be requested by the Administrative Agent to effectuate the purposes and objectives of this Agreement and the Security Agreement; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130168"></a>in the event that such Obligor acquires Intellectual Property during the term of this Agreement, then the provisions of this Agreement and the Security Agreement shall and hereby does automatically apply thereto and any such Intellectual Property shall automatically constitute part of the Collateral under the Security Documents, without further action by any party, in each case from and after the date of such acquisition; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40130169"></a>without limiting the generality of the foregoing, each Obligor will, and will cause each Person that is required to be a Subsidiary Guarantor to, take such action from time to time (including joining the Security Agreement and delivering shares of stock together with undated transfer powers executed in blank, applicable control agreements and other instruments) as shall be reasonably requested by the Administrative Agent to create, in favor of the Secured Parties, perfected security interests and Liens in substantially all of the personal property (other than Excluded Assets (as defined in the Security Agreement)) of such Obligor as collateral security for the Obligations as and when required by the terms of the Security Agreement; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that any such security interest or Lien shall be subject to the relevant requirements of the Security Documents; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u> that, without limiting the right of the Administrative Agent to require a Lien or security interest in any newly acquired or created Subsidiary or asset, upon the prior written request of the Borrower, the Borrower and the Administrative Agent shall consult, in good faith, as to whether the cost of obtaining a Lien or </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">security interest thereon would be unreasonably excessive relative to the benefit thereof. Notwithstanding anything to the contrary herein or in any other Loan Document, none of the Obligors and their respective Subsidiaries shall be required to take any action in any non-U.S. jurisdiction or required by the Laws of any non-U.S. jurisdiction to create any security interests in assets located or titled outside of the United States or to perfect or make enforceable any security interests in any such assets (it being understood that there shall be no security agreements, pledge agreements or other collateral documents governed under the laws of any jurisdiction other than the United States, any State thereof or the District of Columbia).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130170"></a><b style="font-weight:bold;">CFCs, etc</b>.<font style="display:inline-block;width:19.02pt;"></font><a name="DocXTextRef387"></a><a name="DocXTextRef388"></a>Notwithstanding any term or provision of this Agreement to the contrary, (x) no Subsidiary that is a (i) CFC, (ii) CFC Holding Company or (iii) Domestic Subsidiary of either of the foregoing, shall be required to become a Subsidiary Guarantor, and (y) the Obligors shall not be required to pledge (or cause to be pledged) to the Administrative Agent, for the benefit of the Secured Parties, Equity Interests of any Subsidiary representing, in the aggregate, more than sixty-five percent (65%) of the Equity Interests of any CFC or CFC Holding Company; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that the above restrictions shall apply only to the extent the Borrower reasonably determines (after consultation with the Administrative Agent) that the failure to impose such restrictions could reasonably be expected to generate material adverse tax consequences to the Borrower or any of its Subsidiaries (as determined in good faith from time to time); provided, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, that if the burden, cost or consequences of causing any such Subsidiary in clause (x) to become a Subsidiary Guarantor is excessive in relation to the benefits to be obtained by the Secured Parties under the Loan Documents as reasonably determined by the Administrative Agent, then such Subsidiary shall not be required to become a Subsidiary Guarantor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Limitations on Certain Obligations</b>. Notwithstanding anything to the contrary contained in this Agreement or any other Loan Document, no Obligor shall be required to enter into or obtain any mortgage, deed of trust, leasehold mortgage or any similar agreement in respect to any fee interest or leasehold interest in real property.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.13</font><a name="_Toc256000378"></a><a name="_Toc256000225"></a><a name="_Toc256000072"></a><a name="_Ref40130172"></a><a name="_Toc69324646"></a><a name="_Toc70875944"></a>Termination of Non-Permitted Liens<font style="font-weight:normal;">. In the event that any Obligor shall become aware of, or be notified by the Administrative Agent or any Lender of the existence of, any outstanding Lien against any assets or property of such Obligor or any of its Subsidiaries, which Lien is not a Permitted Lien, such Obligor shall use its commercially reasonable efforts to promptly terminate or cause the termination of such Lien.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:8pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.14</font><a name="_Toc256000379"></a><a name="_Toc256000226"></a><a name="_Toc256000073"></a><a name="_Toc69324647"></a><a name="_Toc70875945"></a><a name="_Ref40130173"></a>Board Materials<font style="font-size:11pt;font-weight:normal;line-height:1.28;">. </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;line-height:1.28;"><a name="_Ref32683303"></a><a name="_Ref26142022"></a><a name="_Toc480909609"></a></font><font style="font-size:11pt;font-weight:normal;line-height:1.28;">The Borrower shall deliver to the Administrative Agent: (i) copies of any agenda and other written materials provided to the board of directors (or any committee thereof) of the Borrower prior to any meeting of the board of directors (or such committee thereof), at or promptly after such materials are furnished to the members of the board of directors (or such committee thereof), (ii) copies of all minutes of meetings of the board of directors (or any committee thereof) of the Borrower at or promptly after such minutes are furnished to the members of the board of directors (or such committee thereof), (iii) copies of all material written consents duly passed by the board of directors (or any committee thereof) of the Borrower and </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;line-height:1.28;"><a name="DocXTextRef309"></a></font><font style="font-size:11pt;font-weight:normal;line-height:1.28;">(iv)</font><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> promptly upon presentation of any regular periodic materials to the board of directors (or any committee thereof) of the Borrower reporting on the current, past or future financial performance and business and operations of the Borrower or any of its Subsidiaries (which shall include, among other things, development updates with respect to material Products, and </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">updates with respect to material events relating to other Material Agreements), copies of such materials; </font><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;"> that any such material may be redacted by the Borrower to (A) exclude information relating to the performance of the Administrative Agent or any Lender, to Borrower&#8217;s strategy regarding the Loans or performance or non-performance under the Loan Documents or to </font><u style="border-bottom-style:solid;border-bottom-width:0.5pt;color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;text-decoration:underline;">matters of conflict of interest to the Administrative Agent or any Lender</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">, (B) preserve attorney-client privilege or (C) protect individually identifiable health information (as defined under HIPAA) or other confidential information relating to healthcare patients; </font><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">, </font><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;text-decoration:underline;text-decoration-color:#000000;">further</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;"> that such redactions are restricted so as to be only as extensive as is reasonably necessary in order to exclude information described in clauses (A), (B) or (C); </font><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">, </font><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;text-decoration:underline;text-decoration-color:#000000;">further</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;"> that documents required to be furnished pursuant to this Section </font><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;line-height:1.28;text-align:left;">8.14 </b><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">shall be deemed furnished on the date that such documents are posted to the Borrower&#8217;s board portal to which the Administrative Agent has been granted access.</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;"> </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.15</font><a name="_Toc40400709"></a><a name="_Toc40400710"></a><a name="_Toc70875946"></a><a name="_Toc69324648"></a><a name="_Ref40130174"></a><a name="_Toc256000074"></a><a name="_Toc256000227"></a><a name="_Toc256000380"></a>[Reserved]<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.16</font><a name="_Toc256000381"></a><a name="_Toc256000228"></a><a name="_Toc256000075"></a><a name="_Toc40859644"></a><a name="_Toc69324649"></a><a name="_Ref70778910"></a><a name="_Toc70875947"></a><a name="_Ref40130175"></a>Maintenance of Regulatory Approvals, Contracts, Intellectual Property, Etc.<font style="font-weight:normal;"><a name="DocXTextRef390"></a>. With respect to the Products and all Product Commercialization and Development Activities, such Obligor will, and will cause each of its Subsidiaries (to the extent applicable) to, (i) maintain in full force and effect all Material Product Authorizations, Material Agreements, Material Intellectual Property and other rights, interests or assets (whether tangible or intangible) reasonably necessary for the operations of the business of Borrower and its Subsidiaries, except as would not reasonably be expected to have a Material Adverse Effect, (ii)&#160;<a name="DocXTextRef393"></a>maintain in full force and effect, and pay all costs and expenses relating to, such Regulatory Approvals, Material Agreements and Material Intellectual Property owned, used or controlled by such Obligor or any such Subsidiary that are used in or necessary for any related Product Commercialization and Development Activities, except as would not be reasonably expected to have </font><font style="font-weight:normal;">a Material Adverse Effect, (iii)</font><font style="font-weight:normal;"> promptly after obtaining knowledge thereof, notify the Administrative Agent of any material violation, misappropriation or other infringement by any Person of such Obligor&#8217;s or any such Subsidiaries&#8217; Material Intellectual Property, and use commercially reasonable efforts to stop, curtail or abate such violation, misappropriation or infringement if determined appropriate by the Borrower in the exercise of its business judgment and (iv) except as set forth on </font>Schedule 7.05(b)<font style="font-weight:normal;">, promptly after obtaining knowledge thereof, notify the Administrative Agent of any Claim by any Person that the conduct of the business of Borrower or any of its Subsidiaries, including in connection with any Product Commercialization and Development Activities, has violated, misappropriated or otherwise infringed any Intellectual Property of such Person, where such Claim could reasonably be expected to have a Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.17</font><a name="_Toc256000382"></a><a name="_Toc256000229"></a><a name="_Toc256000076"></a><a name="_Ref40130176"></a><a name="_Toc69324650"></a><a name="_Toc70875948"></a>ERISA Compliance<font style="font-weight:normal;">. Such Obligor shall comply, and shall cause each of its Subsidiaries to comply, with the provisions of ERISA with respect to any Plans to which such Obligor or such Subsidiary is a party as an employer, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.18</font><a name="_Toc256000383"></a><a name="_Toc256000230"></a><a name="_Toc256000077"></a><a name="_Ref40130177"></a><a name="_Toc69324651"></a><a name="_Ref70778923"></a><a name="_Toc70875949"></a>Cash Management<font style="font-weight:normal;">. Such Obligor shall, and shall cause each of its Subsidiaries to:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130178"></a>maintain at all times after the Account Control Agreement Completion Date an aggregate amount of cash of the Borrower and its Subsidiaries equal to the Minimum Liquidity Amount in deposit accounts, disbursement accounts, investment accounts (and other similar </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">accounts) and lockboxes with a bank or financial institution within the U.S. which has executed and delivered to the Administrative Agent an account control agreement, in form and substance reasonably acceptable to the Administrative Agent (each such deposit account, disbursement account, investment account (or similar account) and lockbox, a &#8220;<font style="font-style:italic;font-weight:bold;">Controlled Account</font>&#8221;); each such Controlled Account shall be a cash collateral account, with all cash, checks and other similar items of payment in such account securing payment of the Obligations, and each Obligor shall have granted a Lien to the Administrative Agent, for the benefit of the Secured Parties, over such Controlled Accounts;<font style="font-size:10pt;white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130179"></a>deposit promptly, and in any event no later than five (5) Business Days after the date of receipt thereof (or such longer period of time as agreed by the Administrative Agent in its sole discretion), all cash, checks, drafts or other similar items of payment in an amount in excess of $250,000 and relating to or constituting payments made in respect of any and all accounts and other rights and interests into (i) on and after the Account Control Agreement Completion Date, Controlled Accounts and (ii) prior to the Account Control Agreement Completion Date, deposit accounts held by the Obligors in the United States; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that this <b style="font-weight:bold;">Section 8.18(b)</b> shall not apply to any Foreign Subsidiary to the extent that the Borrower reasonably determines (after consultation with the Administrative Agent) that imposing such obligations on a Foreign Subsidiary could reasonably be expected to generate material adverse tax consequences to the Borrower or any of its Subsidiaries (as determined in good faith from time to time); and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130180"></a>at any time after the occurrence and during the continuance of an Event of Default, at the request of the Administrative Agent, each Obligor shall cause all payments constituting proceeds of accounts to be directed into lockbox accounts under agreements in form and substance satisfactory to the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">8.19</font><a name="_Toc256000384"></a><a name="_Toc256000231"></a><a name="_Toc256000078"></a><a name="_Toc70875950"></a><a name="_Ref70778934"></a>Post-Closing Obligations<font style="font-weight:normal;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Controlled Accounts</b><font style="white-space:pre-wrap;">.  Within thirty (30) days following the Closing Date (or such longer period of time as agreed by the Administrative Agent in its sole discretion) (the &#8220;</font><font style="font-style:italic;font-weight:bold;">Account Control Agreement Completion Date</font>&#8221;), the Administrative Agent shall have received evidence that (i) all deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts (other than Excluded Accounts) of each Obligor located within the U.S. are Controlled Accounts to the extent required to comply with the requirement of <b style="font-weight:bold;">Section 8.18</b> and (ii) such Controlled Accounts are subject to one or more account control agreements, in favor of, and in form and substance reasonably satisfactory to, the Administrative Agent that (A) ensures, to the extent necessary under applicable Law, the perfection of a first priority security interest in favor of the Administrative Agent on such Controlled Account, subject only to Permitted Liens, (B) provides that, upon written notice from the Administrative Agent, such bank or financial institution shall comply with instructions originated by the Administrative Agent directing disposition of the funds in such Controlled Account without further consent by the applicable Obligor, and (C) may not be terminated by the applicable Obligor without prior written consent of the Administrative Agent; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Within ninety (90) days after the Closing Date, (or such longer period of time as agreed by the Administrative Agent in its sole discretion), the Borrower shall use commercially </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">reasonable efforts to obtain a Landlord Consent with respect to the leased property at 5 Radnor Corporate Center, 100 Matsonford Rd, Suite 500, Radnor, PA 19087.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Hlk71299965"></a>Within thirty (30) days following the Closing Date (or such longer period of time as agreed by the Administrative Agent in its sole discretion), all such insurance policies required pursuant to each Loan Document shall name the Administrative Agent (for its benefit and the benefit of the Lenders) loss payee or additional insured, as applicable, and provide that no cancellation of the policies will be made without at least ten (10) days prior written notice to the Administrative Agent and the Administrative Agent shall have received certified copies of such insurance policies (or binders in respect thereof).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 9.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000385"></a><a name="_Toc256000232"></a><a name="_Toc256000079"></a><a name="_Ref40130188"></a><a name="_Toc69324652"></a><a name="_Toc70875951"></a>NEGATIVE COVENANTS</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Obligor covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made), have been indefeasibly paid in full in cash:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.01</font><a name="_Toc256000386"></a><a name="_Toc256000233"></a><a name="_Toc256000080"></a><a name="_Ref40130189"></a><a name="_Toc69324653"></a><a name="_Toc70875952"></a>Indebtedness<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or indirectly, except:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130190"></a>the Obligations;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130191"></a>Indebtedness existing on the date hereof and set forth on <b style="font-weight:bold;">Schedule 7.13(a) </b>and Permitted Refinancings thereof; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that, if such Indebtedness is intercompany Indebtedness, such Indebtedness shall be subject to the Intercompany Subordination Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130192"></a>accounts payable to trade creditors for goods and services and current operating liabilities (not the result of the borrowing of money) incurred in the ordinary course of such Obligor&#8217;s or such Subsidiary&#8217;s business in accordance with customary terms and paid within the specified time, unless contested in good faith by appropriate proceedings and reserved for in accordance with GAAP;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130193"></a>Indebtedness consisting of guarantees resulting from the endorsement of negotiable instruments for collection in the ordinary course of business;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130194"></a>Indebtedness of an Obligor owing to any other Obligor or a Pledged Entity owing to any other Pledged Entity, in each case subject to the Intercompany Subordination Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130195"></a>Indebtedness of any Subsidiary that is neither an Obligor nor a Pledged Entity owing to any other Subsidiary that is neither an Obligor nor a Pledged Entity;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130196"></a>Indebtedness of any Obligor or any Pledged Entity owing to any Subsidiary that is not an Obligor, subject to the Intercompany Subordination Agreement; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> any Indebtedness owing by an Obligor to a Pledged Entity shall not exceed $5,000,000 in the aggregate outstanding at any one time;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40130197"></a>[reserved];</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130198"></a>Guarantees by any Obligor of Permitted Indebtedness of any other Obligor;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40130199"></a>Ordinary Course equipment and software financing and leasing (including Capital Leases and purchase money Indebtedness); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><a name="DocXTextRef410"></a> that (i) if secured, the collateral therefor consists solely of the assets being financed, the products and proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding principal amount of such Indebtedness does not exceed $10,000,000 (or the Equivalent Amount in other currencies) at any time;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40130200"></a><a name="_Hlk71100156"></a>Indebtedness under (i) Permitted Hedging Agreements and (ii) Permitted Bond Hedge Transactions, in the case of (ii) not exceeding, net of the proceeds of any Permitted Warrant Transactions entered in connection therewith, 15% of the proceeds obtained in the related Permitted Convertible Debt issuance;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref40130201"></a><a name="_Hlk71100126"></a>Indebtedness assumed pursuant to any Permitted Acquisition; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><a name="DocXTextRef412"></a> that (i) no such Indebtedness (individually) shall exceed 15% of the total purchase price paid in connection with such Permitted Acquisition, (ii) the aggregate outstanding principal amount of Indebtedness permitted pursuant to this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.01(l)</b><b style="font-weight:bold;"> </b>shall not exceed $10,000,000 (or the Equivalent Amount in other currencies) at any time outstanding and (iii) no such Indebtedness was created or incurred in connection with, or in contemplation of, such Permitted Acquisition;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_Ref40130202"></a>[reserved]; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><a name="_Ref42521273"></a>Indebtedness pursuant to any Revenue Interest Financing; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><a name="_Ref40130203"></a>other Indebtedness in an aggregate outstanding principal amount not to exceed $10,000,000 (or the Equivalent Amount in other currencies); </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font>Permitted Convertible Debt; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that the aggregate principal amount of Indebtedness incurred pursuant to this <u style="text-decoration:underline;text-decoration-color:#000000;">clause (p)</u> shall not exceed $250,000,000 at any time outstanding; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(q)</font><a name="_Ref447711319"></a><a name="_Ref42517529"></a>Indebtedness in respect of letters of credit, bank guarantees, bankers&#8217; acceptances or similar instruments issued or created, or related to obligations or liabilities incurred, in the ordinary course of business, including in respect of workers compensation claims, health, disability or other employee benefits or property, leases, commercial contracts, Indebtedness permitted pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 9.01(s)</u>, casualty or liability insurance or self-insurance or other reimbursement-type obligations regarding workers compensation claims;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(r)</font><a name="_Ref42517536"></a>Indebtedness arising in connection with the financing of insurance premiums in the ordinary course of business;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(s)</font><a name="_Ref42517552"></a>Indebtedness in respect of (i) performance bonds, bid bonds, appeal bonds, surety bonds and completion guarantees and similar obligations arising in the ordinary course of business and (ii) customary indemnification obligations to purchasers in connection with Asset Sales permitted by <b style="font-weight:bold;">Section 9.09</b>;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(t)</font><a name="_Ref42517555"></a>Indebtedness in respect of netting services, overdraft protections, business credit cards, purchasing cards, payment processing, automatic clearinghouse arrangements, arrangements in respect of pooled deposit or sweep accounts, check endorsement guarantees, and otherwise in connection with deposit accounts or cash management services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(u)</font>purchase price adjustments, indemnity payments and other Deferred Acquisition Consideration in connection with any Permitted Acquisition, in each case that are permitted pursuant to the definition of &#8220;Permitted Acquisition&#8221;; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>Permitted Refinancings of any items of Permitted Indebtedness (a)&#160;through (u) &#160;above.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.02</font><a name="_Toc256000387"></a><a name="_Toc256000234"></a><a name="_Toc256000081"></a><a name="_Ref40130204"></a><a name="_Toc69324654"></a><a name="_Toc70875953"></a>Liens<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on any property now owned by it or such Subsidiary, except:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130205"></a>Liens securing the Obligations;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130206"></a>any Lien on any property or asset of such Obligor or any of its Subsidiaries existing on the date hereof and set forth on <b style="font-weight:bold;">Schedule 7.13(b) </b>and renewals and extensions thereof in connection with Permitted Refinancings of the Indebtedness being secured by such Lien; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><a name="DocXTextRef414"></a> that (i) no such Lien (including any renewal or extension thereof) shall extend to any other property or asset of such Obligor or any of its Subsidiaries and (ii) any such Lien shall secure only those obligations which it secures on the date hereof and renewals, extensions and replacements thereof in connection with Permitted Refinancings of the Indebtedness being secured by such Lien that do not increase the outstanding principal amount thereof (other than by an amount equal to unpaid interest and premiums thereon, including tender premium, and any customary underwriting discounts, fees, commissions and expenses associated with such extension, renewal or replacement);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130207"></a>Liens securing Indebtedness permitted under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.01(j)</b>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that such Liens are restricted solely to the collateral described in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.01(j)</b>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130208"></a><a name="DocXTextRef417"></a><a name="DocXTextRef418"></a>Liens imposed by any Law arising in the ordinary course of business, including (but not limited to) carriers&#8217;, warehousemen&#8217;s, landlords&#8217;, and mechanics&#8217; liens, liens relating to leasehold improvements and other similar Liens arising in the ordinary course of business and which (x) do not in the aggregate materially detract from the value of the property subject thereto or materially impair the use thereof in the operations of the business of such Person or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing the forfeiture or sale of the property subject to such Liens and for which adequate reserves have been made if required in accordance with GAAP;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130209"></a>pledges or deposits made in the Ordinary Course in connection with bids, contract leases, appeal bonds, workers&#8217; compensation, unemployment insurance or other similar social security legislation;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130210"></a>Liens securing Taxes, assessments and other governmental charges, the payment of which is not past due or is being contested in good faith by appropriate proceedings promptly </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">initiated and diligently conducted and for which such reserve or other appropriate provisions, if any, as shall be required by GAAP shall have been made;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130211"></a>servitudes, easements, rights of way, restrictions and other similar encumbrances on real property imposed by any Law and Liens consisting of zoning or building restrictions, easements, licenses, restrictions on the use of real property or minor imperfections in title thereto which, in the aggregate, are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors or any of their Subsidiaries; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40130212"></a><a name="DocXTextRef419"></a>with respect to any real property, (i) such defects or encroachments as might be revealed by an up-to-date survey of such real property; (ii) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by the original owner of such real property pursuant to all applicable Laws; and (iii) rights of expropriation, access or user or any similar right conferred or reserved by or in any Law, which, in the aggregate for <b style="font-weight:bold;">clauses (i)</b>, <b style="font-weight:bold;">(ii) </b>and <b style="font-weight:bold;">(iii)</b>, are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors or its Subsidiaries;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130213"></a>Bankers liens, rights of setoff and similar Liens incurred on deposits or other assets credited to any deposit or securities account made in the Ordinary Course;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40130214"></a>Liens securing Indebtedness permitted under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.01(l)</b>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><a name="DocXTextRef420"></a> that (i)&#160;such Lien is not created in contemplation of or in connection with such Permitted Acquisition pursuant to which such Indebtedness was assumed, (ii) such Lien shall not apply to any other property or assets of the Borrower or any Subsidiary and (iii) such Lien shall secure only those obligations that it secured immediately prior to the consummation of such Permitted Acquisition and extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font>Liens securing Indebtedness permitted under <b style="font-weight:bold;">Sections 9.01(q), (r), (s)</b> and <b style="font-weight:bold;">(t)</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref40130216"></a>Any judgment lien or lien arising from decrees or attachments not constituting an Event of Default;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_Ref40130217"></a>Liens arising from precautionary UCC financing statement filings regarding operating leases of personal property and consignment arrangements entered into in the Ordinary Course in an Arm&#8217;s Length Transaction; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><a name="_Ref40130218"></a>other Liens which secure obligations in an aggregate amount not to exceed $5,000,000 (or the Equivalent Amount in other currencies) at any time outstanding;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><a name="_Ref43192642"></a>To the extent permitted by the definition of Revenue Interest Financing, Liens securing Indebtedness permitted under clause (n) of <b style="font-weight:bold;">Section 9.01</b> and which are subject to a Permitted Intercreditor Agreement;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font><a name="_cp_text_2_4047"></a>Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods and incurred in the ordinary course of business; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(q)</font>Permitted Licenses;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(r)</font>Liens on cash and Cash Equivalents securing obligation under Permitted Hedging Agreements; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(s)</font>(i) Liens to secure payment of workers&#8217; compensation, employment insurance, old age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA) and (ii) deposits in respect of letters of credit, bank guarantees or similar instruments issued for the account of any Obligor or any Subsidiary in the Ordinary Course supporting obligations of the type set forth in clause (i) above;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(t)</font>to the extent constituting a Lien, customary cash escrow arrangements securing indemnification obligations associated with a Permitted Acquisition or any other Investment permitted under <b style="font-weight:bold;">Section 9.05</b> not to exceed $5,000,000 in the aggregate; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(u)</font>Liens of a collection bank arising under Section 4-210 of the Uniform Commercial Code on items in the course of collection;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>Liens of sellers of goods to the Borrower and any of its Subsidiaries arising under Article 2 of the Uniform<font style="letter-spacing:-0.15pt;"> Commercial Code </font>or similar provisions of applicable law in the ordinary course of business, covering only the goods sold and securing only the unpaid purchase price for such goods and related expenses;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(w)</font>rights of first refusal, voting, redemption, transfer or other restrictions (including call provisions and buy-sell provisions) with respect to the Equity Interests of any Joint Venture or other Persons that are not Subsidiaries; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(x)</font>any Lien arising under conditional sale, title retention, consignment or similar arrangements for the sale of goods in the Ordinary Course; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that such Lien attaches only to the goods subject to such sale, title retention, consignment or similar arrangement. </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that no Lien otherwise permitted under any of the foregoing <b style="font-weight:bold;">clauses (c), (d), (e)</b>,<b style="font-weight:bold;"> (g)</b> through<b style="font-weight:bold;"> (k), (m), (n), (p)</b> and <b style="font-weight:bold;">(r)</b> through <b style="font-weight:bold;">(x) </b>of this<b style="font-weight:bold;"> Section 9.02 </b>shall apply to any Material Intellectual Property.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.03</font><a name="_Toc256000388"></a><a name="_Toc256000235"></a><a name="_Toc256000082"></a><a name="_Ref40130219"></a><a name="_Toc69324655"></a><a name="_Toc70875954"></a>Fundamental Changes and Acquisitions<font style="font-weight:normal;"><a name="DocXTextRef423"></a>. Such Obligor will not, and will not permit any of its Subsidiaries to, (i) enter into any transaction of merger, amalgamation or consolidation, (ii) liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution), (iii) sell or issue any of its Disqualified Equity Interests or (iv) other than Permitted Acquisitions and </font><font style="font-weight:normal;letter-spacing:-0.15pt;">any Acquisition permitted by </font><b style="font-weight:bold;letter-spacing:-0.15pt;">Section 9.05(a)</b><font style="font-weight:normal;letter-spacing:-0.15pt;"> or </font><b style="font-weight:bold;letter-spacing:-0.15pt;">Section 9.05(s)</b><font style="font-weight:normal;">, make any Acquisition or otherwise acquire any business or substantially all the property from, or Equity Interests of, or be a party to any Acquisition of, any Person, except:</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130220"></a><a name="DocXTextRef424"></a>the merger, amalgamation or consolidation or liquidation of any (i) Subsidiary with or into any Obligor or Pledged Entity; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><a name="DocXTextRef425"></a><a name="DocXTextRef426"></a> that with respect to any such transaction involving (x) the Borrower, the Borrower must be the surviving or successor entity of such transaction, (y) any other Obligor, such Obligor must be the surviving or successor entity of such transaction<font style="letter-spacing:-0.15pt;"> </font><a name="DocXTextRef427"></a>or the surviving Person shall concurrently therewith become an Obligor (unless such transaction involves more than one Obligor, then an Obligor must be the surviving or successor entity of such transaction) and (z) any Pledged Entity (but not a transaction involving the Borrower or another Obligor, which is subject to <b style="font-weight:bold;">clauses (x) </b><a name="DocXTextRef428"></a>and <b style="font-weight:bold;">(y)</b><b style="font-weight:bold;"> </b>above, respectively), such Pledged Entity must be the surviving or successor entity of such transaction (unless such transaction involves more than one Pledged Entity, then a Pledged Entity must be the surviving or successor entity of such transaction) or (ii) any Subsidiary that is not an Obligor nor a Pledged Entity with or into any other Subsidiary that is not an Obligor nor a Pledged Entity;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130221"></a><a name="DocXTextRef429"></a>the sale, lease, transfer or other disposition by (i) any Subsidiary of any or all of its property (upon voluntary liquidation or otherwise) to any Obligor, (ii) any Subsidiary that is not an Obligor of any or all of its property (upon voluntary liquidation or otherwise) to any Pledged Entity or (iii) any Subsidiary that is neither an Obligor nor a Pledged Entity of any or all of its property (upon voluntary liquidation or otherwise) to any other Subsidiary that is neither an Obligor nor a Pledged Entity; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130222"></a><a name="DocXTextRef430"></a>the sale, transfer or other disposition of the Equity Interests of (i) any Subsidiary to any Obligor, (ii) any Subsidiary that is not an Obligor to any Pledged Entity or (iii) any Subsidiary that is neither an Obligor nor a Pledged Entity to any other Subsidiary that is neither an Obligor nor a Pledged Entity; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>mergers, amalgamations or consolidations of any Subsidiary to effectuate an Asset Sales permitted under <b style="font-weight:bold;">Section 9.09</b>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that such merger, amalgamation or consolidation does not include the Borrower; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>in connection with any Permitted Acquisition or other Investment permitted under <b style="font-weight:bold;">Section 9.05</b>, the Borrower or any Subsidiary of the Borrower may merge into or consolidate with any other Person or permit any other Person to merge into or consolidate with it, so long as (i) the Person surviving such merger with any Subsidiary shall be a direct or indirect wholly-owned Subsidiary of the Borrower, (ii) in the case of any such merger to which the Borrower is a party, the Borrower is the surviving Person, and (iii) in the case of any such merger to which a Subsidiary Guarantor is a party, the surviving Person is <font style="letter-spacing:-0.15pt;">such Subsidiary Guarantor or concurrently therewith becomes a Subsidiary Guarantor; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_cp_blt_1_3770"></a>any Subsidiary may dissolve, liquidate or wind up its affairs at any time, provided, that, such dissolution, liquidation or winding up could not reasonably be expected to have a Material Adverse Effect and all of its assets and business are transferred to an Obligor or solely in the case of a Subsidiary that is not an Obligor, another Subsidiary that is not an Obligor prior to or concurrently with such dissolution, liquidation or winding up. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.04</font><a name="_Toc40400720"></a><a name="_Toc70875955"></a><a name="_Toc69324656"></a><a name="_Ref40130224"></a><a name="_Toc256000083"></a><a name="_Toc256000236"></a><a name="_Toc256000389"></a>Lines of Business<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to, engage in any business other than the business engaged in on the date hereof by such Persons or </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">a business reasonably related, incidental or complementary thereto or reasonable expansions or extensions thereof.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.05</font><a name="_Toc256000390"></a><a name="_Toc256000237"></a><a name="_Toc256000084"></a><a name="_Ref40130225"></a><a name="_Toc69324657"></a><a name="_Toc70875956"></a>Investments<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to, make, directly or indirectly, or permit to remain outstanding any Investments except:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130226"></a>Investments (but without giving effect to the cash return provision contained in the definition thereof) outstanding on the date hereof and identified in <b style="font-weight:bold;">Schedule 9.05(a) </b>and any renewals, amendments and replacements thereof that do not increase the amount thereof of any such Investment, net of cash returns thereon, or require that any additional Investment be made (unless otherwise permitted hereunder);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130227"></a>deposit accounts with banks (or similar deposit-taking institutions) and securities accounts maintained by the Obligors and their respective Subsidiaries, which in the case of the Obligors shall, after the Account Control Agreement Completion Date, be Controlled Accounts (unless Excluded Accounts);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130228"></a>extensions of credit in the nature of accounts receivable or notes receivable arising from the sales of goods or services in the Ordinary Course in an Arm&#8217;s Length Transaction;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130229"></a>Cash Permitted Cash Equivalent Investments, which in the case of the Obligors shall be maintained after the Account Control Agreement Completion Date in Controlled Accounts (unless maintained in Excluded Accounts);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130230"></a>Investments by an Obligor in another Obligor;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130231"></a>Investments by a Subsidiary that is not an Obligor in any other Subsidiary that is not an Obligor;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130232"></a>Permitted Hedging Agreements;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40130233"></a>Investments consisting of prepaid expenses, deposits under commercial contracts for the purchase of assets, negotiable instruments held for collection or deposit, security deposits with utilities, landlords and other like Persons and deposits in connection with workers&#8217; compensation and similar deposits, in each case, made in the Ordinary Course, and other deposits and cash collateral constituting Permitted Liens;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130234"></a>employee, officer and director loans, travel advances and guarantees in accordance with the Borrower&#8217;s usual and customary practices with respect thereto (if permitted by applicable Laws) and non-cash loans to employees, officers, or directors relating to the purchase of Equity Interests of the Borrower pursuant to employee stock purchase plans or agreements, which in the aggregate shall not exceed $2,500,000 outstanding at any time (or the Equivalent Amount in other currencies);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40130235"></a>Investments received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients and in settlement of delinquent obligations of, and other disputes with, customers, suppliers or clients;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40130236"></a>the increase in value of any Investment otherwise permitted pursuant to this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.05</b>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref40130237"></a>other Investments in an aggregate amount not to exceed $10,000,000 (or the Equivalent Amount in other currencies) in any fiscal year;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font>Investments of any Person in existence at the time such Person becomes a Subsidiary&#894; provided such Investment was not made in connection with or anticipation of such Person becoming a Subsidiary and any modification, replacement, renewal or extension thereof; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><a name="_Ref40130238"></a>Investments permitted under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.03</b>; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font>Permitted Acquisitions and earnest money deposits in connection with Permitted Acquisitions and Investments acquired as a result of a Permitted Acquisition to the extent that such Investments were not made in contemplation of or in connection with such Permitted Acquisition and were in existence prior to the date of such Permitted Acquisition; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font>Investments consisting of the non-cash portion of the sales consideration received by the Borrower or any of its Subsidiaries in connection with any Asset Sale permitted under <b style="font-weight:bold;">Section 9.09</b>; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(q)</font>Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(r)</font>to the extent constituting Investments, Guarantees of Indebtedness, which Guarantees are permitted under <b style="font-weight:bold;">Section 9.01</b>; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(s)</font>Investments contemplated by <b style="font-weight:bold;">Schedule </b><b style="font-weight:bold;">9.05</b><b style="font-weight:bold;">(s)</b>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(t)</font><a name="_cp_blt_1_3868"></a>to the extent constituting Investments, Investments in the form of Permitted Bond Hedge Transactions and Permitted Warrant Transactions, in each case, entered into in connection with Permitted Convertible Debt; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(u)</font>Investments consisting of Permitted Liens.</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding anything in this Agreement to the contrary, (i) the Borrower shall not, and shall not permit any of its Subsidiaries to (x) directly or indirectly transfer, by means of contribution, sale, assignment, lease or sublease, license or sublicense, or other disposition of any kind (including, for avoidance of doubt, as an Investment, Restricted Payment or Asset Sale), any Material Intellectual Property other than (I) pursuant to Permitted Licenses or (II) as permitted pursuant to </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Section 9.09(g)</b><font style="font-family:'Times New Roman','Times','serif';"> or </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(n)</b><font style="font-family:'Times New Roman','Times','serif';"> or (y) permit any Person other than the Borrower or a Subsidiary Guarantor to license or own any interest in such Material Intellectual Property owned by the Borrower or such Subsidiary Guarantor other than pursuant to (I) Permitted Licenses or (II) as permitted pursuant to </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Section 9.09(g)</b><font style="font-family:'Times New Roman','Times','serif';"> or </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(n)</b><font style="font-family:'Times New Roman','Times','serif';">, and (ii) no Material Intellectual Property shall be contributed as an Investment or distributed as a Restricted Payment to any Subsidiary other than a Subsidiary Guarantor (other than pursuant to Permitted Licenses).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.06</font><a name="_Toc256000391"></a><a name="_Toc256000238"></a><a name="_Toc256000085"></a><a name="_Ref40130239"></a><a name="_Toc69324658"></a><a name="_Toc70875957"></a>Restricted Payments<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment; </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"> that the following Restricted Payments shall be permitted so long as no Event of Default has occurred and is continuing or could reasonably be expected to occur or result from such Restricted Payment:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130240"></a>dividends with respect to the Borrower&#8217;s Equity Interests payable solely in shares of its Qualified Equity Interests (or the equivalent thereof);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130241"></a>the Borrower&#8217;s purchase, redemption, retirement, or other acquisition of shares of its Equity Interests with the proceeds received from a substantially concurrent issue of new shares of its Qualified Equity Interests;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130242"></a>each Subsidiary that is an Obligor may make Restricted Payments to any other Obligor, and (ii) each Subsidiary that is not an Obligor may make Restricted Payments to an Obligor and to another Subsidiary that is not an Obligor and pro rata Restricted Payments to minority stockholders of any such Subsidiary;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130243"></a>any purchase, redemption, retirement or other acquisition of Equity Interests of the Borrower held by consultants, officers, directors and employees or former consultants, officers, directors or employees (or their transferees, estates, or beneficiaries under their estates) of Borrower and its Subsidiaries not to exceed $1,000,000 (or the Equivalent Amount in other currencies) in any fiscal year (it being agreed that, to the extent constituting an Investment permitted by <b style="font-weight:bold;">Section 9.05(i)</b>, the amount of any Indebtedness of such Persons owing to the Borrower or any Subsidiary forgiven in connection with such Restricted Payment shall be excluded from any determination pursuant to this clause (d)); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the portion of such basket that is not used by the Borrower or its Subsidiaries in any fiscal year shall be carried-forward and shall increase such basket for succeeding fiscal years;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130244"></a>cashless repurchases of Equity Interests deemed to occur upon exercises of options and warrants;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130245"></a>cash payments made by the Borrower to redeem, purchase, repurchase or retire its obligations under options, warrants and other convertible securities issued by it in the nature of customary cash payments in lieu of fractional shares in accordance with the terms thereof; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font>Borrower may acquire (or withhold) its Equity Interests pursuant to any employee stock option or similar plan to pay withholding taxes for which Borrower is liable in respect of a current or former officer, director, employee, member of management or consultant upon such grant or award (or upon vesting or exercise thereof) and the Borrower may make deemed repurchases in connection with the exercise of stock options; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_cp_change_362"></a>any payment of interest, principal or fees in respect of any Indebtedness owed by any Obligor or any of its Subsidiaries to any holder of any Equity Interests of any Obligor or any of its Subsidiaries, in each case to the extent permitted under <b style="font-weight:bold;">Section 9.07</b>; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130246"></a>so long as no Default or Event of Default has occurred and is continuing (or could reasonably be expected to occur after giving effect to such Restricted Payment), other Restricted </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Payments in an aggregate amount not to exceed $1,000,000 (or the Equivalent Amount in other currencies) in any fiscal year.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:8pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.07</font><a name="_Toc67489139"></a><a name="_Toc67489666"></a><a name="_Toc67500596"></a><a name="_Toc70875958"></a><a name="_Toc69324659"></a><a name="_Ref40130247"></a><a name="_Toc256000086"></a><a name="_Toc256000239"></a><a name="_Toc256000392"></a>Payments of Indebtedness<font style="font-size:11pt;font-weight:normal;line-height:1.28;">. Such Obligor will not, and will not permit any of its Subsidiaries to, make any payments in respect of any Indebtedness other than </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;line-height:1.28;"><a name="DocXTextRef439"></a></font><font style="font-size:11pt;font-weight:normal;line-height:1.28;">(i)</font><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> payments of the Obligations, (ii) </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;line-height:1.28;"><a name="DocXTextRef438"></a></font><font style="font-size:11pt;font-weight:normal;line-height:1.28;">scheduled</font><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> payments of other Indebtedness (including scheduled and required payments in respect of the Revenue Interest Financing) to the extent permitted pursuant to the terms, if any, of any applicable subordination or intercreditor agreement in respect of the Obligations, (iii) intercompany indebtedness permitted under </font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">Section 9.01</b><font style="font-size:11pt;font-weight:normal;line-height:1.28;">, (iv) Indebtedness permitted to be incurred under </font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">Sections 9</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;line-height:1.28;"><a name="_Hlk68762319"></a></font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">.01(b), (j), (k), (l), (m), (o), (q) and (t)</b><font style="font-size:11pt;font-weight:normal;line-height:1.28;">,</font><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> (v) Indebtedness permitted to be incurred under </font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">Section 9.01(p)</b><font style="font-size:11pt;font-weight:normal;line-height:1.28;">; </font><u style="font-size:11pt;font-weight:normal;line-height:1.28;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> that any such payments shall only be made or settled in Equity Interests and cash in lieu of fractional shares (as well as cash to pay any accrued interest on the date of any payment made in Equity Interests), (vi) scheduled payments of interest on such Indebtedness permitted pursuant to </font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">Section 9.01(p)</b><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> and (vii) Permitted Refinancings permitted hereunder.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.08</font><a name="_Toc256000393"></a><a name="_Toc256000240"></a><a name="_Toc256000087"></a><a name="_Ref40130248"></a><a name="_Toc69324660"></a><a name="_Toc70875959"></a>Change in Fiscal Year<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to, change the last day of its fiscal year from that in effect on the date hereof without the prior written consent of Administrative Agent, except to change the fiscal year of a Subsidiary acquired in connection with an Acquisition to conform its fiscal year to that of the Borrower.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.09</font><a name="_Toc256000394"></a><a name="_Toc256000241"></a><a name="_Toc256000088"></a><a name="_Ref40130249"></a><a name="_Toc69324661"></a><a name="_Toc70875960"></a>Sales of Assets, Etc.<font style="font-weight:normal;white-space:pre-wrap;"> Such Obligor will not, and will not permit any of its Subsidiaries to, sell, lease or sublease (as lessor or sub-lessor), sale and leaseback, assign, convey, exclusively license (in terms of geography or field of use), transfer, or otherwise dispose of any of its businesses, assets or property of any kind, whether real, personal, or mixed and whether tangible or intangible, whether now owned or hereafter acquired (including accounts receivable and Equity Interests of Subsidiaries), or forgive, release or compromise any amount owed to such Obligor or Subsidiary, in each case, in one transaction or series of transactions (any thereof, an &#8220;</font><font style="font-style:italic;">Asset Sale</font><font style="font-weight:normal;">&#8221;), except:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130250"></a>sales, transfers and other dispositions of receivables in connection with the compromise, settlement or collection thereof in the Ordinary Course;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130251"></a>sales of inventory, including to end users (through wholesalers or other typical sales channels) or to distributors, in the Ordinary Course in an Arm&#8217;s-Length Transaction;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130252"></a>the forgiveness, release or compromise of any amount owed to any Obligor or Subsidiary in the Ordinary Course;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130253"></a>Permitted Licenses and the transfer of any non-U.S. Product Authorization in connection therewith;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130254"></a>transfers of assets, rights or property by any Obligor to any other Obligor or (ii) any Subsidiary that is not an Obligor to an Obligor;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130255"></a>dispositions (including by way of abandonment or cancellation) of any equipment and other tangible property that is obsolete or worn out or no longer used or useful in the Business disposed of in the Ordinary Course in an Arm&#8217;s-Length Transaction;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130256"></a>dispositions resulting from Casualty Events (without giving effect to the Dollar exception set forth in the definition thereof);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40130257"></a>the unwinding of any Hedging Agreement permitted by <b style="font-weight:bold;">Section 9.05</b> pursuant to its terms;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130258"></a>in connection with any transaction permitted under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.03</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">9.05</b>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40130259"></a>Asset Sales identified in <b style="font-weight:bold;">Schedule </b><b style="font-weight:bold;">9.09</b>; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40130260"></a>so long as no Default or Event of Default has occurred and is continuing (or could reasonably be expected to occur after giving effect to such Asset Sale), other Asset Sales (other than with respect to Material Intellectual Property) with a fair market value not in excess of $5,000,000 (or the Equivalent Amount in other currencies) in the aggregate in any fiscal year; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font>other Asset Sales (other than with respect to Material Intellectual Property) not in excess of $10,000,000 (or the Equivalent Amount in other currencies) in the aggregate in any fiscal year in which any Obligor or any Subsidiary will receive cash proceeds in an amount equal to no less than seventy-five percent (75%) of the total consideration (fixed or contingent) paid or payable to such Obligor or Subsidiary, but only so long as, unless otherwise waived by Administrative Agent in its sole discretion, the net cash proceeds of such Asset Sale are utilized to repay or prepay, in whole or in part, Indebtedness under and in accordance with this Agreement and the other Loan Documents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_cp_blt_1_1033"></a>dispositions in the ordinary course of business consisting of the abandonment of Intellectual Property (other than Material Intellectual Property) which, in the reasonable good faith determination of Borrower, are not material to the conduct of the business of Borrower or any of its Subsidiaries; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font>so long as no Default or Event of Default has occurred and is continuing (or could reasonably be expected to occur after giving effect to such Asset Sale), the sale, transfer or disposition of the priority review voucher received by the Borrower in connection with Ganaxolone FDA Approval, but only so long as, unless otherwise waived by Administrative Agent in its sole discretion, the Net Cash Proceeds of such Asset Sale are used by the Borrower for working capital purposes, capital expenditures, Investments, Permitted Acquisitions and expenses associated with Product Commercialization and Development Activities with respect to Ganaxolone; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font>dispositions of cash and Permitted Cash Equivalents Investment in the Ordinary Course or otherwise in transactions permitted hereunder; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font>the sale, transfer, issuance or other disposition of a <i style="font-style:italic;">de minimis</i> number of shares of the Equity Interests of a CFC in order to qualify members of the governing body of such CFC if required by applicable Law; </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(q)</font>to the extent constituting an Asset Sale, any Permitted Liens; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(r)</font>the sale or transfer of the Revenue Strip Proceeds pursuant to a Revenue Interest Financing.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.10</font><a name="_Toc256000395"></a><a name="_Toc256000242"></a><a name="_Toc256000089"></a><a name="_Ref40130261"></a><a name="_Toc69324662"></a><a name="_Toc70875961"></a>Transactions with Affiliates<font style="font-weight:normal;"><a name="DocXTextRef451"></a><a name="_cp_text_1_4520"></a><a name="_cp_text_2_4522"></a>. Such Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into or permit to exist any transaction to sell, lease, license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with, any of its Affiliates, unless such arrangement or transaction (i) is an Arm&#8217;s-Length Transaction, (ii) is of the kind which would be entered into by a prudent Person in the position of the Borrower with another Person that is not an Affiliate, (iii) is between or among (x) one or more Obligors, on the one hand, and, on the other hand, one or more Obligors, (y) one or more Subsidiaries of the Obligors that are not Obligors, on the one hand, and, on the other hand, one or more Subsidiaries of the Obligors that are not Obligors and (z) one or more Obligors or their Subsidiaries that are not Obligors, on the one hand, and, on the other hand, one or more Obligors or their Subsidiaries that are Obligors (</font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"> that, with respect to </font>clause (z)<font style="font-weight:normal;"> only, the terms thereof are no less favorable than those that would be obtained in a comparable arm&#8217;s-length transaction with a non-affiliated Person), (iv) is permitted under </font>Section 9.01, 9.03, 9.05, 9.06, 9.07 <font style="font-weight:normal;">or </font>9.09<font style="font-weight:normal;"><a name="DocXTextRef452"></a><a name="DocXTextRef453"></a>, (v) constitutes customary compensation (including performance, discretionary, retention, relocation, transaction and other special bonuses and payment, severance payments and payments pursuant to employment agreements), other benefits (including retirement, health, stock option and other benefit plans, life insurance, disability insurance and other equity (or equity-linked) awards) and indemnification of, and other employment arrangements with, directors, officers, and employees of any Obligor or its Subsidiaries in the ordinary course of business, (vi) constitutes payment of customary fees, reimbursement of expenses, and payment of indemnification to officers and directors and customary payment of insurance premiums on behalf of officers and directors by the Obligors or their Subsidiaries, in each case, in the ordinary course of business, (vii) are the transactions set forth on </font>Schedule 7.19<font style="font-weight:normal;"> or (viii) is a transaction (with any series of related transactions being aggregated for the purposes of this clause (viii)) including consideration of less than $50,000.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.11</font><a name="_Toc256000396"></a><a name="_Toc256000243"></a><a name="_Toc256000090"></a><a name="_Ref40130262"></a><a name="_Toc69324663"></a><a name="_Toc70875962"></a>Restrictive Agreements<font style="font-weight:normal;"><a name="DocXTextRef455"></a><a name="DocXTextRef456"></a>. Such Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into, incur or permit to exist any Restrictive Agreement other than (i) restrictions and conditions imposed by applicable Laws or by the Loan Documents, (ii) Restrictive Agreements listed on </font>Schedule 7.15, <font style="font-weight:normal;">(iii) limitations associated with Permitted Liens or any document or instrument governing any Permitted Lien, (iv) any documentation governing Indebtedness referenced in clauses (l), (n) or (p) of </font>Section 9.01 <font style="font-weight:normal;">(or any Permitted Refinancing thereof), (v) customary provisions in leases, Permitted Licenses and other Contracts restricting the assignment thereof or restricting the assignment, pledge, transfer or sublease or sublicense of the property leased, licensed or otherwise the subject thereof; (vi) any restrictions or conditions set forth in any agreement in effect at any time any Person becomes a Subsidiary (but not any modification or amendment expanding the scope of any such restriction or condition); </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u> <font style="font-weight:normal;">that such agreement was not entered into in contemplation of such Person becoming a Subsidiary; (vii) restrictions or conditions in any Indebtedness permitted pursuant to </font>Section 9.01 <font style="font-weight:normal;">that is incurred or assumed by Subsidiaries that are not Obligors to the extent such restrictions or conditions are no more restrictive in any material respect than the restrictions and </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">conditions in the Loan Documents; (viii) restrictions or conditions imposed by any agreement relating to purchase money Indebtedness and other secured Indebtedness or to leases and licenses permitted by this Agreement if such restrictions or conditions apply only to the property or assets securing such Indebtedness or the property leased or licensed; (ix) customary provisions in contracts for the disposition of any assets; </font><u style="color:#000000;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;"> that the restrictions in any such contract shall apply only to the assets or Subsidiary that is to be disposed of and such disposition is permitted hereunder; (x) customary provisions regarding confidentiality or restricting assignment, pledges or transfer of any Permitted License or any other agreement entered into in the ordinary course of business; (xi) customary restrictions or encumbrances in any agreement evidencing Permitted Convertible Debt that restricts the merger or consolidation of, or the sale of all or substantially all of the assets of, the Borrower or taken as a whole, are not more restrictive to the Obligors in any material respect than the comparable restrictions and encumbrances in the Loan Documents, taken as a whole (as reasonably determined by the a Responsible Officer of Borrower in good faith and as certified to by a certificate from such Responsible Officer delivered to the Administrative Agent); and (xii) restrictions or encumbrances in any agreement in effect at the time any Person becomes a Subsidiary, so long as (x) such agreement was not entered into in contemplation of such Person becoming a Subsidiary and (y) such restrictions or encumbrances do not extend beyond such Subsidiary or its assets.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.12</font><a name="_Toc256000397"></a><a name="_Toc256000244"></a><a name="_Toc256000091"></a><a name="_Ref40130263"></a><a name="_Toc69324664"></a><a name="_Toc70875963"></a>Modifications and Terminations of Material Agreements and Organic Documents<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130264"></a>waive, amend, terminate, replace or otherwise modify any term or provision of any Organic Document in any way or manner adverse to the interests of the Administrative Agent and the Lenders; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>waive, amend, replace or otherwise modify any term or provision of any Material Agreement in a manner adverse to the rights and remedies the Administrative Agent and the Lenders hereunder; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130265"></a><a name="DocXTextRef457"></a>(x) take or omit to take any action that results in the termination of, or permits any other Person to terminate, any Material Agreement or any rights in or to Material Intellectual Property or (y) take any action that permits any Material Agreement or any rights in or to Material Intellectual Property to be terminated by any counterparty thereto prior to its stated date of expiration.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.13</font><a name="_Toc256000398"></a><a name="_Toc256000245"></a><a name="_Toc256000092"></a><a name="_Ref40130266"></a><a name="_Toc69324665"></a><a name="_Toc70875964"></a>Outbound Licenses<font style="font-weight:normal;white-space:pre-wrap;">.  No Obligor will, nor will it permit any of its Subsidiaries to, enter into or become or remain bound by any outbound license, covenant not to sue or other grant of rights under Material Intellectual Property relating to the Product Ganaxolone, except for Permitted Licenses.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.14</font><a name="_Toc256000399"></a><a name="_Toc256000246"></a><a name="_Toc256000093"></a><a name="_Ref40130267"></a><a name="_Toc69324666"></a><a name="_Toc70875965"></a>Sales and Leasebacks<font style="font-weight:normal;"><a name="DocXTextRef459"></a>. Except as disclosed on </font>Schedule 9.14<font style="font-weight:normal;"><a name="DocXTextRef458"></a>, except as otherwise consented to in writing by the Administrative Agent (such consent not to be unreasonably withheld), such Obligor will not, and will not permit any of its Subsidiaries to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation, of any property (whether real, personal, or mixed), whether now owned or hereafter acquired, (i) which such Person has sold or transferred or is to sell or transfer to any other Person </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">and (ii) which such Obligor or Subsidiary intends to use for substantially the same purposes as property which has been or is to be sold or transferred.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.15</font><a name="_Toc256000400"></a><a name="_Toc256000247"></a><a name="_Toc256000094"></a><a name="_Ref40130268"></a><a name="_Toc69324667"></a><a name="_Toc70875966"></a>Hazardous Material<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to, use, generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except as would not reasonably be expected to result in a Material Environmental Liability. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.16</font><a name="_Toc256000401"></a><a name="_Toc256000248"></a><a name="_Toc256000095"></a><a name="_Ref40130269"></a><a name="_Toc69324668"></a><a name="_Toc70875967"></a>Accounting Changes<font style="font-weight:normal;">. Such Obligor will not, and will not permit any of its Subsidiaries to, make any significant change in accounting treatment or reporting practices, except as required or permitted by GAAP.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.17</font><a name="_Toc256000402"></a><a name="_Toc256000249"></a><a name="_Toc256000096"></a><a name="_Ref40130270"></a><a name="_Toc69324669"></a><a name="_Toc70875968"></a>Compliance with ERISA<font style="font-weight:normal;white-space:pre-wrap;"><a name="DocXTextRef460"></a>.  No ERISA Affiliate shall cause or suffer to exist (i) any event that could result in the imposition of a Lien with respect to any Title IV Plan or Multiemployer Plan or (ii) any other ERISA Event that could, in the aggregate, reasonably be expected to result in a Material Adverse Effect. No Obligor or any of its Subsidiaries shall cause or suffer to exist any event that could result in the imposition of a Lien with respect to any Benefit Plan.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">9.18</font><a name="_Toc256000403"></a><a name="_Toc256000250"></a><a name="_Toc256000097"></a><a name="_Ref40130273"></a><a name="_Toc69324670"></a><a name="_Toc70875969"></a>Sanctions; Anti-Corruption Use of Proceeds<font style="font-weight:normal;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Toc480909706"></a>Neither the Borrower or any of its Subsidiaries or their respective agents shall (i)&#160;<a name="_Toc480909708"></a>conduct any business or engage in any transaction or dealing with any Sanctioned Person in violation of Sanctions, including making or receiving any contribution of funds, goods or services to or for the benefit of any Sanctioned Person; (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to any Sanctions; or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any applicable Sanctions, the Patriot Act or any other Anti-Terrorism Law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="DocXTextRef461"></a><a name="DocXTextRef462"></a><a name="DocXTextRef463"></a>The Borrower will not, directly or , to the knowledge of the Borrower, indirectly, use the proceeds of the Loans, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person, (i) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any applicable anti-corruption Law, or (ii) (A) for the purpose of funding any activities or business of or with any Sanctioned Person or any Designated Jurisdiction in violation of Sanctions or (B) in any other manner that would result in a violation of Sanctions by any party to this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 10.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000404"></a><a name="_Toc256000251"></a><a name="_Toc256000098"></a><a name="_Ref40130274"></a><a name="_Toc69324671"></a><a name="_Toc70875970"></a>FINANCIAL COVENANT</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">10.01</font><a name="_Toc256000405"></a><a name="_Toc256000252"></a><a name="_Toc256000099"></a><a name="_Ref40130275"></a><a name="_Toc69324672"></a><a name="_Toc70875971"></a>Minimum Liquidity<font style="font-weight:normal;">. The Obligors shall at all times maintain the Minimum Liquidity Amount in cash and/or Permitted Cash Equivalent Investments in, at all times after the Account Control Agreement Completion Date, one or more Controlled Accounts that is free and clear of all Liens, other than Liens granted under the Loan Documents in favor of the Administrative Agent and Liens permitted under </font>Section 9.02(f)<font style="font-weight:normal;"> or </font>Section 9.02(l)<font style="font-weight:normal;">.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 11.</font><a name="_Toc40400742"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000406"></a><a name="_Toc256000253"></a><a name="_Toc256000100"></a><a name="_Ref40130277"></a><a name="_Toc69324673"></a><a name="_Toc70875972"></a>EVENTS OF DEFAULT</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">11.01</font><a name="_Toc256000407"></a><a name="_Toc256000254"></a><a name="_Toc256000101"></a><a name="_Ref40130278"></a><a name="_Toc69324674"></a><a name="_Toc70875973"></a>Events of Default<font style="font-weight:normal;">. Each of the following events shall constitute an &#8220;</font><font style="font-style:italic;">Event of Default</font><font style="font-weight:normal;">&#8221;:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130279"></a><b style="font-weight:bold;">Principal Payment Default</b>. The Borrower shall fail to pay any principal of the Loan, when and as the same shall become due and payable, whether at the due date thereof, at a date fixed for prepayment thereof or otherwise.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130280"></a><b style="font-weight:bold;">Other Payment Defaults</b>. Any Obligor shall fail to pay interest or any other Obligation (other than an amount referred to in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(a)</b>) when and as the same shall become due and payable, and such failure shall continue unremedied for a period of five (5) Business Days.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130281"></a><b style="font-weight:bold;">Representations and Warranties</b>. Any representation or warranty made or deemed made by or on behalf of any Obligor or any of its Subsidiaries in or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, shall (i) have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material Adverse Effect qualifier; or (ii) have been incorrect in any material respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130282"></a><b style="font-weight:bold;">Certain Covenants</b>. Any Obligor shall fail to observe or perform any covenant, condition or agreement contained in (i) <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.01(a)</b><b style="font-weight:bold;">, (b) </b>or<b style="font-weight:bold;"> (c) </b>and such failure shall continue unremedied for a period of five (5) Business Days or (ii) <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.02</b>, <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.03</b><b style="font-weight:bold;"> </b>(solely as to the Borrower), <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.05</b>, <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.11</b>, <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.12</b>,<b style="font-weight:bold;"> Section </b><b style="font-weight:bold;">8.16</b>, <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.18</b>, <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.19</b>, <b style="font-weight:bold;">Section 9</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">Section 10</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130283"></a><b style="font-weight:bold;">Other Covenants</b>. Any Obligor shall fail to observe or perform any covenant, condition or agreement contained in this Agreement (other than those specified in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(a)</b><a name="DocXTextRef477"></a>, <b style="font-weight:bold;">(b)</b><b style="font-weight:bold;"> </b><a name="DocXTextRef478"></a>or <b style="font-weight:bold;">(d)</b><a name="DocXTextRef476"></a>) or any other Loan Document, and, in the case of any failure that is capable of cure, such failure shall continue unremedied for a period of seven (7) or more days after the earlier to occur of the date on which (i) a Responsible Officer of any Obligor becomes aware of such failure or (ii) written notice thereof shall have been given to any Obligor by the Administrative Agent or any Lender.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130284"></a><b style="font-weight:bold;">Payment Default on Other Indebtedness</b>. Any Obligor or any of its Subsidiaries shall fail to make any payment (whether of principal or interest and regardless of amount) in respect of any Material Indebtedness, when and as the same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such Indebtedness.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130285"></a><b style="font-weight:bold;">Other Defaults on Other Indebtedness</b><a name="DocXTextRef482"></a>. (i) Any material breach of, or &#8220;event of default&#8221; or similar event under, any Contract governing any Material Indebtedness shall occur and such breach or &#8220;event of default&#8221; or similar event shall continue unremedied, uncured or </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><a name="DocXTextRef483"></a><a name="DocXTextRef480"></a><a name="DocXTextRef484"></a><a name="DocXTextRef481"></a>unwaived after the expiration of any grace or cure period thereunder, or (ii) any event or condition occurs (x) that results in any Material Indebtedness becoming due prior to its scheduled maturity or (y) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of such Material Indebtedness or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(g)</b><b style="font-weight:bold;"> </b>shall not apply to (x) secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Material Indebtedness, (y) any conversion of any convertible Indebtedness or satisfaction of any condition giving rise to or permitting a conversion of any convertible Indebtedness; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the Borrower has the right to settle any such Indebtedness into Equity Interests of the Borrower (and nominal cash payments in respect of fractional shares and cash payments in respect of accrued and unpaid interest) in accordance with the terms or conditions thereof) and (z) with respect to any Material Indebtedness consisting of Hedging Agreements, termination events or equivalent events pursuant to the terms of such Hedging Agreements and not as a result of any default thereunder by any Obligor or any Subsidiary.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40130286"></a><b style="font-weight:bold;">Insolvency, Bankruptcy, Etc</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130287"></a>Any Obligor or any of its Material Subsidiaries becomes insolvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become due, or admits in writing its inability to pay its debts generally, or declares any general moratorium on its indebtedness, or proposes a compromise or arrangement or deed of company arrangement between it and any class of its creditors.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130288"></a>Any Obligor or any of its Material Subsidiaries commits an act of bankruptcy or makes an assignment of its property for the general benefit of its creditors or makes a proposal (or files a notice of its intention to do so).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40130289"></a>Any Obligor or any of its Material Subsidiaries institutes any proceeding seeking to adjudicate it an insolvent, or seeking liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), or composition of it or its debts or any other relief, under any Law, whether U.S. or non-U.S., now or hereafter in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity, or files an answer admitting the material allegations of a petition filed against it in any such proceeding.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref40130290"></a>Any Obligor or any of its Material Subsidiaries applies for the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><a name="_Ref40130291"></a>Any Obligor or any of its Material Subsidiaries takes any action, corporate or otherwise, to approve, effect, consent to or authorize any of the actions described in this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(h)</b>, or otherwise acts in furtherance thereof or fails to act in a timely and appropriate manner in defense thereof.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font><a name="_Ref40130292"></a>Any petition is filed, application made or other proceeding instituted against or in respect of any Obligor or any of its Material Subsidiaries:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(A)</font><a name="_Ref40130293"></a>seeking to adjudicate it as insolvent;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(B)</font><a name="_Ref40130294"></a>seeking a receiving order against it;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(C)</font><a name="_Ref40130295"></a>seeking liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), deed of company arrangement or composition of it or its debts or any other relief under any Law, whether U.S. or non-U.S., now or hereafter in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(D)</font><a name="_Ref40130296"></a>seeking the entry of an order for relief or the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property, and such petition, application or proceeding continues undismissed, or unstayed and in effect, for a period of forty-five (45) days after the institution thereof; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that if an order, decree or judgment is granted or entered (whether or not entered or subject to appeal) against such Obligor or such Subsidiary thereunder in the interim, such grace period will cease to apply; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, that if such Obligor or Material Subsidiary files an answer admitting the material allegations of a petition filed against it in any such proceeding, such grace period will cease to apply.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(vii)</font><a name="_Ref40130297"></a>Any other event occurs which, under the Laws of any applicable jurisdiction, has an effect equivalent to any of the events referred to in this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(h)</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130298"></a><b style="font-weight:bold;">Judgments</b>. One or more final judgments for the payment of money in an aggregate amount in excess of $5,000,000 (or the Equivalent Amount in other currencies) (to the extent not fully covered (other than to the extent of customary deductibles) by insurance pursuant to which the insurer has not denied coverage) shall be rendered against any Obligor or any of its Subsidiaries or any combination thereof and the same shall remain undischarged for a period of forty-five (45) calendar days during which execution shall not be effectively stayed or bonded pending appeal, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Obligor to enforce any such judgment.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40130299"></a><b style="font-weight:bold;">ERISA</b>. An ERISA Event shall have occurred that when taken together with all other ERISA Events that have occurred, could reasonably be expected to result in liability of the Borrower and its Subsidiaries in an aggregate amount in excess of $5,000,000 (or the Equivalent Amount in other currencies).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40130300"></a><b style="font-weight:bold;">Change of Control</b>. A Change of Control shall have occurred.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><b style="font-weight:bold;">[Reserved].</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_Ref40130302"></a><b style="font-weight:bold;">Regulatory Matters, Etc. </b><a name="DocXTextRef489"></a>If any of the following occurs: (i) the FDA or any other Regulatory Authority initiates enforcement action against, or issues a warning letter with </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><a name="_Hlk68767172"></a>respect to, any Obligor, Ganaxolone or any manufacturing facilities for Ganaxolone that (x) causes any Obligor to discontinue or withdraw, or could reasonably be expected to cause any Obligor to discontinue or withdraw, marketing or sales of Ganaxolone, or causes a delay in the manufacture or sale of Ganaxolone, and (y) could reasonably be expected to result in a Material Adverse Effect, or (ii) a recall of Ganaxolone that could reasonably be expected to result in a Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><a name="_Ref40130303"></a><b style="font-weight:bold;">[Reserved].</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><a name="_Ref40130304"></a><b style="font-weight:bold;">Impairment of Security, Etc. </b><a name="DocXTextRef490"></a>Subject in all respects to any applicable post-closing periods and certain other time periods and exceptions under the Loan Documents for any Obligor or Subsidiary to take perfection actions, if any of the following events occurs: (i) Any Lien created by any of the Security Documents shall at any time (except as expressly permitted by the terms of any Loan Document) not constitute a valid and perfected Lien on the applicable Collateral in favor of the Secured Parties, free and clear of all other Liens (other than Permitted Liens) except due to the action or inaction of the Administrative Agent, (ii) except for expiration in accordance with its terms, any of the Security Documents or any Guarantee of any of the Obligations (including that contained in <b style="font-weight:bold;">Section 13</b>) shall for whatever reason cease to be in full force and effect, (iii) any Obligor shall, directly or indirectly, contest in any manner such effectiveness, validity, binding nature or enforceability of any such Lien or any Loan Document or (iv) following the sale of Ganaxolone by any Obligor in the United States to treat CDKL5 deficiency disorder, any injunction, whether temporary or permanent, shall be rendered against any Obligor that prevents the Obligors from selling or manufacturing Ganaxolone or its commercially available successors in the United States for more than forty-five (45) calendar days and after the termination of such forty-five (45) day period the existence of such circumstance could reasonably be expected to result in a Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">11.02</font><a name="_Toc256000408"></a><a name="_Toc256000255"></a><a name="_Toc256000102"></a><a name="_Ref40130305"></a><a name="_Ref40186370"></a><a name="_Ref40264217"></a><a name="_Toc69324675"></a><a name="_Toc70875974"></a>Remedies<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130306"></a><b style="font-weight:bold;">Defaults Other Than Bankruptcy Defaults</b>. Upon the occurrence of any Event of Default, then, and in every such event (other than an Event of Default described in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(h)</b>), and at any time thereafter during the continuance of such event, the Administrative Agent may, by notice to the Borrower, declare the Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and other Obligations, including any applicable Yield Protection Premium and the Exit Fee, shall become due and payable immediately (in the case of the Loans, at the Prepayment Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130307"></a><b style="font-weight:bold;">Bankruptcy Defaults</b>. In case of an Event of Default described in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(h)</b>, the principal of the Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, including any applicable Yield Protection Premium and the Exit Fee, shall automatically become due and payable immediately (in the case of the Loans, at the Prepayment Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">11.03</font><a name="_Toc256000409"></a><a name="_Toc256000256"></a><a name="_Toc256000103"></a><a name="_Ref40130308"></a><a name="_Toc69324676"></a><a name="_Toc70875975"></a>Additional Remedies<font style="font-weight:normal;">. If an Event of Default has occurred and is continuing, if any Obligor shall be in default under a Material Agreement, the Administrative Agent shall have the right (but not the obligation) to cause the default or defaults under such Material Agreement to be remedied (including without limitation by paying any unpaid amount thereunder) and otherwise exercise any and all rights of such Obligor, as the case may be, thereunder, as may be necessary to prevent or cure any default. Without limiting the foregoing, upon any such default, each Obligor shall promptly execute, acknowledge and deliver to the Administrative Agent such instruments as may reasonably be required of such Obligor to permit the Administrative Agent to cure any default under the applicable Material Agreement or permit the Administrative Agent to take such other action required to enable the Administrative Agent to cure or remedy the matter in default and preserve the interests of the Administrative Agent. Any amounts paid by the Administrative Agent pursuant to this </font>Section 11.03 <font style="font-weight:normal;">shall be payable in accordance with </font>Section 14.03(a)<font style="font-weight:normal;white-space:pre-wrap;">, shall accrue interest at the Default Rate if not paid when due, and shall constitute &#8220;Obligations.&#8221;  The Administrative Agent and the Lenders agree that in connection with any foreclosure or other exercise of rights under this Agreement or any other Loan Document with respect to Intellectual Property, the rights of the non-Affiliate licensees under Permitted Licenses will not be terminated, limited or otherwise adversely affected so long as no default exists under the Permitted License that would permit the licensor to terminate such Permitted License (commonly known as a non-disturbance); </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"> that the Administrative Agent shall be entitled to exercise any rights of the Obligors under such licenses, including termination rights, upon the exercise of remedies during an Event of Default.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">11.04</font><a name="_Toc256000410"></a><a name="_Toc256000257"></a><a name="_Toc256000104"></a><a name="_Toc69324677"></a><a name="_Toc70875976"></a>[Reserved]<font style="font-weight:normal;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">11.05</font><a name="_Toc256000411"></a><a name="_Toc256000258"></a><a name="_Toc256000105"></a><a name="_Toc69324678"></a><a name="_Toc70875977"></a>[Reserved]<font style="font-weight:normal;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">11.06</font><a name="_Toc40400749"></a><a name="_Ref40130309"></a><a name="_Toc70875978"></a><a name="_Toc69324679"></a><a name="_Ref40342320"></a><a name="_Toc256000106"></a><a name="_Toc256000259"></a><a name="_Toc256000412"></a>Payment of Yield Protection Premium and Exit Fee<font style="font-weight:normal;">. Notwithstanding anything in this Agreement to the contrary, the Yield Protection Premium and the Exit Fee shall automatically be due and payable at any time the Obligations become due and payable prior to the Maturity Date in accordance with the terms hereof as though such Indebtedness was voluntarily prepaid and shall constitute part of the Obligations, whether due to acceleration pursuant to the terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to Borrower in accordance with </font>Section 11.02(a)<font style="font-weight:normal;">, or automatically, in accordance with </font>Section 11.02(b)<font style="font-weight:normal;">), by operation of law or otherwise (including, without limitation, on account of any bankruptcy filing), in view of the impracticability and extreme difficulty of ascertaining the actual amount of damages to the Lenders or profits lost by the Lenders as a result of such acceleration, and by mutual agreement of the parties as to a reasonable estimation and calculation of the lost profits or damages of the Lenders as a result thereof. If the Yield Protection Premium and/or Exit Fee become due and payable pursuant to the preceding sentence, the Yield Protection Premium and Exit Fee, as applicable, shall be deemed to be principal of the Loans and interest shall accrue on the full principal amount of the Loans (including the Yield Protection Premium and Exit Fee, as applicable) from and after the applicable triggering event. Any Yield Protection Premium or Exit Fee (or, if required, both the Yield Protection Premium and the Exit Fee) payable pursuant to this Agreement shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, acceleration or prepayment and each Obligor agrees that such Yield Protection Premium or Exit Fee is reasonable under the circumstances currently existing. The Yield Protection Premium and Exit Fee shall also be payable in the event the Obligations </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">(and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any other means.  </font><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;text-transform:uppercase;">Each Obligor hereby waives the provisions of any present or future statute or law that prohibits or may prohibit the collection of the Yield Protection Premium or exit fee and any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise</b><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;">.</b><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;"> The Obligors, the Administrative Agent and the Lenders acknowledge and agree that any Yield Protection Premium and the Exit Fee due and payable in accordance with this Agreement shall not constitute unmatured interest, whether under Section 5.02(b)(3) of the Bankruptcy Code or otherwise. Each Obligor further acknowledges and agrees, and waives any argument to the contrary, that payment of such amount does not constitute a penalty or an otherwise unenforceable or invalid obligation. Each Obligor expressly agrees that (i) the Yield Protection Premium and Exit Fee are each reasonable and each is the product of an arm&#8217;s-length transaction between sophisticated business people, ably represented by counsel, (ii) the Yield Protection Premium and Exit Fee shall be payable notwithstanding the then prevailing market rates at the time payment is made, (iii) there has been a course of conduct between the Lenders and the Obligors giving specific consideration in this transaction for such agreement to pay the Yield Protection Premium and Exit Fee, (iv)&#160;the Obligors shall be estopped hereafter from claiming differently than as agreed to in this </font><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;">Section </b><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;">11.06</b><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">, (v) their agreement to pay the Yield Protection Premium and Exit Fee is a material inducement to the Lenders to make the Loans, and (vi) the Yield Protection Premium and Exit Fee represent a good faith, reasonable estimate and calculation of the lost profits, losses or other damages of the Lenders and that it would be impractical and extremely difficult to ascertain the actual amount of damages to the Lenders or profits lost by the Lenders as a result of such event.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 12.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000413"></a><a name="_Toc256000260"></a><a name="_Toc256000107"></a><a name="_Ref40130310"></a><a name="_Toc69324680"></a><a name="_Toc70875979"></a>THE ADMINISTRATIVE AGENT</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.01</font><a name="_Toc256000414"></a><a name="_Toc256000261"></a><a name="_Toc256000108"></a><a name="_Ref40130311"></a><a name="_Toc69324681"></a><a name="_Toc70875980"></a>Appointment and Duties<font style="font-weight:normal;">. Subject in all cases to clause (c) below:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130312"></a><b style="font-weight:bold;">Appointment of the Administrative Agent</b>. Each of the Lenders hereby irrevocably appoints Oaktree Fund Administration, LLC (together with any successor Administrative Agent pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">12.09</b><a name="DocXTextRef499"></a>) as the Administrative Agent hereunder and authorizes the Administrative Agent to (i) execute and deliver the Loan Documents and accept delivery thereof on its behalf from any Obligor or any of its Subsidiaries, (ii) take such action on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to the Administrative Agent under such Loan Documents and (iii) exercise such powers as are reasonably incidental thereto. Except as expressly set forth herein, the provisions of this <b style="font-weight:bold;">Section 12</b> (other than <b style="font-weight:bold;">Sections 12.09</b>, <b style="font-weight:bold;">12.10</b> and <b style="font-weight:bold;">12.13</b>, and solely to the extent expressly set forth therein) are solely for the benefit of the Administrative Agent and the Lenders, and no Obligor or any Affiliate thereof shall have rights as a third-party beneficiary of any such provisions.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130313"></a><b style="font-weight:bold;">Duties as Collateral and Disbursing Agent</b>. Without limiting the generality of <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">12.01(a)</b><a name="DocXTextRef501"></a>, the Administrative Agent shall have the sole and exclusive right and authority (to the exclusion of the Lenders), and is hereby authorized, to (i) act as the disbursing and collecting agent for the Lenders with respect to all payments and collections arising in </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">connection with the Loan Documents (including in any proceeding described in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(h)</b><b style="font-weight:bold;"> </b>or any other bankruptcy, insolvency or similar proceeding), and each Person making any payment in connection with any Loan Document to any Secured Party is hereby authorized to make such payment to the Administrative Agent, (ii) file and prove claims and file other documents necessary or desirable to allow the claims of the Secured Parties with respect to any Obligation in any proceeding described in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">11.01(h)</b><b style="font-weight:bold;"> </b><a name="DocXTextRef502"></a><a name="_cp_text_1_4429"></a>or any other bankruptcy, insolvency or similar proceeding (but not to vote, consent or otherwise act on behalf of such Secured Party), (iii) act as collateral agent for each Secured Party for purposes of acquiring, holding, enforcing and perfecting all Liens created by the Loan Documents and all other purposes stated therein, (iv) manage, supervise and otherwise deal with the Collateral, (v) take such other action as is necessary or desirable to maintain the perfection and priority of the Liens created or purported to be created by the Loan Documents, (vi) except as may be otherwise specified in any Loan Document, exercise all remedies given to the Administrative Agent and the other Secured Parties with respect to the Collateral, whether under the Loan Documents, applicable Laws or otherwise, (vii) enter into a Permitted Intercreditor Agreement, (viii) enter into non-disturbance agreements and similar agreements and (ix) execute any amendment, consent or waiver under the Loan Documents on behalf of any Lender that has consented in writing to such amendment, consent or waiver; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the Administrative Agent hereby appoints, authorizes and directs each Lender to act as collateral sub-agent for the Administrative Agent and the Lenders for purposes of the perfection of all Liens with respect to the Collateral, including any deposit account maintained by a Obligor with, and cash and Cash Equivalents held by, such Lender, and may further authorize and direct the Lenders to take further actions as collateral sub-agents for purposes of enforcing such Liens or otherwise to transfer the Collateral subject thereto to the Administrative Agent, and each Lender hereby agrees to take such further actions to the extent, and only to the extent, so authorized and directed.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130314"></a><b style="font-weight:bold;">Limited Duties</b><a name="DocXTextRef506"></a>. The Lenders and the Obligors hereby each acknowledge and agree that the Administrative Agent (i) has undertaken its role hereunder purely as an accommodation to the parties hereto and the Transactions, (ii) is receiving no compensation for undertaking such role and (iii) subject only to the notice provisions set forth in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">12.09</b><a name="DocXTextRef507"></a>, may resign from such role at any time for any reason or no reason whatsoever. Without limiting the foregoing, the parties hereto further acknowledge and agree that under the Loan Documents, the Administrative Agent (i) is acting solely on behalf of the Lenders (except to the limited extent provided in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">12.11</b>), with duties that are entirely administrative in nature, notwithstanding the use of the defined term &#8220;the Administrative Agent&#8221;, the terms &#8220;agent&#8221;, &#8220;administrative agent&#8221; and &#8220;collateral agent&#8221; and similar terms in any Loan Document to refer to the Administrative Agent, which terms are used for title purposes only, (ii) is not assuming any duty or obligation under any Loan Document other than as expressly set forth therein or any role as agent, fiduciary or trustee of or for any Lender or any other Secured Party and (iii) shall have no implied functions, responsibilities, duties, obligations or other liabilities under any Loan Document (fiduciary or otherwise), in each case, regardless of whether a Default has occurred and is continuing, and each Lender hereby waives and agrees not to assert any claim against the Administrative Agent based on the roles, duties and legal relationships expressly disclaimed in this <b style="font-weight:bold;">clause (c)</b>. Without in any way limiting the foregoing, the Administrative Agent shall not, except as expressly set forth in this Agreement and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Obligor or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.02</font><a name="_Toc256000415"></a><a name="_Toc256000262"></a><a name="_Toc256000109"></a><a name="_Ref40130315"></a><a name="_Toc69324682"></a><a name="_Toc70875981"></a>Binding Effect<font style="font-weight:normal;"><a name="DocXTextRef510"></a>. Each Lender agrees that (i) any action taken by the Administrative Agent or the Majority Lenders (or, if expressly required hereby, a greater proportion of the Lenders) in accordance with the provisions of the Loan Documents, (ii) any action taken by the Administrative Agent in reliance upon the instructions of the Majority Lenders (or, where so required, such greater proportion) and (iii) the exercise by the Administrative Agent or the Majority Lenders (or, where so required, such greater proportion) of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Secured Parties.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.03</font><a name="_Toc256000416"></a><a name="_Toc256000263"></a><a name="_Toc256000110"></a><a name="_Ref40130316"></a><a name="_Toc69324683"></a><a name="_Toc70875982"></a>Use of Discretion<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130317"></a><b style="font-weight:bold;">No Action without Instructions</b>. The Administrative Agent shall not be required to exercise any discretion or take, or to omit to take, any action, including with respect to enforcement or collection, except (subject to <b style="font-weight:bold;">clause (b) </b><a name="DocXTextRef511"></a>below) any action it is required to take or omit to take (i) under any Loan Document or (ii) pursuant to written instructions from the Majority Lenders (or, where expressly required by the terms of this Agreement, a greater proportion of the Lenders).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130318"></a><b style="font-weight:bold;">Right Not to Follow Certain Instructions</b>. Notwithstanding <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">12.03(a)</b><b style="font-weight:bold;"> </b>or any other term or provision of this <b style="font-weight:bold;">Section 12</b><a name="DocXTextRef512"></a>, the Administrative Agent shall not be required to take, or to omit to take, any action (i) unless, upon demand, the Administrative Agent receives an indemnification satisfactory to it from the Lenders (or, to the extent applicable and acceptable to the Administrative Agent, any other Secured Party) against all liabilities that, by reason of such action or omission, may be imposed on, incurred by or asserted against the Administrative Agent or any Related Person thereof or (ii) that is, in the opinion of the Administrative Agent, in its sole and absolute discretion, contrary to any Loan Document, Law or the best interests of the Administrative Agent or any of its Affiliates or Related Persons, including, for the avoidance of doubt, any action that may be in violation of the automatic stay in connection with any Insolvency Proceeding..</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.04</font><a name="_Toc256000417"></a><a name="_Toc256000264"></a><a name="_Toc256000111"></a><a name="_Ref40130319"></a><a name="_Toc69324684"></a><a name="_Toc70875983"></a>Delegation of Rights and Duties<font style="font-weight:normal;">. The Administrative Agent may, upon any term or condition it specifies, delegate or exercise any of its rights, powers and remedies under, and delegate or perform any of its duties or any other action with respect to, any Loan Document by or through any trustee, co-agent, employee, attorney-in-fact and any other Person (including any Secured Party). The Administrative Agent and any such Person may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. Any such Person and its Related Parties shall benefit from this </font>Section 12 <font style="font-weight:normal;">to the extent provided by the Administrative Agent; provided, however, that the exculpatory provisions of this </font>Section 12 <font style="font-weight:normal;">shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and of any such sub-agent, and shall apply to their respective activities in connection with their activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and non-appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.05</font><a name="_Toc256000418"></a><a name="_Toc256000265"></a><a name="_Toc256000112"></a><a name="_Ref40130320"></a><a name="_Toc69324685"></a><a name="_Toc70875984"></a>Reliance and Liability<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130321"></a><a name="DocXTextRef516"></a>the Administrative Agent may, without incurring any liability hereunder, (i) consult with any of its Related Persons and, whether or not selected by it, any other advisors, accountants and other experts (including advisors to, and accountants and experts engaged by, any Obligor) and (ii) rely and act upon any notice, request, certificate, consent, statement, instrument, document or other writing (including and electronic message, Internet or intranet website posting or other distribution), telephone message or conversation or oral conversation, in each case believed by it to be genuine and transmitted, signed or otherwise authenticated by the appropriate parties. In determining compliance with any condition hereunder to the making of a Loan that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have received written notice to the contrary from such Lender prior to the making of such Loan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130322"></a>Neither the Administrative Agent nor any of its Related Persons shall be liable for any action taken or omitted to be taken by any of them under or in connection with any Loan Document, and each Lender and the Borrower hereby waive and shall not assert (and the Borrower shall cause each other Obligor to waive and agree not to assert) any right, claim or cause of action based thereon, except to the extent of liabilities resulting primarily from the fraudulent conduct or behavior of the Administrative Agent or, as the case may be, such Related Person (each as determined in a final, non-appealable judgment or order by a court of competent jurisdiction) in connection with the duties expressly set forth herein. Without limiting the foregoing, the Administrative Agent:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130323"></a>shall not be responsible or otherwise incur liability for any action or omission taken in reliance upon the instructions of, or with the consent of, the Majority Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith to be necessary, under the circumstances as provided in <b style="font-weight:bold;">Section 14.04</b>) or for the actions or omissions of any of its Related Persons selected with reasonable care (other than employees, officers and directors of the Administrative Agent, when acting on behalf of the Administrative Agent);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130324"></a>shall not be responsible to any Secured Party for the (a) validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or (b) due execution, legality, validity, enforceability, effectiveness, genuineness, sufficiency or value of, or the attachment, perfection or priority of any Lien created or purported to be created under or in connection with, any Loan Document;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40130325"></a>makes no warranty or representation, and shall not be responsible, to any Secured Party for, and shall not have any duty to ascertain or inquire into, any statement, document, information, certificate, report, representation or warranty made or furnished by or on behalf of any Related Person, in or in connection with any Loan Document or any transaction contemplated therein, whether or not transmitted by the Administrative Agent, including as to completeness, accuracy, scope or adequacy thereof, or for the scope, nature or results of any due diligence performed by the Administrative Agent in connection with the Loan Documents, including, for the avoidance of doubt, the satisfaction of any condition set forth in <b style="font-weight:bold;">Section 6</b> of </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">this Agreement or elsewhere herein (other than to confirm receipt of items expressly required to be delivered to the Administrative Agent); and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref40130326"></a>shall not have any duty to ascertain or to inquire as to the performance or observance of any provision of any Loan Document or whether any condition set forth in any Loan Document is satisfied or waived, including, without limiting the generality of the foregoing, as to the financial condition of any Obligor or as to the existence or continuation or possible occurrence or continuation of any Default or Event of Default and shall not be deemed to have notice or knowledge of such occurrence or continuation unless it has received a notice from the Borrower, any Lender describing such Default or Event of Default clearly labeled &#8220;notice of default&#8221; (in which case the Administrative Agent shall promptly give notice of such receipt to all Lenders);</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">and, for each of the items set forth in <b style="font-weight:bold;">clauses (i) </b>through <b style="font-weight:bold;">(iv) </b>above, each Lender and the Borrower hereby waives and agrees not to assert (and the Borrower shall cause each other Obligor to waive and agree not to assert) any right, claim or cause of action it might have against the Administrative Agent based thereon.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.06</font><a name="_Toc256000419"></a><a name="_Toc256000266"></a><a name="_Toc256000113"></a><a name="_Ref40130327"></a><a name="_Toc69324686"></a><a name="_Toc70875985"></a>Administrative Agent Individually<font style="font-weight:normal;">. The Administrative Agent and its Affiliates may make loans and other extensions of credit to, acquire stock and stock equivalents of, accept deposits from, act as the financial advisor for or in any other advisory capacity for, or engage in any kind of business with, any Obligor or Affiliate thereof as though it were not acting as the Administrative Agent and may receive separate fees and other payments therefor. To the extent the Administrative Agent or any of its Affiliates makes any Loan or otherwise becomes a Lender hereunder, it shall have and may exercise the same rights and powers hereunder and shall be subject to the same obligations and liabilities as any other Lender and the terms &#8220;Lender&#8221;, &#8220;Majority Lender&#8221;, and any similar terms shall, except where otherwise expressly provided in any Loan Document, include, without limitation, the Administrative Agent or such Affiliate, as the case may be, in its individual capacity as Lender or as one of the Majority Lenders, respectively.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.07</font><a name="_Toc256000420"></a><a name="_Toc256000267"></a><a name="_Toc256000114"></a><a name="_Ref40130328"></a><a name="_Toc69324687"></a><a name="_Toc70875986"></a>Lender Credit Decision<font style="font-weight:normal;">. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent, any Lender or any of their Related Persons or upon any document (including the Disclosure Documents) solely or in part because such document was transmitted by the Administrative Agent or any of its Related Persons, conducted its own independent investigation of the financial condition and affairs of each Obligor and has made and continues to make its own credit decisions in connection with entering into, and taking or not taking any action under, any Loan Document or with respect to any transaction contemplated in any Loan Document, in each case based on such documents and information as it shall deem appropriate.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.08</font><a name="_Toc256000421"></a><a name="_Toc256000268"></a><a name="_Toc256000115"></a><a name="_Ref40130329"></a><a name="_Toc69324688"></a><a name="_Toc70875987"></a>Expenses; Indemnities<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130330"></a>Each Lender agrees to reimburse the Administrative Agent and each of its Related Persons (to the extent not reimbursed by any Obligor) promptly upon demand for such Lender&#8217;s Proportionate Share of any costs and expenses (including fees, charges and disbursements of financial, legal and other advisors and Other Taxes paid in the name of, or on behalf of, any </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Obligor) that may be incurred by the Administrative Agent or any of its Related Persons in connection with the preparation, syndication, execution, delivery, administration, modification, consent, waiver or enforcement (whether through negotiations, through any work-out, bankruptcy, restructuring or other legal or other proceeding or otherwise) of, or legal advice in respect of its rights or responsibilities under, any Loan Document.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130331"></a>Each Lender further agrees to indemnify the Administrative Agent (or any sub-agent thereof) and any Related Persons of the Administrative Agent (or any such sub-agent) (to the extent not indefeasibly paid by any Obligor), from and against such Lender&#8217;s aggregate Proportionate Share of the liabilities (including taxes, interests and penalties imposed for not properly withholding or backup withholding on payments made to on or for the account of any Lender) that may be imposed on, incurred by or asserted against the Administrative Agent (or any sub-agent thereof) or any Related Persons of the Administrative Agent (or any such sub-agent) in any matter relating to or arising out of, in connection with or as a result of any Loan Document, any Related Document or any other act, event or transaction related, contemplated in or attendant to any such document, or, in each case, any action taken or omitted to be taken by the Administrative Agent (or any sub-agent thereof) or any Related Persons of the Administrative Agent (or any such sub-agent) under or with respect to any of the foregoing; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that no Lender shall be liable to the Administrative Agent (or any sub-agent thereof) or any Related Persons of the Administrative Agent (or any such sub-agent) to the extent such liability has resulted primarily from the gross negligence or willful misconduct of the Administrative Agent (or any sub-agent thereof) or, as the case may be, such Related Person of the Administrative Agent (or any sub-agent thereof), as determined by a court of competent jurisdiction in a final non-appealable judgment or order.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.09</font><a name="_Toc256000422"></a><a name="_Toc256000269"></a><a name="_Toc256000116"></a><a name="_Ref40130332"></a><a name="_Toc69324689"></a><a name="_Toc70875988"></a>Resignation of the Administrative Agent<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130333"></a>At any time upon not less than 30 days prior written notice, the Administrative Agent may resign as the &#8220;the Administrative Agent&#8221; hereunder, in whole or in part (in the sole and absolute discretion of the Administrative Agent). If the Administrative Agent delivers any such notice, the Majority Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be (i) a Lender holding at least thirty percent (30%) of the outstanding principal amount of the Loans or any Affiliate thereof or (ii) any other financial institution consented to by the Borrower (<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the consent of the Borrower shall not be required to the extent an Event of Default has occurred and is continuing). If a successor Administrative Agent has not been appointed on or before the effectiveness of the resignation of the resigning Administrative Agent (or such earlier date as shall be agreed by the Majority Lenders) (the &#8220;<font style="font-style:italic;font-weight:bold;">Resignation Effective Date</font>&#8221;), then the resigning Administrative Agent may (but shall not be obligated to), on behalf of the Lenders, appoint any Person reasonably chosen by it as the successor Administrative Agent, notwithstanding whether the Majority Lenders have appointed a successor or the Borrower has consented to such successor. Whether or not a successor has been appointed, such resignation shall become effective on the Resignation Effective Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130334"></a><a name="DocXTextRef517"></a>Effective from the Resignation Effective Date, (i) the resigning Administrative Agent shall be discharged from its duties and obligations under the Loan Documents to the extent set forth in the applicable resignation notice, (ii) the Majority Lenders shall assume and </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><a name="DocXTextRef518"></a><a name="DocXTextRef519"></a>perform all of the duties of the Administrative Agent until a successor Administrative Agent shall have accepted a valid appointment hereunder, (iii) the resigning Administrative Agent and its Related Persons shall no longer have the benefit of any provision of any Loan Document other than with respect to (x) any actions taken or omitted to be taken while such resigning Administrative Agent was, or because the Administrative Agent had been, validly acting as the Administrative Agent under the Loan Documents or (y) any continuing duties such resigning Administrative Agent will continue to perform, and (iv) subject to its rights under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">12.04</b>, the resigning Administrative Agent shall take such action as may be reasonably necessary to assign to the successor Administrative Agent its rights as the Administrative Agent under the Loan Documents. Effective immediately upon its acceptance of a valid appointment as the Administrative Agent, a successor Administrative Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the resigning Administrative Agent under the Loan Documents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.10</font><a name="_Toc256000423"></a><a name="_Toc256000270"></a><a name="_Toc256000117"></a><a name="_Ref40130335"></a><a name="_Toc69324690"></a><a name="_Toc70875989"></a>Release of Collateral or Guarantors<font style="font-weight:normal;">. Each Lender hereby consents to the release and hereby directs the Administrative Agent to release, and the Administrative Agent hereby agrees, (or, in the case of </font>Section 12.10(b)<font style="font-weight:normal;">, release or subordinate) the following:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130336"></a><a name="DocXTextRef522"></a>any Subsidiary of the Borrower from its guaranty of any Obligation of any Obligor (i) if all of the Equity Interests in such Subsidiary owned by any Obligor or any of its Subsidiaries are disposed of in an Asset Sale permitted under the Loan Documents (including pursuant to a waiver or consent), to the extent that, after giving effect to such Asset Sale, such Subsidiary would not be required to guaranty any Obligations pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">8.12(a)</b><b style="font-weight:bold;"> </b><a name="DocXTextRef523"></a><a name="DocXTextRef524"></a>and (ii) upon (x) termination of the Commitments and (y) payment and satisfaction in full of all Loans and all other Obligations that the Administrative Agent has been notified in writing are then due and payable (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made); and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130337"></a><a name="DocXTextRef526"></a>any Lien held by the Administrative Agent for the benefit of the Secured Parties against (i) any Collateral that is disposed of by an Obligor in an Asset Sale permitted by the Loan Documents (including pursuant to a valid waiver or consent), (ii) any property subject to a Lien described in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.02(c)</b> or <b style="font-weight:bold;">(j)</b><a name="DocXTextRef527"></a><a name="DocXTextRef528"></a>, and (iii) all of the Collateral and all Obligors, upon (x) termination of the Commitments and (y) payment and satisfaction in full of all Loans and all other Obligations that the Administrative Agent has been notified in writing are then due and payable (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made).</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Each Lender hereby directs the Administrative Agent, and the Administrative Agent hereby agrees, upon receipt of reasonable advance notice from the Borrower, to execute and deliver or file such documents and to perform other actions reasonably necessary to release the guarantees and Liens when and as directed in this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">12.10</b> and deliver to the Borrower, at the expense of the Borrower, any portion of such Collateral so released pursuant to this <b style="font-weight:bold;">Section 12.10 </b><font style="white-space:pre-wrap;">that is in possession of the Administrative Agent.  In addition, in connection with any Permitted Licenses, each Lender hereby authorizes Administrative Agent to, and at the request of the Borrower, the Administrative Agent shall, negotiate and enter into a non-disturbance agreement and other similar agreements in form and substance reasonably satisfactory to Administrative Agent.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing or anything to the contrary herein, (i) the release of any Obligor from its guaranty of any Obligations under this <b style="font-weight:bold;">Section 12.10</b> or otherwise hereunder shall only be permitted if any such permitted transaction or series of related transactions is not consummated for the primary purpose of effecting a release of such Obligor from its Obligations under the Loan Documents in accordance with the terms hereof, and (ii) the Administrative Agent may not effect a release of any Obligor that ceases to be an Obligor due solely to a disposition of Equity Interests in (or issuance of Equity Interests by) such Obligor, unless in the case of this clause (ii) the transaction related to such release is a disposition of Equity Interests for fair market value to an unaffiliated third party and for a bona fide primary business purpose.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:8pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.11</font><a name="_Toc256000424"></a><a name="_Toc256000271"></a><a name="_Toc256000118"></a><a name="_Ref40130338"></a><a name="_Toc69324691"></a><a name="_Toc70875990"></a>Additional Secured Parties<font style="font-size:11pt;font-weight:normal;line-height:1.28;">. The benefit of the provisions of the Loan Documents directly relating to the Collateral or any Lien granted thereunder shall extend to and be available to any Secured Party that is not a Lender as long as, by accepting such benefits, such Secured Party agrees, as among the Administrative Agent and all other Secured Parties, that such Secured Party is bound by (and, if requested by the Administrative Agent, shall confirm such agreement in a writing in form and substance acceptable to the Administrative Agent) this </font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">Section 12</b><b style="font-size:11pt;font-weight:bold;line-height:1.28;"> </b><font style="font-size:11pt;font-weight:normal;line-height:1.28;">and the decisions and actions of the Administrative Agent and the Majority Lenders (or, where expressly required by the terms of this Agreement, a greater proportion of the Lenders) to the same extent a Lender is bound; </font><u style="font-size:11pt;font-weight:normal;line-height:1.28;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> that, notwithstanding the foregoing, </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:normal;line-height:1.28;"><a name="DocXTextRef531"></a></font><font style="font-size:11pt;font-weight:normal;line-height:1.28;">(i)</font><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> such Secured Party shall be bound by </font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">Section </b><b style="font-size:11pt;font-weight:bold;line-height:1.28;">12.08</b><b style="font-size:11pt;font-weight:bold;line-height:1.28;"> </b><font style="font-size:11pt;font-weight:normal;line-height:1.28;">only to the extent of liabilities, costs and expenses with respect to or otherwise relating to the Collateral held for the benefit of such Secured Party, in which case the obligations of such Secured Party thereunder shall not be limited by any concept of Proportionate Share or similar concept, (ii) each of the Administrative Agent and each Lender shall be entitled to act at its sole discretion, without regard to the interest of such Secured Party, regardless of whether any Obligation to such Secured Party thereafter remains outstanding, is deprived of the benefit of the Collateral, becomes unsecured or is otherwise affected or put in jeopardy thereby, and without any duty or liability to such Secured Party or any such Obligation and (iii) such Secured Party shall not have any right to be notified of, consent to, direct, require or be heard with respect to, any action taken or omitted in respect of the Collateral or under any Loan Document.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:8pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.12</font><a name="_Toc256000425"></a><a name="_Toc256000272"></a><a name="_Toc256000119"></a><a name="_Toc69324692"></a><a name="_Toc70875991"></a>Agent May File Proofs of Claim<font style="font-size:11pt;font-weight:normal;line-height:1.28;white-space:pre-wrap;">.  In case of the pendency of any Insolvency Proceeding or any other judicial proceeding relating to any Obligor, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower or any other Obligor) shall be entitled and empowered (but not obligated) by intervention or such proceeding or otherwise: </font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under <b style="font-weight:bold;">Section</b><i style="font-style:italic;"> </i><b style="font-weight:bold;">14.03</b>) allowed in such judicial proceeding; and</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same; </div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due to the Administrative Agent under </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Section 14.03</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:8pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.13</font><a name="_Toc256000426"></a><a name="_Toc256000273"></a><a name="_Toc256000120"></a><a name="_Ref43043956"></a><a name="_Ref43053118"></a><a name="_Toc69324693"></a><a name="_Toc70875992"></a>Intercreditor Agreement<font style="font-size:11pt;font-weight:normal;line-height:1.28;white-space:pre-wrap;">.  In connection with the incurrence by the Borrower of any Permitted Indebtedness pursuant to clause </font><font style="font-size:11pt;font-weight:normal;line-height:1.28;">(</font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">n)</b><font style="font-size:11pt;font-weight:normal;line-height:1.28;"> of </font><b style="font-size:11pt;font-weight:bold;line-height:1.28;">Section 9.01</b><font style="font-size:11pt;font-weight:normal;line-height:1.28;">, the Administrative Agent shall use commercially reasonable efforts, and is hereby authorized, to enter into an intercreditor agreement with respect to such Permitted Indebtedness in form and substance satisfactory to the Administrative Agent in its sole discretion, such intercreditor agreement shall in any event provide that (i) such debt financing provider shall, subject to the prior written consent of the Administrative Agent (which consent shall not be unreasonably withheld) have a silent second lien on the Intellectual Property relating to Ganaxolone (except as specifically provided in clause (ii)), (ii) such debt financing provider shall be entitled to a senior Lien on the Revenue Strip Proceeds, provided such debt financing provider shall not be entitled to take any enforcement or similar action with respect to such senior Lien on the Revenue Strip Proceeds that would be adverse to any senior Lien held by the Administrative Agent on the Lenders&#8217; behalf and unless otherwise agreed to in writing by the Administrative Agent, shall be subject to the same restrictions on enforcement and other conditions as a silent second lien (other than with respect to payment of the Revenue Strip Proceeds), which shall be subject to a customary waterfall and (iii) to the extent such debt financing provider becomes a Lender hereunder, such debt financing provider shall be required to support any debt restructuring, restructuring, or enforcement action or agreement supported by the Oaktree Lender so long as such Lender&#8217;s Loans hereunder are treated pro rata with the Loans held by the Oaktree Lender (such intercreditor agreement, a &#8220;</font><font style="font-size:11pt;font-style:italic;line-height:1.28;">Permitted Intercreditor Agreement</font><font style="font-size:11pt;font-weight:normal;line-height:1.28;">&#8221;). Each Lender agrees to be bound by the terms thereof and directs the Administrative Agent to enter into such Permitted Intercreditor Agreement on behalf of such Lender in connection with the Revenue Interest Financings and agrees that the Administrative Agent may take such actions on its behalf as is contemplated by the terms of such Permitted Intercreditor Agreement.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:8pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">12.14</font><a name="_Toc256000427"></a><a name="_Toc256000274"></a><a name="_Toc256000121"></a><a name="_Toc69324694"></a><a name="_Toc70875993"></a>Acknowledgements of Lenders<font style="font-size:11pt;font-weight:normal;line-height:1.28;white-space:pre-wrap;">.  </font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>If the Administrative Agent notifies a Lender, or any Person who has received funds on behalf of a Lender (any such Lender or other recipient, a &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Payment Recipient</u>&#8221;), that the Administrative Agent has determined in its sole discretion (whether or not after receipt of any notice under immediately succeeding clause (b)) that any funds received by such Payment Recipient from the Administrative Agent or any of its Affiliates were erroneously transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender or other Payment Recipient on its behalf) (any such funds, whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">otherwise, individually and collectively, an &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Erroneous Payment</u>&#8221;) and demands the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of the Administrative Agent and shall be segregated by the Payment Recipient and held in trust for the benefit of the Administrative Agent, and such Lender shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than two Business Days thereafter, return to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the greater of the Federal Funds Effective Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect. A notice of the Administrative Agent to any Payment Recipient under this clause (i) shall be conclusive, absent manifest error.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Without limiting immediately preceding clause (a), each Lender, or any Person who has received funds on behalf of a Lender, hereby further agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y) that was not preceded or accompanied by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates), or (z) that such Lender or other such recipient otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part) in each case: (i) (A) in the case of immediately preceding clauses (x) or (y), an error shall be presumed to have been made (absent written confirmation from the Administrative Agent to the contrary) or (B) an error has been made (in the case of immediately preceding clause (z)), in each case, with respect to such payment, prepayment or repayment; and (ii) such Lender shall (and shall cause any other recipient that receives funds on its respective behalf to) promptly (and, in all events, within one Business Day of its knowledge of such error) notify the Administrative Agent of its receipt of such payment, prepayment or repayment, the details thereof (in reasonable detail) and that it is so notifying the Administrative Agent pursuant to this Section 12.14(b)(ii).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Each Lender hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender under any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Lender from any source, against any amount due to the Administrative Agent under immediately preceding clause (a) or under the indemnification provisions of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><font style="white-space:pre-wrap;">In the event that an Erroneous Payment (or portion thereof) is not recovered by the Administrative Agent for any reason, after demand therefor by the Administrative Agent in accordance with immediately preceding clause (a), from any Lender that has received such Erroneous Payment (or portion thereof) (and/or from any Payment Recipient who received such Erroneous Payment (or portion thereof) on its respective behalf)  (such unrecovered amount, an &#8220;</font><u style="text-decoration:underline;text-decoration-color:#000000;">Erroneous Payment Return Deficiency</u>&#8221;), upon the Administrative Agent&#8217;s notice to such Lender at any time, (i) such Lender shall be deemed to have assigned its Loans (but not its </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Commitments) with respect to which such Erroneous Payment was made (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Erroneous Payment Impacted Loans</u>&#8221;) in an amount equal to the Erroneous Payment Return Deficiency (or such lesser amount as the Administrative Agent may specify) (such assignment of the Loans (but not Commitments) of the Erroneous Payment Impacted Loans, the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Erroneous Payment Deficiency Assignment</u><font style="white-space:pre-wrap;">&#8221;) at par plus any accrued and unpaid interest (with the assignment fee to be waived by the Administrative Agent in such instance), and is hereby (together with the Borrower) deemed to execute and deliver an Assignment and Assumption with respect to such Erroneous Payment Deficiency Assignment, and such Lender shall deliver any Notes evidencing such Loans to the Borrower or the Administrative Agent, (ii) the Administrative Agent as the assignee Lender shall be deemed to acquire the Erroneous Payment Deficiency Assignment, (iii) upon such deemed acquisition, the Administrative Agent as the assignee Lender shall become a Lender, as applicable, hereunder with respect to such Erroneous Payment Deficiency Assignment and the assigning Lender or assigning Issuing Bank shall cease to be a Lender or Issuing Bank, as applicable, hereunder with respect to such Erroneous Payment Deficiency Assignment, excluding, for the avoidance of doubt, its obligations under the indemnification provisions of this Agreement and its applicable Commitments which shall survive as to such assigning Lender and (iv) the Administrative Agent may reflect in the Register its ownership interest in the Loans subject to the Erroneous Payment Deficiency Assignment. The Administrative Agent may, in its discretion, sell any Loans acquired pursuant to an Erroneous Payment Deficiency Assignment and upon receipt of the proceeds of such sale, the Erroneous Payment Return Deficiency owing by the applicable Lender shall be reduced by the net proceeds of the sale of such Loan (or portion thereof), and the Administrative Agent shall retain all other rights, remedies and claims against such Lender (and/or against any recipient that receives funds on its respective behalf). For the avoidance of doubt, no Erroneous Payment Deficiency Assignment will reduce the Commitments of any Lender and such Commitments shall remain available in accordance with the terms of this Agreement.  In addition, each party hereto agrees that, except to the extent that the Administrative Agent has sold a Loan (or portion thereof) acquired pursuant to an Erroneous Payment Deficiency Assignment, and irrespective of whether the Administrative Agent may be equitably subrogated, the Administrative Agent shall be contractually subrogated to all the rights and interests of the applicable Lender under the Loan Documents with respect to each Erroneous Payment Return Deficiency (the &#8220;</font><u style="text-decoration:underline;text-decoration-color:#000000;">Erroneous Payment Subrogation Rights</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>The parties hereto agree that an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by the Borrower or any other Obligor, except, in each case, to the extent such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the Borrower or any other Obligor for the purpose of making such Erroneous Payment.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font>To the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payment received, including without limitation waiver of any defense based on &#8220;discharge for value&#8221; or any similar doctrine.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font>Each party&#8217;s obligations, agreements and waivers under this <b style="font-weight:bold;">Section 12.14(g)</b> shall survive the resignation or replacement of the Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender or Issuing Bank, the termination of the Commitments and/or the repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Loan Document.</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 13.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000428"></a><a name="_Toc256000275"></a><a name="_Toc256000122"></a><a name="_Toc69324695"></a><a name="_Toc70875994"></a>GUARANTY</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">13.01</font><a name="_Toc256000429"></a><a name="_Toc256000276"></a><a name="_Toc256000123"></a><a name="_Toc69324696"></a><a name="_Toc70875995"></a>The Guaranty<font style="font-weight:normal;">. The Subsidiary Guarantors hereby unconditionally jointly and severally guarantee to the Administrative Agent and the Lenders, and their successors and assigns, the full and punctual payment in full or performance (whether at stated maturity, by acceleration or otherwise) of the Obligations, including (i) principal of and interest on the Loans, (ii) all fees and other amounts and Obligations from time to time owing to the Administrative Agent and the Lenders by the Borrower and each other Obligor under this Agreement or under any other Loan Document, in each case strictly in accordance with the terms hereof and thereof and (iii) the punctual and faithful performance, keeping, observance and fulfillment by the Borrower and Subsidiary Guarantors of all the agreements, conditions, covenants and obligations of the Borrower and Subsidiary Guarantors contained in the Loan Documents (such obligations being herein collectively called the &#8220;</font><font style="font-style:italic;">Guaranteed Obligations</font><font style="font-weight:normal;">&#8221;). The Subsidiary Guarantors hereby further jointly and severally agree that if the Borrower or any other Obligor shall fail to pay any amount in full when due or perform any such obligation (whether at stated maturity, by acceleration or otherwise), the Subsidiary Guarantors will promptly pay the same or perform such obligation at the place and in the manner specified herein or in the relevant Loan Document, as the case may be, without any demand or notice whatsoever, and that in the case of any extension of time of payment or performance or renewal of any of the Guaranteed Obligations, the same will be promptly paid in full or performed when due (whether at extended maturity, by acceleration or otherwise) in accordance with the terms of such extension or renewal.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">13.02</font><a name="_Toc40400765"></a><a name="_Toc70875996"></a><a name="_Toc69324697"></a><a name="_Ref40130341"></a><a name="_Toc256000124"></a><a name="_Toc256000277"></a><a name="_Toc256000430"></a>Obligations Unconditional<font style="font-weight:normal;white-space:pre-wrap;">.  The obligations of the Subsidiary Guarantors under </font>Section 13.01 <font style="font-weight:normal;">shall constitute a guaranty of payment and performance and not of collection and are absolute and unconditional, joint and several, irrespective of the value, genuineness, validity, regularity or enforceability of the Guaranteed Obligations under this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by all applicable Laws, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, it being the intent of this </font>Section 13.02 <font style="font-weight:normal;">that the obligations of the Subsidiary Guarantors hereunder shall be absolute and unconditional, joint and several, under any and all circumstances. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following shall not alter or impair the liability of the Subsidiary Guarantors hereunder, which shall remain absolute and unconditional as described above:</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130342"></a>at any time or from time to time, without notice to the Subsidiary Guarantors, the time for any performance of or compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130343"></a>any of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to herein shall be done or omitted;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130344"></a>the maturity of any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed Obligations shall be extended, modified, supplemented or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall be waived or any other guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130345"></a>any lien or security interest granted to, or in favor of, the Secured Parties as security for any of the Guaranteed Obligations shall fail to be perfected or preserved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>any modification or amendment of or supplement to this Agreement or any other Loan Document, including any such amendment which may increase the amount of, or the interest rates applicable to, any of the Guaranteed Obligations guaranteed hereby;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font>any change in the corporate, partnership, limited liability company or other existence, structure or ownership of the Borrower, any Subsidiary Guarantor or any other guarantor of any of the Guaranteed Obligations, or any Insolvency Proceeding or other similar proceeding affecting the Borrower, any Subsidiary Guarantor or any other guarantor of the Guaranteed Obligations, or any of their respective assets, or any resulting release or discharge of any obligation of the Borrower, any Subsidiary Guarantor or any other guarantor of any of the Guaranteed Obligations;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font>the existence of any claim, setoff or other rights which any Subsidiary Guarantor may have at any time against the Borrower, any other Subsidiary Guarantor or any other guarantor of any of the Guaranteed Obligations, the Administrative Agent, any Secured Party or any other Person, whether in connection herewith or in connection with any unrelated transactions; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that, notwithstanding any other provisions in this Guaranty, nothing in this Guaranty shall prevent the assertion of any such claim by separate suit or compulsory counterclaim;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font>the unenforceability or invalidity of the Guaranteed Obligations or any part thereof or the lack of genuineness, enforceability or validity of any agreement relating thereto or with respect to the Collateral, if any, securing the Guaranteed Obligations or any part thereof, or any other invalidity or unenforceability relating to or against the Borrower, any Subsidiary Guarantor or any other guarantor of any of the Guaranteed Obligations, for any reason, related to this Agreement or any other Loan Document, or any provision of applicable Law, decree, order or regulation of any jurisdiction purporting to prohibit the payment of any of the Guaranteed Obligations by the Borrower, any Subsidiary Guarantor or any other guarantor of the Guaranteed Obligations;</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>the disallowance, under any state or federal bankruptcy, insolvency or similar law, of all or any portion of the claims of the Secured Parties or the Administrative Agent for repayment of all or any part of the Guaranteed Obligations;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font>the failure of any other guarantor to sign or become party to this Agreement or any amendment, change, or reaffirmation hereof;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font>any release, surrender, compromise, settlement, waiver, subordination or modification, with or without consideration, of any Collateral securing the Guaranteed Obligations or any part thereof, any other guaranties with respect to the Guaranteed Obligations or any part thereof, or any other obligation of any person or entity with respect to the Guaranteed Obligations or any part thereof, or any nonperfection or invalidity of any direct or indirect security for the Guaranteed Obligations; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font>any other act or omission to act or delay of any kind by the Borrower, such Guarantor, any other guarantor of the Guaranteed Obligations, the Administrative Agent, any Secured Party or any other Person or any other circumstance whatsoever which might, but for the provisions of this <b style="font-weight:bold;">Section 13.02</b>, constitute a legal or equitable discharge of any Guarantor&#8217;s obligations hereunder.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Subsidiary Guarantors hereby expressly waive diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that the Administrative Agent or any Lender exhaust any right, power or remedy or proceed against the Borrower or any other Subsidiary Guarantor under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other guarantee of, or security for, any of the Guaranteed Obligations.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36pt;white-space:nowrap;">13.03</font><b style="font-weight:bold;">Discharge Only Upon Payment in Full</b>. Subject to any prior release herefrom of any Subsidiary Guarantor by the Administrative Agent in accordance with (and pursuant to authority granted to the Administrative Agent under) the terms of this Agreement, each Subsidiary Guarantor&#8217;s obligations hereunder shall remain in full force and effect until all of the Guaranteed Obligations shall have been indefeasibly paid in full in cash (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made) and all other financing arrangements among the Borrower or any Subsidiary Guarantor and the Secured Parties under or in connection with this Agreement and each other Loan Document shall have terminated (herein, the &#8220;<font style="font-style:italic;font-weight:bold;">Termination Conditions</font>&#8221;), and until the prior and complete satisfaction of the Termination Conditions all of the rights and remedies under this Guaranty and the other Loan Documents shall survive. Notwithstanding the foregoing, the Administrative Agent hereby agrees to release any Subsidiary of the Borrower from its guaranty of any Obligation of any Obligor if all of the Equity Interests in such Subsidiary owned by any Obligor or any of its Subsidiaries are disposed of in an Asset Sale permitted under the Loan Documents (including pursuant to a waiver or consent), to the extent that, after giving effect to such Asset Sale, such Subsidiary would not be required to guarantee any Obligations pursuant to <b style="font-weight:bold;">Section 8.12(a)</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36pt;white-space:nowrap;">13.04</font><b style="font-weight:bold;">Additional Waivers; General Waivers</b>.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref26142162"></a><i style="font-style:italic;white-space:pre-wrap;">Additional Waivers.  </i>Notwithstanding anything herein to the contrary, each of the Subsidiary Guarantors hereby absolutely, unconditionally, knowingly, and expressly waives:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref26142163"></a>any right it may have to revoke this Guaranty as to future indebtedness or notice of acceptance hereof;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref26142164"></a><a name="DocXTextRef440"></a>(A) notice of acceptance hereof; (B)&#160;<a name="DocXTextRef441"></a>notice of any other financial accommodations made or maintained under the Loan Documents or the creation or existence of any Guaranteed Obligations; (C)&#160;<a name="DocXTextRef442"></a>notice of the amount of the Guaranteed Obligations, subject, however, to each Subsidiary Guarantor&#8217;s right to make inquiry of the Administrative Agent and the Secured Parties to ascertain the amount of the Guaranteed Obligations at any reasonable time; (D)&#160;<a name="DocXTextRef443"></a>notice of any adverse change in the financial condition of the Borrower or of any other fact that might increase such Subsidiary Guarantor&#8217;s risk hereunder; (E)&#160;<a name="DocXTextRef444"></a>notice of presentment for payment, demand, protest, and notice thereof as to any instruments among the Loan Documents; (F)&#160;<a name="DocXTextRef445"></a>notice of any Event of Default; and (G)&#160;all other notices (except if such notice is specifically required to be given to such Subsidiary Guarantor under this Guaranty or under the other Loan Documents) and demands to which each Subsidiary Guarantor might otherwise be entitled;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref26142165"></a>its right, if any, to require the Administrative Agent and the Secured Parties to institute suit against, or to exhaust any rights and remedies which the Administrative Agent and the Secured Parties now have or may hereafter have against, any other guarantor of the Guaranteed Obligations or any third party, or against any Collateral provided by such other guarantors or any third party; and each Subsidiary Guarantor further waives any defense arising by reason of any disability or other defense (other than the defense that the Guaranteed Obligations shall have been fully and finally performed and indefeasibly paid) of any other guarantor of the Guaranteed Obligations or by reason of the cessation from any cause whatsoever of the liability of any other guarantor of the Guaranteed Obligations in respect thereof;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref26142166"></a><a name="DocXTextRef450"></a>(A) any rights to assert against the Administrative Agent and the Secured Parties any defense (legal or equitable), set-off, counterclaim, or claim which such Subsidiary Guarantor may now or at any time hereafter have against any other guarantor of the Guaranteed Obligations or any third party liable to the Administrative Agent and the Secured Parties; (B)&#160;any defense, set-off, counterclaim or claim, of any kind or nature, arising directly or indirectly from the present or future lack of perfection, sufficiency, validity or enforceability of the Guaranteed Obligations or any security therefor; (C)&#160;<a name="DocXTextRef446"></a>any defense such Subsidiary Guarantor has to performance hereunder, and any right such Subsidiary Guarantor has to be exonerated, arising by reason of: (1)&#160;<a name="DocXTextRef447"></a>the impairment or suspension of the Administrative Agent&#8217;s and the Secured Parties&#8217; rights or remedies against any other guarantor of the Guaranteed Obligations; (2)&#160;<a name="DocXTextRef448"></a>the alteration by the Administrative Agent and the Secured Parties of the Guaranteed Obligations; (3)&#160;<a name="DocXTextRef449"></a>any discharge of the obligations of any other guarantor of the Guaranteed Obligations to the Administrative Agent and the Secured Parties by operation of law as a result of the Administrative Agent&#8217;s and the Secured Parties&#8217; intervention or omission; or (4)&#160;the acceptance by the Administrative Agent and the Secured Parties of anything in partial satisfaction of the Guaranteed Obligations; and (D)&#160;the benefit of any statute of limitations affecting such Subsidiary Guarantor&#8217;s liability hereunder or the enforcement thereof, and any act which shall defer or delay the operation of any statute of limitations applicable to the Guaranteed Obligations </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;">shall similarly operate to defer or delay the operation of such statute of limitations applicable to such Subsidiary Guarantor&#8217;s liability hereunder; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><a name="_Ref26142167"></a>any defense arising by reason of or deriving from (A)&#160;any claim or defense based upon an election of remedies by the Administrative Agent and the other Secured Parties; or (B)&#160;any election by the Administrative Agent and the other Secured Parties under any provision of any state or federal bankruptcy, insolvency or similar law to limit the amount of, or any Collateral securing, its claim against the Subsidiary Guarantors.</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><i style="font-style:italic;">General Waivers</i><font style="white-space:pre-wrap;">.  Each Subsidiary Guarantor irrevocably waives, to the fullest extent permitted by law, any notice not provided for herein.</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">13.05</font><a name="_Toc40400767"></a><a name="_Toc70875997"></a><a name="_Toc69324698"></a><a name="_Ref40130346"></a><a name="_Toc256000125"></a><a name="_Toc256000278"></a><a name="_Toc256000431"></a>Reinstatement<div style="margin-top:12pt;"></div><font style="font-weight:normal;">. The obligations of the Subsidiary Guarantors under this </font>Section 13<font style="font-weight:normal;"> shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of the Borrower in respect of the Guaranteed Obligations is at any time rescinded, annulled, avoided, set aside, invalidated, declared to be fraudulent or must be otherwise restored or repaid by any holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization, equitable cause or otherwise, and the Subsidiary Guarantors jointly and severally agree that they will indemnify the Secured Parties on demand for all reasonable costs and expenses (including fees of counsel) incurred by such Persons in connection with such rescission, repayment or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any state or federal bankruptcy, insolvency or similar law. The provisions of this </font>Section 13.05<font style="font-weight:normal;"> shall survive termination of this Guaranty.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">13.06</font><a name="_Toc256000432"></a><a name="_Toc256000279"></a><a name="_Toc256000126"></a><a name="_Ref40130347"></a><a name="_Toc69324699"></a><a name="_Toc70875998"></a>Subrogation<font style="font-weight:normal;white-space:pre-wrap;">. The Subsidiary Guarantors hereby jointly and severally agree that, until the prior and complete satisfaction of all Termination Conditions, they (i) shall have no right of subrogation with respect to the Guaranteed Obligations and (ii) (ii) waive any right to enforce any remedy which the Secured Parties or the Administrative Agent now have or may hereafter have against the Borrower, any endorser or any other guarantor of all or any part of the Guaranteed Obligations or any other Person, and each Subsidiary Guarantor waives any benefit of, and any right to participate in, any security or Collateral that may from time to time be given to the Secured Parties and the Administrative Agent to secure the payment or performance of all or any part of the Guaranteed Obligations or any other liability of the Borrower to the Secured Parties.  Should any Subsidiary Guarantor have the right, notwithstanding the foregoing, to exercise its subrogation rights prior to complete satisfaction of the Termination Conditions, each Subsidiary Guarantor hereby expressly and irrevocably (A)&#160;subordinates any and all rights at law or in equity to subrogation, reimbursement, exoneration, contribution, indemnification or set-off that such Subsidiary Guarantor may have prior to the complete satisfaction of the Termination Conditions, and (B)&#160;</font><font style="font-weight:normal;white-space:pre-wrap;">waives any and all defenses available to a surety, guarantor or accommodation co-obligor until all Termination Conditions are satisfied in full.  Each Subsidiary Guarantor acknowledges and agrees that this subordination is intended to benefit the Administrative Agent and the Secured Parties and shall not limit or otherwise affect such Subsidiary Guarantor&#8217;s liability hereunder or the enforceability of this Guaranty, and that the Administrative Agent, the Secured Parties and their respective successors and assigns are intended third party beneficiaries of the waivers and agreements set forth in this </font>Section 13.06<font style="font-weight:normal;">.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">13.07</font><a name="_Toc256000433"></a><a name="_Toc256000280"></a><a name="_Toc256000127"></a><a name="_Ref40130348"></a><a name="_Toc69324700"></a><a name="_Toc70875999"></a>Remedies<font style="font-weight:normal;">. The Subsidiary Guarantors jointly and severally agree that, as between the Subsidiary Guarantors, on one hand, and the Administrative Agent and the Lenders, on the other hand, the obligations of the Borrower under this Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in </font>Section 11 <font style="font-weight:normal;">(and shall be deemed to have become automatically due and payable in the circumstances provided in </font>Section 11<font style="font-weight:normal;">) for purposes of </font>Section 13.01 <font style="font-weight:normal;">notwithstanding any stay, injunction or other prohibition, including any such stay upon an Insolvency Proceeding, preventing such declaration (or such obligations from becoming automatically due and payable) as against the Borrower and that, in the event of such declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether or not due and payable by the Borrower) shall forthwith become due and payable by the Subsidiary Guarantors for purposes of </font>Section 13.01<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">13.08</font><a name="_Toc256000434"></a><a name="_Toc256000281"></a><a name="_Toc256000128"></a><a name="_Ref40130349"></a><a name="_Toc69324701"></a><a name="_Toc70876000"></a>Instrument for the Payment of Money<font style="font-weight:normal;">. Each Subsidiary Guarantor hereby acknowledges that the guarantee in this </font>Section 13 <font style="font-weight:normal;">constitutes an instrument for the payment of money, and consents and agrees that the Administrative Agent and the Lenders, at their sole option, in the event of a dispute by such Subsidiary Guarantor in the payment of any moneys due hereunder, shall have the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y. Civ. Prac. L&amp;R &#167; 3213.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">13.09</font><a name="_Toc256000435"></a><a name="_Toc256000282"></a><a name="_Toc256000129"></a><a name="_Ref40130350"></a><a name="_Toc69324702"></a><a name="_Toc70876001"></a>Continuing Guarantee<font style="font-weight:normal;">. The guarantee in this </font>Section 13<font style="font-weight:normal;"> is a continuing guarantee, and shall apply to all Guaranteed Obligations whenever arising.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36pt;white-space:nowrap;">13.10</font><a name="_Toc480909434"></a><a name="_Toc480909767"></a><a name="_Toc480909927"></a><a name="_Toc480910064"></a><a name="_Toc480910199"></a><a name="_Toc480912442"></a><a name="_Toc480918408"></a><a name="_Toc480920333"></a><a name="_Toc480920468"></a><a name="_Ref26142173"></a><a name="_Toc32683695"></a><a name="_Ref40350451"></a><a name="_Ref40350482"></a><a name="_Ref40350548"></a><a name="_Ref40359561"></a><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Contribution with Respect to Guaranteed Obligations</b><font style="font-family:'Times New Roman','Times','serif';">.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref26142174"></a><font style="font-family:'Times New Roman','Times','serif';">To the extent that any Subsidiary Guarantor shall make a payment under this Guaranty (a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Guarantor Payment</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) which, taking into account all other Guarantor Payments then previously or concurrently made by any other Subsidiary Guarantor, exceeds the amount which otherwise would have been paid by or attributable to such Subsidiary Guarantor if each Subsidiary Guarantor had paid the aggregate Guaranteed Obligations satisfied by such Guarantor Payment in the same proportion as such Subsidiary Guarantor&#8217;s &#8220;Allocable Amount&#8221; (as defined below) (as determined immediately prior to such Guarantor Payment) bore to the aggregate Allocable Amounts of each of the Subsidiary Guarantors as determined immediately prior to the making of such Guarantor Payment, </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">then</i><font style="font-family:'Times New Roman','Times','serif';">, following the prior and complete satisfaction of the Termination Conditions, such Subsidiary Guarantor shall be entitled to receive contribution and indemnification payments from, and be reimbursed by, each other Subsidiary Guarantor for the amount of such excess, </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">pro rata</i><font style="font-family:'Times New Roman','Times','serif';"> based upon their respective Allocable Amounts in effect immediately prior to such Guarantor Payment.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref26142175"></a><font style="font-family:'Times New Roman','Times','serif';">As of any date of determination, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Allocable Amount</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; of any Subsidiary Guarantor shall be equal to the maximum amount of the claim which could then be recovered from such Subsidiary Guarantor under this Agreement without rendering such claim voidable or avoidable under any state or federal bankruptcy, insolvency or similar law or other applicable Law.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref26142176"></a><font style="font-family:'Times New Roman','Times','serif';">This </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.10</b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">is intended only to define the relative rights of the Subsidiary Guarantors, and nothing set forth in this </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.10</b><font style="font-family:'Times New Roman','Times','serif';"> is intended to or shall impair the obligations of the Subsidiary Guarantors, jointly and severally, to pay any amounts as and when the same shall become due and payable in accordance with the terms of this Agreement.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref26142177"></a><font style="font-family:'Times New Roman','Times','serif';">The parties hereto acknowledge that the rights of contribution and indemnification hereunder shall constitute assets of the Subsidiary Guarantor or Subsidiary Guarantors to which such contribution and indemnification is owing.</font><a name="_Ref26142178"></a></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';">The rights of the indemnifying Subsidiary Guarantors against other Subsidiary Guarantors under this </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Section</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.10</b><font style="font-family:'Times New Roman','Times','serif';"> shall be exercisable only upon the prior and complete satisfaction of the Termination Conditions.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">13.11</font><a name="_Toc256000436"></a><a name="_Toc256000283"></a><a name="_Toc256000130"></a><a name="_Ref40130351"></a><a name="_Toc69324703"></a><a name="_Toc70876002"></a>General Limitation on Guarantee Obligations<font style="font-weight:normal;">. In any action or proceeding involving any provincial, territorial or state corporate law, or any state or federal bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if the obligations of any Subsidiary Guarantor under </font>Section 13.01 <font style="font-weight:normal;">would otherwise be held or determined to be void, invalid or unenforceable, or subordinated to the claims of any other creditors, on account of the amount of its liability under </font>Section 13.01<font style="font-weight:normal;">, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by such Subsidiary Guarantor, the Administrative Agent, any Lender or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated to the claims of other creditors as determined in such action or proceeding.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Section 14.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc256000437"></a><a name="_Toc256000284"></a><a name="_Toc256000131"></a><a name="_Ref40130352"></a><a name="_Toc69324704"></a><a name="_Toc70876003"></a>MISCELLANEOUS</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.01</font><a name="_Toc256000438"></a><a name="_Toc256000285"></a><a name="_Toc256000132"></a><a name="_Ref40130353"></a><a name="_Toc69324705"></a><a name="_Toc70876004"></a>No Waiver<font style="font-weight:normal;">. No failure on the part of the Administrative Agent or the Lenders to exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege under any Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.02</font><a name="_Toc256000439"></a><a name="_Toc256000286"></a><a name="_Toc256000133"></a><a name="_Ref40130354"></a><a name="_Toc69324706"></a><a name="_Toc70876005"></a>Notices<font style="font-weight:normal;">. All notices, requests, instructions, directions and other communications provided for herein (including any modifications of, or waivers, requests or consents under, this Agreement) or in the other Loan Documents shall be given or made in writing (including by telecopy or email) delivered, if to the Borrower, another Obligor, the Administrative Agent or any Lender, to its address specified on the signature pages hereto or its Guarantee Assumption Agreement, as the case may be, or at such other address as shall be designated by such party in a written notice to the other parties. Except as otherwise provided in this Agreement or therein, all such communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by telecopy shall be confirmed in writing promptly after the delivery of such communication (it being understood that non-receipt of written confirmation of such communication shall not invalidate such communication).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.03</font><a name="_Toc256000440"></a><a name="_Toc256000287"></a><a name="_Toc256000134"></a><a name="_Ref40130355"></a><a name="_Toc69324707"></a><a name="_Toc70876006"></a>Expenses, Indemnification, Etc.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130356"></a><b style="font-weight:bold;">Expenses</b><a name="DocXTextRef546"></a>. Each Obligor, jointly and severally, agrees to pay or reimburse within fifteen (15) Business Days of receipt of a reasonably detailed invoice (i) the Administrative Agent and the Lenders and their respective Affiliates for all of their reasonable and documented </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><a name="DocXTextRef547"></a><a name="DocXTextRef548"></a><a name="DocXTextRef549"></a>out of pocket costs and expenses (including the reasonable and documented out of pocket fees, expenses, charges and disbursements of Sullivan &amp; Cromwell LLP, counsel to the Administrative Agent and the Lenders, the fees (if necessary) of local counsel and regulatory counsel for both of the Administrative Agent and the Lenders in each relevant material jurisdiction, and any sales, goods and services or other similar Taxes applicable thereto, and reasonable and documented printing, reproduction, document delivery, communication and travel costs) in connection with (x) the negotiation, preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Loans (exclusive of post-closing costs), (y) post-closing costs (including, without limitation, costs of the administration of this Agreement and the other Loan Documents) and (z) the negotiation or preparation of any modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not consummated); <i style="font-style:italic;">provided</i>, that, in the case of such expenses on the Closing Date, the amount of such expenses obligated to be paid by the Obligors shall not exceed $300,000 and shall be net of any amounts previously paid by the Borrower to the Administrative Agent or any Lender as a deposit against such fees, costs and expenses and (ii) each of the Administrative Agent and the Lenders for all of their documented out of pocket costs and expenses (including the fees and expenses of any legal counsel) in connection with the enforcement, exercise or protection of their rights in connection with this Agreement and the other Loan Documents, including their rights under this <b style="font-weight:bold;">Section 14.03</b><a name="_Ref40130357"></a>, or in connection with the Loans made hereunder, including such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans and in connection with any enforcement or collection proceedings resulting from the occurrence of an Event of Default.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref70848637"></a><b style="font-weight:bold;">Indemnification</b>. Each Obligor, jointly and severally, hereby indemnifies the Administrative Agent (and any sub-agent thereof), the Lenders and their respective Affiliates, directors, officers, employees, attorneys, agents, advisors and controlling parties (each, an &#8220;<font style="font-style:italic;font-weight:bold;">Indemnified Party</font>&#8221;) from and against, and agrees to hold them harmless against, any and all Claims and Losses of any kind including reasonable and documented out of pocket fees and disbursements of any counsel for each Indemnified Party (limited to one legal counsel in each relevant jurisdiction), that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or relating to (i) this Agreement or any of the other Loan Documents or the Transactions, (ii) any use made or proposed to be made with the proceeds of the Loans, (ii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by any Obligor or any of its Subsidiaries, or (iv) any actual or prospective claim, investigation, litigation or proceeding relating to any of the foregoing, whether based on contract, tort, or any other theory, whether or not such investigation, litigation or proceeding is brought by any Obligor, any of its Subsidiaries, shareholders or creditors, an Indemnified Party or any other Person, or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in <b style="font-weight:bold;">Section 6</b><b style="font-weight:bold;"> </b>are satisfied or the other transactions contemplated by this Agreement are consummated, except to the extent such Claim or Loss is (i) found in a final, non-appealable judgment by a court of competent jurisdiction to have resulted from such Indemnified Party&#8217;s gross negligence or willful misconduct or (ii) is determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from a claim brought by any Obligor against an Indemnified Party for material breach in bad faith or reckless disregard of such Indemnified Party&#8217;s obligations hereunder or under any other Loan Document. No Obligor shall assert any claim against any Indemnified Party, on any theory of liability, for consequential, indirect, special or punitive </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual or proposed use of the proceeds of the Loans. The Borrower, its Subsidiaries and Affiliates and their respective directors, officers, employees, attorneys, agents, advisors and controlling parties are each sometimes referred to in this Agreement as a &#8220;<font style="font-style:italic;font-weight:bold;">Borrower Party</font><font style="white-space:pre-wrap;">&#8221;.  None of the Administrative Agent and the Lenders shall assert any claim against any Borrower Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual or proposed use of the proceeds of the Loans. Notwithstanding the foregoing in this Section 14.03(b), the Obligors shall not be liable for any settlement of any proceeding effected without the Obligors&#8217; consent (which consent shall not be unreasonably withheld, delayed or conditioned), but if settled with the Obligors&#8217; written consent, or if there is a judgment against an Indemnified Party in any such proceeding, the Obligors shall indemnify and hold harmless each Indemnified Party to the extent and in the manner set forth above.  The Obligors shall not, without the prior written consent of an Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed), effect any settlement of any pending or threatened proceeding against such Indemnified Party in respect of which indemnity could have been sought hereunder by such Indemnified Party unless (a) such settlement includes an unconditional release of such Indemnified Party from all liability or claims that are the subject matter of, or arise out of, such proceeding and (b) such settlement does not include any statement as to, or any admission of fault, culpability, wrongdoing or a failure to act by or on behalf of such Indemnified Party. This Section shall not apply with respect to (x) Taxes other than Taxes relating to a non-Tax Claim or Loss governed by this </font><b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.03(a)</b> and (y) yield protection matters covered by <b style="font-weight:bold;">Section 5.01</b>, which shall be governed exclusively by <b style="font-weight:bold;">Section 5.01</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.04</font><a name="_Toc256000441"></a><a name="_Toc256000288"></a><a name="_Toc256000135"></a><a name="_Ref40130358"></a><a name="_Toc69324708"></a><a name="_Toc70876007"></a>Amendments, Etc.<font style="font-weight:normal;white-space:pre-wrap;"> Except as otherwise expressly provided in this Agreement, any provision of this Agreement and any other Loan Document may be modified or supplemented only by an instrument in writing signed by the Borrower, the Administrative Agent and the Majority Lenders; </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"> that:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130359"></a>any such modification or supplement that is disproportionately adverse to any Lender as compared to other Lenders or subjects any Lender to any additional obligation shall not be effective without the consent of such affected Lender;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130360"></a>the consent of all of the Lenders shall be required to:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40130361"></a>amend, modify, discharge, terminate or waive any of the terms of this Agreement or any other Loan Agreement if such amendment, modification, discharge, termination or waiver would increase the amount of the Loans or Commitment, reduce the fees payable hereunder, reduce interest rates (<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the Majority Lenders may rescind an imposition of default interest hereunder) or other amounts payable with respect to the Loans (excluding mandatory prepayments), extend any date fixed for payment of principal (excluding mandatory prepayments) (it being understood that the waiver of any prepayment of Loans shall not constitute an extension of any date fixed for payment of principal), interest or other amounts payable relating to the Loans or extend the repayment dates of the Loans (excluding mandatory prepayments); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that a waiver of any condition precedent set forth in <b style="font-weight:bold;">Section 6.02</b> or of </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">any Default or Event of Default or a mandatory reduction in Commitments is not considered an increase in Commitments of any Lender)</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40130362"></a>amend, modify, discharge, terminate or waive any Security Document if the effect is to release all or substantially all of the Collateral subject thereto other than pursuant to the terms hereof or thereof; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40130363"></a>amend this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.04</b><b style="font-weight:bold;"> </b>or the definition of &#8220;Majority Lenders&#8221;.</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding anything to the contrary herein, (A) the Administrative Agent and the Borrower may amend or modify this Agreement and any other Loan Document to (1) cure any factual or typographical error, omission, defect or inconsistency therein, or (2) grant a new Lien for the benefit of the Lenders, extend an additional Lien over additional property for the benefit of the Lenders or join additional Persons as Obligors and (B) no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.05</font><a name="_Toc256000442"></a><a name="_Toc256000289"></a><a name="_Toc256000136"></a><a name="_Ref40130364"></a><a name="_Toc69324709"></a><a name="_Toc70876008"></a>Successors and Assigns<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130365"></a><b style="font-weight:bold;">General</b>. The provisions of this Agreement and the other Loan Documents shall be binding upon and inure to the benefit of the parties hereto or thereto and their respective successors and assigns permitted hereby or thereby, except that no Obligor may assign or otherwise transfer any of its rights or obligations hereunder or under any of the other Loan Documents (except in connection with an event permitted under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">9.03</b><a name="DocXTextRef553"></a>) without the prior written consent of the Administrative Agent. Any Lender may assign or otherwise transfer any of its rights or obligations hereunder or under any of the other Loan Documents (i) to an assignee in accordance with the provisions of <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(b)</b>, (ii) by way of participation in accordance with the provisions of <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(e)</b>, or (iii) by way of pledge or assignment of a security interest subject to the restrictions of <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(f)</b>. Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(e)</b> and, to the extent expressly contemplated hereby, the Indemnified Parties) any legal or equitable right, remedy or claim under or by reason of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130366"></a><b style="font-weight:bold;">Assignments by Lender</b>. Any Lender may at any time assign to one or more Eligible Transferees (or, if an Event of Default has occurred and is continuing, to any Person that is not a Defaulting Lender) all or a portion of its rights and obligations under this Agreement (including all or a portion of the Loans at the time owing to it) and the other Loan Documents; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that no such assignment shall be made to any Obligor, any Affiliate of any Obligor, any employees or directors of any Obligor at any time and no such assignment shall be made without the prior written consent of the Administrative Agent. The consent of the Borrower (such consent not to be unreasonably withheld, conditioned or delayed) shall be required unless (x) an </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Event of Default under <b style="font-weight:bold;">Section</b> <b style="font-weight:bold;">11.01(a)</b>, <b style="font-weight:bold;">11.01(b)</b> or <b style="font-weight:bold;">11.01(h)</b> has occurred and is continuing at the time of such assignment or (y) such assignment is to an Eligible Transferee described in clause (vi) of the definition thereof); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after having received written notice thereof. Subject to the recording thereof by the Administrative Agent pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(d)</b>, and to receipt by the Administrative Agent of a processing and recordation fee in the amount of $3,500 (<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment) from and after the date such Assignment and Assumption is recorded in the Register, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of the Lender under this Agreement and the other Loan Documents, and correspondingly the assigning Lender shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the Lender&#8217;s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) and the other Loan Documents but shall continue to be entitled to the benefits of <b style="font-weight:bold;">Section 5</b><b style="font-weight:bold;"> </b>and <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.03</b>. Any assignment or transfer by the Lender of rights or obligations under this Agreement that does not comply with this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(b)</b><b style="font-weight:bold;"> </b>shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(e)</b>. If an assignee is not a Lender, the assignee shall provide the Administrative Agent with all &#8220;know your customer&#8221; documents requested by the Administrative Agent pursuant to anti-money laundering rules and regulations.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130367"></a><b style="font-weight:bold;">Amendments to Loan Documents</b>. Each of the Administrative Agent, the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably acceptable to the Administrative Agent, the Lenders and the Obligors, as shall reasonably be necessary to implement and give effect to any assignment made under this <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40130368"></a><b style="font-weight:bold;">Register</b>. The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain at one of its offices in the United States a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;<font style="font-style:italic;font-weight:bold;">Register</font>&#8221;). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior written notice. Notwithstanding anything to the contrary, any assignment of any Loan shall be effective only upon appropriate entries with respect thereto being made in the Register.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40130369"></a><b style="font-weight:bold;">Participations</b>. Any Lender may at any time, without the consent of, or notice to, the Borrower, sell participations to any Eligible Transferee (other than a natural person, a Defaulting Lender or any Obligor or any of its Affiliates or Subsidiaries) (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Participant</font>&#8221;) in all or a portion of the Lender&#8217;s rights and/or obligations under this Agreement (including all or a portion of the Commitment and/or the Loans owing to it); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><a name="DocXTextRef567"></a> that (i) such Lender&#8217;s obligations under this Agreement and the other Loan Documents shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower shall continue to deal solely and directly with such Lender in connection therewith. Any agreement or instrument pursuant to which any Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce the Loan Documents and to approve any amendment, modification or waiver of any provision of the Loan Documents; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u><a name="DocXTextRef568"></a> that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i) increase or extend the term of such Lender&#8217;s Commitment (it being understood and agreed that a waiver of any condition precedent set forth in <b style="font-weight:bold;">Section 6.02</b> or of any Default or Event of Default or a mandatory reduction in Commitments is not considered an increase of any Commitment), (ii) extend the date fixed for the payment of principal (excluding mandatory prepayments) of or interest on the Loans or any portion of any fee hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal, or (iv) reduce the rate at which interest is payable thereon to a level below the rate at which the Participant is entitled to receive such interest (other than a waiver of default interest). Subject to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(f)</b>, the Borrower agrees that each Participant shall be entitled to the benefits of <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">5.03</b><b style="font-weight:bold;"> </b>(subject to the requirements and limitations therein, including the requirements under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(f)</b><b style="font-weight:bold;"> </b>(it being understood that the documentation required under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.03(f)</b><b style="font-weight:bold;"> </b>shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(b)</b>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that such Participant (i) shall not be entitled to such benefits unless such Participant agrees, for the benefit of the Borrower, to comply with the documentation requirements of <b style="font-weight:bold;">Section 5.03(e)(ii)</b> as if it were a Lender and complies with such requirements, (ii) agrees to be subject to the provisions of <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.04</b><b style="font-weight:bold;"> </b>as if it were an assignee under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">14.05(b)</b><b style="font-weight:bold;"> </b>and (iii) shall not be<b style="font-weight:bold;"> </b>entitled to receive any greater payment under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">5.03</b>, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a change in Law that occurs after the Participant acquired the applicable participation. To the extent permitted by Law, each Participant also shall be entitled to the benefits of <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">4.03(a)</b><b style="font-weight:bold;"> </b>as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#8217;s interest in the Loans or other obligations under the Loan Documents (the &#8220;<font style="font-style:italic;font-weight:bold;">Participant Register</font>&#8221;); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant&#8217;s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under <a name="DocXTextRef569"></a>Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40130370"></a><b style="font-weight:bold;">Limitations on Rights of Participants</b>. A Participant shall not be entitled to receive any greater payment under <b style="font-weight:bold;">Section </b><b style="font-weight:bold;">5.01</b><b style="font-weight:bold;"> </b>or <b style="font-weight:bold;">5.03</b><b style="font-weight:bold;"> </b>than such Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower&#8217;s prior written consent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40130371"></a><b style="font-weight:bold;">Certain Pledges</b>. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under the Loan Documents to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><b style="font-weight:bold;">Certain Additional Payments</b><font style="white-space:pre-wrap;">. In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable Proportionate Share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full Proportionate Share of all Loans.  Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.06</font><a name="_Toc256000443"></a><a name="_Toc256000290"></a><a name="_Toc256000137"></a><a name="_Ref40130372"></a><a name="_Toc69324710"></a><a name="_Toc70876009"></a>Survival<font style="font-weight:normal;">. The obligations of the Borrower under </font>Sections<font style="font-weight:normal;"> </font>5.01<font style="font-weight:normal;">, </font>5.03<font style="font-weight:normal;">, </font>14.03<font style="font-weight:normal;">, </font>14.05<font style="font-weight:normal;">, </font>14.06<font style="font-weight:normal;">, </font>14.09<font style="font-weight:normal;">, </font>14.10<font style="font-weight:normal;">, </font>14.11<font style="font-weight:normal;">, </font>14.12<font style="font-weight:normal;">, </font>14.13<font style="font-weight:normal;"> and </font>14.14 <font style="font-weight:normal;">and the obligations of the Subsidiary Guarantors under </font>Section 13 <font style="font-weight:normal;">(solely to the extent guaranteeing any of the obligations under the foregoing Sections) shall survive the repayment of the Obligations and the termination of the Commitments and, in the case of the Lenders&#8217; assignment of any interest in the Commitments or the Loans hereunder, shall survive, in the case of any event or circumstance that occurred prior to the effective date of such assignment, the making of such assignment, notwithstanding that the Lenders may cease to be &#8220;Lenders&#8221; hereunder. In addition, each representation and warranty made, or deemed to be made by a Borrowing Notice, herein or pursuant hereto shall survive the making of such representation and warranty.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.07</font><a name="_Toc256000444"></a><a name="_Toc256000291"></a><a name="_Toc256000138"></a><a name="_Ref40130373"></a><a name="_Toc69324711"></a><a name="_Toc70876010"></a>Captions<font style="font-weight:normal;">. The table of contents and captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.08</font><a name="_Toc256000445"></a><a name="_Toc256000292"></a><a name="_Toc256000139"></a><a name="_Ref40130374"></a><a name="_Toc69324712"></a><a name="_Toc70876011"></a>Counterparts, Effectiveness<font style="font-weight:normal;">. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof. This Agreement shall become effective when counterparts hereof executed on behalf of the Obligors, the Administrative Agent and the Lender shall have been received by the Administrative Agent.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.09</font><a name="_Toc256000446"></a><a name="_Toc256000293"></a><a name="_Toc256000140"></a><a name="_Ref40130375"></a><a name="_Toc69324713"></a><a name="_Toc70876012"></a>Governing Law<font style="font-weight:normal;">. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"> that Section 5-1401 of the New York General Obligations Law shall apply.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.10</font><a name="_Toc256000447"></a><a name="_Toc256000294"></a><a name="_Toc256000141"></a><a name="_Ref40130376"></a><a name="_Toc69324714"></a><a name="_Toc70876013"></a>Jurisdiction, Service of Process and Venue<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130377"></a><b style="font-weight:bold;">Submission to Jurisdiction</b>. Each party hereby irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or tort or otherwise, against such other party in any way relating to this Agreement or any Loan Document or the transactions relating hereto or thereto, in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable Law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130378"></a><b style="font-weight:bold;">[Reserved]</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40130379"></a><b style="font-weight:bold;">Waiver of Venue, Etc</b>. Each party hereto irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document and hereby further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such party is or may be subject, by suit upon judgment.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.11</font><a name="_Toc256000448"></a><a name="_Toc256000295"></a><a name="_Toc256000142"></a><a name="_Ref40130380"></a><a name="_Toc69324715"></a><a name="_Toc70876014"></a>Waiver of Jury Trial<font style="font-weight:normal;">. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.12</font><a name="_Toc256000449"></a><a name="_Toc256000296"></a><a name="_Toc256000143"></a><a name="_Ref40130381"></a><a name="_Toc69324716"></a><a name="_Toc70876015"></a>Waiver of Immunity<font style="font-weight:normal;">. To the extent that any Obligor may be or become entitled to claim for itself or its property or revenues any immunity on the ground of sovereignty or the like from suit, court jurisdiction, attachment prior to judgment, attachment in aid of execution of a judgment or execution of a judgment, and to the extent that in any such jurisdiction there may be attributed such an immunity (whether or not claimed), such Obligor hereby irrevocably agrees not to claim and hereby irrevocably waives such immunity with respect to its obligations under this Agreement and the other Loan Documents.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.13</font><a name="_Toc256000450"></a><a name="_Toc256000297"></a><a name="_Toc256000144"></a><a name="_Ref40130382"></a><a name="_Ref40130735"></a><a name="_Toc69324717"></a><a name="_Toc70876016"></a>Entire Agreement<font style="font-weight:normal;">. This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof, including any confidentiality (or similar) agreements. EACH OBLIGOR ACKNOWLEDGES, REPRESENTS AND WARRANTS THAT IN DECIDING TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS OR IN TAKING OR NOT TAKING ANY ACTION HEREUNDER OR THEREUNDER, IT HAS NOT RELIED, AND WILL NOT RELY, ON ANY STATEMENT, REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR UNDERSTANDING, WHETHER WRITTEN OR ORAL, OF OR WITH ADMINISTRATIVE AGENT OR THE LENDERS OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.14</font><a name="_Toc256000451"></a><a name="_Toc256000298"></a><a name="_Toc256000145"></a><a name="_Ref40130383"></a><a name="_Toc69324718"></a><a name="_Toc70876017"></a>Severability<font style="font-weight:normal;"><a name="_cp_text_2_4465"></a>. If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by any Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.</font><font style="font-weight:normal;"> Without limiting the foregoing provisions of this </font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Section 14.14</b><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">,</u><font style="font-weight:normal;"> if and</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;"><a name="_cp_text_5_4466"></a></font><font style="font-weight:normal;">to the extent that the </font><font style="font-weight:normal;"><a name="_cp_text_2_4467"></a></font><font style="font-weight:normal;">enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by the </font><font style="font-weight:normal;">Bankruptcy Code, or any other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect</font><font style="font-weight:normal;">, as determined in good faith by the Administrative Agent, then such provisions shall be deemed to be in effect only to the extent not so limited.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.15</font><a name="_Toc256000452"></a><a name="_Toc256000299"></a><a name="_Toc256000146"></a><a name="_Ref40130384"></a><a name="_Toc69324719"></a><a name="_Toc70876018"></a>No Fiduciary Relationship<font style="font-weight:normal;">. The Borrower acknowledges that the Administrative Agent and the Lenders have no fiduciary relationship with, or fiduciary duty to, the Borrower arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between the Lenders and the Borrower is solely that of creditor and debtor. This Agreement and the other Loan Documents do not create a joint venture among the parties.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.16</font><a name="_Toc256000453"></a><a name="_Toc256000300"></a><a name="_Toc256000147"></a><a name="_Ref40130385"></a><a name="_Toc69324720"></a><a name="_Toc70876019"></a>Confidentiality<font style="font-weight:normal;">. The Administrative Agent and each Lender agree to keep confidential, and not disclose to any Person all non-public information provided to them by or on behalf of any Obligor pursuant to this Agreement that is designated by such Obligor as confidential in accordance with its customary procedures for handling its own confidential information; </font><u style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-weight:normal;"><a name="DocXTextRef593"></a> that nothing herein shall prevent the Administrative Agent or any Lender from disclosing any such information (i) to the Administrative Agent, any other Lender, any Affiliate of a Lender or subject to an agreement to comply with the provisions of this Section, any Eligible Transferee or other assignee permitted under </font>Section 14.05(b)<font style="font-weight:normal;">, (ii) subject to an agreement to comply with the provisions of this Section, to any actual or prospective direct or indirect </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-left:0pt;margin-right:0pt;"><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">counterparty to any Hedging Agreement (or any professional advisor to such counterparty), (iii) to its employees, officers, directors, agents, attorneys, accountants, trustees and other professional advisors or those of any of its affiliates (collectively, its &#8220;</font><font style="color:#000000;font-style:italic;font-weight:bold;text-align:left;">Related Parties</font><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;"><a name="DocXTextRef594"></a>&#8221;) (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (iv) upon the request or demand of any Governmental Authority or any Regulatory Authority purporting to have jurisdiction over such Person or its Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (v) in response to any order of any court or other Governmental Authority or as may otherwise be required pursuant to any Law, (vi) if requested or required to do so in connection with any litigation or similar proceeding, (vii) that has been publicly disclosed (other than as a result of a disclosure in violation of this </font><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;">Section </b><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;">14.16</b><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;"><a name="DocXTextRef595"></a><a name="DocXTextRef596"></a><a name="DocXTextRef597"></a>), (viii) to the National Association of Insurance Commissioners or any similar organization or any nationally recognized rating agency that requires access to information about a Lender&#8217;s investment portfolio in connection with ratings issued with respect to such Lender, (ix) in connection with the exercise of any remedy hereunder or under any other Loan Document, (x) on a confidential basis to (A) any rating agency in connection with rating the Borrower or its Subsidiaries or the Loans or (B) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers of other market identifiers with respect to the Loans or (xi) to any other party hereto; </font><u style="color:#000000;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;"> that, in the case of disclosure pursuant to </font><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;">clause (iv), </b><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;"><a name="DocXTextRef598"></a></font><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;">(v)</b><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;"> </b><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">and </font><b style="color:#000000;font-style:normal;font-weight:bold;text-align:left;">(vi) </b><font style="color:#000000;font-style:normal;font-weight:normal;text-align:left;">above, the Administrative Agent or applicable Lender, as applicable, shall promptly provide notice to the Borrower to the extent reasonable and not prohibited by Law or any applicable Governmental Authority.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.17</font><a name="_Toc256000454"></a><a name="_Toc256000301"></a><a name="_Toc256000148"></a><a name="_Ref40130386"></a><a name="_Toc69324721"></a><a name="_Toc70876020"></a>Interest Rate Limitation<font style="font-weight:normal;">. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Loan, together with all fees, charges and other amounts that are treated as interest on such Loan under applicable Law (collectively, &#8220;</font><font style="font-style:italic;">charges</font><font style="font-weight:normal;">&#8221;), shall exceed the maximum lawful rate (the &#8220;</font><font style="font-style:italic;">Maximum Rate</font><font style="font-weight:normal;">&#8221;) that may be contracted for, charged, taken, received or reserved by the Administrative Agent and the Lender holding such Loan in accordance with applicable Law, the rate of interest payable in respect of such Loan hereunder, together with all charges payable in respect thereof, shall be limited to the Maximum Rate. To the extent lawful, the interest and charges that would have been paid in respect of such Loan but were not paid as a result of the operation of this Section shall be cumulated and the interest and charges payable to such Lender in respect of other Loans or periods shall be increased (but not above the amount collectible at the Maximum Rate therefor) until such cumulated amount, together with interest thereon at the Federal Funds Effective Rate for each day to the date of repayment, shall have been received by such Lender. Any amount collected by such Lender that exceeds the maximum amount collectible at the Maximum Rate shall be applied to the reduction of the principal balance of such Loan so that at no time shall the interest and charges paid or payable in respect of such Loan exceed the maximum amount collectible at the Maximum Rate.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.18</font><a name="_Toc256000455"></a><a name="_Toc256000302"></a><a name="_Toc256000149"></a><a name="_Ref40130387"></a><a name="_Toc69324722"></a><a name="_Toc70876021"></a>Judgment Currency<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130388"></a>If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder in Dollars into another currency, the parties hereto agree, to the fullest extent permitted by Law, that the rate of exchange used shall be that at which, in accordance with normal banking procedures, the Administrative Agent could purchase Dollars with such other currency at the buying spot rate of exchange in the New York foreign exchange market on the </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Business Day immediately preceding that on which any such judgment, or any relevant part thereof, is given.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130389"></a>The obligations of the Obligors in respect of any sum due to the Administrative Agent hereunder and under the other Loan Documents shall, notwithstanding any judgment in a currency other than Dollars, be discharged only to the extent that on the Business Day following receipt by the Administrative Agent of any sum adjudged to be so due in such other currency the Administrative Agent may, in accordance with normal banking procedures, purchase Dollars with such other currency. If the amount of Dollars so purchased is less than the sum originally due to the Administrative Agent in Dollars, the Borrower agrees, to the fullest extent that it may effectively do so, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent against such loss. If the amount of Dollars so purchased exceeds the sum originally due to the Administrative Agent in Dollars, the Administrative Agent shall remit such excess to the Borrower.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.19</font><a name="_Toc256000456"></a><a name="_Toc256000303"></a><a name="_Toc256000150"></a><a name="_Ref40130390"></a><a name="_Toc69324723"></a><a name="_Toc70876022"></a>USA PATRIOT Act<font style="font-weight:normal;"><a name="DocXTextRef601"></a>. The Administrative Agent and the Lenders hereby notify the Obligors that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the &#8220;</font><font style="font-style:italic;">Patriot Act</font><font style="font-weight:normal;">&#8221;), they are required to obtain, verify and record information that identifies the Obligors, which information includes the name and address of each Obligor and other information that will allow such Person to identify such Obligor in accordance with the Patriot Act.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.20</font><a name="_Toc256000457"></a><a name="_Toc256000304"></a><a name="_Toc256000151"></a><a name="_Ref40130391"></a><a name="_Toc69324724"></a><a name="_Toc70876023"></a>Acknowledgement and Consent to Bail-In of EEA Financial Institutions<font style="font-weight:normal;">. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any EEA Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40130392"></a>the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an EEA Financial Institution; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40130393"></a>the effects of any Bail-In Action on any such liability, including, if applicable:</div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:12.5pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:12.5pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';">a reduction in full or in part or cancellation of any such liability;</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:72pt;margin:0pt 20.65pt 12.5pt 5.95pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">(ii)</font></font><font style="font-family:'Times New Roman','Times','serif';">a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement</font><a name="_Ref40130394"></a><font style="font-family:'Times New Roman','Times','serif';"> or any other Loan Document; or</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:72pt;margin:0pt 20.65pt 12.5pt 5.95pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">(iii)</font></font><font style="font-family:'Times New Roman','Times','serif';">the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of any EEA Resolution Authority.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">14.21</font><a name="_Toc256000458"></a><a name="_Toc256000305"></a><a name="_Toc256000152"></a><a name="_Toc70876024"></a>Certain ERISA Matters<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Each Person that becomes party hereto after the date hereof as a Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and its Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower or Guarantors, that at least one of the following is and will be true:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>such Lender is not using &#8220;plan assets&#8221; (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Employee Benefit Plans with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Notes or this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Notes and this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>(A) such Lender is an investment fund managed by a &#8220;Qualified Professional Asset Manager&#8221; (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Notes and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Notes and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84- 14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Notes and this Agreement; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font>such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a)&#160;is true with respect to a Lender making the representation in clause (a) or (2) a Lender making the representation in clause (a) has provided another representation, warranty and covenant in accordance with sub-clause (iv) in the immediately preceding clause (a), such Lender further (x)&#160;represents and warrants, as of the date such Person became a Lender party hereto, to, and (y)&#160;covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and its Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower, that none of the Administrative Agent or its Affiliates is a fiduciary with respect to the assets of such Lender involved in such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Notes and this Agreement (including in connection with the reservation or </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">exercise of any rights by the Administrative Agent under this Agreement, any other Loan Documents or any documents related hereto or thereto).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signature Pages Follow]</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="color:#2a312d;font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.</p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#2a312d;">BORROWER:</font></p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="color:#2a312d;font-weight:bold;">MARINUS PHARMACEUTICALS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Steven Pfanstiel</p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Steven Pfanstiel</p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices: <br>Marinus Pharmaceuticals, Inc.<br>5 Radnor Corporate Center<br>100 Matsonford Rd, Suite 500<br>Radnor, PA 19087<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Steven Pfanstiel, Chief Financial Officer<br>Tel.:<font style="display:inline-block;width:17.4pt;"></font>(484) 801-4670</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Fax:</font></font>484-801-4669</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>spfanstiel@marinuspharma.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Marinus Pharmaceuticals, Inc.<br>5 Radnor Corporate Center<br>100 Matsonford Rd, Suite 500<br>Radnor, PA 19087<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Martha E. Manning, Esq., General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: mmanning@marinuspharma.com </p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">ADMINISTRATIVE AGENT</b>:</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE FUND ADMINISTRATION, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:53.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:53.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Managing Member</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:53.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:53.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:59.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;"><a name="_Hlk68014912"></a></font><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:40.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LENDERS</b>:</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TCDRS STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">EXELON STRATEGIC CREDIT HOLDINGS, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE-NGP STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE-MINN STRATEGIC CREDIT LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE-FORREST MULTI-STRATEGY, LLC </b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:65.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND C, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:59.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:59.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:59.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:59.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:65.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND F, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:64.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND G, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:58.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:58.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:58.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:58.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:64.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TSE 16 STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">INPRS STRATEGIC CREDIT HOLDINGS, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Oaktree Gilead Investment Fund AIF (Delaware), L.P.&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Fund AIF Series, L.P. &#8211; Series T</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Fund GP AIF, LLC</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Managing Member</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Fund GP III, L.P.</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Managing Member</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Oaktree PRE Life Sciences Fund, L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Pre Life Sciences Fund GP, L.P.</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Fund GP IIA, LLC</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Fund GP II, L.P.</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Managing Member</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Oaktree Huntington-GCF Investment Fund (Direct </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Lending AIF), L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:11.5pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF) GP, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:11.5pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF) GP, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:11.5pt;">Oaktree Fund GP III, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Managing Member </p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Oaktree Global Credit Plus Fund, L.P. </b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Fund GP, LLC</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Fund GP I, L.P.</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Managing Member</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Oaktree Strategic Income II, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Fund Advisors, LLC</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Investment Advisor</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Oaktree Specialty Lending Corporation</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Oaktree Fund Advisors, LLC</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Investment Advisor </p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jessica Dombroff</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Brian Price</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Senior Vice President</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071<br>Attn:<font style="display:inline-block;width:15.44pt;"></font>Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Email:</font></font>Oaktreeagency@alterdomus.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="line-height:1.19;">333 S. Grand Avenue, 28</font><sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="line-height:1.19;"> Fl.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: AmKumar@oaktreecapital.com</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:24pt 0pt 24pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Schedule 1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Loans Schedule</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Tranche A-1 Term Loans</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Lenders and their respective Applicable Commitments:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Lender</b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Applicable Commitment</b></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TCDRS Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $749,160 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exelon Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $455,520 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-NGP Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $760,080 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Minn Strategic Credit LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $367,680 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Forrest Multi-Strategy, LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $602,520 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund C, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $358,920 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund F, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $562,320 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund G, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $918,360 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TSE 16 Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $820,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">INPRS Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $228,240 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Gilead Investment Fund AIF (Delaware), L.P.&#160; </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,936,080 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree PRE Life Sciences Fund, L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $2,082,360 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF), L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $524,880 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">Oaktree Global Credit Plus Fund, L.P.  </font></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $349,920 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Strategic Income II, Inc.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $843,240 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Specialty Lending Corporation</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $3,440,520 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Tranche A-1 Commitment </b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$15,000,000</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">The following defined terms apply to the Tranche A-1 Term Loans:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-1 Funding Condition</font>&#8221;<b style="font-weight:bold;"> </b>means that (i) a Borrowing Notice with respect to the Tranche A-1 Term Loans shall have been received by the Administrative Agent and (ii) the Closing Date shall have occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Tranche A-2 Term Loans</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Lenders and their respective Applicable Commitments:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Lender</b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Applicable Commitment</b></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TCDRS Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,498,320 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exelon Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $911,040 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-NGP Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,520,160 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Minn Strategic Credit LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $735,360 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Forrest Multi-Strategy, LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,205,040 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund C, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $717,840 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund F, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,124,640 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund G, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,836,720 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TSE 16 Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,640,400 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">INPRS Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $456,480 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Gilead Investment Fund AIF (Delaware), L.P.&#160; </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $3,872,160 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree PRE Life Sciences Fund, L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $4,164,720 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF), L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,049,760 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">Oaktree Global Credit Plus Fund, L.P.  </font></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $699,840 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Strategic Income II, Inc.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,686,480 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Specialty Lending Corporation</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $6,881,040 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Tranche A-2 Commitment </b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$30,000,000</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">The following defined terms apply to the Tranche A-2 Term Loans:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Ganaxolone Filing Acceptance</font>&#8221; means written acceptance by the FDA of an NDA filing relating to use of Ganaxolone in treatment of CDKL5 deficiency disorder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-2 Availability Period</font>&#8221;<b style="font-weight:bold;"> </b>means the period starting on the Closing Date and ending on the applicable Commitment Termination Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche A-2 Funding Condition</font>&#8221;<b style="font-weight:bold;"> </b>means that (i) the Closing Date shall have occurred and (ii) the Ganaxolone Filing Acceptance shall have been received by the Borrower and the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Tranche B Term Loans</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Lenders and their respective Applicable Commitments:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Lender</b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Applicable Commitment</b></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TCDRS Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,498,320 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exelon Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $911,040 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-NGP Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,520,160 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Minn Strategic Credit LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $735,360 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Forrest Multi-Strategy, LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,205,040 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund C, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $717,840 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund F, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,124,640 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund G, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,836,720 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TSE 16 Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,640,400 </font></p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">INPRS Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $456,480 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Gilead Investment Fund AIF (Delaware), L.P.&#160; </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $3,872,160 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree PRE Life Sciences Fund, L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $4,164,720 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF), L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,049,760 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">Oaktree Global Credit Plus Fund, L.P.  </font></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $699,840 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Strategic Income II, Inc.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,686,480 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Specialty Lending Corporation</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $6,881,040 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Tranche B Commitment </b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$30,000,000</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">The following defined terms apply to the Tranche B Term Loans:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Ganaxolone FDA Approval</font>&#8221; means the receipt of written approval from the FDA of an NDA permitting the marketing of Ganaxolone in interstate commerce in the United States to treat CDKL5 deficiency disorder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Tranche B Availability Period</font>&#8221;<b style="font-weight:bold;"> </b>means the period starting on the date of the Ganaxolone FDA Approval and ending on the applicable Commitment Termination Date.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Tranche B Funding Condition</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">means that (i) the Closing Date shall have occurred and (ii) the Ganaxolone FDA Approval shall have been received by the Borrower and the Administrative Agent.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Tranche C Term Loans</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Lenders and their respective Applicable Commitments:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Lender</b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Applicable Commitment</b></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TCDRS Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,248,600 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exelon Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $759,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-NGP Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,266,800 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Minn Strategic Credit LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $612,800 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Forrest Multi-Strategy, LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,004,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund C, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $598,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund F, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $937,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund G, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,530,600 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TSE 16 Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,367,000 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">INPRS Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $380,400 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Gilead Investment Fund AIF (Delaware), L.P.&#160; </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $3,226,800 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree PRE Life Sciences Fund, L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $3,470,600 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF), L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $874,800 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">Oaktree Global Credit Plus Fund, L.P.  </font></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $583,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Strategic Income II, Inc.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,405,400 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Specialty Lending Corporation</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $5,734,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Tranche C Commitment </b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$25,000,000</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">The following defined terms apply to the Tranche C Term Loans:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Qualified Financing</font>&#8221; means one or more financings permitted to be incurred or entered under the Loan Documents, including through the issuance of Equity Interests, convertible Indebtedness, subordinated Indebtedness, a synthetic royalty or a Permitted License in which the Borrower has received gross proceeds in an aggregate amount of at least $40,000,000 and net proceeds in an aggregate amount of at least $36,000,000.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Tranche C Availability Period</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the period starting on the first Business Day following receipt by the Administrative Agent of the Tranche C Condition Certificate and ending on the applicable Commitment Termination Date.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Tranche C Condition Certificate</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">means a certificate signed by a Responsible Officer of the Borrower certifying that (A) Ganaxolone has achieved statistical significance (p value &lt; 0.05) across all primary endpoints and is generally well tolerated, with a safety profile generally consistent with previous clinical trials, in each case </font><font style="font-family:'Times New Roman','Times','serif';">in either (x) the RSE Phase 3 clinical trial (1042-SE-3001) or (y) the TSC Phase 3 clinical trial (1042-TSC-3001)</font><font style="font-family:'Times New Roman','Times','serif';">and (B)&#160;a Qualified Financing has been consummated.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Tranche C Funding Condition</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">means that (i) the Closing Date shall have occurred, (ii) the Ganaxolone FDA Approval shall have been received by the Borrower and the Administrative Agent and (iii) the Administrative Agent shall have received the Tranche C Condition Certificate.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:45pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Tranche D Term Loans</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Lenders and their respective Applicable Commitments:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Lender</b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Applicable Commitment</b></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TCDRS Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,248,600 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exelon Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $759,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-NGP Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,266,800 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Minn Strategic Credit LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $612,800 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-Forrest Multi-Strategy, LLC </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,004,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund C, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $598,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund F, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $937,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TBMR Strategic Credit Fund G, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,530,600 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree-TSE 16 Strategic Credit, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,367,000 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">INPRS Strategic Credit Holdings, LLC</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $380,400 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Gilead Investment Fund AIF (Delaware), L.P.&#160; </p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $3,226,800 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree PRE Life Sciences Fund, L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $3,470,600 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF), L.P.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $874,800 </font></p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">Oaktree Global Credit Plus Fund, L.P.  </font></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $583,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Strategic Income II, Inc.</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $1,405,400 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Oaktree Specialty Lending Corporation</p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> $5,734,200 </font></p></td></tr><tr><td style="vertical-align:top;width:69.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Tranche D Commitment </b></p></td><td style="vertical-align:top;width:30.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$25,000,000</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">The following defined terms apply to the Tranche D Term Loans:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:45pt;margin:0pt 0pt 8pt 0pt;"><a name="_Hlk68707916"></a><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Market Net Revenue</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, for any period, aggregate net revenues by the Borrower and its Subsidiaries from (i) sales of Ganaxolone in the United States by the Borrower and its Subsidiaries, (ii) licensees of Borrower or its Subsidiaries in the United States, and (iii) any other commercialization partners of Borrower or its Subsidiaries in the United States for such period (which aggregate net revenues shall be calculated in accordance with GAAP), determined on a consolidated basis and consistent with the manner in which the Borrower reports product net revenues in the Borrower&#8217;s financial statements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:45pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:45pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Tranche D Availability Period</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the period starting on the first Business Day following receipt by the Administrative Agent of the Tranche D Condition Certificate and ending on the applicable Commitment Termination Date. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:45pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:45pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Tranche D Condition Certificate</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">means a certificate signed by a Responsible Officer of the Borrower certifying that (A) Market Net Revenue for the most recently ended trailing six (6) consecutive month period exceeded $50,000,000.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:45pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-indent:45pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Tranche D Funding Condition</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">means that (i) the Closing Date shall have occurred, (ii) the Ganaxolone FDA Approval shall have been received by the Borrower and the Administrative Agent and (iii) the Administrative Agent shall have received the Tranche D Condition Certificate.</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>mrns-20210331xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/17/2021 08:23:07 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;border-top:3px double #000000;margin:108pt 0pt 12pt 0pt;">SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">by and among</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">MARINUS PHARMACEUTICALS, INC.,</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">a Delaware corporation<br>(the &#8220;Borrower&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">the Borrower&#8217;s Subsidiaries named in the signature pages hereto or having acceded hereto pursuant to Section&#160;24</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(each a &#8220;Subsidiary Guarantor&#8221;<br>and, together with the Borrower, each a &#8220;Grantor&#8221;<br>and, collectively, the &#8220;Grantors&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">OAKTREE FUND ADMINISTRATION, LLC,</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">as Administrative Agent for the Lenders referred to below<br>(in such capacity, together with its successors and assigns,<br>the &#8220;Administrative Agent&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;border-bottom:3px double #000000;margin:0pt 0pt 12pt 0pt;">Dated as of May 11, 2021</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Page</b></p><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;1</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Definitions; Interpretation</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;2</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Security Interest</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;3</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Perfection and Priority</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">9</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;4</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Representations and Warranties</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">12</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;5</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Covenants</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">16</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;6</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Rights to Payment and Pledged Collateral.</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">21</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;7</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Authorization; Agent Appointed Attorney-in-Fact</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">23</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;8</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Agent Performance of Grantor Obligations</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">25</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;9</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Agent&#8217;s Duties</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">25</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;10</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Remedies</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">25</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;11</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Certain Waivers</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">29</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;12</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Notices</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">29</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;13</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">No Waiver; Cumulative Remedies</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">29</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;14</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Costs and Expenses; Indemnification</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">30</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;15</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Binding Effect</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">30</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;16</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Governing Law</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">31</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;17</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Submission to Jurisdiction</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">31</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;18</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Waiver of Jury Trial</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">31</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;19</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Entire Agreement; Amendment</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">31</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;20</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Severability</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">32</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;21</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Counterparts</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">32</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;22</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Incorporation of Provisions of the Credit Agreement</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">32</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;23</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">No Inconsistent Requirements</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">32</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;24</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Accession</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">32</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;25</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Termination</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">32</font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:18.18%;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-transform:uppercase;">Section&#160;26</font></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Right of Set-Off</font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">33</font></font></p></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECURITY AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">THIS SECURITY AGREEMENT (this &#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221;), dated as of May 11, 2021, is made by and among Marinus Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Borrower</font>&#8221;), the Borrower&#8217;s Subsidiaries named in the signature pages hereto or having acceded hereto pursuant to <b style="font-weight:bold;">Section&#160;24</b><b style="font-weight:bold;"> </b>(each a &#8220;<font style="font-style:italic;font-weight:bold;">Subsidiary Guarantor</font>&#8221; and, together with the Borrower, each a &#8220;<font style="font-style:italic;font-weight:bold;">Grantor</font>&#8221; and, collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Grantors</font>&#8221;), and Oaktree Fund Administration, LLC, as administrative agent for the Lenders referred to below (in such capacity, together with its successors and assigns, the &#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Borrower, the Subsidiary Guarantors from time to time party thereto, the lenders from time to time party thereto (the &#8220;<font style="font-style:italic;font-weight:bold;">Lenders</font>&#8221;) and the Administrative Agent are parties to that certain Credit Agreement and Guaranty, dated as of May 11, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<font style="font-style:italic;font-weight:bold;">Credit Agreement</font>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, in order to guarantee the indebtedness and other obligations of the Borrower under the Credit Agreement, each Subsidiary Guarantor has executed the Credit Agreement, or will execute and deliver on the date such Subsidiary Guarantor accedes hereto, a Guarantee Assumption Agreement (as defined in the Credit Agreement); and </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, it is a condition precedent to the Borrowing under the Credit Agreement that the Grantors enter into this Agreement and grant to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, the security interests hereinafter provided to secure the obligations of the Borrower and the Subsidiary Guarantors described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, the parties hereto agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;1</font><a name="_Ref40146072"></a><a name="_Ref40146785"></a><a name="_Toc71361868"></a>Definitions; Interpretation<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146073"></a><b style="font-weight:bold;">Terms Defined in Credit Agreement</b>. All capitalized terms used in this Agreement (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Credit Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146074"></a><b style="font-weight:bold;">Certain Defined Terms</b>. As used in this Agreement, the following terms shall have the following meanings:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Acceding Grantor</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section&#160;24</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Accession Agreement</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section&#160;24</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Books</font>&#8221; means all books, records and other written, electronic or other documentation in whatever form maintained now or hereafter by or for any Grantor in connection with the ownership of its assets or the conduct of its business or evidencing or containing information relating to the Collateral, including: (i)&#160;ledgers; (ii)&#160;records indicating, summarizing, or evidencing any Grantor&#8217;s assets (including Inventory and Rights to Payment), business operations or financial condition; (iii)&#160;computer programs and software; (iv)&#160;computer discs, tapes, files, manuals, spreadsheets; (v)&#160;computer printouts and output of whatever kind; (vi)&#160;any other </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">computer prepared or electronically stored, collected or reported information and equipment of any kind; and (vii)&#160;any and all other rights now or hereafter arising out of any Contract or agreement between any Grantor and any service bureau, computer or data processing company or other Person charged with preparing or maintaining any of any Grantor&#8217;s books or records or with credit reporting, including with regard to any such Grantor&#8217;s Accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Collateral</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section&#160;2</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Excluded Asset</font>&#8221; means:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(i)</font>any Equity Interests of any Foreign Subsidiary that is a CFC (and any of its Subsidiaries) and any Equity Interests of any CFC Holding Company (and any of its Subsidiaries), in each case, other than 65% of the issued and outstanding voting Equity Interests of a CFC or CFC Holding Company; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that the above exclusion shall apply only to the extent the Borrower reasonably determines (after consultation with the Administrative Agent) that the failure to impose such exclusion could reasonably be expected to generate material adverse tax consequences to the Borrower or any of its Subsidiaries (as determined in good faith from time to time);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(ii)</font>any leases, licenses, permits, letters of credit, bonds, guarantees, chattel paper, contracts, rights, instrument, document or other agreements or purchase money arrangements contained within the Collateral to which any Grantor is a party or any of its rights or interests are subject thereto (including pursuant to a purchase money security interest or similar arrangement) to the extent and solely to the extent that the grant of such security interest shall (1)&#160;constitute or result in the abandonment, invalidation or unenforceability of any right, title, interest or purchase money arrangement of such Grantor therein, (2)&#160;create a situation under which such Grantor shall be deemed to have breached or terminated pursuant to the terms of, or defaulted under, or a termination right shall arise under any such Collateral; and in each cause under <b style="font-weight:bold;">clauses&#160;(1) </b>and <b style="font-weight:bold;">(2) </b>above such abandonment, invalidation, unenforceability, breach, termination or default (x) would not be rendered ineffective pursuant to Sections&#160;9-406, 9-407, 9-408 or 9-409 of the NY UCC (or any successor provision or provisions) of any relevant jurisdiction or any applicable Law or principles or equity or (y) is waivable by any Grantor or Subsidiary thereof, or (3)&#160;violate any material provisions of law applicable to such Grantor of lease, license, contract, right or other agreement (so long as such term was not incurred or entered into in contemplation of this Agreement); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that the Excluded Assets shall not include, and such security interest shall attach immediately at such time as the condition causing such abandonment, invalidation, unenforceability, breach, termination, default, termination right or violation shall be remedied and to the extent severable, shall attach immediately to, any portion of such lease, license, permit, letter of credit, bond, guarantee, chattel paper, contract, right, instrument, document, agreement or purchase money arrangement that does not result in any of the consequences specified in <b style="font-weight:bold;">(1)</b>, <b style="font-weight:bold;">(2) </b>or <b style="font-weight:bold;">(3) </b>above;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(iii)</font>assets to the extent (and only to the extent) and for so long as the grant of a security interest by any Grantor in such assets hereunder would violate any provision of Law applicable to such Grantor or such assets, after giving effect to any applicable anti-assignment provision of the NY UCC or other applicable Law and other than proceeds thereof to the extent </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;">that the assignment of the same is effective under the NY UCC or other applicable Law notwithstanding such restriction;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(iv)</font>any United States &#8220;intent-to-use&#8221; trademark or service mark application filed pursuant to Section 1(b) of the Lanham Act prior to the filing of an &#8220;Amendment to Allege Use&#8221; or a &#8220;Statement of Use&#8221; pursuant to Sections 1(c) or 1(d) of the Lanham Act, solely to the extent that, and only for so long as, the grant of such security interest therein would impair the validity or enforceability of, render void or voidable, or result in the cancellation of, such &#8220;intent-to-use&#8221; trademark or service mark application under federal law;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(v)</font>any particular assets if the burden, cost or consequences of creating or perfecting such pledges or security interests in such assets is excessive in relation to the benefits to be obtained by the Secured Parties under the Loan Documents as mutually agreed by the Borrower and the Administrative Agent;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(vi)</font>any property or assets of a CFC or CFC Holding Company (and in each case its Subsidiaries) to the extent a security interests therein would result in material adverse tax consequences to the Borrower or any of its Domestic Subsidiaries, as reasonably determined by the Borrower in consultation with the Administrative Agent; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(vii)</font>motor vehicles and other assets subject to certificates of title, except to the extent a security interest therein can be perfected by the filing of a UCC financing statement; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(viii)</font>equity interests of joint ventures permitted by the Credit Agreement to the extent and for so long as the pledge of such equity interests is prohibited by such Person&#8217;s organizational or joint venture documents or any contractual obligation of such Person, to the extent such contractual obligation is permitted under the Loan Documents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(ix)</font>any property subject to a Permitted Lien pursuant to Section 9.02(c) of the Credit Agreement; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:81pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:27pt;text-indent:0pt;white-space:nowrap;">(x)</font>Excluded Accounts.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">provided</i> that the Proceeds of any Excluded Assets shall not constitute Excluded Assets and shall be subject to the Security Interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Grantors</font>&#8221; has the meaning set forth in the preamble to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Intellectual Property Collateral</font>&#8221; means the following properties and assets owned or otherwise controlled by any Grantor or in which any Grantor otherwise has any interest, now existing or hereafter acquired or arising:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(i)</font></font>all Patents, domestic or foreign, all Licenses relating to any of the foregoing and all income and royalties with respect to any Licenses (including such Patents and Patent licenses as are described in <b style="font-weight:bold;">Schedule&#160;2</b>), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(ii)</font></font>all Copyrights, domestic or foreign, together with the underlying works of authorship (including titles), whether or not the underlying works of authorship have been published and whether said Copyrights are statutory or arise under the common law, and all other rights and works of authorship (including the Copyrights described in <b style="font-weight:bold;">Schedule&#160;2</b>), all computer programs, computer databases, computer program flow diagrams, source codes, object codes and all tangible property embodying or incorporating any Copyrights, all Licenses relating to any of the foregoing and all income and royalties with respect to any Licenses, and all other rights, Claims and demands in any way relating to any such Copyrights or works, including royalties and rights to sue for past, present or future infringement, and all rights of renewal and extension of such Copyrights;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(iii)</font></font>all state (including common law), federal and foreign Trademarks, internet websites, and internet domain names and associated URL addresses, all Licenses relating to any of the foregoing and all income and royalties with respect to any Licenses (including such Trademarks and Trademark licenses as described in <b style="font-weight:bold;">Schedule&#160;2</b>), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(iv)</font></font>all Technical Information, trade secrets, mask-works, mask-work registrations, mask-work applications, software, confidential and proprietary information, customer lists, advertising materials, operating manuals, methods, processes, know-how, algorithms, formulae, data (including business data and technical data), databases, quality control procedures, product, service and technical specifications, operating, production and quality control manuals, sales literature, drawings, specifications, blue prints, descriptions, inventions, name plates, catalogs;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(v)</font></font>the entire goodwill of or associated with the businesses now or hereafter conducted by such Grantor connected with and symbolized by any of the aforementioned properties and assets; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(vi)</font></font>all accounts, all other proprietary rights, all other Intellectual Property or other similar property and all other intangibles associated with or arising out of any of the aforementioned properties and assets and not otherwise described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Intellectual Property Security Agreement</font>&#8221; means each Copyright Security Agreement in substantially the form of <b style="font-weight:bold;">Exhibit&#160;C</b>, each Trademark Security Agreement in substantially the form of <b style="font-weight:bold;">Exhibit D</b>, each Patent Security Agreement in substantially the form of <b style="font-weight:bold;">Exhibit&#160;E</b> or any amendment thereto and prepared for purposes of recordation with the U.S. Copyright Office or the U.S. Patent and Trademark Office, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">License</font>&#8221; shall mean any written agreement pursuant to which any Grantor grants or receives any license, sublicense, release, covenant not to assert or other right to the extent the foregoing is with respect to any Intellectual Property, including those listed on <b style="font-weight:bold;">Schedule 2</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">NY UCC</font>&#8221; means the Uniform Commercial Code as from time to time in effect in the State of New York.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Partnership and LLC Collateral</font>&#8221; means any and all limited, limited liability and general partnership interests and limited liability company interests of any type or nature (including any such interests in the Borrower&#8217;s direct or indirect Subsidiaries now or hereafter owned by any Grantor), whether now existing or hereafter acquired or arising, including any such interests specified in <b style="font-weight:bold;">Schedule&#160;3</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Perfection Certificate</font>&#8221; means the Perfection Certificate dated the Closing Date delivered to the Administrative Agent, as amended, restated, supplemented or otherwise modified from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Pledge Supplement</font>&#8221; has the meaning specified in <b style="font-weight:bold;">Section&#160;3(i)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Pledged Collateral</font>&#8221; means any and all (i)&#160;Pledged Shares; (ii)&#160;additional capital stock or other Equity Interests of the direct Subsidiaries of any Grantor, whether certificated or uncertificated; (iii)&#160;other Investment Property of any Grantor; (iv)&#160;warrants, options or other rights entitling any Grantor to acquire any interest in Equity Interests or other securities of such Subsidiaries or any other Person; (v)&#160;Partnership and LLC Collateral; (vi)&#160;Instruments and Pledged Debt Securities; (vii)&#160;securities, property, interest, dividends and other payments and distributions from time to time received, receivable or otherwise distributed in respect of, or issued as an addition to, in redemption of, in renewal or exchange for, in substitution or upon conversion of, or otherwise on account of, any of the foregoing; (viii)&#160;certificates and instruments now or hereafter representing or evidencing any of the foregoing; (ix)&#160;rights, interests and Claims with respect to the foregoing, including under any and all related agreements, instruments and other documents, and (x)&#160;cash and non-cash proceeds of any of the foregoing, in each case whether presently existing or owned or hereafter arising or acquired and wherever located, and as from time to time received or receivable by, or otherwise paid or distributed to or acquired by, any Grantor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Pledged Collateral Agreements</font>&#8221; has the meaning specified in <b style="font-weight:bold;">Section&#160;5(p)(i)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Pledged Debt Securities</font>&#8221; means any and all the debt securities and promissory notes and other instruments evidencing Indebtedness for borrowed money with a principal amount in excess of $100,000 held by such Grantor on the date hereof (including all such debt securities listed opposite the name of such Grantor on <b style="font-weight:bold;">Schedule 1</b>) and not an Excluded Asset and (ii) any debt securities or promissory notes or other instruments evidencing Indebtedness for borrowed money in the future issued to such Grantor and not an Excluded Asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Pledged Shares</font>&#8221; means all of the issued and outstanding shares of Equity Interests, whether certificated or uncertificated, of the Borrower&#8217;s direct or indirect Subsidiaries, now or hereafter owned by any Grantor, including each Subsidiary identified on <b style="font-weight:bold;">Schedule&#160;3</b><b style="font-weight:bold;"> </b>(as amended or supplemented from time to time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Proceeds Account</font>&#8221; has the meaning set forth in <b style="font-weight:bold;">Section&#160;10(c)</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Quarterly Reporting Date</font>&#8221; means each date on which a Compliance Certificate is required to be delivered pursuant to Section 8.01(c) of the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Registered Intellectual Property Collateral</font>&#8221; means all Intellectual Property Collateral covered by issued patent, copyright or trademark registrations, or pending applications </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">or applications for patent, copyright or trademark registration, at the United Stated Patent and Trademark Office or the United States Copyright Office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Rights to Payment</font>&#8221; means any and all of any Grantor&#8217;s Accounts and any and all of any Grantor&#8217;s rights and Claims to the payment or receipt of money or other forms of consideration of any kind in, to and under or with respect to its Chattel Paper, Documents, General Intangibles, Instruments, Investment Property, Letter-of-Credit Rights, Proceeds and Supporting Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Secured Obligations</font>&#8221; means all Obligations (as defined in the Credit Agreement) other than inchoate indemnification and expense reimbursement obligations for which no claim has been made.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146075"></a><b style="font-weight:bold;">Terms Defined in the NY UCC</b>. Where applicable and except as otherwise defined herein or in the Credit Agreement, terms used in this Agreement shall have the meanings assigned to them in the NY UCC; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that to the extent that the NY UCC is used to define any term herein and such term is defined differently in different Articles of the NY UCC, the definition of such term contained in (and ascribed thereto in) Article&#160;9 shall govern.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40146076"></a><b style="font-weight:bold;">Interpretation</b>. The rules of interpretation set forth in Section&#160;1.03 of the Credit Agreement shall be applicable to this Agreement and are incorporated herein by this reference.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;2</font><a name="_Ref40146077"></a><a name="_Ref40146786"></a><a name="_Toc71361869"></a>Security Interest<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146078"></a><b style="font-weight:bold;">Grant of Security Interest</b>. As security for the payment or performance, as the case may be, in full in cash of the Secured Obligations, each Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest (the &#8220;<font style="font-style:italic;font-weight:bold;">Security Interest</font>&#8221;) in and lien on all of such Grantor&#8217;s right, title and interest in, to and under all of such Grantor&#8217;s personal property, wherever located and whether now existing or owned or hereafter acquired by such Grantor, or in which such Grantor now has or at any time in the future may acquire, including the following property (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Collateral</font>&#8221;): (i)&#160;all Accounts; (ii)&#160;all Chattel Paper; (iii)&#160;all Commercial Tort Claims specified in <b style="font-weight:bold;">Schedule&#160;1</b> or notified to the Administrative Agent pursuant to <b style="font-weight:bold;">Section&#160;5(o)</b>; (iv)&#160;all Deposit Accounts, Securities Accounts and Commodity Accounts; (v)&#160;all Documents; (vi)&#160;all Equipment; (vii)&#160;all General Intangibles; (viii)&#160;all Instruments; (ix)&#160;all Inventory; (x)&#160;all Investment Property; (xi)&#160;all Letter-of-Credit Rights; (xii)&#160;all other Goods; (xiii)&#160;all Intellectual Property Collateral; (xiv)&#160;all money; (xv)&#160;all Pledged Collateral; (xvi) all Books pertaining to the foregoing; and (xvii)&#160;all products, proceeds and Supporting Obligations of any and all of the foregoing.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing or anything herein to the contrary, (x) in no event shall the &#8220;<font style="font-style:italic;font-weight:bold;">Collateral</font>&#8221; include or the Security Interest attach to any Excluded Asset and (y) the representations and covenants set forth herein regarding the assets of the Grantors shall not apply to any such Excluded Asset.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146079"></a><b style="font-weight:bold;">Grantors Remain Liable</b>. The Security Interest is granted as security only and shall not subject the Administrative Agent or any other Secured Party to, or in any way alter or modify, any obligation or liability of any Grantor with respect to or arising out of the Collateral. </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Anything herein to the contrary notwithstanding, (i)&#160;each Grantor shall remain liable under any Contracts included in the Collateral, to the extent set forth therein, to perform all of its duties and obligations thereunder to the same extent as if this Agreement had not been executed, (ii)&#160;the exercise by the Administrative Agent of any of the rights granted to the Administrative Agent hereunder shall not release any Grantor from any of its duties or obligations under any such Contracts included in the Collateral and (iii)&#160;neither the Administrative Agent nor any other Secured Party shall have any obligation or liability under any such Contracts included in the Collateral by reason of this Agreement, nor shall the Administrative Agent or any other Secured Party be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any action to collect or enforce any such Contract included in the Collateral.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146080"></a><b style="font-weight:bold;">Continuing Security Interest; Ratable Benefit. </b>Each Grantor agrees that this Agreement shall create a continuing security interest in the Collateral which shall remain in effect until terminated in accordance with <b style="font-weight:bold;">Section&#160;25</b>, and such security has been granted to the Administrative Agent for itself and on behalf of and for the ratable benefit of the Secured Parties.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;3</font><a name="_Ref40146081"></a><a name="_Ref40146787"></a><a name="_Toc71361870"></a>Perfection and Priority<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146082"></a><b style="font-weight:bold;">Financing Statements, Etc</b>. Each Grantor hereby authorizes the Administrative Agent to file at any time and from time to time in any relevant jurisdiction in the United States (including any jurisdiction within or of the United States) any financing statements (or similar filings) with respect to the Collateral or any part thereof and amendments thereto that (i) indicate the Collateral as &#8220;all assets&#8221; of such Grantor or words of similar effect, and (ii) contain the information required by Article 9 of the Uniform Commercial Code of each applicable jurisdiction for the filing of any financing statement or amendment, including (A) whether such Grantor is an organization, the type of organization and any organizational identification number issued to such Grantor and (B) in the case of a financing statement filed as a fixture filing, a sufficient description of the real property to which such Collateral relates. Each Grantor agrees to provide such information to the Administrative Agent promptly upon its reasonable request (and in any case within three (3) Business Days of such reasonable request or such longer period as the Administrative Agent may agree). The Agent is further authorized to file with the United States Patent and Trademark Office or United States Copyright Office (or any successor office) such documents as may be necessary or advisable for the purpose of perfecting, confirming, continuing, enforcing or protecting the Security Interest granted by each Grantor, without the signature of any Grantor, and naming any Grantor or the Grantors as debtors and the Administrative Agent as secured party. Each Grantor shall execute and deliver to the Administrative Agent, and each Grantor hereby authorizes the Administrative Agent to file, at any time and from time to time, all amendments to financing statements, continuation financing statements, termination statements, Intellectual Property Security Agreements, assignments, fixture filings, affidavits, reports, notices and all other documents and instruments, in form reasonably satisfactory to the Administrative Agent, as the Administrative Agent or the Majority Lenders may reasonably request, to perfect and continue perfected, maintain the priority of or provide notice of the Administrative Agent&#8217;s security interest in the Collateral and to accomplish the purposes of this Agreement. Without limiting the generality of the foregoing, each Grantor shall from time to time take the actions specified in <b style="font-weight:bold;">subsections&#160;(b) </b>through <b style="font-weight:bold;">(j)</b> below.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Delivery of Pledged Collateral</b>. Each Grantor hereby agrees to deliver promptly (but in any event, no later than the next Quarterly Reporting Date following its acquisition thereof or such longer period as the Administrative Agent may agree in its sole discretion) to the Administrative Agent, the certificates and instruments representing any Pledged Collateral issued by any Subsidiary or by any other Person with a value in excess of $100,000 (other than Instruments subject to <b style="font-weight:bold;">subsection&#160;</b><b style="font-weight:bold;">(c)</b> below), which shall be in suitable form for transfer by delivery, or shall be accompanied by duly executed instruments of transfer or assignment in blank, in form and substance reasonably satisfactory to the Administrative Agent. If any Grantor shall become entitled to receive or shall receive any certificates or instruments representing Pledged Collateral (other than Instruments subject to <b style="font-weight:bold;">subsection&#160;</b><b style="font-weight:bold;">(c)</b> below) after the date hereof, such Grantor shall accept the foregoing as the agent for the Administrative Agent, shall hold it in trust for the Administrative Agent, shall segregate it from other property or funds of such Grantor, and shall promptly (but in any event, no later than the next Quarterly Reporting Date) deliver the same forthwith to or for the account of the Administrative Agent, at the address designated by the Administrative Agent and to the Person to be designated by the Administrative Agent, which shall be in suitable form for transfer by delivery, or shall be accompanied by duly executed instruments of transfer or assignment in blank in form reasonably satisfactory to the Administrative Agent. &#160; &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146084"></a><b style="font-weight:bold;">Instrument Collateral</b>. Anything herein to the contrary notwithstanding, so long as no Event of Default shall have occurred and be continuing, each Grantor may retain for collection in the ordinary course any Instruments representing amounts not exceeding $1,000,000 individually and any notes evidencing intercompany balances, in each case received by such Grantor in the ordinary course, and the Administrative Agent shall, promptly upon request of such Grantor, make appropriate arrangements for making any other Instruments pledged by such Grantor available to the payor of any such Instrument for purposes of presentation, collection or renewal (any such arrangement to be effected, to the extent required under applicable Law to continue to have perfected the Administrative Agent&#8217;s security interest in such Instruments, against trust receipt or like document). </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40146085"></a><b style="font-weight:bold;">Transfer of Security Interest Other Than by Delivery</b>. If for any reason Pledged Collateral cannot be delivered to or for the account of the Administrative Agent as provided in Section 3(b), each applicable Grantor shall promptly take such other steps as may be necessary or as shall be reasonably requested from time to time by the Administrative Agent to effect a transfer of a perfected first priority security interest in and pledge of the Pledged Collateral to the Administrative Agent for itself and on behalf of and for the ratable benefit of the other Secured Parties pursuant to the NY UCC. To the extent practicable, each such Grantor shall thereafter deliver the Pledged Collateral to or for the account of the Administrative Agent as provided in <b style="font-weight:bold;">Section 3(b)</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40714077"></a><a name="_Ref40146086"></a><b style="font-weight:bold;">Intellectual Property Collateral</b><a name="_Ref40146087"></a>. (i)&#160;Each Grantor shall execute and deliver to the Administrative Agent, concurrently with the execution of this Agreement, such Intellectual Property Security Agreements as the Administrative Agent may reasonably request, and record such Intellectual Property Security Agreements with the United States Copyright Office or the United States Patent and Trademark Office, as applicable, and take such other action as may be necessary, or as the Administrative Agent may reasonably request, to perfect the Administrative Agent&#8217;s security interest in the Registered Intellectual Property Collateral. Notwithstanding </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">anything herein to the contrary, for the avoidance of doubt, no Grantor shall be required to take any action to perfect Administrative Agent&#8217;s security interest in Intellectual Property Collateral in any jurisdiction except the U.S.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40146088"></a>Following the creation or other acquisition of any Intellectual Property Collateral by any Grantor after the date hereof which is or becomes Registered Intellectual Property Collateral, such Grantor shall include details of such newly created or acquired Registered Intellectual Property Collateral on the next Quarterly Reporting Date, and modify this Agreement by amending <b style="font-weight:bold;">Schedule&#160;2</b><b style="font-weight:bold;"> </b>to include any Registered Intellectual Property Collateral which becomes part of the Collateral and which was not included on <b style="font-weight:bold;">Schedule&#160;2</b><b style="font-weight:bold;"> </b>as of the date hereof and record such Intellectual Property Security Agreement with the United States Copyright Office or the United States Patent and Trademark Office, as applicable, and take such other action as may be necessary, or as the Administrative Agent or the Majority Lenders may reasonably request, to perfect the Administrative Agent&#8217;s security interest in such Registered Intellectual Property Collateral.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40146089"></a><b style="font-weight:bold;">Documents, Etc. </b>Each Grantor shall deliver to the Administrative Agent, or an agent designated by it, appropriately endorsed or accompanied by appropriate instruments of transfer or assignment, all Documents and Chattel Paper, and all other Rights to Payment, in each case, representing amounts in excess of $250,000 at any time evidenced by promissory notes, trade acceptances or other instruments, not already delivered hereunder pursuant to this <b style="font-weight:bold;">Section&#160;3</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40146090"></a><b style="font-weight:bold;">Bailees</b>. Any Person (other than the Administrative Agent) at any time and from time to time holding all or any portion of the Collateral shall be deemed to, and shall, hold the Collateral as the agent of, and as pledge holder for, the Administrative Agent. At any time and from time to time, upon the consent of the applicable Grantor (not to be unreasonably withheld), the Administrative Agent may give notice to any such Person holding all or any portion of the Collateral that such Person is holding the Collateral as the agent and bailee of, and as the pledge holder for, the Administrative Agent and obtain such Person&#8217;s written acknowledgement thereof. In connection with the immediately preceding sentence and subject to such Grantor&#8217;s consent as provided therein, each Grantor will, upon the reasonable request of the Administrative Agent, join with the Administrative Agent in notifying any Person who has possession of any Collateral of the Administrative Agent&#8217;s security interest therein and exercising commercially reasonable efforts to obtain an acknowledgement from such Person that it is holding the Collateral for the benefit of the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40146091"></a><b style="font-weight:bold;">Control</b>.<b style="font-weight:bold;"> </b>Each Grantor will cooperate with the Administrative Agent in obtaining control (as defined in the NY UCC) of Collateral consisting of any Deposit Accounts, Securities Accounts, Electronic Chattel Paper, Investment Property or Letter-of-Credit Rights, including delivery of Control Agreements with respect to Controlled Accounts (as defined in the Credit Agreement), but excluding any Excluded Accounts, as the Administrative Agent may reasonably request, to perfect and continue perfected, maintain the priority of or provide notice of the Administrative Agent&#8217;s security interest in such Collateral.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146092"></a><b style="font-weight:bold;">Additional Subsidiaries</b>. In the event that any Grantor acquires rights in any Subsidiary after the date hereof and such Subsidiary is required to become a Subsidiary Guarantor under Section&#160;8.12 of the Credit Agreement, such applicable Grantor shall deliver to </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">the Administrative Agent a completed pledge supplement, substantially in the form of <b style="font-weight:bold;">Exhibit&#160;B</b><b style="font-weight:bold;"> </b>(the &#8220;<font style="font-style:italic;font-weight:bold;">Pledge Supplement</font>&#8221;), together with all schedules thereto, reflecting such new Subsidiary. Notwithstanding the foregoing, it is understood and agreed that the security interest of the Administrative Agent shall attach to the Pledged Collateral (other than Excluded Assets) related to such Subsidiary immediately upon any Grantor&#8217;s acquisition of rights therein and shall not be affected by the failure of any Grantor to deliver a Pledge Supplement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40146093"></a><b style="font-weight:bold;">Further Assurances</b>. Each Grantor agrees that, at its own expense, it will promptly execute, acknowledge, deliver and cause to be filed all further instruments and documents and take all other actions as the Administrative Agent may from time to time reasonably request in order to assure, obtain, perfect, preserve and protect any security interest granted or purported to be granted under this Agreement, in each case, to the extent required by the other provisions of this Agreement, or enable the Administrative Agent to exercise and enforce its rights and remedies hereunder with respect to any Collateral, including the payment of any fees and Other Taxes required in connection with the execution and delivery of this Agreement, the granting of the Security Interest and the filing of any financing or continuation statements (including fixture filings) or other documents in connection herewith or therewith.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><b style="font-weight:bold;">Taxes</b>. At its option, the Administrative Agent may discharge past due Taxes, assessments, charges, fees, Liens, security interests or other encumbrances at any time levied or placed on the Collateral and not expressly permitted pursuant to the Credit Agreement, and may pay for the maintenance and preservation of the Collateral to the extent any Grantor fails to do so to the extent required by the Credit Agreement or this Agreement, and each Grantor jointly and severally agrees to reimburse the Administrative Agent on demand for any reasonable payment made or any reasonable expense incurred by the Administrative Agent pursuant to the foregoing authorization; provided, however, that nothing in this paragraph shall be interpreted as excusing any Grantor from the performance of, or imposing any obligation on the Agent or any Secured Party to cure or perform, any covenants or other promises of any Grantor with respect to Taxes, assessments, charges, fees, Liens, security interests or other encumbrances and maintenance as set forth herein or in the other Loan Documents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;4</font><a name="_Ref40146094"></a><a name="_Ref40146788"></a><a name="_Ref40148535"></a><a name="_Toc71361871"></a>Representations and Warranties<font style="font-weight:normal;">. Each Grantor represents and warrants to each Secured Party as of the date of this Agreement that:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146095"></a><b style="font-weight:bold;">Location of Chief Executive Office and Collateral</b>. Such Grantor&#8217;s chief executive office and principal place of business (as of the date of this Agreement) is located at the address set forth in <b style="font-weight:bold;">Schedule&#160;1</b>, and all other locations (as of the date of this Agreement) leased or owned by such Grantor or where Collateral is kept are set forth in the <b style="font-weight:bold;">Schedule&#160;1</b> (other than (A) Equipment or Inventory in transit with common carriers or in the possession of employees, customers, development partners or vendors, in each case in the ordinary course of business, (B) Collateral which is out for repair or processing (C) Equipment that is mobile in nature, including vehicles and portable computing equipment and (E) locations within the United States having Collateral, in each case, with a fair market value of less than $100,000 per location and $250,000 in the aggregate for all locations).</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146096"></a><b style="font-weight:bold;">Locations of Books</b>. All Books pertaining to the Rights to Payment of such Grantor are kept at such Grantor&#8217;s chief executive office, principal place of business or place where such Grantor conducts business.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146097"></a><b style="font-weight:bold;">Jurisdiction of Organization and Names</b>. Such Grantor&#8217;s jurisdiction of organization is set forth in <b style="font-weight:bold;">Schedule&#160;1</b>; and such Grantor&#8217;s exact legal name is as set forth in the signature pages of this Agreement. All trade names and trade styles under which such Grantor presently conducts its business operations are set forth in <b style="font-weight:bold;">Schedule&#160;1</b>, and, except as set forth in <b style="font-weight:bold;">Schedule&#160;1</b>, such Grantor has not, at any time in the past: (i)&#160;been known as or used any other corporate, trade or fictitious name or (ii)&#160;changed its name; (iii)&#160;been the surviving or resulting corporation in a merger or consolidation; or (iv)&#160;acquired through asset purchase or otherwise any business of any Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40146098"></a><b style="font-weight:bold;">Collateral</b>. Such Grantor has rights in or the power to transfer the Collateral, and such Grantor has legal title to the Collateral (or, in the case of after-acquired Collateral, at the time such Grantor acquires rights in such Collateral, will have good and valid title therein), free from any Lien other than Permitted Liens. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40146099"></a><b style="font-weight:bold;">Enforceability; Priority of Security Interest</b>. (i)&#160;This Agreement creates a valid security interest in the Collateral which is enforceable against the Collateral in which such Grantor now has rights and will create a valid security interest which is enforceable against the Collateral in which such Grantor hereafter acquires rights at the time such Grantor acquires any such rights; and (ii)&#160;upon the completion of the filings described in <b style="font-weight:bold;">Section&#160;4</b><b style="font-weight:bold;">(f)</b> and delivery of certificates, instruments and other writing representing Pledged Collateral (if any) and performance of other actions described in Section&#160;3 (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Perfection Actions</font>&#8221;), the Administrative Agent will have a perfected security interest in the Collateral in which such Grantor now has rights, and will have a perfected security interest in the Collateral in which such Grantor hereafter acquires rights at the time such Grantor acquires any such rights, in each case, for the Administrative Agent&#8217;s own benefit and for the ratable benefit of the other Secured Parties to the extent such Collateral can be perfected by the Perfection Actions, subject to Permitted Liens and securing the payment and performance of the Secured Obligations.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40713799"></a><a name="_Ref41903336"></a><a name="_Ref40146100"></a><b style="font-weight:bold;">Perfection Certificate</b>. The Perfection Certificate has been duly prepared, completed and executed and the information set forth therein is correct and complete in all material respects as of the Closing Date. The Uniform Commercial Code financing statements attached as <b style="font-weight:bold;">Schedule 4</b> have been prepared by the Administrative Agent based upon the information provided to the Administrative Agent and the Secured Parties in the Perfection Certificate for filing in each United States governmental, municipal or other office specified in the Perfection Certificate, which are all the filings, recordings and registrations (other than filings required to be made in the United States Patent and Trademark Office and the United States Copyright Office in order to perfect the Security Interest in the Collateral consisting of United States Patents, Trademarks and Copyrights) that are necessary as of the Closing Date to perfect the Security Interest in favor of the Administrative Agent (for the ratable benefit of the Secured Parties) in respect of all Collateral in which the Security Interest may be perfected by filing a Uniform Commercial Code Financing Statement. Each Grantor represents and warrants that upon filing and recording of the Intellectual Property Security Agreements executed in favor of and delivered to the Administrative Agent pursuant to <b style="font-weight:bold;">Section&#160;3(e)</b>, together with the consummation of the other actions set forth above in </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">this <b style="font-weight:bold;">clause </b><b style="font-weight:bold;">(f)</b>, to the extent that a security interest with respect to Registered Intellectual Property Collateral and exclusive Licenses in or to Copyrights registered with the United States Copyright Office may be perfected by the filing and recording of financing statements and short-form security agreements of the type described in this <b style="font-weight:bold;">clause</b> <b style="font-weight:bold;">(f)</b>, the Administrative Agent will have a perfected security interest in all Registered Intellectual Property Collateral and all Collateral consisting of exclusive Licenses in or to Copyrights registered with the United States Copyright Office.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><b style="font-weight:bold;">Other Financing Statements</b>. Other than (i)&#160;financing statements disclosed to the Administrative Agent, (ii)&#160;financing statements in favor of the Administrative Agent for itself and on behalf of and for the ratable benefit of the Secured Parties or (iii)&#160;financing statements in respect of Permitted Liens, no effective financing statement naming such Grantor as debtor, assignor, grantor, mortgagor, pledgor or the like and covering all or any part of the Collateral is on file in any filing or recording office in any jurisdiction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40146101"></a><b style="font-weight:bold;">Rights to Payment.</b><b style="font-weight:bold;"> &#160;</b>In each case with respect to Rights of Payment in excess of $100,000 in the aggregate for all Grantors: </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146102"></a>To the knowledge of each Grantor, the Rights to Payment of such Grantor represent valid, binding and enforceable obligations of the account debtors or other Persons obligated thereon, representing undisputed, bona fide transactions completed in accordance with the terms and provisions contained in any documents related thereto, and are and will be genuine and what they purport to be, in each case, in all material respects;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40146103"></a>such Grantor has not assigned any of its rights under any of its Rights to Payment except as provided in this Agreement or as set forth in the other Loan Documents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40146104"></a>all such Rights to Payment of such Grantor comply in all material respects with all applicable Law concerning form, content and manner of preparation and execution;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref40146105"></a>to the knowledge of each Grantor, all account debtors and other obligors on such Rights to Payment of such Grantor are solvent and generally paying their debts as they come due; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><a name="_Ref40146106"></a>no Grantor has knowledge of any fact or circumstance which would materially impair the validity or collectability of any of such Rights to Payment of such Grantor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146107"></a><b style="font-weight:bold;">Inventory</b>. No Inventory of such Grantor is stored with any bailee, warehouseman or similar Person or on any premises leased to such Grantor, no such Inventory has been consigned to such Grantor or consigned by such Grantor to any Person, nor is any such Inventory held by such Grantor for any Person under any &#8220;bill and hold&#8221; or other arrangement, except, in each case, (i) as set forth in <b style="font-weight:bold;">Schedule&#160;1</b><b style="font-weight:bold;">,</b> (ii) Inventory in transit with common carriers or in the possession of employees, customers, development partners or vendors, in each case in the ordinary course of business and (iii) locations within the United States having Inventory with a fair market value of less than $100,000 per location and $250,000 in the aggregate for all locations).</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40146108"></a>[Reserved].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40146109"></a><b style="font-weight:bold;">Instrument Collateral</b>. (i)&#160;Such Grantor has not previously assigned any interest in any Instruments with a principal amount in excess of $100,000 held by such Grantor (other than such interests as will be released on or before the date hereof), (ii)&#160;no Person other than such Grantor owns an interest in such Instruments (whether as joint holders, participants or otherwise), and (iii)&#160;to the knowledge of such Grantor, no material default exists under or in respect of such Instruments.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref40146110"></a><a name="_Ref41904625"></a><b style="font-weight:bold;">Pledged Shares, Partnership and LLC Collateral and other Pledged Collateral</b>. As of the Closing Date, <b style="font-weight:bold;">Schedule 3</b> correctly sets forth (A) with respect to the Pledged Collateral, the percentage of the issued and outstanding shares of each class of Equity Interests of the issuer thereof and (B) includes all Equity Interests required to be pledged hereunder. &#160;(i) To the extent issued by a Subsidiary of a Grantor, all of the Pledged Shares and Partnership and LLC Collateral of such Grantor have been, and upon issuance of any additional Pledged Collateral consisting of Pledged Shares, Partnership and LLC Collateral or any other securities of such Grantor, will be, duly and validly issued, and are and will be fully paid and non-assessable, subject in the case of Partnership and LLC Collateral to future assessments required under applicable Law and any applicable partnership or operating agreement, (ii) with respect to the Pledged Collateral,&#160;such Grantor is or, in the case of any such additional Pledged Collateral will be, the legal record and beneficial owner thereof, (iii)&#160;there are no restrictions on the transferability of such Pledged Collateral or such additional Pledged Collateral to the Administrative Agent or with respect to the foreclosure, transfer or disposition thereof by the Administrative Agent, except as provided under applicable securities or &#8220;Blue Sky&#8221; laws, (iv)&#160;to extent relating to a wholly-owned Subsidiary of a Grantor, the Pledged Shares and Partnership and LLC Collateral of such Grantor constitute 100% of the issued and outstanding shares of capital stock of directly owned Subsidiaries of such Grantor (or, subject to the limitation in subclause (i) of the definition of &#8220;Excluded Asset&#8221;, if applicable, 65% of the outstanding voting stock of such Subsidiary), and no securities convertible into or exchangeable for any shares of capital stock of any such Subsidiary, or any options, warrants or other commitments entitling any Person to purchase or otherwise acquire any shares of capital stock of any such Subsidiary, are issued and outstanding, (v)&#160;any and all Pledged Collateral Agreements which affect or relate to the voting or giving of written consents with respect to any of the Pledged Shares pledged by such Grantor, and any and all other Pledged Collateral Agreements relating to the Partnership and LLC Collateral of such Grantor, have been disclosed in writing to the Administrative Agent and the Lenders, and (vi)&#160;as to each such Pledged Collateral Agreement relating to the Partnership and LLC Collateral of such Grantor, (A)&#160;such agreement contains the entire agreement between the parties thereto with respect to the subject matter thereof, has not been amended or modified, and is in full force and effect in accordance with its terms, (B)&#160;there exists no material violation or material default under any such agreement by such Grantor or, to the knowledge of such Grantor party thereto, the other parties thereto, and (C)&#160;such Grantor has not knowingly waived or released any of its material rights under or otherwise consented to a material departure from the terms and provisions of any such agreement. No consent or approval of any Governmental Authority, any securities exchange or any other person was or is necessary to the validity of the pledge of any Equity Interests (other than such as have been obtained and are in full force and effect).</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_Ref40146111"></a><b style="font-weight:bold;">Control Agreements</b>. No Control Agreements exist with respect to any Collateral held by such Grantor other than any Control Agreements in favor of the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><a name="_Ref40146112"></a><b style="font-weight:bold;">Letter-of-Credit Rights</b>. Such Grantor does not have any Letter-of- Credit Rights with an undrawn face amount in excess of $100,000 except as set forth in <b style="font-weight:bold;">Schedule&#160;1</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><a name="_Ref40146113"></a><b style="font-weight:bold;">Commercial Tort Claims</b>. Such Grantor does not have any Commercial Tort Claims the recovery from which (less any legal expenses incurred or reasonably expected to be incurred by such Grantor) would reasonably be expected to exceed $1,000,000 except as set forth in <b style="font-weight:bold;">Schedule&#160;1</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font><a name="_Ref40146114"></a><b style="font-weight:bold;">Leases</b>. Such Grantor is not and will not become a lessee under any real property lease or other agreement governing the location of Collateral at the premises of another Person pursuant to which the lessor or such other Person may obtain any rights in any of the Collateral, and no such lease or other such agreement now prohibits, restrains, impairs or will prohibit, restrain or impair such Grantor&#8217;s right to remove any Collateral from the premises at which such Collateral is situated, except for (A) the usual and customary restrictions contained in such leases of real property and (B) leases for which such Grantor has obtained a Landlord Consent in form and substance reasonably satisfactory to the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(q)</font><b style="font-weight:bold;">Pledged Debt Securities</b>. As of the Closing Date, <b style="font-weight:bold;">Schedule 1</b> correctly sets forth a list of all Collateral constituting Pledged Debt Securities, the aggregate principal amount and maturity date of all Indebtedness represented by any Pledged Debt Securities and (ii) includes all debt securities, promissory notes and other Collateral constituting Pledged Debt Securities required to be pledged hereunder. To the knowledge of such Grantor, the Collateral constituting Pledged Debt Securities are valid and binding obligations of the issuers thereof, subject as to the enforcement of remedies to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting rights generally and to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(r)</font><b style="font-weight:bold;">No Transfer Restrictions</b>. Except for (i) restrictions and limitations imposed by the Loan Documents or securities laws generally or (ii) otherwise expressly permitted hereunder, the Pledged Collateral is and will continue to be freely transferable and assignable, and none of such Pledged Collateral is or will be subject to any option, right of first refusal, shareholders agreement, charter or by-law provisions or contractual restriction of any nature that might prohibit, impair, delay or otherwise affect the pledge of such Pledged Collateral hereunder, the sale or disposition thereof pursuant hereto or the exercise by the Administrative Agent of rights and remedies hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;5</font><a name="_Ref40146115"></a><a name="_Ref40146789"></a><a name="_Ref40148580"></a><a name="_Toc71361872"></a>Covenants<font style="font-weight:normal;">.</font><font style="display:inline-block;width:14.99pt;"></font><font style="font-weight:normal;">So long as any of the Secured Obligations remain unsatisfied or any Lender shall have any Commitment, each Grantor agrees that:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146116"></a><b style="font-weight:bold;">Defense of Collateral</b>. Such Grantor will use commercially reasonable efforts (which shall be conclusively determined by the Administrative Agent) to appear in and defend any action, suit or proceeding which may to a material extent affect its title to, or right or interest in, or the Administrative Agent&#8217;s right or interest in, the Collateral, including any action, </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">suit or proceeding with respect to any Liens on the Collateral (other than any Lien not prohibited by the Loan Documents).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146117"></a><b style="font-weight:bold;">Preservation of Collateral</b>. Such Grantor will do and perform all commercially reasonable acts that may be necessary and appropriate to maintain, preserve and protect the Collateral, except to the extent permitted by Section 5(n).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146118"></a><b style="font-weight:bold;">Compliance with Laws, Etc. </b>Such Grantor will comply with all applicable Laws, except where the failure to do could not reasonably be expected to result in a Material Adverse Effect, and will comply with all policies of insurance, except where the failure to do so could not reasonably be expected to result in a loss of any such policy, relating to the possession, operation, maintenance and control of the Collateral. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40146119"></a><b style="font-weight:bold;">Location of Books and Chief Executive Office</b>. Such Grantor will: (i)&#160;keep all Books pertaining to the Rights to Payment of such Grantor at such Grantor&#8217;s chief executive office, principal place of business or place where such Grantor conducts business and (ii)&#160;promptly notify the Administrative Agent of any changes in the location of such Grantor&#8217;s chief executive office or principal place of business.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40146120"></a><b style="font-weight:bold;">Location of Collateral</b>. Such Grantor will: (i)&#160;keep the Collateral (to the extent such Collateral is tangible or a tangible embodiment of Collateral) held by such Grantor at the locations set forth in <b style="font-weight:bold;">Schedule&#160;1</b><b style="font-weight:bold;"> </b>or at such other locations as may be disclosed in writing to the Administrative Agent pursuant to <b style="font-weight:bold;">clause&#160;(ii) </b><a name="_Hlk71051636"></a>and will not remove any such Collateral from such locations (other than (A) in connection with sales of Inventory in the ordinary course of such Grantor&#8217;s business, other dispositions permitted by <b style="font-weight:bold;">Section&#160;5</b><b style="font-weight:bold;"> </b>and movements of Collateral from one disclosed location to another disclosed location, (B) Equipment or Inventory in transit with common carriers or in the possession of employees, customers, development partners or vendors, in each case in the ordinary course of business, (C) Collateral which is out for repair or processing, (D) Equipment that is mobile in nature, including vehicles and portable computing equipment and (E) locations within the United States having Collateral, in each case, with a fair market value of less than $100,000 per location and $250,000 in the aggregate for all locations); and (ii)&#160;give the Administrative Agent prompt notice (but in any event, no later than the next Quarterly Reporting Date) of any change in the locations set forth in <b style="font-weight:bold;">Schedule&#160;1</b>.<u style="border-bottom-style:solid;border-bottom-width:0.5pt;color:#0000ff;text-decoration:underline;"> </u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40146121"></a><b style="font-weight:bold;">Change in Name, Identity or Structure</b>. Such Grantor will not effect or permit (i)&#160;any change in name, (ii)&#160;any change in its jurisdiction of organization, (iii)&#160;any change in its registration as an organization (or any new registration); and (iv)&#160;any changes in its identity or structure in any manner which might make any financing statement filed hereunder incorrect or misleading unless within two (2) Business Days (or such longer period as the Administrative Agent may agree) of such change all filings have been made under the Uniform Commercial Code or otherwise that are required in order for the Administrative Agent to continue at all times following such change to have a valid, legal and perfected first priority (subject to Liens permitted under the Loan Documents) security interest in all the Collateral that can be perfected by making such filings under the Uniform Commercial Code; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that such changes are otherwise permitted by the Loan Documents and no Grantor shall change its jurisdiction of organization to a jurisdiction outside of the United States.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40146122"></a><b style="font-weight:bold;">Maintenance of Records</b>. Such Grantor will keep, at its own cost and expense, separate, accurate and complete Books as is consistent with its practices as of the date hereof in all material respects with respect to the Collateral held by such Grantor. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40146123"></a><b style="font-weight:bold;">Disposition of Collateral</b>. Such Grantor will not surrender or lose possession of (other than to the Administrative Agent), sell, lease, rent, or otherwise dispose of or transfer any of the Collateral held by such Grantor or any right or interest therein, except to the extent permitted by the Loan Documents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146124"></a><b style="font-weight:bold;">Leased Premises; Collateral Held by Warehouseman, Bailee, Etc. </b>At the Administrative Agent&#8217;s reasonable request and with the consent of the Grantor, such Grantor will use commercially reasonable efforts to obtain from each Person so reasonably requested by the Administrative Agent from whom such Grantor leases any premises, and from each other Person so reasonably requested by the Administrative Agent at whose premises any Collateral held by such Grantor is present (including any bailee, warehouseman or similar Person), any such collateral access, subordination, landlord waiver, bailment, consent and estoppel agreements as the Administrative Agent may reasonably request, in form and substance reasonably satisfactory to the Administrative Agent; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that such landlord waiver shall be in substantially the form of Exhibit&#160;G<b style="font-weight:bold;"> </b>to the Credit Agreement and such bailee letter shall be in substantially the form of <b style="font-weight:bold;">Exhibit&#160;F</b><b style="font-weight:bold;"> </b>hereto. For the avoidance of doubt, the failure to obtain such collateral access, subordination, landlord waiver, bailment or consent and estoppel agreements after the use of commercially reasonable efforts shall not be a Default or an Event of Default.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40146125"></a><b style="font-weight:bold;">Rights to Payment</b>. Such Grantor will:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146126"></a>with such frequency as the Administrative Agent may reasonably require or as may be required under the Credit Agreement, furnish to the Administrative Agent full and complete reports, in form and substance reasonably satisfactory to the Administrative Agent, with respect to the Accounts;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40146127"></a>if any Accounts of such Grantor in an aggregate amount in excess of $1,000,000 per fiscal year arise from Contracts with the United States or any department, agency or instrumentality thereof, promptly (but in any event, no later than the next Quarterly Reporting Date) notify the Administrative Agent thereof and execute any documents and instruments and take any other steps reasonably requested by the Administrative Agent in order that all monies due and to become due thereunder shall be assigned to the Administrative Agent upon the occurrence and continuance of an Event of Default;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40146128"></a>upon the occurrence and during the continuation of an Event of Default and upon the request of the Administrative Agent (A)&#160;notify all or any designated portion of the account debtors and other obligors on the Rights to Payment of such Grantor of the security interest hereunder, and (B)&#160;notify the account debtors and other obligors on the Rights to Payment or any designated portion thereof that payment shall be made directly to the Administrative Agent or to such other Person or location as the Administrative Agent shall specify; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref40146129"></a>upon the occurrence and during the continuation of an Event of Default and upon the request of the Administrative Agent, establish such lockbox or similar </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">arrangements for the payment of the Accounts and other Rights to Payment of such Grantor as the Administrative Agent shall require.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40146130"></a><b style="font-weight:bold;">Instruments</b><b style="font-weight:bold;">, Investment Property, Etc.</b> Upon the reasonable request of the Administrative Agent, such Grantor will (i)&#160;promptly deliver to the Administrative Agent, or an agent designated by it in New York, appropriately endorsed or accompanied by appropriate instruments of transfer or assignment, all Instruments, Documents, Chattel Paper, in each case with respect to such Instruments, Documents or Chattel Paper in an amount in excess of $100,000 and certificated securities with respect to any Investment Property held by such Grantor, all letters of credit of such Grantor, and all other Rights to Payment, in each case with respect to such Investment Property, letters of credit or other Rights to Payment, as applicable, in an amount in excess of $100,000 held by such Grantor at any time evidenced by promissory notes, trade acceptances or other instruments, (ii)&#160;cause any securities intermediaries to show on their books that the Administrative Agent is the entitlement holder with respect to any Investment Property held by such securities intermediary on behalf of such Grantor, and/or obtain Control Agreements in favor of the Administrative Agent from such securities intermediaries, in form and substance reasonably satisfactory to the Administrative Agent, with respect to any such Investment Property, as reasonably requested by the Administrative Agent, and (iii)&#160;provide such notice, obtain such acknowledgments and take all such other action, with respect to any Chattel Paper, Documents and Letter-of-Credit Rights held by such Grantor, as the Administrative Agent shall reasonably specify.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref40146131"></a><b style="font-weight:bold;">Deposit Accounts and Securities Accounts.</b> Such Grantor shall not open or hold funds or other Collateral in any Deposit Account, Securities Account or Commodity Account (other than any Excluded Account) unless such Grantor has concurrently (i) obtained a Control Agreement in favor of the Administrative Agent with respect to such Deposit Account, Securities Account or Commodity Account, in form and substance reasonably satisfactory to the Administrative Agent, or (ii) amended an existing Control Agreement such that the relevant Deposit Account, Securities Account or Commodity Account becomes subject to such Control Agreement, which amendment shall be in form and substance reasonably satisfactory to the Administrative Agent. &#160;Administrative Agent hereby agrees that, unless an Event of Default has occurred, Administrative Agent will not give a notice of control under any Control Agreement. It is agreed and understood that the Loan Parties shall have until the date that is sixty (60) days following the closing date of a Permitted Acquisition (or such later date following the closing date of such Permitted Acquisition as may be agreed to by the Administrative Agent in its sole discretion) to comply with the provisions of this Section 5(l) with regard to such accounts (other than Excluded Accounts) acquired by the Grantors in connection with such Permitted Acquisition.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_Ref40146132"></a><b style="font-weight:bold;">Inventory</b>. Such Grantor will not store any Inventory with a bailee, warehouseman or similar Person or on premises leased to such Grantor, nor dispose of any Inventory on a bill-and-hold, guaranteed sale, sale and return, sale on approval, consignment or similar basis, nor acquire any Inventory from any Person on any such basis, without in each case giving the Administrative Agent written notice thereof no later than the next Quarterly Reporting Date.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><a name="_Ref40146133"></a><b style="font-weight:bold;">Intellectual Property Collateral. </b>Such Grantor will:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146134"></a>not allow any Material Intellectual Property owned or controlled by such Grantor to become abandoned, nor any registration thereof to be abandoned, terminated, forfeited, expired or dedicated to the public;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40146135"></a>notify the Administrative Agent promptly if such Grantor knows (A) that any Material Intellectual Property owned or controlled by Borrower or any of its Subsidiaries may become abandoned, terminated, forfeited, expired or dedicated to the public, except to the extent permitted by the Credit Agreement or (B) of any materially adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, United States Copyright Office or any court or similar office of any other jurisdiction, but excluding ordinary course prosecution of pending intellectual property rights) regarding the Borrower&#8217;s or its applicable Subsidiaries&#8217; ownership or control of any such Material Intellectual Property, its right to register the same, or its right to keep and maintain the same. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>upon the delivery of a Compliance Certificate pursuant to Section&#160;8.03(c) of the Credit Agreement, give the Administrative Agent notice of any new Registered Intellectual Property Collateral for which such Grantor has filed any application for registration; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref40146136"></a>to the extent constituting Material Intellectual Property, diligently prosecute all applications for Patents, Copyrights and Trademarks, and file and prosecute any and all continuations, divisionals, continuations-in-part, applications for reissue, applications for certificate of correction and like matters as shall be reasonable and appropriate in accordance with prudent business practice, and promptly and timely pay any and all maintenance, license, registration and other fees, taxes and expenses incurred in connection with any Material Intellectual Property held by such Grantor; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>in the event that any Grantor knows that any Material Intellectual Property has been or will imminently be infringed, misappropriated or otherwise violated by a third person in any manner that would reasonably be expected to result in a Material Adverse Change or a material adverse effect on any Product Commercialization and Development Activities with respect to Ganaxolone, such Grantor shall promptly (and in any case within three (3) Business Days after obtaining knowledge thereof) notify the Administrative Agent and shall, if consistent with good business judgment, promptly take such commercially reasonable measures to cause a cessation of such infringement, misappropriation or other violation and to recover damages therefor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><a name="_Ref40146137"></a><b style="font-weight:bold;">Notices, Reports and Information</b>. Such Grantor will (i)&#160;no later than the next Quarterly Reporting Date following the occurrence thereof, (A) notify the Administrative Agent of any other modifications of or additions to the information contained in <b style="font-weight:bold;">Schedule&#160;1</b><b style="font-weight:bold;"> </b>(including any acquisition or holding of an interest in any Chattel Paper, Commercial Tort Claims and Letter-of- Credit Rights) and (B) notify the Administrative Agent of any material Claim made or asserted against the Collateral by any Person and of any event which could materially adversely affect the value of the Collateral (taken as a whole) or the Administrative Agent&#8217;s Lien thereon </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">and (ii)&#160;upon the reasonable request of the Administrative Agent, make such demands and requests for information and reports as such Grantor is entitled to make in respect of the Collateral. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font><a name="_Ref40146138"></a><b style="font-weight:bold;">Shareholder Agreements; Other Agreements.</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146139"></a>Such Grantor shall comply in all material respects with all of its obligations under any shareholders agreement, operating agreement, partnership agreement, voting trust, proxy agreement or other agreement or understanding (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Pledged Collateral Agreements</font>&#8221;) to which it is a party and shall enforce all of its rights thereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40146140"></a>To the extent relating to a Subsidiary of a Grantor, such Grantor will take all actions necessary to cause each such Pledged Collateral Agreement relating to Partnership and LLC Collateral to provide specifically at all times that: (A) no such Partnership and LLC Collateral shall be a security governed by Article&#160;8 of the NY UCC or any other applicable state&#8217;s Uniform Commercial Code; and (B) no consent of any member, manager, partner or other Person shall be a condition to the admission as a member or partner of any transferee (including the Administrative Agent) that acquires ownership of such Partnership and LLC Collateral as a result of the exercise by the Administrative Agent of any remedy hereunder or under applicable Law. Additionally, such Grantor agrees that no such Partnership and LLC Collateral for which the issuer thereof is a Subsidiary (A)&#160;shall be dealt in or traded on any securities exchange or in any securities market, (B)&#160;shall constitute an investment company security, or (C)&#160;shall be held by such Grantor in a Securities Account.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40146141"></a>Such Grantor shall not vote to enable or take any other action to: amend or terminate, or waive compliance with any of the terms of, any such Pledged Collateral Agreement, certificate or articles of incorporation, bylaws or other organizational documents in any way that materially changes the rights of such Grantor with respect to any such Pledged Collateral in a manner adverse to the Administrative Agent or the other Secured Parties or that adversely affects the validity, perfection or priority of the Administrative Agent&#8217;s security interest therein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;6</font><a name="_Ref40146142"></a><a name="_Ref40146792"></a><a name="_Ref40810731"></a><a name="_Toc71361873"></a>Rights to Payment and Pledged Collateral<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146143"></a><b style="font-weight:bold;">Collection of Rights to Payment</b>. Until the Administrative Agent has given notice to the relevant Grantor of the Administrative Agent&#8217;s intent to exercise its rights hereunder to collect any Rights to Payment of any Grantor, each such Grantor shall endeavor in the first instance diligently to collect all amounts due or to become due on or with respect to the Rights to Payment held by such Grantor. At the request of the Administrative Agent, upon the occurrence and during the continuation of an Event of Default, all remittances received by such Grantor shall be held in trust for the Administrative Agent and, in accordance with the Administrative Agent&#8217;s instructions, remitted to the Administrative Agent or deposited to an account with the Administrative Agent in the form received (with any necessary endorsements or instruments of assignment or transfer).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146144"></a><b style="font-weight:bold;">Pledged Collateral</b>. Unless and until an Event of Default shall have occurred and is continuing and the Administrative Agent shall have given notice to the relevant Grantor of the Administrative Agent&#8217;s intent to exercise its rights pursuant to Section 10, each </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Grantor shall be entitled to receive and retain for its own account any cash dividend on or other cash distribution or payment, if any, in respect of the Pledged Collateral, to the extent not prohibited under the Credit Agreement. At the request of the Administrative Agent, upon the occurrence and during the continuation of an Event of Default, the Administrative Agent shall have the sole and exclusive right and authority to receive all distributions and payments of any nature with respect to any Pledged Collateral, and all such distributions or payments received by such Grantor shall be held in trust for the Administrative Agent and, in accordance with the Administrative Agent&#8217;s instructions, remitted to the Administrative Agent or deposited to an account with the Administrative Agent in the form received (with any necessary endorsements or instruments of assignment or transfer). All dividends, interest, principal or other distributions received by any Grantor contrary to the provisions of this <b style="font-weight:bold;">Section&#160;6</b><b style="font-weight:bold;">(b)</b> shall be held in trust for the benefit of the Administrative Agent, shall be segregated from other property or funds of such Grantor and shall be forthwith delivered to the Administrative Agent upon demand in the same form as so received (with any necessary endorsement or instrument of assignment). Following the occurrence and during the continuation of an Event of Default, any such distributions and payments with respect to any such Pledged Collateral held in any Securities Account shall be held and retained in such Securities Account, in each case as part of the Collateral hereunder. Additionally, the Administrative Agent shall have the right, upon the occurrence and during the continuation of an Event of Default, following prior written notice to any applicable Grantor, to vote and to give consents, ratifications and waivers with respect to any Pledged Collateral held by such Grantor, and to exercise all rights of conversion, exchange, subscription or any other rights, privileges or options pertaining thereto, as if the Administrative Agent were the absolute owner thereof; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that the Administrative Agent shall have no duty to exercise any of the foregoing rights afforded to it and shall not be responsible to such Grantor or any other Person for any failure to do so or delay in doing so.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146145"></a><b style="font-weight:bold;">Voting Prior to an Event of Default</b>. Unless and until an Event of Default shall have occurred and is continuing<font style="color:#0000ff;"> </font>and the Administrative Agent shall have given notice to the relevant Grantor of the Administrative Agent&#8217;s intent to exercise its rights pursuant to Section 10, each Grantor shall have the right to vote the Pledged Collateral held by such Grantor and to give consents, ratifications and waivers in respect thereof, and shall retain the power to control the direction, management and policies of any Person comprising such Pledged Collateral to the same extent as such Grantor would if such Pledged Collateral were not pledged to the Administrative Agent pursuant to this Agreement; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that no vote shall be cast or consent, waiver or ratification given or action taken which would have the effect of materially impairing the position or interest of the Administrative Agent and the other Secured Parties in respect of such Pledged Collateral or which would alter the voting rights with respect to the stock or other ownership interest in or of any such Person or be inconsistent with or violate any provision of this Agreement, the Credit Agreement, or any other Loan Documents. If applicable, such Grantor shall be deemed the beneficial owner of all such Pledged Collateral for purposes of Sections&#160;13 and 16 of the Exchange Act and agrees to file all reports required to be filed by beneficial owners of securities thereunder. The Administrative Agent shall execute and deliver (or cause to be executed and delivered) to each Grantor all such proxies and other instruments as such Grantor may reasonably request for the purpose of enabling such Grantor to exercise the voting and other rights which it is entitled to exercise pursuant to this <b style="font-weight:bold;">subsection&#160;</b><b style="font-weight:bold;">(c)</b> and to receive the distributions which it is authorized to receive and retain pursuant to this <b style="font-weight:bold;">subsection&#160;</b><b style="font-weight:bold;">(c)</b>.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40146146"></a><b style="font-weight:bold;">Certain Other Administrative Matters</b>. Upon the occurrence and during the continuation of an Event of Default and after the Administrative Agent shall have given notice to the relevant Grantor of the Administrative Agent&#8217;s intent to exercise its rights pursuant to Section 10, the Administrative Agent may cause any of the Pledged Collateral to be transferred into its name or into the name of its nominee or nominees (subject to the revocable rights specified in this <b style="font-weight:bold;">Section&#160;6</b>). Upon the occurrence and during the continuation of an Event of Default, the Administrative Agent shall have the right to exchange uncertificated Pledged Collateral for certificated Pledged Collateral, and to exchange certificated Pledged Collateral for certificates of larger or smaller denominations, for any purpose consistent with this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;7</font><a name="_Ref40146147"></a><a name="_Ref40146793"></a><a name="_Toc71361874"></a>Authorization; Agent Appointed Attorney-in-Fact<font style="font-weight:normal;">. In addition to (and not in limitation of) any other right or remedy provided to the Administrative Agent hereunder, the Administrative Agent shall have the right to, in the name of any Grantor, or in the name of the Administrative Agent or otherwise, without notice to or assent by any such Grantor, and each Grantor hereby constitutes and appoints the Administrative Agent (and any of the Administrative Agent&#8217;s officers or employees or agents designated by the Administrative Agent) as such Grantor&#8217;s true and lawful attorney-in-fact, with full power and authority to:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146148"></a>file any of the financing statements which must be filed to perfect or continue perfected, maintain the priority of, or provide notice of, the Administrative Agent&#8217;s Lien in the Collateral;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146149"></a>take possession of and endorse any notes, acceptances, checks, drafts, money orders or other forms of payment or security and collect any Proceeds of any Collateral;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146150"></a>sign and endorse any invoice or bill of lading relating to any of the Collateral, warehouse or storage receipts, drafts against customers or other obligors, assignments, notices of assignment, verifications and notices to customers or other obligors;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40146151"></a>notify the U.S. Postal Service and other postal authorities to change the address for delivery of mail addressed to such Grantor to such address as the Administrative Agent may designate; and, without limiting the generality of the foregoing, establish with any Person lockbox or similar arrangements for the payment of the Rights to Payment of such Grantor;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40146152"></a>receive, open and dispose of all mail addressed to such Grantor;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref40146153"></a>send requests for verification of Rights to Payment to the customers or other obligors of such Grantor;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref40146154"></a>contact, or direct such Grantor to contact, all account debtors and other obligors on the Rights to Payment of such Grantor and instruct such account debtors and other obligors to make all payments directly to the Administrative Agent;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref40146155"></a>assert, adjust, sue for, compromise or release any claims under any policies of insurance;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146156"></a>exercise dominion and control over, and refuse to permit further withdrawals from, any Deposit Accounts of such Grantor maintained with the Administrative </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Agent, any Lender or any other bank, financial institution or other Person, in each case other than any Excluded Accounts;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref40146157"></a>notify each Person maintaining lockbox or similar arrangements for the payment of the Rights to Payment of such Grantor to remit all amounts representing collections on such Rights to Payment directly to the Administrative Agent;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref40146158"></a>execute any and all applications, documents, papers and instruments necessary for the Administrative Agent to use or otherwise exploit the Intellectual Property Collateral and grant or issue any exclusive or non-exclusive License with respect to any Intellectual Property Collateral;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font>ask, demand, collect, receive and give acquittances and receipts for any and all Rights to Payment of such Grantor, enforce payment or any other rights in respect of the Rights to Payment and other Collateral, grant consents, agree to any amendments, modifications or waivers of the agreements and documents governing such Rights to Payment and other Collateral, and otherwise file any Claims, take any action or institute, defend, settle or adjust any actions, suits or proceedings with respect to the Collateral, as the Administrative Agent may deem necessary or desirable to maintain, preserve and protect the Collateral, to collect the Collateral or to enforce the rights of the Administrative Agent with respect to the Collateral;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><a name="_Ref40146160"></a>execute any and all endorsements, assignments or other documents and instruments necessary to sell, lease, assign, convey or otherwise transfer title in or dispose of the Collateral;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><a name="_Ref40146161"></a>execute and deliver to any securities intermediary or other Person any entitlement order or other notice, document or instrument which the Administrative Agent may deem necessary or advisable to maintain, protect, realize upon and preserve the Deposit Accounts and Investment Property of such Grantor constituting Collateral and the Administrative Agent&#8217;s security interest therein;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font>commence and prosecute any and all suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect or otherwise realize on all or any of the Collateral or to enforce any rights in respect of any Collateral;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font>settle, compromise, compound, adjust or defend any actions, suits or proceedings relating to all or any of the Collateral; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(q)</font><a name="_Ref40146162"></a>use, sell, assign, transfer, pledge, make any agreement with respect to or otherwise deal with all or any of the Collateral, and execute any and all such other documents and instruments, and do any and all acts and things for and on behalf of such Grantor, which the Administrative Agent may deem necessary or advisable to maintain, protect, realize upon and preserve the Collateral and the Administrative Agent&#8217;s security interest therein and to accomplish the purposes of this Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;">The Administrative Agent agrees that, except upon the occurrence and during the continuation of an Event of Default, it shall not exercise the power of attorney, or any rights granted to the Administrative Agent, pursuant to <b style="font-weight:bold;">clauses&#160;</b><b style="font-weight:bold;">(b)</b> through <b style="font-weight:bold;">(q)</b>. The foregoing power of attorney is </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">coupled with an interest and irrevocable so long as the Lenders have any Commitments or the Secured Obligations have not been paid and performed in full. Each Grantor hereby ratifies, to the extent permitted by Law, all that the Administrative Agent shall lawfully and in good faith do or cause to be done by virtue of and in compliance with this <b style="font-weight:bold;">Section&#160;7</b>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;8</font><a name="_Ref40146163"></a><a name="_Ref40146794"></a><a name="_Toc71361875"></a>Agent Performance of Grantor Obligations<font style="font-weight:normal;">. Upon the occurrence and continuation of an Event of Default, the Administrative Agent shall have the right (but not any obligation) to perform or pay any obligation which any Grantor has agreed to perform or pay under or in connection with this Agreement, and such Grantor shall reimburse the Administrative Agent on demand for all documented out of pocket costs and expenses by the Administrative Agent pursuant to this </font>Section&#160;8<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;9</font><a name="_Ref40146164"></a><a name="_Ref40146795"></a><a name="_Toc71361876"></a>Agent&#8217;s Duties<font style="font-weight:normal;">. Notwithstanding any provision contained in this Agreement, the Administrative Agent shall have no duty to exercise any of the rights, privileges or powers afforded to it and shall not be responsible to any Grantor or any other Person for any failure to do so or delay in doing so. Without limiting the generality of the foregoing, nothing herein contained shall be construed as requiring or obligating the Administrative Agent to make any commitment or to make any inquiry as to the nature of sufficiency of any payment received by the Administrative Agent, or to present or file any claim or notice, or to take any action with respect to the Collateral or any part thereof or the moneys due or to become due in respect thereof or any property covered thereby. With the exception of any act or failure to act (in each case, with gross negligence or willful misconduct) to assure the safe custody of Collateral in the Administrative Agent&#8217;s possession and the accounting for moneys actually received by the Administrative Agent hereunder, the Administrative Agent and its officers, directors, employees, agents or sub-agents shall have no duty or liability to exercise or preserve any rights, privileges or powers pertaining to the Collateral. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;10</font><a name="_Ref40146165"></a><a name="_Ref40146796"></a><a name="_Toc71361877"></a>Remedies<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146166"></a><b style="font-weight:bold;">Remedies</b>. Solely upon the occurrence and during the continuation of an Event of Default, each Grantor agrees to deliver each item of Collateral to the Administrative Agent on demand, and the Administrative Agent shall have, in addition to all other rights and remedies granted to it in this Agreement, the Credit Agreement, or any other Loan Document, all rights and remedies of a secured party under the NY UCC and other applicable Law. Without limiting the generality of the foregoing, each Grantor agrees that:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref40146167"></a>The Administrative Agent may peaceably, with or without legal process and with or without notice, without liability for trespass enter any premises of such Grantor, take possession of any Collateral, remove or dispose of all or part of the Collateral on any premises of such Grantor or elsewhere, or, in the case of Equipment, render it nonfunctional, and otherwise collect, receive, appropriate and realize upon all or any part of the Collateral, and demand, give receipt for, settle, renew, extend, exchange, compromise, adjust, or sue for all or any part of the Collateral, as the Administrative Agent may determine, and, generally, exercise any and all rights afforded to a secured party under the Uniform Commercial Code or other applicable law.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref40146168"></a>The Administrative Agent may require such Grantor to assemble all or any part of the Collateral and make it available to the Administrative Agent, at any place and time designated by the Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref40146169"></a>The Administrative Agent may use or transfer any of such Grantor&#8217;s rights and interests in any Intellectual Property Collateral, by license, by sublicense (solely to the extent permitted by such applicable license) or otherwise, on such conditions and in such manner as the Administrative Agent may determine.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref40146170"></a>The Administrative Agent may secure the appointment of a receiver of the Collateral or any part thereof (to the extent and in the manner provided by applicable Law).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><a name="_Ref40146171"></a>The Administrative Agent may withdraw (or cause to be withdrawn) any and all funds from any Deposit Accounts, Securities Accounts or Commodity Accounts, in each case other than Excluded Accounts.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font><a name="_Ref40146172"></a>The Administrative Agent may sell, resell, lease, use, assign, transfer or otherwise dispose of any or all of the Collateral in its then condition or following any commercially reasonable preparation or processing (utilizing in connection therewith any of such Grantor&#8217;s assets, without charge or liability to the Administrative Agent therefor) at public or private sale or at any broker&#8217;s board or any securities exchange, by one or more Contracts, in one or more parcels, at the same or different times, for cash or credit or for future delivery without assumption of any credit risk, all as the Administrative Agent deems advisable; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that such Grantor shall be credited with the net proceeds of a sale only when such proceeds are finally collected by the Administrative Agent. The Administrative Agent and each of the other Secured Parties shall have the right upon any such public sale, and, to the extent permitted by Law, upon any such private sale, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption, which right or equity of redemption such Grantor hereby releases, to the extent permitted by Law. The Administrative Agent shall give such Grantor such notice of any public or private sale as may be required by the NY UCC or other applicable Law. Such Grantor recognizes that the Administrative Agent may be unable to make a public sale of any or all of the Pledged Collateral, by reason of prohibitions contained in applicable securities laws or otherwise, and expressly agrees that a private sale to a restricted group of purchasers for investment and not with a view to any distribution thereof shall be considered a commercially reasonable sale. Each such purchaser at any such sale shall hold the property sold absolutely, free from any claim or right on the part of any Grantor, and each Grantor hereby waives and releases (to the extent permitted by law) all rights of redemption, stay, valuation and appraisal that such Grantor now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted.</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><a name="_Ref40146173"></a>The Administrative Agent shall give each applicable Grantor not less than 10 days&#8217; written notice (which each Grantor agrees is reasonable notice within the meaning of Section 9-611 of the NY UCC or its equivalent in other jurisdictions) of the Agent&#8217;s intention to make any sale of Collateral. Such notice, in the case of a public sale, shall state the time and place for such sale and, in the case of a sale at a broker&#8217;s board or on a securities exchange, shall state the board or exchange at which such sale is to be made and the day on which the Collateral, or portion thereof, will first be offered for sale at such board or exchange. Any such public sale shall be held at such time or times within ordinary business hours and at such place or places as the Administrative Agent may fix and state in the notice (if any) of such sale. At any such sale, </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;">the Collateral, or portion thereof, to be sold may be sold in one lot as an entirety or in separate parcels, and by the Administrative Agent in its own right or by one or more agents or contractors, upon any premises owned, leased or occupied by any Grantor, the Administrative Agent or any such agent or contractor, and any such sale may include any other property, in each case, as the Administrative Agent may (in its sole and absolute discretion) determine. The Administrative Agent shall not be obligated to make any sale of any Collateral if it shall determine not to do so, regardless of the fact that notice of sale of such Collateral shall have been given. The Administrative Agent may, without notice or publication, adjourn any public or private sale or cause the same to be adjourned from time to time by announcement at the time and place fixed for sale, and such sale may, without further notice, be made at the time and place to which the same was so adjourned. In case any sale of all or any part of the Collateral is made on credit or for future delivery, the Collateral so sold may be retained by the Administrative Agent until the sale price is paid by the purchaser or purchasers thereof, but the Administrative Agent shall not incur any liability in case any such purchaser or purchasers shall fail to take up and pay for the Collateral so sold and, in case of any such failure, such Collateral may be sold again upon like notice. At any public (or, to the extent permitted by law, private) sale made pursuant to this Agreement, any Secured Party may bid for or purchase, free (to the extent permitted by applicable law) from any right of redemption, stay, valuation or appraisal on the part of any Grantor (all said rights being also hereby waived and released to the extent permitted by applicable law), the Collateral or any part thereof offered for sale and may make payment on account thereof by using any claim then due and payable to such Secured Party from any Grantor as a credit against the purchase price, and such Secured Party may, upon compliance with the terms of sale, hold, retain and dispose of such property without further accountability to any Grantor therefor. For purposes hereof, a written agreement to purchase the Collateral or any portion thereof shall be treated as a sale thereof; the Administrative Agent shall be free to carry out such sale pursuant to such agreement and no Grantor shall be entitled to the return of the Collateral or any portion thereof subject thereto, notwithstanding the fact that after the Administrative Agent shall have entered into such an agreement all Events of Default shall have been remedied and the Obligations shall have been indefeasibly paid in full in cash. As an alternative to exercising the power of sale herein conferred upon it, the Administrative Agent may proceed by a suit or suits at law or in equity to foreclose this Agreement and to sell the Collateral or any portion thereof pursuant to a judgment or decree of a court or courts having competent jurisdiction or pursuant to a proceeding by a court-appointed receiver. Any sale pursuant to the provisions of this <b style="font-weight:bold;">Section&#160;10</b><b style="font-weight:bold;">(a)</b> shall be deemed to conform to the commercially reasonable standards as provided in Section 9-610(b) of the NY UCC or its equivalent in other jurisdictions. Neither the Administrative Agent nor the Secured Parties shall be required to marshal any present or future Collateral or to resort to such Collateral in any particular order.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(vii)</font>Neither the Administrative Agent nor any other Secured Party shall have any obligation to clean up or otherwise prepare the Collateral for sale. The Administrative Agent has no obligation to attempt to satisfy the Secured Obligations by collecting them from any other Person liable for them and the Administrative Agent and the other Secured Parties may release, modify or waive any Collateral provided by any other Person to secure any of the Secured Obligations, all without affecting the Administrative Agent&#8217;s or any other Secured Party&#8217;s rights against such Grantor. Such Grantor waives any right it may have to require the Administrative Agent or any other Secured Party to pursue any third Person for any of the Secured Obligations. The Administrative Agent and the other Secured Parties may comply with any applicable state or </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">federal law requirements in connection with a disposition of the Collateral and compliance will not be considered to adversely affect the commercial reasonableness of any sale of the Collateral. The Administrative Agent may sell the Collateral without giving any warranties as to the Collateral. The Administrative Agent may specifically disclaim any warranties of title or the like. This procedure will not be considered to adversely affect the commercial reasonableness of any sale of the Collateral. If the Administrative Agent sells any of the Collateral upon credit, such Grantor will be credited only with payments actually made by the purchaser, received by the Administrative Agent and applied to the indebtedness of the purchaser. In the event the purchaser fails to pay for the Collateral, the Administrative Agent may resell the Collateral and the Grantors shall be credited with the proceeds of the sale.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146174"></a><b style="font-weight:bold;">License</b>. For the purpose of enabling the Administrative Agent to exercise its rights and remedies under this <b style="font-weight:bold;">Section&#160;10</b><b style="font-weight:bold;"> </b>or otherwise in connection with this Agreement, and solely during the continuance of an Event of Default, each Grantor hereby grants to the Administrative Agent an irrevocable, non-exclusive license (exercisable without payment or royalty or other compensation to such Grantor) to use, license or sublicense any Intellectual Property Collateral and, including in such license, all access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that nothing in this <b style="font-weight:bold;">Section&#160;10(b)</b><b style="font-weight:bold;"> </b>shall require a Grantor to grant any license that (i)&#160;violates the express terms of any agreement between a Grantor and a third party governing such Grantor&#8217;s use of such Intellectual Property Collateral, or gives such third party any right of acceleration, modification or cancellation therein, or (ii)&#160;is prohibited by any applicable Law; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, that such licenses to be granted hereunder with respect to Trademarks shall be subject to maintenance of quality standards with respect to the goods and services on which such Trademarks are used sufficient to preserve the validity of such Trademarks.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146175"></a><b style="font-weight:bold;">Proceeds Account</b>. To the extent that any of the Secured Obligations may be contingent, unmatured or unliquidated at such time as an Event of Default has occurred and is continuing, the Administrative Agent may, at its election, (i)&#160;retain the proceeds of any sale, collection, disposition or other realization upon the Collateral (or any portion thereof) in a special purpose non-interest-bearing restricted deposit account (the &#8220;<font style="font-style:italic;font-weight:bold;">Proceeds Account</font>&#8221;) created and maintained by the Administrative Agent for such purpose (which shall constitute a Deposit Account included within the Collateral hereunder) until such time as the Administrative Agent may elect to apply such proceeds to the Secured Obligations, and each Grantor agrees that such retention of such proceeds by the Administrative Agent shall not be deemed strict foreclosure with respect thereto; (ii)&#160;in any manner elected by the Administrative Agent, estimate the liquidated amount of any such contingent, unmatured or unliquidated Claims and apply the proceeds of the Collateral against such amount; or (iii)&#160;otherwise proceed in any manner permitted by applicable Law. Each Grantor agrees that the Proceeds Account shall be a blocked account and that upon the irrevocable deposit of funds into the Proceeds Account, such Grantor shall not have any right of withdrawal with respect to such funds. Accordingly, each Grantor irrevocably waives until the termination of this Agreement in accordance with <b style="font-weight:bold;">Section&#160;25</b><b style="font-weight:bold;"> </b>the right to make any withdrawal from the Proceeds Account and the right to instruct the Administrative Agent to honor drafts against the Proceeds Account.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40146176"></a><b style="font-weight:bold;">Application of Proceeds</b>. The cash proceeds actually received from the sale or other disposition or collection of any Grantor&#8217;s Collateral, and any other amounts received in respect of such Collateral the application of which is not otherwise provided for herein, shall be applied as provided in Section&#160;4.01(b) of the Credit Agreement. Any surplus thereof which exists after payment and performance in full of the Secured Obligations shall be promptly paid over to such Grantor or otherwise disposed of in accordance with the NY UCC or other applicable Law. Each Grantor shall remain liable to the Administrative Agent and the other Secured Parties for any deficiency which exists after any sale or other disposition or collection of Collateral.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;11</font><a name="_Ref40146177"></a><a name="_Ref40146797"></a><a name="_Toc71361878"></a>Certain Waivers<font style="font-weight:normal;">. Each Grantor waives, to the fullest extent permitted by Law, (i)&#160;any right of redemption with respect to the Collateral, whether before or after sale hereunder, and all rights, if any, of marshalling of the Collateral or other collateral or security for the Secured Obligations; (ii)&#160;any right to require the Administrative Agent or the other Secured Parties (w)&#160;to proceed against any Person, (x)&#160;to exhaust any other collateral or security for any of the Secured Obligations, (y)&#160;to pursue any remedy in the Administrative Agent&#8217;s or any of the other Secured Parties&#8217; power, or (z)&#160;to make or give any presentments, demands for performance, notices of nonperformance, protests, notices of protests or notices of dishonor in connection with any of the Collateral; and (iii)&#160;all Claims, damages, and demands against the Administrative Agent or the other Secured Parties arising out of the repossession, retention, sale or application of the proceeds of any sale of the Collateral.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;12</font><a name="_Ref40146178"></a><a name="_Ref40146798"></a><a name="_Toc71361879"></a>Notices<font style="font-weight:normal;">. All notices, requests, instructions, directions and other communications provided for herein (including any modifications of, or waivers, requests or consents under, this Agreement) shall be given or made in writing (including by telecopy or email) delivered, if to any of the parties hereto, as specified in the Credit Agreement. Except as otherwise provided in this Agreement or therein, all such communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by telecopy shall be confirmed in writing promptly after the delivery of such communication (it being understood that non-receipt of written confirmation of such communication shall not invalidate such communication).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;13</font><a name="_Ref40146179"></a><a name="_Ref40146799"></a><a name="_Toc71361880"></a>No Waiver; Cumulative Remedies<font style="font-weight:normal;">. No failure on the part of the Administrative Agent or any other Secured Party to exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege under this Agreement preclude any other or further exercise thereof or the exercise of any other right, power or privilege. Any waiver or consent shall be effective only in the specific instance and for the purpose for which given. Without limiting the generality of the foregoing, the making of a Loan shall not be construed as a waiver of any Default, regardless of whether the Administrative Agent or any Lender may have had notice or knowledge of such Default at the time. No notice or demand on any Grantor in any case shall entitle any Grantor to any other or further notice or demand in similar or other circumstances. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;14</font><a name="_Ref40146180"></a><a name="_Ref40146800"></a><a name="_Toc71361881"></a>Costs and Expenses; Indemnification<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146181"></a><b style="font-weight:bold;">Costs and Expenses</b><a name="_Hlk70668556"></a>. In addition to the payment and reimbursement obligations set forth in Section&#160;14.03(a) of the Credit Agreement, each Grantor jointly and severally agrees to pay (i)&#160;all reasonable and documented out-of-pocket expenses incurred by the Administrative Agent and any other Secured Party (including the fees and expenses of legal counsel; in connection with the enforcement or collection proceedings resulting from the occurrence of an Event of Default (A)&#160;in connection with this Agreement, including its rights under this <b style="font-weight:bold;">Section&#160;14</b>, (B)&#160;subject to the limitations set forth in Section&#160;14.03(a) of the Credit Agreement with respect to expenses incurred on or prior to the Closing Date, in connection with the Secured Obligations, including all such reasonable and documented out-of-pocket expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement or in respect of the Secured Obligations, and including in or in connection with any Insolvency Proceeding, and (C)&#160;in connection with the protection, sale or collection of, or other realization upon, any of the Collateral, including all reasonable and documented out of pocket expenses of taking, collecting, holding, sorting, handling, preparing for sale, selling, or the like, and other such expenses of sales and collections of Collateral, and (ii)&#160;all reasonable and documented out of pocket title, appraisal, survey, audit, environmental inspection, consulting, search, recording, filing and similar costs, fees and expenses incurred or sustained by the Administrative Agent or any of its Affiliates in connection with this Agreement or the Collateral.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146182"></a><b style="font-weight:bold;">Indemnification</b>. Each Grantor, jointly and severally, hereby indemnifies each Indemnified Party pursuant to Section&#160;14.03(b) of the Credit Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146183"></a><b style="font-weight:bold;">Payment</b>. All amounts due under this <b style="font-weight:bold;">Section&#160;14</b><b style="font-weight:bold;"> </b>shall be due payable within fifteen (15) Business Days of receipt of a reasonably detailed invoice therefor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref40146184"></a><b style="font-weight:bold;">Interest</b>. Any amounts payable to the Administrative Agent or any Secured Party under this <b style="font-weight:bold;">Section&#160;14</b><b style="font-weight:bold;"> </b>or otherwise under this Agreement if not paid upon the due date shall bear interest from the date of such demand until paid in full, at the rate of interest set forth in Section&#160;3.02(b) of the Credit Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref40146185"></a><b style="font-weight:bold;">Survival</b>. The agreements in this <b style="font-weight:bold;">Section&#160;14</b><b style="font-weight:bold;"> </b>shall survive the termination of the Commitments and the repayment of all Secured Obligations.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;15</font><a name="_Ref40146186"></a><a name="_Ref40146801"></a><a name="_Toc71361882"></a>Binding Effect<font style="font-weight:normal;">. This Agreement shall be binding upon, inure to the benefit of and be enforceable by each Grantor, the Administrative Agent, each Secured Party, each Indemnified Party referred to in </font>Section&#160;14<font style="font-weight:normal;">, and their respective successors and assigns and shall bind any Person who becomes bound as a debtor to this Agreement. This Agreement shall be construed as a separate agreement with respect to each Grantor and may be amended, modified, supplemented, waived or release with respect to any Grantor without the approval of any other Grantor and without affecting the obligations of any other Grantor hereto. No Grantor shall assign or delegate this Agreement, any of its rights or obligations hereunder or any interest herein or in the Collateral (in each case, except as expressly contemplated by this Agreement or the Credit Agreement) without the prior written consent of the Administrative Agent, and any attempted assignment without such consent shall be null and void.</font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;16</font><a name="_Ref40146187"></a><a name="_Ref40146802"></a><a name="_Toc71361883"></a>Governing Law<font style="font-weight:normal;">. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;17</font><a name="_Ref40146188"></a><a name="_Ref40146803"></a><a name="_Toc71361884"></a>Submission to Jurisdiction<font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref40146189"></a><b style="font-weight:bold;">Submission to Jurisdiction</b>. Each party hereto agrees that any suit, action or proceeding with respect to this Agreement or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state courts in New York, New York or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding or judgment.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref40146190"></a><b style="font-weight:bold;">Waiver of Venue</b>. Each party hereto irrevocably waives to the fullest extent permitted by Law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document and hereby further irrevocably waives to the fullest extent permitted by Law any Claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such Grantor is or may be subject, by suit upon judgment.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref40146191"></a><b style="font-weight:bold;">Alternative Process</b>. Nothing herein shall in any way be deemed to limit the ability of the parties hereto to serve any process or summons in any manner permitted by any Law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;18</font><a name="_Ref40146192"></a><a name="_Ref40146804"></a><a name="_Toc71361885"></a>Waiver of Jury Trial<font style="font-weight:normal;">. </font>EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;19</font><a name="_Ref40146193"></a><a name="_Ref40146805"></a><a name="_Toc71361886"></a>Entire Agreement; Amendment<font style="font-weight:normal;">. This Agreement and the other Loan Documents contain the entire agreement of the parties with respect to the subject matter hereof and supersedes any and all previous agreements and understandings, oral or written, relating to the subject matter hereof, including any confidentiality (or similar) agreements. EACH GRANTOR ACKNOWLEDGES, REPRESENTS AND WARRANTS THAT IN DECIDING TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS OR IN TAKING OR NOT TAKING ANY ACTION HEREUNDER OR THEREUNDER, IT HAS NOT RELIED, AND WILL NOT RELY, ON ANY STATEMENT, REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR UNDERSTANDING, WHETHER WRITTEN OR ORAL, OF OR WITH THE LENDERS OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS. This Agreement shall not be amended except by the written agreement of the parties as provided in the Credit Agreement. </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;20</font><a name="_Ref40146194"></a><a name="_Ref40146806"></a><a name="_Toc71361887"></a>Severability<font style="font-weight:normal;">. If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by any Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;21</font><a name="_Ref40146195"></a><a name="_Ref40146807"></a><a name="_Toc71361888"></a>Counterparts<font style="font-weight:normal;">. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;22</font><a name="_Ref40146196"></a><a name="_Ref40146808"></a><a name="_Toc71361889"></a>Incorporation of Provisions of the Credit Agreement<font style="font-weight:normal;">. To the extent the Credit Agreement contains provisions of general applicability to the Loan Documents, including any such provisions contained in Section&#160;14 thereof, such provisions are incorporated herein by this reference.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;23</font><a name="_Ref40146197"></a><a name="_Ref40146809"></a><a name="_Toc71361890"></a>No Inconsistent Requirements<font style="font-weight:normal;">. Each Grantor acknowledges that this Agreement and the other Loan Documents may contain covenants and other terms and provisions variously stated regarding the same or similar matters, and agrees that all such covenants, terms and provisions are cumulative and all shall be performed and satisfied in accordance with their respective terms.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;24</font><a name="_Ref40146198"></a><a name="_Ref40146810"></a><a name="_Ref40146891"></a><a name="_Ref40148511"></a><a name="_Toc71361891"></a>Accession<font style="font-weight:normal;">. At such time following the date hereof as any Person (an &#8220;</font><font style="font-style:italic;">Acceding Grantor</font><font style="font-weight:normal;">&#8221;) is required to accede hereto pursuant to the terms of Section&#160;8.12 of the Credit Agreement, such Acceding Grantor shall execute and deliver to the Administrative Agent an accession agreement substantially in the form of </font>Exhibit&#160;A <font style="font-weight:normal;">(an &#8220;</font><font style="font-style:italic;">Accession Agreement</font><font style="font-weight:normal;">&#8221;), signifying its agreement to be bound by the provisions of this Agreement as a Grantor to the same extent as if such Acceding Grantor had originally executed this Agreement as of the date hereof. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;25</font><a name="_Ref40146199"></a><a name="_Ref40146811"></a><a name="_Toc71361892"></a>Termination<font style="font-weight:normal;">. Upon the termination of the Commitments of the Lenders and payment and satisfaction in full of all Secured Obligations (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made), the security interests created by this Agreement shall automatically terminate and the Administrative Agent shall promptly execute and deliver to each Grantor such documents and instruments reasonably requested by such Grantor as shall be necessary to evidence the termination of all security interests given by such Grantor to the Administrative Agent hereunder and deliver to the Borrower, at the expense of the Borrower, any portion of the Collateral that is in possession of the Administrative Agent. &#160;Any execution and delivery of such documents pursuant to this </font>Section 25<font style="font-weight:normal;"> shall be without recourse to or representation or warranty by the Administrative Agent or any Secured Party. The Borrower shall reimburse the Administrative Agent upon demand for all reasonable and documented costs and out of pocket expenses, including the reasonable fees, charges and expenses of counsel, incurred by it in connection with any action contemplated by this </font>Section 25<font style="font-weight:normal;">.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt;">Upon the consummation of any transaction permitted under the Credit Agreement as a result of which such Grantor ceases to be a Subsidiary Guarantor, such Grantor shall be automatically released from its obligations hereunder arising after the date on which such Grantor </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">ceases to be a Subsidiary Guarantor and the security interests created hereunder in the Collateral of such Grantor shall be automatically released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Upon any sale, lease, transfer or other disposition by any Grantor of any Collateral that is permitted under the Credit Agreement to any Person that is not another Grantor, the security interest in such Collateral shall be automatically released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">In addition, in connection with any Permitted Licenses, the Administrative Agent shall, at the request of any Grantor, negotiate and enter into a non-disturbance agreement and other similar agreements in form and substance reasonably satisfactory to the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, the Administrative Agent shall not be required to take any action under this <b style="font-weight:bold;">Section 25</b> unless the applicable Grantor shall have delivered to the Administrative Agent together with such request, which may be incorporated into such request, a certificate of an authorized officer of the Borrower or such Grantor in form and substance reasonably satisfactory to the Administrative Agent which certifies that the transaction giving rise to such termination or release is permitted by the Credit Agreement and was, or will concurrently with the release be, consummated in compliance with the Loan Documents.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">Section&#160;26</font><a name="_Toc71361893"></a>Right of Set-Off<font style="font-weight:normal;">. If an Event of Default shall have occurred and is continuing, each Secured Party is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all Collateral (including any deposits (general or special, time or demand, provisional or final)) at any time held and other obligations at any time owing by such Secured Party to or for the credit or the account of any Grantor against any and all of the obligations of such Grantor now or hereafter existing under this Agreement and the other Loan Documents held by such Secured Party, irrespective of whether or not such Secured Party shall have made any demand under this Agreement or any other Loan Document and although such obligations may be unmatured. The rights of each Secured Party under this Section 26 are in additional to others rights and remedies (including other rights of setoff) which such Secured Party may have.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of page intentionally left blank; signature pages follow</i>]</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;"><b style="font-weight:bold;">GRANTOR: <br><br></b><b style="font-family:'Times New Roman Bold';font-weight:bold;text-transform:uppercase;">Marinus Pharmaceuticals</b><b style="font-weight:bold;">, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Steven Pfanstiel</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:88.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u>Name: Steven Pfanstiel<br>Title: Chief Financial Officer</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;"><b style="font-weight:bold;">ADMINISTRATIVE AGENT:<br><br>OAKTREE FUND ADMINISTRATION, LLC<br></b><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:81.35pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name: Jessica Dombroff<br>Title: Vice President</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Brian Price</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:111.35pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u>Name: Brian Price<br>Title: Senior Vice President</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Schedule_1"></a><a name="_Ref40146430"></a>Schedule&#160;1<b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-transform:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-transform:none;">TO THE SECURITY AGREEMENT</b></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146812"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Locations of Chief Executive Office and other Locations, including of Collateral</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">a.</font></font>Chief Executive Office and Principal Place of Business of each Grantor:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;width:100%;"><tr><td style="vertical-align:top;width:44.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name</u></p></td><td style="vertical-align:top;width:55.47%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Address</u></p></td></tr><tr><td style="vertical-align:top;width:44.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:55.47%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">b.</font></font>Other locations where any Grantor conducts business or where Collateral is kept:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;width:100%;"><tr><td style="vertical-align:top;width:44.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name</u></p></td><td style="vertical-align:top;width:55.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Address</u></p></td></tr><tr><td style="vertical-align:top;width:44.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:55.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146813"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Jurisdiction of Organization of each Grantor</b></td></tr></table><div style="margin-top:12pt;"></div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;width:100%;"><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name</u></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Jurisdiction</u></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146814"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Trade Names and Trade Styles of each Grantor; Other Corporate, Trade or Fictitious Names of each Grantor; Etc.</b></td></tr></table><div style="margin-top:12pt;"></div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;width:100%;"><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name</u></p></td><td style="vertical-align:top;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Other Names</u></p></td><td style="vertical-align:top;width:33.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Period of Use</u></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146815"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Deposit Accounts of each Grantor</b></td></tr></table><div style="margin-top:12pt;"></div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;width:100%;"><tr><td style="vertical-align:top;width:24.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Name and Address of Bank</b></p></td><td style="vertical-align:top;width:24.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Type of Account</b></p></td><td style="vertical-align:top;width:24.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Account Number</b></p></td><td style="vertical-align:top;width:25.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Borrower/Subsidiary Name</b></p></td></tr><tr><td style="vertical-align:top;width:24.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146816"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Investment Property of each Grantor</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146817"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Instruments and Chattel Paper of each Grantor</b></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146818"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Commercial Tort Claims of each Grantor</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146819"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Inventory of each Grantor Stored with Warehousemen or on Leased Premises, Etc.</b></td></tr></table><div style="margin-top:12pt;"></div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;width:100%;"><tr><td style="vertical-align:top;width:28.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name</u></p></td><td style="vertical-align:top;width:38.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Address</u></p></td><td style="vertical-align:top;width:33.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:6pt 0pt 6pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Brief Description of Location</u></p></td></tr><tr><td style="vertical-align:top;width:28.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:1pt 0pt 1pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.5pt 0pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;"><a name="_Ref40146820"></a></b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Letter-of-Credit Rights of each Grantor</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:12pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">Pledged Debt Securities of each Grantor</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Ref40146821"></a>Schedule&#160;2<b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-transform:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-transform:none;">TO THE SECURITY AGREEMENT</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PATENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Issued Patents and Patent Applications of each Grantor</u></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:96.43%;" align="center"><tr><td style="vertical-align:top;width:34.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:19.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-weight:bold;">Country </b></p></td><td style="vertical-align:top;width:23.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-weight:bold;">Application No.</b></p></td><td style="vertical-align:top;width:22.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-weight:bold;">Patent No.</b></p></td></tr><tr style="height:25pt;"><td style="vertical-align:top;width:34.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Licenses of each Grantor Related to Patents </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">TRADEMARKS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Registered Trademarks and Trademark Applications of each Grantor</u></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:22.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Mark/Application</b></p></td><td style="vertical-align:top;width:15.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Registration No.</b></p></td><td style="vertical-align:top;width:13.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Serial No.</b></p></td><td style="vertical-align:top;width:31.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Owner</b></p></td><td style="vertical-align:top;width:16.94%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Jurisdiction</b></p></td></tr><tr><td style="vertical-align:top;width:22.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.94%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Licenses of each Grantor Related to Trademarks</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">COPYRIGHTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Registered Copyrights and Pending Copyright Applications of each Grantor</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Licenses of each Grantor Related to Copyrights </u></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Schedule_3"></a><a name="_Ref40146833"></a>Schedule&#160;3<b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-transform:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-transform:none;">TO THE SECURITY AGREEMENT</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">PARTNERSHIP AND LLC COLLATERAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Limited Liability Company Interests Constituting Collateral</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Partnership Interests Constituting Collateral</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">PLEDGED SHARES</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Shares Held by each Grantor</u></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 5.75pt 2.9pt 5.75pt;"><tr><td style="vertical-align:top;width:19.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Grantor</u></p></td><td style="vertical-align:top;width:19.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name of Issuer</u> <u style="text-decoration:underline;text-decoration-color:#000000;">of Pledged</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Shares</u></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Certificate</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Number</u></p></td><td style="vertical-align:top;width:20.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Certificate Date</u></p></td><td style="vertical-align:top;width:20.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Percentage</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Ownership</u></p></td></tr><tr><td style="vertical-align:top;width:19.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">SCHEDULE 4</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FINANCING STATEMENTS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Ref40146834"></a>Exhibit&#160;A</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">TO THE SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">FORM OF ACCESSION AGREEMENT</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">To:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Re:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="text-transform:uppercase;">Marinus Pharmaceuticals</font>, INC., as the Borrower</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Accession Agreement is made and delivered as of [__________], 20[__] pursuant to <b style="font-weight:bold;">Section&#160;24</b><b style="font-weight:bold;"> </b>of that certain Security Agreement, dated as of [&#8226;], 2021 (as amended, modified, renewed or extended from time to time, the &#8220;<font style="font-style:italic;font-weight:bold;">Security Agreement</font>&#8221;), between each Grantor party thereto (each a &#8220;<font style="font-style:italic;font-weight:bold;">Grantor</font>&#8221; and collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Grantors</font>&#8221;), and Oaktree Fund Administration, LLC (in such capacity, together with its successors and assigns, the &#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221;). All capitalized terms used in this Accession Agreement and not otherwise defined herein shall have the meanings assigned to them in either the Security Agreement or the Credit Agreement (as defined in the Security Agreement), as the context may require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The undersigned, ____________________ <i style="font-style:italic;">[insert name of Acceding Grantor]</i>, a<i style="font-style:italic;"> __________ [corporation, partnership, limited liability company, etc.]</i>, hereby acknowledges for the benefit of the Secured Parties that it shall be a &#8220;Grantor&#8221; for all purposes of the Security Agreement effective from the date hereof. The undersigned confirms that the representations and warranties set forth in <b style="font-weight:bold;">Section&#160;4</b><b style="font-weight:bold;"> </b>of the Security Agreement are true and correct as to the undersigned as of the date hereof. The undersigned further represents and warrants to the Administrative Agent and the other Secured Parties that this Accession Agreement has been duly authorized, executed and delivered by it and constitutes its valid and binding obligation, enforceable against it in accordance with its terms, subject, as to the enforcement of remedies, to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting rights generally and to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Without limiting the foregoing, the undersigned hereby agrees to perform all of the obligations of a Grantor under, and to be bound in all respects by the terms of, the Security Agreement, including <b style="font-weight:bold;">Section&#160;5</b><b style="font-weight:bold;"> </b>thereof, to the same extent and with the same force and effect as if the undersigned were an original signatory thereto. The undersigned hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in all of the undersigned&#8217;s right, title and interest in, to and under all of its personal property other than Excluded Assets, wherever located and whether now existing or owned or hereafter acquired or arising, including all Collateral, as security for the payment and performance of the Secured Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The undersigned agrees to reimburse the Administrative Agent for its reasonable and documented out-of-pocket expenses in connection with this Accession Agreement, including the reasonable fees, other charges and disbursements of counsel for the Administrative Agent, in accordance with the terms of the Security Agreement. </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Schedules&#160;1</b><b style="font-weight:bold;"> </b>through <b style="font-weight:bold;">3</b><b style="font-weight:bold;"> </b>to the Security Agreement are hereby amended by adding <b style="font-weight:bold;">Schedules&#160;1</b><b style="font-weight:bold;"> </b>through <b style="font-weight:bold;">3</b><b style="font-weight:bold;"> </b>attached hereto to the Security Agreement. <i style="font-style:italic;">[Attach hereto completed </i><font style="font-style:italic;font-weight:bold;">Schedules&#160;1</font><font style="font-style:italic;font-weight:bold;"> </font><i style="font-style:italic;">through </i><font style="font-style:italic;font-weight:bold;">3</font><font style="font-style:italic;font-weight:bold;"> </font><i style="font-style:italic;">in the form of </i><font style="font-style:italic;font-weight:bold;">Schedules&#160;1</font><font style="font-style:italic;font-weight:bold;"> </font><i style="font-style:italic;">through </i><font style="font-style:italic;font-weight:bold;">3</font><font style="font-style:italic;font-weight:bold;"> </font><i style="font-style:italic;">attached to the Security Agreement.]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Accession Agreement shall constitute a Loan Document under the Credit Agreement. Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by any Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">THIS ACCESSION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of page intentionally left blank; signature pages follow</i>]</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the undersigned has executed this Accession Agreement as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;">[ACCEDING GRANTOR]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u>Name:<br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Address for Notices:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">[___________________]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Attn:<font style="display:inline-block;width:11.33pt;"></font>[___________________]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Tel.:<font style="display:inline-block;width:13.68pt;"></font>[___________________]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Fax:<font style="display:inline-block;width:14.67pt;"></font>[___________________]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;">Email:<font style="display:inline-block;width:4.01pt;"></font>[___________________]</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Ref40146835"></a>Exhibit&#160;B</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">TO THE SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">FORM OF PLEDGE SUPPLEMENT</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">To:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Re:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="text-transform:uppercase;">Marinus Pharmaceuticals</font>, INC., as the Borrower</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Pledge Supplement (this &#8220;<font style="font-style:italic;font-weight:bold;">Pledge Supplement</font>&#8221;) is made and delivered as of [__________], 20[__] pursuant to <b style="font-weight:bold;">Section&#160;3(i)</b><b style="font-weight:bold;"> </b>of that certain Security Agreement, dated as of [&#8226;], 2021 (as amended, modified, renewed or extended from time to time, the &#8220;<font style="font-style:italic;font-weight:bold;">Security Agreement</font>&#8221;), among each Grantor party thereto (each a &#8220;<font style="font-style:italic;font-weight:bold;">Grantor</font>&#8221; and collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Grantors</font>&#8221;), and Oaktree Fund Administration, LLC, (in such capacity, together with its successors and assigns, the &#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221;). All capitalized terms used in this Pledge Supplement and not otherwise defined herein shall have the meanings assigned to them in either the Security Agreement or the Credit Agreement (as defined in the Security Agreement), as the context may require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The __________ undersigned, ____________________ <i style="font-style:italic;">[insert __________ name __________ of __________ Grantor]</i>, a<i style="font-style:italic;"> __________ [corporation, partnership, limited liability company, etc.]</i>, confirms and agrees that all Pledged Collateral of the undersigned other than Excluded Assets, including the property described on the supplemental schedule attached hereto (such property, the &#8220;<b style="font-weight:bold;">New Collateral</b>&#8221;), shall be and become part of the Pledged Collateral and shall secure all Secured Obligations. The undersigned confirms that the representations and warranties set forth in <b style="font-weight:bold;">Section&#160;4(l)</b><b style="font-weight:bold;"> </b>of the Security Agreement are true and correct as to the New Collateral as of the date hereof. The undersigned further represents and warrants to the Administrative Agent and the other Secured Parties that this Pledge Supplement has been duly authorized, executed and delivered by it and constitutes its valid and binding obligation, enforceable against it in accordance with its terms, subject, as to the enforcement of remedies, to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting rights generally and to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The undersigned agrees to reimburse the Administrative Agent for its reasonable and documented out-of-pocket expenses in connection with this Pledge Supplement, including the reasonable fees, other charges and disbursements of counsel for the Administrative Agent, in accordance with the terms of the Security Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Schedule&#160;3</b><b style="font-weight:bold;"> </b>to the Security Agreement is hereby amended by adding to such <b style="font-weight:bold;">Schedule&#160;3</b><b style="font-weight:bold;"> </b>the information set forth in the supplement attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Pledge Supplement shall constitute a Loan Document under the Credit Agreement. THIS PLEDGE SUPPLEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by any Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of page intentionally left blank; signature pages follow</i>]</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the undersigned has executed this Pledge Supplement, as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">[<u style="text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:209pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="margin-bottom:36pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">By:<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:198.66pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Name:<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:184.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;">Title:<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:190.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">SUPPLEMENT TO SCHEDULE 3<br>TO THE SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">PARTNERSHIP AND LLC COLLATERAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;">Limited Liability Company Interests Constituting Collateral</u></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 5.75pt 2.9pt 5.75pt;"><tr><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Grantor</u></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name of Issuer of</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Interests</u></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Number of Units</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Held by Grantor</u></p></td><td style="vertical-align:top;width:19.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Date Units Issued to</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Grantor</u></p></td><td style="vertical-align:top;width:20.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Percentage</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Ownership Interest</u></p></td></tr><tr><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Partnership Interests Constituting Collateral</u></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 5.75pt 2.9pt 5.75pt;"><tr><td style="vertical-align:top;width:16.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Grantor</u></p></td><td style="vertical-align:top;width:16.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name of Issuer</u> <u style="text-decoration:underline;text-decoration-color:#000000;">of Interests</u></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Type of</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Partnership</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Interest</u></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Number of Units</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Held by Grantor</u></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Date Units</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Issued to</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Grantor</u></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Percentage</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Ownership</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Interest</u></p></td></tr><tr><td style="vertical-align:top;width:16.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">PLEDGED SHARES</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;">Pledged Shares Held by each Grantor</u></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 5.75pt 2.9pt 5.75pt;"><tr><td style="vertical-align:top;width:15.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Grantor</u></p></td><td style="vertical-align:top;width:18.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Name of Issuer of</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Pledged Shares</u></p></td><td style="vertical-align:top;width:16.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Number and</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Class of Pledged</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Shares</u></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Certificate</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Numbers</u></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Certificate Dates</u></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Percentage</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Ownership</u> <u style="text-decoration:underline;text-decoration-color:#000000;">Interest</u></p></td></tr><tr><td style="vertical-align:top;width:15.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:18.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Ref40146836"></a>Exhibit&#160;C</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">TO THE SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">FORM OF COPYRIGHT SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This COPYRIGHT SECURITY AGREEMENT, dated as of [__________], 20[<u style="text-decoration:underline;text-decoration-color:#000000;">__</u>] (&#8220;<font style="font-style:italic;font-weight:bold;">Copyright Security Agreement</font>&#8221;), made by each of the signatories hereto (the &#8220;<font style="font-style:italic;font-weight:bold;">Copyright Grantors</font>&#8221;), is in favor of Oaktree Fund Administration, LLC, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the &#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">W</u> <u style="text-decoration:underline;text-decoration-color:#000000;">I</u> <u style="text-decoration:underline;text-decoration-color:#000000;">T</u> <u style="text-decoration:underline;text-decoration-color:#000000;">N</u> <u style="text-decoration:underline;text-decoration-color:#000000;">E</u> <u style="text-decoration:underline;text-decoration-color:#000000;">S</u> <u style="text-decoration:underline;text-decoration-color:#000000;">S</u> <u style="text-decoration:underline;text-decoration-color:#000000;">E</u> <u style="text-decoration:underline;text-decoration-color:#000000;">T</u> <u style="text-decoration:underline;text-decoration-color:#000000;">H</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Copyright Grantors are party to a Security Agreement dated as of [&#8226;], 2021 (the &#8220;<font style="font-style:italic;font-weight:bold;">Security Agreement</font>&#8221;) in favor of the Administrative Agent, pursuant to which the Copyright Grantors are required to execute and deliver this Copyright Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, pursuant to the terms of the Security Agreement, each Copyright Grantor has created in favor of the Administrative Agent a security interest in, and the Administrative Agent has become a secured creditor with respect to, the Copyright Collateral (as defined below);</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Copyright Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Copyright Grantor or in which such Copyright Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Copyright Collateral</font>&#8221;), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(a)</font></font>all Copyrights of such Copyright Grantor, including, without limitation, the registered and applied-for Copyrights of such Copyright Grantor listed on <b style="font-weight:bold;">Schedule&#160;1 </b>attached hereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(b)</font></font>to the extent not covered by <b style="font-weight:bold;">clause&#160;(a)</b>, all income, royalties and other payments now or hereafter due and payable with respect to any of the foregoing; </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(c)</font></font>to the extent not covered by <b style="font-weight:bold;">clause&#160;(a)</b>, all causes of action for past, present or future infringement of any of the Copyrights. &#160;The security interest granted pursuant to this Copyright Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement, and the Copyright Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Copyrights made and granted hereby are more fully set forth in the </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Security Agreement. In the event that any provision of this Copyright Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(d)</font></font>all exclusive Licenses pursuant to which such Copyright Grantor receives rights in, to or under any Copyrights registered with the United States Copyright Office, including, without limitation, the Licenses listed on <b style="font-weight:bold;">Schedule 1</b> attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Each Copyright Grantor hereby authorizes and requests that the Register of Copyrights record this Copyright Security Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">THIS COPYRIGHT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS COPYRIGHT SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This Copyright Security Agreement may be executed by one or more of the parties to this Copyright Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Copyright Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of This Page Intentionally Left Blank.</i>]</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, each Copyright Grantor has caused this COPYRIGHT SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;">[GRANTOR(S)]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 216pt;">Address:<font style="display:inline-block;width:11.34pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">Accepted and Agreed:<br>OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">By<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><br>Title:<font style="display:inline-block;width:10.01pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">By<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><br>Title:<font style="display:inline-block;width:10.01pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 0pt;">Address:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Schedule 1</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">COPYRIGHTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;">Copyright Registrations</u></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 5.75pt 2.9pt 5.75pt;"><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Title of Work</p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Reg. No.</p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Reg. Date</p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Owner</p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><a name="_Ref40146837"></a><u style="text-decoration:underline;text-decoration-color:#000000;">Exclusive Copyright Licenses</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">[&#9679;]</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Ref71623978"></a>Exhibit&#160;D</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">TO THE SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">FORM OF TRADEMARK SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This TRADEMARK SECURITY AGREEMENT, dated as of [_________], 20[__] (&#8220;<font style="font-style:italic;font-weight:bold;">Trademark Security Agreement</font>&#8221;), made by each of the signatories hereto (the &#8220;<font style="font-style:italic;font-weight:bold;">Trademark Grantors</font>&#8221;), is in favor of Oaktree Fund Administration, LLC, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the &#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">W</u> <u style="text-decoration:underline;text-decoration-color:#000000;">I</u> <u style="text-decoration:underline;text-decoration-color:#000000;">T</u> <u style="text-decoration:underline;text-decoration-color:#000000;">N</u> <u style="text-decoration:underline;text-decoration-color:#000000;">E</u> <u style="text-decoration:underline;text-decoration-color:#000000;">S</u> <u style="text-decoration:underline;text-decoration-color:#000000;">S</u> <u style="text-decoration:underline;text-decoration-color:#000000;">E</u> <u style="text-decoration:underline;text-decoration-color:#000000;">T</u> <u style="text-decoration:underline;text-decoration-color:#000000;">H</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Trademark Grantors are party to a Security Agreement, dated as [&#8226;], 2021 (the &#8220;<font style="font-style:italic;font-weight:bold;">Security Agreement</font>&#8221;) in favor of the Administrative Agent, pursuant to which the Trademark Grantors are required to execute and deliver this Trademark Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, pursuant to the terms of the Security Agreement, each Trademark Grantor has created in favor of the Administrative Agent a security interest in, and the Administrative Agent has become a secured creditor with respect to, the Trademark Collateral (as defined below);</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Trademark Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Trademark Grantor or in which such Trademark Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Trademark Collateral</font>&#8221;), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(a)</font></font>all Trademarks of such Trademark Grantor, including, without limitation, the registered and applied-for Trademarks of such Trademark Grantor listed on <b style="font-weight:bold;">Schedule&#160;1 </b>attached hereto; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that no Lien or security interest is granted hereunder with respect to any United States &#8220;intent-to-use&#8221; trademark or service mark application filed pursuant to Section 1(b) of the Lanham Act prior to the filing of an &#8220;Amendment to Allege Use&#8221; or a &#8220;Statement of Use&#8221; pursuant to Sections 1(c) or 1(d) of the Lanham Act, solely to the extent that, and only for so long as, the grant of a security interest therein would impair the validity or enforceability of, render void or voidable, or result in the cancellation of, such &#8220;intent-to-use&#8221; trademark or service mark application under federal law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(b)</font></font>to the extent not covered by <b style="font-weight:bold;">clause&#160;(a)</b>, all income, royalties and other payments now or hereafter due and payable with respect to any of the foregoing;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(c)</font></font>to the extent not covered by <b style="font-weight:bold;">clause&#160;(a)</b>, the goodwill of the businesses with which the Trademarks are associated; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(d)</font></font>to the extent not covered by <b style="font-weight:bold;">clause&#160;(a)</b>, all causes of action for past, present, or future infringement of any of the Trademarks or unfair competition regarding the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement, and the Trademark Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Trademarks made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Each Trademark Grantor hereby authorizes and requests that the Commissioner of Trademarks record this Trademark Security Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This Trademark Security Agreement may be executed by one or more of the parties to this Trademark Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of This Page Intentionally Left Blank.</i>]</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, each Trademark Grantor has caused this TRADEMARK SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;">[GRANTOR(S)]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 216pt;">Address:<font style="display:inline-block;width:11.34pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">Accepted and Agreed:<br>OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">By<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><br>Title:<font style="display:inline-block;width:10.01pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">By<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><br>Title:<font style="display:inline-block;width:10.01pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 0pt;">Address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Schedule 1</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">TRADEMARKS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;">Trademark Registrations and Applications</u></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 5.75pt 2.9pt 5.75pt;"><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Trademark</p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Reg. No.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">(App. No.)</p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Reg. Date</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">(App. Date)</p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Owner</p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Ref40146838"></a>Exhibit&#160;E</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">TO THE SECURITY AGREEMENT </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">FORM OF PATENT SECURITY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This PATENT SECURITY AGREEMENT, dated as of [__________], 20[<u style="text-decoration:underline;text-decoration-color:#000000;"> </u>] (&#8220;<font style="font-style:italic;font-weight:bold;">Patent Security Agreement</font>&#8221;), made by each of the signatories hereto (the &#8220;<font style="font-style:italic;font-weight:bold;">Patent Grantors</font>&#8221;), is in favor of Oaktree Fund Administration, LLC, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the &#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">W</u> <u style="text-decoration:underline;text-decoration-color:#000000;">I</u> <u style="text-decoration:underline;text-decoration-color:#000000;">T</u> <u style="text-decoration:underline;text-decoration-color:#000000;">N</u> <u style="text-decoration:underline;text-decoration-color:#000000;">E</u> <u style="text-decoration:underline;text-decoration-color:#000000;">S</u> <u style="text-decoration:underline;text-decoration-color:#000000;">S</u> <u style="text-decoration:underline;text-decoration-color:#000000;">E</u> <u style="text-decoration:underline;text-decoration-color:#000000;">T</u> <u style="text-decoration:underline;text-decoration-color:#000000;">H</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Patent Grantors are party to a Security Agreement dated as of [&#8226;], 2021 (the &#8220;<font style="font-style:italic;font-weight:bold;">Security Agreement</font>&#8221;) in favor of the Administrative Agent, pursuant to which the Patent Grantors are required to execute and deliver this Patent Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, pursuant to the terms of the Security Agreement, each Patent Grantor has created in favor of the Administrative Agent a security interest in, and the Administrative Agent has become a secured creditor with respect to, the Patent Collateral (as defined below);</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Patent Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Patent Grantor or in which such Patent Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Patent Collateral</font>&#8221;), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(a)</font></font>all Patents of such Patent Grantor, including, without limitation, the registered and applied-for Patents of such Patent Grantor listed on <b style="font-weight:bold;">Schedule&#160;1 </b>attached hereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(b)</font></font>to the extent not covered by <b style="font-weight:bold;">clause&#160;(a)</b>, all income, royalties and other payments now or hereafter due and payable with respect to any of the foregoing; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">(c)</font></font>to the extent not covered by <b style="font-weight:bold;">clause&#160;(a)</b>, all causes of action for past, present or future infringement of any of the Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt;">The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement, and the Patent Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Each Patent Grantor hereby authorizes and requests that the Commissioner of Patents record this Patent Security Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This Patent Security Agreement may be executed by one or more of the parties to this Patent Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Patent Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[Remainder of This Page Intentionally Left Blank.]</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, each Patent Grantor has caused this PATENT SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;">[GRANTOR(S)]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 216pt;">Address:<font style="display:inline-block;width:11.34pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><br></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:162pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">Accepted and Agreed:<br>OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">By<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><br>Title:<font style="display:inline-block;width:10.01pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">By<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><br>Title:<font style="display:inline-block;width:10.01pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">Address:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Schedule 1</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">PATENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Patents and Patent Applications</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 5.75pt 2.9pt 5.75pt;"><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Patent</p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Reg. No.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">(App. No.)</p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Reg. Date</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">(App. Date)</p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;">Owner</p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:22.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:2.9pt 5.5pt 2.9pt 5.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="color:#010000;display:inline-block;font-weight:normal;min-width:18pt;white-space:nowrap;">1</font><a name="_Ref40146839"></a>Exhibit&#160;F</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">TO THE SECURITY AGREEMENT </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">FORM OF BAILEE LETTER</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">[INSERT DATE]</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">To:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">[INSERT NAME AND ADDRESS OF BAILEE]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:112.63pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:144pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:justify;">Re:</font></font>[INSERT NAME OF RELEVANT OBLIGOR]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are the agent for certain lending institutions that are making or have made certain credit extensions to [Marinus Pharmaceuticals, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font><a name="_Ref40146841"></a>&#8221;)]<sup style="font-size:9pt;vertical-align:top;"><a style="line-height:1.19;margin-bottom:12pt;vertical-align:super;" href="#footnote-2">1</a></sup> [Marinus Pharmaceuticals, Inc., the [direct] [indirect] parent of [OBLIGOR] (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font><a name="_Ref40146842"></a>&#8221;), and the Company has provided a guaranty thereof].<sup style="font-size:9pt;vertical-align:top;"><a style="line-height:1.19;margin-bottom:12pt;vertical-align:super;" href="#footnote-3">2</a></sup> The Company has entered into (i)&#160;that certain Credit Agreement and Guaranty, dated as of [&#8226;], 2021, among [Marinus Pharmaceuticals, Inc.] [the Company], as borrower, the Subsidiary Guarantors from time to time party thereto [including the Company], the Lender and ourselves, as Administrative Agent (as amended or otherwise modified from time to time, the &#8220;<font style="font-style:italic;font-weight:bold;">Credit Agreement</font>&#8221;) and (ii)&#160;that certain Security Agreement, dated as of [&#8226;], 2021 among [Marinus Pharmaceuticals, Inc.] [the Company], the other Grantors from time to time party thereto [including the Company], and ourselves, as Administrative Agent (as amended or otherwise modified from time to time, the &#8220;<font style="font-style:italic;font-weight:bold;">Security Agreement</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Security Agreement, we have obtained a continuing security interest in all of the Company&#8217;s personal property other than Excluded Assets (the &#8220;<font style="font-style:italic;font-weight:bold;">Collateral</font>&#8221;), until all Obligations have been paid in full indefeasibly in cash and the Commitment under the Credit Agreement has been terminated (the capitalized terms used above but not defined shall have the definition provided in the Credit Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We understand that the Company has made arrangements with you to locate from time to time certain Collateral at the location(s) described in <b style="font-weight:bold;">Annex A </b>hereto (the &#8220;<font style="font-style:italic;font-weight:bold;">Premises</font>&#8221;). (The agreement between you and the Company governing the location of the Collateral at the Premises shall be hereinafter referred to as the &#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>.&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because Collateral will be located at the Premises, we will require certain agreements and acknowledgments from you. Accordingly, we would appreciate your execution of this letter.</p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="footnote-2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><sup style="font-size:9pt;vertical-align:top;">1</sup> Insert if obligor is Marinus Pharmaceuticals, Inc.</p><a name="footnote-3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><sup style="font-size:9pt;vertical-align:top;">2</sup> Insert if obligor is a guarantor</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By your signature below you acknowledge notice of our security interest in the Collateral.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This letter will also confirm your agreement to the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Collateral located at the Premises will be and remain personal property of the Company, and such Collateral will not be deemed a fixture or part of the Premises even if the Collateral may be affixed to or placed in, or about the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until such time as the security interests in the Collateral granted to us by the Company have been terminated, you hereby waive and release in favor of us: (a) any liens on, claims to, or interest in the Collateral and the proceeds thereof and agree not to assert any claim against the Collateral or proceeds thereof and (b) any and all other interests or claims of every nature whatsoever which you may now or hereafter have in or against the Collateral for any rent, storage charges, or other sums due or to become due to you.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You will allow us, or our auditors or other agents or representatives, reasonable access to the Premises from time to time to inspect the Collateral in accordance with the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the Company defaults in its obligations under the Agreement or abandons or surrenders the Premises, or you desire or elect to terminate or exercise remedies under the Agreement for any reason, you will provide notice to us in writing of this fact, at the address provided beneath our signature block, prior to your terminating or exercising remedies under the Agreement and retaking possession of the Premises. In such event, you will allow us, at our option, 30 days from our receipt of such notice in which to cure or request the Company to cure such default. If any order or injunction is issued or stay granted that prohibits us from exercising any of our rights hereunder, then the period to exercise our rights shall be stayed during the period of such prohibition and shall continue thereafter for the greater of (a) the number of days remaining in the initial period or (b) thirty (30) days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon our request, you will grant us, or our agents or representatives on our behalf, access to the Premises at reasonable times and upon reasonable prior notice so that we may preserve, protect and enforce our security interests. In such event you will allow us, or our agents or representatives on our behalf, access to the Premises to assemble, appraise, repair, service and maintain the Collateral, to show the Collateral to potential purchasers or lessees, to prepare the Collateral for removal for return to us or for other sale or disposition and to remove the Collateral from the Premises. At your option, you may elect to have an agent accompany us or our agents or representatives while on the Premises; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that your failure to have your agent accompany us or our agents or representatives will not in any way limit our right to enter upon the Premises. While on the Premises, we will use reasonable efforts so as not to disturb any other tenant, occupant or you. We will reimburse you for, or repair, at our cost, any damage to the Premises caused by the removal of the Collateral or otherwise caused by us or our agents or representatives during our possession of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You will permit us to remain on the Premises for a period of up to 30 days following receipt by us of written notice from you that you are in possession and control of the Premises, have terminated the Agreement and are directing removal of the Collateral. Any extensions of the foregoing period shall be with your written consent.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing herein contained will be deemed to make us a tenant at the Premises, or be deemed to delegate any duties or obligations to us under the Agreement or constitute any assumption thereof by us of any unperformed or unpaid obligations of the Company under the Agreement. This letter and any right, remedy, obligation, claim, controversy, dispute or cause of action (whether in contract, tort or otherwise) based upon, arising out of or relating to this letter will be governed and controlled by, and interpreted under, the laws of the State of New York. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You will notify any purchaser or successor owner or landlord of the Premises of the existence of this letter, which will be binding upon your executors, administrators, successors, transferees or assignees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This letter may be executed in one or more counterparts, each of which, when executed and delivered, shall be deemed an original, and all of which, when taken together, shall constitute but one and the same agreement. Delivery of an executed counterpart of this letter by facsimile shall be equally as effective as delivery of a manually executed counterpart of this letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of page intentionally left blank</i>]</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;">Very truly yours,<br><br>OAKTREE FUND ADMINISTRATION, LLC<br><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 36pt 216pt;">Address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">Accepted and approved:<br>[BAILEE&#8217;S NAME]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">By<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><br>Title:<font style="display:inline-block;width:10.01pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">Address for Notices:<br>[<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:32pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>]<br>[<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:32pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>]<br>Attn:<font style="display:inline-block;width:11.33pt;"></font>[<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:176pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>]<br>Tel.:<font style="display:inline-block;width:13.68pt;"></font>[<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:176pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>]<br>Fax:<font style="display:inline-block;width:14.67pt;"></font>[<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:176pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>]<br>Email: [<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:177.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">Acknowledged and agreed to:<br>[COMPANY&#8217;S NAME]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:24pt 0pt 24pt 0pt;">By<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:180pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><br>Title:<font style="display:inline-block;width:10.01pt;"></font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>mrns-20210331xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/17/2021 08:23:12 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 10.3</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-bottom:0.15pt;padding-top:0.15pt;width:59.69%;" align="center"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'SimSun';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-transform:uppercase;">Oaktree Capital Management, L.P.</b></p><p style="font-family:'SimSun';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;">333 South Grand Ave., 28</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;"> Floor</font></p><p style="font-family:'SimSun';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Los Angeles, CA 90071</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 24pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">CONFIDENTIAL</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">May 17, 2021</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Letter Agreement re: Minimum Liquidity Amount</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Marinus Pharmaceuticals, Inc.<br>5 Radnor Corporate Center<br>100 Matsonford Rd, Suite 500</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Radnor, PA 19087<br></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;white-space:pre-wrap;">Attn:  Steven Pfanstiel, Chief Financial Officer</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Mr. Pfanstiel:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Reference is made to that certain Credit Agreement and Guaranty, dated as of May 11, 2021 (including the exhibits and other attachments thereto, as amended, restated or otherwise modified prior to the date hereof, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Credit Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) by and among Marinus Pharmaceuticals, Inc. (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Borrower</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), the lenders from time to time party thereto (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Lenders</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) and Oaktree Fund Administration, LLC (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Agent</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;white-space:pre-wrap;">&#8221;).  Capitalized terms used but not otherwise defined in this letter agreement (this &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) are used with the meanings assigned to such terms in the Credit Agreement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Amendment</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The Agent, the Lenders and the Borrower hereby agree to amend and restate the defined term &#8220;Minimum Liquidity Amount&#8221; as follows:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Minimum Liquidity Amount</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means (i) from the Closing Date until the Applicable Funding Date of the Tranche A-2 Term Loans, $10,000,000, (ii) from the Applicable Funding Date of the Tranche A-2 Term Loans until the Applicable Funding Date of the Tranche B Term Loans, $20,000,000 and (iii) from the Applicable Funding Date of the Tranche B Term Loans until the Maturity Date, $15,000,000.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Miscellaneous</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">On and after the date hereof, each reference in the Credit Agreement to &#8220;this Agreement,&#8221; &#8220;hereunder,&#8221; &#8220;hereof,&#8221; &#8220;herein&#8221; or words of like import, and each reference in the Loan Documents to the Credit Agreement, shall mean and be a reference to the Credit Agreement, as amended by this Agreement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Except as specifically amended above, the Credit Agreement and the other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;white-space:pre-wrap;">The execution, delivery and effectiveness of this Agreement shall not operate as a waiver of any right, power or remedy of the Agent or any of the Lenders under the Credit Agreement (as amended hereby) or any of the other Loan Documents, nor constitute a waiver of any provision thereof, except to the extent expressly provided for herein.  Nothing contained herein is intended, or shall be deemed or construed to constitute a waiver of any past or future Defaults or Events of Default or compliance with any term or provision of the Loan Documents or applicable law.  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;white-space:pre-wrap;">The entering into of this Agreement by the Agent and the Lenders and any consent to this Agreement by any Lender shall not be deemed to limit or hinder any rights of any such party under the Credit Agreement (as amended hereby) or any other Loan Document, nor shall it be deemed to create or infer a custom or course of dealing between any such party, on the one hand, and the Borrower, on the other hand, with regard to any provision thereof.  Nothing contained in this Agreement shall be deemed to obligate the Agent or any Lender to enter into any forbearance agreement or to waive any Defaults or Events of Default.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The Borrower agrees to pay on demand all reasonable out-of-pocket costs and expenses of the Agent and the Lenders in connection with the preparation, execution and delivery of (i)&#160;this Agreement and (ii)&#160;any other instruments and documents to be delivered hereunder, including, without limitation, the fees and out-of-pocket expenses of Sullivan &amp; Cromwell LLP, as outside counsel to Agent and the Lenders, with respect thereto.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Agreement may not be amended or any provision hereof waived or modified except by an instrument in writing signed by each of the parties hereto.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;white-space:pre-wrap;">Any provision of this Agreement held to be invalid, illegal or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and enforceability of the remaining provisions hereof; and the invalidity of a particular provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction.  The parties hereto shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The parties agree that, until the payment in full of the Loans and the termination of the Credit Agreement, this Agreement shall be deemed a &#8220;Loan Document&#8221; as defined in the Credit Agreement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;white-space:pre-wrap;">This Agreement and any claim, controversy or dispute arising under or relating to this Agreement (whether in contract, tort or otherwise) shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York without regard to conflict of law principles that would result in the application of any law other than the laws of the State of New York.  This Agreement and its contents shall be subject to the indemnification, jurisdiction, venue, service of process, waiver of jury trial and confidentiality provisions of the Credit </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;white-space:pre-wrap;">Agreement, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Agreement may be executed in any number of counterparts, each of which, when so executed, will be deemed to be an original and all of which, taken together, will constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by electronic transmission will be as effective as delivery of an original executed counterpart of this Agreement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:normal;">[The remainder of this page is intentionally left blank]</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Please confirm that the foregoing is our mutual understanding by signing and returning to us an executed counterpart of this Agreement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 12pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Very truly yours,</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">OAKTREE FUND ADMINISTRATION, LLC, as Agent<br></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">By:  Oaktree Capital Management, L.P.<br></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">Its:  Managing Member<br></font><font style="font-family:'Times New Roman','Times','serif';margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:65.64pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">     Name:</font><font style="font-family:'Times New Roman','Times','serif';"> Jessica Dombroff</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">     Title:</font><font style="font-family:'Times New Roman','Times','serif';"> Vice President</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';">By:</font><font style="font-family:'Times New Roman','Times','serif';"> </font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">/s/ Brian Price</u><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:95.64pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">     Name:</font><font style="font-family:'Times New Roman','Times','serif';"> Brian Price</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">     Title:</font><font style="font-family:'Times New Roman','Times','serif';"> Senior Vice President</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">LENDERS</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">:</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OAKTREE-TCDRS STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>                                               </u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXELON STRATEGIC CREDIT HOLDINGS, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OAKTREE-NGP STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OAKTREE-MINN STRATEGIC CREDIT LLC</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OAKTREE-FORREST MULTI-STRATEGY, LLC </b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:27pt;"><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:65.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND C, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:59.7%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:59.7%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:59.7%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:279.65pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:59.7%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:50.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND F, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:59.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:59.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:59.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:277.95pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:59.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="7" style="vertical-align:top;width:64.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND G, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="5" style="vertical-align:top;width:58.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="5" style="vertical-align:top;width:58.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="5" style="vertical-align:top;width:58.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:176.8pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="5" style="vertical-align:top;width:58.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:top;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OAKTREE-TSE 16 STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="3" style="vertical-align:top;width:53.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="3" style="vertical-align:top;width:53.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="3" style="vertical-align:top;width:53.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="3" style="vertical-align:top;width:53.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:top;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INPRS STRATEGIC CREDIT HOLDINGS, LLC</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="3" style="vertical-align:top;width:53.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Capital Management, L.P</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="3" style="vertical-align:top;width:53.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Manager</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="3" style="vertical-align:top;width:53.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="3" style="vertical-align:top;width:53.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Oaktree Gilead Investment Fund AIF (Delaware), L.P.&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund AIF Series, L.P. &#8211; Series T</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund GP AIF, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Managing Member</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund GP III, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Managing Member</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title: </font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Authorized Signatory</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Authorized Signatory</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Oaktree PRE Life Sciences Fund, L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Pre Life Sciences Fund GP, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund GP IIA, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund GP II, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Managing Member</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Authorized Signatory</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Authorized Signatory</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Oaktree Huntington-GCF Investment Fund (Direct </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Lending AIF), L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF) GP, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;">Oaktree Huntington-GCF Investment Fund (Direct Lending AIF) GP, LLC</p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund GP III, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Managing Member </font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Jessica Dombroff</font><font style="display:inline-block;width:9.35pt;"></font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Authorized Signatory</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Authorized Signatory</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Oaktree Global Credit Plus Fund, L.P. </b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund GP, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund GP I, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Managing Member</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Jessica Dombroff</font><font style="display:inline-block;width:9.35pt;"></font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Authorized Signatory</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Authorized Signatory</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Oaktree Strategic Income II, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund Advisors, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Investment Advisor</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Oaktree Specialty Lending Corporation</b></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Oaktree Fund Advisors, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Its:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Investment Advisor </font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">/s/ Jessica Dombroff</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:252.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:56.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Brian Price</font></p></td></tr><tr><td style="vertical-align:top;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Senior Vice President</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';">Accepted and agreed to as of the date first above written:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;margin:0pt 0pt 6pt 216pt;"><a name="_cp_text_1_62"></a><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">MARINUS PHARMACEUTICALS, INC.<br></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-family:'Times New Roman','Times','serif';">By: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">/s/ Steven Pfanstiel</u><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:72.3pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">     Name: Steven Pfanstiel<br></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">     Title: Chief Financial Officer</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>mrns-20210331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/17/2021 08:23:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Chief Executive Officer Pursuant to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange Act Rules&#160;13a-14(a)&#160;or 15d-14(a)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Scott Braunstein, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">1.</font></font>I have reviewed this quarterly report on Form&#160;10-Q of Marinus Pharmaceuticals,&#160;Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">4.</font></font>The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15(d)-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(a)</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(b)</font></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(c)</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(d)</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">5.</font></font>The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(a)</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(b)</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: May 17, 2021</p></td><td style="vertical-align:top;width:49.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Scott Braunstein</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Scott Braunstein,</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>mrns-20210331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/17/2021 08:23:16 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Chief Financial Officer Pursuant to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange Act Rules&#160;13a-14(a)&#160;or 15d-14(a)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Steven Pfanstiel, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">1.</font></font>I have reviewed this quarterly report on Form&#160;10-Q of Marinus Pharmaceuticals,&#160;Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">4.</font></font>The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15(d)-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(a)</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(b)</font></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(c)</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(d)</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">5.</font></font>The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(a)</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">(b)</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="line-height:1;">4</font></p></div></div></td><td style="vertical-align:top;width:49.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: May 17, 2021</p></td><td style="vertical-align:top;width:49.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Steven Pfanstiel</p></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Steven Pfanstiel,</p></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer and Treasurer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>mrns-20210331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/17/2021 08:23:19 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification Pursuant to 18 U.S.C. Section&#160;1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with the quarterly report of Marinus Pharmaceuticals,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(1)</font></font>The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(2)</font></font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4</p></div></div></td><td style="vertical-align:top;width:49.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 17, 2021</p></td><td style="vertical-align:top;width:49.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Scott Braunstein</p></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal executive officer)</p></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 17, 2021</p></td><td style="vertical-align:top;width:49.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven Pfanstiel</p></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:50.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal financial and accounting officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>mrns-20210331x10q004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrns-20210331x10q004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !U >P# 2(  A$! Q$!_\0
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MEOL2:!X;VEN3>ZAU/N >WX&NS\+_  UT;P\%GF3[=J'5KB<9P?\ 9';^==F
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M^07:_P#7)?Y4[4+5;[3KBU89$L;)^8KR4[3N0?._PEN5M_'ML'./-C=!]?\
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MYW-W_ 9-<IX)T=KNRT[3\?Z):#SISC >1N<?R'X5F:M-=?$GQPEM9 MI6GG
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MD=N*9XAL;G5+BSLUB)M-^Z9L\8]*Z#%&*2JR33[%2P\9*2?4PO\ A$-$V_\
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0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>mrns-20210331x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrns-20210331x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (L \P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***8TH65(R#E@2/PH ?1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%,:0+(B$'+9Q3Z "BBB@ HHHH **** "BBB@ HHHH ****
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MW@BMK0QX*^;N=LAB!D8P.A]ZKV-'K/U(]M6Z0]/P_P""=//JUA;23QSW*1M
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M5M0D@%M$R%)1]H\T28^[@8&VNCK.K&,6N7_,TI2E)/F"BBBLC4**** ()_\
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M&T3?=<,,'\:;>7UO86[3W$@5%&3W./I7$MX6U);&UB2T@Q!O5XA(I$A/\8W
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MJ[_A8?A#_H8M._[_  H_X6'X0_Z&+3O^_P *^3\GUHR?6CZI'N'UF78^L/\
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MS@X]>U2-!.L"3M#*(7)5)"I"L1U /0TOJD>X?69=CZK_ .%A^$/^ABT[_O\
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M $,6G?\ ?X5%)\0?"+2Q$>(M.PIY_?"OE3)]:,FCZI'N'UF78^L/^%A^$/\
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MA#_H8M._[_"OD_)]:,GUH^J1[A]9EV/K#_A8?A#_ *&+3O\ O\*/^%A^$/\
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M (4?V5IW_/A:_P#?E?\ "K>:,T78614_LK3O^?"U_P"_*_X4?V5IW_/A:_\
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M\+7_ +\K_A1_96G?\^%K_P!^5_PJW11=A9%3^RM._P"?"U_[\K_A1_96G?\
M/A:_]^5_PJW11=A9%3^RM._Y\+7_ +\K_A1_96G?\^%K_P!^5_PJW11=A9%3
M^RM._P"?"U_[\K_A1_96G?\ /A:_]^5_PJW11=A9%3^RM._Y\+7_ +\K_A5B
M**.&,1Q1JB#HJC 'X4^BE<84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M4R:5((7E<X1%+$^PKEQ\0=%/1;L_]L?_ *]:0I3G\*N1.I"'Q.QU=%8.F^+]
M-U2]2T@2Z61\[3)"0OYUO4IPE!VDK#C.,U>+N%%%%04%>=_&.[N;/PC!):W$
MT#F[0;HG*'&#QD5Z)7FWQL_Y$V#_ *_$_D:VH?Q8@>(_V]K'_06O_P#P)?\
MQH_M[6/^@M?_ /@2_P#C6?17L\J["-#^WM8_Z"U__P"!+_XT?V]K'_06O_\
MP)?_ !K/HHY5V T/[>UC_H+7_P#X$O\ XT?V]K'_ $%K_P#\"7_QK/HHY5V
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M78#0_M[6/^@M?_\ @2_^-']O:Q_T%K__ ,"7_P :SZ*.5=@-#^WM8_Z"U_\
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M.!@#)H ZRBN;M_\ A(&\N8O/Y:.@$,Z0AY%+X8N5X!"Y("XZ#Z5TE !1110
M4444 9^N7[:9HMU>(BN\2$JK="?>O,86\57T!N[8WKPL20T1XZ\X%>A>,/\
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MNY_X133/[LW_ '\-'_"*:9_=F_[^&@#AJ*[G_A%-,_NS?]_#1_PBFF?W9O\
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M=4#Z$HKY[_X7/XI_N:=_WX;_ .*H_P"%S^*?[FG?]^&_^*H^IU0/H2BOGO\
MX7/XI_N:=_WX;_XJC_A<_BG^YIW_ 'X;_P"*H^IU0/H2BOGO_A<_BG^YIW_?
MAO\ XJC_ (7/XI_N:=_WX;_XJCZG5 ^A**^>_P#A<_BG^YIW_?AO_BJ/^%S^
M*?[FG?\ ?AO_ (JCZG5 ^A**^>_^%S^*?[FG?]^&_P#BJ/\ A<_BG^YIW_?A
MO_BJ/J=4#Z"<,2NTX /-.KY[/QG\4_W-/'_; _\ Q5'_  N?Q3_<T[_OPW_Q
M5'U.J!]"45\]_P#"Y_%/]S3O^_#?_%4?\+G\4_W-._[\-_\ %4?4ZH'T)17S
MW_PN?Q3_ '-._P"_#?\ Q5'_  N?Q3_<T[_OPW_Q5'U.J!]"45\]_P#"Y_%/
M]S3O^_#?_%4O_"Y_%/\ <T[_ +\-_P#%4?4ZH'T'17@EE\9?$,ERL=RMBJ-Q
MN6$\'_OJM_\ X6+KWK:?]^3_ (TGA:BW*C%RV/7**\D_X6)KWK:?]^3_ (T?
M\+$U[UM/^_)_QJ?J\RO9R/6Z*\D_X6)KWK:?]^3_ (T?\+$U[UM/^_)_QH^K
MS#V<CUNBO)X?B+K0E4RBU://($1!_G6\GB_4)$#J("I&0=A_QJ)TY0W)E%QW
M.ZI&!.,'OS7$?\)9J/\ =@_[X/\ C1_PEFH_W8/^^#_C69)W%%</_P )9J/]
MV#_O@_XT?\)9J/\ =@_[X/\ C0!W%%</_P )9J/]V#_O@_XT?\)9J/\ =@_[
MX/\ C0!W%%</_P )9J/]V#_O@_XT?\)9J/\ =@_[X/\ C0!W%%</_P )9J/]
MV#_O@_XT?\)9J/\ =@_[X/\ C0!W%%</_P )9J/]V#_O@_XT?\)9J/\ =@_[
MX/\ C0!W%%</_P )9J/]V#_O@_XT?\)9J/\ =@_[X/\ C0!W%%</_P )9J/]
MV#_O@_XT?\)9J/\ =@_[X/\ C0!W%%</_P )9J/]V#_O@_XT?\)9J/\ =@_[
MX/\ C0!VS G&#WIU<.?%FI'M!_WP?\:/^$LU'^[!_P!\'_&@#N**X?\ X2S4
M?[L'_?!_QH_X2S4?[L'_ 'P?\: .XHKA_P#A+-1_NP?]\'_&C_A+-1_NP?\
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M16;I5]]HC\F0_O$'!]16E7G2BXNS.9JSL%%%%2(**** "BBB@ HHHH ****
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M6L"Q)VZGU-<N)Y;+N8U;$U%%%<AB%%%% !1110 4444 %%%% !1110 4444
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M\.Z/]A@^T3+_ *1(.A_A'I6[110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<MX\\*3>+]#CT^"[CMF2=9=\B%@0 >, CU
MKJ:*J,G%\R \0_X47J/_ $';3_P&;_XJC_A1>H_]!VT_\!F_^*KV^BM_K=7N
M!XA_PHO4?^@[:?\ @,W_ ,51_P *+U'_ *#MI_X#-_\ %5[?11];J]P/$/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>%T4?5*78#W,_'+1\C&DZC[\Q_\ Q5+_ ,+RT;_H$ZC^<?\ \57A=%'U2EV
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MO^$QM/\ GVG_ /'?\:/^$QM/^?:?_P =_P :XVBD!V7_  F-I_S[3_\ CO\
MC1_PF-I_S[3_ /CO^-<;10!V7_"8VG_/M/\ ^._XT?\ "8VG_/M/_P"._P"-
M<;10!V7_  F-I_S[3_\ CO\ C1_PF-I_S[3_ /CO^-<;10!V7_"8VG_/M/\
M^._XT?\ "8VG_/M/_P"._P"-<;10!V7_  F-I_S[3_\ CO\ C1_PF-I_S[3_
M /CO^-<;10!V)\8VO:VG_P#'?\:7_A,;3_GVG_\ '?\ &N-HH [+_A,;3_GV
MG_\ '?\ &C_A,;3_ )]I_P#QW_&N-HH [+_A,;3_ )]I_P#QW_&C_A,;3_GV
MG_\ '?\ &N-HH [+_A,;3_GVG_\ '?\ &C_A,;3_ )]I_P#QW_&N-HH [+_A
M,;3_ )]I_P#QW_&C_A,;3_GVG_\ '?\ &N-HH [+_A,;3_GVG_\ '?\ &C_A
M,;3_ )]I_P#QW_&N-HH [+_A,;3_ )]I_P#QW_&C_A,;3_GVG_\ '?\ &N-H
MH [+_A,;3_GVG_\ '?\ &C_A,;3_ )]I_P#QW_&N-HH [+_A,;3_ )]I_P#Q
MW_&C_A,;3_GVG_\ '?\ &N-HH [+_A,;3_GVG_\ '?\ &C_A,;3_ )]I_P#Q
MW_&N-HH [+_A,;3_ )]I_P#QW_&C_A,;3_GVG_\ '?\ &N-HH [2+Q=922JC
M0S(&."S8P/UKH 0P!!R#T->5UUOAC6-P%A<-\P_U3'N/2@#J**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH
M;NZCLK62XEW;(QD[1DGV ]:S)_$4-C )=1M9[)2Q!,K(0 .K95B,?K0!LDX%
M<]!XOL[BR:>.UO'9$W&-(2<GC*@]"1N!./Z5;_X2/32BN)6*,I*XC;<<$# 3
M&X]<\#ISTJBMSX;LE^R0HIP&9417()*AF 8\9P <9R!0!9_X2BP\N*3R[PI+
MMPPM7XW-M3/'&X]*?-XFTN&2)#.S>8>"L9( XY)[#Y@,^N1V-4)UT@:F(IM,
MG2&QDBB^T^:!$K *Z;E#Y.,C!9< FI4/AN>*)DV(D)9U'SQ]6!.1QD$L" <@
MYR* +(\36!0,J73,Q^1!;OO=?[X7&2O7FII=?T^*V@N/,=XYVVQE(V;=\P7T
MZ9(K.GG\.W2@."RQC9YB%T(5<XP1@E3D@;<ANG-,=O"\DC1/P+F-=R?O515!
MQ@CI'DI@@XR1@@]* .GHK(A\3Z//_J[P8"ER61E& -W<=QR!W'(R*>OB'3&9
M%%P2[KN"^4^1SC##'RG(P <$GCK0!J456TZ^BU/3K:^@#K%<1K*@D4JP!&1D
M59H **** .%U_P 5ZC&+F.'3WCM(YO+-RLVTM@\@8Y&>F:3PUXUGO;VUTVXM
MMQ?*^<9,MW(SQSZ4K^$1KINIC=K#_I<N,6ZEN&(Y;J1[5#8^$)M US3[I[R.
M9&GV!1&5/(/O[5ZG^S>S<.OS/.OB/:*73Y'H%%<REQK&N7=VUA>QV-G;R&%&
M\H2-*PZDYZ"KV@ZE<WBW5K?*@O+.3RY&C^Z^1D,/3([5P2I.*O?8[(U4W:QL
M4445D:A7FWQL_P"1-@_Z_$_D:])KS;XV?\B;!_U^)_(UMA_XL0/ :***]H0J
MJSL%52S'H ,DTKH\;;71D8?PLI!_(UJ>&GCB\0VCRLZQJ26*-M8#!Z$]#70-
M%87U]#$3/=P0V1>Q:Y;SY+@DC(8!EY7YODSV[YJ)3L[ <9'%)*2(XW<J"Q"J
M3@#J>.U,KLG%MI\M_%#;)"\MB@FC=-F"9%'RJ'8KD<D$_A1<VEK)=ZA_96B6
M-S+!=>2MOEB%B'\>-_S$G@MGBE[0#C:78VS?M.W.-V.,^F:["XTN"*>[_L[1
M[2\N%G1'MFD,BP)L4Y7##=EB1NR<5%:BUDT^.QNH+6&$ZIAU$F2HV'CS,],\
M9]*/: <G17:6UA9H#/JVBVEI<()C':JS*LJA&.2-Q/#!<'/S9[UESV]@VA?V
MN((4>5?LRV\>0%FSDN!GIMY^M-5$P, (Q4L%8JO5@#@?4T,C(0&4J2,@$8XK
MJ-(6\E\.3PB9K>V"RN)XY1L!V\I,G<,!P>N>E6+A8[^5I(=/M+J\BL;?RK?&
M 01\S8#?,5]/>ESZ@<>$9@Q"L0O)('3ZTE=O<K;:=!?1?V?8VYEL(6FA#>8%
M<R\@'<<'&#CM59]&MK6]NY9=/$MK)<Q"R17'[U"<D)SS\M"J(#D:*T]?M%L]
M7EB5(47:K!(5*A<CH5).UO49-9E6G=7 ****8!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &UX;UU]%OP6)-M+Q*OI[_A7JT<B2QK)&P9&
M&58="*\/KM/!?B'RG72[I_W;']RQ/0_W:XL70YESQW [ZBBBO,&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4IM3A@FDC>*X*Q8\R5
M8B43(SR?_K4 7:*C\^'<JF:(,PR%+@$CUQ4,&H6L\+2K/&J*YC)9U R#]: +
M5%1R3)';O-RZ*I8^6-Q('IZU%%?03,BH6)>'SA\I^Y_GM0!9HJL;Z'[&ERHD
M='QL"(2S9Z "H/[8M?[L^1_K!Y1S%SCY_P"[S0!H451;5K97*D3A>=K^4=KD
M=0I[FI[:ZCN@^U9$9#ADE3:R_44 3T444 %%%% !2JS(X=&*LIR".QI** /0
M-#U9=3M,.0+B/AQZ^]:M>9V-[+I]VEQ$>5ZC^\/2O1+.[BOK5+B%LJP_(^E
M%BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH1%4$D 8Y.32T45Y PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K-FM;SS+P0K 5N< .[D%1MVG@#G\ZTJ* ,&71)O(-ND5I(IF203RD[
MP 0<8VGGC YJ6/2);>995BM9@#)F*3A?F;((^4\]CQ6S10!GV%A):Z(MD_E"
M01LO[O.P$YZ>W-5AH@DD@,Y#+%:"#Y)'3YO7Y2.*V:* ,V&SO+/2UAMIE:=8
MPBB0_NU]^F3^-5UTNYBCF2(0C[1&$D9Y"Q!!Y;[OS$Y]JVJ* ,S[-??;'N&6
M!S&A2U4RL O'5AMZGOZ#@5/IUO+;Q/\ : IG=MTCJ^[>?R&!V JY10 4444
M%%%% !1110 H!)  ))Z 5WOA_3'TZQ_>L?-E.YESPOM61X8T?S&%_<+\H_U2
MD=3ZUUU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5YM\;/^1-@_P"OQ/Y&O2:X+XLZ1J.L^%H;?3;.6ZF%TCE(AD@ 'FM:
M#2J)L#YUHKH_^$!\6_\ 0O7W_? _QH_X0'Q;_P!"]??]\#_&O8]I#NA'.45T
M?_" ^+?^A>OO^^!_C1_P@/BW_H7K[_O@?XT>TAW0'.45T?\ P@/BW_H7K[_O
M@?XT?\(#XM_Z%Z^_[X'^-'M(=T!SE%='_P (#XM_Z%Z^_P"^!_C1_P (#XM_
MZ%Z^_P"^!_C1[2'= <Y171_\(#XM_P"A>OO^^!_C1_P@/BW_ *%Z^_[X'^-'
MM(=T!SE%='_P@/BW_H7K[_O@?XT?\(#XM_Z%Z^_[X'^-'M(=T!SE%='_ ,(#
MXM_Z%Z^_[X'^-'_" ^+?^A>OO^^!_C1[2'= <Y171_\ " ^+?^A>OO\ O@?X
MT?\ " ^+?^A>OO\ O@?XT>TAW0'.45T7_"!>+/\ H7[[_O@?XTO_  @/BW_H
M7K[_ +X'^-'M(=T!SE%='_P@/BW_ *%Z^_[X'^-'_" ^+?\ H7K[_O@?XT>T
MAW0'.45T?_" ^+?^A>OO^^!_C1_P@/BW_H7K[_O@?XT>TAW0'.45T?\ P@/B
MW_H7K[_O@?XT?\(#XM_Z%Z^_[X'^-'M(=T!SE%='_P (#XM_Z%Z^_P"^!_C1
M_P (#XM_Z%Z^_P"^!_C1[2'= <Y171_\(#XM_P"A>OO^^!_C1_P@/BW_ *%Z
M^_[X'^-'M(=T!SE%='_P@/BW_H7K[_O@?XT?\(#XM_Z%Z^_[X'^-'M(=T!SE
M%='_ ,(#XM_Z%Z^_[X'^-'_" ^+?^A>OO^^!_C1[2'= <Y171_\ " ^+?^A>
MOO\ O@?XTG_"!>+/^A?OO^^!_C1[2'= <[1UZ5T?_" ^+?\ H7K[_O@?XUT'
MA7X=:T+S[9J6E7$:Q']W$X&6;U//2IG6A&-[@3^$/#_]FVOVRY3_ $J8< _P
M+Z?6NHJ__8FI_P#/C-^0_P :/[$U/_GQF_(?XUX\YN<N9C*%%7_[$U/_ )\9
MOR'^-']B:G_SXS?D/\:@"A15_P#L34_^?&;\A_C1_8FI_P#/C-^0_P : *%%
M7_[$U/\ Y\9OR'^-']B:G_SXS?D/\: *%%7_ .Q-3_Y\9OR'^-']B:G_ ,^,
MWY#_ !H H45?_L34_P#GQF_(?XT?V)J?_/C-^0_QH H45?\ [$U/_GQF_(?X
MT?V)J?\ SXS?D/\ &@"A15_^Q=3'_+C-^0H_L34_^?&;\A_C0!0HJ_\ V)J?
M_/C-^0_QH_L34_\ GQF_(?XT 4**O_V)J?\ SXS?D/\ &C^Q-3_Y\9OR'^-
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M 9YY%.R/44 +129'J*,CU% "T4F1ZBC(]10 M%)D>HHR/44 +129'J*,CU%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>>T5Z%_PC^E?\^:?F?\ &C_A']*_Y\D_,_XT >>T5Z%_PC^E?\^2?F?\:/\
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M!U*[W2 _9XSES_>/I76?\(_I7_/DGYG_ !J];VT-I"(H(UC0= * )%4(H50
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M .O0!W5%<+_PE>I^L'_?O_Z]'_"5ZGZP?]^__KT =U17"_\ "5ZGZP?]^_\
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M&T,Y47*<\# 8>HH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M++Y)E";@"1C.,]*<M_$;B")OD,T7FAF8  9 Q]>: +5%5([]9=/CNXX9'\S
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MR+DEW9K;W_EW5U+)=8(1X\ ?-GYCDY-,TZXM;>WE\ZXDVNI62V,>1)Q\I!Z
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M-V5RYI5C]GC\Z0?O7' _NBM*BBO.E)R=V<S=W<****D04444 %%%% !1110
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M .?JR_[Z;_"O5**/K$P]I(\K_P"%::O_ ,_5E_WTW^%'_"M-7_Y^K+_OIO\
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M^+?_ ,>_PKM** .+_P"$/OO^?BW_ /'O\*/^$/O?^?BW_P#'O\*[2B@#C/\
MA#[W_GXM_P#Q[_"C_A#[W_GXM_\ Q[_"NSHH XS_ (0^]_Y^+?\ \>_PH_X0
M^]_Y^+?]?\*[.FN"5^4\T <?_P (==_\_4'Y&C_A#KO_ )^H?R-=E10!QO\
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M^@I+_P!\K_A1]6EW#V;/:Z*\4_X3'Q!_T%)?^^5_PH_X3'Q!_P!!27_OE?\
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MO_/X_P"0_P */[?U7_G\?\A_A0!Z'17GG]OZK_S^/^0_PH_M_5?^?Q_R'^%
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M/[MCP?[IKH*\^I!P=C"4;,****S)"BBB@ HHHH **** "BBB@ HHHH ****
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M@@YZ8.:U*QX_#EJDYGDGN99C UOOD<$^6<<=.V/S)SFM=5"*%'0#% "T444
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M6E+XT5'<\KHHHKT3H'PS2V\RRPR-'(IRK*<$5934[@77VF1C)*$*(QXV<8!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%)F@!:*3-&: %HI,T9H 6
MBDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
M%HI,T9H 6BDS1F@!:*3-&: $8*=NXXYXIU-90V,]CFES0 M%)FC- "T4F:,T
M +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "TC $<]*,T$;A@T +129H
MS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC-  P!4
M@G I1TXIK#<"#WI1P* %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*
M3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>mrns-20210331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/17/2021 8:23:37 PM-->
<!--Modified on: 5/17/2021 8:23:37 PM-->
<xsd:schema xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrns="http://www.marinuspharma.com/20210331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsd="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.marinuspharma.com/20210331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
        <link:definition>00205 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40301 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40401 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40801 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureLeasesDetailsCalc2" id="DisclosureLeasesDetailsCalc2">
        <link:definition>40801 - Disclosure - Leases (Details) (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidity" id="DisclosureDescriptionOfBusinessAndLiquidity">
        <link:definition>10101 - Disclosure - Description of the Business and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10401 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureInvestments" id="DisclosureInvestments">
        <link:definition>10501 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStock" id="DisclosureLossPerShareOfCommonStock">
        <link:definition>10601 - Disclosure - Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10701 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10801 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30403 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockTables" id="DisclosureLossPerShareOfCommonStockTables">
        <link:definition>30603 - Disclosure - Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30703 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30803 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails" id="DisclosureDescriptionOfBusinessAndLiquidityDetails">
        <link:definition>40101 - Disclosure - Description of the Business and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails" id="DisclosureLossPerShareOfCommonStockDetails">
        <link:definition>40601 - Disclosure - Loss Per Share of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40701 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mrns-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrns-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrns-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrns-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_ClinicalTrialsAndDrugDevelopmentCurrent" name="ClinicalTrialsAndDrugDevelopmentCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="SeriesAConvertiblePreferredStockMember" id="mrns_SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionAndIncentivePlan2005Member" id="mrns_StockOptionAndIncentivePlan2005Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityAbstract" id="mrns_LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="mrns_TermLoanTrancheBMember" name="TermLoanTrancheBMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_TermLoanTrancheCMember" name="TermLoanTrancheCMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_TermLoanTrancheDMember" name="TermLoanTrancheDMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_EquityIncentivePlan2014Member" name="EquityIncentivePlan2014Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_NumberOfTranches" name="NumberOfTranches" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_BusinessDescriptionAndLiquidityTextBlock" name="BusinessDescriptionAndLiquidityTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_NonCashOperatingLeaseExpenseOperatingActivities" name="NonCashOperatingLeaseExpenseOperatingActivities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_InterestExpenseIncomeOnLeaseLiabilities" name="InterestExpenseIncomeOnLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_LeaseLiabilityShortTerm" name="LeaseLiabilityShortTerm" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_EquityIncentivePlanEmployeeMember" name="EquityIncentivePlanEmployeeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_PaymentsForDepositAndPropertyAndEquipment" name="PaymentsForDepositAndPropertyAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_InvestmentsDisclosureTextBlock" name="InvestmentsDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_PublicOfferingMember" name="PublicOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" name="AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_ConvertiblePreferredStockDeemedDividends" name="ConvertiblePreferredStockDeemedDividends" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_MaximumAwardAvailableUnderContract" name="MaximumAwardAvailableUnderContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_ContractBasePeriod" name="ContractBasePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_ContractFundingProvidedDuringBasePeriod" name="ContractFundingProvidedDuringBasePeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod" name="ContractAdditionalFundingToBeProvidedFollowingBasePeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_ContractCostSharingAmount" name="ContractCostSharingAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_ContractCostSharingAmountCounterparty" name="ContractCostSharingAmountCounterparty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_ContractPeriodOfPerformance" name="ContractPeriodOfPerformance" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_OaktreeCapitalManagementLpCreditAgreementMember" name="OaktreeCapitalManagementLpCreditAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_TermLoansTranche1Member" name="TermLoansTranche1Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_TermLoansTranche2Member" name="TermLoansTranche2Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_DebtInstrumentUpfrontFeesPercentage" name="DebtInstrumentUpfrontFeesPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage" name="DebtInstrumentPeriodicPaymentPrincipalPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_DebtInstrumentCommitmentFee" name="DebtInstrumentCommitmentFee" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_DebtInstrumentCommitmentFeeAccrualPeriod" name="DebtInstrumentCommitmentFeeAccrualPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" name="DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" name="DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum" name="DebtInstrumentFundingAvailableNetProductRevenueMinimum" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" name="DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>mrns-20210331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/17/2021 8:23:37 PM-->
<!--Modified on: 5/17/2021 8:23:37 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLeasesDetails" roleURI="http://www.marinuspharma.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLeasesDetailsCalc2" roleURI="http://www.marinuspharma.com/role/DisclosureLeasesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637568798165806276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637568798165806276" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637568798165806276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637568798165806276" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637568798165806276" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637568798165806276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637568798165806276" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637568798165806276" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637568798165806276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637568798165806276" xlink:to="us-gaap_ShortTermInvestments_637568798165806276" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_637568798165806276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637568798165806276" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_637568798165806276" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637568798165806276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637568798165806276" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637568798165806276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637568798165806276" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637568798165806276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637568798165806276" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637568798165816274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637568798165806276" xlink:to="us-gaap_LiabilitiesCurrent_637568798165816274" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637568798165816274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637568798165816274" xlink:to="us-gaap_AccountsPayableCurrent_637568798165816274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637568798165816274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637568798165816274" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637568798165816274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_637568798165816274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637568798165806276" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_637568798165816274" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637568798165816274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637568798165816274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637568798165816274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637568798165816274" xlink:to="us-gaap_PreferredStockValue_637568798165816274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637568798165816274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637568798165816274" xlink:to="us-gaap_CommonStockValue_637568798165816274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637568798165816274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637568798165816274" xlink:to="us-gaap_AdditionalPaidInCapital_637568798165816274" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637568798165816274" xlink:to="us-gaap_TreasuryStockValue_637568798165826269" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637568798165816274" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637568798165826269" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637568798165826269" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637568798165826269" xlink:to="us-gaap_OperatingIncomeLoss_637568798165826269" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637568798165826269" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_637568798165826269" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637568798165826269" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637568798165826269" order="2" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637568798165826269" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637568798165826269" order="3" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637568798165826269" xlink:to="us-gaap_InvestmentIncomeInterest_637568798165826269" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637568798165826269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637568798165826269" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637568798165826269" order="3" use="optional" weight="1" priority="4" />
  </calculationLink>
  <calculationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xlink:type="extended" xlink:title="00205 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - Calc 2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637568798165836272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_637568798165836272" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_637568798165836272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment_637568798165836272" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637568798165836272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" xlink:to="us-gaap_ProfitLoss_637568798165836272" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637568798165836272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" xlink:to="us-gaap_Depreciation_637568798165836272" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637568798165836272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" xlink:to="us-gaap_ShareBasedCompensation_637568798165836272" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_NonCashOperatingLeaseExpenseOperatingActivities" xlink:label="mrns_NonCashOperatingLeaseExpenseOperatingActivities_637568798165836272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" xlink:to="mrns_NonCashOperatingLeaseExpenseOperatingActivities_637568798165836272" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_InterestExpenseIncomeOnLeaseLiabilities" xlink:label="mrns_InterestExpenseIncomeOnLeaseLiabilities_637568798165836272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" xlink:to="mrns_InterestExpenseIncomeOnLeaseLiabilities_637568798165836272" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637568798165846269" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637568798165846269" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798165836272" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637568798165846269" order="8" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637568798165846269" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637568798165846269" xlink:to="us-gaap_PaymentsToAcquireInvestments_637568798165846269" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_PaymentsForDepositAndPropertyAndEquipment" xlink:label="mrns_PaymentsForDepositAndPropertyAndEquipment_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637568798165846269" xlink:to="mrns_PaymentsForDepositAndPropertyAndEquipment_637568798165846269" order="2" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637568798165846269" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_637568798165846269" order="3" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637568798165846269" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_637568798165846269" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637568798165846269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637568798165846269" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637568798165856266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637568798165846269" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637568798165856266" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_637568798165856266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637568798165846269" xlink:to="us-gaap_PaymentsOfFinancingCosts_637568798165856266" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637568798165856266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637568798165856266" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637568798165856266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637568798165856266" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635521591599969281" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637568798165856266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_635521591599969281" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637568798165856266" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ClinicalTrialsAndDrugDevelopmentCurrent" xlink:label="mrns_ClinicalTrialsAndDrugDevelopmentCurrent_637568798165856266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_635521591599969281" xlink:to="mrns_ClinicalTrialsAndDrugDevelopmentCurrent_637568798165856266" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637568798165856266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_635521591599969281" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637568798165856266" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_LeaseLiabilityShortTerm" xlink:label="mrns_LeaseLiabilityShortTerm_637568798165856266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_635521591599969281" xlink:to="mrns_LeaseLiabilityShortTerm_637568798165856266" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637568798165866272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_635521591599969281" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637568798165866272" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.marinuspharma.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_636921615389014707" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637568798165866272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_636921615389014707" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637568798165866272" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637568798165866272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_636921615389014707" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637568798165866272" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.marinuspharma.com/role/DisclosureLeasesDetailsCalc2" xlink:type="extended" xlink:title="40801 - Disclosure - Leases (Details) (Calc2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637568798165866272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637568798165866272" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637568798165866272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637568798165866272" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>mrns-20210331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/17/2021 8:23:37 PM-->
<!--Modified on: 5/17/2021 8:23:37 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureDescriptionOfBusinessAndLiquidityDetails" roleURI="http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLossPerShareOfCommonStockDetails" roleURI="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLeasesDetails" roleURI="http://www.marinuspharma.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <definitionLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637568798165876278" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_637568798165876278" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_SeriesAConvertiblePreferredStockMember" xlink:label="mrns_SeriesAConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mrns_SeriesAConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_SeriesAConvertiblePreferredStockMember" xlink:label="mrns_SeriesAConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mrns_SeriesAConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637568798165896278" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637568798165896278" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" xlink:label="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798165936276" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798165936276" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of the Business and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637568798165946281" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637568798165946281" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_PublicOfferingMember" xlink:label="mrns_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrns_PublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637568798165946281" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637568798165946281" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LineOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoansTranche1Member" xlink:label="mrns_TermLoansTranche1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditMember" xlink:to="mrns_TermLoansTranche1Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoansTranche2Member" xlink:label="mrns_TermLoansTranche2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditMember" xlink:to="mrns_TermLoansTranche2Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheBMember" xlink:label="mrns_TermLoanTrancheBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditMember" xlink:to="mrns_TermLoanTrancheBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheCMember" xlink:label="mrns_TermLoanTrancheCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditMember" xlink:to="mrns_TermLoanTrancheCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheDMember" xlink:label="mrns_TermLoanTrancheDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditMember" xlink:to="mrns_TermLoanTrancheDMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637568798165956268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637568798165956268" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" xlink:label="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_637568798165966264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_637568798165966264" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_OaktreeCapitalManagementLpCreditAgreementMember" xlink:label="mrns_OaktreeCapitalManagementLpCreditAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="mrns_OaktreeCapitalManagementLpCreditAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_LiquidityAbstract" xlink:label="mrns_LiquidityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="mrns_LiquidityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_NumberOfTranches" xlink:label="mrns_NumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_NumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" xlink:label="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentUpfrontFeesPercentage" xlink:label="mrns_DebtInstrumentUpfrontFeesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_DebtInstrumentUpfrontFeesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage" xlink:label="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentCommitmentFee" xlink:label="mrns_DebtInstrumentCommitmentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_DebtInstrumentCommitmentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentCommitmentFeeAccrualPeriod" xlink:label="mrns_DebtInstrumentCommitmentFeeAccrualPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_DebtInstrumentCommitmentFeeAccrualPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_MaximumAwardAvailableUnderContract" xlink:label="mrns_MaximumAwardAvailableUnderContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_MaximumAwardAvailableUnderContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractBasePeriod" xlink:label="mrns_ContractBasePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_ContractBasePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractFundingProvidedDuringBasePeriod" xlink:label="mrns_ContractFundingProvidedDuringBasePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_ContractFundingProvidedDuringBasePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod" xlink:label="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractCostSharingAmount" xlink:label="mrns_ContractCostSharingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_ContractCostSharingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractCostSharingAmountCounterparty" xlink:label="mrns_ContractCostSharingAmountCounterparty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_ContractCostSharingAmountCounterparty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractPeriodOfPerformance" xlink:label="mrns_ContractPeriodOfPerformance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_ContractPeriodOfPerformance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="mrns_LiquidityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637568798166036283" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637568798166036283" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637568798166036283" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637568798166036283" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637568798166046273" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637568798166046273" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Loss Per Share of Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637568798166056259" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637568798166056259" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637568798166066282" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637568798166066282" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_StockOptionAndIncentivePlan2005Member" xlink:label="mrns_StockOptionAndIncentivePlan2005Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrns_StockOptionAndIncentivePlan2005Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_EquityIncentivePlan2014Member" xlink:label="mrns_EquityIncentivePlan2014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrns_EquityIncentivePlan2014Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_EquityIncentivePlanEmployeeMember" xlink:label="mrns_EquityIncentivePlanEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrns_EquityIncentivePlanEmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_SeriesAConvertiblePreferredStockMember" xlink:label="mrns_SeriesAConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mrns_SeriesAConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637568798166086271" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637568798166086271" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637568798166096268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637568798166096268" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ConvertiblePreferredStockDeemedDividends" xlink:label="mrns_ConvertiblePreferredStockDeemedDividends" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="mrns_ConvertiblePreferredStockDeemedDividends" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.marinuspharma.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>mrns-20210331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/17/2021 8:23:37 PM-->
<!--Modified on: 5/17/2021 8:23:37 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Asset, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal contract revenue receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A convertible preferred stock, $0.001 par value; 25,000,000 shares authorized, 4,753 shares issued and outstanding at March 31, 2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value; 150,000,000 shares authorized, 36,640,797 issued and 36,633,490 outstanding at March 31, 2021 and 36,585,767 issued and 36,578,400 outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury stock at cost, 7,307 shares at March 31, 2020 and December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury stock, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Not from Contract with Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal contract revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Dividends, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividends on convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss applicable to common shareholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share of common stock-basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted weighted average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_NonCashOperatingLeaseExpenseOperatingActivities" xlink:label="mrns_NonCashOperatingLeaseExpenseOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_NonCashOperatingLeaseExpenseOperatingActivities" xlink:to="mrns_NonCashOperatingLeaseExpenseOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_NonCashOperatingLeaseExpenseOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the non-cash portion of lease expenses for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_NonCashOperatingLeaseExpenseOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cash Operating Lease Expense, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_NonCashOperatingLeaseExpenseOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash lease expense</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_InterestExpenseIncomeOnLeaseLiabilities" xlink:label="mrns_InterestExpenseIncomeOnLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_InterestExpenseIncomeOnLeaseLiabilities" xlink:to="mrns_InterestExpenseIncomeOnLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_InterestExpenseIncomeOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense (income) on lease liabilities during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_InterestExpenseIncomeOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense (Income) On Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_InterestExpenseIncomeOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Net, Amortization of Discount and Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of discount on investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current and non-current assets and federal contract revenue receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable, accrued expenses and other long term-liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale, Maturity and Collection of Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of short-term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of short-term investments</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_PaymentsForDepositAndPropertyAndEquipment" xlink:label="mrns_PaymentsForDepositAndPropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_PaymentsForDepositAndPropertyAndEquipment" xlink:to="mrns_PaymentsForDepositAndPropertyAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_PaymentsForDepositAndPropertyAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for deposit on property and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_PaymentsForDepositAndPropertyAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Deposit and Property and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrns_PaymentsForDepositAndPropertyAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposit on property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents-end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents-beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of restricted stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of restricted stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" xlink:label="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" xlink:to="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in additional paid in capital as a result of the deemed dividend on the beneficial conversion feature of the convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Deemed Dividend on Beneficial Conversion Feature, Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividend on beneficial conversion feature - Series A convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs under equity distribution agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of the Business and Liquidity</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_BusinessDescriptionAndLiquidityTextBlock" xlink:label="mrns_BusinessDescriptionAndLiquidityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_BusinessDescriptionAndLiquidityTextBlock" xlink:to="mrns_BusinessDescriptionAndLiquidityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_BusinessDescriptionAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. The disclosure also includes when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_BusinessDescriptionAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description And Liquidity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_BusinessDescriptionAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of the Business and Liquidity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_InvestmentsDisclosureTextBlock" xlink:label="mrns_InvestmentsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_InvestmentsDisclosureTextBlock" xlink:to="mrns_InvestmentsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_InvestmentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_InvestmentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_InvestmentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Contract Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of major categories of financial assets and liabilities measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from the computation of diluted weighted average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total compensation cost recognized in the statement of operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_LiquidityAbstract" xlink:label="mrns_LiquidityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_LiquidityAbstract" xlink:to="mrns_LiquidityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_LiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_LiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_NumberOfTranches" xlink:label="mrns_NumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_NumberOfTranches" xlink:to="mrns_NumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches within term loan for notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured term loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, face amount</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" xlink:to="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum requirement that must be met on gross proceeds from a sublicense in determining availability of funding per the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Funding Available, Gross Proceeds from Sublicense, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from sublicense, minimum</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" xlink:to="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum requirement that must be met on net proceeds from a sublicense in determining availability of funding per the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Funding Available, Net Proceeds from Sublicense, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from sublicense, minimum</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum" xlink:to="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum requirement that must be met on net product revenue over a specified time period in determining availability of funding per the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Funding Available, Net Product Revenue, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net product revenue, minimum</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" xlink:label="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" xlink:to="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consecutive period in which the amount of minimum revenue required to be achieved for debt to be available, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Revenue Requirement, Consecutive Earning Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net product revenue, consecutive earning period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentUpfrontFeesPercentage" xlink:label="mrns_DebtInstrumentUpfrontFeesPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_DebtInstrumentUpfrontFeesPercentage" xlink:to="mrns_DebtInstrumentUpfrontFeesPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_DebtInstrumentUpfrontFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of upfront fees payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_DebtInstrumentUpfrontFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Upfront Fees, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_DebtInstrumentUpfrontFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of upfront fees</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage" xlink:label="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage" xlink:to="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of periodic principal payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment, Principal, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of periodic principal payment</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentCommitmentFee" xlink:label="mrns_DebtInstrumentCommitmentFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_DebtInstrumentCommitmentFee" xlink:to="mrns_DebtInstrumentCommitmentFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_DebtInstrumentCommitmentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage points added to the commitment fees on the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_DebtInstrumentCommitmentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Commitment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_DebtInstrumentCommitmentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment fees</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentCommitmentFeeAccrualPeriod" xlink:label="mrns_DebtInstrumentCommitmentFeeAccrualPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_DebtInstrumentCommitmentFeeAccrualPeriod" xlink:to="mrns_DebtInstrumentCommitmentFeeAccrualPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_DebtInstrumentCommitmentFeeAccrualPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the commitment fees accrues until the applicable tranche is either funded or terminated, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_DebtInstrumentCommitmentFeeAccrualPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Commitment Fee Accrual Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_DebtInstrumentCommitmentFeeAccrualPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment fee accrual period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original principal amount</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_MaximumAwardAvailableUnderContract" xlink:label="mrns_MaximumAwardAvailableUnderContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_MaximumAwardAvailableUnderContract" xlink:to="mrns_MaximumAwardAvailableUnderContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_MaximumAwardAvailableUnderContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount to be awarded under the contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_MaximumAwardAvailableUnderContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Award Available under the Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_MaximumAwardAvailableUnderContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount to be awarded under the contract</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractBasePeriod" xlink:label="mrns_ContractBasePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_ContractBasePeriod" xlink:to="mrns_ContractBasePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_ContractBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The base period as defined in the contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_ContractBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Base Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_ContractBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract base period</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractFundingProvidedDuringBasePeriod" xlink:label="mrns_ContractFundingProvidedDuringBasePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_ContractFundingProvidedDuringBasePeriod" xlink:to="mrns_ContractFundingProvidedDuringBasePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_ContractFundingProvidedDuringBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of funding to be provided during the base period as defined in the contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_ContractFundingProvidedDuringBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Funding Provided During Base Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_ContractFundingProvidedDuringBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of funding to be provided during contract base period</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod" xlink:label="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod" xlink:to="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of additional funding to be provided as defined in the contract, following successful completion of clinical trial and preclinical studies in the base period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract, Additional Funding to be Provided Following Base Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of additional funding to be provided following successful completion of clinical trial and preclinical studies in base period</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractCostSharingAmount" xlink:label="mrns_ContractCostSharingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_ContractCostSharingAmount" xlink:to="mrns_ContractCostSharingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_ContractCostSharingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cost sharing the Company is responsible as defined in the contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_ContractCostSharingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract, Cost Sharing Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_ContractCostSharingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost sharing, amount</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractCostSharingAmountCounterparty" xlink:label="mrns_ContractCostSharingAmountCounterparty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_ContractCostSharingAmountCounterparty" xlink:to="mrns_ContractCostSharingAmountCounterparty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_ContractCostSharingAmountCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cost sharing the counterparty is responsible as defined in the contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_ContractCostSharingAmountCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Cost Sharing Amount, Counterparty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_ContractCostSharingAmountCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost sharing, BARDA amount</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractPeriodOfPerformance" xlink:label="mrns_ContractPeriodOfPerformance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_ContractPeriodOfPerformance" xlink:to="mrns_ContractPeriodOfPerformance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_ContractPeriodOfPerformance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The contract period-of-performance (base period plus option exercises).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_ContractPeriodOfPerformance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract, Period-of-Performance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_ContractPeriodOfPerformance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract period-of-performance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from equity offerings, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related costs</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ClinicalTrialsAndDrugDevelopmentCurrent" xlink:label="mrns_ClinicalTrialsAndDrugDevelopmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_ClinicalTrialsAndDrugDevelopmentCurrent" xlink:to="mrns_ClinicalTrialsAndDrugDevelopmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_ClinicalTrialsAndDrugDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials and drug development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_ClinicalTrialsAndDrugDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trials and Drug Development Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_ClinicalTrialsAndDrugDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trials and drug development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_LeaseLiabilityShortTerm" xlink:label="mrns_LeaseLiabilityShortTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_LeaseLiabilityShortTerm" xlink:to="mrns_LeaseLiabilityShortTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_LeaseLiabilityShortTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of short-term lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_LeaseLiabilityShortTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability, Short-Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_LeaseLiabilityShortTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Compensation Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from the computation of diluted weighted average shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_StockOptionAndIncentivePlan2005Member" xlink:label="mrns_StockOptionAndIncentivePlan2005Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_StockOptionAndIncentivePlan2005Member" xlink:to="mrns_StockOptionAndIncentivePlan2005Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_StockOptionAndIncentivePlan2005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2005 Stock Option and Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_StockOptionAndIncentivePlan2005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option And Incentive Plan2005 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_StockOptionAndIncentivePlan2005Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2005 Plan</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_EquityIncentivePlan2014Member" xlink:label="mrns_EquityIncentivePlan2014Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_EquityIncentivePlan2014Member" xlink:to="mrns_EquityIncentivePlan2014Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_EquityIncentivePlan2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2014 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_EquityIncentivePlan2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_EquityIncentivePlan2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Plan</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_EquityIncentivePlanEmployeeMember" xlink:label="mrns_EquityIncentivePlanEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_EquityIncentivePlanEmployeeMember" xlink:to="mrns_EquityIncentivePlanEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_EquityIncentivePlanEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity incentive plan pertaining to inducements for new employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_EquityIncentivePlanEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_EquityIncentivePlanEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan, Employee Inducments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option and incentive plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total compensation cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, weighted-average exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issued for each convertible Series A preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Features of Convertible Preferred Stock [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed Dividends</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ConvertiblePreferredStockDeemedDividends" xlink:label="mrns_ConvertiblePreferredStockDeemedDividends" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_ConvertiblePreferredStockDeemedDividends" xlink:to="mrns_ConvertiblePreferredStockDeemedDividends_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_ConvertiblePreferredStockDeemedDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The deemed dividends on the convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_ConvertiblePreferredStockDeemedDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Deemed Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_ConvertiblePreferredStockDeemedDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividends on Series A convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease agreement term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease renewal term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term operating lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average incremental borrowing rate used to determine right-of-use assets and lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments, Due, Rolling Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining nine months of 2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_SeriesAConvertiblePreferredStockMember" xlink:label="mrns_SeriesAConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_SeriesAConvertiblePreferredStockMember" xlink:to="mrns_SeriesAConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents Series A Convertible Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_PublicOfferingMember" xlink:label="mrns_PublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_PublicOfferingMember" xlink:to="mrns_PublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information regarding the sale of stock by a company to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit facility</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoansTranche1Member" xlink:label="mrns_TermLoansTranche1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_TermLoansTranche1Member" xlink:to="mrns_TermLoansTranche1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_TermLoansTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to A-1 Term Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_TermLoansTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loans Tranche1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_TermLoansTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loans Tranche A-1</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoansTranche2Member" xlink:label="mrns_TermLoansTranche2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_TermLoansTranche2Member" xlink:to="mrns_TermLoansTranche2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_TermLoansTranche2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to A-2 Term Loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_TermLoansTranche2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loans Tranche2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_TermLoansTranche2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loans Tranche A-2</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheBMember" xlink:label="mrns_TermLoanTrancheBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_TermLoanTrancheBMember" xlink:to="mrns_TermLoanTrancheBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_TermLoanTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information for Term Loan Tranche B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_TermLoanTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_TermLoanTrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche B</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheCMember" xlink:label="mrns_TermLoanTrancheCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_TermLoanTrancheCMember" xlink:to="mrns_TermLoanTrancheCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_TermLoanTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information for Term Loan Tranche C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_TermLoanTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_TermLoanTrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche C</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheDMember" xlink:label="mrns_TermLoanTrancheDMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_TermLoanTrancheDMember" xlink:to="mrns_TermLoanTrancheDMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_TermLoanTrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information for Term Loan Tranche D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_TermLoanTrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_TermLoanTrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Tranche D</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" xlink:label="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" xlink:to="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Biomedical Advanced Research and Development Authority (BARDA) contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biomedical Advanced Research And Development Authority Contract [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BARDA Contract</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lender Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit Facility Lender [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Lender [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_OaktreeCapitalManagementLpCreditAgreementMember" xlink:label="mrns_OaktreeCapitalManagementLpCreditAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrns_OaktreeCapitalManagementLpCreditAgreementMember" xlink:to="mrns_OaktreeCapitalManagementLpCreditAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrns_OaktreeCapitalManagementLpCreditAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Credit Agreement and Gauranty  with Oaktree Capital Management, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrns_OaktreeCapitalManagementLpCreditAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Oaktree Capital Management Lp Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrns_OaktreeCapitalManagementLpCreditAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Oaktree Capital Management LP Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificates Of Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificates of deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>mrns-20210331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/17/2021 8:23:37 PM-->
<!--Modified on: 5/17/2021 8:23:37 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureDescriptionOfBusinessAndLiquidity" roleURI="http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureFairValueMeasurements" roleURI="http://www.marinuspharma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureAccruedExpenses" roleURI="http://www.marinuspharma.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureInvestments" roleURI="http://www.marinuspharma.com/role/DisclosureInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLossPerShareOfCommonStock" roleURI="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureStockholdersEquity" roleURI="http://www.marinuspharma.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLeases" roleURI="http://www.marinuspharma.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.marinuspharma.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLossPerShareOfCommonStockTables" roleURI="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLeasesTables" roleURI="http://www.marinuspharma.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureDescriptionOfBusinessAndLiquidityDetails" roleURI="http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLossPerShareOfCommonStockDetails" roleURI="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrns-20210331.xsd#DisclosureLeasesDetails" roleURI="http://www.marinuspharma.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637568798166186282" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637568798166186282" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637568798166186282" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637568798166186282" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637568798166186282" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637568798166186282" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637568798166186282" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637568798166186282" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637568798166186282" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637568798166186282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637568798166186282" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637568798166196290" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637568798166196290" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637568798166196290" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637568798166196290" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637568798166196290" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637568798166196290" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637568798166196290" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637568798166196290" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637568798166196290" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637568798166196290" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637568798166196290" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637568798166196290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637568798166196290" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637568798166206274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637568798166206274" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637568798166206274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637568798166206274" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637568798166206274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637568798166206274" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637568798166206274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637568798166206274" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637568798166206274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637568798166206274" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637568798166206274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637568798166206274" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637568798166206274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637568798166206274" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637568798166206274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637568798166206274" order="30" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_635521591599189276" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637568798166326292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635521591599189276" xlink:to="us-gaap_AssetsAbstract_637568798166326292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637568798166326292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637568798166326292" xlink:to="us-gaap_AssetsCurrentAbstract_637568798166326292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637568798166326292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637568798166326292" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637568798166326292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637568798166326292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637568798166326292" xlink:to="us-gaap_ShortTermInvestments_637568798166326292" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_637568798166326292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637568798166326292" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_637568798166326292" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637568798166326292" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637568798166336301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637568798166326292" xlink:to="us-gaap_AssetsCurrent_637568798166336301" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637568798166326292" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637568798166336301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637568798166326292" xlink:to="us-gaap_OtherAssetsNoncurrent_637568798166336301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637568798166326292" xlink:to="us-gaap_Assets_637568798166336301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635521591599189276" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637568798166336301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637568798166336301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637568798166336301" xlink:to="us-gaap_AccountsPayableCurrent_637568798166336301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637568798166336301" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637568798166336301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637568798166336301" xlink:to="us-gaap_LiabilitiesCurrent_637568798166336301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_637568798166336301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_Liabilities_637568798166336301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637568798166336301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_StockholdersEquityAbstract_637568798166336301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637568798166346284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_PreferredStockValue_637568798166346284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637568798166346284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_CommonStockValue_637568798166346284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637568798166346284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_AdditionalPaidInCapital_637568798166346284" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue_637568798166346284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_TreasuryStockValue_637568798166346284" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637568798166346284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637568798166346284" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637568798166346284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_StockholdersEquity_637568798166346284" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637568798166346284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637568798166336301" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637568798166346284" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_635521591599501278" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637568798166346284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635521591599501278" xlink:to="us-gaap_StatementTable_637568798166346284" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166346284" xlink:to="us-gaap_StatementClassOfStockAxis_637568798166356288" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637568798166356288" xlink:to="us-gaap_ClassOfStockDomain_637568798166356288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_SeriesAConvertiblePreferredStockMember" xlink:label="mrns_SeriesAConvertiblePreferredStockMember_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637568798166356288" xlink:to="mrns_SeriesAConvertiblePreferredStockMember_637568798166356288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166346284" xlink:to="us-gaap_StatementLineItems_637568798166356288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637568798166356288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_PreferredStockSharesAuthorized_637568798166356288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_PreferredStockSharesIssued_637568798166356288" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_PreferredStockSharesOutstanding_637568798166356288" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637568798166356288" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_CommonStockSharesAuthorized_637568798166356288" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_CommonStockSharesIssued_637568798166356288" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_CommonStockSharesOutstanding_637568798166356288" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares_637568798166356288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166356288" xlink:to="us-gaap_TreasuryStockShares_637568798166356288" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_637568798166369098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637568798166369098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637568798166369098" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637568798166369098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637568798166369098" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637568798166369098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637568798166369098" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeInterest_637568798166369098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637568798166369098" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637568798166369098" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_637568798166369098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment_637568798166369098" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637568798166376290" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637568798166376290" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637568798166376290" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637568798166376290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637568798166376290" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637568798166376290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637568798166376290" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637568798166376290" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_636597528276628208" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636597528276628208" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637568798166376290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637568798166376290" xlink:to="us-gaap_ProfitLoss_637568798166376290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637568798166376290" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637568798166376290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637568798166376290" xlink:to="us-gaap_Depreciation_637568798166376290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637568798166376290" xlink:to="us-gaap_ShareBasedCompensation_637568798166376290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_NonCashOperatingLeaseExpenseOperatingActivities" xlink:label="mrns_NonCashOperatingLeaseExpenseOperatingActivities_637568798166376290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637568798166376290" xlink:to="mrns_NonCashOperatingLeaseExpenseOperatingActivities_637568798166376290" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_InterestExpenseIncomeOnLeaseLiabilities" xlink:label="mrns_InterestExpenseIncomeOnLeaseLiabilities_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637568798166376290" xlink:to="mrns_InterestExpenseIncomeOnLeaseLiabilities_637568798166386303" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637568798166376290" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637568798166386303" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637568798166376290" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637568798166386303" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637568798166386303" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637568798166386303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637568798166386303" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637568798166386303" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637568798166376290" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637568798166386303" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636597528276628208" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637568798166386303" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637568798166386303" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_637568798166386303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637568798166386303" xlink:to="us-gaap_PaymentsToAcquireInvestments_637568798166386303" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_PaymentsForDepositAndPropertyAndEquipment" xlink:label="mrns_PaymentsForDepositAndPropertyAndEquipment_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637568798166386303" xlink:to="mrns_PaymentsForDepositAndPropertyAndEquipment_637568798166386303" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637568798166386303" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_637568798166386303" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637568798166386303" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637568798166386303" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637568798166386303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636597528276628208" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637568798166386303" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637568798166396288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637568798166386303" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637568798166396288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_637568798166396288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637568798166386303" xlink:to="us-gaap_PaymentsOfFinancingCosts_637568798166396288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637568798166396288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637568798166386303" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637568798166396288" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637568798166396288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636597528276628208" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637568798166396288" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637568798166396288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636597528276628208" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637568798166396288" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6375687981663962881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636597528276628208" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6375687981663962881" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_635521591599501278" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637568798166396288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_635521591599501278" xlink:to="us-gaap_StatementTable_637568798166396288" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637568798166396288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166396288" xlink:to="us-gaap_StatementClassOfStockAxis_637568798166396288" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_SeriesAConvertiblePreferredStockMember" xlink:label="mrns_SeriesAConvertiblePreferredStockMember_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637568798166396288" xlink:to="mrns_SeriesAConvertiblePreferredStockMember_637568798166406294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637568798166396288" xlink:to="us-gaap_ClassOfStockDomain_637568798166406294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166396288" xlink:to="us-gaap_StatementEquityComponentsAxis_637568798166406294" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166406294" xlink:to="us-gaap_PreferredStockMember_637568798166406294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166406294" xlink:to="us-gaap_CommonStockMember_637568798166406294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166406294" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637568798166406294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166406294" xlink:to="us-gaap_TreasuryStockMember_637568798166406294" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166406294" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637568798166406294" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166406294" xlink:to="us-gaap_RetainedEarningsMember_637568798166406294" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166406294" xlink:to="us-gaap_EquityComponentDomain_637568798166406294" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166396288" xlink:to="us-gaap_StatementLineItems_637568798166406294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166406294" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_StockholdersEquity_637568798166406294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637568798166406294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_SharesOutstanding_637568798166406294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637568798166416287" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637568798166416287" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637568798166416287" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637568798166416287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637568798166416287" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637568798166416287" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637568798166416287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock" xlink:label="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock_637568798166416287" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637568798166416287" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637568798166416287" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637568798166416287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637568798166416287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637568798166416287" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637568798166426301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637568798166426301" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637568798166426301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_NetIncomeLoss_637568798166426301" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637568798166426301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_StockholdersEquity_637568798166426301" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637568798166426301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637568798166406294" xlink:to="us-gaap_SharesOutstanding_637568798166426301" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidity" xlink:type="extended" xlink:title="10101 - Disclosure - Description of the Business and Liquidity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_BusinessDescriptionAndLiquidityTextBlock" xlink:label="mrns_BusinessDescriptionAndLiquidityTextBlock_637568798166426301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mrns_BusinessDescriptionAndLiquidityTextBlock_637568798166426301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637568798166436329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637568798166436329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637568798166436329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637568798166436329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10401 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637568798166436329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637568798166436329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureInvestments" xlink:type="extended" xlink:title="10501 - Disclosure - Investments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_InvestmentsDisclosureTextBlock" xlink:label="mrns_InvestmentsDisclosureTextBlock_637568798166436329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="mrns_InvestmentsDisclosureTextBlock_637568798166436329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStock" xlink:type="extended" xlink:title="10601 - Disclosure - Loss Per Share of Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637568798166436329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637568798166436329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10701 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637568798166436329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637568798166436329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10801 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637568798166446326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637568798166446326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_636597532044985692" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637568798166446326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636597532044985692" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637568798166446326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637568798166446326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636597532044985692" xlink:to="us-gaap_UseOfEstimates_637568798166446326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637568798166446326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636597532044985692" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637568798166446326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637568798166446326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637568798166446326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637568798166446326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637568798166446326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockTables" xlink:type="extended" xlink:title="30603 - Disclosure - Loss Per Share of Common Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637568798166456286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_637568798166456286" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166456286" xlink:to="us-gaap_AwardTypeAxis_637568798166456286" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637568798166456286" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798166456286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798166456286" xlink:to="us-gaap_EmployeeStockOptionMember_637568798166456286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798166456286" xlink:to="us-gaap_RestrictedStockMember_637568798166456286" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166456286" xlink:to="us-gaap_StatementLineItems_637568798166456286" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166456286" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637568798166456286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637568798166456286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637568798166456286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of the Business and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635521591599813280" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635521591599813280" xlink:to="us-gaap_StatementTable_637568798166466302" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166466302" xlink:to="us-gaap_StatementEquityComponentsAxis_637568798166466302" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166466302" xlink:to="us-gaap_EquityComponentDomain_637568798166466302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637568798166466302" xlink:to="us-gaap_CommonStockMember_637568798166466302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166466302" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637568798166466302" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637568798166466302" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637568798166466302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_PublicOfferingMember" xlink:label="mrns_PublicOfferingMember_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637568798166466302" xlink:to="mrns_PublicOfferingMember_637568798166466302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166466302" xlink:to="us-gaap_DebtInstrumentAxis_637568798166466302" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637568798166466302" xlink:to="us-gaap_DebtInstrumentNameDomain_637568798166466302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637568798166466302" xlink:to="us-gaap_LineOfCreditMember_637568798166466302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoansTranche1Member" xlink:label="mrns_TermLoansTranche1Member_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditMember_637568798166466302" xlink:to="mrns_TermLoansTranche1Member_637568798166466302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoansTranche2Member" xlink:label="mrns_TermLoansTranche2Member_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditMember_637568798166466302" xlink:to="mrns_TermLoansTranche2Member_637568798166466302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheBMember" xlink:label="mrns_TermLoanTrancheBMember_637568798166466302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditMember_637568798166466302" xlink:to="mrns_TermLoanTrancheBMember_637568798166466302" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheCMember" xlink:label="mrns_TermLoanTrancheCMember_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditMember_637568798166466302" xlink:to="mrns_TermLoanTrancheCMember_637568798166476298" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_TermLoanTrancheDMember" xlink:label="mrns_TermLoanTrancheDMember_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditMember_637568798166466302" xlink:to="mrns_TermLoanTrancheDMember_637568798166476298" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166466302" xlink:to="us-gaap_TypeOfArrangementAxis_637568798166476298" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637568798166476298" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637568798166476298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember" xlink:label="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637568798166476298" xlink:to="mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_637568798166476298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166466302" xlink:to="us-gaap_LineOfCreditFacilityAxis_637568798166476298" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_637568798166476298" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_637568798166476298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_OaktreeCapitalManagementLpCreditAgreementMember" xlink:label="mrns_OaktreeCapitalManagementLpCreditAgreementMember_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_637568798166476298" xlink:to="mrns_OaktreeCapitalManagementLpCreditAgreementMember_637568798166476298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637568798166466302" xlink:to="us-gaap_StatementLineItems_637568798166476298" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_LiquidityAbstract" xlink:label="mrns_LiquidityAbstract_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637568798166476298" xlink:to="mrns_LiquidityAbstract_637568798166476298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637568798166476298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_NetIncomeLoss_637568798166476298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637568798166486291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637568798166486291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637568798166486291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637568798166486291" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_NumberOfTranches" xlink:label="mrns_NumberOfTranches_637568798166486291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_NumberOfTranches_637568798166486291" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637568798166486291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_DebtInstrumentTerm_637568798166486291" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637568798166486291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_DebtInstrumentFaceAmount_637568798166486291" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum_637568798166486291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum_637568798166486291" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum_637568798166486291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum_637568798166486291" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum" xlink:label="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum_637568798166496304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum_637568798166496304" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod" xlink:label="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod_637568798166496304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod_637568798166496304" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637568798166496304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637568798166496304" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentUpfrontFeesPercentage" xlink:label="mrns_DebtInstrumentUpfrontFeesPercentage_637568798166496304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_DebtInstrumentUpfrontFeesPercentage_637568798166496304" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage" xlink:label="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage_637568798166496304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage_637568798166496304" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentCommitmentFee" xlink:label="mrns_DebtInstrumentCommitmentFee_637568798166496304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_DebtInstrumentCommitmentFee_637568798166496304" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_DebtInstrumentCommitmentFeeAccrualPeriod" xlink:label="mrns_DebtInstrumentCommitmentFeeAccrualPeriod_637568798166496304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_DebtInstrumentCommitmentFeeAccrualPeriod_637568798166496304" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637568798166506293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637568798166506293" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_MaximumAwardAvailableUnderContract" xlink:label="mrns_MaximumAwardAvailableUnderContract_637568798166506293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_MaximumAwardAvailableUnderContract_637568798166506293" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractBasePeriod" xlink:label="mrns_ContractBasePeriod_637568798166506293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_ContractBasePeriod_637568798166506293" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractFundingProvidedDuringBasePeriod" xlink:label="mrns_ContractFundingProvidedDuringBasePeriod_637568798166506293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_ContractFundingProvidedDuringBasePeriod_637568798166506293" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod" xlink:label="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod_637568798166506293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod_637568798166506293" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractCostSharingAmount" xlink:label="mrns_ContractCostSharingAmount_637568798166506293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_ContractCostSharingAmount_637568798166506293" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractCostSharingAmountCounterparty" xlink:label="mrns_ContractCostSharingAmountCounterparty_637568798166516295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_ContractCostSharingAmountCounterparty_637568798166516295" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ContractPeriodOfPerformance" xlink:label="mrns_ContractPeriodOfPerformance_637568798166516295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="mrns_ContractPeriodOfPerformance_637568798166516295" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637568798166516295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637568798166516295" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637568798166516295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637568798166516295" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637568798166526305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrns_LiquidityAbstract_637568798166476298" xlink:to="us-gaap_CommonStockSharesAuthorized_637568798166526305" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_635521591599813280" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637568798166526305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_635521591599813280" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637568798166526305" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637568798166526305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637568798166526305" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637568798166526305" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637568798166526305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637568798166526305" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637568798166526305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637568798166526305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637568798166526305" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637568798166526305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637568798166526305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637568798166526305" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637568798166526305" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637568798166526305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637568798166526305" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637568798166526305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637568798166526305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637568798166526305" xlink:to="us-gaap_FairValueInputsLevel1Member_637568798166526305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637568798166526305" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637568798166536304" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637568798166536304" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637568798166536304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637568798166536304" xlink:to="us-gaap_MoneyMarketFundsMember_637568798166536304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637568798166536304" xlink:to="us-gaap_CertificatesOfDepositMember_637568798166536304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637568798166526305" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637568798166536304" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637568798166536304" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_637568798166536304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637568798166536304" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637568798166536304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637568798166536304" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637568798166536304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637568798166536304" xlink:to="us-gaap_AssetsFairValueDisclosure_637568798166536304" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_635521591599969281" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635521591599969281" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637568798166536304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ClinicalTrialsAndDrugDevelopmentCurrent" xlink:label="mrns_ClinicalTrialsAndDrugDevelopmentCurrent_637568798166536304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635521591599969281" xlink:to="mrns_ClinicalTrialsAndDrugDevelopmentCurrent_637568798166536304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635521591599969281" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637568798166546301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_LeaseLiabilityShortTerm" xlink:label="mrns_LeaseLiabilityShortTerm_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635521591599969281" xlink:to="mrns_LeaseLiabilityShortTerm_637568798166546301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635521591599969281" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637568798166546301" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635521591599969281" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637568798166546301" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Loss Per Share of Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637568798166546301" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637568798166546301" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637568798166546301" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637568798166546301" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637568798166546301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637568798166546301" xlink:to="us-gaap_ConvertiblePreferredStockMember_637568798166546301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637568798166546301" xlink:to="us-gaap_RestrictedStockMember_637568798166546301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637568798166546301" xlink:to="us-gaap_StockCompensationPlanMember_637568798166546301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637568798166546301" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637568798166546301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637568798166546301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637568798166546301" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637568798166546301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635521591600281283" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635521591600281283" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" xlink:to="us-gaap_PlanNameAxis_637568798166556306" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637568798166556306" xlink:to="us-gaap_PlanNameDomain_637568798166556306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_StockOptionAndIncentivePlan2005Member" xlink:label="mrns_StockOptionAndIncentivePlan2005Member_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637568798166556306" xlink:to="mrns_StockOptionAndIncentivePlan2005Member_637568798166556306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_EquityIncentivePlan2014Member" xlink:label="mrns_EquityIncentivePlan2014Member_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637568798166556306" xlink:to="mrns_EquityIncentivePlan2014Member_637568798166556306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_EquityIncentivePlanEmployeeMember" xlink:label="mrns_EquityIncentivePlanEmployeeMember_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637568798166556306" xlink:to="mrns_EquityIncentivePlanEmployeeMember_637568798166556306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" xlink:to="us-gaap_AwardTypeAxis_637568798166556306" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637568798166556306" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798166556306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798166556306" xlink:to="us-gaap_EmployeeStockOptionMember_637568798166556306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637568798166556306" xlink:to="us-gaap_RestrictedStockMember_637568798166556306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" xlink:to="us-gaap_StatementEquityComponentsAxis_637568798166556306" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637568798166556306" xlink:to="us-gaap_EquityComponentDomain_637568798166556306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637568798166556306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637568798166556306" xlink:to="us-gaap_CommonStockMember_637568798166556306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" xlink:to="us-gaap_StatementClassOfStockAxis_637568798166566297" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637568798166566297" xlink:to="us-gaap_ClassOfStockDomain_637568798166566297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_SeriesAConvertiblePreferredStockMember" xlink:label="mrns_SeriesAConvertiblePreferredStockMember_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637568798166566297" xlink:to="mrns_SeriesAConvertiblePreferredStockMember_637568798166566297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" xlink:to="us-gaap_IncomeStatementLocationAxis_637568798166566297" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637568798166566297" xlink:to="us-gaap_IncomeStatementLocationDomain_637568798166566297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637568798166566297" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637568798166566297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637568798166566297" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637568798166566297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" xlink:to="srt_RangeAxis_637568798166566297" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637568798166566297" xlink:to="srt_RangeMember_637568798166566297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637568798166566297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637568798166566297" xlink:to="srt_MinimumMember_637568798166566297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637568798166566297" xlink:to="srt_MaximumMember_637568798166576305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637568798166556306" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637568798166576305" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637568798166576305" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637568798166576305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637568798166576305" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637568798166576305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637568798166576305" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637568798166576305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637568798166576305" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637568798166576305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637568798166576305" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637568798166576305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637568798166576305" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637568798166576305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637568798166576305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637568798166576305" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637568798166576305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637568798166586299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637568798166576305" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637568798166586299" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637568798166586299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637568798166576305" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637568798166586299" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637568798166586299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637568798166576305" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637568798166586299" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637568798166586299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637568798166586299" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637568798166586299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637568798166586299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637568798166586299" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637568798166586299" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637568798166586299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637568798166586299" xlink:to="us-gaap_PreferredStockSharesOutstanding_637568798166586299" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637568798166586299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637568798166586299" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637568798166586299" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_637568798166596308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637568798166576305" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_637568798166596308" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrns-20210331.xsd#mrns_ConvertiblePreferredStockDeemedDividends" xlink:label="mrns_ConvertiblePreferredStockDeemedDividends_637568798166596308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_637568798166596308" xlink:to="mrns_ConvertiblePreferredStockDeemedDividends_637568798166596308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.marinuspharma.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637568798166596308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637568798166596308" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637568798166596308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637568798166596308" xlink:to="srt_RangeAxis_637568798166596308" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637568798166596308" xlink:to="srt_RangeMember_637568798166606311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637568798166606311" xlink:to="srt_MinimumMember_637568798166606311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637568798166606311" xlink:to="srt_MaximumMember_637568798166606311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637568798166596308" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_637568798166606311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637568798166606311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637568798166606311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637568798166606311" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_OperatingLeaseLiability_637568798166606311" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_LeaseCost_637568798166606311" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_ShortTermLeaseCost_637568798166606311" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_637568798166606311" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637568798166606311" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_637568798166616300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_637568798166616300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_637568798166616300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_637568798166616300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_637568798166616300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_637568798166616300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_637568798166616300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_637568798166616300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_637568798166616300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_637568798166616300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637568798166616300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637568798166616300" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637568798166616300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637568798166616300" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637568798166616300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_OperatingLeaseLiability_637568798166616300" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637568798166630537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiability_637568798166616300" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637568798166630537" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637568798166630537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637568798166630537" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637568798166630537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_637568798166606311" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637568798166630537" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>mrns-20210331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrns="http://www.marinuspharma.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrns-20210331.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9qSklwBu70CQBbrRqgCIeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xe6FgdUkT0W6DZbRuNQ59g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_9_23_2020_To_9_23_2020_4pfvEsABsU28FwAbvP4CKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <startDate>2020-09-23</startDate>
            <endDate>2020-09-23</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p3HF39Ap80yUDNAvRPhqUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oJu87ySZZki8kiQ1GgZDcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q90XYQ7tOkisnJxjUpL-ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AxRkO1I5G0qDl6t4aKuHoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__1HOy6MZR0e8GBW9z_KEVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LVfSiRHgy0mWRf270n3lEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LMklHntNS0KTgOI-HIEIZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_38j9McOA-0-YH6InNJKJ4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YoVSkI9ULUWZpDKnuk0EFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_8LfUPpiv40evSUbKT82rhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_XPMAdE0OMUeOyqAqZ3qvag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sebYK2miu0aqZYM6o8RohQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrns:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_vfbrhNgDVUi6DlCWD3nLsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RYRdkpHKOUS-exHXDlAIug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_4wMl9Q4G70GOJY3bS-fs4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrns:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_Sj-IYJqIT0uvP3_uuR6sEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VGad9KiNbkCwtKgt7DZ1aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_CTJ2VL88jESgyvVb6KfD6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_njBmuTxXb0KulNqEpHrpQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zOQDZ8Ya_keC_MZKml4WdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bG_5QgjxIkC2qi039sgXpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_StockOptionAndIncentivePlan2005Member_sjKwPS8R-k2wWxUVOhk1vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:StockOptionAndIncentivePlan2005Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlanEmployeeMember_pk1X2Uuu6kuHPbfxMPJLKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlanEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_Tlqw9BGm20WqLo6p9EcJFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YOD3KDe7RkmYKbUKW8SRfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlanEmployeeMember_caVUlUeydkqE7PHUeTsG9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlanEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_gLlExmIpREOOfxJPC2-Pbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_WbOyI-9dVEWarpASvcUfqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_i4ZJeDhk3U6qg2ej0yRhjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BRnhyVEI0ESba0YijHvmHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_yYSr99WKYE6jflmONGtLZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrns:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_XPNC2p02pUyKefB5bvQ_xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrns:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrns:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrns:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uY0NqY9x4UOmsA4sPTj80w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GIw8jfZogk2-5MB_FX3uBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_9f43HPsrZUqXrvBNmnWl-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_ZwEUgE2a10mD4z6DCHCsrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CertificatesOfDepositMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z1HxUQ7enE6srbvlBfnnog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CertificatesOfDepositMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_57Xm1ecNsEuUhzUcp-ldRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_KbsB3GMfAUq42-N8CF5g_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_1yiPQ20dfUWNVt0Z6jH0tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_QQZsn1a07kGp7D1O83thbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheBMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_ZmO_zJI8K06Yju3bXZvlvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoansTranche2Member_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_WxLVUu7A2kuoA3YQnOT7vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoansTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoansTranche1Member_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_OrcnVjZcjkCJd82NJIXdYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoansTranche1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="As_Of_9_23_2020_OiMX-o5boE2EQwMEi2ZK0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <instant>2020-09-23</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_PlanNameAxis_mrns_StockOptionAndIncentivePlan2005Member_pY1EQZSCQUasDgjSyWC4ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:StockOptionAndIncentivePlan2005Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_GCzbaEQkcUGyXqr_QnLvtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrns:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_-5H7uHTQeUmpUP0b5XFP-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_EtowpBGbYUOlW68H-Qhr0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6x5DJ-CH0kaeJKGdgTq8DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ISpIebOIi0K7bmbED0LKSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gL2saeIEhkKPbHdqHSO8XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0gArs46GskGjg-CwXqnRlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-8-0nnBWpUmAFY7t2su3eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__S1TL6asNEie8J964p41pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IzM8ejDq1U-vXqJ7UOOeDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjNZhWbkFkS38HEN4C5ekA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_2cQC38nN50yIRWLWCjpsrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_FpMZWQoGrEyhGmLadR_5Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_aw6tpevnx0S7VX16wF9x-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_oVLJcKieMkeJ0tQmMG3asQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_JVIEoiUCiEixZFqFpl2TMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_8zaVZ-69uEiVQSid1i2tuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mJOVLW9KpUmbnUt7bOmsLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ixflgqi17U--7GUSGs7m5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_sxnFk15oLESa5jxtU2OmMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qtmIWYk-lEaiK7KXwRoNrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_fWJfXvsKtk6Kfv55TO39uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_AEmW4zZq7kqttYoG44orKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4XykMpFDvkyUJxaaGlZIDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_9G2E0G-1K0CaojyNjXJupA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nU2_qSegwUeO8XJe6mN6gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7Cd3y9g6skeNkAsc9FaMAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_NjRPlVBuoU-719KqeaSsww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrns:BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_z1I9GUU03U6WTDF7U-xORg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-11</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_0C8_gqPMo0uWm48asEGVyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrns:TermLoanTrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-11</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mrns:OaktreeCapitalManagementLpCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-11</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_PIGm1dm3nUqea624wnjONw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrns:BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lPrWUD3wcUerfah8Cn28qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrns:BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oMWaBvb6M0CZ9X6c2Oqqrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6LQBITHZ60WRlNBE8j_w_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_14_2021_nqLk6j5gAUKPkNMDBhI2ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267813</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_tranche_vnw-gVYtlEWJf_vMJ-ObdA">
        <measure>mrns:tranche</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:TreasuryStockValue
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      id="Hidden_FrwVqWPd5Uu639TYjhsx3g"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValue
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      id="Hidden_k0sGbtc31ky9iG80YzL8RA"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_i4ZJeDhk3U6qg2ej0yRhjA"
      id="Hidden_dow7_ZuMpUWqCMzjx0ZHwQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_B53x9hAptUW-SvKVqd2NVQ_3_1">0001267813</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_wS24HH6aL0Kwhm-hZxhDxQ_4_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_UUvPAA5sJ0mn0Zh-4h5xEQ_5_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_IM7Eag56DUGIxWP0DuZGVQ_6_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_JzGgH3aovkC47l6TKzKU8w_7_1">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      id="Hidden_zvqnfLCJd0yr4jXmjicT5Q">us-gaap:OtherAccruedLiabilitiesNoncurrent us-gaap:AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      id="Hidden_mFAODsPqSk-Q7CVVsygbpQ">us-gaap:OtherAccruedLiabilitiesNoncurrent us-gaap:AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g"
      decimals="INF"
      id="Hidden_CcYeHKS1dEGZIBACVsWKZw"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4753</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA"
      decimals="INF"
      id="Hidden_BdERH6GTDk-WwMAmTfEUMQ"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4753</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_9_23_2020_To_9_23_2020_4pfvEsABsU28FwAbvP4CKg"
      decimals="2"
      id="Hidden_pGDrPi0GAkW2ail2SFXw3w"
      unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <mrns:DebtInstrumentRevenueRequirementConsecutiveEarningPeriod
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_z1I9GUU03U6WTDF7U-xORg"
      id="Hidden_6rtYHnKztUW0WBec3xybnQ">P6M</mrns:DebtInstrumentRevenueRequirementConsecutiveEarningPeriod>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_qP2K_NFYKk2exwU_56yaZQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_0FmRdi5Wh06sflP-FHFdgg">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_XVOXIQcdE0Sro70Es_f1iQ">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_BJH3fxJElEOh45vLju-vvA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_yueqAxkBbEyrBHaW-MNKNg">001-36576</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_ODMo6ovKrEifALrCnOxUDA">MARINUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_QSWaTUEBA0Kt_xJ7j8JWYw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_eDAR9ysKnkmrP05EJATmFw_1_2">20-0198082</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_v3WzqqSTG02UZqZjEfIQrA">5 Radnor Corporate Center, Suite 500</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_Vbjmpg8pqEifp1nvx_i6xw">100 Matsonford Rd</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_ziGiDqa9lkCtgpEoE-aEvw">Radnor</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_nZv3E8yUdkiCYBaLFuLeug">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_2k-r9KhfsEW3FhEwqeOL4g">19087</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_IXRuQpm5TU-1fPwfcGLtsA">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_Tul5p9PzOU2sKZSvdwQIdw">801-4670</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_vuOsnsW37Eu3fWmzNp6vbg_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_bcxKFJYFuESGnV4Xj6rNHw_2_2">MRNS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tc_jeM31ZsZgEqNxMeyT7AU1g_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_DJVNHl1sTECk3nNdZlHnBA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_uarIQYuV906jduao2EWdqQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_OkimuC54j0y6uPQOGZ0LJQ">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_jxJZNUUNYk6yR3cn9g2EBw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_r4AK3f8ERUCKZwV5D1KYkQ">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Narr_VQwTLkAUI0-HJ7Hbaq5hkQ">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_14_2021_nqLk6j5gAUKPkNMDBhI2ug"
      decimals="INF"
      id="Narr__Fky5Nksn0if7R-t6K8kAg"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">36633490</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_bCFr77N0U0CPwO_WFOjItQ_7_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">123472000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_FrGFdpjWdkOc_ihWNJzxHg_7_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">138509000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_LL8pEJfLGkaROhJAS9aiWQ_8_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1474000</us-gaap:ShortTermInvestments>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_VMprOfBg50CytytqJLcSOg_9_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2650000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_dj5FtzhDoEaUqibpEN7X6g_9_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1646000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_9xliDVjvYUGOG5Rlf1awjA_10_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">3676000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_75aaw6oSNkCKWimYrw_Snw_10_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">4638000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_8zobtrHcAk64-y6ceBs-UA_11_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">129798000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_ub7rwYtKW06xOpPQRBGvww_11_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">146267000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_mTlx4KtI5Ua1Z_n0wSOv8g_12_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1894000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_a2tFgIdE1k6rD2p0Owrxmg_12_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1945000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_UM-trd681UuS8JqW3puopw_13_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2167000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_ihe9QBgwAE6X_fbqcIl4VQ_13_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_oKds0bD3TkKOHqYC3KjeWw_14_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">133859000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_k_XCsERZX0Gq9i2GgfDXYA_14_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">150462000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_ErPcH8bRgkKhdpq_naIHJw_17_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">5167000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_VvD90Yebzk6HtZQYRCqszQ_17_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2211000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_9DTjM-hxMUq1iMWP-uXU6Q_18_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">10954000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_j2Am4pMapkS-mjc-gGxayQ_18_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">8518000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_i4xgUz0k0Ea5BgZUGJDiMw_19_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">16121000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_Gu2jW3Bn90-dGtq0LaX7ew_19_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">10729000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_zw7XnSbMCUOcrehZ841GwA_20_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2404000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_BTKJqIoC00C9rJruBXmvVw_20_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2534000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_euA4bAq_PkeTQmQr6K_Aow_21_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">18525000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_l4MVI1w_ZEejumf5Lp93Xg_21_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">13263000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g"
      decimals="3"
      id="Narr_RbL98xfqSkCpj-YjfgyQAw"
      unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA"
      decimals="3"
      id="Narr_cMXVx0mJeE6VjLi8apRMLw"
      unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g"
      decimals="INF"
      id="Narr_K_xJ5I4UZECsX77shOyVHw"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA"
      decimals="INF"
      id="Narr_vgc1JamcO0CDtOWhAb3X-g"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g"
      decimals="INF"
      id="Narr_lQfB-cwd4UCm6k8arDPqWg"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4753</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_DDE5yEUdkkethNHOwA8iPA"
      decimals="INF"
      id="Narr_BdNNYuY4WkqIskMr0KR7gQ"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4753</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_iZtBQrxVLUSEYVfvv1NhNg_23_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">4469000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_mQQnpmV150SlKnPnI_E8kg_23_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">4469000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="INF"
      id="Narr_oFB1EpncoUiNhzs4szuCgw"
      unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="INF"
      id="Narr_aBT-Aq7BcU-ZvIEnQKL-bA"
      unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="INF"
      id="Narr_jTsY0EJXhkul8IRCmpMc-A"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="INF"
      id="Narr_1fNA0fk8VEi9w9S4nTUiZw"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="INF"
      id="Narr_m9JLJkRB2UCvEg7E3qPrfg"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">36640797</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="INF"
      id="Narr_ybwR8D92H0KXtm39WFQIAg"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">36633490</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="INF"
      id="Narr_PMgrC7zv4k22cgA1JXEV9g"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">36585767</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="INF"
      id="Narr_LmZ8tyIvnEuDmcNyHUVoyg"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">36578400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc__hrjIsdBxkWv6oP01xGptw_24_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">37000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_sS55s-LMFUCM1s9DXQnUCQ_24_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">37000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_nFoQ2XDHYUGBz6CupFTzeA_25_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">449898000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_H2tOmowMbEOFwuD-lNdzZA_25_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">444622000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="INF"
      id="Narr_yeibdIGBvUeB9aXtUXmLYw"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">7307</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="INF"
      id="Narr_i3wzAMg8h0eYHa-3aFI9xw"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">7307</us-gaap:TreasuryStockShares>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_KQ9Q86mL8kCGZ3eREN2TCQ_27_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-339070000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_0CF39gn3Okq3LDz7x5quaQ_27_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-311929000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_Xv8eNnpwpkSW2e2HOE8VnA_28_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">115334000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_fVTt3u0LFESvSulCRuZYtw_28_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">137199000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_R5F4Pw9lTUe9EaR8tT86JQ_29_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">133859000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_ih42WeCUzUqnAaAMcY1bwg_29_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">150462000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_CNux-Uwxfky68MOYpK6fIw_4_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1806000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_0ZXpxWAVHkS1p2eo9BeMsg_6_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">18591000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_FtBS4GMX1USZdIIreQ-KAg_6_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">15004000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_YrSnmvwcrU6-ig7QW5PrxA_7_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">10376000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_Fuak0ENeBUyKZhu9ekfo-Q_7_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">3850000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_aLPZpfa7cUS61c6BA_OlWQ_8_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-27161000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_-xwpQncX3EOjSmsLNocwjA_8_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-18854000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_8W-ah3Q_EkmT1ey2Q2NL7A_9_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">24000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_XO1QPRKx8U-4t2WfWfoudA_9_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">222000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_SeXjiwiQYUCZfK7HGvm1ug_10_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_KuKo6XqcQkWH7edIW0aMlQ_10_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-40000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_VPfQwRh2fEOi11PW2fZv4Q_11_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-27141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_JMGrplYhr0e8kxu6ZqBgKw_11_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-18672000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_F1_M7FbCDk-jqzG_libBZQ_12_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">8880000</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc__Te9__wMqEWe__50cDIAtg_13_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-27141000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_oDuiMrCOW06IkmLVe3TIsw_13_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-27552000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="2"
      id="Tc_FAPXelY2fUSQqGusWT6kOQ_15_3"
      unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="2"
      id="Tc_eo-ldEjdj0e07T5wqBKe-w_15_6"
      unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">-1.27</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="0"
      id="Tc_xaFc8nlc-EWioRVIAxwWlA_16_3"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">36599701</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="0"
      id="Tc_fCf7ahiQ0kCbr0I4Lcs-xA_16_6"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">21665461</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_m4oIbA3acEq7ihnt1yGIaw_5_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-27141000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_8pqeQbMaaU-j1QM_oU8R6Q_5_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-18672000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_8x3JuqKSiUyn6xAELaAmBg_7_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">85000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_c3Q9ZYOL-0KiEYmjygVMqg_7_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">84000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_Dwce8ZH8ZU2LlsuPUk6T4g_8_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">5035000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_ZM94s1ar6kO1NZ9UXmGUog_8_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1876000</us-gaap:ShareBasedCompensation>
    <mrns:NonCashOperatingLeaseExpenseOperatingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_GN0IU57MvEWCwW4eg_tCEg_9_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">73000</mrns:NonCashOperatingLeaseExpenseOperatingActivities>
    <mrns:NonCashOperatingLeaseExpenseOperatingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_RqnEeOzJRk2gMCIxy5Remw_9_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">62000</mrns:NonCashOperatingLeaseExpenseOperatingActivities>
    <mrns:InterestExpenseIncomeOnLeaseLiabilities
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_IJ_wBDfCZkyTMo5oVdcXBQ_10_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">82000</mrns:InterestExpenseIncomeOnLeaseLiabilities>
    <mrns:InterestExpenseIncomeOnLeaseLiabilities
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_Jk3lnALohk674sPyCwnEMg_10_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">95000</mrns:InterestExpenseIncomeOnLeaseLiabilities>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_Tz4Xx8p7Bk6owdP4wlueQQ_11_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-1000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_LKhHiLYrvEq4U5EKewbG6A_13_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-366000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_bIzR55ml7Uq50jnw2SQ3ag_13_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-258000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_PmBfOcwSQUW3eKEk7qQRaQ_14_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">5325000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_hcz2u2A5eUOYMZZzbWbgJQ_14_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2259000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_BbweGBsfjU2QTZ7NnQRTYQ_15_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-16175000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_ppXal1VfL0G0LjKnKI9kog_15_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-14037000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_Q6UzVFOheUKk_E-ObBB7sQ_17_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1474000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_-BioWM3nf0mvK8jX16ytkw_17_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1737000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_lptuMEaWmUyUYWmp-Yy96w_18_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">8433000</us-gaap:PaymentsToAcquireInvestments>
    <mrns:PaymentsForDepositAndPropertyAndEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_gkcsKqH7I0yXzxcM4oQ5YA_19_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">404000</mrns:PaymentsForDepositAndPropertyAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_hc2Yiug5TEGdaVfh3OC4wg_20_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">28000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_LFR652UUokKmzoao2Chd0Q_20_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc__7Bbajc8bE66_BNzY2TA9A_21_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1042000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_xZIBFrNgOkuPL8SN-Pg52w_21_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-6697000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_Xgtld55OZUWgvJabFE3Ojg_23_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">244000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_HG3HVpX53Eu8jaCo3CJKUw_23_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">312000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_z-kaJCht9ku8_sbLecHHWw_24_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">148000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_JlY5dYrit0C7jKLLpT8e9w_24_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">195000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_gKLRT-CERk62__LJeETrlw_25_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">96000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_lIbEAnXH6kC088Rjtr7RBg_25_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">117000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_cRS7h6wERk2s6JKSMgdWyQ_26_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-15037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_XlCwApaLEkiBzN81YRZFnA_26_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-20617000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_JUFlKf3dCkeQN-cqYyL9EQ_27_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">138509000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_EtowpBGbYUOlW68H-Qhr0g"
      decimals="-3"
      id="Tc_wCCHoPcq-0iMzGJdOymiKQ_27_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">90943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_vwfb7rJGaUe8_1pl0OioJA_28_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">123472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2020_-5H7uHTQeUmpUP0b5XFP-A"
      decimals="-3"
      id="Tc_SFzjmIZm0EiX4rCP6RGBpQ_28_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">70326000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bG_5QgjxIkC2qi039sgXpg"
      decimals="-3"
      id="Tc_dF3crfRJeUa-Ct7aFH-_Hg_5_7"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">21625088000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bG_5QgjxIkC2qi039sgXpg"
      decimals="-3"
      id="Tc_8tuJyqPTHkOD973ZeX-K8A_5_10"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YoVSkI9ULUWZpDKnuk0EFw"
      decimals="-3"
      id="Tc_v_aafKq3DEKaVwEi3-0Kdw_5_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">295056000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zOQDZ8Ya_keC_MZKml4WdQ"
      decimals="-3"
      id="Tc_wIJncaDoM0GnjAM1e4YSLA_5_15"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">7307000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_38j9McOA-0-YH6InNJKJ4Q"
      decimals="-3"
      id="Tc_s78IAdrnNkiR9EHVmu-4LA_5_24"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-235574000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_EtowpBGbYUOlW68H-Qhr0g"
      decimals="-3"
      id="Tc_b6szLHUVDk275_bgvfwABg_5_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">59569000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6LQBITHZ60WRlNBE8j_w_g"
      decimals="-3"
      id="Tc_E8m2N96aN0WXIrSUJG_T1A_6_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1876000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_b3GkF-N1IUOmf2sDD1YHUA_6_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1876000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xe6FgdUkT0W6DZbRuNQ59g"
      decimals="-3"
      id="Tc_DVIsCMLFBUagDoikwFKbDw_7_7"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">59978000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6LQBITHZ60WRlNBE8j_w_g"
      decimals="-3"
      id="Tc_zMdGPP96AUGjGckdVgagEA_7_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">312000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_KucI-BbCC0yhcFGLPtFOJQ_7_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">312000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xe6FgdUkT0W6DZbRuNQ59g"
      decimals="-3"
      id="Tc_VA2vfrK3Wk23lbjvaxp78A_8_7"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">5250000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uY0NqY9x4UOmsA4sPTj80w"
      decimals="-3"
      id="Tc_QZPEVJSLq0q82piEBUpTqg_9_21"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">28000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_yDlCbORj70as59iH4DbeOQ_9_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">28000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <mrns:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6LQBITHZ60WRlNBE8j_w_g"
      decimals="-3"
      id="Tc_MEySj9EXBkC_A97XUDq9nw_10_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">8880000</mrns:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock>
    <mrns:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oMWaBvb6M0CZ9X6c2Oqqrw"
      decimals="-3"
      id="Tc_oiX89DSebEe_Ks-JdWmTMQ_10_24"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-8880000</mrns:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oMWaBvb6M0CZ9X6c2Oqqrw"
      decimals="-3"
      id="Tc_uu3KIwlLvEqJgxRLDx50lA_11_24"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-18672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-3"
      id="Tc_rvAalXez002MrlHpZ3B6qA_11_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-18672000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_njBmuTxXb0KulNqEpHrpQA"
      decimals="-3"
      id="Tc_O8kP-j94BkuUFgKIK-glGA_12_7"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">21690316000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_njBmuTxXb0KulNqEpHrpQA"
      decimals="-3"
      id="Tc_ZsrcZPmD1Ee6w7LPBKF_8w_12_10"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LVfSiRHgy0mWRf270n3lEg"
      decimals="-3"
      id="Tc_rs1a_-tutEOlyx9vsWuhRQ_12_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">306124000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_CTJ2VL88jESgyvVb6KfD6A"
      decimals="-3"
      id="Tc_jgl5tlso9UKx6F7c9SRPKA_12_15"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">7307000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LMklHntNS0KTgOI-HIEIZQ"
      decimals="-3"
      id="Tc_TP1bzcXG9EKst51Nmd3O9w_12_21"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__1HOy6MZR0e8GBW9z_KEVg"
      decimals="-3"
      id="Tc_c46pemDUl02buhm-j169tQ_12_24"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-263126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_-5H7uHTQeUmpUP0b5XFP-A"
      decimals="-3"
      id="Tc_SXF1zp_8M0Ch-LXUbxgYlQ_12_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">43113000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_4wMl9Q4G70GOJY3bS-fs4Q"
      decimals="-3"
      id="Tc__09iZnqdsECuEYh3alrZFg_14_2"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4753000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_4wMl9Q4G70GOJY3bS-fs4Q"
      decimals="-3"
      id="Tc_286nMANgTkCdg169Con2AQ_14_5"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">4469000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VGad9KiNbkCwtKgt7DZ1aQ"
      decimals="-3"
      id="Tc_XkKH0qFNh0SCdhIjSGwMlw_14_7"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">36585767000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VGad9KiNbkCwtKgt7DZ1aQ"
      decimals="-3"
      id="Tc_6moTdAYvekiuRfrxqT1A0A_14_10"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AxRkO1I5G0qDl6t4aKuHoA"
      decimals="-3"
      id="Tc_KYncWdqNdkWkHJGj7GpyHw_14_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">444622000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_Sj-IYJqIT0uvP3_uuR6sEQ"
      decimals="-3"
      id="Tc_D2sL0OYVaEa7IkM75BTmoQ_14_15"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">7307000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q90XYQ7tOkisnJxjUpL-ig"
      decimals="-3"
      id="Tc_6vlgUgX8bkiVaO53oXTzJg_14_24"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-311929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_eu7d1EXeBEqbmtumslZp8g_14_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">137199000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7Cd3y9g6skeNkAsc9FaMAA"
      decimals="-3"
      id="Tc_lPdYKV3Q9E6E8aQl4KexYw_15_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">5035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_-YCln3PlLUKf2ZzAXvnhCA_15_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">5035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9qSklwBu70CQBbrRqgCIeQ"
      decimals="-3"
      id="Tc_oYr7Zdwo9EKEvvQ5fEnNNw_16_7"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">55030000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7Cd3y9g6skeNkAsc9FaMAA"
      decimals="-3"
      id="Tc_fjvXEQSWsUqeV7l6QkeFrA_16_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">244000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_GUL_rPM2jkWJ_LjxU7N-rw_16_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">244000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7Cd3y9g6skeNkAsc9FaMAA"
      decimals="-3"
      id="Tc_OXVZyvohfkiH2QOhBfmckw_17_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_seA9Fshiw0-disWREKbY_A_17_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GIw8jfZogk2-5MB_FX3uBg"
      decimals="-3"
      id="Tc_rGrwBViUf0uPQdYd726NLw_18_24"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-27141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-3"
      id="Tc_ZsQ82YWhDkCB77td-18jig_18_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-27141000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sebYK2miu0aqZYM6o8RohQ"
      decimals="-3"
      id="Tc_lacfZGqNMU-jSRsHXEolKA_19_2"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4753000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sebYK2miu0aqZYM6o8RohQ"
      decimals="-3"
      id="Tc_m_FWmUNl90yY5dwdOTXLPA_19_5"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">4469000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RYRdkpHKOUS-exHXDlAIug"
      decimals="-3"
      id="Tc_IWouHfpvSkuD06LnMpnHOA_19_7"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">36640797000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RYRdkpHKOUS-exHXDlAIug"
      decimals="-3"
      id="Tc_fOqLIe9F2k26UzzEt7f8Uw_19_10"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oJu87ySZZki8kiQ1GgZDcw"
      decimals="-3"
      id="Tc_ZVwWh4nexECFCvIfeZDtkg_19_13"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">449898000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_vfbrhNgDVUi6DlCWD3nLsg"
      decimals="-3"
      id="Tc_Hmg37uRwmEyTun83RYwbkw_19_15"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">7307000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p3HF39Ap80yUDNAvRPhqUQ"
      decimals="-3"
      id="Tc_hSajshnwdU6EB05EJhNg1A_19_24"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-339070000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_QRzx8BMnXk2EcJAmO8YDRA_19_27"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">115334000</us-gaap:StockholdersEquity>
    <mrns:BusinessDescriptionAndLiquidityTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_IUwT6vGKvkij8bzJCbURtw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Description of the Business and Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We are a clinical stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Our clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABA&lt;sub style="font-size:7.5pt;vertical-align:sub;"&gt;A&lt;/sub&gt;&#160;that is being developed in formulations for two different routes of administration: intravenous (IV)&#160;and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. The different formulations are intended to maximize potential therapeutic applications of ganaxolone for adult and pediatric patient populations, in both acute and chronic care, and for both in-patient and self-administered settings. Ganaxolone acts at both synaptic and extrasynaptic GABA&lt;sub style="font-size:7.5pt;vertical-align:sub;"&gt;A&lt;/sub&gt;&#160;receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus was declared a pandemic by the World Health Organization in March 2020 and has spread to nearly every country in the world, including the United States (U.S.). Efforts to contain the spread of COVID-19 have intensified and many countries, including the U.S., have implemented severe travel restrictions, business shutdowns and social distancing measures that have impacted clinical development through supply chain shortages and clinical trial enrollment difficulties as hospitals reduce and redeploy staff, divert resources to patients suffering from COVID-19 and limit hospital access for non-patients. The pandemic poses the risk that we, our employees, contractors, suppliers, or other partners may be prevented from conducting normal business activities for an indefinite period of time, including those due to shutdowns that may be requested or mandated by governmental authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The continued global spread of COVID-19 has impacted our operations but did not have a material impact on our business, operating results, financial condition or cash flows as of and for the three months ended March 31, 2021. For example, several of our Phase 1 trials of oral ganaxolone to support the development of CDD have experienced delays in enrollment due to COVID-19; however we do not expect these delays to impact our ability to file an NDA. Further, i&lt;span style="white-space:pre-wrap;"&gt;n response to COVID-19, for our ongoing clinical trials, we have implemented multiple measures consistent with the U.S. Food and Drug Administration&#x2019;s guidance on the conduct of clinical trials of medical products during the COVID-19 pandemic, including implementing remote site monitoring and remote visits using telemedicine where needed. However, COVID-19 may still adversely impact our clinical trials.  For example, our Phase 3 clinical trial in RSE is conducted in hospitals and resources related to the COVID-19 outbreak may divert staffing in hospitals, taking resources away from our clinical trial.  Our ganaxolone clinical trials in the outpatient setting may be negatively impacted if patients and their caregivers do not want to participate in a clinical trial while COVID-19 outbreaks continue. Although operations have not been materially affected by the COVID-19 pandemic as of and for the three months ended March 31, 2021, we are unable to predict the impact that COVID-19 will have in the future on our business, financial position, operating results and cash flows due to numerous uncertainties. The duration and severity of the pandemic and its long-term impact on our business are uncertain at this time, and our ability to raise sufficient additional financing depends on many factors beyond our control, including the current volatility in the capital markets as a result of the COVID-19 pandemic.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We have not generated any product revenues and have incurred operating losses since inception, including losses of $27.1 million for the three months ended March 31, 2021. There is no assurance that profitable operations will ever be achieved, and if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, if approved, and commercialization of our product candidates will require significant additional financing.   Our accumulated deficit as of March 31, 2021 was $339.1 million and we expect to incur substantial losses in future periods.  We plan to finance our future operations with a combination of proceeds from the issuance of equity securities, the issuance of debt, government funding, collaborations, licensing transactions and other commercial transactions and revenues from future product sales, if any. We have not generated positive cash flows from operations, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;and there are no assurances that we will be successful in obtaining an adequate level of financing for the development and, if approved, commercialization of our product candidates.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 11, 2021 (the Closing Date), we entered into a Credit Agreement and Guaranty (as amended by that certain letter agreement on May 17, 2021, the Credit Agreement) with Oaktree Fund Administration, LLC, as administrative agent and the lenders party thereto that provides for a five-year senior secured term loan facility in an aggregate original principal amount of up to $125.0 million available to us in five tranches as follows (collectively, the Term Loans):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$15.0 million of tranche A-1 term loans advanced on the Closing Date. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million of tranche A-2 term loans subject to written acceptance by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) filing relating to the use of ganaxolone in the treatment of CDKL5 deficiency disorder (CDD).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million of tranche B term loans subject to receipt of written approval from the FDA of an NDA permitting the marketing of ganaxolone in interstate commerce in the United States to treat CDD (the FDA Approval).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million of tranche C term loans subject to receipt of the FDA Approval and the completion of one or more financings, including through the issuance of common stock, convertible debt, subordinated debt, a synthetic royalty or a sublicense in which we receive gross proceeds in an aggregate amount of at least &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$40.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million and net proceeds in an aggregate amount of at least &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$36.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million. In addition, the availability of this tranche is subject to either our current Phase 3 trial in RSE or a Phase 3 trial in tuberous sclerosis complex (TSC) achieving statistical significance (p value &amp;lt; 0.05) across all primary endpoints and ganaxolone must be generally well tolerated, with a safety profile generally consistent with previous clinical trials.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million of tranche D term loans subject to receipt of the FDA Approval and us earning at least &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million in net product revenue in the United States for a period of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_6rtYHnKztUW0WBec3xybnQ;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; consecutive months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;The Term Loans will bear interest at a fixed per annum rate (subject to increase during an event of default) of 11.50% and are scheduled to mature on the fifth anniversary of the Closing Date (the Maturity Date). In addition, at the time of funding of any tranche of the Term Loans, we are required to pay an upfront fee of 2.0% of the aggregate principal amount being funded. We are required to make quarterly interest payments until the Maturity Date. We are also required to make principal payments, which are payable in quarterly installments beginning on the last day of the first quarter ending after the third anniversary of the Closing Date in an amount equal to 5.0% of the aggregate amount of the Term Loans outstanding on the date of the first such quarterly principal payment and continuing until the Maturity Date, on which date all outstanding Term Loans and other amounts owed under the Credit Agreement will be required to be paid in full. A commitment fee of 75 basis points per annum will accrue on each of the tranche B, C and D commitments for the period beginning 120 days after the funding date of the tranche A-2 term loans until the applicable tranche is either funded or terminated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;In September 2020, we entered into a contract (BARDA Contract) with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response. Under the BARDA Contract, we receive&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;d&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; an award of up to an estimated &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$51&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; million for development of IV-administered ganaxolone for the treatment of refractory status epilepticus (RSE). &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;The BARDA Contract provides for &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;f&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;unding &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;to &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;include support&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;on a cost-sharing basis&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;, the &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;completion of a Phase 3 clinical trial of IV-administered ganaxolone in patients with RSE &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;(our &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;Phase 3 clinical trial evaluating IV &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;ganaxolone for the treatment of RSE &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;(RAISE Trial)) &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;, funding of pre-clinical studies to &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;provide support &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;that IV-administered &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;ganaxolone &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;could be &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;an effective treatment for RSE due to chemical nerve gas agent exposure, and funding of certain manufacturing scale-up and regulatory activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The BARDA Contract consists of an approximately two-year base period-during which BARDA will provide approximately $21 million of funding for the RAISE Trial on a cost share basis and funding of additional preclinical studies of ganaxolone in nerve agent exposure models. Following successful completion of the RAISE Trial and preclinical studies in the base period, the BARDA Contract provides for approximately $30 million of additional BARDA funding for three options in support of manufacturing, supply chain, clinical, regulatory and toxicology activities. Under the BARDA Contract, we will be responsible for cost sharing in the amount of approximately $33 million and BARDA will be responsible for approximately $51 million, if all development options are completed. The contract period-of-performance (base period plus option exercises) is up to approximately five years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the closing of an equity financing in December 2020, we issued a total of 5,000,000 shares of common stock in an underwritten public offering resulting in aggregate net proceeds, after underwriting discounts and commissions in the public offering and other estimated offering expenses, of $64.9 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;In connection with the closing of an equity financing in June 2020, we issued a total of 4,600,000 shares of common stock in an underwritten public offering resulting in aggregate net proceeds, after underwriting discounts and commissions in the public offering and other estimated offering expenses, of $42.9 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;We believe that our cash and cash equivalents balances as of March 31, 2021, including the net upfront proceeds received in May 2021 from our Credit Agreement, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reverse stock split&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On September 23, 2020, we effected a &lt;span style="-sec-ix-hidden:Hidden_pGDrPi0GAkW2ail2SFXw3w;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;1&lt;/span&gt;&lt;/span&gt;-for-4 reverse split of shares of our common stock (Reverse Split), as approved by our board of directors and stockholders. The par value per share of our common stock was not adjusted as a result of the Reverse Split, and our authorized shares of common stock was reduced to 150,000,000&lt;span style="white-space:pre-wrap;"&gt;.  All of the share and per share amounts included in the accompanying financial statements and these notes have been adjusted to reflect the Reverse Split&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrns:BusinessDescriptionAndLiquidityTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-5"
      id="Narr_K9tNWKi26EaeZIshBH_TFg"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-27100000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-5"
      id="Narr_7yCDlLuCkUSJoBCay4gNXQ"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">-339100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g"
      id="Narr_iqnukyZBtUepuUxI6Y_n4Q">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_KbsB3GMfAUq42-N8CF5g_g"
      decimals="-5"
      id="Narr_6QUD_RIVDkWAqBZP5ipkfA"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">125000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <mrns:NumberOfTranches
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g"
      decimals="INF"
      id="Narr_jygqPm6P5kaxjO2fHH-iCQ"
      unitRef="Unit_Standard_tranche_vnw-gVYtlEWJf_vMJ-ObdA">5</mrns:NumberOfTranches>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoansTranche1Member_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_OrcnVjZcjkCJd82NJIXdYw"
      decimals="-5"
      id="Narr_zEBbHJHSJUa5SvirRhyTOw"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoansTranche2Member_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_WxLVUu7A2kuoA3YQnOT7vg"
      decimals="-5"
      id="Narr_CblPLfMIsEeAfAHwznqj0w"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheBMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_ZmO_zJI8K06Yju3bXZvlvg"
      decimals="-5"
      id="Narr_C179B5_tn0-e31m8BhQ8ew"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_QQZsn1a07kGp7D1O83thbw"
      decimals="-5"
      id="Narr_qPFyitpXxUeCEX75OPYYGA"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">25000000.0</us-gaap:DebtInstrumentFaceAmount>
    <mrns:DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_0C8_gqPMo0uWm48asEGVyA"
      decimals="-5"
      id="Narr_jlMKPs5ohEONtnIFXsvn0Q"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">40000000.0</mrns:DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum>
    <mrns:DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheCMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_0C8_gqPMo0uWm48asEGVyA"
      decimals="-6"
      id="Narr_CureKLKPl0a9J_dtokSgRA"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">36000000.0</mrns:DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_1yiPQ20dfUWNVt0Z6jH0tw"
      decimals="-5"
      id="Narr_ry_QrNwV1U2PKjtdZ4DoUg"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">25000000.0</us-gaap:DebtInstrumentFaceAmount>
    <mrns:DebtInstrumentFundingAvailableNetProductRevenueMinimum
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_DebtInstrumentAxis_mrns_TermLoanTrancheDMember_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_z1I9GUU03U6WTDF7U-xORg"
      decimals="-6"
      id="Narr_yXUk6isQ6U2Tl5pDyJQ0Gw"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">50000000</mrns:DebtInstrumentFundingAvailableNetProductRevenueMinimum>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_KbsB3GMfAUq42-N8CF5g_g"
      decimals="4"
      id="Narr_L1Gp5yV70EiqSvPjF7yVXA"
      unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw">0.1150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <mrns:DebtInstrumentUpfrontFeesPercentage
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g"
      decimals="3"
      id="Narr_rOWyNrQXg0O5aJWl_6_YIA"
      unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw">0.020</mrns:DebtInstrumentUpfrontFeesPercentage>
    <mrns:DebtInstrumentPeriodicPaymentPrincipalPercentage
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g"
      decimals="3"
      id="Narr_veP1GQ_nZ0Kl0zC802IAyA"
      unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw">0.050</mrns:DebtInstrumentPeriodicPaymentPrincipalPercentage>
    <mrns:DebtInstrumentCommitmentFee
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g"
      decimals="4"
      id="Narr_J4VPiGRxJEm7k-FLJE4-3w"
      unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw">0.0075</mrns:DebtInstrumentCommitmentFee>
    <mrns:DebtInstrumentCommitmentFeeAccrualPeriod
      contextRef="Duration_5_11_2021_To_5_11_2021_us-gaap_LineOfCreditFacilityAxis_mrns_OaktreeCapitalManagementLpCreditAgreementMember_mZweb2isr0irVzuX_5vW-g"
      id="Narr_OcrNnxvV4E2vgqMVAFud4w">P120D</mrns:DebtInstrumentCommitmentFeeAccrualPeriod>
    <mrns:MaximumAwardAvailableUnderContract
      contextRef="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_NjRPlVBuoU-719KqeaSsww"
      decimals="-6"
      id="Narr_XtIrRwzfMUi0r9Zq-SPf0Q"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">51000000</mrns:MaximumAwardAvailableUnderContract>
    <mrns:ContractBasePeriod
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_PIGm1dm3nUqea624wnjONw"
      id="Narr_vJFyZa34-0Oo9QUeGD0zwA">P2Y</mrns:ContractBasePeriod>
    <mrns:ContractFundingProvidedDuringBasePeriod
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-6"
      id="Narr_-40Nw_hdsk6bzBJNGqQp3w"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">21000000</mrns:ContractFundingProvidedDuringBasePeriod>
    <mrns:ContractAdditionalFundingToBeProvidedFollowingBasePeriod
      contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lPrWUD3wcUerfah8Cn28qQ"
      decimals="-6"
      id="Narr_rFOp4Gw8Y0-sKlyQLRILfw"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">30000000</mrns:ContractAdditionalFundingToBeProvidedFollowingBasePeriod>
    <mrns:ContractCostSharingAmount
      contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lPrWUD3wcUerfah8Cn28qQ"
      decimals="-6"
      id="Narr_EWeL9rc_xk6EeFjBf6l4dg"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">33000000</mrns:ContractCostSharingAmount>
    <mrns:ContractCostSharingAmountCounterparty
      contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_lPrWUD3wcUerfah8Cn28qQ"
      decimals="-6"
      id="Narr_VkZHTTPmXUKZ90DTPfcjoA"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">51000000</mrns:ContractCostSharingAmountCounterparty>
    <mrns:ContractPeriodOfPerformance
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember_PIGm1dm3nUqea624wnjONw"
      id="Narr_LFEFP_p-LUKnHhJI7MxZ6g">P5Y</mrns:ContractPeriodOfPerformance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_yYSr99WKYE6jflmONGtLZg"
      decimals="0"
      id="Narr_YCHxMOV_W0qbnVz44xYuvA"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_10_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_yYSr99WKYE6jflmONGtLZg"
      decimals="-5"
      id="Narr_O43haOvfykeRmZlSFmy79w"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">64900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_XPNC2p02pUyKefB5bvQ_xQ"
      decimals="0"
      id="Narr_hIFlLO6TPUyHqStKHJqVLA"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrns_PublicOfferingMember_XPNC2p02pUyKefB5bvQ_xQ"
      decimals="-5"
      id="Narr_Ka3nY5NDUE2FtZ4VWunocQ"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">42900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_23_2020_OiMX-o5boE2EQwMEi2ZK0w"
      decimals="INF"
      id="Narr__fU8kTXKD0CXqygcvISthg"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_sAmFP7aQ_E-aZJ1cxZwrfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of Marinus Pharmaceuticals, Inc. (a Delaware corporation) as well as the accounts of Marinus Pharmaceuticals Emerald Limited (an Ireland company incorporated in February 2021), a wholly owned subsidiary requiring consolidation. Marinus Pharmaceuticals Emerald Limited serves as a corporate presence in the European Union for regulatory purposes. The unaudited interim consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the U.S. (GAAP) for annual financial statements. In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of our financial position and results of operations and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2020 and accompanying notes thereto included in our annual report on Form&#160;10-K filed with the SEC on March 9, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Federal Contract Revenue&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="white-space:pre-wrap;"&gt;We recognize federal contract revenue from the BARDA Contract in the period in which the allowable research and development expenses are incurred, and receivables associated with this revenue are recorded as federal contract revenue receivable on our interim consolidated balance sheets.  This revenue is not within the scope of Accounting Standards Codification (ASC) 606 &#x2013; Revenue from contracts with customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_VhCSYLLJGk-h1l6yYZKy4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of Marinus Pharmaceuticals, Inc. (a Delaware corporation) as well as the accounts of Marinus Pharmaceuticals Emerald Limited (an Ireland company incorporated in February 2021), a wholly owned subsidiary requiring consolidation. Marinus Pharmaceuticals Emerald Limited serves as a corporate presence in the European Union for regulatory purposes. The unaudited interim consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the U.S. (GAAP) for annual financial statements. In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of our financial position and results of operations and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2020 and accompanying notes thereto included in our annual report on Form&#160;10-K filed with the SEC on March 9, 2021.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_zHDPI6JllkO-ALImKk0AyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_BCaRHlroFUCe50dmo2J5mQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Federal Contract Revenue&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="white-space:pre-wrap;"&gt;We recognize federal contract revenue from the BARDA Contract in the period in which the allowable research and development expenses are incurred, and receivables associated with this revenue are recorded as federal contract revenue receivable on our interim consolidated balance sheets.  This revenue is not within the scope of Accounting Standards Codification (ASC) 606 &#x2013; Revenue from contracts with customers.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_B6dx9oHMI0SNPa269Z1TLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value hierarchy is broken down into three levels based on the source of inputs as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Level&#160;1 &#x2014; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Level&#160;2 &#x2014; Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Level&#160;3 &#x2014; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122,210&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122,210&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138,509&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138,509&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139,983&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139,983&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_i8GJYDhwZ0G19Ka3pSJs0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122,210&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122,210&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138,509&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138,509&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139,983&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 139,983&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6x5DJ-CH0kaeJKGdgTq8DA"
      decimals="-3"
      id="Tc_Bdkw3hwpJkCR643WUttP5A_4_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">122210000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ISpIebOIi0K7bmbED0LKSg"
      decimals="-3"
      id="Tc_kDpr_jT1g0WCuMZ2DMriFw_4_12"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">122210000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_3_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-8-0nnBWpUmAFY7t2su3eg"
      decimals="-3"
      id="Tc_o57FWSHAikajpZK0mirFOA_5_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">122210000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__S1TL6asNEie8J964p41pg"
      decimals="-3"
      id="Tc_5Yu2U8mPCUugn0TNmkX69A_5_12"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">122210000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gL2saeIEhkKPbHdqHSO8XQ"
      decimals="-3"
      id="Tc_K18Rs0-HkU63XAKwHFW_bA_8_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">138509000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0gArs46GskGjg-CwXqnRlQ"
      decimals="-3"
      id="Tc_ywoZYHZznUqVnsP9uzr3cg_8_12"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">138509000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CertificatesOfDepositMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z1HxUQ7enE6srbvlBfnnog"
      decimals="-3"
      id="Tc_YOhdb3yQTECGrrAQ4DYgeA_9_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1474000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CertificatesOfDepositMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_57Xm1ecNsEuUhzUcp-ldRA"
      decimals="-3"
      id="Tc_DBeBoj80R0-fcsYbe8pZhg_9_12"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1474000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IzM8ejDq1U-vXqJ7UOOeDw"
      decimals="-3"
      id="Tc_9xBahyPuw0GnzM5yLl-IWQ_10_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">139983000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjNZhWbkFkS38HEN4C5ekA"
      decimals="-3"
      id="Tc_--mUzuvfwkOSmQXjBFge9g_10_12"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">139983000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_zeeW9s0jxUy0nttFO_HwPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,533&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,097&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Clinical trials and drug development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,158&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 927&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 510&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 532&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_QzuOFaDz0EiTKsFN7JnK1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,533&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,097&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Clinical trials and drug development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,158&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 927&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 510&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 532&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_Bx9mMfGowUyv2mc-KzssLw_3_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2533000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_bfNuG5uyfEqRsiDfDAQlVg_3_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">4097000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mrns:ClinicalTrialsAndDrugDevelopmentCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_EVe5uPSkX02DiqG55uyPrg_4_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">6645000</mrns:ClinicalTrialsAndDrugDevelopmentCurrent>
    <mrns:ClinicalTrialsAndDrugDevelopmentCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_dkLqOeEoskqHkT1WtbzI8g_4_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2452000</mrns:ClinicalTrialsAndDrugDevelopmentCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_Qmelyphzf0StP9SxGAvV7A_5_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1158000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_YWF22-yvJUGUOcppsTzOFA_5_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">927000</us-gaap:AccruedProfessionalFeesCurrent>
    <mrns:LeaseLiabilityShortTerm
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc__87lCCoss06A4lZ0GYs0Ow_6_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">519000</mrns:LeaseLiabilityShortTerm>
    <mrns:LeaseLiabilityShortTerm
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_O-qwZEKb2UuTL66r9qHA1g_6_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">510000</mrns:LeaseLiabilityShortTerm>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_bJYUlPrsLUmszglJbQkyDQ_7_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">99000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_lIQuCBkte0KCrfpO_o1-3w_7_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">532000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_5VpHm7lOLU2e12V3qmlrhg_8_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">10954000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-3"
      id="Tc_GsvNzuO8f0S37mlvwKpU4w_8_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">8518000</us-gaap:AccruedLiabilitiesCurrent>
    <mrns:InvestmentsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_SXum22ruxU-X9RJT8mM_Ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We did not have any investments as of March 31, 2021. As of December 31, 2020, our investments consisted of certificates of deposit with various financial institutions with original maturities of six to nine months.&#160;&#160;Investments are classified as short- or long-term investments on our balance sheets based on original maturity. Certificates of deposits were classified as held-to-maturity and were recorded at amortized cost, which approximated fair value.&#160; &lt;span style="color:#222222;"&gt;We have never experienced a credit loss on the principal or interest receivable of our cash equivalents or short-term investments.&#160;&lt;/span&gt;&lt;span style="color:#222222;white-space:pre-wrap;"&gt; Our certificates of deposit are each individually and fully insured by the federal Depsot Insurance Company (FDIC).  Accordingly, we did not record any allowance for potential credit losses as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrns:InvestmentsDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_Ra8wnd6sBk2Dp9QNkKvA-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Loss Per Share of Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. These potentially dilutive securities are more fully described in Note&#160;7, and summarized in the table below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 950,600&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,436,778&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,264,041&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,409,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,269,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_9wyFyUBGmUWt9_8LE2LDAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 950,600&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,436,778&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,264,041&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,409,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,269,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_aw6tpevnx0S7VX16wF9x-Q"
      decimals="INF"
      id="Tc_TY5x_1mTNEGBlE23F9J8Nw_3_2"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">950600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_8zaVZ-69uEiVQSid1i2tuQ"
      decimals="INF"
      id="Tc_kdQbfeGVAESLjp6P7HQ1XQ_3_4"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_FpMZWQoGrEyhGmLadR_5Fw"
      decimals="INF"
      id="Tc__lP5L8rpC0y235Pzcff53g_4_2"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">22000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_JVIEoiUCiEixZFqFpl2TMA"
      decimals="INF"
      id="Tc_H8u9S7-dIE2XQWCLTS42mg_4_4"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">5250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_2cQC38nN50yIRWLWCjpsrA"
      decimals="INF"
      id="Tc_OsAPFP57IEim1mjNZTkYQQ_5_2"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4436778</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_oVLJcKieMkeJ0tQmMG3asQ"
      decimals="INF"
      id="Tc_mr2F3ZJkd0a_sfdMOX_1Dw_5_4"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">3264041</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="INF"
      id="Tc_rZXbzWKGYUmpVbbvlA3cNA_6_2"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">5409378</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="INF"
      id="Tc_ZN5OKD9S0U69t69Wv5XThw_6_4"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">9269291</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_GeRfjbyTrE6TAqPuidnWmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In 2005, we adopted the 2005 Stock Option and Incentive Plan (2005 Plan) that authorizes us to grant stock options, restricted stock and other equity-based awards. As of March 31, 2021, 6,565&lt;span style="white-space:pre-wrap;"&gt; options to purchase shares of common stock were outstanding pursuant to grants in connection with the 2005 Plan.  &lt;/span&gt;No&lt;span style="white-space:pre-wrap;"&gt; additional shares are available for issuance under the 2005 Plan.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In August 2014, we adopted our 2014 Equity Incentive Plan, most recently amended in May 2020 (2014 Plan), that authorizes us to grant stock options, restricted stock, and other equity-based awards, subject to adjustment in accordance with the 2014 Plan.  The amount, terms of grants, and exercisability provisions are determined and set by our board of directors.  As of March 31, 2021, &lt;/span&gt;3,386,335 options to purchase shares of common stock were outstanding pursuant to grants in connection with the 2014 Plan, and 646,221 shares of common stock were available for future issuance.&lt;span style="white-space:pre-wrap;"&gt; The amount, terms of grants, and exercisability provisions are determined and set by our board of directors.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;There were 4,436,778 stock options outstanding as of March 31, 2021 at a weighted-average exercise price of $11.97 per share, including 1,043,878&lt;span style="white-space:pre-wrap;"&gt; stock options outstanding outside of the 2014 Plan, granted as inducements to new employees.  &lt;/span&gt;During the three months ended March 31, 2021, 1,235,351 options were granted to employees and directors at a weighted-average exercise price of $13.33&lt;span style="white-space:pre-wrap;"&gt; per share.  Of the options granted, 1,005,038 options were granted pursuant to the 2014 Plan and 230,313 were granted outside of the 2014 Plan as inducements for new employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Total compensation cost recognized for all stock option awards in the statements of operations is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,190&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 729&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,980&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,875&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;All issued and outstanding restricted shares of common stock are time-based, and become vested between &lt;span style="-sec-ix-hidden:Hidden_dow7_ZuMpUWqCMzjx0ZHwQ;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one&lt;/span&gt;&lt;/span&gt; and three years&lt;span style="white-space:pre-wrap;"&gt; after the grant date.  Compensation expense is recorded ratably over the requisite service period. Compensation expense related to restricted stock is measured based on the fair value using the closing market price of our common stock on the date of the grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We issued 0 and 5,250 restricted shares of common stock during the three months ended March 31, 2021 and 2020, respectively.  As of March 31, 2021 there were 22,000 restricted shares of common stock outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Total compensation cost recognized for all restricted stock awards in the statements of operations is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="background-color:#ffffff;"&gt;As of March 31, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;4,753 &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of our Series A Convertible Preferred Stock (Preferred Stock) remained outstanding, convertible into &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;950,600&lt;/span&gt;&lt;span style="background-color:#ffffff;white-space:pre-wrap;"&gt; shares of our common stock.  In May 2020, a registration statement covering the resale of shares of our common stock underlying our Preferred Stock was declared effective by the SEC.  In accordance with the securities purchase agreements underlying the Preferred Stock, the liquidation preference was terminated, and we reclassified the Preferred Stock into permanent equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;font-style:italic;font-weight:bold;"&gt;Deemed Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;On March 31, 2020, our stockholders approved an &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;amendment to our company charter, which was filed with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock, which resulted in the recognition of a beneficial conversion feature on our Preferred Stock.  Accordingly, we recorded &lt;/span&gt;$8.9 million in deemed dividends in the three months ended March 31, 2020, which was calculated as t&lt;span style="background-color:#ffffff;"&gt;he difference between the conversion price and the fair value of our common stock on the commitment date (transaction date) i&lt;/span&gt;n connection with the closing of concurrent equity financings during the fourth quarter of 2019.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_StockOptionAndIncentivePlan2005Member_sjKwPS8R-k2wWxUVOhk1vg"
      decimals="INF"
      id="Narr_4NnGknZSkUO0MlOLACM1bA"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">6565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2021_us-gaap_PlanNameAxis_mrns_StockOptionAndIncentivePlan2005Member_pY1EQZSCQUasDgjSyWC4ug"
      decimals="INF"
      id="Narr_X7mDt7Q8JkCwPn3aXk9d2w"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_Tlqw9BGm20WqLo6p9EcJFg"
      decimals="INF"
      id="Narr_VMOgT22_90q_Ks3j1R3rWQ"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">3386335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2021_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_GCzbaEQkcUGyXqr_QnLvtA"
      decimals="INF"
      id="Narr_sxamlrEO00e91f94iSd81w"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">646221</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YOD3KDe7RkmYKbUKW8SRfA"
      decimals="INF"
      id="Narr_lVZgSy3RP0mB2K7Mj8-IqA"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4436778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YOD3KDe7RkmYKbUKW8SRfA"
      decimals="2"
      id="Narr_zLc4VPC3D0WsXawQxobxtg"
      unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">11.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlanEmployeeMember_pk1X2Uuu6kuHPbfxMPJLKA"
      decimals="INF"
      id="Narr_zKNCLlpnYEqkp2BsqMH7sA"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">1043878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw"
      decimals="INF"
      id="Narr_gmzBTjUy006g5LDT3kUS6w"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">1235351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw"
      decimals="2"
      id="Narr_TAiJjJARcUeIKDwr_7IPGw"
      unitRef="Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g">13.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlan2014Member_gLlExmIpREOOfxJPC2-Pbw"
      decimals="INF"
      id="Narr_U5qXTzPMYUesbQi4NTHlzQ"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">1005038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mrns_EquityIncentivePlanEmployeeMember_caVUlUeydkqE7PHUeTsG9A"
      decimals="INF"
      id="Narr_79KB3vE6X0uQHfMTewy1Sg"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">230313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw"
      id="Tb_gayTwzj3vEyZ-r815Zbyqg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Total compensation cost recognized for all stock option awards in the statements of operations is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,190&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 729&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,980&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,875&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ixflgqi17U--7GUSGs7m5w"
      decimals="-3"
      id="Tc_NaXn4jbBfkuMdFathvHW0Q_4_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1190000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_AEmW4zZq7kqttYoG44orKg"
      decimals="-3"
      id="Tc_wKofTD2_U06Q1xufAC4C9Q_4_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">729000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_sxnFk15oLESa5jxtU2OmMA"
      decimals="-3"
      id="Tc_XyaomUpcEUOnYmJTk16pQQ_5_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">3790000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4XykMpFDvkyUJxaaGlZIDw"
      decimals="-3"
      id="Tc_6Yogu3ayDUWbNsL5Pd1KPQ_5_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw"
      decimals="-3"
      id="Tc_9GM5uKusL0OT1l1KWNHtWQ_6_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">4980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nU2_qSegwUeO8XJe6mN6gA"
      decimals="-3"
      id="Tc_9wLGtd3Uqk6OEAVfjvm7zQ_6_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1875000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BRnhyVEI0ESba0YijHvmHw"
      id="Narr_k5cP1t73HkW1T0Jwg3oc7w">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qtmIWYk-lEaiK7KXwRoNrQ"
      decimals="INF"
      id="Narr_RxvOgn7E20uQL39sT9tG_A"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_9G2E0G-1K0CaojyNjXJupA"
      decimals="INF"
      id="Narr_PDigX9SzBkezVuE9wZLT0g"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">5250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_WbOyI-9dVEWarpASvcUfqA"
      decimals="INF"
      id="Narr_K-k8UVWp-kKouJszHpuD-g"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qtmIWYk-lEaiK7KXwRoNrQ"
      id="Tb_U9dSvG-_eEOH3WxVtpm2dw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Total compensation cost recognized for all restricted stock awards in the statements of operations is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mJOVLW9KpUmbnUt7bOmsLg"
      decimals="-3"
      id="Tc_cgKJovDGNUiILBcZv_AS-w_4_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">55000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_fWJfXvsKtk6Kfv55TO39uQ"
      decimals="-3"
      id="Tc_dfZVGLOYzkWheiBUXGsP8A_4_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qtmIWYk-lEaiK7KXwRoNrQ"
      decimals="-3"
      id="Tc_-Fr_OvARbUC5wiOOC9nUnQ_5_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">55000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_9G2E0G-1K0CaojyNjXJupA"
      decimals="-3"
      id="Tc_6r98Ss4lxkGKeeY78xt5Pw_5_6"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_mrns_SeriesAConvertiblePreferredStockMember_yE6MNXF5wEKWbstDMfvB0g"
      decimals="INF"
      id="Narr_xjbNxnlg_Uui6Mi052SOcA"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">4753</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="INF"
      id="Narr_aQlkf7uJDkiwh3Btns-LmQ"
      unitRef="Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg">950600</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <mrns:ConvertiblePreferredStockDeemedDividends
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-5"
      id="Narr_2BKoatKLAkWJqPjcHYP-3Q"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">8900000</mrns:ConvertiblePreferredStockDeemedDividends>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_VtuSckQiEkKloQNgizUhRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We have entered into operating leases for real estate. These leases have terms which range from 36 to 78 months, and include renewal terms which can extend the lease terms by 24 to 60 months, which are included in the lease term when it is reasonably certain that we will exercise the option.&#160;&#160;As of March 31, 2021, our operating leases had a weighted average remaining lease term of 53 months.&#160;&#160;These right-of-use (ROU) assets are included in "Other assets" on our interim consolidated balance sheets as of March 31, 2021 and December 31, 2020, respectively, and represent our right to use the underlying asset for the lease term. Our obligations to make lease payments are included in "Accrued expenses" and "Other long-term liabilities" on our interim consolidated balance sheets as of &lt;span style="-sec-ix-hidden:Hidden_zvqnfLCJd0yr4jXmjicT5Q;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;March 31, 2021&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_mFAODsPqSk-Q7CVVsygbpQ;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;December 31, 2020, respectively&lt;/span&gt;&lt;/span&gt;.&#160;&#160;The ROU assets were initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred, less any lease incentives received.&#160;&#160;The ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received.&#160;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2021 and December 31, 2020, ROU assets were $1.9 million and $2.0 million, respectively, and operating lease liabilities were $2.9 million and $3.0 million, respectively. We have entered into various short-term operating leases, primarily for clinical trial equipment, with an initial term of twelve months or less. These leases are not recorded on our balance sheets. All operating lease expense is recognized on a straight-line basis over the lease term. During each of the three months ended March 31, 2021 and 2020, we recognized $0.2 million in total lease costs, which included less than $0.1 million in short-term lease costs related to short-term operating leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Because the rate implicit in each lease is not readily determinable, we use our incremental borrowing rate to determine the present value of the lease payments. The weighted average incremental borrowing rate used to determine the initial value of ROU assets and lease liabilities was 11.0%, derived from a corporate yield curve based on a synthetic credit rating model using a market signal analysis. We have certain contracts for real estate which may contain lease and non-lease components which we have elected to treat as a single lease component.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ROU assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment &#x2013; Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&#160;&#160;As of March 31, 2021 and December 31, 2020, we have not recognized any impairment losses for our ROU assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We monitor for events or changes in circumstances that require a reassessment of one of our leases. When a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in our interim consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:2pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Maturities of operating lease liabilities as of March 31, 2021 were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remaining nine months of 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 823&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 642&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (805)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,404&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_9f43HPsrZUqXrvBNmnWl-A"
      id="Narr_LGse8HE1r06Gzdfw13wWSA">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_ZwEUgE2a10mD4z6DCHCsrQ"
      id="Narr_eNYiVPFDq061UL6zz2blqw">P78M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_9f43HPsrZUqXrvBNmnWl-A"
      id="Narr_45LMaQKP10irvvFahqXfzA">P24M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_ZwEUgE2a10mD4z6DCHCsrQ"
      id="Narr_HrQPiEEV1k2ik785QYvAZA">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      id="Narr_bIkD_ldMEkOnTA_YWaj_FA">P53M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-5"
      id="Narr_gPa_JoDbeU-pIl4AZTA9FA"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">1900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-5"
      id="Narr_yjNeJ8VcTkC87AeGsa-gBA"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-5"
      id="Narr_NczADI5sYU26pOqNyT8qkQ"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_ORni4uN-wUK4egcUOWdKTw"
      decimals="-5"
      id="Narr_0WJrPmHKxU-Kd93NNiJR8g"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">3000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2020_To_3_31_2020_FPluL3xVgkeNQ2Y8W3Wyzw"
      decimals="-5"
      id="Narr_eLeaoKsntEq673NkxxcjEg"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">200000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      decimals="-5"
      id="Narr_DHOT8A3vEUqc0cchp7Q62Q"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">200000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_XPMAdE0OMUeOyqAqZ3qvag"
      decimals="-5"
      id="Narr_XE6Ms7V3LU-Z3pKnsP7qQg"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">100000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_8LfUPpiv40evSUbKT82rhw"
      decimals="-5"
      id="Narr_j710FdGgMUGQvznxPFtrQg"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">100000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="4"
      id="Narr_rq2GrdlpKkiRIwL761vMRg"
      unitRef="Unit_Standard_pure_QJ87HOfdVUmgcpZGhVqVGw">0.110</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ"
      id="Tb_I73bbuL4tUGMeOKoIVShCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Maturities of operating lease liabilities as of March 31, 2021 were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remaining nine months of 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 616&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 823&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 642&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (805)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,404&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_CDgVrPzrBkePlKV277b8Jw_3_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_7NfNZWUxXUKMmVpxNIJ4-A_4_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">807000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_BtF4ZK4wQ0WE3MPQXAzvyQ_5_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">823000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_OIe_Hk1Oq0G2MKi6uhHpjA_6_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">840000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_-RENL7TgAkqaf2OKkt_XuQ_7_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">642000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc__qZ5KnuHZE2LTil-uZUaMw_8_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">3728000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_chPazXN3lUWri-FdVtaZTQ_9_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">805000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_b9eT3uBwrUuOFRziTUvjnw_10_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2923000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_L9SaWWfdbkiOR8nazwOXbA_12_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">519000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_kt4Ahuj9UEaRoUDttyfmxw_13_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2404000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw"
      decimals="-3"
      id="Tc_PZERjAL6_0qu2D4NwB2KBg_14_3"
      unitRef="Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg">2923000</us-gaap:OperatingLeaseLiability>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555644718504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MARINUS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0198082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Radnor Corporate Center, Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">100 Matsonford Rd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Radnor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">801-4670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRNS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,633,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001267813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555644725416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,472<span></span>
</td>
<td class="nump">$ 138,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Federal contract revenue receivable</a></td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">4,638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">129,798<span></span>
</td>
<td class="nump">146,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,894<span></span>
</td>
<td class="nump">1,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,167<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">133,859<span></span>
</td>
<td class="nump">150,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,167<span></span>
</td>
<td class="nump">2,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">10,954<span></span>
</td>
<td class="nump">8,518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,121<span></span>
</td>
<td class="nump">10,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,404<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,525<span></span>
</td>
<td class="nump">13,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A convertible preferred stock, $0.001 par value; 25,000,000 shares authorized, 4,753 shares issued and outstanding at March 31, 2021</a></td>
<td class="nump">4,469<span></span>
</td>
<td class="nump">4,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 150,000,000 shares authorized, 36,640,797 issued and 36,633,490 outstanding at March 31, 2021 and 36,585,767 issued and 36,578,400 outstanding at December 31, 2020</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">449,898<span></span>
</td>
<td class="nump">444,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost, 7,307 shares at March 31, 2020 and December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(339,070)<span></span>
</td>
<td class="num">(311,929)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">115,334<span></span>
</td>
<td class="nump">137,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 133,859<span></span>
</td>
<td class="nump">$ 150,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555727630024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">36,640,797<span></span>
</td>
<td class="nump">36,585,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">36,633,490<span></span>
</td>
<td class="nump">36,578,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">7,307<span></span>
</td>
<td class="nump">7,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrns_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">4,753<span></span>
</td>
<td class="nump">4,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,753<span></span>
</td>
<td class="nump">4,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrns_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrns_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555641636216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Federal contract revenue</a></td>
<td class="nump">$ 1,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,591<span></span>
</td>
<td class="nump">$ 15,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,376<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(27,161)<span></span>
</td>
<td class="num">(18,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(27,141)<span></span>
</td>
<td class="num">(18,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Deemed dividends on convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,880)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss and comprehensive loss applicable to common shareholders</a></td>
<td class="num">$ (27,141)<span></span>
</td>
<td class="num">$ (27,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock-basic and diluted</a></td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (1.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares outstanding</a></td>
<td class="nump">36,599,701<span></span>
</td>
<td class="nump">21,665,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (27,141)<span></span>
</td>
<td class="num">$ (18,672)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555644666424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (27,141)<span></span>
</td>
<td class="num">$ (18,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,035<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_NonCashOperatingLeaseExpenseOperatingActivities', window );">Noncash lease expense</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_InterestExpenseIncomeOnLeaseLiabilities', window );">Noncash lease liability</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of discount on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets and federal contract revenue receivables</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other long term-liabilities</a></td>
<td class="nump">5,325<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,175)<span></span>
</td>
<td class="num">(14,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_PaymentsForDepositAndPropertyAndEquipment', window );">Deposit on property and equipment</a></td>
<td class="num">(404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="num">(6,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing costs</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(15,037)<span></span>
</td>
<td class="num">(20,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents-beginning of period</a></td>
<td class="nump">138,509<span></span>
</td>
<td class="nump">90,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents-end of period</a></td>
<td class="nump">$ 123,472<span></span>
</td>
<td class="nump">$ 70,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_InterestExpenseIncomeOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) on lease liabilities during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_InterestExpenseIncomeOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_NonCashOperatingLeaseExpenseOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the non-cash portion of lease expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_NonCashOperatingLeaseExpenseOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_PaymentsForDepositAndPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for deposit on property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_PaymentsForDepositAndPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555641598408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Series A Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 295,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (235,574)<span></span>
</td>
<td class="nump">$ 59,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,625,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock', window );">Deemed dividend on beneficial conversion feature - Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,672)<span></span>
</td>
<td class="num">(18,672)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">306,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="num">(263,126)<span></span>
</td>
<td class="nump">43,113<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,690,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 4,469<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">444,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(311,929)<span></span>
</td>
<td class="nump">137,199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">4,753<span></span>
</td>
<td class="nump">36,585,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Financing costs under equity distribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,141)<span></span>
</td>
<td class="num">(27,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 4,469<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 449,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (339,070)<span></span>
</td>
<td class="nump">$ 115,334<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">4,753<span></span>
</td>
<td class="nump">36,640,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital as a result of the deemed dividend on the beneficial conversion feature of the convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555643035832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of the Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_BusinessDescriptionAndLiquidityTextBlock', window );">Description of the Business and Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Description of the Business and Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Our clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABA<sub style="font-size:7.5pt;vertical-align:sub;">A</sub>&#160;that is being developed in formulations for two different routes of administration: intravenous (IV)&#160;and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. The different formulations are intended to maximize potential therapeutic applications of ganaxolone for adult and pediatric patient populations, in both acute and chronic care, and for both in-patient and self-administered settings. Ganaxolone acts at both synaptic and extrasynaptic GABA<sub style="font-size:7.5pt;vertical-align:sub;">A</sub>&#160;receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus was declared a pandemic by the World Health Organization in March 2020 and has spread to nearly every country in the world, including the United States (U.S.). Efforts to contain the spread of COVID-19 have intensified and many countries, including the U.S., have implemented severe travel restrictions, business shutdowns and social distancing measures that have impacted clinical development through supply chain shortages and clinical trial enrollment difficulties as hospitals reduce and redeploy staff, divert resources to patients suffering from COVID-19 and limit hospital access for non-patients. The pandemic poses the risk that we, our employees, contractors, suppliers, or other partners may be prevented from conducting normal business activities for an indefinite period of time, including those due to shutdowns that may be requested or mandated by governmental authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The continued global spread of COVID-19 has impacted our operations but did not have a material impact on our business, operating results, financial condition or cash flows as of and for the three months ended March 31, 2021. For example, several of our Phase 1 trials of oral ganaxolone to support the development of CDD have experienced delays in enrollment due to COVID-19; however we do not expect these delays to impact our ability to file an NDA. Further, i<span style="white-space:pre-wrap;">n response to COVID-19, for our ongoing clinical trials, we have implemented multiple measures consistent with the U.S. Food and Drug Administration&#8217;s guidance on the conduct of clinical trials of medical products during the COVID-19 pandemic, including implementing remote site monitoring and remote visits using telemedicine where needed. However, COVID-19 may still adversely impact our clinical trials.  For example, our Phase 3 clinical trial in RSE is conducted in hospitals and resources related to the COVID-19 outbreak may divert staffing in hospitals, taking resources away from our clinical trial.  Our ganaxolone clinical trials in the outpatient setting may be negatively impacted if patients and their caregivers do not want to participate in a clinical trial while COVID-19 outbreaks continue. Although operations have not been materially affected by the COVID-19 pandemic as of and for the three months ended March 31, 2021, we are unable to predict the impact that COVID-19 will have in the future on our business, financial position, operating results and cash flows due to numerous uncertainties. The duration and severity of the pandemic and its long-term impact on our business are uncertain at this time, and our ability to raise sufficient additional financing depends on many factors beyond our control, including the current volatility in the capital markets as a result of the COVID-19 pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have not generated any product revenues and have incurred operating losses since inception, including losses of $27.1 million for the three months ended March 31, 2021. There is no assurance that profitable operations will ever be achieved, and if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, if approved, and commercialization of our product candidates will require significant additional financing.   Our accumulated deficit as of March 31, 2021 was $339.1 million and we expect to incur substantial losses in future periods.  We plan to finance our future operations with a combination of proceeds from the issuance of equity securities, the issuance of debt, government funding, collaborations, licensing transactions and other commercial transactions and revenues from future product sales, if any. We have not generated positive cash flows from operations, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">and there are no assurances that we will be successful in obtaining an adequate level of financing for the development and, if approved, commercialization of our product candidates.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 11, 2021 (the Closing Date), we entered into a Credit Agreement and Guaranty (as amended by that certain letter agreement on May 17, 2021, the Credit Agreement) with Oaktree Fund Administration, LLC, as administrative agent and the lenders party thereto that provides for a five-year senior secured term loan facility in an aggregate original principal amount of up to $125.0 million available to us in five tranches as follows (collectively, the Term Loans):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$15.0 million of tranche A-1 term loans advanced on the Closing Date. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$30.0</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million of tranche A-2 term loans subject to written acceptance by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) filing relating to the use of ganaxolone in the treatment of CDKL5 deficiency disorder (CDD).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$30.0</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million of tranche B term loans subject to receipt of written approval from the FDA of an NDA permitting the marketing of ganaxolone in interstate commerce in the United States to treat CDD (the FDA Approval).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$25.0</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million of tranche C term loans subject to receipt of the FDA Approval and the completion of one or more financings, including through the issuance of common stock, convertible debt, subordinated debt, a synthetic royalty or a sublicense in which we receive gross proceeds in an aggregate amount of at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$40.0</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million and net proceeds in an aggregate amount of at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$36.0</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million. In addition, the availability of this tranche is subject to either our current Phase 3 trial in RSE or a Phase 3 trial in tuberous sclerosis complex (TSC) achieving statistical significance (p value &lt; 0.05) across all primary endpoints and ganaxolone must be generally well tolerated, with a safety profile generally consistent with previous clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$25.0</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million of tranche D term loans subject to receipt of the FDA Approval and us earning at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$50</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million in net product revenue in the United States for a period of </span><span style="-sec-ix-hidden:Hidden_6rtYHnKztUW0WBec3xybnQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> consecutive months.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The Term Loans will bear interest at a fixed per annum rate (subject to increase during an event of default) of 11.50% and are scheduled to mature on the fifth anniversary of the Closing Date (the Maturity Date). In addition, at the time of funding of any tranche of the Term Loans, we are required to pay an upfront fee of 2.0% of the aggregate principal amount being funded. We are required to make quarterly interest payments until the Maturity Date. We are also required to make principal payments, which are payable in quarterly installments beginning on the last day of the first quarter ending after the third anniversary of the Closing Date in an amount equal to 5.0% of the aggregate amount of the Term Loans outstanding on the date of the first such quarterly principal payment and continuing until the Maturity Date, on which date all outstanding Term Loans and other amounts owed under the Credit Agreement will be required to be paid in full. A commitment fee of 75 basis points per annum will accrue on each of the tranche B, C and D commitments for the period beginning 120 days after the funding date of the tranche A-2 term loans until the applicable tranche is either funded or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">In September 2020, we entered into a contract (BARDA Contract) with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response. Under the BARDA Contract, we receive</span><span style="background-color:#ffffff;">d</span><span style="background-color:#ffffff;"> an award of up to an estimated </span><span style="background-color:#ffffff;">$51</span><span style="background-color:#ffffff;"> million for development of IV-administered ganaxolone for the treatment of refractory status epilepticus (RSE). </span><span style="background-color:#ffffff;">The BARDA Contract provides for </span><span style="background-color:#ffffff;">f</span><span style="background-color:#ffffff;">unding </span><span style="background-color:#ffffff;">to </span><span style="background-color:#ffffff;">include support</span><span style="background-color:#ffffff;">, </span><span style="background-color:#ffffff;">on a cost-sharing basis</span><span style="background-color:#ffffff;">, the </span><span style="background-color:#ffffff;">completion of a Phase 3 clinical trial of IV-administered ganaxolone in patients with RSE </span><span style="background-color:#ffffff;">(our </span><span style="background-color:#ffffff;">Phase 3 clinical trial evaluating IV </span><span style="background-color:#ffffff;">ganaxolone for the treatment of RSE </span><span style="background-color:#ffffff;">(RAISE Trial)) </span><span style="background-color:#ffffff;">, funding of pre-clinical studies to </span><span style="background-color:#ffffff;">provide support </span><span style="background-color:#ffffff;">that IV-administered </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">ganaxolone </span><span style="background-color:#ffffff;">could be </span><span style="background-color:#ffffff;">an effective treatment for RSE due to chemical nerve gas agent exposure, and funding of certain manufacturing scale-up and regulatory activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The BARDA Contract consists of an approximately two-year base period-during which BARDA will provide approximately $21 million of funding for the RAISE Trial on a cost share basis and funding of additional preclinical studies of ganaxolone in nerve agent exposure models. Following successful completion of the RAISE Trial and preclinical studies in the base period, the BARDA Contract provides for approximately $30 million of additional BARDA funding for three options in support of manufacturing, supply chain, clinical, regulatory and toxicology activities. Under the BARDA Contract, we will be responsible for cost sharing in the amount of approximately $33 million and BARDA will be responsible for approximately $51 million, if all development options are completed. The contract period-of-performance (base period plus option exercises) is up to approximately five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the closing of an equity financing in December 2020, we issued a total of 5,000,000 shares of common stock in an underwritten public offering resulting in aggregate net proceeds, after underwriting discounts and commissions in the public offering and other estimated offering expenses, of $64.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>In connection with the closing of an equity financing in June 2020, we issued a total of 4,600,000 shares of common stock in an underwritten public offering resulting in aggregate net proceeds, after underwriting discounts and commissions in the public offering and other estimated offering expenses, of $42.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>We believe that our cash and cash equivalents balances as of March 31, 2021, including the net upfront proceeds received in May 2021 from our Credit Agreement, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse stock split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On September 23, 2020, we effected a <span style="-sec-ix-hidden:Hidden_pGDrPi0GAkW2ail2SFXw3w;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1</span></span>-for-4 reverse split of shares of our common stock (Reverse Split), as approved by our board of directors and stockholders. The par value per share of our common stock was not adjusted as a result of the Reverse Split, and our authorized shares of common stock was reduced to 150,000,000<span style="white-space:pre-wrap;">.  All of the share and per share amounts included in the accompanying financial statements and these notes have been adjusted to reflect the Reverse Split</span><span style="white-space:pre-wrap;">.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_BusinessDescriptionAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. The disclosure also includes when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_BusinessDescriptionAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555644378104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying unaudited interim consolidated financial statements include the accounts of Marinus Pharmaceuticals, Inc. (a Delaware corporation) as well as the accounts of Marinus Pharmaceuticals Emerald Limited (an Ireland company incorporated in February 2021), a wholly owned subsidiary requiring consolidation. Marinus Pharmaceuticals Emerald Limited serves as a corporate presence in the European Union for regulatory purposes. The unaudited interim consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the U.S. (GAAP) for annual financial statements. In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of our financial position and results of operations and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2020 and accompanying notes thereto included in our annual report on Form&#160;10-K filed with the SEC on March 9, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Federal Contract Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="white-space:pre-wrap;">We recognize federal contract revenue from the BARDA Contract in the period in which the allowable research and development expenses are incurred, and receivables associated with this revenue are recorded as federal contract revenue receivable on our interim consolidated balance sheets.  This revenue is not within the scope of Accounting Standards Codification (ASC) 606 &#8211; Revenue from contracts with customers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555735432056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">3. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level&#160;1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level&#160;2 &#8212; Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level&#160;3 &#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,210</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,210</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138,509</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138,509</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,983</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,983</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555647511928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">4. Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,533</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,097</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trials and drug development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,158</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 927</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555735585816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_InvestmentsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We did not have any investments as of March 31, 2021. As of December 31, 2020, our investments consisted of certificates of deposit with various financial institutions with original maturities of six to nine months.&#160;&#160;Investments are classified as short- or long-term investments on our balance sheets based on original maturity. Certificates of deposits were classified as held-to-maturity and were recorded at amortized cost, which approximated fair value.&#160; <span style="color:#222222;">We have never experienced a credit loss on the principal or interest receivable of our cash equivalents or short-term investments.&#160;</span><span style="color:#222222;white-space:pre-wrap;"> Our certificates of deposit are each individually and fully insured by the federal Depsot Insurance Company (FDIC).  Accordingly, we did not record any allowance for potential credit losses as of December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_InvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_InvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555644480824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share of Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6. Loss Per Share of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. These potentially dilutive securities are more fully described in Note&#160;7, and summarized in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 950,600</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,436,778</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,264,041</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,409,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,269,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555643235000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">7. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In 2005, we adopted the 2005 Stock Option and Incentive Plan (2005 Plan) that authorizes us to grant stock options, restricted stock and other equity-based awards. As of March 31, 2021, 6,565<span style="white-space:pre-wrap;"> options to purchase shares of common stock were outstanding pursuant to grants in connection with the 2005 Plan.  </span>No<span style="white-space:pre-wrap;"> additional shares are available for issuance under the 2005 Plan.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In August 2014, we adopted our 2014 Equity Incentive Plan, most recently amended in May 2020 (2014 Plan), that authorizes us to grant stock options, restricted stock, and other equity-based awards, subject to adjustment in accordance with the 2014 Plan.  The amount, terms of grants, and exercisability provisions are determined and set by our board of directors.  As of March 31, 2021, </span>3,386,335 options to purchase shares of common stock were outstanding pursuant to grants in connection with the 2014 Plan, and 646,221 shares of common stock were available for future issuance.<span style="white-space:pre-wrap;"> The amount, terms of grants, and exercisability provisions are determined and set by our board of directors.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were 4,436,778 stock options outstanding as of March 31, 2021 at a weighted-average exercise price of $11.97 per share, including 1,043,878<span style="white-space:pre-wrap;"> stock options outstanding outside of the 2014 Plan, granted as inducements to new employees.  </span>During the three months ended March 31, 2021, 1,235,351 options were granted to employees and directors at a weighted-average exercise price of $13.33<span style="white-space:pre-wrap;"> per share.  Of the options granted, 1,005,038 options were granted pursuant to the 2014 Plan and 230,313 were granted outside of the 2014 Plan as inducements for new employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total compensation cost recognized for all stock option awards in the statements of operations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,190</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 729</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,980</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,875</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">All issued and outstanding restricted shares of common stock are time-based, and become vested between <span style="-sec-ix-hidden:Hidden_dow7_ZuMpUWqCMzjx0ZHwQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one</span></span> and three years<span style="white-space:pre-wrap;"> after the grant date.  Compensation expense is recorded ratably over the requisite service period. Compensation expense related to restricted stock is measured based on the fair value using the closing market price of our common stock on the date of the grant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We issued 0 and 5,250 restricted shares of common stock during the three months ended March 31, 2021 and 2020, respectively.  As of March 31, 2021 there were 22,000 restricted shares of common stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total compensation cost recognized for all restricted stock awards in the statements of operations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="background-color:#ffffff;">As of March 31, 2021, </span><span style="background-color:#ffffff;">4,753 </span><span style="background-color:#ffffff;">shares of our Series A Convertible Preferred Stock (Preferred Stock) remained outstanding, convertible into </span><span style="background-color:#ffffff;">950,600</span><span style="background-color:#ffffff;white-space:pre-wrap;"> shares of our common stock.  In May 2020, a registration statement covering the resale of shares of our common stock underlying our Preferred Stock was declared effective by the SEC.  In accordance with the securities purchase agreements underlying the Preferred Stock, the liquidation preference was terminated, and we reclassified the Preferred Stock into permanent equity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Deemed Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">On March 31, 2020, our stockholders approved an </span><span style="white-space:pre-wrap;">amendment to our company charter, which was filed with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock, which resulted in the recognition of a beneficial conversion feature on our Preferred Stock.  Accordingly, we recorded </span>$8.9 million in deemed dividends in the three months ended March 31, 2020, which was calculated as t<span style="background-color:#ffffff;">he difference between the conversion price and the fair value of our common stock on the commitment date (transaction date) i</span>n connection with the closing of concurrent equity financings during the fourth quarter of 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555647096712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into operating leases for real estate. These leases have terms which range from 36 to 78 months, and include renewal terms which can extend the lease terms by 24 to 60 months, which are included in the lease term when it is reasonably certain that we will exercise the option.&#160;&#160;As of March 31, 2021, our operating leases had a weighted average remaining lease term of 53 months.&#160;&#160;These right-of-use (ROU) assets are included in "Other assets" on our interim consolidated balance sheets as of March 31, 2021 and December 31, 2020, respectively, and represent our right to use the underlying asset for the lease term. Our obligations to make lease payments are included in "Accrued expenses" and "Other long-term liabilities" on our interim consolidated balance sheets as of <span style="-sec-ix-hidden:Hidden_zvqnfLCJd0yr4jXmjicT5Q;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">March 31, 2021</span></span> and <span style="-sec-ix-hidden:Hidden_mFAODsPqSk-Q7CVVsygbpQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">December 31, 2020, respectively</span></span>.&#160;&#160;The ROU assets were initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred, less any lease incentives received.&#160;&#160;The ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2021 and December 31, 2020, ROU assets were $1.9 million and $2.0 million, respectively, and operating lease liabilities were $2.9 million and $3.0 million, respectively. We have entered into various short-term operating leases, primarily for clinical trial equipment, with an initial term of twelve months or less. These leases are not recorded on our balance sheets. All operating lease expense is recognized on a straight-line basis over the lease term. During each of the three months ended March 31, 2021 and 2020, we recognized $0.2 million in total lease costs, which included less than $0.1 million in short-term lease costs related to short-term operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because the rate implicit in each lease is not readily determinable, we use our incremental borrowing rate to determine the present value of the lease payments. The weighted average incremental borrowing rate used to determine the initial value of ROU assets and lease liabilities was 11.0%, derived from a corporate yield curve based on a synthetic credit rating model using a market signal analysis. We have certain contracts for real estate which may contain lease and non-lease components which we have elected to treat as a single lease component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ROU assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment &#8211; Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&#160;&#160;As of March 31, 2021 and December 31, 2020, we have not recognized any impairment losses for our ROU assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We monitor for events or changes in circumstances that require a reassessment of one of our leases. When a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in our interim consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Maturities of operating lease liabilities as of March 31, 2021 were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remaining nine months of 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 616</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 823</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 642</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: imputed interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (805)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,404</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555735604360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying unaudited interim consolidated financial statements include the accounts of Marinus Pharmaceuticals, Inc. (a Delaware corporation) as well as the accounts of Marinus Pharmaceuticals Emerald Limited (an Ireland company incorporated in February 2021), a wholly owned subsidiary requiring consolidation. Marinus Pharmaceuticals Emerald Limited serves as a corporate presence in the European Union for regulatory purposes. The unaudited interim consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the U.S. (GAAP) for annual financial statements. In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of our financial position and results of operations and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2020 and accompanying notes thereto included in our annual report on Form&#160;10-K filed with the SEC on March 9, 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Federal Contract Revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Federal Contract Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="white-space:pre-wrap;">We recognize federal contract revenue from the BARDA Contract in the period in which the allowable research and development expenses are incurred, and receivables associated with this revenue are recorded as federal contract revenue receivable on our interim consolidated balance sheets.  This revenue is not within the scope of Accounting Standards Codification (ASC) 606 &#8211; Revenue from contracts with customers.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555646587736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of major categories of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,210</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,210</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138,509</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138,509</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,983</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,983</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555642858664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,533</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,097</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trials and drug development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,158</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 927</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555644432920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 950,600</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,436,778</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,264,041</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,409,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,269,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555735813176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of total compensation cost recognized in the statement of operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total compensation cost recognized for all stock option awards in the statements of operations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,190</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 729</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,980</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,875</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of total compensation cost recognized in the statement of operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total compensation cost recognized for all restricted stock awards in the statements of operations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555647100392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Maturities of operating lease liabilities as of March 31, 2021 were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remaining nine months of 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 616</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 823</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 642</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: imputed interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (805)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,404</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555640444984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Liquidity (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 11, 2021 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Sep. 23, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339,070)<span></span>
</td>
<td class="num">$ (311,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_ContractFundingProvidedDuringBasePeriod', window );">Amount of funding to be provided during contract base period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=mrns_OaktreeCapitalManagementLpCreditAgreementMember', window );">Oaktree Capital Management LP Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Secured term loan</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate (as a percent)</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_DebtInstrumentUpfrontFeesPercentage', window );">Percentage of upfront fees</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage', window );">Percentage of periodic principal payment</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_DebtInstrumentCommitmentFee', window );">Commitment fees</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_DebtInstrumentCommitmentFeeAccrualPeriod', window );">Commitment fee accrual period</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Original principal amount</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember', window );">BARDA Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_MaximumAwardAvailableUnderContract', window );">Maximum amount to be awarded under the contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_ContractBasePeriod', window );">Contract base period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod', window );">Amount of additional funding to be provided following successful completion of clinical trial and preclinical studies in base period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_ContractCostSharingAmount', window );">Cost sharing, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_ContractCostSharingAmountCounterparty', window );">Cost sharing, BARDA amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_ContractPeriodOfPerformance', window );">Contract period-of-performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrns_TermLoansTranche1Member', window );">Term Loans Tranche A-1 | Oaktree Capital Management LP Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, face amount</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrns_TermLoansTranche2Member', window );">Term Loans Tranche A-2 | Oaktree Capital Management LP Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, face amount</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheBMember', window );">Term Loan Tranche B | Oaktree Capital Management LP Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, face amount</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheCMember', window );">Term Loan Tranche C | Oaktree Capital Management LP Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, face amount</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum', window );">Gross proceeds from sublicense, minimum</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum', window );">Net proceeds from sublicense, minimum</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheDMember', window );">Term Loan Tranche D | Oaktree Capital Management LP Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, face amount</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum', window );">Net product revenue, minimum</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod', window );">Net product revenue, consecutive earning period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offerings, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,900<span></span>
</td>
<td class="nump">$ 42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional funding to be provided as defined in the contract, following successful completion of clinical trial and preclinical studies in the base period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_ContractBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The base period as defined in the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_ContractBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_ContractCostSharingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost sharing the Company is responsible as defined in the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_ContractCostSharingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_ContractCostSharingAmountCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost sharing the counterparty is responsible as defined in the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_ContractCostSharingAmountCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_ContractFundingProvidedDuringBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of funding to be provided during the base period as defined in the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_ContractFundingProvidedDuringBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_ContractPeriodOfPerformance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contract period-of-performance (base period plus option exercises).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_ContractPeriodOfPerformance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_DebtInstrumentCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the commitment fees on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_DebtInstrumentCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_DebtInstrumentCommitmentFeeAccrualPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for which the commitment fees accrues until the applicable tranche is either funded or terminated, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_DebtInstrumentCommitmentFeeAccrualPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum requirement that must be met on gross proceeds from a sublicense in determining availability of funding per the credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum requirement that must be met on net proceeds from a sublicense in determining availability of funding per the credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum requirement that must be met on net product revenue over a specified time period in determining availability of funding per the credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of periodic principal payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consecutive period in which the amount of minimum revenue required to be achieved for debt to be available, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_DebtInstrumentUpfrontFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront fees payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_DebtInstrumentUpfrontFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_MaximumAwardAvailableUnderContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount to be awarded under the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_MaximumAwardAvailableUnderContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of tranches within term loan for notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=mrns_OaktreeCapitalManagementLpCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=mrns_OaktreeCapitalManagementLpCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrns_TermLoansTranche1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrns_TermLoansTranche1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrns_TermLoansTranche2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrns_TermLoansTranche2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrns_TermLoanTrancheDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrns_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrns_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555647488440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 122,210<span></span>
</td>
<td class="nump">$ 139,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">122,210<span></span>
</td>
<td class="nump">138,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">122,210<span></span>
</td>
<td class="nump">139,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">$ 122,210<span></span>
</td>
<td class="nump">138,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555644438200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related costs</a></td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="nump">$ 4,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_ClinicalTrialsAndDrugDevelopmentCurrent', window );">Clinical trials and drug development</a></td>
<td class="nump">6,645<span></span>
</td>
<td class="nump">2,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_LeaseLiabilityShortTerm', window );">Short-term lease liabilities</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 10,954<span></span>
</td>
<td class="nump">$ 8,518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_ClinicalTrialsAndDrugDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials and drug development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_ClinicalTrialsAndDrugDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_LeaseLiabilityShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_LeaseLiabilityShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555641586968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Stock (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">5,409,378<span></span>
</td>
<td class="nump">9,269,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">950,600<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock options.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">4,436,778<span></span>
</td>
<td class="nump">3,264,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555641268600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issued for each convertible Series A preferred stock</a></td>
<td class="nump">950,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Deemed Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrns_ConvertiblePreferredStockDeemedDividends', window );">Deemed dividends on Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrns_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">55,030,000<span></span>
</td>
<td class="nump">59,978,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">$ 4,980<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">4,436,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,235,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 13.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">$ 1,190<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">3,790<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrns_StockOptionAndIncentivePlan2005Member', window );">2005 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrns_StockOptionAndIncentivePlan2005Member', window );">2005 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">6,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrns_EquityIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option and incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">646,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrns_EquityIncentivePlan2014Member', window );">2014 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">3,386,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,005,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrns_EquityIncentivePlanEmployeeMember', window );">Equity Incentive Plan, Employee Inducments | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">1,043,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">230,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrns_ConvertiblePreferredStockDeemedDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The deemed dividends on the convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrns_ConvertiblePreferredStockDeemedDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrns_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrns_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrns_StockOptionAndIncentivePlan2005Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrns_StockOptionAndIncentivePlan2005Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrns_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrns_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrns_EquityIncentivePlanEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrns_EquityIncentivePlanEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140555640355320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">53 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 2,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherAccruedLiabilitiesNoncurrent us-gaap:AccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:OtherAccruedLiabilitiesNoncurrent us-gaap:AccruedLiabilitiesCurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Weighted-average incremental borrowing rate used to determine right-of-use assets and lease liabilities</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract', window );"><strong>Maturities of operating lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">Remaining nine months of 2021</a></td>
<td class="nump">$ 616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2022</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2023</a></td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2024</a></td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">Thereafter</a></td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">2,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">$ 2,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease agreement term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease agreement term</a></td>
<td class="text">78 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term operating lease costs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,3*OAEO! ;85@.\/4IK7!WLKTMR"+?X#4$L#!!0    (  ^#L5*Z@PT6^@(
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MFI#Q[''^//TQ?5K<_YJ2A]EB02[(S\6$_/'M3_*-Y!5YR?A&LBJ50T<A-)W
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MF^$W#PAM@/\O.5<?#SI!^Q4U^A=02P,$%     @ #X.Q4E[*&"%E!0  #!0
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M-8#?-U*:EQ<[07T!N/@?4$L#!!0    (  ^#L5+L3LQ2D04  %T6   8
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M_30'X$<)6X$JUEE"W@<NZ*S&]G"R;2*!6LRF3C63)NUN3;BU)?:8Y(7UJC(
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M,<)?2*]5!4H@[*!)?1:+.W08APJ=FQZO9WBN\P"L+]#I0D)]01_$/8F9*[H
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M 7S?>$R?]H$=]/?+\[\ 4$L#!!0    (  ^#L5(P;;J%[ 0  !@/   8
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULS5=M;]LV$/XK!V\84L#PB^PT;TZ
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MGFY2X;&@JRM:%J#ON:&=N7YA ^UE^.(O4$L#!!0    (  ^#L5+>W';PKP(
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M"2U)UWV<QY*\CE$,JA&-YA\9E!3X"O:UD1JHMO5T, *5A4H9+XFS'>:QD*F
M#G=2$3RTZ V*>.&"TJ.6/%L*R1K7"*TWDN56/%"LF&1 S,?]T>S4QF+T$%-0
MJE #?NYDUO:I\4/VODY:#G_&^!=J'&N 2@P8I\W.Z$Y9VQNONO@EQ>Y$)6R.
M25Z%&KV(>\0V2&L^Q=54BC4U;>S1G]X^/JU_EDXL8\:,V]JCI.A+,_>93.TL
M.]$^@>4-@998U,;^.LL*GAK]FY;.QY,R_'_O'!=G]U^#?IMN^=C\G>/^*AQG
MQX?DOK\_OX3WKY"<-&FM !8K@4[R7V\S\/W-W@^8VG2;;HCE;DZ?M3R&Z&.
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M["2_NPIG)[Y.UCBZ"B+692G#_3E9OSD=3 ?=BVNS+A*_&)^=5')-"THWU57
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M]@[V ]!-4]$LK)K[AWRJ++4%?EI2'X;:*=#_0BF[7+@-NLYN] M02P,$%
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M5?_HI,TDZKT?)H8JUC6V[[CQ=)Q7;_LV?33OAQU=SEX0K1I+<F47E], =#]
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MV('ML,!O)$@3@,\W0NCWB6G#W5=W]A]02P,$%     @ #X.Q4GOAV"/^ @
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MM$#OWWU [Q!/T?-69(JF*W4ST.#.& VB GJ60Y,6:!\]B%1O%?J4KMCJU'X
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M6Z6*)M%=5 K.DQKG(9XTDR&5SA'/20;:6C_Z;X0*Y)/6$GA!"Z-*"XE;"Q]
M"),L<>WG*T$CY.?VP*12*^)6J_,M'-U(EF^'VK:_%P#]\/+^EU3R1MSR=DX/
M$LKVL!Q:R5U0RZ #N4H-B5L-'^CKI916*D?"GTQII5BDZVZW<TK=@*-QAZA5
M>D;<>O:O4^J&"[T.Y"H1(VX1>]H*J?N&2DTV6K>K!>3)]U=MOWIA4$YW<'0@
MD3"YL0<["CQGJ<Z_]\NGY>'1G3TR.7L^P]?S_ BH@LE/I.!K?L-3!7-: Z1W
M-8(2E_DA3WZCQ<X>>RR%UB*QEUM&5TR: ?!^+80^W!@'Y5';]!]02P,$%
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M8?^N(8<"$RY?X)H:^S/*LY4BS:5[-#HZ;BI747,^P;ZEF$N:]Z\N^M<NEW\
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M*JB055 AJZ!"5D&%K.(_R?KNW/*OO]W;M3!2V8,_ZWZ0S#X!4$L! A0#%
M  @ #X.Q4@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  /@[%2='@$LN\    K @  $0
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M=#(N>&UL4$L! A0#%     @ #X.Q4KJ##1;Z @  (@H  !@
M ("!%!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  ^#
ML5+KJZ/;)00  %$-   8              " @406  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  /@[%27LH8(64%   ,%   &
M        @(&?&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ #X.Q4NQ.S%*1!0  718  !@              ("!.B   'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  ^#L5+.1N>B] X  )TF   8
M              " @0$F  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  /@[%2O/$"$[X%  !K#@  &               @($K-0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ #X.Q4C!MNH7L!
M& \  !@              ("!'SL  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    (  ^#L5+>W';PKP(  -(&   9              " @4%
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ #X.Q4D'%
MQN19 P  :@<  !D              ("!)T,  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  /@[%29NRL8[,#  #G"   &0
M    @(&W1@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M  ^#L5):+Z0_Z08  *$3   9              " @:%*  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ #X.Q4@)K/I4(!P  QA(  !D
M             ("!P5$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  /@[%2MP;MLMD%   C#P  &0              @($ 60  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  ^#L5+%#QS%]0(
M .4)   9              " @1!?  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ #X.Q4OT(CV*] @  PP8  !D              ("!
M/&(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  /@[%2
M%;QFT)D"  #1!0  &0              @($P90  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    (  ^#L5(CM?.(V0(   ()   9
M      " @0!H  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ #X.Q4KCZ'CN= @  " <  !D              ("!$&L  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  /@[%2NYH=CLT&  "$'@
M&0              @('D;0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    (  ^#L5)2Q='@\P(  (\*   9              " @>AT  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ #X.Q4L>@V@2M
M @  @0<  !D              ("!$G@  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  /@[%2>^'8(_X"  ";"@  &0
M@('V>@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  ^#
ML5+8#HR=1@8  %$>   9              " @2M^  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ #X.Q4B'H=@"]!   =A,  !D
M         ("!J(0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    "  /@[%2^XB8V! #   P$0  #0              @ &<B0  >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    (  ^#L5*7BKL<P    !,"   +
M  "  =>,  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  ^#L5)ZOR9BZP(  /H1
M   /              "  <"-  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  /@[%2_^2]XT(!  !%$   &@              @ '8D   >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  /@[%2JAT0L'8!   H$0
M$P              @ %2D@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..(@ B "4)  #YDP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>92</ContextCount>
  <ElementCount>240</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of the Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidity</Role>
      <ShortName>Description of the Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStock</Role>
      <ShortName>Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockTables</Role>
      <ShortName>Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStock</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureLeases</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of the Business and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails</Role>
      <ShortName>Description of the Business and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Loss Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails</Role>
      <ShortName>Loss Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrns-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.marinuspharma.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.marinuspharma.com/role/DisclosureLeasesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mrns-20210331x10q.htm">mrns-20210331x10q.htm</File>
    <File>mrns-20210331.xsd</File>
    <File>mrns-20210331_cal.xml</File>
    <File>mrns-20210331_def.xml</File>
    <File>mrns-20210331_lab.xml</File>
    <File>mrns-20210331_pre.xml</File>
    <File>mrns-20210331xex10d1.htm</File>
    <File>mrns-20210331xex10d2.htm</File>
    <File>mrns-20210331xex10d3.htm</File>
    <File>mrns-20210331xex31d1.htm</File>
    <File>mrns-20210331xex31d2.htm</File>
    <File>mrns-20210331xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrns-20210331x10q004.jpg</File>
    <File>mrns-20210331x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>48
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrns-20210331x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 92,
   "dts": {
    "calculationLink": {
     "local": [
      "mrns-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrns-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mrns-20210331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrns-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrns-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrns-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 278,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 8,
    "http://www.marinuspharma.com/20210331": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 14
   },
   "keyCustom": 25,
   "keyStandard": 215,
   "memberCustom": 12,
   "memberStandard": 18,
   "nsprefix": "mrns",
   "nsuri": "http://www.marinuspharma.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Accrued Expenses",
     "role": "http://www.marinuspharma.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrns:InvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Investments",
     "role": "http://www.marinuspharma.com/role/DisclosureInvestments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrns:InvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Loss Per Share of Common Stock",
     "role": "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStock",
     "shortName": "Loss Per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stockholders' Equity",
     "role": "http://www.marinuspharma.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Leases",
     "role": "http://www.marinuspharma.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.marinuspharma.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Loss Per Share of Common Stock (Tables)",
     "role": "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockTables",
     "shortName": "Loss Per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_O7jmS1W8_0GEeKzr75UCiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Leases (Tables)",
     "role": "http://www.marinuspharma.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Description of the Business and Liquidity (Details)",
     "role": "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
     "shortName": "Description of the Business and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "-6",
      "lang": null,
      "name": "mrns:ContractFundingProvidedDuringBasePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__S1TL6asNEie8J964p41pg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__S1TL6asNEie8J964p41pg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Loss Per Share of Common Stock (Details)",
     "role": "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails",
     "shortName": "Loss Per Share of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZS5dKhW8PUWesfvV4DMKmg",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Leases (Details)",
     "role": "http://www.marinuspharma.com/role/DisclosureLeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_jLtAgP67y06Rlri7nWocBw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_3sw1TcvDnEKKWTYJUrv5-g",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bG_5QgjxIkC2qi039sgXpg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bG_5QgjxIkC2qi039sgXpg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_trvr3Wv9eEmNgHdIUaukmg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrns:BusinessDescriptionAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Description of the Business and Liquidity",
     "role": "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidity",
     "shortName": "Description of the Business and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrns:BusinessDescriptionAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Fair Value Measurements",
     "role": "http://www.marinuspharma.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrns-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_LkjcpbjIH0STr4EYjHC1FQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrns_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital as a result of the deemed dividend on the beneficial conversion feature of the convertible preferred stock.",
        "label": "Adjustments to Additional Paid in Capital, Deemed Dividend on Beneficial Conversion Feature, Convertible Preferred Stock",
        "terseLabel": "Deemed dividend on beneficial conversion feature - Series A convertible preferred stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnBeneficialConversionFeatureConvertiblePreferredStock",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Biomedical Advanced Research and Development Authority (BARDA) contract.",
        "label": "Biomedical Advanced Research And Development Authority Contract [Member]",
        "terseLabel": "BARDA Contract"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_BusinessDescriptionAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. The disclosure also includes when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Business Description And Liquidity [Text Block]",
        "terseLabel": "Description of the Business and Liquidity"
       }
      }
     },
     "localname": "BusinessDescriptionAndLiquidityTextBlock",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrns_ClinicalTrialsAndDrugDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials and drug development.",
        "label": "Clinical Trials and Drug Development Current",
        "terseLabel": "Clinical trials and drug development"
       }
      }
     },
     "localname": "ClinicalTrialsAndDrugDevelopmentCurrent",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_ContractAdditionalFundingToBeProvidedFollowingBasePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional funding to be provided as defined in the contract, following successful completion of clinical trial and preclinical studies in the base period.",
        "label": "Contract, Additional Funding to be Provided Following Base Period",
        "terseLabel": "Amount of additional funding to be provided following successful completion of clinical trial and preclinical studies in base period"
       }
      }
     },
     "localname": "ContractAdditionalFundingToBeProvidedFollowingBasePeriod",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_ContractBasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The base period as defined in the contract.",
        "label": "Contract Base Period",
        "terseLabel": "Contract base period"
       }
      }
     },
     "localname": "ContractBasePeriod",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrns_ContractCostSharingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost sharing the Company is responsible as defined in the contract.",
        "label": "Contract, Cost Sharing Amount",
        "terseLabel": "Cost sharing, amount"
       }
      }
     },
     "localname": "ContractCostSharingAmount",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_ContractCostSharingAmountCounterparty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost sharing the counterparty is responsible as defined in the contract.",
        "label": "Contract Cost Sharing Amount, Counterparty",
        "terseLabel": "Cost sharing, BARDA amount"
       }
      }
     },
     "localname": "ContractCostSharingAmountCounterparty",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_ContractFundingProvidedDuringBasePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of funding to be provided during the base period as defined in the contract.",
        "label": "Contract Funding Provided During Base Period",
        "terseLabel": "Amount of funding to be provided during contract base period"
       }
      }
     },
     "localname": "ContractFundingProvidedDuringBasePeriod",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_ContractPeriodOfPerformance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contract period-of-performance (base period plus option exercises).",
        "label": "Contract, Period-of-Performance",
        "terseLabel": "Contract period-of-performance"
       }
      }
     },
     "localname": "ContractPeriodOfPerformance",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrns_ConvertiblePreferredStockDeemedDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deemed dividends on the convertible preferred stock.",
        "label": "Convertible Preferred Stock, Deemed Dividends",
        "terseLabel": "Deemed dividends on Series A convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockDeemedDividends",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_DebtInstrumentCommitmentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the commitment fees on the debt instrument.",
        "label": "Debt Instrument, Commitment Fee",
        "terseLabel": "Commitment fees"
       }
      }
     },
     "localname": "DebtInstrumentCommitmentFee",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrns_DebtInstrumentCommitmentFeeAccrualPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which the commitment fees accrues until the applicable tranche is either funded or terminated, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Commitment Fee Accrual Period",
        "terseLabel": "Commitment fee accrual period"
       }
      }
     },
     "localname": "DebtInstrumentCommitmentFeeAccrualPeriod",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrns_DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum requirement that must be met on gross proceeds from a sublicense in determining availability of funding per the credit agreement.",
        "label": "Debt Instrument Funding Available, Gross Proceeds from Sublicense, Minimum",
        "terseLabel": "Gross proceeds from sublicense, minimum"
       }
      }
     },
     "localname": "DebtInstrumentFundingAvailableGrossProceedsFromSublicenseMinimum",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum requirement that must be met on net proceeds from a sublicense in determining availability of funding per the credit agreement.",
        "label": "Debt Instrument Funding Available, Net Proceeds from Sublicense, Minimum",
        "terseLabel": "Net proceeds from sublicense, minimum"
       }
      }
     },
     "localname": "DebtInstrumentFundingAvailableNetProceedsFromSublicenseMinimum",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_DebtInstrumentFundingAvailableNetProductRevenueMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum requirement that must be met on net product revenue over a specified time period in determining availability of funding per the credit agreement.",
        "label": "Debt Instrument Funding Available, Net Product Revenue, Minimum",
        "terseLabel": "Net product revenue, minimum"
       }
      }
     },
     "localname": "DebtInstrumentFundingAvailableNetProductRevenueMinimum",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_DebtInstrumentPeriodicPaymentPrincipalPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of periodic principal payment.",
        "label": "Debt Instrument, Periodic Payment, Principal, Percentage",
        "terseLabel": "Percentage of periodic principal payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipalPercentage",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrns_DebtInstrumentRevenueRequirementConsecutiveEarningPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consecutive period in which the amount of minimum revenue required to be achieved for debt to be available, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Revenue Requirement, Consecutive Earning Period",
        "terseLabel": "Net product revenue, consecutive earning period"
       }
      }
     },
     "localname": "DebtInstrumentRevenueRequirementConsecutiveEarningPeriod",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrns_DebtInstrumentUpfrontFeesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront fees payable.",
        "label": "Debt Instrument, Upfront Fees, Percentage",
        "terseLabel": "Percentage of upfront fees"
       }
      }
     },
     "localname": "DebtInstrumentUpfrontFeesPercentage",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrns_EquityIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2014 Equity Incentive Plan.",
        "label": "Equity Incentive Plan2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2014Member",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_EquityIncentivePlanEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plan pertaining to inducements for new employees.",
        "label": "Equity Incentive Plan Employee [Member]",
        "terseLabel": "Equity Incentive Plan, Employee Inducments"
       }
      }
     },
     "localname": "EquityIncentivePlanEmployeeMember",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_InterestExpenseIncomeOnLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense (income) on lease liabilities during the period.",
        "label": "Interest Expense (Income) On Lease Liabilities",
        "terseLabel": "Noncash lease liability"
       }
      }
     },
     "localname": "InterestExpenseIncomeOnLeaseLiabilities",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_InvestmentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments.",
        "label": "Investments Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsDisclosureTextBlock",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrns_LeaseLiabilityShortTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of short-term lease liabilities.",
        "label": "Lease Liability, Short-Term",
        "terseLabel": "Short-term lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityShortTerm",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_LiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Abstract]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityAbstract",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrns_MaximumAwardAvailableUnderContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount to be awarded under the contract.",
        "label": "Maximum Award Available under the Contract",
        "terseLabel": "Maximum amount to be awarded under the contract"
       }
      }
     },
     "localname": "MaximumAwardAvailableUnderContract",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_NonCashOperatingLeaseExpenseOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the non-cash portion of lease expenses for the period.",
        "label": "Non-Cash Operating Lease Expense, Operating Activities",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NonCashOperatingLeaseExpenseOperatingActivities",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_NumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of tranches within term loan for notes payable.",
        "label": "Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "NumberOfTranches",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrns_OaktreeCapitalManagementLpCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Credit Agreement and Gauranty  with Oaktree Capital Management, L.P.",
        "label": "Oaktree Capital Management Lp Credit Agreement [Member]",
        "terseLabel": "Oaktree Capital Management LP Credit Agreement"
       }
      }
     },
     "localname": "OaktreeCapitalManagementLpCreditAgreementMember",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_PaymentsForDepositAndPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for deposit on property and equipment.",
        "label": "Payments for Deposit and Property and Equipment",
        "negatedLabel": "Deposit on property and equipment"
       }
      }
     },
     "localname": "PaymentsForDepositAndPropertyAndEquipment",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrns_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information regarding the sale of stock by a company to the public.",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Series A Convertible Preferred Stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_StockOptionAndIncentivePlan2005Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2005 Stock Option and Incentive Plan.",
        "label": "Stock Option And Incentive Plan2005 [Member]",
        "terseLabel": "2005 Plan"
       }
      }
     },
     "localname": "StockOptionAndIncentivePlan2005Member",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_TermLoanTrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information for Term Loan Tranche B.",
        "label": "Term Loan Tranche B [Member]",
        "terseLabel": "Term Loan Tranche B"
       }
      }
     },
     "localname": "TermLoanTrancheBMember",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_TermLoanTrancheCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information for Term Loan Tranche C.",
        "label": "Term Loan Tranche C [Member]",
        "terseLabel": "Term Loan Tranche C"
       }
      }
     },
     "localname": "TermLoanTrancheCMember",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_TermLoanTrancheDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information for Term Loan Tranche D.",
        "label": "Term Loan Tranche D [Member]",
        "terseLabel": "Term Loan Tranche D"
       }
      }
     },
     "localname": "TermLoanTrancheDMember",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_TermLoansTranche1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to A-1 Term Loans.",
        "label": "Term Loans Tranche1 [Member]",
        "terseLabel": "Term Loans Tranche A-1"
       }
      }
     },
     "localname": "TermLoansTranche1Member",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrns_TermLoansTranche2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to A-2 Term Loans.",
        "label": "Term Loans Tranche2 [Member]",
        "terseLabel": "Term Loans Tranche A-2"
       }
      }
     },
     "localname": "TermLoansTranche2Member",
     "nsuri": "http://www.marinuspharma.com/20210331",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r149",
      "r150",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r149",
      "r150",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r140",
      "r149",
      "r150",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r140",
      "r149",
      "r150",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r29"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r42",
      "r43",
      "r77",
      "r78",
      "r79",
      "r183",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r170"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r167",
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r151",
      "r153",
      "r172",
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r129",
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Financing costs under equity distribution agreement"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r153",
      "r164",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total compensation cost"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the computation of diluted weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Loss per share of common stock"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r74",
      "r115",
      "r117",
      "r121",
      "r124",
      "r179",
      "r184",
      "r196",
      "r229",
      "r241"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r37",
      "r74",
      "r124",
      "r179",
      "r184",
      "r196"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r154",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r23",
      "r68"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r68",
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents-end of period",
        "periodStartLabel": "Cash and cash equivalents-beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r197"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates Of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r72",
      "r74",
      "r91",
      "r92",
      "r93",
      "r96",
      "r98",
      "r104",
      "r105",
      "r106",
      "r124",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 150,000,000 shares authorized, 36,640,797 issued and 36,633,490 outstanding at March 31, 2021 and 36,585,767 issued and 36,578,400 outstanding at December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r51",
      "r236",
      "r246"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r137",
      "r138",
      "r139"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Federal contract revenue receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r13",
      "r14",
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of common shares issued for each convertible Series A preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r11",
      "r12",
      "r230",
      "r231",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Accrued interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Secured term loan"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r126"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share of common stock-basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r81",
      "r86",
      "r88",
      "r103",
      "r125",
      "r129",
      "r132",
      "r167",
      "r168",
      "r169",
      "r175",
      "r176",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r189",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r191",
      "r192",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r141",
      "r142",
      "r147",
      "r148",
      "r189",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r193",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FeaturesOfConvertiblePreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Features of Convertible Preferred Stock [Abstract]",
        "terseLabel": "Deemed Dividends"
       }
      }
     },
     "localname": "FeaturesOfConvertiblePreferredStockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses and other long term-liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current and non-current assets and federal contract revenue receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r54",
      "r114"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization of discount on investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r214",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Weighted-average incremental borrowing rate used to determine right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureLeasesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months",
        "terseLabel": "Remaining nine months of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureLeasesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease agreement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r74",
      "r118",
      "r124",
      "r180",
      "r184",
      "r185",
      "r196"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r74",
      "r124",
      "r196",
      "r232",
      "r243"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r74",
      "r124",
      "r180",
      "r184",
      "r185",
      "r196"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r27",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line Of Credit Facility Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Original principal amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line Of Credit [Member]",
        "terseLabel": "Credit facility"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r44",
      "r46",
      "r50",
      "r67",
      "r74",
      "r80",
      "r82",
      "r83",
      "r84",
      "r85",
      "r87",
      "r88",
      "r94",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122",
      "r124",
      "r196",
      "r235",
      "r245"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85",
      "r89",
      "r90",
      "r95",
      "r98",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss and comprehensive loss applicable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r115",
      "r116",
      "r119",
      "r120",
      "r122"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments, Due, Rolling Maturity [Abstract]",
        "terseLabel": "Maturities of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.marinuspharma.com/role/DisclosureLeasesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r213",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of the Business and Liquidity"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r29"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r38",
      "r39",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedTerseLabel": "Financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r154",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Series A convertible preferred stock, $0.001 par value; 25,000,000 shares authorized, 4,753 shares issued and outstanding at March 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "verboseLabel": "Proceeds from equity offerings, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r60",
      "r166"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r44",
      "r46",
      "r62",
      "r74",
      "r80",
      "r87",
      "r88",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122",
      "r124",
      "r178",
      "r181",
      "r182",
      "r186",
      "r187",
      "r196",
      "r237"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r127",
      "r244"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r174",
      "r254"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r132",
      "r170",
      "r242",
      "r252",
      "r253"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r81",
      "r86",
      "r88",
      "r125",
      "r167",
      "r168",
      "r169",
      "r175",
      "r176",
      "r249",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Federal contract revenue"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Federal Contract Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from the computation of diluted weighted average shares outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r153",
      "r163",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of total compensation cost recognized in the statement of operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of major categories of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r154",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stock option and incentive plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r158",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Outstanding, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r152",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r10",
      "r233",
      "r234",
      "r240"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r212",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term operating lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r72",
      "r74",
      "r91",
      "r92",
      "r93",
      "r96",
      "r98",
      "r104",
      "r105",
      "r106",
      "r124",
      "r129",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r77",
      "r78",
      "r79",
      "r81",
      "r86",
      "r88",
      "r103",
      "r125",
      "r129",
      "r132",
      "r167",
      "r168",
      "r169",
      "r175",
      "r176",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Disclosures"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r103",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityTables",
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Stock Compensation Plan [Member]",
        "terseLabel": "Stock options."
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r129",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r129",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r129",
      "r132",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)",
        "verboseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquityDetails",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r129",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r14",
      "r15",
      "r129",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r129",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r18",
      "r19",
      "r74",
      "r123",
      "r124",
      "r196"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r132",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityDividendsAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).",
        "label": "Temporary Equity, Dividends, Adjustment",
        "negatedLabel": "Deemed dividends on convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityDividendsAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r35",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r35",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r35",
      "r134",
      "r135"
     ],
     "calculation": {
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock at cost, 7,307 shares at March 31, 2020 and December 31, 2020"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureDescriptionOfBusinessAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.marinuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r255": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r256": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r257": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r258": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r259": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001558370-21-007409-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-007409-xbrl.zip
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M/U7['[3LRYX'PAU"*MDM!\B95!&@ K.[;U.*+8+.VA8KR4DXO_Y(QA (OLC
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M]ZBB#>,K]ETT03.#,_ E>%NB;WO$62Q=QCC_;([1+*V1F4D>>2/4V)Y,<\E
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MY0.@'D3%:36[L%HN$5!>NL9 9'>.L75"EF02+53D%6X6AL*3]CSVV]/SD/U
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M9]DLT\1R2<@>A7@][8N23HEC(V0EAW2B5()0IR=!Q>VLA(; F4M9;:U.F)(
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MS\]L'Q883__+^<GEU>7]Y?D=F5^?D;O[Q>E__K*X.CN_O?N:G/_EU\O[OZ.
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M+A<L< )WH#VF]L2GB3D=C6B 1RTI3P^KNBHX$(YEXDQWCVELB^[N,2TS$V*
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MN '-<Y<X43)% SW01Q; @[YZ,UEYYTZL9*Y"WZ-1#)9(7LT?O*OMBQRP6YE
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M#E[Z_.#3=$/9;J<R.MD&'HU$2;3DE4^$8*GQ82NVZIW'B%*[[[XMDA6-X/Q
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M$$RLP%2=S4.'CQC-[13-'>?FIB5SRPII)9.+3OS[9\H>5_"'\\0GRX]4O:9
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M@&0MI[<(EV8*6P1.)2#_HU CZ L(29246 ]M6C)YX>";Q=6K'JUSO:VKJ3L
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M__)S&-#7ST[T&TTNMH%7#T+:QLCAI5[)(G!4MT0,"0T"=W59099(ND00MAS
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M1@>#*,!]\>.9F+CA]ZCQ_XXL% +DOM^#M8^JV$ IV3\<1 1((1FKA.0165X
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M+(3>\0XSOIA*X8%074UY(0)QF1[U)3:$+@\O/@H? 5H5,\E4SGL518TB@["
MU/M;:[SJ)D>@\2TB):/?]V*)_PK#E[,H"/T57J\2E=R"L/H$3:*F46#7E9=Z
M2ZS^N-^RYE -:^X06%LPN]"/[>$B?$FU$;!9(U"SJ,7)=#(<]9<U=>6E7F?K
MUVPA0@ESP1>&N>RHEX39#RU7(<QWR%\#%+[?N5:2OP OC=9D.L2VD6H(Z%4T
M)8'TT)>4D+%*D"'#*T!/?L5<,5;#C9S!N_4]FVD**LN:P09QT4Q<,"2",R<
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M0K03"+";+Z"780#F4D)([HP1[<0!["F#!'FDS?6#"&&5!3:"<9\7R],H@![
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M RSR[SC5@MQ#*)/R0RBDU4'<["#?;E^>/=DH92L4[S435I4_='FD9-/)>1"
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MF'@80E'#K>_9=?BTK?=)*4&=9(9FV"VM*F_M_OPMP18F]U[_\_\!4$L#!!0
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M;6HJ?14V-ZT=(?&\F&N#<KHHDVN#'3],QXK4CD(AL7F;-0)&4I*@I)>]=RG
MK.J:Y/ )X;7<;^1RTH<I\F'U\;DDF6:3M8Q9G[<FD48LW>V:ZV%_=A:2O*>3
M3:0'3.&I%95+HUZ\WND!<[#HLIE*":GEM[#E::H-3=*J:)JU =976)<AXU2
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M%3O'[(0<7I1PB_$B.S(G5[.?RJ6?PU*%UJP ^K6"0I9B_6F?SY#E4BNP=EE
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MKA2?)(<WOQCNEF.86S9!>@SDT>'79Z:@G/WRY8!<GGWH=FS_:8<S7I[MW5>
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M#'UK8I]Y-1)M$T_%>Z5K@4$;!RX!) J:GXE(@TBGVP;1=[=CH-F@G YT[S&
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ML<!$DMY"Y_37NLL$R'@P=/76%;IN4XA\$>U;B.@#Y!=WK^/EFQP[Q/FEYT+
MD6-C18;K:0+T:3# Y0!&J(C34$>C6BBNIO!T@,_+"#GAFW/"'L@01*$L1B?
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M"SLOKFQS"VDVZQDB Y KX<1$CPPMW1Z*)8ENG2QH)#I_S:!O+Z(==N>CK)A
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M$;\83?M#OOF%QD(4<$B(HGX2V4(U64T7DF6B4$4,G&P7:E6'(SQQO&ODO;*
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MX#PI(<'2<2X(;C,6$-%O*" "O"9X9(1O:*%4^(I2@>-7(Z6O6*9 Q\E8+!X
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M#6<7K:S_&PAV:P!'08(4HW)?B T826!%6102$A@(,LEQ5)QA*4I.W/RZQAK
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M7]H5SAFH_7^?<I;!VHCX/:[_-%J<7'D&8LE#8(? #I?\^M1Y +3VSDS3MF%
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MW'!ZH=-_'?@,SSN%Y_-"O'Y+O%YZ*;]S?,5-'F_!]K"K)#+@\$!1#:F9 0;
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M]O5=P/,ZYDO-YJ YJ,JR&!TSS:IDB:D6UY02)[Z$_*JLDTL),>RN#<5=[C:
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M&@B\>5_D)EDZE6J-73O9R@P1SR,[CB$3H:XE/(?,.#6X3 ?=C8)-.M3&B']
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M-+CF!.1M'NE(5$/!QN-$0Q)U060G.3*A=(+V:R])"%O0@%!Z&-%^#74$I%R
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MXB98"=E\=E'20#_G3H98\L2@0Q%/1U+I%!$_814_UZK\S^9S=&P@.YZ]WK<
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M\,%,^;Q]<'X+3C?A6]R?,>Y0#>R)ABXTYFSX'Z5 6P<9]LA<&P)J-I*AH%:
MAZU]*C#WH+^B> ZT[B!<5;  AC5#%B "*5PQ1??=0I'T@#[33=-:8(Y'X(<>
M 7X4MA-=J+5=:@;_B)B=<CQ- ^@>74JSK2EEH_TX0'_PX/]":PQK<>>&JGOV
MP29M2_44EU)0;A"9G1%J*)OR"IH/)OQ9A\BF? $$=R$;AN6XF,NF\&M0&EDV
M(HX"G^'_<;S!H?F8O$D@ _*QQP-70K#Q$&G>X)<O[-T1/ Y\V0"@0P1P@4#2
M3>S?H5>A^X#1+Y2[M."AT('AV2EH[B#;&>Y"5J%!H#NNS_(_X7?ACPM@6IY#
M?2_=_?#?A !MV;)Q0Q6VY_2/Z:Q-"&:X48@,V;"&^)GPQ#,;#*%\#2 "Z1&8
MJC7TGVL"S\8@L73UANJ,P-[.'FT<841'6EF%IX((A#)>GT((0> B58V,_#T<
M4_)L9D"(^=^%^]CA!(- AL!W,<U (.FRBS 2$ -\X&SSU@B"'U(IT-N 4/*)
M;&1;)A*3<$<1_ EZ(%X$S:G-0]#G#C"TZ :H\$CH$]=%P;U'L(,N,#R>ZS\"
MPE">^2!4*<A"MKS]Y,^)Q 8*F$&2@^>2*1?R(W"I"?25,8U0.MH&A&0T(/P(
M_DT%$'V.(P=GDLV5;AEKM)\MX#_2I7J#V"B94,8J.$Q*L323QJ0%B1D;Y)CV
MH%L(^8!"%*UC(:Q8$'?R0K<116?K=Z5<E$G_H):R [4/.HRF^SS3]4:R&:&R
M(V@8(+*$].U_"RU5@6+(")V0LR%,P!0"8[#&$KYKV89*%8%L0%S6;4AU^@,F
M)?10OY$0*DX:@W($'^5 X,J8GDUHO1AK"C*NO8;[]"#OK=&7T%.7Z*F(%A7#
M0W8__A"%B. >L,4"3R/>M&]^W%""!E'I;EQA%%+&BX/W(-,V.#5\_2+@*,<_
M-MK3% E8_^TZ< Y>"=\1";XXG1G84,)4#3<-12P2%@8%J06Q4\ _@XW*<T:>
MJT)2\Y6?8V&W'(I6-[B9>HKK.) 3CR39YAV0-^ +MB(WD&OHO7 =E%Q#R#$>
M9'6XZ1$ZJS."IX=BV7_+]GMP0_!?8-J68> O(R&C*U &Z&BI0XTL!U=R.7#[
M4)S[G Y_!#/#6B-)KVD1^"7$8NB EF<K?KSA.0VR!3-ZD $EE;M]!XI<((@@
MGH-FUT9D.+[XVU(45!H8&H"R=6?B@V4)F1*^FP)3M"^ ,(2PC*)HF*LQ+'2
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M+61_W&!!C&90#H.[7-:;*]4WE(/23KKI6U2;O"&*7ABXC $:EP 5+6SZ:.0
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MLE^'<E]65_+ >_DUZQT6OX5;DG :[<F=&,VK\V(")''#'/7C:$\E0\EXXF,
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MF #6RD !K7,A"/ZY"X2I&\0+0.0!$U/WX61 5*X$K-.A/S>QLX$%+Q$L!LB
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MB-]H*//*R\3O)6;/Q@P_(1OL/ 7V=[0KOF+NR(GMQQE1PQE8F3G>]O8%W)#
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MY182Q"8@W(M'@P4QQHBPTG(>$J02;;O,GXN( Z6;E*(HGAW&8]#<)@R8A4I
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M87!CPQVQK.Z3ZI<DTJHIJT;MH1:_?PL< >L31UA*)<SE("Z+9$7PHV +21Q
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MS%]1GX@Z(-G4SB7V!KKZS=(37#(]VUQU?N<9>;FFS& #=_S->?"3;]%<@WR
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M\V!3BI+Z \7N\MY<.\NC61;LB(X/&ECU&-_ ZTCO8(R1>[\W+'P@=SWGD<-
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MH]V]"NN00+X2B?AD/NX?:XF]O9R %1,Y("9GB+ 5GG=^LQQ!Z'F-+ ZYR$-
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MM8X7_PLX4D'9%<X10+@-YY)':1RE<3"#P7SE1*E4&^DTX6&7$5 Q*Q99@9X
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MS@Z/AF^$2H\2=TV)L^%Q@F,RJ^D0]8L2QV#8*#-ME&>8R;FJ^!Q3KQIUZJE
MW[LV4%M6_$:!V@.X/%^.D,:2).F'O_?!'+SZB;"Y!:WBI8>!\,AQ+#:Q(!;+
M)N?M2!EDED2+9/J!T6GTS;C-XML%>RI"&HVILEC":].]*'J19 MJYEW8C&%0
MXMU"@E\)^:H\$+#@5Z5+4F[."8@RV!W)I6>XY0=G;]R4!)FH<#6+2Z2TOR/0
M$JB(I>W5[MT&Z_0:"ZTGV!;<^I4)V;'5(R=(0XS@/>O)8 OQ\^HG'[0XWO#?
MN;X-"?P%B<0W^(2.*'?EM@#1%DAVBR-%6"@N9"A*"TO66H,!:),B 2[&Y.8H
MO1NDUY@/7HEI4?(-WB-O$EVD^I5AWG)$?4<@D8N,2E20)(DBE>ZFNU3X7FJJ
MK-0J!$RN4M4KM[3 9">5F+B:6'S*$B?C/0O+?12M-4KY*.7#4LY]*FR+@1RL
MLW:]-2%%*2A)E3Y=_1OV0QE.=;5EG<X8H529L;&E\HWC4GP*?[M#8CQ*\1V3
M8I"C29)_*)M5/5UKB3:W"QT2FJ_=7G/+;IKWK63C9"S9&$LVMCF4-U>RT96Y
M&?V_+Z'Q^TZVMR##A8>$=W<1!*H%7#MV=X1\Y$E>>W7+<MG.>D/I00M%Y%]G
MH#+%L"XH#"]UV5R8F==EL8BMWTX?Q0)93& F^,-PT)YOZ^UZTG)SUO,"1X4<
M=U(4.PO"%_VEC#>]:==N;BP]C)\,-3<^V!_\2Z=/^M>9[.:"SFUB<J^YGN5
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MO>+' ^_96H!+-39M,8CA5<&[#J_]KJ-]?Q[P..]Y/W_VTR[<PYY=^V&'P3*
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MO?U8S9M_[KW=ZYDQ149_?_U;W)HZ K#QPOR8+=F'_?'PX-##!.%U0X^<F91
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MO,Z;*?N]N;%MY^WADL=2@3+'%I99A6&XI]89EB.^]ET$-23\2.V]3  ^&1.
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MX+6R27$K^C\X/!4#[^.(;VC32,)Q JNE#4(+2T&'ES 6+CV;$LO/1Y;>,3U
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M)JME[WD[%WW^Q# J6I^4%O*:X @H((YP/GA9@]J&J1>7"(.*Z8N^9 \$# (
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M<>/D9XP;I^P)48\Q!.DS!T/%I:6E$VC=V\Q& Q;X7M3V*?=*[4Z(+CMS23.
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M_;9",\!Y":P=)C=RFK&C8E#:)!]$Q4,J$;LIS\[1S8@7-&J &=X;\1T >'^
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M(*CR&),W1LW/W%-T2HU]3-9&.V$\A\22W"SK!;EU.P<R*NT+N_!C(P@K6_)
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M/<_M@5OL\4]S6%*W$[TJU,"A0,W!VZJ[X!=(LP0C><;>T]+16YFH75;>X@,
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MDO@8>>%/"NE.Q9VWU15-UG=$]T W7\[<8*<P"0ADU\PQ!=][^OS-?<4BQ":
M;1V#J$,;" <RU3D7Z"\^1YV:G#Y]T:BQ(\69 TG)59*K'Q052C'9C'B@,[S_
MX*R'KXL^6O;<Z%_%7!OA05+5@]=?<F#N8;BT&35L3'CJX!ELJW5&8M2LD)5>
M4]F87@4;.</"=2/><U24@\\"8[=&:E']W/")%FJ=[T.;6[&/@*^JV2@'F<IP
MU%I"L,%7EN(C9%U'^;"=;Q)2$Y4!MWE=+@A;;I*8'@I5AUW9==3]PPEHG>N5
M7JB!AY]6JP:R0MI85LKU]YMZRYHJP\WTY5:QOT F= !(MN3<;?A?/:E=M:?K
M3RGYKZ;'!K]Z=(?TOX_?H!FS(.Z?#.%$%XZ,AGMV)4[*BZ)#"_\/;UE%*"53
MTBZ=%7Y0T,F=-(G79B9&0?DEDF .7N(^^@7&P?;1B$K=4!<^^ 2PH62Y]C=M
M")$^[J"PPH.>X6D!7<>.<CBUFYHS]XPZJ$BDFL%KK; T#%KMN?EDSOZ;, N0
M^'XHG?)85+U1S=_3O!2M(-'HZO;_0,.6WQ(:2OCM?]L@ GG_RRH8;(M9-\VR
M6DMEB8>"T=R5OXRTUNQ(M_A);,NQ2 8YT_ %F+O:'$:A RT=5F%>(0 [/@=7
M)///4)S2D%EM_];@C>[UHH-QKQ91"><C=#+&ZSJ=+7'/;]O):N/(XVB:7]ZN
MPU:85"Z/[Y &>9TTS^'T)TXYL%=X4")I#_33*;D?WU:&7HS*%X+M?3KKF(TA
M2J+%J_LB;9F(P06\="I7UAY.CF7B;"9X'[^Z^X,J'#RKNCX,K-EQZ+L0I ,<
M.E;ZK'<D:@5F6HHUX,0&<R4WF%S!J\MB,^O,]!BJ39L:W""?E#\K'"3TBG+=
M& >B$Q,=<*QJ3PM=A=-Q- QO6E^*]=I?XL[XLB80.I-"Y53(0%-(-:'DA%WB
M-;E;:=/\\)&XAC\+6VPUX%*!(K@OR]HQ&+]TQ&)D2#*JYL7/Z&[^#%:G'BXG
MEK"9\X>C$$C^X+,TD8<2%O73/9NZ&=I$2;.QHTF?GGSQ'%DM)[)Y:3[1VTRF
MM:,TI(^%]*@]S5UT@FJ0(T#/88_%GFUVU[A^.-'JE1MWEWGC%+U8OA)/8$YS
MUPT*;2S9V@GQIQB%W;C1@CL:X#^0(;$&BH%??;U0'"#62T'+L/?/7='Q((6+
MPZ.95X=&CCD-_=/62\RB#\B#\ZJ&N)3%<D>N0,*\0<)N6@3I,4WS*$[R6%R<
M4%TD#OD-U&@&'@JKBG7IHCI)ZN3KV!K4;)RZLV7$0D"6Y6^&?LIU;4>?9E7S
MZU-5\U35O!-5S;O@N))&46_H^^_?SEZ]_(ZM'!,$+,>R22"'!'ED%:TB*56%
MJ='4GS:T#7P;UOAB$!B^_&SVG?=3U3/ER1!2U)OR7>4AOV+M,XDOBS2' ZPH
MZ6#LF(?3]# E:Y27,HZAX&D29 N@?@FH$R%8$:TF9__J#0PZM=L%':J.U6_D
M+_/46LDS-H>FYY>1NL4R72;C;>:W( 6E$-X\D[9HVC8$$;]Q*_J'#8\9 R.-
MV2DNGPJ8D!IQ[*3=FT?*%M;BRJC925%\I)HUJ'+'K(F$:H(:B!RK%25]WZ<V
MU_+XAO"407;3)M,1^7A>T2\U'_ S93O*\#*?KL*Q"L?NWL]/[\\T2T4\/.%I
MWRXNJB4%ZO>^??OV?MX+C]D1NB;G6^HND25S!Z0/B@\N3EBRS6G; 'F)?2M9
M"V0"PYV-;%4VU3P?E %\IY:R,B?#^6BDDP.@IU2P_:A\48H7B?<- IG91=#:
M"BSA7>R#;= S\:^Y+^[>M\\8L&F%UJS\A86M+;+M?UZM0#ES[_FKY_>+R8IY
M6"6(9Y\U97C2[X)OO+Q_=XX3Y1/"D].F)37B_VZV#W2CGHH7[Y."NFOX'&%=
M%2/.K&]DCSE$3GZP\F>-__.@?(-,!A"EM)+SVKG-.4>%Q-@1#6HTH&4 R&!$
M&,."H>=G^@"S%4L#A4C3M8 /"TF/Q-;8]W L_#BE'I%\D$$"$*;AENY/+APM
MUDVGH$VD:PR$9Y81D(^GQCZ[+0B]E[_]-(53J".*],>6-?B;"@P.K[43U;1?
MIJ4F9S.BR&K2B+BM4H#08;?]Z"2&A-['EA=$[:II01*G'TF&-B39ZR8A7&^&
MX+ 2L+:D5.?A<C1ACZP^GS8[#B1203$PFM38TW-33M^./1Y.LZ[PJ5&N)?UG
M>T),RXPX_3YH4ZT7M =N[^E<.LH5K8?.8GZ\:7F)\0G7'RRKL/G\)6-E(;6%
MD11L00+>-3VIPYG ?(L'/NW9[-N8.($IC91[\43#NOV)\>1  T* 8?$I; ]&
M,B2.K=TE=J(K\^VSIZX[;&PHF::B> 0+XQ/6()@G'F6^>M=(0I]V+GD?CBN=
M-K':@F/;^'DP]*!;&=F<$&<D=$^%J['^_I-S=Q*V_[_&ALDC[T]:1''/*/"Z
MW#.G^+K"?8*=CA9/S5($&^#)V07UUBTEL[2G 04MU@U1!+3.W$MY+A)(>GSG
M;L\&0%EA'/'H+0+Q/^T\*:=4W$FXW'8>VX!BU+W=]AMN)YBB<X+GX)'S8^J:
M@L9UB2( KT$ %H$&I]UL0R#F5!@<VYRB&HQL/3H+^<4PINCBPL4YK>-G8'Y5
MG.P,^.(*Q<"VDDO#LZQ;L<<5;J$*])90">"%R3#_LX9)FE[;ME#K'84%3^];
M[TN'5NU\4DW1:%&WT>UEI.SR@%/5D$%@3<;0)/_ B=(QD]8^( 16 $BC?V.X
MB6;7* I?"]RE_E3H()T"$FBG3.$@*QGUA!(<>FZMIS/$JE2?91E9A1MM%PIF
M*<;2FFQ$P/5&<7+/@G%FS94\^^B.T*<Q["ZH"\Q*3C\8 .1,XA%I/=.XLW,(
MLE=HWP+CK?)0<8=PQ-].WT\V"60XI0LTL21Q@PHD)@Z90LR :\E:U^R#SYOF
MG9Y=PEQ2?VX1UE2"_$PFV]DO7 $ND084]Q2N*V&D;&FXP*Y1NL)(LI(>6L+T
MK9?LY!4*D;_D(2_ZR9:&_K+P#.B\9@J,J '6_J$-KF6EX$,C]H)?2(AVZ@?S
MMIY7#-&40>[R^P(&,]0 VH+"H:-JEI2:G[_Z"U_J[8MGC%=]R>U?>"7>,9!K
M#K=X_+Z_D^*@%&C&6F9/[@G)I)]85&.F#VN%U$F(GQ>L=Z0F5>)Y0Y#Y#Z8-
M"%[Q)FL<LQO;_*W'L(BPO'(8,CB2\'S!) '=HP(+)*9Z<Q"5V-R/?@(V-C:A
MD3N!RV9A1,V";R;?)_BA=7.H-!J) XV?8E'HBX>GHM"I*/0_J"@T[1GE'H7'
M7/>(MZ8G1J)OGD4JR>P9&2:K!R0Q(L+?D@)QJT 050&5\/U]1KN!#0U$*DI0
MBL,@\[8P#W\.%E =_6*6]SM6[X,'(S29C&'+':6"7DAJMN_4GG1=%7E,CX8<
MXMG1T!49^<3CT7>J=IX^ODHRI(LU>7$8XP=JG;D?[&T=U&/LDDFP",;B$>V(
M)AQO'[4]EEW.$N1<-M1-$N?@V:I1O' LN$3]*H\NE]Q\GN#U&-/W8!Y<4#RM
MJ<VC>MX\1,:6:XCL89V.1X8#2A@*+#7Y8.UF'M>8D5$<2RF%9[<EV^3*34S:
M8P^G,A$CP6<*HBK$RWAZ!Z@4_6(';(WX9!Z\FTH9CYR:<,GTL]G/F&-P<0Q4
M!7,LV9T'J7TDG5JP&+O%D#=&D3EK&+QKGUR3ZRH/NE\NWQJ6%O+:Q.TPCW*,
MR!EW(J^=J8:U@=;-5.@T!569MI=U!%J7"8[C3QZ>X?P!E=A(TX =QLH(P/89
MV=6F97=>NXSL?B.?Y5!/=-]%O>.+1K[F)FLF"Q_L5H>9D"<AX3) _?I0(;OR
MN4,=>[.AMVV>UF'+(@2_;;7K'7^'0WR32N?80W<QW)&V!,5D1Q] D%J>)#/4
M8B).)O&.<6VX7RH-U7OM:R#E;&\VB8<B]/U8>'M7LYE,Y1Y%1 Y$BF\\ N*J
M&+D>K"W6!A&VOJL7[\@O+\(^E[V0-,S5M [0F,>R<JFZ#I:*S!?;'%,/AOA6
MB/)PRDMEHH<Q!&%WX:2**,9(UMC48S;L@H._52W&5&FM2XC[+>=%OQ]!X"\<
M56#<6&4N6P/$C),"0=G3++6U"@L913Q?"9:FT+F/I)Z38N T=R:WJO+V)8A
M$+"43&"E- = P\J%K;"I]<$#)B(Q;YMRN3YX0<PDKQA()NK#K,^+F\OE3,B4
M#IY!,/++>X"9Y-$-HLA.F]8>LWHG[V?!C*7BB0;W=-[OTP:0L]F+2Y01^2)&
M(D]?L48C!375^?J<S<&@"$@]TI<LYSF.C6M#T6.O:LBG=]U>[MB)%1=U3%?H
MZS?R,M)@;'_M0;4O?*'H=@F]#6%:1 9+&2MU8O+!B\X%(#-C]Z+;1'^QXX%Y
M>X9$+V:5DL\QG+7@/!DB\U!81DZ.4IVT&>;$&.O'?0E_W)$IR<$E<6CK[IWS
M]3CCO%ZCN^/?H>WVV"G-MR!THES+NMQUU;_K/[[Y"(9-$T^D^+YQ"0\H2UK$
M@Z#5@I/_[ZOZ?;7TZ0[-V+ MW+?AOTM=,7\,"I82-ONE_^/15>>KO*1VCQ!>
M2=X!^CNL[YMPA/?5@V >%I2QN&K+G:[M*Z2<D.Z1Q?WQ#U]_\>77W^3K2#^4
M6/,TK74;F96]@U%\2FKT/T6-PDLBS73OZ7^^=16;<>:9="Z>SJZ0,P,]>Y\5
M;>#!4K^) #GWVTHS]E.5&4QB=A=">?6N)A1&IB[L><"GK:[*=BEL650+(4+8
M8-7"B:QEJ54$(V'6)%=8P2=C'0<]AX548WBYWK *F1F; 6!S#KZZKN0*>I$5
M$YAZL/@]D]QUVMP6C;!-Y/$D$D:$;&Y^2*2J7;F*R#E!*/R-.3HDH7^BL_0G
M'+Z3(C@I NEEN>:@>Z[0QJ$A4=1UG6J(HU3,)EPRP [G*>6/-)M?B@='+A<Y
M#OT:H2#Y<]P1JW7>!-9 !@?#W^,=-^4[W TW&KDISE7X;<\$G'Q;KI#A8)+7
M(.=0^F-0(781M#:N4=_B8:RK)UF/-!0@(8MYKJ9FLAHAPY9*+@!4RS47CZ^[
MF:J#>-/3,3\=\ZECSF?3^O)=I"396W,7D]/L8@"+T3WIDOGW?,5X<&0257QK
M=-LBD;=MM@_<X17\M!P@]23))TD^9K!D.N#EMNM;M!*\;MJ]09@%27O*:3O]
ME3 H/OKZZR]8%Q_AL)W=(REB0"+R0+]_^?KIT_M"U]S%8X"T-G)4$3T-+>M<
MD6($N<5%N 575?2L)*Y@)O@^0Q]"QTO&"DGB\J:5W(9"0TA#U90G3@>S7G'[
MU/2I^M0Z"!Z=.@A.'01WHH/@9(\^HCWZI R1\]8;&=NG?_<[WU>_DLH=1R10
M__HW4<[.:QIM_V!\S#4!Q'$E+P9"9&Z&QH2<N7"]SJ483@[5R:&Z42KPM9:?
M9J^U;>AM3PGK+2!4BQ3!DB>A7NTJ]W'#IC54MW2F7<'4"O3=@N9Q7A/TE,(M
M*R=DUP,9IAO)CM7=!+*&KVP@!']V4:^7;16IS(>>HZXWSM+S#!=73$#9X5I[
M'-&@-5;%2A,:DU?RF.@YQP>MIB=-,C2;0-K X1]+L<*1ES]^;!U!OHPU&RNS
M8057VW!C- :@W<51IQ$N>$?88X3]-#_D14:&!JTWM//H:X?\A1=!*&Y"!!/+
M*^!J] PA37M>;F5.KP-OQDG9G)3-A+(I@\ VY]3/QZ4YY ZDH6Z\:4!SV_IY
M5_)UF8<DE^%83C&\CW:8-==$77$[+^;*-;BI'N<SS=DG%C7B"N)(I7D-2AB.
ME%.'P5U->@A_<XV ?-SY>4?KE;%C)^M*3U3M73N*#T\G\2Z=Q(GSQ[(E2,5!
M2!<RN::MJ]9MD&,""*41(:[5[:+?4/\AS/M&6M#X5/)0+W=K84:/I3WK'*3P
MFZT:,!CI!%+SPXYFC7<R0H'$#+68]#IZMRAE),=&3"J"@??$C8-C,!Y-PVQ8
M)/^[]P:]X&7S3""@"0Q]QAI3AFTXZ5B@(5K6V%# -$0K?EU+!-HP9+R(<='>
MHV$2'4!41:7.H" @08;8_3 J6O<:B]@X?$8C\30>OL8X<0TG3KXC3Y>H3T\]
MCK50M"4\??E.I$VPW"3C!M7ZMI7I0&E@TMQTVDV.(A$W+SL3,-U^%-LTKME+
MC-SGG9%MCA>4MIC*D7'MU%1VIE_N![RLXYTL:OCZSD-;N@Z_0:-ND>8V,WQU
MUXAGS7?"R$J5K;IKI/!E7&6#7F*JU*6TZ8X0[7@%VT&F]N03KW7@$YW^O<Y9
M-_E&8^_1^A9=WK'WEC3?6'$3\G-U$9[BRK.I^H[CY$4*$!2"^'3*+85:89K(
MP\A+T3>@[8_TUM/WX#HDHSOA^.%NONE3>"9??URRB(_9X/K+F"!C,&+45OF3
M$0P&Y?0F2J<F7IW19EH3'P$>](M]!HC@>UFY-I"<*(>G<M&WRS4W(J=M;$?9
MA+_X6MF$LS]]]M<O'TXBO7_Y\-'TMQY/?^O);4'8P(A;<24!DTMG7<P=*>+[
MQ4NCD-O!%,=&!1H59<R/VIF\%#\HO?VXP^.ZYL$0D^#&9D&YMO'*KPEF0,)S
M_T&DF,.3731]/@3$L;A H4<MH^C,2H2$?,;C;VB/R2RG,P5L+,X9D6^,[LDS
M6)$VG.O<T9[!2L8=O#PQR8\KA2Z.BFB#YM5%N5[Q&$.Z60#!H?,K-QRYC? [
M>3_&=5]2JTC9$B+4M@L7[/=1X^4]S.G0''3$_0@7Y+3'A.)P<L@))DC*V>SI
M.K;GJE=JO6ONLN*<:DM,T',VCJ2."6&^V")T*S7EHP._+JEK*-[^2N/FPZ%H
M 5>Y8/SH%8%SV8 ;?L52$HN'O'W4.<--;(*E4WW0N;(Y>G;42]Z-!]G1 2HE
MPU$ZQ+F]03L(U",H;;W+G\UQ&Q)(VN(0NW^/A-"C;S\9D\(58&&H/AA$+*PP
MSO6P+?=-QLDV"/@0T7,%_]1N%L?EAHMEL![ .^,TZEUF]ZJS\[-B]E9^][E-
MJ_SXC#.S:L&>T>!1TV[KDFI>?+'7<F= <3PC*(Y_,BQ31YM!%LEN1K;E&X9D
MLQ$D '5V@R2XZ7_:$QIF(Q10\<L+@S>:&;S1F4$2FO&UEU/NPT_;*JS>N-(0
MM*Q)4,.=K!L]?C#.U5I;^KI^5ZT90*K>]LK!([#W&,4("T?&8,*W^O+A[X85
ME_M7/IT1PN@'2&@ !S0*#(,BD'R$1VO>.3"HA(GK\<.S&<:R\,E(XA%'6 =\
M?#A!.@&@4[4PW4'-@\2=IP0K>%]$"IUX=3(CL.(>.<BTT3R.'F_ :%@,MUU.
MLS@4)L_BQ6&.--I[:$EZPT;]8R!F"IJU3@8'HG_W-EP)D!78UY8-1DD*:X[&
MX,CG<5D)R8>,@--K>/%3,3;R&O3DP(]UNHX&6T>2B1X(21R Q'6E'4\<G3;9
MAWHKPP7\G#H)$1\UT<C>K_W4&DL>GQI+3HTE=Z*QY'>-OB>L _"Z(]B.QYZ1
MM@=&+P>Y6D)/E'37B2XWAR;'#(]H4>L&I=]@@PDIE^<8098AV1WFMR!.$ZC6
M]$I>K>FT/T-#=7N!/@3!CZ2QI:E"E9D5=@2/D2.-J/J/V9M$XP+W*]+IZ#QB
MO<5#BO.=H#I.9O<4>@/V26?A^^V*V+%8_OH]$5%U,X]XQ8^^]$X70 ZHY+XF
M#X[NO]E5R]J:3KC))((BA.TADZ"3B44<]@8!Y$+=9+F3)-S@Z/&-(I_ABCS-
MDA/5[+$AN[@7"DT=C:/BL\:F-C,>TRWQ^9!T9- "XGCI;-0FXI1OFB4!?8+-
MC80@O/)N[P'28LKX=F> ;^2AN0 .T9H%;S%./N!_MQB#)Z3;B"6!::5C_ %#
M- _+C[JD97Z"^63&<&9X($C&@#0+_@)&?@S;!4B2,HFH8K(]?*## *4+HE+V
M*N?&N5,R E:#T%&*K+3 OJ:0@]F(/_QL3IY+@1XY=C)%HE.XU10RP4'[Q9E-
M'B7VT9<CJ6TU]VZXV7_KE^>F4(DI<FTM97K-:UN7>ZFY]2W# VGW!R<X&BEA
M?UK:Q=[>!ZB8CZ1.!N&?I73OIJ))*=U&XZH@@8LIA,ABEHX<TRN^+AD1WM_C
MAX^^*B3BL38M'QFY-5 Z?4U*?U'NE"4A)G"@5"R'IU$Z5U%1R.2PM54*QVKK
MA,Q$)D\*IE<%VDCB:OALW$@8F._*BY]FWW$*8O:<KOPZ*M4WD1+YWG?/7[\Q
M,@!$+=AU>A0+RG\(3L'CS\&-_96.F'$>VQ1%OZ/'^>Q_<TT1T.3GZV9.>=&^
MW9(^PRZR)JYX>%PZW%PX&/;M[IM)3]]%Y;IMVQ!HAH)-U().LSUOQ'55*OH,
M7DW#[YZF]<)M7P1!:C;U8O8T;-+L'O[V@A)H9-N&P"D @8_(69;!\) %_)X,
M!_(F\H#/L4PD^?!XT;Q<HE,LC69SQ:LNK$O18V2D;K898A+^I&])_R#93OY[
MI&7W8Z*ZD2^>DE?,QM,]='@8RUFJS!GV4.YO< E\E</BTK4M/)&D%"ZL)Z&K
M+JL!TW2S]8"T(!D6CO#LN1E5%8TM.-X"*D>$K9TR?.AF#K:-/ !=<EAGH@?X
M#?UT]E;2P'!IX5,E[!<3T&"\8_Z!5K_9EMJ.*GL&NEM+\ZT8AHNTBZ!E;45A
M\HDPMAE6_8YB$6IYW2S/I4N%$K%2<>_Z'<5B'<@H8A](P2#B1K2K!EW$6.H^
MX5K5MHO,E=*L($!9"" HQSV$?:*GY.<=XF39[DKU6;G,N4_B2!+P@X'S(V+^
M6'Z<%V$0*;3[C2T$8/^4W&0(795I:PE)$/ 0$U,0W"2.C 7CALP$J*R)?AN!
MK:VHB[D2/$))[VO*D[%X"8_$O*E! 7]$_(L9X6Z?ESY"S(&>QGAH@GL/?>.B
M]F^9ZSU)IOYG>.AELS%W@W("6GODS"OWG3%N! =*08?]N:4/%G ?.%=-+."2
M]-Y;68^4(9Z+#<PP^V%J/76C9%7'?<A'#W\#+O>/9X;_S&C(AM)7;<)S,U#I
M#I@@%>@ _!B!T(6@]/#JYY?/'SSZ>D8HEE4PND523XM50DK* 5E 2M9>NRI]
M/"DK+E3F$:7R_)(PP[,CS_#9@;K=?6M!ZOF%B"R\\2ZI_K!;R?)9UI)N@K0K
MT,@"*_#^XCC&$"H;A!"PJ;LJ#PKC#B"VVU*V$"U98^%RW AGHS\%#TZ: V!H
MMI5F)^#$,(-1Y&SB)WN@-F[004#[%R&S@3E/02)^3[*(=$'8$^'"^8W2*?]4
M_L0 HZA@CD=!B O?XZYF5ZY17+];D]&'![Q%>N1L1Z)QYXP-$U4C%Q?Q*\T%
M'/A_'KJ6[%+8MK=!-/Y1M6O$:YVY\*3"?$M9?F.O+]CS)P<B[/FW&#DO29\"
M+>DO??@.U6BEF$L,\[2$OQ"IW2*N1L.;8'LD33+V<2"4K$N8P(O*0O>W%S6-
M$CU76HM[]B^*1?_TZ/'G#^^3Y(7H_R;/=?U>.MOLO&=VUP:/^"G7'Y^<ZH^G
M^N.I_B@:>L6^.ZS>4MP_QY5CRF)4W_Y4N.C-<K:;BD*:NMN@Z6VK0ZQOE2[U
MF4.9?;8F7[:;W7O[[%EWGQ4J919:2493E'QP.<O+"@ASSLZ#MPIVA,EDKC>2
MMT8F>9/W\6H[>UOM]A@,G7U5.#NCK5=Y#HO,W$OGGH6@5IIUPQ7N??O\]<MG
M]VG/4K,(+FR"P-K59)YT^(-SJ"4CM(9O=-T#6(',+'W;EIL*(<>RJ3H9'$)K
M[LSS^HR]+^M5BI.\,#U^>6I_?.Y;&)?H<=B!E9D 6BP)#P-7[R5P)VI!I(MU
M*=26FL 2\MIDU4M[Z ,@QZG<KE$U5=Z[3C&SJ9P24VQ8#GNY]./8\VH 2KN8
MU* '8@XF,_)[)0W]]YYJ9,32:6>,'K3@)C@V]GI\KS'UXZ<W<Y9NMU#[XT6$
M.5])'D S@)C\I)V"NR.=K=C5_T3[M<P?A2?2SE:)^4C8,.U>"VBL5,.41Y.9
MK5-*4_(@6I"[2FO$LF_92QO_ ]VBAS(30J2849'E2Y9"TT4K:PB'MHS3LG[M
M7'I)9T^-ML(-H3*:7K->NBUI*^H.[F+BQ#55[T%9M=39I_#Q!V';?FS+)0?9
MSQH+F1,^5$R&66^G\%RSVVF#4&,[?8XD#K42@" V7+5#H?.!##,NM-Y3=_$P
M,CW8T^VV>J^ZP-;">H#_)E^@H[HRC:2 H>YMT,-^]\-K:FK?58N8"M2/*EX]
M9QL7BZ" F0AP920N^/ZR6?1,5"STM>=4#E452&145Y0-+QP:FPE*9P-8\W*_
MH"06<$Q3-N3PHH ,!SD4"'W.ZC$X]=6L(>HV1,CX_7>TO>&TU-Q3C@1'C8KN
M:O9B>T['NIB]731[Z%7Z[R\EPEO-<.XER0:J X[/11W1/"&4RW;VDKP6:=$M
M\AQ<$)\DK/;9&\9$5G7C2HP(LC-.]QL*HU8R+0\?)%Y(5H2/;/"N%V7;TM@L
MU0M$<[,.?HU4A%[H)F]>3>?P,BP3-SM/,&#5-NQTRW-^I9[/H/3,I")+7O'S
MZJP&$B!;9J38TBUX!<W6M;=R!RZ.8#HR92+5.-:;;$(S[IN372^7AH%=SH7^
M9C6B "&B+.G[BOU"VHY$]G7'D.WMMS6E8EHVV[13G!/&.Z'7?<W%<)A+"FKK
M!N(?S@7](5CUJV9V"(YY)]0D::?UD[/9]WIL1;"2NC9KM_!;))%DL(?S]]>M
MB+:9>)-WZZ##8],Q*<]P8)L6(A/TWJ8J;;!TH$+C2 W=J%IJVHIKZE'IJQ_<
M5LGG'MA'@\W;<IW;%<K9^DC;M_*:4S$39Y,/>3=EHX+<)OJ'CZ$TXG15$%G4
MK^*I[_JYSI&),2R, ,',(Q15_+I5UWYX.JF13.]F<P,Z#B.'=>HQS V0S[UX
M]CO1C\R3&Z2#F&^"[]G-WD0PG)=AB4C5TDE[#:#;_>$__C3_F/[:QYPDY<PO
M"6Z_59(!\8N%C=T]STZ>1^<0./MZ[<> &[(U)W^E>692;H1X=-"*7T;*44B%
M;K.K]I+IEP ])B;)]ZINV2E^U2?G,G@0"R9A(M8)S"6"%@DD\VQ(MWD,(%5;
M'L$0[M5=N=>)7!U"&MODD2AFP)O-WX\-S/G<W?3KZ#"LV%*BDOQD6,R.P)K!
M1KJ'I5\TNP/7OV40E3I2@X\7Y[M\"0I-;4$:J80A"EG:+-7PROH<U^=VF0Y#
M%J"_M:$M(.N']85%8EJ#77_9%3R TFY[T6;@!NX:-,$*RH6& V5A5(56%%-]
M'3N9YI)YD/$-+T';XE&RZ([4:+2.&UU77;+5T8APU$G.0,[Y\;OQT_X(=P:/
MK)L#?V)>-[FDI/%/;"F1,(0\!>HU"Q(2_FGA3F&P&M*.SND P3)B(=?@VI$S
M8JJ*@CSQ%M"^ALD[*=K T0E"$0OGL))*$2;9J^ ?D@M9S+H@O>'_-&8MM,SC
M473=X68P,\%7X/W)6MM 1L@;)_J/A9W%H._8?J7"/+(]['8%'V'7N=H<7XI&
MFWGB,#@NVV-R+2O0,467@>-O"2UAL/<1R$1"L?Q26?DU_$@NBK$L7V<%"A[7
MJC$U(>VUG.D822(EO0I4U5%2.'4_F.7/&C0&NT,@%"&<D*A& *W4\"CCW<B)
M]IA93*0(T2(90<9(#D14N=95,M>1:RZ-<0MYJBPH)I&85 SC.CAF(<I7ST88
M+B)3G>1,U@<-:$3BN$S%4WJ);+&F;+HJ65AZ?4ET9%=4$=$,8>]8!-WS-JE!
M+I>7X=)H+!(W@C0MAE"3FG)\,ZFK<<3N9=G((R9*R\#)J]H[_>66;Z^(@[>N
M1_S(3 7.V:"5LH\A_=J9'J#X=6(U-I-#*9\>D4XK:EQ;M%+;+_X"PU2GMZ!/
M?I+EN\].Y;M3^>Y?HGPWI05$]>9=D42J^I*16X%;GR!_C>E+1!':?2-X$P?1
M;$Q+R7V2C/ERR;W['3.[B'M*":S.G!8_@)(K-8%KB&/>\XI \02F;-_0-,3>
M*^X1#8M[;B8&_Y]\IG6]D3]]/OVG+VZK&OA+CE#B/;MB=I-B(;T"Q^1,)@9%
M,93X8,OK<R;]/&S);:@[[F;"#!"X.^4]5C1#3^0-#]G01V9$*N V*C6Y^RGU
MC9$EG,TL-AJ^R,G8)F''7?/$%"^=P#TV5? _EE+48;#O>.?"KV);;ANXP(MU
MY+"&>R Y,X/]I5H&,:D!RYBJ@G7P_ 0+[>7/81,XL;AQ4W<2,%-$(.2M2_ZN
M6T#Z%?@@LGCR'RAGQE3)7?H0""A%3<G^4PG=RE7.?U/'JVES=XM38NRWN"\<
M<4U9$^"*5 ?0"UGAH9")&-!UD&N/"1#A%47QUI]T;1!51VXR*#V34:&L@5E9
M<?)V4QLEV%!.%1$@(;XD(6+'G:?J6:5OA+TX0E$IHRN%[@-*/QN]NF ?^NW$
MFQC; ])'XSNP!\J46T!\ZM>8P(NM\00 !&C[RL+^#HXCRF/!EZ/Z 8-"4L?T
MNCPG!*C:BA9,UQLO(L K'Y)4&(.P0,KYL*-M78L#;VJ#$^F/OOKC'QY]$=RB
MH ,O"+F""GV2XV"R0)YN+SLI:% .@L3)*,(Y?M=N!$P]8-DB&F0AN'^RW$J0
MJ2=WVJJA79.JKG7;[;DS]5TE,QAFQ!"WL2Y V]_5EL^2!3TN'#H:U#7MARPE
M;(X,U0VMVXH+A'&1OU-&9BSGJ(^<2$]\"9+("*_LG K-^S3KH-,+6F9P?HS;
M=JZ&^NOWV[7F_UE 5!JT1(R#-OC>V4P[XGWZA='1[/M*[ L0QTMH ')Z,+5&
M^]T UWV0LV&L2I^U*7)U:V^?#262)R9%(V!KXKTM+JC38WL>;3#Y4B)PO&H>
M$+XV%7@V>TM;8A?4% 9JA/+===-UHUD&SH-P0D,FTPRCF[<ZR0M4VG(J>]-O
MLYR62K'EKWQG*J<]\A@UA#")+>DC5U^J4EWTR]XJ1@J/!.XQS;+L6\L^C8?O
MUR0"SJSCBDZ%23T2#A%,K8^^<*X,%/V*[TQ9%;M1$1/;7AL?+7S4'<,%DS 7
M$<DK(BT-=.^\LI  8$+QS\ *%K&,5^(9<PLBB%]KS]3=$74]S=2UD\F^X]D[
M,J6<?%T;%V-RR!+"<621A.=%%*9;A#P&+HF)!GN@6]*FSUS:AU\,KS;Q,?*M
MBP@1 ,'B2;KJVJT,5K/A4DR59U';@:#Z^2_=MFU%Z2).R?K.)8!DXYPS*LBJ
MDES3\1>;98]]B8?U"0M5NR'N$[J=J1; ;6F^30STM05#R2?F&6JZ M0+=4%U
M33&BCVOJ6>"&Q7.M1%=D #L[ZS:KQTHV72Z%*;K:HZN,=D)(YA7RQM^2&A#G
M53S?HT!\/PQSN7P\=%8^23@:B*!3O$L /^]1W@#X'T_@:L.6X8H+MUZU-1J3
M8T\(($[VV,[ $8BI90)HTR%&3 [I"*-,*VH%P<K$ZE[[-P7K(&+--%"<-4ZU
MCF -C2[R;/9?4>;9)D4[Z;:!43 $F&,<",.V)S5Q ] +G3Z6"56;*DDF8[C?
M+3FQ42 *H+S2  :'-HM:(=K-OS'W5:1JS;T,/>R$6.S,7*^E<Q&NPJKG;A78
MXMC6Q$K>&>7,FRO%,[,\ /*NW3"&DE@6 4I^D?#L6HL+ K/5M)9[,23I3E?%
MG5%XB)Y[H>AQFC8OH=$J=5YP7O$$/3:DQ$00"'N2?>'010 ,,=Y-SM'Z8+6C
M#:*2>3J&Z:6GW) .]J&=E9268S.UXP?*C^?NQP)E6'!5 1.3F+&=(<X^0C8$
M=1;3L[UT!%$B[L!:S)<X.4J7X2)*+<X5188 +QJJ*R9#\F[T^H)1F(&BDT']
M8(OK3:+YFB2'R-#R,AW*R8-R?>BD.P0(0J3;PFXQSC(7QO3NW &DL#?P<?2(
MID!!*G 1]8,-B8QR$90FPW9(%6=#/:S[9O'N=VH2^N#&FQ\_R+[1G*5U_4NE
MS2G9ZU4^AQ "QA0[)ZY4\*SN+#GA437Y^[;93'?6<%--)[8EC51$- O??EUH
M!QW#&U/K"!>W)0I)FDE(.],^^*QE+40?EY4R,#0<1O1M[/%P&31#^ [ZA_:;
M=?2^D4P$C#<9 U(LA<AV"3G/#IK3J!Y<Y)CSDK?VC.A<>_!/LK;X^:FV>*HM
M_DO4%CV891#-5=5R*S<98$R=IYZ6E>N&B:C7L9?P1^O/>X74U>S>3V]?__CJ
M/MJ<,Y-$4U7M/O5Y)?/D0JXYH]-MXW"AS\OZ#%S6CY+$K]HQDC#)6"!>NC C
MCAH>MWA^I-\\.]=T8O6RF++TV ?<Q,^=RGF6ZXA6=9WJXW&3];PX?U-7PI!,
M<JLU?:"DZ6]\$\,\U#Z/_/Q9>,/4S:-F.R,;\\_.:6!?JYD?)%B!7D,.@"']
M/N@YA]&1)'N<\Y_8L'Q9])+73)Z <J%B. I648@T*"A;2LHSE4(.*B0$[2<J
M7$>6#^0S)$LD:8#G]]YZ! ,R>)(TC'0$QD-7"1";<E;RCC]SX^#EIDDEC=\G
M8X4FS]$D#K.F7PU)<AQA\Y;R;+]<U.O*OP;7[2T^+3<E"A1=M^^76I#,\.D@
M2_-J75>7$F@CT=OE+]K?@?4-$CDWN@=Q:J[9I;*2GVLOJ]X3"1\")AN*"Z_Z
MR>>8(WUVIB057'][_.6C>]5]_O<X;*2 '.*J(M!:&O&B'[%*7:.&*8J#;SI&
M5CWK]W#C'7RH(JP0?^';YT]G]VR.V7U;C,A+OY@7N@?WT64[L?&@V@((5W-5
MMB,])S(^A42VU2C*T<?'F?+F1_&\R.N&?+EZ;KT/[OZ*8O)FI8452 [!7(:%
MCS$+CHFFE'&U/X!P%=&=+I@Z&FCX6TLZ)::2+5M35UFAP1<4AKE1B^TYX[@E
M""YE;49UEN_D!FP4XUL3BQ;.C]AV546V3E8_(RE:T?#0N+>D/\:H0Q\_>OSY
MXZ\9QB8.Y?-$_JMP*+%[Y0Z]!^&0O=PNSF;WZ _W.=3#I'BO>41F^5&,!23M
M.LRF<=/YL!-7P!BXCUKT/7Y'@X,;C*A/")4V.\1.$W)5GS_'2EX_>_[]HZ_/
M^ GH=:$H72K*D)=_2P[D+=E4.'4"1A0\XI%,9<A7N)^Y5[&[0AJ!X2E*#!M'
ML5$298.7F7^%Q$3)6%8D.8A"<@_")9-60C.233\=F61I)?>MQW,B#6S/8[C(
MCHXS<6+&/!CL%Y*(8^C, QP?!5HMM$5+?-YPQ8N@V_9:;XYC;L R6Z_3)B-(
M1RH,A>8 LQ7J')9CXHHMQ;%"'#\/3QN"A2%6358WLWG+-;O,WK#(%:[?3#D@
MY9#HF/(*Z%\2A)0^<[,N^RT&=48>$4D1?41J+S&XL$)""^1YZ 4+'UQ7KC#Y
M%<)RX8%C ]QY',OO:<KSP2_E^PU-J2_VEI/9VM JSP_8H+^+",048I/LI#>:
M1I(W=MWKBJ,$&@%<EL$Y0U":^?DRU#SJY[],7JU&$;KZP3(;.'\-IQ)+'UGD
M-V$1K5-WB2BGM-R7AF"CJD&/GOU,J>KD^W-1,##Q6W<BI#L%394'?H:V.63D
MJF++.FD6\.<)ADB/4^[Y'WTU-,C=G%<\8N(3H5-9YPDGFB2*8?"Z\$*NRE8;
M6B9[D<@_Q).J/UENK,^![6=B4+H/L2CC!N7M"YE?/K*HVMI7N,6TXXF.\&T_
M>R,N-FR -C&G_<O[:^Z#+#=J4:Z+3-B)_]GG?//V!8)0"=#*3D;RRWESR5B4
MG;QD?EL*AQ%5/J^&_:%2(01^@Y3W;T $.ZC,WG" 5\PX(2[07ETU[?IWGJ6]
M(>#2M^A7+)*!3,;<727B9E1E$TX\O>T(]))_8FP[8HE$+3@WE[K&'IWIF>HF
M.MXCI$T^-IP[.1>G$0"\J0@"BF(^#WV-Q969BX-&,T7:C(SAY&71,LAT!V\K
M+J?@H&'1@\%-[N,QU@>]O>(CJ! >%\ FJD$\$7J;)[@KQY\N17[D$5O?V9TW
M=@.\ 2&^:@]NQ](@#L+$8X95,CGI9BY<<WK2CAO9)P?,?_IMCF[1),!4D^Y:
M4YLN(7Q$H?* SESHUD[K9=N?^XC41W^+K,LIC0*N;:H<3+U&NBI.H85+$;BL
MTGY7[XL977Y_<3 KODZ:!&)<ZIW3[Z8?Q;6-"PJZ 5.$E?+NBZNI&R(103=,
M7_[ X,BVY3$]"G01^_W+H!_*8O:7DM04T&(N@DDLV%F@)^W7@&B/,^V05AZV
ME*D&WP/26G<IO0^T@?33J5R T*+I7SPY.30NG8@3S@?3+5M<)6EUY:EXXWZI
M5XG'IC[>,@TEX@)M$9\RIN@7I\+AJ7#X+U$XO(E+E02[27EMLLJQ)-ZLNKO0
MK-$ "4%"C;R1/+8[(FBCK^T(X*+?"C=!TH+H6@]]3^LU$#.",ZE>FZA8!SOC
M"W\)W%;,4M@T>T1/'^]0O%6XF2F??[(;TTUZ\"/9@ UMQGI]$]\3T3?72257
MU7AP3#?V"NR T7O1&VA]-27U;LT;2%PJYO_P;HLVWB0C:[DG1M-X;64U-@9J
MD]G_$10'ZQN2]#?U_[K^(.G7#SY_T^Y=S[=KP8H@+HU!AP%J)UG'R&C'/$0;
M_"$/,*\<\!V1[1"H6VFIYC$GV/J3X_ Q>WO"F9)4/J?W2EQW3H-L![EN#722
MAO^T67#RA#J1M1D]ADA0!(94BMW(WH[SI'B0WE7Q4CFYG<,H3J2./F+G !DH
M5&4);V';A,/*4SL[-ZB2Q+'7!8OJ)&J@EAV6URXM[ <"XEN+EQJ]Q+4=U['A
M>I^H:H371A['"I3G8>. >DH)Y!J#;]@)/-7UFTMF,K'F+HB"7)!IW7;M(F@N
M&TP?)C7Z1DMD@XZ7F$I&G%M16M=ZH(4&PA76I*W3JA22V;1S8UXYI1"7Z-3
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M8!/ [7&",>*RC-<4IZ=;<O2$\Y"=#(&/>X:<.9E#VW:*6-C!4-,Z&R#_] W
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MDOFT5#?"4ZZ7G_8JG5J8]%Q9+H%U$H)M<1H7>;4V'$QFZM@D'QBZ]MK$R%R
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MJ\&8C)7#RXELV(NDFKOMH%Q(H6F[9:"RW$7%)B-G:I/QB<#EWXT>P3A8=B:
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MA3"U#'A^L!@IBG-E*TS9,P,IW/\K$A-FN95)Q@L)E!T[)=(NGVF-J.](1'3
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MI"O<.:(PSNVGYK8$G@(;(XT;7-L!S(4"A7J8)?4*WSL8[!\>#:8'(V?]O(?
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M@KABM5QKQ?YEKO0Q".Z",:T-)DV?Z7C S* A39)84SG4IPNV,[^$W@ATN$%
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M2-.FS9]L'J-P"E0^2] @P0E<07",Z@1I3[BG0\T9N;D44JHY]?H\$$)]YCW
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M?S!3/\='S$)Z=7]H2;%P%.%"^R20I='*(<NA_A/NM(A!G<!MC3,?A67H$(A
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M2#-9SD@(BP"A$!@*_-=?JYWV$3T;$ME?\_^WPE^_C?1W"[L?[=WWH[WPY]U
MU ZEY7X= _T8&_MSVTXPA+YNDT!*-#,5"7!0I,C;.:\*/3&@HY%TT:39;=)X
MLU9NSMWI42[<)5(LYZH!GU0P1N\0Q=)0#V$NW_!F.%P9E)"_ +EDRAQ@+?18
MV!06Y&*[W13:@]OVS4Y'9:S9S2\443NG199@022=^-*,&;QUH8_"/3K ,R**
MP;@1)I<(MD^L#SM3MH?Y7P9-+P"&!C>&DZHPY'/"S@K$K*U]WZUSWY+ OV91
MO9I!6D=2NJQP"R8D6>G+B7^9^H64*'EZ.$OF+M'_@%]<A@E.GU/+&"E,)8)/
M0F:;=TZ:0+HY,,$4,E@F3R792(X37>V._ R"OXP=> 0[+N;6M[K'S<]\Y3]Q
M D]\DMPD!SW*H$<9; 7*H'D^-H@+'^#H-VJ#?.%6W=$6?G[5KCYJ07T/7T^%
MY4T'ERS?!;<S9:^U7APC619(D!=4BA^ E;;2_F42:YT<P5.]CF<0I@7BJ:7<
MTQ2<-(X*KZ:G!>-OG\X&>MCR<#U#I(J_4J][4XHG<]=#W(SOO:W6@SA=W][L
MW#[C$EUJ8XP AQGV%'0H#:["'&PW)NX0>N:&YW,KR[-F&:$[=\,SM2W"=/LY
M15LQ1X3$[04QB9O0/!"4$#-#'EJ7_HK2E]#:;1X:$#9R*\Y4>:54RE%[XLUD
MQZW5'P7KA0:#I-!(2X%9P#"G](OP6$A%&3Y<6@%8YFC<%E?P,;,:7<;JBOQ
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M,\[6:J[OFWKNA<(J]SE2MR_#7%E:B6RE7V3#5?R%QZA_6Z4P=93"V>[X^4E
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MUMZ\GI3R>SS@'?V[196S R &;A!N[G07_A.(*ZF3%]#Y)>LS\+!7R<'O7")
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M'.!U];5:5D0M ]M &,U5^:R4'HX?<8H>K7V8,ZE5JKS TC:9I_E5N<X"./X
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M0QM>9R<VXHTQ%Q04TB3.(Q86HKHSK.^Y=KZ EV#A(_,L-I8LN)4Z&ZM].G(
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MN4I:B4TT4DR=D@J!W$U5;[I/<APS""IR >DQCA# _;6SK<$^1G\%.V[A4PA
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MI1IR[ORTS_VP:_Y'8\\_$T/Z07:C<\@"A:NPR?NEIDFABOXA%1ZZCEC?/?)
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MKW[7:@$HO95)0O<7?/FX?,0DBMPK@2HR1Z+F17^R_>Q-SS<+**.Z6JM)"O.
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M<(@SID.;3V4I%I+C55=YOT=V^A#PR^ZUX7']S(KYS=O/H(EE$*6.$00(>2
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MRP5'QKF0"7AK8D6UBS(B(I!O4/@P1F!I8J/F.?=VK(K:7L^!&O$(&"82$_5
M"N!IE C6>=X9:U-*L[ECN).M: 8^CQM^YS0>QI*PE!=X8CA.H0_]5%=]JQ[5
M.CUW/:B/YE!HK@ESH]E7PQ%M1]PBE3'T#XWRPY !MC8+@E\I9 S<%1T8TCEJ
M$4@ <[-NQ+ZSCFQT.\LDK G8NIA[=7Z7"E']+*UD=)W-"+ I?(/P63@Z\HTA
M*B.%Q6GH);H2I6E1,I]A34S4$G^TSI++O=O99@UYOS0RSR^U?M37W5=>B4%N
M')62D'DP$6;>T% Q8LM4A==]V?Z\RI&]0^A=\=+#H@]Y8=.M=_',K+99U2]X
M;3.]5+F$'GP0F>"XSJD/-[$\@WL8*^"_OZN?<\U=9K]S++"S+)@>KQ"UB:W!
M%D_87N/F.HY7,CDUTVDD<?0FC $]<R,M?QH]R\F]2KVJV^^H7X%9(F*O4>(I
MQO/PL19Z>?KSR6]AJG,%UO<;VJC</_A#/OI\?C@UQHXT&*KA6@&;BJ&HH(/2
M2!"E=@JA^_(A6D9W?TD>-9AK' ;AHR":,QI.P.D)*Y;@[(,IO!*KN./5:JK0
M0*CXV,O&YV?[B6_E^YL=HKY290:ON-&C//@D#VR[[SXOZOI:F<ITHSA#]80)
MC)3A/.5GHG24Z\H0U05[AZT[K=WEE@LRM8CC9FMQ62ULU P(!I%RW[2EH)B#
M]0?1N>*-K1?*=_NYC4.OS.I0PI@1<^KN^H=VGS#C.DM66J*&0%NKQ+:B3;V0
M^):DJIX^+B?$3Y3+9/1F^[T+IDGNI/LQ^XB ^7"$!0*-N&O<.*X%ZE5EB*6E
MO9\QR:<R^NZ/^*MA;0<M]D['Y@VF W:&TWAGU7[8'AK?>NQ(1;3*HA?-L^=?
MEX\]:VY&_"H+]R)_S(>'3.4IY2.H=WF4Y _#&7*'<8\,T!40$PIW_;J7W=>(
MH&:ZGR>W0K7LI,2^6#)NBLT,4BBOK0>W+W17M4/!ONKS66 U4/#4O?+M>&.&
M*E:"TD7N?#6L8>=8.>V,-P0RGYQ)L'YD^1%M'<[I"3E)!P(^SZY:JD1E14-=
MG)Z K!5UKU@73L>^8E)DTO'1X"=R7D(&!8-R'4%]S=A'XM,%F#CT>)0?E>7'
M3PDX$]23QYK_W=#*OT,V[G9ZWK@WN%0SLFWY6_L7&OF2%+*$743P$@3J)(C%
M&$4C+:\?'24[U^7<SI#-E@ABG%N%X#U-<.JPY[_W=/4M ;^$$7Z+U.@J> P3
MI>89_$J,>V-?4&-1"J3>50!ZZ1G'2[.?S(+940.8H2@G<% ) PH.RO,%7H+7
MV;1&4?U/TU!451V?1\W4S];2QPEISDJ1IE1@:PP^[\S5C _J)Z.[3MVH +32
M\XDV7[?'TU,YO[)&?%-FG@:==C=9<??MDFP'X9T3'L\E!*CK RR45'74*S7H
MGRUY3-\I3:^Z('LEIDQO\Z==JS\SX3&)Y2J]%0<4_G*U7::@<VD(7)KDQT\H
M0PLSR"&HY<+_G!=Z68C8\WJ\T",Y[%NM][3N,P_]C.O6X0;,_CV&'=7J@-("
M8<HM$=Q_.$BY/,]0YT&>#/.5?+K;"]P;WZK.S14XO[M7I!KM)F??N_!\(\M:
M280@WA,G>14"6-CQ,@L'6F29FJX0D\XZG#S.$"(NX7YL9A6-+AW:/X.",ZU#
M<-V&U6<U)$+@9(&K@5>FVVONP-H;R=&WQCJ-][_*>^NX.)9N7;B!H"&0D"'!
MG4"0X 27D$&#NR>!X.X2&"2$0' -[N[!+4B"!'<GN+O;,'Q#MB7[O.\Y^WWO
M/O>>>[\_^C==4[6>9]7J[NI:55VKJ'D, 7>E2=E;:Q768@1/>I<Z'HA01I%[
M-*[T87F59R=C:D)N&COTLUN+T7F?H$5XXQ$C)C8Z'*;#NT\Z7S-GJ"I91>65
MYXT_^*$Q. J>!&D>XE:"@5=?Y[9XU CN^\3@O25K=WD'+8;L)(TFEE5,W HL
M*/;$>5(;Z6>,SJ!<B2@[4K::C%9@OE!:]G;BM@JMO)Z0C%7R<UN%_E]N2=LP
M;=W5>Z,?.1-+)ZG"9)?SYV0&;$_$-Q3R8]\6,+X94"NHK^%*<H[GIC1N;"0Y
M*N>[,]5$=9?6:%$A/ZN*H[=M;DMCA/2CAI.7^&8;6K!%X>HGS[Q,MC>1T^%G
M\?L!X1]K=2EDT2%M/B>7$&GHNC3!-Z/R>@L)"CL)@X TUEEF],F1,O9NSEMT
MS;Q2;BVJ5*5$430Y LLY:R[X@_;:3PZGV5.W*F_0!R9<.F<\;*FNW8'I!5!%
MX%9< 90O_6D+;:V*.$_AOAV%&>G1:5+[:/K//I29X-Y+5(]^,.X6&KWPH:,4
MVO923;$P*SZES_+EAH?XG/4ZMDMO80&'T6(_^X5:.;U1E[RSC69]T(K!-UD<
M<Z[9H/E,Z3PU+"-U&4SA6:<HT8D""I#6I7B.!7OM!_VWE+=C,C#UU,1BJNAQ
MN0 7;VV=@KS)IOSU8,XB>Y<'22:3$G<1[F!AS4M,[L\N6.I:F-"^%M'SH[B+
M%JOT8J4][ 7D=6_9F1GAC3M]QXM*MIVN"%^ITP<%HXG+PIBY)DKND9T_QR@U
M3ONFT\2P^_DB6ULO=.SV[9+&7B)L7<DU726I3FD9\/#B1W7J2A%K$"O"0V7+
M.J3[4 FJ68-D ?**@T(66ZNFQ8H'3]+QZTH/:C&/!*#QBBOAXPA=Y?$Y*^9O
MZJQ*5,/8&3R\@^M0'NY+V5+7J?20=KYA2S5K15BL;!#NME/EZ:[O&3<_RHM#
M?B=^J\RJY #=@/<MUF#5G81OD7?7'3"3S.];5#[XHN$6]Y7J+9+%UC3G0I+.
MD*U -I:-N,X#1+48/ _10[*%(<-R8[&YBQ@-Y3!-VAOB05M\<TJ6%VE<? <#
MF7NW+LN/ANOZM25L'_7.5!#K]4 \M<+J[(G9!LJ35,H&.<R?3DVT\3D*B*3;
M/"4RF\BBY--W.)=;HC="N;-[M ]F*ZZ0I?;?,AYB?X.9X'U:C,;G,M Y=_;"
M*<VT_G%OM &YIF>=11,^WD)1@3$XV[@K>OY"+FR?.V:L^;CJ@)"TUH[RS8N^
MPX4AY;QZ(9/!<1'S'(T.O,;4R4U>*F0A5%;S17V2P^H,*VY\"B-J)^TG96;*
M'IO"39G#W2KZ52-,!L&$)'/CUH.$@8H%]QKACQ/S7QK5'MF%!3\JR:$RDOSR
MACT,>X[DVU&2L2G'UI!#'[DQ%9<<_<BA-@4QH:R4T:YN?O#E<J&9M*4A(>,8
M 5K*'24<(;S%Q8%^L#/27^+JCATYZ*J[G8]L8854&Z)D/N&$E-13!F]V\.TD
MZKPM0C7$,_5#9!_R-MX@TC->"< R43OT,U]65Z%7]V U>,BE&_,1[4R6/QBW
M% P8CJE)F*8RAI\]$29DVCXHOIN8.#7\(A6=RJ-'A$'%"SM,3#9N=(G2?SS5
M@^U%:5WIP BA<6266C-M"&S+[5P?QJ%M5_LA+8;B=G"9*(ZH\\W;PDN?=KID
MW/),_(&N"XZ329*Y*%26%"EEUN*;;2J$+HDP;T_%M9']R2_P1AC#T&&:,F_[
M&X3<<PRC^N?7*NV-$( JT4/5=>Z2Y7"#]%O)P2O>&-OF"Q6QM^P0%I_+9FC:
MI4+HT/FH]E]X>_Z;QY_FJ:J8WO.(IN6?:A"Z<?9HYO@,<(N_%0=(3#5NT?D5
M"]BGU@B>"KW6O *>')U<[@JV!O^4J@\VQEH5XP;;078]3BMA/AL[%[,0N/OY
M0X)D@+B/: D7[K0V(\W/G-\O:MCQO/[Z]X>$J[BCD&V$JM@5@(;]'K*J\^D*
M^(1Z[>;^E-PBGT;HD=<FA9(),%X!*2X7L%/2!;&?4V6^=JC_6[6Y#R7388#S
MNW_GE_J_0>7_0]H,0)J1YWO/[^_\4:;,?NU/VFBC^K@3FSXYV(J-BK0F^ )Q
MO.L99:G8*QDS\D;/U5/P#9_@99SI<6?$%2#YP0I[EREKI,:_X=(OYPKH#9@)
MN?;@2S@$S_;B]DD7=/B65QX9L/K@0B[N*L)=>/P&<KB>+TT@!PN/%P5;DS%
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M;J-UN@8$*&>459C2OA3WZGGQ@:^@//+=<[;!8+U$VAKA%*D+'8Z(3MPP,88
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MG6)TY)V+M$8'+SMK:N"#T.-,PI1F[X9"UZ1>L$0[\OCWI&X[0X>ETUQM0%=
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M@-IYN[6/J*>3KWL<R]XKP^Q[%FB1:VA&_BHR<^0BRM$'+63 O9@C="-W3\0
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M#(+'%#9VY05<8X@TOM7I0J>M9=LT!)LR!E;:9QD":!5?LTS#2[&K3!</.5Y
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M\Z9>C)7!UEA+9E6FW,!ALE,+;7BVM*"0:!/+JB>V(;Q<J''"+ !D A\K(N,
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MRPOT# SUXP*GTM;%=RU>2^IT> <]/.8PWR5O6GR>KB8<QG\4Z0/")-+E<ZQ
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M0$8U.(O]&[V9*.E$F-.QF,;&[B:LXS_0<P&+([,W3?.@5;?"$B?>=U@X3_%
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M)DS7U%=G7776U2\!(<L=O!CV8@6\B/5 ZZ.3PNR(EI")G;T2L7"AEX[FS,0
M7)0%P<9\B$XH-NRA5VZ0)?<I]#2#9D9;;PR2,300N@/CA6P=/?02XW\BY-*R
MV!30)BPP$9*!2Z*^A.1Q^3NI,I_8CK6BH(MVH8X:%!GL"Y!@(C0O@IZZ0620
M$X9 N<%4 *.NHY6YI+5DS3(PQA/1$8(Z#42S5QHQI%=2I]TEHKMBFD)2C/.>
MJ7O6\'SA5^0(3$(W:QP6)TG47PX3X6]":SEM"G?E8P,J_94(#)11 )U+=2RG
M\BFIRC691#F1-GX;&A?A59N8I!%^3]LJ+6N7/];0:B0&V9XP]E^D)!X%U@7)
MK"'-L0-DK*6P,>3S*DT>8"4\E--O+4[SG<E<][7\*<83'"F]8@Q=J@0)ER-8
MZKAT\KS9+!N.8=IPL<4ZH#D^-=U:&),.; 2$1*^W@-<;M$); PU;"IY[5/52
MV%)8?$Y@.+9(B-[8V]]$F;:,AJ'"1$RT*/&1],(;)$F8^DRMPJRD,$?5$)8I
M/R'CJ"2>]PVA#^2U3@X6@+NVX*-;CKLQ*@P=%4NB[E@(*E_',XDDK#A'Y<PC
MT0_).&TKLE8>&]M9:9A^!84^P<VFA)FX<GM22!P'Y;<RI*7Z&NQS\XCU=$EJ
MO'\DL5+G%.OUH74;]*3,<G6O+(]1M%OS>(P3QS)E5H 3KBOK6QWBU+:E#TI)
MV-[.Y399,(3T2D-/=N_/F77BGJ-W.;LBXS BG?1098GH2?G5KQV3:O\QY1Z^
M%VU2L@HI]ZPG-4QK23'[KW9W!Z(?8!L />"004, Z=AU-&G$7RY(UP8< %U8
M?*^$K[(XXE-CU&;/U#6%BT_L\J&G'-6G28L75R;!VV=SYM3"[!;4F  KX?"C
M*?6RND<6QPBSMYX^2$["F^*:I;!F#:SBPD(,'&9[%$0\C7"N2 X2B&?7IOF8
M,W5K\PE %D^67QX:]HY5O*Y<&GWONHY;5<F16ZM;N@!RE9!BB4JI9RD!2J ;
M_#:<XUYA5*]L( Q-TRF@<O5FC<FT=CU7C&5H)8J9!@Y@OMJ8==@7SXTHV5K-
M$F9I!$8+KR!-C1["73)<JW5Z50YPS)I/)EDG7LGZ7W8 I[_6B>Z;1.#QLUBR
MCO%H>(;2(GM(XKDN)B9K/-NYQ!M/T=WM&H-WI<)DE:&\]QCG>&P$7!,1EU"Q
M"HO;V;A_2V%4QZ);&X;$2R,QEEF9C\V_IID/)=R3*:VI]6LPRQAAR\/V&&<#
MPV_C]=^2._SHMCI \W"P+KLJ2Z([DA8OT$))U$Q?L+-V+,,(1JU1I$X9NC(W
MS]1654G%2BTG94LPFJT1HQR9%O,\H#0[.V&,JDY(%WJ2[V"BB:@X,AUS%$ZA
MJS&CZ8<DDZUBSE;/*%13IC\88R1KC],8I%/Z,/9-4<:F(B,LWR></&<*)%,@
M!DH-.CB(O3(4UE_>H(>B5]I\2]=K0]I$[3 W3[((/(P]V@2Q>Q@U(M$>32*!
MU9Z*8X?D)7:8L>ADD^'WK$HDXKZ.,+BB&B;VQDR?17WIK+O.NOM%2)4KBO8"
M'0JQB@P3S8[QB-EHS=6V 0O_3D/*V)4*Y;A/N!R/F(7NDS2:U&-=Y-I0IZ]=
M8'@B6EJO4Y ",-H*_AXE\P==]AP/_6L5W++GR#JGZBDY#>%AWCJDH))N2_S#
M'*C UK:5,G.RRM6ES8]U7<[)5LRS4Q[T((C1J&K.:?R5OFA@G:ZFX$C)M)K)
M=!%VJ[K>O>5ML_49SDG0K;"H&G6?E F5AI5H95!B,D1!:Y=K).%;X>,'VPS#
M1:1J T)<0W:RDLE4JC%VH&:X4N;2[VLBW(AJV\;(Z@'*[O^$1AZ8LKB8]2I$
M3%RJ_GM(D+O][9WUT<N$&KN=]@'DNZA''NF80YMA9X(& XL=Y)R<N$&0#PC9
M"&: A4@6+:';*#X%M]"MNAD%\X,"=JU,%'HD-BMQZ!+55H9H3S&-@J@513!:
MUBB+V$4G;5,[5VK<5S9L+=9!EK>!>LE]S"C97&IKL'MD](F5BA"18Q!=$C*<
MACV$!&P T5XEU5M\5^3'LM.^C1:^:>IJ M#C+W4[;4_[9L4?:[MH;=->F1J]
M8&BS\J;M5C2Q$537O$Q-=DL)T'YD"EYJ69]\C5,[.9XHZ9'AD=CW*/2-3A#[
MYU2Q)>+>HKO53FELLGA[A>(77[)Y+.8,-%\)AX<>-DY.1JL);S7.ZF?'=8^=
M/7.]\O4@B[T4K2(Z'%V\)<@513/)#AUR[TJ O-Z9;2-6XPPHA4 N 1=7[I,X
M'JF]16J.L5XG:37^MMV3ALDM% ;#Q=SX=7K@3$7E%N]#9:28RVAQ/(0#P^=,
M\K* ('X9PZY'>_/1MC@D0=+))%HI*.N=F5 GO5P8 H6UAD)XPD7'6[.'_ECT
M9%D+U>4B2Z+,HY2H/ZDZ:XUC:2FK6=MZ+7P#:"N6E+"&;4/FMH;@#M;FN487
MD^'DN7&@R/!3-1.>6QK_B56:1@AC/7(2R&/H_5Z)?0M5S?XWF/\OPN__[OSO
M8'M///15^FI^DD^Z2J0CMQ3V >72QG)[U@M-!*E>])5-PNTCJX/6?@0,=1.J
M5/(UFT#IM,9"F>',T! K_#:5+!/OSH\*9>P*"V_S-/T!@I!X!DS[PXSLJ)L]
M'9YJCRW)P6+'D4Q& -M8BL;6'E5&]/B3/PIY_%2R)KERJY'JQ >J/^C,PTH_
MK$:B(3C%(ZA ARK_.0'$S,I?DNFT7OB-A>[OY&;#-L>)I/$)\SZ-/@_> B6W
M\-I1AVD-P<1_XGF26YY>SCV2\DM8)?I."=/C9]3<^(VESR/GLJC];\DRJ"-^
M:[:!G5,@!YX)F]?\*HLZHZ<Y9F%-DS(OL4AXG:TWYJ;RA^7<1(2Q<:+[XM[E
MU?*B("0RQ52;@0OT7DE1[<5(V1LI/QY/:AX277R\5S[VQ'";:2"Z3JD ZT/G
MA_0OL(QS[Z\L3[981OZ@:^[XFA:1L\&&W&,A()TCO"S>I^^(U T79)Y)2H2)
MNRG=9?9.62CFY0B#G67WB]?].29/PQ!C5=ZLW2A8O^P)"'I^Z],1UG'<./?O
M5TV/KJ<@U]PXADF3F"TUWR+37&I:3:+H2@+)O^&T6RJ4QAR/O;(TEIU^VI-@
M2])P JSGEBQ09"8EM:=4JQ'1RV]C7JW6G*L_TB+X7$Y[H6O&&-5(H;4^,,BY
MVDO*/&(KK6*ABQ,*5F2"/GCEI&#^3@SG8ON"A)-E-09=(:4G<88+==/;RJ@V
M5KF7L]8V$%]*O*9%KDA=I^!%_[[S9ZH40OF2V!LVS"M_AO/'(GSWAR%4S?;9
M#9^UXAGT_H:X.D#[CRUVYGF$(G//NWV8HQ"@TR0T$X<A8=36+4O%!ZFNF(U3
M+2?C:SZ%,:EQ>#L(X)AZ":I,EH"(F"[$$%.>$+GQ<=M,J@'6*(3S%I)PS'+/
M47:_2)F:3Z0M\+YG]1R;GX;"$(+W"2L(#B2H=UOW6*<JF9<H@+$%%'H9(I7T
MU++UH?)KB% VZX:\KT@0Z)6]T6LT]LF@7$4?*_K0&OQ8'DPV*LLARD\MNU2/
ML4?+AXJ(L]N[(2/YXH3#'SU;[R_K=.J8AZ3V2'X274*IG+@!#7UE(>5ZJ+@(
M'>8E]P87 L6 >"OQ34XA8T'] YJ737@:-S?U.IA+;0,*A+"#*TB5UG@@!4,Q
ML\X0RZ+&G+/1;;'O4@BM;J)9M!I3&XQN.I=-1"['4ORFE4;]@*>%Z41"RANK
MR==?T7V(2OQFB*(SB_.>Q$9'Q[FN[/3T5HN==>'VPR'U3I* D\)6D1'K]<5P
M4;]G3T>NZ?EPV9F':EJ6LG19U>;;Q)W7D\B]Q\,##)BT! 2(<*8CEYH8,)AQ
MRJXM,9&V]ZR,N5[UUJ QDE!L$TVUU+R-*:O#*II*+%0]/JR$9IOD\&&SV3Q?
MJ?]<VJ0H:XD>4IW;>DR)5=NV<FIRB0HU68NEG7FZ/DESP.)*E4T&;)^LQDFL
MP? LI,#RH(""=2,K!ATKI&^P+X74D#+G(DCHW)KX,_^&K>41"31+/&!:?--!
MF+SXBKC\3&2&M/;I!_G0*_/DZ&O]J6?2.0O40-DX)8=_CI*>K0YBZW"'D F_
M9U7#0H.6JC!1T6=/ZA>,"\.U3/E:-^1F+& 0(LX DI <"C[/R6H>9J6J1\-4
M22RT$N_9>4@'E!;]B(^J%$I,=&P]?9^NZ_PR?(=U5W'4FM4P.8+000U=YL)P
MNG*E]G1*K@BYCA#C/@>2:#,-IYAK:CA,MDL2$\.R HN)"D^-R-FGF0A4;-6F
MTT;]I,B-ST'J5J&D:#Q1> V#CMTD3ABR'R](?Z*F?A'1C(J<4I9!#3-L':DT
M5*N(*Z[AI?7QLH=F#19#/.'*)1=8 .S!9M2RDP /7AT>OAKL'EB5L9XD76:7
MDV$J1<&<I=I9JK]H">,CO:L\"3XU'J_R9'XU\I\&G_0%*-B)FJC7,&#%I470
M]Y' Z._=K[RJ.4]!5&83R8CXYFHCAIU]NE=PH>J&28$CW'!R&9,-\]]Q,+=6
M]>/FD+0]BZTHK_"%EDQ4ED>XITLP4+AN>8FQ^?0L9BY+]EK@;Z/R+W47-*=A
M4'[G_6V"$I )Q+(B8BA2A^./44%;N <I)KC%>&EHU7!92)/5QYZM:O@L/%$T
MV:10/2L"B.0G,C:#'$:%1Y!"E$]5/<ZI-J_78G@JK^' HCM^J@ZI9UI>D=U$
MM8(/=WX8"8<11XLEL20$(\%)KUUI$R6M3CI?YG=7FK0&![#>,\O#[U'\%,&[
MGF:.',P194?:)DV;YHF+'LH8VO2CBXRCED4!AWW(]K;!T>XNSHSURZDFK"PO
MV;-#M475[7D9+._H82$O6<*/_#%Q3].TET5N3;B/Z?-CK.>268WQAUX+#G&P
M31/TE&ACTPU_$;]PW1Y8U@#M>V^7L.78*>_P=%BG_HVI&22T.96(E<4%TWTS
MH^G3:4D8CU0A.J*P=4NT7%\:D&]]=FT\LGJ(F;!UX:S/^"YAXVK2^Q;S:RHL
MVH0(=OEZ<7JLHKJ9,$J+ZI3W9T59[$DL;>;]>;\'0CW^CXN3P56GI<-AR \.
M=52,T*W SNQ^K5=K]KXDVZ[QZM(@)$4)HH<RR%PJKV)*JCE<](^;/8Y$+D.R
M2W<DTFW'OB3/DR]$+7I0X/NFYW_3$S=7#1/LV31)O;+>,'P_Q@IOU,5>U2S[
M;7U=.7X1U48F^T+;B-Y"5<LQ27%B2]/T:JL>AY0%ONQ(Y)3J.N?/P>[AX$@2
MR7_T>;DV&[:YWD'K::;ME\VWU1=%K-#J1L!+.^E61736Z:J%Y9I>='STZC#>
MMCQ-@M 3S_':3/$3\($+UPZ&(C?QC*_#6(F#<AEI")J.;[V-_5^RHMI7:OT1
M-.$.'8"!'VW!BV[BUWF"V6;Y[2\_PQV_8L1,3,02UCB/ #11 ,$7=W\8I3!%
MRPC"0BKK36]1<9H$=42BA])UH+EXA:AZUQ1^\O>SO_>\B_YYO]G2LB]GP*NC
MK:-#4Q&NJ10('TR2$I&9VAA4X9VJF5(\"4/*C/K"[!U<.\M*>0&X0#^OIV":
M0Q'H TSG@(U!&F9I9H;+R^)U1P<@+6+^PC_[V%#N7G.GA-1Y;T?WZ&-,9;FN
MN(F.#\/9HK]AC[8D"K3OT3#.BE27@%G<H7\].SM;ND?WK#W:^Z)-BL>[KEI3
MMB)[R'(UHU]Y$T(K%/*;1@_:18NVO8FEOF6UG0E=M7;F_LH[<W_5G=GE51+&
MX:R8>>>F$#2KK\W!H""=4W9L_4"#-9*'$1M2RSC+MP7KW"=65B"F5@4H=GC7
MF*%*'M.>]^?!MM&H#1F:>=-7/-)J4.7(QU<9Y;W[DX<>9"GXE'H744N ',7O
M5B[%8E"T2:R*",U[0+RL>O_L;6]'&_[FQB[YTD\OSZZ&/8LA!<U@^)TWG&)X
M)TX2A3[4R(^9A/BA5A;<).VVAI!T?L+>GPQ7YT[;/WRD#,:^KM.#',5?6?6B
MM=C$OF9:>(IB$]]87()X$U-8%W;L+M[Q_:M.O*3:B=^T\N#,&V&RM+#XM9A<
M&Y?"@46/V30^\-R"B-U/*=<8;3^@L%,@+MGIIE-ES>KCFGZO*<E;8J&R,MN;
MSP>,^T$;%_[74&V.%96%:J>>UGD_&U;B(@=XRUO$NFSHWBF.%"GJF%E"I)--
ML9E-%%HD)$$F5=2R) 8)I7D\Q6/<_*-F3+S?+&UJ2N+(B+)*0O"D=,%$^]3*
M(#--S6"-=+T@536FE)[ ^4&()<046J'*P'SHJ>80I?0+1:GR6#J;OMOD^@],
M5B5<^FUO>*AT#,-O4R095QG&[(79K23OV[YOS2V@+;762RP*+O;251<C4X"1
M;*^+22"/:G*O$UCM0'KYQ>>#)Q:V8LNR*?SD5G70-K\Q93IDR&=,;KY,$8.1
MPO1D(D 9"AFLMKI4++SD:4PLM]I"'?3&UQ+J_<MFL5B@ :=H-ZH@@1%65O9[
ME8KY"T/FLY4R_0<;?ZQ0,@L[01='?''C'ME=MH%$ [%K)!"><%2%-=!-Z\4&
M!*Q;T4SIMFSF*2Z 0_JT&[L>K-T6I>WIFA65MUJU[&T&@[+  _5L\[@\]9I
M>DC)-U>83?02@?@1''5H^'5H:,VZ0\)N(^&*>&;->)>Q[#M5GJA7I%R!1_W_
ML??NS6TCU[[H5T'E9)\BJV"%U,.RQSFI*\MVXE,S'E_;<[)3IV[M DE0PI@D
M& "4S/WI;Z]7]VJ@ 4*V9$L:_I&);>+1Z%Z]>CU_/PI[P J@K]3)UIAE'8?6
M2=>AQ7YV'%)M5'.#>A!*K%!'IC4HE%B5,;' E[F[%D#<T$T4$*FZ@L+=QNJY
ME@EROGRSY*(+"@=4&S62@KZH"'-*7A8Z>\WSG/1B>,+V3)*/]L*\B)F3]A'Q
MQQ41;P^V,-@> (VA8+(+W'!HQ9/U*%C"I/*,1*^0PY#IKK*@=](<")U&"HE3
M@A)X+^"J93,NY75/JAE7#$+8)>D//ZJ5M^12$RSJ!%S]8HN F'$'%'%?3)8S
MU,5DY<4=6,]^<CO79UE&9!P%%4"B^7-KG<''CZ(S^-V_HM_.S]L!O,[/B49*
MRF^:+H#Y#;[Q7WGQ^>%7T?R:?*X*[&$&^6D-LK-XR?GIGYT%%]3.(&;*7'F6
M$$9>(,QTO]C:VSCZ^>#](YA!USD0CCR&?%96H@1-Q&9-[-/.>=VI4A#'S9L;
MZ9L ]!"C$+9K\8* 28=!+= ,KON(_'ZO$=NK:-<DA#.-P#Y4?=S2%)I2+1U9
MT-+:B3C0V1K!ZP2(%<XI*(C"*V.N0:WU?L?-Q@-72$FP070C_WE O82+5$KV
MZ$K-T^AX2X8Q%,$#"PH#44L:)H9&CHAF9I*BIXN='>&67J/J 0#YVM%,FG^$
M*2 O7SX7UN+2J.>K5!=$<NN(!GKQN&\)UTD:\W5-F>U2F0NQKEVQFY#Y/GWF
MPMW9W!>,K/3.%9),3F+:A(.#NJE]!S+7X9?;2DN'@H)2D5:98!<[2AN4&7L'
MLMFNIJE\*L^'I;CQZ6]T0:AK)P[.<L)(-7,"IZF>V,'QW]7H!-H%RWN1)9<-
M'<$V]EZDR(;QA=1O;?V;@=]Y'3N.X5H+-L:@J/=Z&*MI=OVU@#1A'O"O# H0
MC658\<YY7Z3+#/#[7W_)\**8 'ZQ ]R]T;6UZ\;OV.YD<6V*-%MZHQ*?"]TJ
MN(*1%C?+DI_M.3XB3H^UDTB:R_I!BM2:VK!@Q 7G6,\">Q'_FA5R4$"PPN*$
M:@0TM A1K3W\CI1?WYR))=8'\[ZM(9JF0\%5(T0X)X4Q1VS]'![JF='^3SZE
M9FF,PEX";%9Y($^W.-8/?7)]P/*@:==% XUA$/ZY J8?)#?CHF,T!#51^I;@
MIED?RT,<OO0*FD07ZCTD[?8-KG4T$OYI(P44^G6MI#.(Y)GG/GS)QX-L:O5B
M'^*(.(A3[D@ 9QH2QUH'4)!BRQ%BC&=IC!]$P1=X7+0<)MLG"[,?XOIE"CC7
M1]'5% '^+8KX"8,49HLZ_'IU&R\^;&4?_PAJ',P9DS+OM\-\C*.KG+(IQ4:B
MB@'PW[)6BA&:P"9B&<^ZJOJ8V=[<^:.IFR#NS'-G@[=2BX9=F ^I,?(S7#]*
M%PE[:(V#-_& J(Q$$ 6"O'625M>ID'/89]KCTJN+P3<@! 9<;-[J)0+<0QT!
M!'KOM4<SOHK$5V(77(G% T@X601Q&.X73V<-N'-V9FR S+)HUW\P'[Z/ZOY1
MHKH.GC,$F\BBD:XN,&#B,;DH,GHO/>=P V8A%QG.W9RZDJPEE&A79N7NRFO)
MK(??MZDH@%N;-)M(>&65+->QHV,5!9\4Z%M7Y@#)\+PD"%8\29W/*"<-Z3VV
MA:#\DPEV:CS)O.:VZI<T#QZ+K'JVL0^DH5"8J7SPPF$N0QC%/@I5S)HH1TCN
M)*#?+GM>P6J#=B8@8,QY;IU@[[/3*'R0V..@>79H.EFMP/U?<.IN'^+R!+"0
M+C"9^?"%_[V+M?T8CO630?HXN/S43 (RD=ENC6CX?DIO.J7($]NNE>EWBFW@
MGW41=2E8J<RQ2-<I?L)2\<;#3QCBDS*IC,%OS)_*<H-T=<9U)5!$"^2XD1<5
MZ2J]QA\L\Q@#'7H7PCJ#7>@P&,1)88I<A^CM J*5%R '>("$$.^XR,'Z$.9O
MQ@B\P%!N)5R\CT$(BBS'AN4?LIW&SV]S+XV_<1H#\V>7QTUR(")6N[;GU),-
MHAJ">[S?=6[TN2689CCE.M5>3QCTNDI MA)CQKR4"-6K!#UQ+'OZ)2D Z>1_
M;X!\XZ,Q5]+EA*.NKXR-A'^1:[?&@8@EVX F'1.H9$7)")<($P&F]]0842I%
MX;6&#:0,BTN4)*6"-TN5D3=<5$HK>5^VA Y=<_%BRZP?\&A]O2Y];71\[9BX
M\<$)3MW!(XEGBCA;1WZ'/M%1X0R](-LJ>7@P/AXDC\#\>_GWCDH&KZ7S/1-J
MOF1T"LX]0'38QOXB9 K@0E)*)]O^*FI^<Z#DPF"&C>];\5Y0C[-S)/U3#S]8
M^_[5+^'F-ICF]X7*N;^"3K!?D!D2IL*"MCT[C:/#,7(0G1]$__-_C)^>OJ#_
M1D?FWZ5K=Y#7">($5<[#-6^4I,0V7 8\1*5F'RH5*Q'_&4N#9EXU*X#1+S+J
MC<[-+&SI)F/Q@/5$Y90*Q,[9- ]_;6U2[<R1*;>6P:AK;D"?Z++E$T>% 9S:
MQ07=9]WQ.ZH._NF'KQ+^4+-_H 1QD6Q_RE;XS,DBGW[VG@9+2^&]T.W^5W_3
M-RE)H3R5)RG\3^$/)Y04"&J"+9,,[6&+_^>?\!E6F<3LR+A?R+RXR*X45F@E
M98"K7!"U05*XR')N_XUJ0A%9#VV5@KVA22J^"\>L>F)9V>Z4%WN9^3XR,ZG)
M#/4Z*$5#2XPJ&AMZX&\6P8@#:PP#5:-@@[RV]5'5O_O-Q6O0%\;[_:$K/OKC
M+/BTKB2:)-=Z^0.D2G299OZ.PTI$.F?<XZBN*_1 O-)G$U>5='V1]BS6/T(:
M"MV?P$[*WV)&29M2I?0^.?;XDV.\.[&";,YIE?A&1I2YM593Q9H1>IFXQTHD
M5OI]S 8P'UO.M^3Y"TL&9XGO(.3T[&!\N+L!#GNN%):XQH>@%DYZW_X0_DXZ
M>5;3R<A_\[[( 55ZF40O@?JFOXIM%/ZUJTDL@[;.EZ5AU>CY#(5Z<V$=CT#.
M]C+TG60H#9_KZ95 L<?1]Q$K9K5-6?=EY+%'KU>7Q"%81\2*0[#Q3-"(R6PC
M=6R)Z-96\&B,S*H:9]7N+9W<FA:(8DO:MCG7G69#6^_6,($SKC^&W9*4EU[W
MOO39NV\G,.NOQ[)NX&.S<6T+->KC*Z7&8IZ5 +@( >;]MOM.VVY>VW;?(LM]
M!## <(I03 %F4J?F_]^-&33NQ/HU>SGY3G)R49.3<.J*L<$"/EE#)BS]07*'
M*M$C?OOSH55I,>(>!*QA#OYU4W9F0X@^CUZ8#P!B9;--C!$Z&(^&7O;)ELA2
MZ.JZ@$#I"E1L-FV=%CA,+BC:B5JSW"R7;, C( 5S!:IYF:55DBT041,^ -JQ
M9IE9.F0L ?(@:O0/(*_470=4VB[,X5HM&F70$HP+#-\#4E 8%*[2'5AVH&T+
M^GQA+ROV;&F6^HK[$O/[VI86SPIC%CBY<G71%@TF%U@O*K/2,C20/(U<[*+]
M*@ (3H<9@?/O0[(R%(XC\R*JYU:VJ>6N[LGA!)A]?"%F<F>)_=YE7E98S89D
M"9SGH-/TWYNDJ)#/EM>L$AQ_;)I:H81Y?#9Z+D"E$X9C<-Q0P%9G^K&]UKVK
MSYX!F$G2 _FD%4/C&2/10:EP)Q#'A-ZBM6U+N\SP!C$A3#)??9W<JJY0UXP0
ME+.!?S9;^JIAW"6"%,%45%=XI6/Y BB6!VQKIPP^Y1\AEI!%J_S6&5)9 -@0
MYI\X[[U"K<WE1DVK9H6?!=Q1R&]5I/C/) [GPYL.]63TO8=J:V5N!F<?$9J]
M^<Q]R/N[V%Z7?6RO9XP/N<K[X/#HGG7 PO(C?T.2LSA$,1ZV6@B_B:JM@=P#
M.Y46C0)IPAH*,#91M2$=MR50 EF+Q-$F<E22"O4!XLKUAG.-M;_C7,?G[==!
M[T(B?'8DN$V"D_MS1J5+&CWTWGW38?L''=L/^F^-9;!//OQAD@\::E#ICT_)
MEU@5.*4>W9VZ9]@BTHQ9MUFN/2O4M3I2[AU,A6^B5CR(SOP0E-9!L4^I6N!V
MI1I$M^7(P&6H.EL&304^FI-KS>QA33S-)A.=0@"QX0Z)E2"#/*I4<#.Y&02
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M.K@9)05'G&:X63X"_W-2S"+DOHG>Y[D[]#[@Y67T=^/#KF&V?LGSF4OKD$
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MPH9%X4&V)? >^<#(2&\=[O37; 5P?O/\,RU\C@?$(D-B!PS)0LG]/$.G#[8
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MX\QB;1^</XE9S8N4EC?X3HB3P..<]'(97R_A0/&C!!U>),_HFIS.!S\&/<+
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MS-S SU*)"^\T+J14&YM!S5VM^X"&S<BAOG1SBK#'?""N3^.E*K=)@(?\P%1
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M8%P$(EZ4\+,5/=(O#U\N=BQB^(0K\2Y$29OFZRW:"A!#J7AMT#\#D!\,DF#
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M_9EA1(^GM?GU?JQ/OO<CRX$P%#F>0C<]Q,W)1*7PR]!-#V'>M*#@!I8D_0)
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M!+@HVF:G]MKP5=8B@7@KU>: ].KYO\-YS>8RK3?=OC=:"*LQ;G4E_"?_R+6
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M6-,JYZ"F9'3<9-RA!T&9&/<JV4<*UH_!7>W'8$H>&O"GE6#L8F6,,6.6$&Z
M<R.906V*V3/)%P+.__<&@KW-E,'."8YQ;E?$7$/]: /S+V3HPI:T5$[8J666
M?45OI0Z '*#=5^D\J_0'Z-%/4A=.@<[FW+B(M%]QK(W%& ;! M'I=X922XX%
M$KJ"?CU04_R-.<W72,J<:M3(Z P?W*R=R\+0OW47$./9',MV/G'91-GKK?E
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M9^'I_;H\68W"98(:C/$IY3B,"M)<UF]79;XP&G:ZE6@W'AO?KEP2I)NS 1"
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MS-,$T/:WD:X=C!NY=<F_DX)Y;_1!CIV0G,A?)-=PWQ;0?+-J03%#Z/Q$ *%
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M'.*DVS/#.@P.9<#R*G17\X4%T(]+.\[&^@-#.3,$!B:7N4TY?H5BBF+1*7'
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MAO!072WC*6_]*^-^U$G- ]& LC9";)+PQ-!:7%AB()6H*)N^8*)/!1,R2+\
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M[SY=(@-L</GN=?#WRP\?+M]]>OOF8Z])>K0N:!WT;DZ<3\T$$W7]8$@@B'
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MAZ!.=^NL\R+>@<'6ZU;F\*CTE>T?NFA4N[DEY89T0Z+ 1-OC1ZB? 244D3O
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M#7:_Q%VS-:/:S<"RMS%CM\5VCSR;'8T<ST5>GY$%Z&LJ.)\-3=C82'-)6=;
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MU 6'G%7T5_TX=TF)N4&XV^_R79VN:FVHH6UVNIZYJ@%?29$6'?4O+1QO'6<
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M.K$HN8%.)03;LTY*\QMT8;E*$#.$)S-<YQK)%^Q\U^MPYNTFF2?P!DS%.*(
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M96KP:.JJ)?KY@RJT,EF%WR>%1G5#F.HT=MSMW++JB5R64982IW2A_P!L!8@
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MRE\DI>F$B.RURC?0?5AG"36<0^>YL@T;U)J94<?\?M *%"H' XM+="2,G-P
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MA$9-\F6RL$[(7HYU$0-\,9YEQM,!)&"("91<$+IF74%NP6 NVV ;L.$N((9
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M2 8/Q?ROUI [0U92L/I=7JBO9DU"%@^8_1,!.B"" V((PE&Q:>]!%'S/]Y5
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M"0.;?C:PEE5M#CO[QYI/]PSC,)[HG5/JQT<7L[,3SK5\<N@#G0FB=EMY-SI
M&-S'V,KP<3893-M(? ML;+F>ZM(S1DY+-@!.,N1U&_1UK+/\Z]99G@7Z@#F0
MB\T_X+O_F/WC9'KB6%F;=9.ZZB1XH$.HC.Y-+GD#ML@0;D%2JJ)D8!K=84<"
M*6>KFBG76]8\SNT=:84*0U'I:,> Q@^ =]=#K:-M]6 $V 2H5&X9[99G-)L.
M0D[40RAY5_ /XR%8!L>X'FQD^J#I1JGTS5I#W826W*LT>GM<?!TN80!-;,J
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ME+-_@__Y"/]3P/^LX'\J^)]_LA#FI@.B^.!IW-\&/_AZRP'7-?8W[F-,NE!
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M,.'<%O:EDJHE/CX_Z+,1$->[Z%WY-P&VQKZC;;=MS*TW=UF&8.1T!7$=R-)
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M3GS?7E4>A&=J:="H/=F* *RJ,@LVM@JV@=G?7,HGQ2217CS5B'9"CC.OLR&
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M)A12J2<:S_UN\#FBH3=63=WX0?0G4BY95B+P$5)QV-3'F/@:IJ%]>31@L?Q
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M/M=XY_N,?:X'!BYDG)$M'UEYS9LC76>,W!F?5%QQ=&& ]),!O^S@WU:%<9:
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MKQ]@G95IP1(]I8H"MJ6%<Y.X3UY2ZX"K3P9OX3H4]+$OW97#CF4P=.A!* ?
M>A6YW?A /,'(FK1>0>GB^.6;QECP\AIF%LP)UZQ$1Z&IUC?@)<RI%4-DN]=9
MM0;G%>MR5N&>["J$.$U6<&O!\'=H58G*(#> X2D4:*"PF6+ Q UQDQJAW)P#
MI]X6GLR\0:9/ ?=C;(!5;!0Z!:6);4U):M#3@?&15_<V&&\4FQGGR):%>><D
MH[/(7.<$;A,]HDLA?4IU1F--R,&A7CA _O_SWX\OCMYX3^,2_(WQ7M9F'AP8
M$3WU>9'FI)%F0L:,_3_"CG)!RN?*V?MYU87'VL.%.?OV.>RQ&?!;7#-Y_81I
M@S68.L:J'):9E]*2529RK!J !2V9MP_:1W8[FIM>5]4".)\W-TDD[,Z&!-T)
M_%=#+#'DU72%X"63<.12@9OI_$6A4Q>@82/)"TP*2.[B<R<N*!RU(<GZ.>:O
M:0G.D5?NLV:TD4.LTY.,IKIMZNS$#N+.QP%WD[)7KV_RA7D3CJ#H=> 4.CI]
M8TU.'<]!M^!1+G=]T9?S;E6T;.X]6C^C!'M++E.EY3E1_LM?WT^NWOWMP_<?
M?O[EIZM?/OR7^<]OWW__RU@5L561D\.CX[Y25ZP.*5/:708[;L/AW)3&?L93
M&ON(IE1F^THQA8*M>K?=# 3+!>VYL'W06)EC=XN(@JFQA45U]WILP'E( \[Q
M$(*3*X_?M3-F(G3Y>]**]HX)#I'SVGB5U1P]6N:,;28_I!\W$$I]8Z(6[[*0
MT?ONN[= "N=!P DP1PV'NT%5>P*PFXWVJKN%G W65#*5T:=R[*,8/XFH1<\O
M0 856X<1].?C_-JMXWC5.34KT[?N)4\O>G"L;LN9Y2'$=1)B6-B=-#Q[%T2_
M1.-=+-(RH5P//9W%J$B/M]G>A!_=2O4"HRP;K9GW0!ZO12^N44%H(D-"08E]
M-*(FY6>B^RG\(R3U83<9UPB';E.9!1UI=&\R;.4VRQ&^E9?2U*#S/L,I,8]/
M8&EY_69#?M=,[+),^G]@OG=\A/> $=GYU5.Z)%9 JR(C05X"'"'78FP<-C00
MG!"D7PF+I-*4&YIOH;N75;A$'41.EK:"+3/$"IU2,_KUX@74Q>[Y_G.D4-"M
MWVZ^QL:C88U'QT,H3M[9W:QH&O"TSYN9,<VD46L/C"A,FDGRN5E_?T;\&$_#
MN!T_/V('9CA('A:Z<'L4VR:71:A-O'D%QVN*WW)1(*]V;E;,[4EI3X=%(J<
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M]N@X"VR)R?P-1B1B4$;@E?O6N^YO_$20MNAW%ZQ+PW,NZX2+X[K-,GP;+Q-
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M;;ICB,NS:#,HG&I5>UT/*D608%VP5BO?_I@3DLJJO+A,@#K4VB2W3L 4E!_
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MOO1 MVK#R<ONIJ+C-@4XU'=/C\Y.7YU'Z6Y.C\Y/(U5AEU2(W8R3"IQO0'@
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MS\"A0"B5)A)*MI?&$TP,?X%^WQ' KH'?_,<T"N)^(.:]2 2WV!O"T3PR:T7
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MR#Y[7;1\IM,R/[V2TP?I67J& ,69!XO*I-PU\2+& "G_>NZIX1MYGS5PG&K
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M]D5A,Q[Q5L);C[-XJUF!MR[\"!V#6^R6GYO5SG75%[;3:^G<M*&J-;Z6VO)
M*3XB=&4:*S2:UD.B^(JB7O_B!Z$M^]GO(Q+?G0\3UAGA>>,_5]T&6[A&F1WD
M&((ZUZIAD+*^KPQ" JM;)3+LJ_XN[64^+U-*H4?%F>8(XJN$KYYVJPS>D,S3
MTI#61*(*9;6^\I*9!E@/5S2A.5VE5=YN5(R_I:$\S^I^3DJ]A!"'%S _/L#I
M4ZI.+YWGUZ94RJJO)%,I4Q9* _BJ^#NW@)'WIY\K_Y:9OID]B>AN.M[C(]3^
M352>+IY"$6R WAV6K?7AAT%WJO=N(N%KY6QBBI# B NG$YZ;%^MP(=K2>_+
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MN)T$RR[25B(*Y!B/)9_WISCQ,XLNG,LZ!?D&^WSRJ<QW2P;PI);3]2???='
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MCFBGKSIVHC2)DLF>2.<\![F9 AI4];Q,UR?=9:H"(WD+=F,D,SFY5RZ&LZ0
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M(M&Z9T M[8DF#B(.,H2#J#&:V,CR_9G 1E2*0VX+L2*QHM$;)%8TC!6W-8)
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M*QJ]P?4WOQ\<B59Q^8?L\A<[)OY4F6$[ ]MM70;YG(Y71_[OH%G@<.D^$;;
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M2H]/^*T@CJ?L^0@ZT?[G%* M.OBH&'[3"\>H,:%IKL.>W&4O'_LQ^R2>@HP
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M?@2L41K7NQ2V9E5'5;I,JPK6']9[EH(O$^V!Y-0;F*)YLD[F<!ZU9S-K:KP
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MZ=R!8Q5V!UR,GNMEFI?\&,31%7*+2T;3M.H1>\HEG>6/B4&L ]5#U.2&BVU
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M%P'<D@G@VME&E\4N[N2M>0\C-!R/MYVL=AD=1_OLK'N!^U:JVWM-O\[D3IN
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MR9D85K<#G4..C\?4W+UOM7'<K7,79>10ME)<H$\%)W.ETA,F+(>9$)4G(@C
M/Q5\$;7@X[ZYH7:Y;24FD3^?),QZ);.M\AQ'3_>*28Z&Y6B@D\CQ\3BN_M4Z
MSRQDYQV!*=\T\T,B?.N*D=3H]Y3BUV9]N4T,04:E'SBW#IU3%@=U2'\FAQM%
M<-#B9SU[3Q>7*9;XO5ER;V;',_5'M"YA0(*/S II=[US7/7UAY:7M8^YH2=3
M1,B'@MGRQ]@V%XD[K5GGDFCOY *F/@##NV"@8\7Q\9CZ*K=/(/==(I+68,?
M'OWJ]%KYG*9KDL1;M'#ZLSHWF0@ROXII] Z[ E9\,-! #6()(V9XB=WLVC7>
MARV6WC>:SH2;=L4X?C2&&?Q=,"<Z4N[;%N0P27T&NP DAE#?*/;V7^EJ5BXR
MW1SV)_MAS)(D;&VE]]>KA:>#T=FC[>Z:2:UFT[7QR*/Y@AG%KX51V3ZSLYKU
M_BG__/SXZ.GQ,R6)]U+H3B:WO1Z4SN74JNT6VFK$Z?>UIV,7PY=T%/KD .$"
M_: BL TS^6E.(+3VK</Q/,I/QRTE)>%@0@PG:WL^,(1ME]+H-/*=S&A;WW+C
MSX?:L_3L^CU+X5>OIZ:E;6:'=F>;<]SK_=N?3ELZ:^'$VYMM3'UV>DDQSJ*,
MZ*5XB'B? A1K]'\VE.^ 8_I#BM.H^>]]_UANG\JWAD5M3)2)8S5\8$JS&>KB
M=N)_(\&<PZ=P>#E1I^62C[8%5LS1T%Y1=@+/2=ZEFRE\>Z,>(G3FC\(6&PG!
MUI%Q]'9!E5"4XOK85& CPM[M"RW@H9*:RB/6UM8L\ 6PH-O;'>%_BR'5H=Z4
M7L%D]Z=N4PE.-_B=+?<DFU# =+O7FGUZV;EUK??.G!FI=49T?PK)G,2-*9B[
M2C[S&1LB_46Z72<#BSI1^I]@\4M6YVFR8#I-TDBJ[*[*:._1?O2]&NNODVU-
M+R5'=G'.-1E9N1"^L["B0?N$4B3[YD"6B43UI0TX;-T%]=[@D8K"#?9M\-*A
MIJV%08B8)AM#+9+P6#6Y9KP#]A&A/;($C4ZE-MZ X7(A+Q>V4T:=:JB+'7?.
M&Z^UN]N>DV?FT*>U,.Q;MB*:_93H+9.77CS4?0DDPHQ>YWCGI)Y$5LWV*\G6
M-ZU8_]^^TQ);U*0\0&<.&4QC5\XSMP+8 P$FJ@K@#(UNQ!T;F!,J_A6;!F$J
M&O;P3O.IC&=*;MRSH_9\Z*@=4[CQLQ/V YG_0#0!(?@SG:WH5%-S4MQ9V#9N
M7M9L#PNP/@;%1+2FB+B9@XJBQH]N%RV):-4&$U:3+VY*-->(A0&+TVVKY3#P
M[.!C;168[B@NFD*9P](U1!?_:$RAQVL'030J+X3&6XTE%UJ/BHYLR_%T0P #
M\8M]E,4\CQEWC7%P=%H\JX#]>NYT65D"B2 $OJ<ZK;+P>2]CWG SN3$9INZA
M-L44;\P1^FATC<<B>B]5 B?N,O\DR_P/AP TCKX76E"3BSIM1N H;!(3S<ZT
MUNH1IWV6A!3QGP:!7-\(HH)@/"[HH#@1Q1BDV*,NW222C&5'DT IHM((G Y'
MBAA<YE/.?MF'>G4F-WDT%6W0OC=E'",*1;,ZTE8#>SXV91RGZWYL@Y!SI_AF
M/J<P%%CI'*9BSR_7^@RJLX=%PX<(X%.6E8[%&DRQ=9J[C99V^4+=^8KOKOKC
MJUKPK4FQ<"EF>\%1-RR_PMZS(@*O+X3>8%_WQ]TA4CW;N5;4<EZ8KNR\WB"J
MQ"HQ;A##G;G=$?XP+I#+^-C#Z =Q+Y/+,ENHF;4H-[,F;B=^9?O>5@*5/'A0
M!I="N$&J!6EB=F@7GD6N>0.?Z;4P8=#Y%[VY%#4F'T_GUXWI3$>Q 792MGWI
ML/N_#O>V$<XC259Q2HFB)*2-B_GVNAH<27+*RDG%M0CG0MHLCI:;"FY^,9BB
M([H1S[VJ*.9>W^&)$0<]JU-NG3"U);E-^YE' J[+.#&B<]KEJ<>XKI/:"7,@
MF$IS3!(MLWH.9\<6T<9)A<X.&6AG4FQ2]_4N%(>&27Y8$)-S$GH:AW+!)E36
M9:K8##+C+M)$N] =6HKBM/:._!Y,Q [E4.Q2-9M&P*5HN4G7]?5-4]N:^4+"
MP:NR0'C78I-JT9P4A>,GC0VJ&S/$4!\/;6S3G+N<$P.!B\K*"H?BLW/V3AMR
MUX8<W)$"4^R;_\6FTF)]70I;K-59B\CPLC(_!?N  S0UEG=--H'3,7&14C$;
M2BCM%]MR>5P;FW%8+[EE-[W@U(A)0;LWT%N/H_<E=;O3CEO+Y68W43+(\%+N
MX!#5+AN>AUJZ&?6!@YT?R<WGMU._GELV:GKT\D_=:#%Z1:#WT<!2A-'G6?G%
M#0M,V9XIV]-7RN*TP:E-!GEM=:IK(CMZ< 36=J<&$N=A\K%OW.7B\1C<J=/W
M8'=#(H+3U60OF][C'"PF,H_?K&;J1(0'E50W$KS7 4,OTIR";8,N',=I$A(C
MYXP%4S<CHQ:G^Y]E]3EVZVF0#XM0>U+Y.D<O,RDR8?YP"F]<8QM?R*'B9G-7
M/ DB$S&7QC;C$4=G%T@"F\/&6*=5"R;8=D#;C2EBGXO NY4Z3T.T<619(]_S
M,ILG3L-Y-.Q#%6J!U0[&I/F-.0[)9,SLY7<X1WR&XHZ6&#<= 0D,/+KJ?PAB
ME!P^[1$3UX=^QDE"G SX@(A4FK/$M(E>B+-]079CNJ;XA,.#G;G+:Q%:<R(,
M;]'!DI&*; ),18Y3<E%>B;&95=&,<LZ---KM\>PLIW&3<T"9R1QN)@'AT6W]
M'O =(?@&7Y^CP#<DNG1 T[T3]%6#0UX;NHY )M?WN3NM;B3YP$]A>&KLQ<[!
M-!-ZG[;[K]U?A89-:I:#M*2^.O+Q1CULEWTZ8,21;B>>_8OI=+]QJYW'8Q"F
MKU.R.WT;S2%TTL_Y_/8"ZS83 D)-[B/JB6@)KH"COMRR$@Z'M1X9!QY'AQ?"
M[XFC6C]LUSW;;@A\P;X",SM\<LA20$X5A>:0@\<2S'7TRSCU$CQ[;OIJ=ZJ(
ME&=(^>*3@EF'&7_??ED:MSD1D"+]$DM=;KQ('/2K7=(@*6=I/3G6Y@@X3#^6
M<7<4?]*E*+B"&$Z9;5U2DE@%*.19$R\A^^:+N$\F9$-004&B)0.45>2WM[R8
MG?DXC-[2X4OC8?XTNKINRG)A5X@ ,N^%$-\A7H&YSW(+$M-"CSK[@M#:9T?[
M\/G6A>M21$%H^0S)'<:"!)!SBETT!+)DP<P4P%YP6<70G9AA*7@SF_Z15\50
M\7"H&?%P=9ESP4^5$CB<(<FVR)@<3X]UGWK,V[+UW+0A0K8V(YB):CY7O;15
M2[VO747,$2WZI0Y67O6^_72>W9B-_?$8&&>KZW$/L Y['1OSU>LL>ZVVQR-:
M'E<NMLY_(FZ%")L,'\!>/\"S,X[.-PG^%G<%5N_%3$'&+&'-IBKD _RI-(R(
MM3^R1H]UI+.DSFH>@ML0QSZ?#&2GGX[T<1;D"/T8)Z7D1);UNJ173?_)*!UL
M1/MIV/J:Z:\)8SY%'>^9<AIJ#O!X# H8&ZKD><H4A\9=]ADE NP>$WKEYNB5
MQP*#)<9R-%A(QQGZDO"*<%<WI:2$Y0GWGE?2\QGHY[) J[!0&+1;\6;R=D31
MZ5S-9&G,O WV[C+-A(1[G0DA/U@@$HA3SI+-+,_F4VK[%EB3QT^-1 RB*TQ<
M.6ME)C"F4@L_NH3X;B9/WY=555ZE!CPO+:F\;H)L*;?E[,:2,Q:&W\&4HE/Y
MO:E<UJ(3)$@6 B#E_C/-PMP"> >'C'?/E$F:\IBF&2#-\N!]LB(6Q+7+F=P%
M[[Q/&@5]?L+(*A:4"U%,W+KTK%QON6KA5\-R0G6FY:;R["DE05DZX!FW8BZ.
M$/*3?M$7;=?RPYAK(E3AY.TZ+63\CL08JGRFA]T77T7G307& .L1BM2XP6I/
M>.0R;FZJ/5H=.B,SY\/B&W,1K^TX@+I-T'HUU0W+,,PE3+5#+.I,0F:N?0B%
M1O<%E6/2^)+8DIZH#C?8F4W5>"0E'M_&B\.CQWMSTU>TBZ\<9C^P,0PMT?X@
M @![:)=!,]3C@8NMG8;"M#.8R,*>GB>3P-P"7*)$,[ZV]YC\=^W]10;OS8%3
MU6"I2S''E!6X;*QT,8.I*K7V-; 6R&2YX2*L+6I14W\NR@5Y5#*.Z"1Y'?O?
MP=P<(#@S[@ZE2JF_0. ;)[O)<3FJ[U<2D3S[G$H33BI/,1%)EX:QQ;48Z+"Y
MKC:X:I:^2VLY8WUOMBPH'P-20/V]M]XL."QT,0QKSC6E/I."05,LB7RF2;X(
M:4NWN5,@1C7";@FE<9B38=J4@YO2[$DY^@@!;,U%WY(<:T6BTN1^FQ+*RE;(
MM4Q;DX+F2T2*H1VXRFI'0A=^K2=W=!7H L9(JX4V#/5I,VA<N]I[#9)"GMG>
MI+9.60U&I2;A9\);(N6=P[.@U 0H;J\=&_ 49/@R#$GX,2F2+V4.-G(+,<+[
MV(*S&1?-=IX""6BIX%",]AZWN3RX2(AS1J@S;=,4\>UV8[4IE8&CH&[=[7KO
M<PSQ&VWQ^X83M@Z<G+*V4@\5KD]:P9^;BI/^@@V(B![68_I3(>';>W(BYC9K
M%-OV5[#<TE,N6B2KY%Q;\8)"G>+9-^X0^'@,H_ O9'Z!=N?H*.OWM]A49D7K
MTQ?F-O"H:X9=6VD=!XQJ:AS0\QU)/,G"Q-VJ]13F&G.,8O*_Q3;)[#OY+<7N
MGB5PK\W8;G-3DL267NQ)X;/*=.$0/5T8?6R$W\US7V'C8R?1:$ZZ.0.]&4\&
MQP*:T.?85:Y-Z6QZ4K%J)V-A:<M1Q"IG<MVN.X]_V<8IAHBM]8@]5$M,Z82%
MRCD2%XV@U2>^<A:G8@(73V'^?G"QQ]*WN2EX=&4.3_1#$)W""37Z*;L%KO;A
M+T7;ML D6:W N 63K'\F!T!MD(DC^@Z[E#X>PY3^T3:;<A"")]&O=/+83PB_
M=/_7XO[F4:1,)8  $Q#&,!\1@7HYONUV [1XF+ZN8<+,CF>U_5 )53&FZ7Q\
M63*7;[6IV7C^LG7ZL9;=KK/PD6!L$H[&[B'= 'K)V,^&>0GPV'IT=-)MJ,2$
MFAF6@,Z[+;9L:TSGP'1[Q--,T\V/3_9MO]J,04#TBEOK-F@C07<B)<9B:RL?
M@#%^?_-"3Z08XI,7*W.;!B0VNBZQV &F&H.S3:23H.W683PTPE3T]:*SN1=W
M#.]=R4<K\]V9QW)81@853 !:,+O)K',I&ZG_EICQ\OCAN]J275L/R0V;.8QP
M"O[#7(WP%WH*_O+/Z+>S,Y/<XJUG,Q5$NVELPEZ>16LLNS1!9!>GJQG:X" /
M8)%51BO8C:[4.W;XR*R?*>,AE6HN$(FOQ*1R3^)+U9OQP[22 ^,#?C*KI\45
M!748=U.[&9CEJ!FGP4AL1:9S;&=!SC^OTL7683)51==J#'((=^'Y0"EIB;$#
MC!PK*#;<3RX=]7@U^6]2:\X.,B6^9GT6:9)+:3E71"P,*,FB3],O<Q-6RCK?
M,G5T;,MR]8R2D'?*3IU!Y',EC[G%EN&S9^V1A8F6,.C5Q<5.6GATBBNDAH][
M#0W$<, 13Q1!*=O_*"@^GP&K6[CD%2.+Z1)-E]/J$DT06RU.BQV'ZPXOKRDQ
M;3*D0_HY]I,*2#/1,($ZL33.RVI=:G.9V9::PAH-Y9*P)KG#W""2?87-[KCE
MDW'1E1Z67"$V =K%D[VU**%>KP5%9RGDJ['97>7C%T),:]I%*B"Y5$*(5ABA
MUCA"MJ!-)@R\$G(Q%, #;IPY*;H5^0U3#$Y=4[]ZU]1G _M6T;G=KJDOPU^]
M.#YZ;FI4 EU3!5'7+17&@Z<KR-=HJGKO]?-][3GZ9 S*\4Q<*$X[]%!T_6;*
M%<*U&6  (2[!HHA+OSZE1=,QJ#$HDTIZT-A0COMDC20J**"QD\(,UJ@[Z;O8
ML=_]@PKK;JB 2-)_3'2.05HZ;YR4NOM(]!567(J E#D>QI ^D,Q?EX.J.](P
MR>^I%OF,")K=#1\%%_XB3+Z1NM8*W"!X3->:\FTM:L8".V.8E1X&%(<2\"-$
M@IL%,,: Q[>#B8B@:!1'Y0N3PO"\##[3" &Z-^;M]XS18?U"J3$WY=NM8G);
M0.Z2]$Z]&(?5V5!/SR=C.'(#)XUHL%P[LW'M5:AHS"G0TMHQ^@5S?N/NX2S4
M8E=E+-WB#]*( 2A9='PDZF[*UTSYFKY\34>5N[D247U:S)1PD:<AT%==*IB,
M"P)^+<B!<W )\@V(=3;;&/?!D$/0^1P',C+=31RW(-"M_LG]A)1_SC$Z1CT0
MR+84B!H!D;$ON\!R"5BV:2[8T7+7 [L0.S,J?;]X3DTG56X3%G0L0W.K,#;.
MNGEWMPLV&0-W;PQ$I[2<O'6(X(*=9+<9J=E-_L*XB^&BU @QGMA"ZT"1[?CN
M?\]V0C3HQ)Y]MTL$9FF1+K-=M$%ZCSH5RE#A9^?W-W![N*?0%K19J$S^999R
M3S9:*D%DC^&NY)1SY&#@I;:]9DKX<2+@2X O /O(K=T#VKF1Q6Y*,?JUPG4"
M3+I^>$V 1<!?9WLZ,/J';MK]58L(""83X_7!9A6:&VN%NL<J5-*>=Z?'+;R*
M@EZ=8MG21<1CA-,XF_ 5!3\%D'?.04S*B*#62AH'8T7=%8@-/;Q4?:O4I6SA
MAQDKD;PY$W.$Q^,C*+*I87FB9Z_G5;;6X]G&9OF7I(HNLSP]%YJCM>DG:CHR
M,VD\4<9D0R0<VC4\F<'!A]%]RK1HRN%K<?R/D9VB!-G@D];.GHTQ@PY(STM\
M5T7*([_\@C5*YN!%E6H>5Q!1HR@3K3IS?Y(EZ;64#SO]U.GH L\+=]""1E"7
MDP\YZ$/.AWS(,3SU_S<#$][3EF=SH:T:[MJI#(:4N:LGP2#I?1Z2X^F;AKY^
M-LHQ;.OWT+-=4Y$Z7H7!PMIM*BX-&4A4U"D=$['6CHJX,BDTT82U"66O2]#U
M66I,;=G F*"JLMKT)@R\EJP$&17BQK0!:XS?UQ+6P#U(A9+S(]^-[81-AI_Q
MBKZ6JBUD88V5 .>]V]@CUA8K6/7C+)V(;&D3@@15Y>0T3XH1(:U$6+I9MFR%
MW93U;+?-NYS65D/T4+JSPFDRWT'M6QJ33.?Q)KE670K.279-*")<-Z *G32C
MP1^X>.;2H!N4KT:H3:B:I%VC4&I50*HEN.P%&"? 28B&"PV]8ZK5Z"MZN_0X
M%\/>X )OM7#L?P**\)F/KZ(>9V R\3P$\44J%MIIHE]J08X_IA4[?J:+^D91
M!J=S\9T%#5%*_1IM>0:)FBX67.'/A8VS;6>([%Y86]8!;D6?AK6PI?=?&)Y3
M)&5B'!$_5ZY9N!>E"X*6>0K4S!("Y++4I>7U>@6T-$FX(Y/E_.6YI8;H>(71
M6PYA@M'YCA#;AZLX.S X-WYD?MQ10H-'+UJCK@.ZV_^<L_]I"U]2+9#U'2(/
MK\>1E7_UAKK^F$%/I#E3=/:>V<Z+(=OYV9AT,KN%BNCV=>3/7*LKQO/=4>C;
MMF#WW#3N'2*J:\L1W!L&E[-# XA<*TPN:$W+)08/OQ=_P.#CHL3B4_I>_JR]
M#MX\#Y<E1S'D+023FDH\[/J1P_V[6N5K!H!X6<0DV!0>1W:/L;'C&B>V(K>]
MYDW)FLA!$;#Q6Z]@U!C336DYM'Q>PP!Z/+>M.M]RFR!47QU"]7Q '3[OAU ]
M[L=)21+[5$P0H<U@63Y=KTM4+(OH%":X*M(MLB;\ #[1"+A4]+8P=9HHJ7O<
M8IY\ASQ;98UNL/UVC(^\,<8@JTLWZ%<Z/76NNRUC#:VK<O(0.A:#HU\/I71,
MD;QE/K2*74HND=9A:YTF+U+JF=E"+VN1QVQH)[PB U38-,V.TAX\-9B5J*)
M:KI:Y^4VE>9EYV3%^ST.^O'J+6O?W!_< 5:O>7*UW.11XH@1$O *:3CUW^.X
M1SO1^&I"W=T6=2>%<$*<8F/(&?*#D*.%M122F2&O9(6I,N.+8E4( VZ5 0I.
MQU0_(\8(EZC)@>/&#,_EBA)#!=2_2_T:7[F?/<,> ''=O<4J20$>P=W]/O"D
M>CA7R!E$[BGA=).(H_E%.D<"GD4%IBW\=U7")N86?@X<'4\SLBO6MAN9P5MS
MVSV+CWS/)&PF;CDM\QVD$YY*%1IJ[<["9L5E*11UR!O,!B 5(GEE:E9#N.:F
M832F104M#B<$1RK6C1$,0R8PASDK5YYP:.^ZV,D]$\$P,53X.>DXNL25].+H
M>B$&QOOO/LG.C=WII\<=9LO?#C\>1N]+.!]R<!NKRTR<)<$_\!=Z6DO+&'%'
M**VZ6%28CUIRTM"PT,%QD>N77=YK2ZTN/]_5)M@8*2<,XE'CBXQ,=>K@:A1D
MITS$Y%#=)G8&1R'A[$ _NS$]RW8V*)OD=%!.TR$YE7H0"9/&W#^$?'B'*YU)
MT ;$;%J!P158#JV N)-UVB;"<-5VL'Q#_;@!%3YME6LMU/G00HES3XQ(<\ZA
M<2:YHW'-)5QT?G>=<&T3:7WJB+LK.0KQKBEJ;$Q[VDE8!H7E8DA8!(K"S% @
M"(O?B0BCWM!9&3.D %O/I1R@H;85C+AFWBI+Q^&"$F#Q-Q7Z$=/:W)@_Y:FD
M.DQL?X%16J4;,J3,E]I6NDJ7DMEE;NYHN:EHAZ%] [;Z59+7!&5EO&:GC5=[
M$ZN##\=H'T!YRAU.N<.^R@[3@' ;O4N54<(&?6=)\3G6>!35E#L$[SX;1PNY
MNZ.EV^0.#JN<WX=4SG//':0Y%Z=(M0'Z5E_+06(@!*HNM[*U2M=@S2.N QX]
M-Y7"9([0K[OWG:R&K]H$^ND+<S)UN+A=^NS8LE,@U<XZ%<//Q0S9VH7!2AU8
M2(E#65KB],LZ+S/&5N^DE<?GGJ.848(':69HV+;FB;+2Q8']X!U3:/?TL!U^
MW"1<XWJ0)C4< ESO$NO>CCTP%/=%1%8D+0=G6X>#D"99K>*W4\?$AA;-"5BW
MZPT"Y8!A3HEVP])89,R"@PD$:(HTM'$EA=,]BMO*@(;E@8EM7DQQ#L/SPC1:
M!BPW=F#F4]H[)C'$]+.QY<1)YA:U*FE(7*)EBDM4ITW#'#KL*3B_J-%KR+CR
MS#9;"6--O7'MC/2E*T=+4%BQSJI$JAKT7,(2$3@EJDO3**!1+MI6!:<F)%IE
M/X(W%.$P^>)Z, ,\_'*3%KAQY\9G1_U'C%OGZ&46G#)%K^=T^+S!V&"*[.KD
MT^J-8BY1VOI'C8*=(@*7"A+:"3U.ZWY'3?&>';?7W:*7M6BPKSU\B\./CG>G
M)3TY=?8J[7ZNHM*JE[2<=-?03,GB,JM#FHF4$1YLV*0@Y=) 5E.BL_!!P<;:
M@5;P';/9Z\[2LGEVIMU[R;$F*1['TT_M%112&&Y00P=C;'@]6R=DTB!41H!'
M6!C0;$VK"6XIMJ0X7$H8/+>!F'N<>?I*!:UDAETU<3JUKOZA1SR0(0-HRM7?
MA*":C24WALI_8TA,0ZULSZ!Q-<*4\E+V \M*.=%ID886Z;^'SB!)-FYPP=A$
M4-M [8!8:M^$*9Z6SI#OMHU";V<B8:G#;]VS@@(.#!@_I/AW&#FQ> R^8SZ7
M"[%OS;EZ3L25,DLODGS9]93^A#/PSDXOQ4ICX@EI.^L+M^;(\E!T@,SKK[-=
M1L1,>?M(^+2WNLOAV#6M.>^*:B!KG IRK_2*@9KX.T%SFMH\.3#([QW&[,9>
M2<(@C'^>8QU"/;:42?@_FHNJW)Q?#-^:MC[6?GSR:NH[+X@U6M]^LYZR&W]&
M=N./VX1VTT7X?_B[B'<@V%ZHY!4>9#4,:=O*5JK499276)?(D0S.=M2,.V?+
M:;7*&N.AXC5:W?NKT]A ." :[MBV3C(NRT3(;8E.#MID")H^C-X$0.-<R4Q-
M_?K[]+Y+KCC9/X:3@N';TG,0GDT=QY8)D=G0H>96DF*787S"958UFU0AIEG1
M(4V^9@G/<ZE17$\5)E^QPN3%@#'4*2.Q%29/VE_9"A/!%; \O6<1)B$ R5#)
M=81_3&E)7Q775RC=VIMQ'0<;9V:8^PJ+1S8F)B5K72$FD\N%A;RT=&8O K\V
M5/N!;IOM"GDBCNC6N(.QLYI1N^C^.A7#*;648FXU'9$N?T,SM0;Y2S%P73>M
MCJ!#S0.Z-<HL2"WIVKVZ7Z?B8]KJG:W^<F"K=_:SW>I/^[?Z,V>K&[O\]08#
M=&.V]2]E@^)N^NGX3!%>7[\09\0M297"_%)D#%Z;8,G=];?G5XK^<6U(,PP+
M?;M(/" [=Y8*I20O$1D?E(2"&\\;'3;0HL0B]"@RI4:-!)',-UF!M]V2.:1%
MP,0$2?XE%I]EH+NW&E?2-)S+)=CO0?"S!!! )'R:R"(\&F=Q.;#+E[;S6L,9
M&UTWHH9KI N)V&Q4_])#M-TE^C%WTJ M-4-E)A(TV'A]Q5)#)\Z<7C14>C4K
M)_C)GHN"D2(Z\$!JS&F<$STXUWE@+R&LNUME-?:NV<P;.K>2NMX(]5F=+ 6-
MNZ!E\%L[[/2YG5(B]=$%WHG2@U(N4Y50?IR8/W:O[:B*3C(J&UO#& O4@VI,
M3#%CK*6,>$AN9@?RKX!6@ O .)UE>=92$11Y,_G$[;"><&GHVA)U&$U'VQ]T
MM!T?#9QMG0/,GFW/^L\VP4-]P,+D<>?95+IZR]+59V,8/LR"<"_C,L>^,7<5
M!?.ICPR)DZ8AZ6MXJU5+=0Z2_Q8&Y3*20(]YB9U2>@H7NQ@5QL'P/+CAMZSI
MLY6NPZ\5N\2=WJ.HC5TM 0SN.6BIKZ6#FX6@M+N'7=^J"2X']J.[_WOLWO;F
M?":*K3?*C+']-<Q\BLQ=L:%S,V5VZ3E(/.6FA'NR?85:8;8P3X]9POFAM006
M"2;HM7P D9\2F??3$,'ZY:V7+8'?EHSA:]6#E54?S:\@!/H>2^P(>9U>H5F"
M&\6P1C (>1F] 3-WS5NE8H!SAJ]=+#?%G$F#VZ"K-L MQMT!]F&5)8U2?[G)
MD=RW1WNR1*I8""DGP#@NWM $) POO8HY(KAP>7?=S*26?I#-E)I(P:X![$1O
M<2>U-.8Z3=GI*%.>.Z99J@"U;;^RZ>D :3$>CO+)0?E,Y0I3N<)]4]*#6OK%
M""TM5)(=(#V6=*UFPCLYN(MI\W%?<O"P+L'KU/1MOQ^><&P4YDB,+.P3.Y(Z
MY@%01]_C;I?/7HX0"L'*&]BB1+R"?#V.C:<I+M-,<A?.'=M3PM%.0/F8Z9)G
M\L]HKV:S?" ?Q:6ACI+FG^ZWF)6TT,.TXM71\L?:B7+L433)WP[YNQP0O^='
M(\2/#VR.##%YE>E!H;9/%3+) L&W/5]\G,88LNR&+6RV;3D;#Z'/V9^ZT(/K
M?#QBG;6RM$,LK%\4^YYUQQU3J)U*J 0U#K3MH#@;&G@EMH%U+NVK">S4 TY2
ML$,*ADZ;YX]&;?><?# /3K]Q,?7F(/*Q<(ZO5C!XC"F*6GH!ECIC^KO":<>.
M$7+3&D53$NP&Y [O-)*3I:!2$MLZF+Q6_-7>I@&?]%_XIY^ )>WC-GD.GIQH
M8J$HJH\+;E7%7<:]H')_/@6? A[,/II3:SHY>8#9)3J$=2*E-FQKS:KR<VH?
M/BN3:J$J,]#LG(YC1&50/+[""<6F3'/9.^XW,#MS\'7)JN/\P$I\Z27VK\>1
MHJ0Q-2CU4\/_<C")5@%[(5&*QS#^Z)1@UF'E)3?D=U6&I5\$3!PXMQ%>6%M(
MX==J&1"FCN>1NN7O1=HH(%?C8+1&!0C<%4JGDJ3S%4G%C'O4@IM]_QV6<3^I
MNR&+E.T1[A(01#,(TE+,+9$S'+CXY+L 0ZW?.]))OUUO*I XP1]<790BM/WN
M1HU)SQP>O,32.!$+0P(J 'CX&%XL9=E1*.K@1?XJ*BR*&2MVPJ)VTNE3=,67
M$_R'(3CD%P[O89!P5).SU/+^BQ!(N#04L*!!>2WMP7(JSPLXA^H=^"UYV*:P
M,%Q,@KI+']:Y(<[AF>I20HE(NT.RP;W<O#-R1QEYK>O9F!=L"1(TY5LWGHL#
M=&>-0C_HC509[1L,SJQI$")P%8.8,ULAHVRSK+FCRPR.1DG,>QT@U;CT\N*@
M$J@M3N\Y@J,2\)WL)!F':FCZE,8N^Q"DG-&SZCFAW)O.4Q@$HRU@#"*3PQ9!
M%W)-V48>36T?>2Q5D6K$GF6_;4-[L@\KM-_JT>7NN[I)8)2722XY$^&CK1)0
MR'E >8)908BGDKL_R,10<$#[&/))03K*DL=4&Y9)*81!=E)$ON/MTB^P=()2
MP)=DHO6T2% JAE';9V!RS:H,3+F?TOPRA:V:H%D'MLA!U[8[[MAVCUX,(T;1
M8@N83(]WF$R.0J$5[+9N(R&FMDYDTAX?18MD6\O1WVX M\>Z,90FR6I7?N5Z
MW!SJ0J4)9:UM<Y/HY<&SXV/5!U8]H?V%N@LD 5\!#0A26&XU4KUO:F4#-/62
MQC(P$=5";JK\HU6IG7![XI]</(G$8DN7D8@17I9"4DM5T*R I<^G?S_^"O5.
MGVF% A^VK=J/-S\QW.R)UA#:862UN$>K9)&:1" L;620@^WX.H$,*E=IQ03P
MD ;Q,WR5)>DM>F-Y(WID9TB'T6G "&AW4Y1?TWQB"(E\#)&9LEJ .0/FW6P#
M]C/*)QAY0NJ@/^3YQW'C'[N9')?9%T96T5PJ];:(-K?GW3<6.*O@TY:ZC2>@
M_OT"ZG]EO4M(_1<&J#]FS_"^H^-7K"/Z6QRAO*0V:*!J45%5*2.#,+[(GJ/K
M(A7#*";Q5;$_M;%66XZ8!2?-Q24C^)(QLVU*\JI IFTZQ5D?S>>;==;IMSL
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M>%.'KNI_:0_@^M-!N]L1W9ZXZ'5/6ZVS=N>C:/;:??RW^V4@NA_PQU[KO#G
MKVA([;YH?NRU6I]A.#4:8A?^KR?.N\V...N>?L$?^G@?_C;H-3M]?D]?G'8[
M@];G"W@:C%]-G:_#/^O"B,;&1>/-$M$HQ*2):+Q:+!IJDZ9%0(.)1_-.-#$+
M3^43=T\0E?A#,4ZSJB6EUR9[!#F]779R7U=G3C!]'"@4(][AF$VQ._5(-=C7
MQ_6GX&TY_BQ,;VGRQC6=ZF,DGQ#+XC@,4KGL6L[A6_#F3'4?.2/>V$%B.WSV
M!KO'J2*TW=0(P#-&=?(1!&P 0M0\_:O3_7K>.ON(RJ/7NNBU^B2(J!"^-GMX
M61]$K3E '7#6.FV?*9&&JT!\VYV"=-.MRP0<'C1H_D7*HB<ZW8'^1'J(=0N*
M]I?.&=RN!9T^U41[(#XU^W07Z)=VZZS&(VV#[E)??JN)KE)7 U 9K'#BF37Q
M^34]-;CVM/MWJ]/$:Y(9P$OI??" #LX7KO_4HME\[:$:)>77[37/:TK7?6T/
M/M&<SUMTGYH[K!O,]5.WWP)%C /H@Z;NMP;B0[<'-^!"K+YT"[; U+$IM7FE
MMUM4'6$18"O'Z+DN-N4G?<UVA]GN>+*V;7]OB6TK^':);2M4&22V36V2]*FH
MDP.#58Q9>ZSC \;?TB;&P5X@,V^40O1277O566YNK)@J(5BIAXV*+++JX))P
M\.(>E>H%#N<!4^_@:"=UJGPRM1Q.DZ7OR%V?V<O(S]/L/CP8RR]IP?2FX+,E
M++^X!9/>LSC%"D49(#NM=- \9]%TGH4.<21Y%F\V&7+\9*>>SVTDDB20]5-B
M0OV2CP(7NL8B]+3V#PEPEWM^Q'[CPGX8W >6AY3/OV'N!IA"^V ZR:7'6!=G
MJ1,HEI?,#.^BKJ@";53)^11,VUDV.7 (;0EDUGL&OFK7&OB>8V=_PNS8Q=D'
M08V!TGU#DE/?8/#3IV(L3#IPZ[YX;*D)&-%\:-%<TB3GS9+"ML5-<O265-O3
M^R1)3\<,SF/1\UM)@G,=ODL.H*G *\PA2ZH^ 7'WP!A"%A^2C=WRL8[NEJR?
MIMY0THFQ<9CT=\C?A<?BG7A5DN/RNB")*N;PV*!A_P=C_R5-48H= !/V7]P4
MY4W2% 4EP N=D#BUEX+[NG6G0(AU=*^(N$/TZHD(1J[C9(3M_T+0A"C=:8K!
M-13TB6;67U: N01WSKNE(U5RH@L%R:(E$;]*%:C3BYGMXZ3)D7ISK?R%)4TC
MZ-ZXKRCWGU,]WAGJT2DMI"E6B](+C50]F%0MZ7!0;*\62U5C<?.#-X5":O73
M\:O&XAIK?5>3:H57*TD1S33&P]AW7?]:,SV="M%YN#!=7;P# J>Q#=34"Z_*
M0!R\H$&1."DA7WA??H@QY@&9C 3U%T%G1E([D7F4Y1A!)T.IXWIC?_'9?UJ'
M_#AU@QGEH*:./=^$465I,J320^%LB)G)7*D&8C+#J/1^Q&\"PN$1-\7-*W1'
M:O#8$F_DM@2IL6\^GNO#^AF8>:Q-T5&U.H"=A[U.Z?,P"YH4JUSE]\#OSG@!
M?;#)D!\XE[B1G7:SBZ]0A$^Q=3[W9I3DYI3DDB,EQ:9KB9)<HN[4IN$@.5JT
MBL+[HH_&W7 D27W%/:V4^4ZU'V&+K,H<4@W#%QQ:$CO*^;CB4HPK'[DP/H6L
M"E-3)]B7]#=)^H1A.S<J&XEK/K!QY2Z7UL9]>_6Q@C"&C2F>"5!EJC/@1BM2
M8*-Z@9+ ?@EB2MR'<8&FS)P*X7.&L<?&+2!TNB!,GX]5;3QYS)EJ#RO5S]*3
MJ,ZL@)OA8;K=LTO/G9&+55P7[EV9?\,R_9Y4/Y=8A!,_"+@UL3HPJ6FJ>"KU
M>PI_J-A?FDNAJ'XAZ<^[[ Q&72BKX<V7M.K(K7[6=.)YP,S9)0&2>Z-8):1(
M2K95HT%X*A59J2[,,2R<0J^=K]*3(7,$B\\QZC6,&^ K:5G\+"H 4H=;=373
MXIX6=MRPJ+Q[1SIFYI.+\9.P&45-V%>@STNZ\:@^/+5,[Q\G6M3S1&F8TB,]
M=R!4+BJ8;J;Z:173Q>9.(47'2IDZ@$R27JL$>8X&1ZU#DF+79Z!+,B+D3JCR
M__)2,1N/EVEP/DOTP2US1@XJD(\S2Y\++ $'PJLS.E*=5%. '%0R6WK"2Y<=
MIKK4TFD'KVQT?_XQ-?N C[$/^'#BD'"_P/_A?8)%80763!+MBTU\PGK%(X3:
M!JS(VW7BQTJHBOQBD=Y(, %IO#56&&.9:N>9QB=1>W,Q.@LKF1*SNY*N4:=2
M56"L;\4].\O+G"5=X)3%,,"I 6PO/5(]^TK;FJFE4LNJP++#)2B1M!1)XPGV
M!G-@1K6X81E;<3I"P:AO%IU% .I'LV#(C7<S2435(4ME];*]$2@LY_JCH>K:
MFW),8__?#^;+/,4*$ZOC1T@472JE<Q'I7L(W0R2F4S*1AHU3QOJ6#5$$8]4A
MB"&!(">G]M"KRBHK.@@0-]U?ZJK'>Y;$@:IC'O%131E?M2^:V:P@]LE>;(';
M *XZ16NZUR%(Z)4? (40T E^X7W4M),O=+R3ZEZ\'M92HU>#2H,IICTFB&T(
MJM1A7YR3?>FH*#ENG]%YRBTO.E=XFMX*&6W!X4U@;@")T5_<<$\_<RAKB5.G
M6PZ"(^MD,:^R.7P6&I.-V5PVIG@(.<FKJ(K3GH9<ZLOH97<\7KG&IM@ -"6S
MR[""B^TV\ IURB8E:>J(#"/,>AH,#S^AM,"_*Q7HN @R14<'<*Q<:LHXJ>DJ
MTVSGA?0NJ<(9#<6.WFI%26?8X!H/)^XQ7DORGWP=G;O9W<U,Y4JZHY152@<2
MZ<LX0:^3%04L 'RX.E%GL^RJ3QH]-6L\,_!0>M(:?"E[^CNCQ0I'LP@A+D;5
MN-6.'4V\=$(U.E05;VRE>M$SZ%+9&J28C6!<F%:3N#3XEH>\+!<3&I?*<OA%
M+.T8@%>UB5>]/L9E[)P:0&STCM1.>>PYH0OJ\WC"]&'\N']\BA%3> 5,(QD!
M+^^FH\KL"'1S_I42 :>@\(:! YKUDW1_271$4<N"QGE95+6-@H>R?YSW/HYC
MYR.C35 RN$#A[94S @6GMAGV#N(=C8?QHFSR'0N:=K$/]?U/9]D^2X]P&4?L
M%5 I$OK]'E,9- V:%S%T+>_GNUS-4J@VX_[\PWG_(SM[;4G M979F#Z?5BFJ
M[+M0=F\Q8;7)!+J^6Y&()J_QE/,:MXD5.UC7WVGU^UC^WVMU/]3*R@/9TY^M
MOK4W=@(T9T/_5UR@O]$@+#=#/&8I]AM'+(#+PAYU2.0M!$?!>_I?L;G>@E%"
M=.&._F_1LUWH$KYX_QG[1L]"<7%E@;MFRQFE%<(;&_K51+MS6J?+-KB(&<DH
MG%1]2=^4L9)>Z)/YVYM/RBHQ.:X?*>HHM333=]$[1]APFDS\6S+7^(!WN5]R
M2NK%^S_"/T0_DKB-=#&VL"I6NG_^,5O+LY-GE,X*F^Z,P5)HK5O4 (ODE+YZ
MZ5IAE/U^\2A3-O$7AIW 0>K!K&YSH0?%!;SJQ\?UO0:MNK()0MN&&\F6LFXI
M19>0#Y=Y74M-4CA[WX&8Z&V1H/#K +N;OQ6G5XX<BP_@Q7OH[XLN!_]+1*1B
MOI0QPT_&#-_9 #7//K<[[?Z@UQRT_VZ)YL=69_!6&Z-N\Z]!KX5'G?'L<NI*
M/-]W?GX:&ZQ%:0%Z23Z-\KB>_E.P,O_&,@#;@B!U,@P@UC-6)FUE&O6#5YNU
M,L#V;!T*A$BLP]_8R?TBD"&=&#8<O9RC3P('/-J+ !;-,'.*F1N-S7/SVGVF
M-#$3@>A+#]O)+I,+D]4P[M1&3FVG8^7-;0HMR!PN"<COM%>4W7))-H@:R*NE
M^S[%PZA]^TJ.9J[\9]$I@Z/# W4V05^J3GNMEIQ88,66Y"E(YE?I=5641L6A
M:2VI)WRKC,J=!ZTZ O5;IU]Z[<&WI-L$ITQ((T3<>)YDZE\O]EX(6[JN$I'X
M,])-?];Z@Z408;JPT]I;_<?R?<-[-BM+J1;4&<3%.'ZP>G-_%KT=.[_E*&U5
M>)1:.4>PZM%HI26_429S!I,)X$_+&#W5XTPMK!I0H_[G']$H/:;L[PE[9#7Q
M_;><>2] B>K-^B:E3%#!+/$K7I16RNL>6AF6WZ(YG?MVLM?(^946US#_DBJ_
MDMH=C:].%^)F,.Q8_I#T?R!/_D%,G+-C,9<WU/[]8Y;%+MII.C@JNCVEVC&_
MVBF96&!N-LX6ZJM5EN+%>RO9E*1_EC#!!?<!MUQQX5J,/!IC;NFM5[55_38N
M)J'W_>L%KLT+K917TK0\6UQ'-0=T3Z@DVXNR[L^K^NM7B0I2[H_Z,NN(9_5D
M7M/Y6J,='M9?[<?^F'9&IK]%Z&-K$DU"]3N[8(M^5<[8HI])#@H_IESOE.(4
MK^JO%(_27XO36VO+>QZI]QTE><\U1"\8M7 T-'V?-Q0+B?+J5=I)-D19-U&:
MHU% +4/3="$M;J3F<78+C& \WKIGW!=3KF.\J.5>U##G177)7W9C[_H:"RLR
M)8#@R8QFB*(RC%VH0%V6*G]T0O%33J/M=Z=>&055/7?JT!"EVNZ4D9K'<:>,
M8!AWB@9ODLB/ET3>?RY)9-UM?EN3R/_.P<1T@TO+<_XW[B>03@S>(T&\K>[O
MJSUC32KF^QJ*;(XB6?"_NWJ_AD2/X?J:13=^K_%[']GO/7@N?N_AEON]@P"/
M.J,'PF>%^7,?7UC8$'\G."5\JKM=U-3E?B ^H+&,"%:)'U:XMQ79]6?H.1\<
MU ],*J9BSC,2Y< 096-$83U!BN!.M&D8VFR,-A<P!A^[#HDOH;Q[<&/TVN/$
M-T9U/=ZZ&[5D0DL36CYR:'GX7$++5UL>6IYQGS-$7L#^8860\!D&@_N']=?/
MW'@7C[XMULS+>A!@<$$9"U6D0I7\EO<S;CBSJF%'FCSS&I5UT60PG]*)"B7Q
M=R+%L2'%.DBA2" ZA-%Y>TJ EGOF=?#KHH3NY_M'JB,[)ZV&=PR]C15YG!#0
M6(K'6_=G;A8>9]V-$3 ICZU,>:2;;CR%G,>KYY+S.-KRG$?;^R5# @)$'.^I
MQ,[9JZ4]C'P]HGP=/1?Y>KWU\I6@/6+RY_0* ;5=<6%-N5?Z"I)F6FX]?,LM
MH]T>4;N]?B[:[7C+M1O"",N ^D(/_" 2IXC1N^J^R5:)V!/;DSQ^+A+V9LLE
M#/USC_#1<D(E^O!_<L3 8E^M0%[Y,X+0)BQ(3YPS6NM%("<.(0\^TW+6_>/Z
MH2F#J5HYZW%]WW3/>> ^""O6C!FR;(PL)P&V^3N3H1TX4WU05_=WO'MEJU%Q
MCU1A:;28&D%#O:]1ONYW;S9N]);9]S'[/ML35[YY)G'E_MZ6QY7G,HJ V_WQ
M2X5[32#()G53?1%K[#U%&;MPY>A2CL Y'D8,Y.L0-N;Z2K"WPG@9D!BS8W7'
M'2L#$G,WD)C$IBN4F"P4S+Z!@KD;%$P%,<R7ECU?- <P@?ZF\7_O-?XUY*#:
M83C#?0$KBFL2^&_1G$Y=)X5,DK6[*CE5M+2Q^*]Q2R#]:&L6^5E-3M^P#+P!
M_0R1_PN]-<%+>HMF%X?U@VI6C#:2U$%C:>Z@&3B6NYK_4C3RI0R9=2_NHTG4
M:RGY42)RA)EWZZ,>C3?U@VI6M3\'FIWB*9U@+FY_0N>@?GADR/9(9$LI=]'Q
MZ[>GWG[]V C=8U%/6>@"X=0ND7ZQ#I?4,AC[5[J^JX!+K!AAWTC<->]S/#/3
MM^WD>F8F;^O)];QL7*7)5;G=QXU,=;MRTD\K$7+NP&O#XA:#Z&%258Y$Y,=9
MDCC]L<4$J]@@S1;!PV\1K$>2;[7Q=VO1'O2:9ZW/S=Y?_:>L?'KRT@GAM5(U
M,(:W_4SU,\:/]\_';JA>^VYEV/OU1C5+M%;VK6X5R2\N2RA/%V3C_<] _S]2
M]+]]CO15_7C+(X\'7&Z6QN#NV;%&97N<5G&Y^Q*CE#LM]$&CJAT^JKC0W6OO
M#JVT&D?U-]5LE%S%-<XB[]RY0Y8QCTO2#.O.HAKC^("+;4SCPRVV,8\/R=G&
M3JYIL5=.]JXS[M?9[5L$_D\U%_=$DRRK9'B3[$M%<KP%%]/D4TT^]1Z"=-J]
M^-9K?_PT>"[YU%-_.@_X,!,5MTH/^2#Y>K6\ZA-=IU548FH!B\MASJ48)6G.
MI3S$N11]#.4?C51?/+%R<%!V8N7 G%AYS!,KFS7G%\W>H-/J]3^U+T2S<R;.
MST_%:??\O#EH]9KG3]MT31RT4.>.Q;P%AFHRM;RY:.-H9 CVZA1,>N1$LX@M
MOHLV+;#<BKCVSSL:N[""R)-!>.5,[TVQIY('J)AN.6^=?6R=B?ZG9J_UI,.%
M_I4%["= W$=B.%]<6;'Q @J=M]NOOZ%T'?:Y$^D/MRBQ:+RIOZE:.R(]E?2T
M*@2#LP96RK/-+4KY#;4>G%H$P@:Q+YV"):*)=3P6GJ@:6*SMD:RB;LU6^WN&
MIQZ8ITZ1%F/,*,FU45^CH-V:^O6]JNW_/2L&$&>*"PS9*D^V"QG@:ZS+]8DM
M%5QAA'/W9I[&+[@U+VQRC]]0HT+4,,Y-A4AA3):AQC.D1C4/IB:Y-M-HT&SH
MFJJ7_NFGUMF7\Y8XK&P:>]FA@@_M3K-SVNY\%/U!<T#[E#<UIJOJ)I;1+T:_
MF(*1!VUD>G#(92&MWU? XQ%7A32WJ,AA2;'&EFRE?NCV/HON!]$\/6WU^^UN
M)S>'VS90ORE]=)=&XINRBHL%+&Z_7MQ]!Z+[;\MBGDJ/N=O\:P!D%1^^=,Y$
M\^QSN]/N#WK- 1"\AJ4Y-6&%(KJ2HCD"F59GC'_!QTM@H04QA6&-PC+WY/:Q
M1L8,+#$7GZW \6:AN+BR0/?;<D;$"Y5VKXEVY[0>L]&)'P3^-6X,E;).%8ME
MSJT1]O''4NR/<+6+$(5O'[&TA[A]B>FY<D+1M&T9AM@,H'D92$GHZ/#UQ!I)
MFLA(NB#%6&QN427U]W_B__RHB?T]^/Q#3&=!.+/@SL@7-QR'I\/#JMWX84DQ
M9/9Z:KT*;XVNK B401!9CJ<A$^;)B&MB1!7=:HCHW.X?O:/Q[3?$#GP-;@.L
MR:@F)O[(&3OX5R ]>0TW^8& -:.?Q3CP)R("(N!,\-\:\2(]<.]=22X"_W[K
M1$ #NZR997&HBMGIB8UWNS4QE-&UE%ZV1'UJ(3@]O#J0,) =^LVZ^S#BPHWT
MNXF\6,J#-/DEW?D]YZI>$A9FB._I6C\C6 'Q 0*)C(7P/;(>8@<(&\Y@FK:%
M^C["T?B7$I> <3^=*,0+D%OA)?10"QCWT@OO.>YR>Y690UTT71='1D_Y7SP[
M((-)*&8(.PH#CQ9)$H[2\R/AXSRNG5""/(U!BD<"28M3OK+@R5<6O!@G,9&6
M!VH^5%/C0PKPPP3?(AU:#;RNR%?(QOB+@KA)OD?NUR^EH9;=O1NK72K<^AV!
M IB#A/QWY@2R7F45)@5M6?)JU<0_)?\1?SJ+&>+%^^^.!V.-*+1 ]8%TI&,T
MBJ%__/F' \;)6OZ4U)O%=]L/IK[F[FE2#%H3KJKL=>/*7ILK>VM"1G9=O0N9
M8S@7$'J#]T+%-J$8*P(/06V-@<*D%14MJ<E]0" RI"GA9V:LH4S4AIJ.EGY\
M'EX"NAM"4SXFLX"UY'C,.D+I1[@*]2T-TQ_718X*R$-C!^6#!H.7!W(:R!!W
MH/DH$LK%M17@B'#0H8QP/"CEWBT,R&WL1^G$K #$+IA)I0J# )Y.@D!"EYF3
M%2_0TJF/9P$):3SAS%SC)Y?I'+H0?R1E44[8A8KF"L8W1#,RFKG .+/HR@]0
M40%;_88'D7',6'-@+R=2\U9ER? 25+*_+-SMP%^&#I\G\X<@GXJ;I0>$LB4Y
M[M8EF..0V WH9MFP@B/+LV6BL$E-UD!O#_\#2UM+K:UZ#JNN,:S71*+SA%I?
M6'QJC6(#R_L9S*:1#0("[_+=7]+#OV'U@TO0E?^KAC5!<8,ISR8T\A#$S+4"
MX5K70 !F7YB(.NH%JXV%U[A0'FE8]868@G]J.U-7'1H#[0?LLA/(2RL8P9?T
M[?45&R4R5O%JL"P#<7 UG1$M,:X)/-*W)>L35.'\2!2]" >W6V'=^A6(Z,\B
M5EDX?B0;3%=>^O"I5I 0K;20)XG,X/AC"$!:1LE.PDFTEE;L\-"#:IH>0PP*
MT5/ )82[092F0,(0N18?P];7']<6"#;RBNW.:-575R>O5E,G$<M^37-RB':#
M/$B6)V+^^ ?B#_J>M2B*@#,N+!X$.G@5<(8#Y !6Q.\M D-77F!1UZ@%O[Q1
ML]1(V8,\2G=,0P'5,91@(,9$!/A"&Q>XB\4N:V1*-1)0"Q2W6GI'G7+0%/,+
M4T2[TWC]+F0AA-5#0 QZ>>I>%G_XCF[43T)- LP4^A[)J ]_HQ I;PA6K?4;
MJ0U#:X9@2F!DU[@VH.B$BXC#2OEIR06;"O2"-2+=%@C_VN,P &^B?#+H,O)\
MZ%L(6D-B^(2G<%S) 0Y2:_%*Z*6<6O/8!5220+HQ9[>[B4146!?D62\1<O!B
M)T,(_^1BNZ:8#RZUD(1#1?:1;\]PA7"59Q'",TY]^R=X O+WE _N B^!.O58
M1K5<E1O -'78X8C?-9;(J\PM]A5,487H(R>D@4_(2@-9;% Y("(Q!<M%J<32
MI572 HU4%V:/9:OW<-<L4,NMDCKC&K)=:JQJEX"%+J^6&[R#%9_E+W.9M:7G
MG H:92;C#;;VT6=E19&%@Q JK[)PEO6;0L8F/4D_!T,X5Z(BP_#M#EFBPLKP
M=M>M'R3TG4M''R_IG09[L.'1J1P%>8Z@3LV*WGMT,=LOYG?*.U39_5@0]G*6
M(XE@P24]]\$A/%.^A?(CRQ)C=?0:Y90<<O XP $-(2 ,9Q![2N66L)Y;%&2H
MET/DBDEI^.]XYKH%?U\9_DHN:QN=_SEZU%@B @O+D0V&L6,*OU"SHUL41"HJ
M<SS.#E#$EDH%Q,$0K@&Z\BH> L<7@L=(&0EXU[EUK;QCSFJ0(\FY#0JHU0M4
MD)QZ!P?8O.28474F4\MARJ;OR%WO\PS9^<O/L\K^]J=VOVQ#'<\KGY^+DY;X
MV/V[U>NTSL3)MQIU1SCM=OJ#WA?XIMW!6[N]LV;GM"6^M@>?:E1C<-[\BOOT
M5&Z I5;XH=/Z*KYU>W\]U%K<NKK@^W+=UB/I0QD'4J/+2M&DATX@)7C0V11#
MU_)^OE,A-41=="'RN.OZUZCY?FQ/L9F)($P$P<J[@Z+= 0TAOGYJ]5K=#R4I
M.;)M*O^[>),JF]H>.P$H<&OH0\Q[':#V]C:J'7)3Q&F+?>HG@(XVZ, S+ []
MV&MV!MW>,DF]]T@R_$7+GZ;'RX4$T:,]F;^]N6&0+G:K'_%-6KC7<"0O>4;I
MFX&@P1@TGM8O15Y?Q)'TU4O7"J/L]XM'F=+MN2(=5BRY$ATJ!=0KP_RM=)_0
M.O#&A4W5VF9A.[3VG/'_UK'0U,AI1D?LW^('0O?=:*E'CN_V4FS7'(W0>Z6\
M5<>'M9;A8PWE>\GVZT9%=MFR1)&WNCPVZ@<':7FLTDP&TJVO/I.#^M%Q56?R
MP?J]^D0.ZT>OJS21C&5J@=_IKCR7P_I>XY93,8<)C)MJ#A,\[&&"5R6'"4[,
M88)'.$S _=E$_\L%_&6.$IBC!.8H@3E*8(X25#9?C;DE;@LG^O$6BMBAG-.=
M*[,+#\R593_4086#'6?7'%4 <9KXWN4S/ZA0>P(G%8J":LXI;%H_RO0!@74=
M64C=0*<74I]!N:0^/=Y1AO@L (F!*AM$%8G\I!J)IFHI2PI'EQ9Z9JO^XMK0
MD0SMP!E**G6E6MR8U[&V5E6'B'Q!T [)M7Y*5EJ7Z7[DJW1#[V%*J20',7!#
M7<(:\>ZWGFG)&E %.]U&5:62UJJL8/3Q3E[LN+>QB'<Y?)%=TRJ=ORBJ3W/Z
MPIR^>-(5UP66WY)ZZTJ2=J4J68UO<\]R7:#=PFI=N(O$: /CN<(Z'#KR0(R4
ML3)9<YRWP946R5+E?Z\:1"KT*B0[-U?F98XAF"*B%$N;$EA3 FO*/DW9I]'8
MVZ*Q[U;V6>*_5ZOJ,U-$MHX2/;&V6K^G4%2YO_=FHT65CU5/EIE 3H4=38L%
M*H\+2[AD(E@Z;)A5 U'$Q=$;*P)^'"ISO;"ALZ[1BLLBGP"=,]6AJA[<4%I+
M]-[#4MH4SQIG_PEV^D\2A(.NB/O^'] )E*TO_7RZ<-_K ?3>.I!> V&U-0B]
MAE2/#,\+?ZT-F3%6*88-MH -"/T6&>&+YS#)UL($&N_=8'9O$S<@I"XS NL%
MK(]9&TO<W3@8Q+VG!=D;>YUWQ^XUIJ)"B)B&%(84AA3&@:DN-8P/85![[XC:
MNUVYOAO=NN0(S5/._36.ZD=&^VY+^L]0Z_$S@&N+\O")=\X (B<<&4YX8$X8
MS*=RG1G@E)%9>U;9L-16L%1E\\J&&QXUK[P^?5"9_+1AJ:>6G]ZPT;I-GMNX
MQE5*(QEJ5(T:1O$::AAJ&&H8:AAJF.V'!ZZ8IKX19]@MHM?J;_.NB>[U.!+]
M*PL<=J'3#.EF@UN\&_*JOF]V/[=F-^2XWC#$>C+ET%G-8O;&MH,=.'UM>:.U
M\<&I:W$/.<40:WOP/1C+^*0/S5BG2(ZQ@ZCP:V, 9E;# 5O' 0+W10S=MH-N
MSV7#P<0*54H<F5B@0L0PKGC%J&&LH*&&H8:AAMEO6-M^@VE=A#^8UD4&]_/A
M<#^/2G _3PWNYP/.0.-^GG8OOO7:'S\--CN9VS;E?;V_?/VQQ^ZRH>=0W_+0
M=.O(//SS#S5B%3MWAA<[]:=STE,EG=X+6&F$NZ<W:%4C8>ZT[0?8U5PC*MT+
M\"P9T4+,-H= 2\;6+Y^*W6^&;T.$O2S0B!5CIL1=[E.X/]6&>]OF3?^;./KK
M^K)R:WO28'V;!FM[4FM].UD5?-+Z9K<^VGW")STF'.L-]H@ZPS?[K'^*2I2@
MUQ1RIR^L,F"/I2"EF\49S>CSQ;A0:2A7</CLJV6350B1!#>F.N.G$=FX2?XR
M^R=V%F!J#F?1W9 S+^'%7AHV<P'BY;LM8+,T+58 YZJQUU"@%0$7V!"118S?
M=B,7 .^&^NF.VGF!/VHQE%_I38S61T",ZGY$3B1H)E_9='C0%.$((S\O0RE(
MPC1BZ5"Z_G65:=7I?B5XJ%X+7.U632&]$5@>Z3B]S-- 3IQ00;8!.>'I,WL)
MU)Q>Z7/)*%<@7T@()(=?#O1:?'!R[\3Z25\Y@28!ODDBD@ZBUC!L'#]0/?Y$
M87LS!C&I\,7LQ4AHES="0=8T@IYTQS1>6)^A!$$>,YS.*/86X2Y&2I0><$(,
MZED*(5E;P*X$[ZEN9' :[ (18YE"!"O\:X_AGQ$XU9LS[C-.AS(7PK*5>AO.
MV5<MSAWGXRE%N> 2?!'*1NXU2C6-9X2A@WB[ZG5T"3T"A 0;GO-+U+QVUHC8
M7"9^1?3FD$"BE7#&"ZTIA>"TKHS0\,UC/H05)I0Z@A:\(@!/*78TR*2"4 TC
M4D@3!!$B_Q^!G,#?=V/1"1+UOTL<4H[76F&/X>8^[*GG8]ZG$ MP_N6@!)<C
MZSW=/PG!W*)2/R79H%66YL7['6LW3ES2/TBTF-%(TY3+20KZLD;6P@<7@,"0
M59C)>)B7H%,8CAX#0L14E:.7R(RKO .>%T:,7GP+=,8&@2_F !4K;).>(=,-
M<TRG\7@9*PX=2=N/(8*7DMYV+7! F?#$RT-$]@8>!NX$UZ8F G]NN8PPYVD0
M;:7[0C8J0<J$C!00,UQ!!BWG!C&&G+91P-T^L/^[QP3VR_'6\V0G>_/L9./W
MI*HL1@5&'3:U0@S!&&(;&4EY!XXW#H Q8F#I%-<D:J\N^#4(<5STA\@[@P%G
M8XJ;PC/X7=_(GNU_9EX&Q'C9JY:!@N=#F[)H1OO )<&G!M^U?X+$,0@;V8,Q
MPK2G4-K9'N!/&HM[:=R3E\[R^2G/+65P*&N+;]%3U^-#SP[$FL KYT6\7K.W
MM]6P)*MHDR6P(R7HVFWF"_D+N9'8. NC2LR[@M".\$^20)#9,;C_42*P9:+&
M(:IZRY(4@TJ[7*+V\]X1RU?'5AD_:&=4XGS+W^!6AZCDSAV;\>B+2;X%_G(@
M;0EWAEJ38A(([B$ W1$=))FG]6#*/8_9#=OCX#$AC/;2C-L%76W+E;S^>-RW
M=-]% ^UME:#0;^#8UM($BS6#Y0G@W=JB_7=&72YC<]=3RX_RFZ&*#2KY9L51
MX84A//=E.\$$;82;]71!GSYV3\[;'YN#=K?3U\CM"(;4;O7%E\Y9JR=N?NHJ
M@/'XJ=T9M'H7O=;@K@#R%5[Z&^T-YJZ&,H'&!5;U/<I:D>^C,Z!JXW<EOQ,D
M'%6+%W=;"R7<CT=+;'")@,7Q:2&[B"K-%UK.*/.KB*R?M!6@=I79= UEUCAR
M?UA)(]8.9VA1?@Z<PQF;Y3/>SU"HW\E,LQC8JUEG6)VQ98>@XD!!4>G.Q E#
ME>^2F-H+?,^QLS_A;OG%V0=!6;5H-YD+0\'3=GNHMUUXF$ 6;T:HW?%P4ZOS
ME(#*B4,OD #M#%KY.:*5GR!:>=W DIN0H#(AP2V4;QDL^;)-/HLV3Z.;ZJ90
M]Z4U=FK/EO4W%M^ !Y7R.<#K(H<MJ!C">08?]OO'7K,SZ/9V^KL;A<[.\"B%
M!VF:OER(-9^&I;XQ.(E/2BG09JT@#/JM7AF6D8U!WPX#A2R-.*",//Q0//7J
M,,]3],TRGFJ.1H$,P]49JU$_.#2,5<981_N;9:QU+/0P6-^S#-$,T0S1#-$,
MT0S1[DJT3><1BEF#_4/E!ND_T FR;3G5$0WE7$;DOG6;?PT@]A$?OG3.1//L
M<[O3[@]ZE!M,SB\LVA:LR-Q.YH:;->S9%FB@I[#.#Q=BK1BT'-;W&IF8)0G-
M5@U[]O*/,-)=,:XSTFVD>QNDNRP3N9?-Q9@=![/C\(@[#C3Z!SY>FBZ^6&M<
M4"CT6.N&8[Q=LN4-OY.-(:X&X4N29HQ;U^1[_U7]\(WI^5/DG(7Z?\"'AL;B
MJQ_\O"V<](%IDGB;M08AJXN.JBE;N8W5Z[KI8G7K53ZCWL*W6.:#H_HKT]?P
M-NM,C5OOUE_5J.DJ-<HSBKQ*U##ZOD+$,%;A87M(&OM1-;(8^[%EU##VHT+$
M,/;#V(_G319C/[:,&L9^5(@8QGX8^_&\R6+LQY91P]B/"A'#V ]C/YXW68S]
MV#)J&/M1(6(8^V'LQ_,FB[$?6T8-8S\J1 QC/XS]>-YD,?9CRZAA[$>%B&'L
MA[$?SYLLQGYL&36,_:@0,8S],/;C>9/%V(\MHX:Q'Q4BAK$?#VL__J#SY;JW
MQ.,VPT@]!8_GKSB7*I# $IXU@2'\TY/CP[W&X='QP6ML<F*MI6=#*X8(2=H'
M:-"-&[HX5)X3*S#L[__G?]X<O7[S+M>36O>Q\7P@4:9;RG09!-N=YX'/HD^+
MFVC$DJ05X_'J8F):R#Q\"YG4G1FVR#4J$2= ZCLT5,FN>&,_M^*XE#=W-*'/
MA&:!Z!5O9].I#&PKE'F^UES0("XH;?*4'K%J936!P>AV5O"R;+.KZ\":PFL:
MFDW36O1UXVC_X,WK8]:BK=]7P.,1(^B=+356U>I;,^@RHDRAQ__6=-[YT.U]
M)F"<7O.L];G9^VNSD]D$/,ZRH=<()F&D8!.^_Z/_\Z,F]O?@XP^Q<V< YT%@
MC22,[6<)T$P!R)E "H=SQH]0" X,8.,'",S#Z%ABYUZ0TLF(-%9C81Q.F &A
M[UH_(QBR^###EJVI]JN(_J5;LUK9MJP6H35J".H<'CB!Y1">F6V!'B!HZ1@$
MB&#)$-T"+K!E&"*8)($(A;@4X3T!M<N[QV;F7UG$G77XD5_1613K>%)[;4\:
MK.U)G;4]J;6V)_4K^*3US6Y]M/N$3ZHP4#RA^S3[K'^*2I209!&W:TZ@T:48
MGK&9^4ZZYN@=69C]QCTU^HV6):/-%_70KI5@3BZ9*F(;.@&#M"F4HC1($2,<
M+;-^8@>4/TT*H8M $TY"0=A(PQD#.!-P][43(AS<&&C)Z)!H.0A:[<J"D>,
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MJBD9*CXXN7=B_:2OG$"O/[Y)(DYRC,3*9-),=N('@7]-D@NT)YV]@+$8ZY1
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M3YG5$U1%$GTUV1H!F(T4H-EW6JRC=S]J8G]OOP%+-O%!@I93'0B=6M4?!",
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MT2/_\$X4L3)O->N4E,HB@0!-K)\2!<52>K&X'^,'V3M&8-4N,;XAY3>+,"A
M596*K-C,+HBOD&6I[HN? /[#;$)V,TY+Q*)+=L8#*<"S)>R"PT?<2TZ_+9M"
M*WMM7:13D22B&&[A<M<XLIG74H]4>9J:T@&_P.W DAMP$&8<UO&F%@Z0@X2=
MZRNITB9\#\5C$-)'&?6^*X86JG>T=& [ HX2,-F&40+J=Y=#+[(EN=PIT("W
M)C'[E^@GE\P%YPW) 003@5HIB3*$:UW'B]2/*#(=$V]^\X.?=<'%+%M@)5"!
MC^=$NM@?Y""=G%-<:00>) \1E@,TVJB0%56?Y6]P"Z3'B?;44M=4%*E7?.AP
MJ2+Y)JEM0S_ 4#6IEZ'/\3C0,Z434<#.+!S Y#![66EKG!81E27FR?).ON\1
MZT]\W)(%:X*L9H&[51/2@A5#0XM+ARL(=BF^$_D2- 9HRP#SI[$ITWEL3 HZ
M,"*,!.(49/99$:@H=-TO2<9J26"KU0C6=>#P=-(TM":IW?ZZ../WSUFE)&-+
M32/'!ZB"QI8=@J^*B,]ZT! RPE^HL]#91/O^BS+.H_0+8/$\OFR%%ST4/]SZ
MV-;W/YW%Q0E86HU.VHA3!6C,2?EXJ UIZFB&<=?;^_GG'\[[9775#W5ZUYQS
M?6X^5(XO4/V)_0:?7O@;I34*9BYORX8U.C #_^LV_QKT6BWQX0N=!_O<[K3[
M@UYST.YV:N+\_)2N2_-5_LCLXQX)67""[,;C8GI=3N9O;SX7HD_DUH_441 U
MKVJ=-\K:P <]@G2<.9*U_B-(P(,=L'%O\8^!$[ERHYOEAJ<,3SVD;F[R!M;F
M"T"*CM#^H1J0_@.' U[]5+NRF.,&AAG1,GWG0\*J%KM/Q\HV?X1LM5&?S(WH
MQ+W%-BLY9IT?6D6M:$T.ZWN-C#%)5-NJ]F@O_XAJ2+=2D904[U!>.V2-9)A1
MGU(V0O\DA/Z'86O#UD^4K9M1Y*UNBAKU@X.T*3)"$1/K]='FB360;GUU8AW4
MCXX-L1Z-6!^LWZO3ZK!^]-K0ZM%HU9I8COM6F%5/5OVUCCHVM_ 5B6.2DT^C
MY&@#EAEP.'/:_7S1['PS&99J<ZS)L#P-K[0R&9:'VH6]_Y;K+]\9W;3C^L?0
M'\WAGZMHXK[__U!+ P04    "  /@[%28F7H^ELA  "0D@0 &    &UR;G,M
M,C R,3 S,S%X97@Q,&0S+FAT;>U=#7/B.)/^*[KLO;LS5>  ^2;SIBJ3K\U=
MDDDEF;W;NKK:,E@$[QB;UQ]A<K_^6I(-YBLA8$ VS];.3&*P+;6ZGW[44K>^
M_%NY?.&V3;?)+?;[T^T-L[QFU.%NR)H^-T.ZVK/#-GORNEW39;?<]VW'85]]
MVWKFC!T9U8I1,0X/R^63+_2HL_@>SZVSO>WJP7:M4JNRRF&]ME.OUMC]+?OT
M_>GLL_SV^;>SIS_O+]1;[[]_O;D^8UOE[>W_VCG;WCY_.E<?[!J5*GOR33>P
M0]MS36=[^^)NBVVUP[!;W][N]7I&;\?P_.?MIX?M=MAQ=K<=SPNX8876ULD7
M<87^YJ9U\J7#0Y,UVZ8?\/"?6]^?+LN'](W0#AU^\F4[^5=]M^%9KR=?+/N%
M!>&KP_^YU3']9]LMAUZWOE/IAL=TYS9]//*=G^6>;87M>K52^<=QU[0LVWTN
M.[P5UJM5XV!_<,VWG]N#BY[J7-WGCAG:+UP\/?7<IL--O][PPO;QZ"LFW=E-
M[FMY;EANF1W;>:W_=F8Z=L.W?RO]]CMW7GAH-TWZ.2#!E@/NVZW?CN77 _O_
M.+6+>NC8+B^WN6JH43L\#OG/L$Q/>:;7B:O'2B9U$@<3?P[5OZ()C8E->+([
M/&!WO,<>O([ITNOE%=&,L1;4Z$'RUYYJ0<-S+'KRQ<^VW;!#1FJW\V6[08/0
ME:*B<30;#D]>V_!\B_OEIN<X9C?@]>2']!OVZ0UQ]X14F_0)J7W<*35H9A1Z
MR04U8O)*,H@T(J'7J5>,ZAX]*[DJ5"2^I$9J[\C8/_K'\1:3LJ/AI-=P7ZB>
M3W^LI,TOW!>#XL0BIL<<IT9Z(.OD1?%+V)ZQ*P2?^F6Z$CS:G<?('1/T\%!7
MC])#K5J;?O^"XYL>4/F>4%AWR_,[]:C;Y7[3#(0:?S-_A#[G[,SLVJ'IL%O3
M-9^Y0*82NS'NC?[H?ZBG[W5,?'V^OHW)<.MD9V>'/7H1P><5==%BIR_<*+':
MX9=M\>B3+T$TN>T?L),C:O8$Q=DZ"=M?MNGY&?>(71*X^DG[/RS]#^O9_(W?
M.KGQ G;J/G.'!R5V=LJ.*I6#:KKIVZ$E_O+%7P(\$D1?%W[6=@< .G_'1T2^
M=7+V[>[R^OSB[NGZ].;]D5NPF\-C.MK-C'MV:[ZRZ@%9%)&,(O7LQ0[(R3EV
M^%IOVY;%77KZK[\<UBH[QQEW\\-&*155W)8H:C1?C^4[+-[T?%/RE\@E?RU:
M,OJ)\.&>7_^E(O\39LU#:A([?2;G('FJS^OLUG;M3M1A-_:_(MLBP;'3CA>Y
MX9?M:(DJ038]G0)EJN>^[48!NR?NVC&;/))P3ZAV[3:-+PW_9(\]F);K^>S,
M\[M"<.0VY<B)#XD^D/,, \\E'VNQ!ZO$'B.;OK)7J2S=:E8E(M7_$KL_9=6C
MRN&!Z'C2N<Q>TVN3V,I!EX:@WO5YN>>;PM6>AB%-=]ACR%^XR^Y;))O0Y@XY
MG;;-6^S2=FEZ91.%^=9JV4T^@_O,A=!7AE*';W<P:V/SC<$8UO/;DWC:$L]1
M]E?J5BI3W8I-..^&]9W][A)YP0-O<9^[3<[L@'5,B[/08V';#!E97VC:+COS
M.7F)E!,1]/PJ,HFFAZ\E9LD@AADPK\4DR:@JDL$^V6[3B<3LBY['&5>ST4#>
M3M-S\DMF&)K-MGAF(+[B\] KB2>9=,GBA+T^#T(5(_'5+3T[X*SC67;+IJM=
MWZ8/9'NY; <3#_%:)7E!#%>MTA^N.9WOI#G17+YX5(S2W68XD+*[U>//K/$J
M16QV/)+\F^Z0?=)03E\]W_=Z OF7(Q^E'([0,#]@+=_KL)!NE6HD_NV:/E&B
M6!VUE-"-:OO2%$AH3Q)1N(S$7-SJ$&<,0M6>$KNY.=-2,*?/F=O5%!J3R,I@
M2<R%[K 8L<A.P** ?FQ$(7.], 5;%F]1)RQ&D!JV"6P=1<[-/JY^DI>UD^FR
M\<KTN1*9#)X+M>IPTR6W08X@"&AF)03KL2!JMF,!2PGR,<=DK,(S+\D13Q^@
M-3.1X?ZN71L%,^AK8P['>6-XY1,9J,1CY6]CGR5]B_@]\?*2L0G&(HQ8F+GD
M?O)K,?E3Y"[&3F'_"4).BV/$P"*(9,MS'*\79#PS6;=H1SQ$9D]6OXH'U:5'
M:TY:5)H>/<JX-7T/(=U!0-.)SS%;$]#O>(&86)P+!:&WVXZ\?-KM4K/EXI8@
M+OUOT-1$?"R61IOB:^4:>Q*:=./1DTOLWZN5$N&+_$/O2;]HKB=^O$5?A]M3
MZ[='6@(U:8XV?9W<HELSC'PQ;N(>T?>]Y%WPGX7WG[=VT.2.8[K<BP+X4,V!
M_INK9O(M,4\8BW%PDPBQ/PC?3";%PJ?&#D-.+_H?E!)XC3\5CY6*-.D#>M^$
MJ[:;7/1\UO-\2P:!'/L'M:;3]7SR_:+]DQLJ<(F=QQMH@B2*,]K\$@O:IN-(
M'R ?UN#,3#ULZFV#,)((B QW?25 MRHUF=$:U'*M^KOM]_=^F,T?SS[Y;VL$
M*E+;:(8_B+LXNAA6&8FARGT_Z>TA\?:=H0TBP]?ZVX6ZYC,O-WQN_BA+U:^;
M3L]\#>(='@?[QN[!/X[C72OJ6F5D$U!Q-A>M&8$N?C9Y-Q3&%'1YTVZ)X*'S
MVK<LL^&]\-)DW$F8O@KUCEB[,FJ?=T2 F?YO1?1KR_/)HB5BM%J\J1XAH@/Q
M'$'X-!GW%=>;GMNR_0ZW#)9CVK(AKFQ*%.U)+@OP9J3"BA9WR'#\UY0*T.\N
M#P)%;=,0'FN0C+!UN5S%%8C/>J9XA/B^Z9+&B*Z66%?.-,E'D<)QZS4ARG)Z
M*BZ+K\;7DGFJ](23%?M3RK4HS?P\\I!)*E]B8LV9M#8([3 2S1UI:]?WA#9X
MKHH]2P^OK"_V<316XO7\)TDP")SX#M$*,ARF_+'!V!V]74P)Q!X]4TZ:U4=B
M?<<6V_;DR@K=H238$)-K(1:6-,^/5,#MK;::@11<*Z*Y!&?GO&5&#IDU7;IX
MD09.7XROJN=V:,HB-LZJ()]XAIS*TV>#?B=#, P50K2#"8]C]JB/L/@\6[S8
M;"$TE+31FV#9DJXEUIEXD73\2&B/4,Z8W8[?+KZ@;DC!Q$#1Z1['[MA2,]NV
M_%H?+()$Q66X6:T%S8D%XR"@,$ UR1YID=I!+FZVW99H$6M& 3$I93Z1'\CY
MO<5) TAT#1[V.'='6DIFK;BUYY+3)%&5QN)M@Z_(YJDO29OT^;/IRZ9,1*.)
MR)(L98S"\E#/O(9C/R>!O"',C<>(OB-U0BF$^(  K<'% K/@ _UGJ[5>B43R
M6V_"SB9R_+QW4^%#/S0L1U[.#+OFJ]!;B_BBL'])'<W <Z5+\**P[+7*7:_Y
M@X>DG$&\QX <)2>0"(;=_2B@D J3/KN":] ;^DM0A%ED4O%Z9Y^CR+O[-(6>
M^\G^_.LOU?W1N742M8L_',"!+?VK<FSR6>GYK[0:^>P83=1TG/7W42A+I?XJ
M_(I;)YK;$H*2&RN&A)$6P2-1;/N%T.A7L],])BCS.CU.DKRYN9>S9;HS(#8A
MP(9N<42#)DJL#Q=B1A F"^4PM_QU4YC;D-9VR,QB5YDXM1BI!^Y >0.%PO+C
M_FZ<F*U*_YM2=&%A/9\FQ^0YXM5<^HJ,"<6&*7R732V')N6UF],V>PYISCC3
M:W/'BH'/=E^HM\1%;,<A(N((S8I<[LJ8@(1Y6[&=OR/?#BQ;P;5D&Q*]D@T"
MZ8]+ZL']F>3(1(K:(V^)7VT+_A2_72R/##= CF$??DWUR'AGV^#V_LW2_PS?
M&RN[BGF(6_N2"6*C.NY#[:!)DHXJ"VE&CIF>+@F!I#\9EXPTYOA9@H IICCT
M@+YG2M]-7.]IS"[C1PI8,%\D367/GF>1S@AWX/)G+[2E1Y*#0>[3,9L\W9LW
MQC8E"NE<Y/?35^6PD9_V.G8SB0X)%&K;U".:70KO%["FXP4R#M#U K([9["7
M,1;^1UJ2Y]6P#8$=Q1<3-8VW$-!PEU++G40=$R\D@XRI(,-@-X*(1=BNU-[D
M"^,K"N_,=,QD961HRI?:C#"T_ZM8NY<V1-^F!C7&N+\,43BFW2G)V3*!"C%G
MZ5,L.^C*D!K!K? "*K@@8Y-BX4"XE+&0QJ=>F\?3!_4XLRGTT?/#H8W1GP<Z
M^2Q>J*A6*0F7QY$]\9N( _K4@U"IH]EL>K[5#\_%.V3-7G_J]!C&^PN$K/[T
M_!]]3SB(&HB O&,K7*9[Q>9LMVEW'3&#$Q#<\R)';NH1,<'8!N+ 7F)W0FKB
M5N61Z"[W_99(7S4F?['//$Y2#@92":+&WW+.XL7>@":4KES44'1AF#R\<#?B
M)4:J\&(WY3O).31Y(&9 _6@HW?+*0E]DK/17)80>VHH'I%S8,*Y@::Z82W,K
M)M@#[Y0HE+VDK6!;)YU(1!P")OYU"<:^;-N9^G(X0.T=X,2(02-9Q(N="8&X
M&W4:"A]%-$GX&N)H0:D_ZY>\G6"TS6FFXO5O%Z&ET>BQB$60<R L((*F0-94
M-"Y^2&C^H*>$WK-TD?$C4FM7(A:>\+S [*0"R@8[3X7RZ"W];J1:K29@(G!A
MRK4N@8"35QVX0[[%]UR:H<@J#1T["%1,4?6)*.!@*BKYX-#+^UV<U@KL8<DH
MB5O^FM[5.D-6]]3B&V^D>R\HGKB%+KW/=.AY__/4#Q]8RKBD1DB%3-9V5=D?
MAV@4^5/6<$SWQ_].E*"@H8[Y2D]W^3!;>'.4APG'O&,^KFO]U,Z$I!QB9Q/H
M4X9^ZY[Z%_!DUY":D<B%$X]F,)Y<C19+(+Y@-Q&!L)R6!9+HB.765^D!Q(\J
M,X%<@1O/U:+@+=>Q7-">)9U=(E)-5G#*5J1_<#GUB0AM7L4"=6FU_(WU2\$L
MH6_?3O_SZ>'B@EU^OSMGI^>WUW?7CT\/IT_7W^YD^J.,.:MTPV443TC#2V7E
M_O$]H6>E45,F-5]?ZXR]6]$J$[%/:<%U&% 3Y"N%D=]RP6:S>>.P+QEU)<4=
M:S6L"R:USI_WL!ULL__@Q,>;)COW.@W?:[5D^L/*6S)X8T+!;%<.0L/QFC^.
M1=RNY7B]9.S'O6^*F_X=T22G]9JZ5';,(!R^/KV5,;&72C=<%DVIYY!YQ#14
M$8/]/6-_MY^C19K)$@U-:\C$#J9H9HID;/5-2^:D+)1I+$KN+1$<F/COCB:2
M]<5?04\;U\K%'[K\_C^) J#9". /$5R]]WD@XZ8YAKB-AO9,5&&M[N&K;Q./
MO_=)'>$9YO8,1_ ,67F&(87<,*?PR%U1VFFIOB$OM>#F#-4M.3@W-2"*J-WJ
MHG:C+1W&S665=IVN<Q\:^_FCC^+.N#ZX$.%6=@7-AT9&C7UZ6 8R/MJ7(@[[
MFIL(2 EEADKE.P?&T>'D6N7J&2GYI!X^2@.2WR42UY66BE3L=W6G_[G9"#PG
M"LGUBV+LJ]&BCR'M0LG.LG+U#..Q9QP=8#BT&8XC6(=.P[&[;U3V,1ZK&0]9
M9W_& R_>=2,:2&39I2UB'28_3Q,3(@4[6^^*;;]F5*IZB6UIY\#<7-R=7SP\
MRD- ,EPCJX^- ?1V+KU=E)E 4K.2!DAJ9G^^(:("9!7"U;ZSWK&H>QWVI_'F
MD/+3V?G#(Y/[0BZNKL_8V</%^?63W!_2/W +2@:_N'Y)P2_"+\(O:J!>!8:L
MH6T $[E"[7VNL$?FMUM8 ;VSJ1%&""-<6,?$WE58X=LG! JK\V%ML#:]) 66
M#I8.EJZ!>A48LO+-TI/=./&F+O&=>+-/_\I/%GBB>%2R/VRZ3-=]%D?6.2D9
M-6S*#L]"[$ZN[=6,Y>U.9A_[KW_\"J <4+Y^2168?6Z=#.W*!]-,Q#(M^0RH
M!%320U*%1J7AA!G 4K^RQ-2T'X 20&G]DBHP*"%0AT"=)C+;;,A"H&X9,AU+
M](>=PDYUDE2!J06B,-. 'H $0-)54H4&) 1@)LOEW?(K VS:EJ47DO15#7K]
M84M -8G-RL]>-K"B]L1F#1XJ5>1X\%#70MO1P]0'J;D?3<V]^.^+FV]W8SFY
M[/=O-^?7=U>/2,[%#%LW215XAHW51*PF:B*SS8:L?*\F(CE78\G!")&<FYV$
MD)P+:]-24F#I8.E@Z1JH5X$A*]\L'<FYJV@8\G!G.R4(, P8UD-2!6:.V-*)
MQ%JM; VH!%3"ODXDUFIE:@4&)<Q8D:4&.]TX216:/&!*,U^6VG FR-MG?(KV
M#AW-FJN32W%J+4ZM'=7H?)U:"^H Z@#J@+@#\DG7;3?%[Z%.?B]Y*?)KEZ=.
MR)C=O.% #JQ6PX&LUA6.!Z*QR%.=]PC9NZM['""+6;OVDBKPK!V[W['[71.9
M;39DY7LO 7)4-98<C! YJME)"#FJL#8M)066#I8.EJZ!>A48LO+-TI&CBAQ5
MY*AJ"RZ 83#'[!T6-G0C1U4C6P,J 96P5Q0YJEJ9&D )H(0@&X)LNL@,D 7(
M F0!LG(DL\V&+*P+H!((['3C)%5@:H' \;R50 !( "0 $F+&.M87 #8!FX!-
MNDNJR'"%. QRBU>16WQ[?3?A)%SD%L,KZB4I>$5X17A%#=2KP)"5[]4)Y!9K
M+#D8(7*+LY,0<HMA;5I*"BP=+!TL70/U*C!DY9NE([<8N<7(+=867 ##8([9
M.RQL$4-NL4:V!E0"*F&?&'*+M3*U H,29JQKRWK!<9,X;A+'3>*XR5SX"7A4
MT'P$'Y"?IHV4 $@ ),0=D)^FH[R 3< FS2559+CZ\!X?[8[L_G!?-&CSDD=+
MIVA \E(<PJV1"> 0[MP/!P[AUFHX< CW"L<#<R<DRL^;*'_Y[>'AXO&)W7Z_
M>;HNQQGS?\ICN!ERY3%#UTA2F*%CAHXL' W4J\"0E>\]3<B5UUAR,$+DRF<G
M(>3*P]JTE!18.E@Z6+H&ZE5@R,HW2T>N/'+ED2NO+;@ AL$<LW=8V*Z.7'F-
M; VH!%3"GG7DRFME:@ E@!*"; BRZ2*SS88L!-G65MX#=@H[!;5 % 9% _21
M$@ )@(0 C(9% [3+P"U^-FNRE+A(.NNN<?AF0@T2Q)*7KBB==1?YD_H,QY%1
M?7/:C.%8K754C+T]C,=JQB.><8S(LW:0G6_10$PZYKCN&=5E,^VUY+@^?;U]
M&#\,^O+[W3D[*RUX*#14+2N&D6-)91,J/S**&A%8<M(8;! V>)Q1TEB1C3"3
MG#$8&XPM^Q#OV[-=2&KFB>B&B J0!<C:((Z.E#&DC,V:,G9P9.SO=37,&0,,
M X;!'%>Q6ZG(+#'KG#&@$E )J+22+4O%AJ4L<\8 2@ ES%C7EG^!XU5QO"J.
M5]7Z>-7!%E1X5'A4T'P$'W*6*@5  B !D!!WV.A4J4U-?MHSJCM()UB*ALR7
M_+2';!M]AN/(J&$X]!D.<I\5''6YVN2G;-R(!A+1,<^)IE[+SIS7+<_I<M$\
M)ZA:5F0"DIK5ST-2,[O@#1$5( N0M9Y%])VB!FN7G)L)(X01'F>6FUE@*\PD
M.1/6!FL#2P=+!TO/F\PV&[+RS=*1G8GLS)FS,P^,(RVS,X'#P&%0QQ5MD"PL
M3<PZ.Q.H!%0"*JUJEV2!82G+[$R $D )H(0H&Z)L>9/99D,6HFQKRRB'G<).
M02T0A<E=FBH "8 $0$( 9I5IJL F8!.P27=)%1FN/AR'06:]-IGU.*=O.0HR
M*77X0X$C8P]9Q'H.S9&Q4\/0K'YH9DA6WCTR]HXP-JL9FP_./HI:4VC>W/N#
MF7+O=]]4YP+FWE\MGGL/3<N<;D!J\S"!#91:%DYZ0\0&5 .J+7%WPMX,\CDT
MCHH*8$O/U(<]PAX_E+2_\0:94=(^# ^&!WH/>J^YV(!J0+4-I?=(\4>*_XPI
M_M6#?>.PJV6&/Q 9B R>N;0MY^"4RRH" . "< &XEK<U'<BUG#H!P"W@%G +
M@3W-Q094 ZHAL)>_J@(XIQ[GU..<^D*=4P_O"N^*.0."M/FJ$0+, F8!LQ"?
MS6D9$< 7X OPA3"MYF*+42UY[UAQC(]HXLZ^L?OF(=C(*T]>NH9*&0=OUK7"
MT*QM: B)#C$T*QN:=SW#KE%#Y9(5C4>:5&?J:C20SJI9SRQ+8D?++]JWGE(9
MCQ>LNC]6+..=*AG0N!7,Z=[F'9#:/)1@<Z2VL+?>$%$!U@!KJ]I[,T-X96_'
M*"J +58R [8)VUQJ_8Q--\Y9RF? "&&$6DH-O!^\'[Q?8P,M,*SEFO>CE@9J
M:<Q82Z.V5S-VNZNOI0%T!CIK*;4"D\X%SG(L,L'\8#$-(!>02TNI%1JYYC_T
ML=C0]8%MV@ N )>64BLP<"'.ASB?AO(#K"'.M^[2&C!?F*_.4BLP*T$@:,&$
M?8 60$M+J14:M! #RBIC'_@%_-)2:@7&+X2"$ K24'Z -< :8$T[40'6D J^
M2"KX]=W]P^-8!CC[_=O-^?7=U2-2P=?M$N!(X4CA2.%(=9<?8*T02\5(!<^)
M%&&;2 5?BH"0"@XCS*W4P/O!^\'[-3;0 L-:KGD_4L&1"HY4\%S@#-!9,ZD5
MF'1B!S!2P7-A@T N(->(B6(;,%+!]3?! @,7)L3KRIG$<>0XCAS'D>?I.')X
M6GA:+:56Z"D"@AM(;];;_ !: "W$-9#>G%=+!'X!O["-:47;F(;#/AKT_,-]
MT:#-2QXM#4(/1_MQY"%YZ=CY]>\ZPP/C"*=O+\<$YCE]>\\X.L!P:#,<1[ .
MG89C=]^HO$G=,1[9C4=Z?K6P&]% (JN>'<RP)+I?,RK5(A4A2/(!KVR'FQ:[
M=E]X$(IT0'89N18[O;YDG\[)MGJFSS_+%$'CUU^J^Y7CZ94)H'J93;'>(Q>0
MU*Q^'Y*:V25OB*@ 68"LK#=5S1*5)?-;=AFC]9<7Z).'1_HB#Q1QD,DJU>IQ
M?)$]P29AD\NO*K#Q1GG%7>Z;#KLW_=!]I[P K Y6M]Y5RP*;(N@IC!+T5!=Z
M>G4O&&I<9A/6!^L#$5VRA&1]*^H,N^6=!H@HK Y$5'^QP2AAE""B2R:BU]?7
M*D8*\X/Y@8F"B6HB*5@=F*@V8H-1PB@WB8FB,"@*@VI>&!0P#!C&7D\]ZF(4
M>%_G!XM^ I6 2D"E[ M?,.#2J&!.H[#M^73!8H_4;S/T_%=@$[ )$]>\%O"$
MG<).P2$PL]&MXA\ "8 $0-*DFE^A$0ES&D"3_I(J,#0AXQ^%^C:Y4!].S<"I
M&3@U0[-3,U"Z4F>G@-*5N1\.E*[4:CA0NG*%XX%H DI7SENZ\O[A@MW8+<X>
MFS9WF_0<D565I%,U$+-"S$H722%FA9@5<EXT4*\"0U:^MPZM-/OZWN<3F .[
MND<N-HPQ(UU#+C;*4\+JM)843!&\%$8)7KIV 8U7!3I%>4I8'X@HB*A.DH+5
M@8AJ(S88)8P21'3I1!0145@?B"BJ4VHE*5@=B*@V8H-1PB@WB8BB.B6J4Z(Z
MI;;@ AC&'L_L'19JN* ZI4:V!E0"*AVCD L*N>AG<( F0!.28A!JTT5FFPU9
M"+4M0Z:HIPL[U5I2!:86B,5, WH $@!)5TD5&I 0AD$81C># S0!FA"&03U=
MU--%/5W4TT4]W5@"Q;=Y5 Q&#4Y4#"[V<*!BL%;#@8K!*QP/Q$M0,7C>BL&_
M1VY(W0@]MWQU=LFNW1<>A!WB-BKA]=.Y[?-FR/K%@_/6SQONBF%BI]>7GU$'
M&;%&[22%6"-BC=CRI8%Z%1BR\KWE:Z5E/F;D0VE:@2+)L-3L%!$E05";#E:G
MM:1@BB"M,,HBD]:/MO7M<-;"W%*4/88AP9# *<$I876%E!1,$9P21EED3ID3
M 8W7.T;!8Y@?F.B:"AXSF!W,3B])8<<"=BR J&N@7@6&K'P3=9V+U$RKSYE^
MS<3RPPGX[^RI=L'(8>1:2:K O 05;J:(!=6&@4IZ2ZK0J(0R-RASHYO! 9H
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MMF!N "6 DEZ2*C H(<B&()LF,MMLR$*0#7GWL-.-DU2!J06B,,B[U\7, $@
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M<RTR,#(Q,#,S,2YX<V102P$"% ,4    "  /@[%2/"-XG64*  !IA0  %0
M            @ '8"@  ;7)N<RTR,#(Q,#,S,5]C86PN>&UL4$L! A0#%
M  @ #X.Q4GUO"*:V%P  "WD! !4              ( !<!4  &UR;G,M,C R
M,3 S,S%?9&5F+GAM;%!+ 0(4 Q0    (  ^#L5(\/5FY/T4  (E-!  5
M          "  5DM  !M<FYS+3(P,C$P,S,Q7VQA8BYX;6Q02P$"% ,4
M"  /@[%2<Z+*!6XI  "SV0( %0              @ '+<@  ;7)N<RTR,#(Q
M,#,S,5]P<F4N>&UL4$L! A0#%     @ #X.Q4@8O0!.C0@( ?J43 !4
M         ( !;)P  &UR;G,M,C R,3 S,S%X,3!Q+FAT;5!+ 0(4 Q0    (
M  ^#L5( 'SIPM"D  'LK   8              "  4+? @!M<FYS+3(P,C$P
M,S,Q>#$P<3 P-"YJ<&=02P$"% ,4    "  /@[%2&9F:PGE^  #:N@  &
M            @ $L"0, ;7)N<RTR,#(Q,#,S,7@Q,'$P,#<N:G!G4$L! A0#
M%     @ #X.Q4H_,M')Y00( Z\\5 !@              ( !VX<# &UR;G,M
M,C R,3 S,S%X97@Q,&0Q+FAT;5!+ 0(4 Q0    (  ^#L5*-R)/<+<4  )G?
M!@ 8              "  8K)!0!M<FYS+3(P,C$P,S,Q>&5X,3!D,BYH=&U0
M2P$"% ,4    "  /@[%28F7H^ELA  "0D@0 &               @ 'MC@8
M;7)N<RTR,#(Q,#,S,7AE>#$P9#,N:'1M4$L! A0#%     @ #X.Q4@03?5FL
M"   /#4  !@              ( !?K & &UR;G,M,C R,3 S,S%X97@S,60Q
M+FAT;5!+ 0(4 Q0    (  ^#L5+U6354R0@  -@U   8              "
M 6"Y!@!M<FYS+3(P,C$P,S,Q>&5X,S%D,BYH=&U02P$"% ,4    "  /@[%2
MZA,W;Y@%  "V'0  &               @ %?P@8 ;7)N<RTR,#(Q,#,S,7AE
?>#,R9#$N:'1M4$L%!@     .  X O@,  "W(!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
